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Abstract 
mRNA vaccines are a new frontier of medicine. Unlike pre-existing vaccine technologies, mRNA vaccines 
present the human body with the genetic information to make a protein whose production incites a 
natural immune response. In this manner, mRNA vaccines create antibodies and build immunity towards 
pathogens resulting in the same protection as traditional vaccines yet without presenting the body with 
the foreign virus. Among the many advantages of this new technology is that the manufacturing process, 
rather than being specific to a virus or recombinant protein, is specific to mRNA. In this manner, the 
process is independent of the actual disease the vaccine targets and is only dependent on the biological 
properties of an mRNA strand. This is tremendously advantageous since the same manufacturing 
process can be used for the mRNA strand of any genetic mutation of a virus or even for a completely 
different pathogen. 
This proposal is for a manufacturing process to produce 200 million sterile doses of an mRNA vaccine 
against SARS-CoV-2 in a 13-week period thereby vaccinating 100 million people. The process uses 
Pfizer's pharmaceutical formulation and starts with a plasmid DNA that contains the genetic code for the 
entire viral spike (S) glycoprotein. The pDNA is fed to a WAVE bioreactor for an in vitro transcription (IVT) 
reaction that produces mRNA through phage T7 RNA polymerase. The mRNA is purified through two 
diafiltration steps with an 100 kDa MWCO, a chromatography column to remove undesired dsRNA and a 
sterile filter to remove biological impurities. The purified mRNA is then diluted in 50 mM sodium acetate 
and fed to one of the twenty-five 16X microfluidics devices along with a mixture of lipids in an ethanol 
buffer. With a flowrate ratio of 3:1, the mRNA is encapsulated into the lipid mixture in the microfluidics 
devices to make lipid nanoparticles (LNPs). This step is key since the lipid-based capsule serves as an 
envelope for the mRNA, when injected in the human body, to enter the cell's cytoplasm with high stability 
and without disintegration. The LNPs are purified through a 100 kDa MWCO diafilter in a third tangential 
flow filtration device and a sterile filter. These purified LNPs are diluted with 1X PBS and sucrose to meet 
the desired concentration of all components in the pharmaceutical formulation and the mRNA 
concentration of 0.5 mg/mL. Each week this continuous manufacturing process will fully produce 15.4 
sterile million doses that will be packaged into 2 million vials. The vials will be sent out in thermal 
containers following the regulatory storage and freezer conditions. Throughout the process, the quality of 
the product will be ensured through the use of sterile and FDA approved equipment, the control of the 
length of the mRNA produced from the IVT reactor and an endotoxin level test. The proposed process has 
an internal rate of return of 449%, a return on investment of 475% and a net present value of $19.6 billion 
dollars. Beyond its application in the strategy to address the current COVID-19 global pandemic, this 
proposed process will be part of pushing the frontiers of medicine with the novel use of mRNA vaccines. 
Disciplines 
Biochemical and Biomolecular Engineering | Chemical Engineering | Engineering 
Man fac ing S a eg  fo  he P od c ion of 200 Million S e ile
Do e  of an mRNA Vaccine fo  COVID-19
I e e Laba a
Sa abe h H ff a
A  S
P ed a d ad ed b : D . Sc  D a d
U e  f Pe a a
Sch  f E g ee g
De a e  f Che ca  a d B ec a  E g ee g
A  20, 2021
1
Le e  f T a a
U e  f Pe a a
Sch  f E g ee g a d A ed Sc e ce- Che ca a d B ec a  E g ee g
220 S h 33 d S ee
Ph ade h a, PA 19104
A  20, 2021
Dea  D . Sc  D a d, D . Wa e  Se de , P fe B ce V a a a d E g ee g Fac ,
I  h  e , e e e  he a fac g ce a d a eg   d ce 200 
d e  f he COVID RNA acc e h he g a  f acc a g 100  e e. The
acc e c de  f  he a  e (S) g c e f SARS-C V-2  a c e de- d f ed
e e ge  RNA ha   e ca a ed  a d a a c e. Th  ce  f  he
ha ace ca  f a  f Pf e  BNT162b2 acc e a h ed b  he FDA  Dece be
2020 b  a  E e ge c  U e A h a .
RNA acc e , a  a  a e a e  g c a d e  acc e , a e a e f  fea  
he f e d f ed c e g e  he e   aga f  h ch ha  afe  a d ca e-
ad a age . The ed ce   de g ed  d ce he 200  d e   a h ee- h
e d. Th  ee  he b ec e e  b  he U ed S a e  g e e  f  Pf e -B NTech 
de e  200  d e   O e a  Wa  S eed b  J  31, 2021. The de g  f  h  ce
c de  a  ea  ba ch ce   d ce a d f  RNA h gh a in vitro
a c  a d a c  d ea  ce  e ca a e he RNA  80 a e e
d a a c e . The f a  d c  f h  a fac g ce   he 200  d e ,
each e ca a g 30 c g a  f RNA h a e f 0.3 L e  d e. The d e  
be de e ed  0.45 L a  h ch eed  be ed a   e e a e c d  a d a e
ead   be d ed h d  ch de a  acc a e    ad a .
I ed b  he U e  f Pe a a  egac a ed b  D . Ka a  Ka  h
d c e ed RNA acc e  a d D . D e  We a  h ee ed a  RNA ab g
eac , e a e h ed  e e  h  a fac g ce .
S ce e ,
___________________ __________________ ___________________
I e e Laba a Sa abe h H ff a A  S
2
Man fac ing S a eg  fo  he P od c ion of 200 Million S e ile
Do e  of an mRNA Vaccine fo  COVID-19
I e e Laba a
Sa abe h H ff a
A  S
P ed a d ad ed b : D . Sc  D a d
U e  f Pe a a
Sch  f E g ee g
De a e  f Che ca  a d B ec a  E g ee g
A  20, 2021
1
Le e  f T a a
U e  f Pe a a
Sch  f E g ee g a d A ed Sc e ce- Che ca a d B ec a  E g ee g
220 S h 33 d S ee
Ph ade h a, PA 19104
A  20, 2021
Dea  D . Sc  D a d, D . Wa e  Se de , P fe B ce V a a a d E g ee g Fac ,
I  h  e , e e e  he a fac g ce a d a eg   d ce 200 
d e  f he COVID RNA acc e h he g a  f acc a g 100  e e. The
acc e c de  f  he a  e (S) g c e f SARS-C V-2  a c e de- d f ed
e e ge  RNA ha   e ca a ed  a d a a c e. Th  ce  f  he
ha ace ca  f a  f Pf e  BNT162b2 acc e a h ed b  he FDA  Dece be
2020 b  a  E e ge c  U e A h a .
RNA acc e , a  a  a e a e  g c a d e  acc e , a e a e f  fea  
he f e d f ed c e g e  he e   aga f  h ch ha  afe  a d ca e-
ad a age . The ed ce   de g ed  d ce he 200  d e   a h ee- h
e d. Th  ee  he b ec e e  b  he U ed S a e  g e e  f  Pf e -B NTech 
de e  200  d e   O e a  Wa  S eed b  J  31, 2021. The de g  f  h  ce
c de  a  ea  ba ch ce   d ce a d f  RNA h gh a in vitro
a c  a d a c  d ea  ce  e ca a e he RNA  80 a e e
d a a c e . The f a  d c  f h  a fac g ce   he 200  d e ,
each e ca a g 30 c g a  f RNA h a e f 0.3 L e  d e. The d e  
be de e ed  0.45 L a  h ch eed  be ed a   e e a e c d  a d a e
ead   be d ed h d  ch de a  acc a e    ad a .
I ed b  he U e  f Pe a a  egac a ed b  D . Ka a  Ka  h
d c e ed RNA acc e  a d D . D e  We a  h ee ed a  RNA ab g
eac , e a e h ed  e e  h  a fac g ce .
S ce e ,
___________________ __________________ ___________________
I e e Laba a Sa abe h H ff a A  S
2
Table of Con en
Table of Fig e 9
Table of Table 10
1. Ab ac 11
2. In od c ion and Objec i e Time Cha 12
2.1 I d c 12
2.2 B g ca  Bac g d 13
2.2.1 C a e  a d SARS-C V-2 13
2.1.2 RNA Vacc e 14
2.2.3 M d f ed U d e f  RNA ab 17
2.3 M a 18
2.4 P ec  Cha e 19
2.5 Ob ec e T e Cha 20
2.6 P g e  f P ec 20
3. Inno a ion Ma 22
4. Ma ke  and Com e i i e A e men 23
4.1 Ma e  A e e 23
4.2 C e e A e e 23
5. C ome  Re i emen 26
5.1 U ed S a e  G e e 26
5.2 F d a d D g Ad a  (FDA) 27
5.2 Pa e  e e e 28
6. C i ical- o- ali  (CTQ) Va iable 29
N/A 29
7. P od c  Conce 30
N/A 30
8. S e io  P od c  Conce 31
N/A 31
9. Com e i i e (Pa en ) Anal i 32
3
10. P elimina  P oce  S n he i 33
10.1 P e a a  f DNA e a e 34
10.2 RNA S he  a d P f ca 36
10.2.1 Se ec  f RNA Se e ce 36
10.2.2 5  Ca  Add 37
10.2.3 P  (A) Ta  Add 39
10.2.4 Se ec  f I  V  T a c  Reac T e 40
10.2.5 Rec c e f T7 RNA P e a e 41
10.2.6 RNA P f ca  Me h d Se ec 42
10.3 L d Na a c e S he  a d P f ca 43
11. A embl  of Da aba e 44
11.1 C  f Ra  Ma e a 45
11.3 T a c a  Ac  f T7 RNA P e a e 47
11.5 Pha ac e c /Che ca  P e e  f L d 47
11.5 De a ed Ma  f he RNA S a d U ed I  he Vacc e 50
12. P oce  Flo  Shee  Diag am (PFD) and Ma e ial Balance 51
12.1 O e a  P ce 52
12.2 S he  a d P f ca  f RNA 56
12.3 F a  f L d Na Pa c e -E ca a f RNA 60
12.4 Pac g 64
13. P oce  De c i ion 65
13.1 P e a a  f DNA 65
13.2 S he  a d P f ca  f RNA 65
13.2.1 S he  f RNA: I  V  T a c 65
13.2.2 P f ca  f RNA: Ta ge a  F  F a Bef e Ch a g a h 66
13.2.3 P f ca  f RNA: Ch a g a h 68
13.2.4 P f ca  f RNA: Ta ge a  F  F a Af e  Ch a g a h 69
13.2.5 P f ca  f RNA: S e e F a 71
13.3 F a  f LNP  E ca a  f RNA 71
13.3.1 P e a a  f  M c f d c 71
13.3.2 F a  f LNP: M c f d c 72
13.3.3 P f ca  f LNP: Ta ge a  F  F a 73
13.3.4 P f ca  f LNP: S e e F a 75
13.4 Q a  C 76
4
13.4.1 De e a  f Le g h f RNA P d c 76
13.4.2 De e a  f S e f L d Na a c e 77
13.4.3 Mea e e  f E d  Le e 77
13.5 Pac ag g a d age f d c 78
14. Ene g  Balance and U ili  Re i emen 79
15. E i men  Li  and Uni  De c i ion 80
15.1 P e a a  f DNA 80
15.2 S he  a d P f ca  f RNA 80
15.2.1 T  B ffe  S age Ta 80
15.2.2 WAVE B eac 80
15.2.3 IVT P d c  S age Ta 81
15.2.4 Ta ge a  F  F a  De ce 1 82
15.2.5 TFF1 Pe ea e Wa e Ta 83
15.2.6 TFF1 Re e a e S age Ta 84
15.2.7 Ce e Ch a g a h  C 84
15.2.8 Ch a g a h  B ffe  S age Ta 85
15.2.9 Ce e Re  S age Ta 86
15.2.10 Rec e ed P d c  f  Ch a g a h  C S age Ta 86
15.2.11 E ed D b e S a ded RNA Wa e Ta 87
15.2.12 Ta ge a  F  F a  De ce 2 87
15.2.13 S d  Ace a e B ffe  S age Ta 88
15.2.14 TFF2 Re e a e S age Ta 89
15.2.15 TFF2 Pe ea e Wa e Ta 89
15.2.16 S e e F e  1 90
15.3 F a  f LNP  E ca a  f RNA 91
15.3.1 D  1 Ta 91
15.3.2 E ha  S age Ta 91
15.3.3 L d a d E ha  S  S age Ta 92
15.3.4 M c f d c  De ce 93
15.3.5 M c f d c  P d c  S age Ta 94
15.3.6 Ta ge a  F  F a  De ce 3 95
15.3.7 PBS B ffe  S age Ta 96
15.3.8 TFF3 Re e a e S age Ta 96
15.3.9 TFF3 Pe ea e Wa e Ta 97
15.3.10 S e e F e  2 98
5
15.3.11 PBS a d S c e S  S age Ta 98
15.3.12 D  2 S age Ta 99
15.5 O he 100
15.5.1 F ee e 100
15.5.2 Wa e  P f ca  S e 100
15.5.3 Pe a c P 101
16. S ecifica ion Shee 103
16.1 T  B ffe  S age Ta 103
16.2 WAVE B eac TM 200 e 104
16.3 IVT P d c  S age Ta 106
16.4 Ta ge a  F  F a  1 (TFF1) 108
16.5 TFF1 Pe ea e Wa e Ta 111
16.6 TFF1 Re e a e S age Ta 113
16.7 Ce e Ch a g a h  C 114
16.8 Ch a g a h  B ffe  S age Ta 116
16.9 Ce e Re  S age Ta 117
16.10 Rec e ed P d c  f  Ch a g a h  C S age Ta 118
16.11 E ed D b e S a ded RNA Wa e Ta 120
16.12 Ta ge a  F  F a  2 121
16.13 S d  Ace a e B ffe  S age Ta 123
16.14 TFF2 Re e a e S age Ta 124
16.15 TFF2 Pe ea e Wa e Ta 125
16.16 S e e F e  1 127
16.17 D  1 Ta 128
16.18 E ha  S age Ta 129
16.19 L d a d E ha  S  S age Ta 130
16.20 M c f d c De ce 131
16.21 M c f d c  P d c  S age Ta 133
16.21 Ta ge a  F  F a  3 135
16.22 PBS B ffe  S age Ta 137
16.23 TFF3 Re e a e S age Ta 138
16.24 TFF3 Pe ea e Wa e Ta 140
16.25 S e e F a  2 142
16.26 PBS a d S c e S  S age Ta 144
16.27 D  2 S age Ta 145
6
16.28 Wa e  P f ca  S e 147
16.29 Pe a c P 148
17. E i men  Co  S mma 149
18. Fi ed Ca i al In e men  S mma 154
18.1 E e  C 154
18.2 T a  Pe a e  I e e 155
19. O e a ing Co  - Co  of Man fac e 157
19.1 Ra  Ma e a 157
19.2 U e 158
19.3 Lab 159
19.4 Re a g F ed C 160
19.5 W g Ca a 161
20. P ofi abili  Anal i  - B ine  Ca e 163
20.1 Ba e e Ca h F  S a  a d P f ab 163
20.2 P ce Pe  D e Se  A a 164
20.3 Va ab e C  Se  A a 165
21. O he  Im o an  Con ide a ion 168
21.1 U e f d c 168
21.2 FDA Reg a  Fac 168
21.3 E e  Reg a  Fac 169
21.5 E ee afe , hea h, e fa e fac 170
21.6 P a  ca  fac 170
21.7 G ba , c e a d c a  fac 171
21.8 E h ca  fac 172
21.9 Ba ch Sched e 173
22. Concl ion  and Recommenda ion 177
23. Ackno ledgemen 179
24. Bibliog a h 180
A endi  A - Pha mace ical Fo m la ion 186
A endi  B - E i men  Si ing Calc la ion 189
I   T a c  Reac 189
7
Tangen ial Flo  Fil a ion De ice 190
Ta ge a  F  F a  De ce 1 190
Ta ge a  F  F a  De ce 2 192
Ta ge a  F  F a  De ce 3 193
Ce e Ch a g a h  C 194
P e-M c f d c  D  a d M c f d c  De ce 197
S e e F e 199
F a  D 200
A endi  C - E i men  Co ing Calc la ion 202
I   T a c  Reac 202
Ta ge a  F  F a  De ce 202
Ce e Ch a g a h  C 203
M c f d c  De ce 204
S e e F e 205
S age Ta 205
C d R 206
A endi  D - De ailed P oce  Ma  Balance 208
A endi  E - Addi ional mRNA Se ence Info ma ion 218
A endi  F- P oce  Flo hee  Diag am 221
A endi  G- FDA Reg la o  File 226
A endi  H - E i men  Safe  Shee 227
A endi  I - Ma e ial Safe  Shee 228
A endi  J - Pa en 229
8
Table of Fig e
2.1 SARS C -2 L fe C c e 14
2.2 Ke  C e  f RNA Se e ce 15
2.3 E  f RNA acc e   ce 16
2.4 LNP S c e 17
3.1 I a  Ma 22
10.1. B c  D ag a  f  Ma fac g P ce 33
10.2 E a c Ca g 39
10.3. WAVE B eac  e 41
10.4. P ef ed Ve c e Me h d a d he M c f d c M g Me h d 45
11.1. ALC-0315 L d S c e 50
11.2. ALC-0159 L d S c e 50
11.3. Ch e e  L d S c e 51
11.4. DSCP L d S c e 51
11.5. Ma  f F -Le g h S e P e  ed  RNA Vacc e 52
12.1. O e a  P ce  F  D ag a  f  RNA Ma fac g P ce 54
12.2. P ce  F  D ag a : S he  a d P f ca f RNA 57
12.3 P ce  F  D ag a : F a  f LNP  E ca a f RNA 62
12.4 P ce  F  D ag a : Pac ag g RNA acc e 65
13.1. S agge ed he gb e c f d c g de ce 74
13.2. RNA E ec h e  Ge 78
15.1. D ag a  f a g e agge ed he gb e c f d c g de ce 94
15.2. Sche a c f e e  f 16 a a e ed c f d c de ce 95
17.1. E e  C  B ea d  b  E e  T e 154
18.1. T a  Ba e M d e C  f  P ce 156
18.2.G h e  Fac ed-C  Me h d f  T a  Pe a e I e e 157
18.3. T a  Pe a e  I e e  f  P a 157
19.1. Re a g F ed C  Fac  U ed I  Ma fac g P ce 162
19.2. Fac -C  Pa a e e  f  W g Ca a 163
19.3. W g Ca a  C a  B ea d 164
20.1. Ca h f  a  f  d c 166
20.2. Se  A a  ce e  d e f he COVID-19 RNA acc e 167
20.3. Se  a a  f he ce e  d e a d a ab e c 169
21.1. Ba ch ched e f  1 ba ch 177
21.2. C e e ba ch ched e f  a  13 ba che 178
9
Table of Table
2.1. T e Cha  Sh g Ob ec e  C e 20
4.1. S a  f COVID-19 Vacc e 24
11.1. P ce  f Ra  Ma e a  Needed f  P a  O e a 46
11.2. Pha ac e c  f L d  Needed f  P a O e a 49
12.1. P ce  U  S ec f ca  Shee 54
12.2. S age Ta  S ec f ca  Shee 55
12.3. S ea  S ec f ca  Shee : S he  a d P f ca f RNA 57




12.5. S ea  S ec f ca  Shee : F a  f LNP E ca a  f RNA 62
12.6 (a) Ma e a  Ba a ce: F a  f LNP  E ca a f RNA 63
(b) 64
(c) 64
14.1. S a  f Yea  U e  C 80
15.1 A  f S e e Wa e  Needed Pe  Ba ch f he Ma fac g P ce 102
17.1. E e  C  f  A  U  O e a  U ed I  Ma fac g P ce 151
19.1. C  f Ra  Ma e a  U ed I  Ma fac g P ce 158
19.2. C  f U e  U ed I  Ma fac g P ce 160
10
1. Ab ac
RNA acc e  a e a e  f e  f ed c e. U e e-e g acc e
ech g e , RNA acc e  e e  he h a  b d h he ge e c f a   a e a
e  h e d c  c e  a a a  e e e. I  h  a e , RNA acc e
c ea e a b d e  a d b d  a d  a h ge e g  he a e ec  a
ad a  acc e  e  h  e e g he b d h he f e g  . A g he a
ad a age  f h  e  ech g   ha  he a fac g ce , a he  ha  be g ec f c 
a   ec b a  e ,  ec f c  RNA. I  h  a e , he ce   de e de
f he ac a  d ea e he acc e a ge  a d  de e de   he b g ca  e e  f a
RNA a d. Th   e e d  ad a age  ce he a e a fac g ce  ca  be
ed f  he RNA a d f a  ge e c a  f a   e e  f  a c e e  d ffe e
a h ge .
Th  a   f  a a fac g ce   d ce 200  e e d e  f a
RNA acc e aga  SARS-C V-2  a 13- ee  e d he eb  acc a g 100 
e e. The ce  e  Pf e  ha ace ca  f a a d a  h a a d DNA ha
c a  he ge e c c de f  he e e a  e (S) g c e . The DNA  fed  a WAVE
b eac  f  a in vitro transcription (IVT) eac ha  d ce  RNA h gh hage T7
RNA e a e. The RNA  f ed h gh  d af a e  h a  100 Da
MWCO, a ch a g a h  c   e e de ed d RNA a d a e e f e   e e
b g ca  e . The f ed RNA  he  d ed  50 M d  ace a e a d fed 
e f he e -f e 16X c f d c  de ce  a g h a e f d   a  e ha
b ffe . W h a f a e a  f 3:1, he RNA e ca a ed  he d e  he
c f d c  de ce   a e d a a c e (LNP ). Th  e   e  ce he d-ba ed
ca e e e  a  a  e e e f  he RNA, he  ec ed  he h a  b d ,  e e  he
ce  c a  h h gh ab  a d h  d eg a . The LNP  a e f ed h gh a
100 Da MWCO d af e   a h d a ge a  f f a  de ce a d a e e f e . The e
f ed LNP  a e d ed h 1X PBS a d c e  ee  he de ed c ce a  f a
c e   he ha ace ca  f a  a d he RNA c ce a  f 0.5 g/ L. Each
ee  h  c  a fac g ce   f d ce 15.4 e e  d e  ha
 be ac aged  2  a . The a  be e    he a  c a e  f g
he eg a  age a d f ee e  c d . Th gh he ce , he a  f he d c
 be e ed h gh he e f e e a d FDA a ed e e , he c  f he e g h
f he RNA d ced f  he IVT eac  a d a  e d e e  e . The ed ce
ha  a  e a  a e f e  f 449%, a e  e e  f 475% a d a e  e e  a e f
$19.6 b  d a . Be d  a ca   he a eg   add e  he c e  COVID-19
g ba  a de c, h  ed ce   be a f h g he f e  f ed c e h he
e  e f RNA acc e .
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2. In od c ion and Objec i e Time Cha
2.1 In od c ion
The e e ge ce f a h gh  c ag  a d a h ge c e  c a   a  e e e
ac e e a  d e c a  2 (SARS-C V-2) a d  a c a ed d ea e, c a
d ea e 2019 (COVID-19), ha  e ed  a d de a de c. The f  ca e  f h  d ea e
e e e ed  Dece be  2019  W ha , Ch a1. The e ha e bee  e  130  ca e  f
COVID-19 a d a  3  COVID-19 e a ed dea h d de2.
SARS-C V-2 f e  ca e  e a  fec  f a g e e   h a 1. The e
a e c e  e a ed ea e  f  COVID-19 c d g a a  d g  ch a
e de 3. H e e , acc e  f  COVID-19 de a g ea e  ad a age ha  he e ea e
d e  he fac  ha  acc e  a ge  ed ce a fec , a d e e   he ca e f fec ,
acc e  f  COVID-19  e e  e e e e . The e a e c e  a  d ffe e  acc e
f  COVID-19 ha  ha e bee  a ed b  eg a age c e  ac  he d, a d a  he
acc e  a e c e   de e e  a d a e de g g c ca  a . RNA acc e  a e a
e a e  e  e f acc e a d a e e g. The RNA e c de  a e ,
ec f ca  a  a ge  a c a ed h a g e  d ea e. Whe  ec ed  h a , ce   he
b d   d ce he a ge , a d a  e e e  be a ed4.
Vacc a g a ge be  f e e d de g ea  c b e  e d g he
c e  COVID-19 a de c. P d c g acc e   ch a a ge ca e  f e  d ff c , a d 
a c a  d ff c   he ca e f RNA acc e a   c e c a  RNA acc e  e e
a a ab e   he COVID-19 a de c4. O g e h d  f  d c g RNA acc e
 a a ge ca e d be e e e  a ab e  f  he c e  a de c b  f  f e
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d ea e  a d he b  f SARS-C V-2 a ; he ce e  e ed  a e RNA
acc e  d   a  ch he  he a ge   a ed4.
2.2 Biological Backg o nd
2.2.1 Co ona i e  and SARS-CoV-2
C a e  a e a fa  f RNA e  ha  ca ca e e - e a  ac
fec  f a g e e 5. C a e  fec h a  a d a a , a d ca  ead f
a a   h a 6. S e c a e  ca e e d e e  ch a  he c  c d,
b  he e ha e bee  h ee ece  b ea  f c a e c d g SARS-C V-2 ha  ha e
e ed  ch e e  e e  a d dea h 5. A ece  b ea  cc g  Ch a 
2002 a  e e e ac e e a  d e (SARS), a d a he  b ea , M dd e Ea
e a  d e (MERS),  ace  2012 Sa d  A ab a 7. The e e  e
g a ed  a a 7.
C a e  a e ab e  e e  ce  d e  he e (S) e . The e e  
ab e  b d  ce  face ece ;  he ca e f SARS-C V-2,  e e  b d   he
ce  face ece  a g e  c e g e e 2 (ACE2). Af e  e e g ce , he ge c
RNA f he   e e ed a d e ca ed, ead g  he d c  f e  c e  f he
6. Th  c c e ca  be ee   F g e 2.1.
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Fig e 2.1. SARS-C V-2 fe c c e.8
2.1.2 mRNA Vaccine
RNA acc e  a e a g e  acc e ech g a d ca  ea  be ad ed f
d ffe e  e  a d a  f a g e  . Th e f acc e ca  c  f RNA
e ca a ed b  d a a c e  (LNP ). The RNA c e  f he acc e ha  f  a
e e e : a 5  ca , a a ed eg  (UTR ), a e  ead g f a e (ORF), a d a  (A)
a . The 5  ca   ca ed  he 5  e d f he RNA a  ee   F g e 2.2 a d  a  f
he b d g f RNA  he e a c a a a  fac  4E (eIF4E). Th  b d g 
ece a  f  ec e  f he b e h ch a e  a  f  he RNA  be
a a ed  he e  ha   e c de . The 5 ca  a  ec  RNA f  deg ada . The
UTR  a e ca ed  e he  de f he ORF a  ee  F g e 2.2 a d a e h  e ed he 5  UTR
a d he 3  UTR. The UTR  f  ec da  c e ha  a e  affec  he e e  f e
e e ; e ec f ca , he 5  UTR a  a a  e  a a  a , a d he
3  UTR a d   a a g RNA ab . The ORF  he eg  c a g he RNA
e e ce ha  c de  f  he de ed e . F a , he  (A) a   ca ed  he 3  e d f
14
he RNA. The  (A) a  g f e  he e d f a a , a d  e g h ca  affec  
e ac  h -A-b d g e  (PABP) a d h  e a  RNA ab 9.
Fig e 2.2. Ke  c e  f RNA e e ce.9
A  e  a ed, he RNA  e ca a ed LNP . The LNP  c ea e he ab
f he RNA, a d h  he , he RNA d be h gh ab e. LNP  a  a  f  he
eff c e  de e  f he RNA  a a e  ce . LNP  a e ab e  e e  ce  a e d c ,
a d h  e e a  ead   a a  f he RNA e ca a ed b  he LNP . F g e 2.3
h  he ce  f LNP  e e g ce .
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Fig e 2.3. E  f RNA acc e   ce .10
LNP  ed f  RNA acc e  a e ge e a  a d 80   e a d c a  f
d ffe e  e  f d : ab e  ca c d ( he a  c e ), e h e e g c
(PEG)-c ga ed d , h ha d ch e d , a d ch e e  . The ab e  ca c
d  a e e  cha ged a  a  ac d c H, a g he   b d h ega e  cha ged
RNA; a  a h g ca  H, h e e , he ab e  ca c d  e a  e a  cha ged.
PEG d  a  f  c  e  he e f he LNP , a d he  a  c ea e he e a  ab
f he a c e a  e  a in vivo ha f fe.11 The  e a g e  f d ,
h ha d ch e a d ch e e , c b e he e a  c e f he LNP 12. The
c e f he LNP ca  be ee   F g e 2.4.
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Fig e 2.4. L d a a c e (LNP) c e.4
A  RNA acc e f  COVID-19  ha e a  f he e  d c ed fea e . The
ORF, h ch c de  f  he a ge  f ch ce,  e c de he f - e g h e (S) e . Whe
h  e e   e e ed  a  d d a e ce  af e  he  ha e ece ed he
acc e, he e e   be de ec ed b  he e e , ca g a  e e e.
A acc a ed d d a   be h gh  ec ed aga f e fec  ce he  ha e a ead
bee  e ed  a c e  f he SARS-C V-2 , ec f ca , he e e 13.
2.2.3 Modified U idine fo  mRNA abili
P e d d e  be ed  c ea e he ab f he RNA a d e d h ghe
a a a  ca ac . Th  dec   ba ed f d g  f  D . Ka a  Ka  a d D . D e
We a  e ea ch. W h - d f ed d e, he RNA  ge c a d  c e  a
e e e  he h a  b d  h ch deg ade  he RNA bef e a a   e .
I  he ea  f e ea ch, D . Ka  a d D . We a ed ha  ec g ce h RNA h
d f ed d e e e ed he dead  f a a ca ed b  - d f ed d e.14  15 Th
ed a fac g ce  g d f ed P e d d e.
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2.3 Mo i a ion
O e  e ea  ce  a  dec a ed a d de a de c, COVID-19 c e   be a
a  g ba  b e . W de ead acc a  g ea  c b e  e d g he c e
a de c. T  ach e e de ead acc a , a a eg  be ed f  d c g RNA
acc e  f  COVID-19  a  e e e  a ge ca e a  RNA acc e  ha e e e  bee
d ced  h  ca e bef e. I   a  e h  a fac g a eg  beca e
RNA acc e  e e e , ce -f ee d c e  a d a e h  chea e   d ce ha
he  e  f acc e . Add a , f he acc e d eed  be ad ed f  f e
SARS-C V-2 a , he RNA e e ce  a  ha eed   be ad ed; a  f he d c
e  e a  he a e ega d e  f he a ge  e c ded b  he RNA e e ce. Th  a
ea  ha  h  a fac g a eg  ca  be ed  a e RNA acc e  f  he  d ea e .
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2.4 P ojec  Cha e
P ojec  Name: Ma fac g S a eg  f  he P d c  f 200 M  S e e D e  f a
RNA Vacc e f  COVID-19
P ojec  Leade : Sa abe h H ff a , I e e Laba a, A  S
S ecific Goal : The g a  f h  ec    d ce 200  d e  f a  RNA acc e f
COVID-19, he d ea e ha  e  f  he SARS-C V-2 . The d c  f 200 
d e   a  f  he acc a  f 100 e e d e  he fac  ha   d e  f h
acc e a e e ed.
P ojec  Sco e:
In Scope:
● Se ec  f ec f c RNA e e ce  be c ded  he acc e f a
● De a ed de c  f he ha ace ca  f a f he acc e
● De g  f RNA he  ce
● De g  f RNA f ca  ce
● De g  f RNA e ca a / d a a c e (LNP) f a  ce   e e
a  eff cac  f he acc e
● De g  f LNP f ca  ce
● De c  f ac ag g a d age eeded f  he acc e
● Adhe e ce  g d a fac g ac ce  (GMP)
● Ec c a a  f he ec
Out of Scope:
● P e-c ca  e g f he acc e
● De g  f c ca  a  f  he acc e
● Ac g a a  f  he FDA
● De a ed a  f a fac g fac
● D b  f he acc e
Deli e able :
Business Opportunit  Assessment
● Ca  h  ce  be ed  d ce acc e  f  d ffe e d ea e ?
● I  h  ec  f ab e?
Technical Feasibilit  Assessment
● I   b e  d ce 200  d e  f a RNA acc e f  COVID-19 e  a
e d f h ee h ?
Manufacturing Capabilit  Assessment
● Wha   he ca a  e e  f  he d c fac e  be?
● W  he ce  be c e  h FDA a da d ?
Timeline: Th  ce   de g ed  d ce 200  d e  f a  RNA acc e e  a
e d f h ee h .
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2.5 Objec i e Time Cha
Table 2.1. T e Cha  Sh g Ob ec e  C e

































Bac g d acc e a d
b g ca  e ea ch
P e a  ce
de g
RNA he  a d
f ca  ce
de g
LNP f a  ce
a d f ca
Ide f ca  f a
c  (QC) a a e e
Ec c a d
f ab  a a
F a  e  g
2.6 P og e  of P ojec
The e   a da d ce   a fac e RNA acc e  a d Pf e  a d M de a
eff  a e a  f he f  c e c a a  f a  RNA acc e. G e  h , h  a  
 ba ed  a g e a e ed a fac g ce  e h d g . Ra he , h  a  
he c a  f h gh f  dec  ba ed  de e de ece  f c e f c e ea ch a d
da a a d he e e e ce f he ad  c a . I  fac , he de a  f Pf e  a d M de a
ce e  a e e a  a d ha e  bee  e e ed  b hed  he b c. Th  e e ed
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a cha e ge ha  e ed c ea  a d a   he e  e e  de   f a e h
a .
Th  a  a  b  b  f  ha g a  e a ch g de a d g f he ce  
a e he acc e a d he  c c ca  d g a d e a a g a  ce e  
acc h each e . F  each e , d e e a c e a d ce  f e ea ch e e d ed 
de a d he a  e h d g e  a d he  a dec a  a e  a   h ch ce   
 h  a .
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3. Inno a ion Ma
F g e 3.1. I a  Ma
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4. Ma ke  and Com e i i e A e men
4.1 Ma ke  A e men
The b ea  f a e  c a  a d he e g g ba  a de c ha  c ea ed a
c ea ed d de de a d f  acc e . P  he a de c, he g ba  acc e a e  e
a  e  $40 b  (2019) a d  e ec ed  g  a  $60 b  b  202516. Th  a e
 a e a e  a  b e  f he a ge  g ba ha ace ca  a e  h e e a  a ead
e  $1   2019 a d  e ec ed  each $1.5  b  202517. A h gh acc e  a e a
a e  b e  f he ha ace ca  a e , he a e bec g c ea g  a   he
f gh   e d he COVID-19 a de c. Vacc e  a e a e e e  e e a  f  f e a de c
ha  a  cc .
A  e  d c ed, RNA acc e  a e a  e c g e  acc e ech g  ha
ca  be d ced e chea  ha  he  e  f acc e a d ca  be ed  a e acc e  f
a  d ffe e  e  f d ea e  h e e a  cha ge  he a fac g ce . The
f   RNA acc e   e e  he a e  e e RNA acc e  f  COVID-19 a d e e
a fac ed b  Pf e -B NTech a d M de a. B h Pf e  a d M de a  acc e ha  bee
a ed f  e e ge c  e b  a  eg a  age c e d de, a d b h acc e  e e
a ed f  e e ge c  e b  he FDA  Dece be 2020.
4.2 Com e i i e A e men
I  he U ed S a e , he e a e h ee a  acc e f  COVID-19 ha  a e c e  
he a e  a d  add a  acc e  de g g Pha e III c ca  a , he f a  ha e f
c ca  a  bef e a acc e ca  be   he a e 18. The e acc e  a e a ed 
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Tab e 4.1. Add a , he e f e acc e  a e e he  a h ed f  e  a e de g g
c ca  a   a  he  a  ac  he d.








A o al S a  in U.S.




2 E e ge c  e
a h a
mRNA-1273 M de aTX, I c. RNA
acc e




C a e  f
J h  & J h
V a  ec
acc e
1 E e ge c  e
a h a
AZD1222 A aZe eca V a  ec
acc e
2 N  a ed b  he
FDA;  Pha e III
c ca  a
NVX-CoV2373 N a a , I c. Rec b a
a a c e
acc e
2 N  a ed b  he
FDA;  Pha e III
c ca  a
RNA acc e  ha e e a  ad a age  e he  e  f acc e . The
RNA f d  RNA acc e   d ced  a e a e c ea  a e   ha  he RNA
he   d e a a ce -f ee eac ; he ce ed  d ce he RNA  efe ed  a
in vitro a c ,  IVT. U g he e  b che ca IVT eac   d ce RNA
a d  he a  ed  e  ha  d be ed f ce  e e ed  d ce he RNA.
The a  f d c  f  ce  ca  be e c ca ed e ec a  he  he de ed
d c  e e  ha ace ca -g ade . O he COVID-19 acc e e  c d g a
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ec  acc e  ch a  h e be g ade b  Ja e  a d A aZe eca a  e  a  he
ec b a  a a c e acc e be g d ced b N a a  e e ce  a  a  f he
a fac g ce e . The ce -f ee d c f RNA acc e  de  a  add a
ad a age  h  e f acc e  ha    e e e e a d e  e c g  d ce4.
F he e, he e  c e  c ce  ega d g he c c a  f SARS-C V-2 a . S e
f he e a  e cha ge   he c e f he e e  ch ha  he e e
ha  a h ghe  aff  f  he ACE2 ece ; h a  he   e e  ce  e ea ,
a g he a  e fec 20. I  a  be ece a  ede g  COVID-19 acc e   be
e effec e aga  e  SARS-C V-2 a a . L c , RNA acc e  a e e e 
ede g . The  e e e  ha  eed   be ad ed  he RNA e e ce,   he ca e f
COVID-19, he e e  e e ce. Th  ca  be d e b   de g g a e  DNA
e a e ha  ha  he de ed e e  e e ce ce he RNA  he ed f  a DNA
e a e  he IVT eac . O ce he e  DNA e a e ha  bee  de g ed a d d ced, a
he  e   he a fac g ce  e a  e ac he a e. Th   a a  ad a age f
RNA acc e ; h  a fac g ce  ca  be ed f  SARS-C V-2 a a  a  e  a  f
he  fec  d ea e .
Wh e he e a e a  ad a age  f RNA acc e , he a  d ad a age  he fac
ha  h  e f acc e  e a e  e . P  he a de c, RNA acc e  ha e e e
bee  d ced  a a ge ca e. Th , he e ha  bee ed e ea ch f c ed  d c g
RNA acc e   a ge a e . H e e , ce a c ea  ce  ha  bee  ed, RNA
acc e  ha e he e a   de g ea  be ef  a .
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5. C ome  Re i emen
The e a e h ee c e  g   c de   he de e e  f he COVID RNA
acc e: he g e e  h   cha g he acc e , he eg a  b d  h   a g
he acc e a d he a e  h  a e g he acc e. F  h  e , he e h ee g   be
c de ed h a US ce c a ach, c de g he US g e e  a d he FDA eg a
b d - he e c e a a e e c  ha   he c e  a d e  a cab e  he
c e .
G e  he c e  g ba  a de c, he COVID- RNA acc e  b ec   d ffe e
e e e  a d e  ha  ad a  acc e . P c a , he acc e  be b ec  
he e e e  e ab hed b  O e a  Wa  S eed a d  a  acce e a ed eg a  a a
ce . F he e,  d ffe e ce  he  ha ace ca d c , he acc e   be
cha ed b  he U ed S a e  g e e  a d ded f ee f cha ge  e g b e a .
Th  e  ha  he ce f he acc e  a c ce  f  he a e . F he e, 
d ffe e ce  he  d c  de e e  c c e , a ce c a e  a e  a a
a eh de  ce he c  f he acc e   be c e ed b  he g e e . G e  he e
f RNA acc e   he ea e  f he  c d ch a  a a a a d ca ce ,   c ca  
c e  e a a e he e e e  ha  d be a  a   h e d c  a .
5.1 Uni ed S a e  Go e nmen
The a  c a  e  b  he US g e e  a e he de e  e  a d afe . I  he
Dece be  23 d ag ee e  h Pf e , he US g e e c ed he eed f  a de e  f a
add a  100  d e  b  J  2021, a g he be  f a  d e  eeded  200
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 d e 21. The eed f  a c  a d ag e de e  f acc e   a a  c ce  ha
d e he c ea  f O e a  Wa  S eed  acce e a e he ad a  eg a  ce . A
a  f he de e , he US g e e   a c ce ed h he age f acc e . Th
c de  a  adhe e ce  he f g age h g e e e :22
- U a-C d F ee e : P   g, he acc e  be ed a  e e a e  be ee
-80C a d -60C.
- F ee e : P   g, f  a a  f  ee , he acc e  a  be ed a
e e a e  be ee  -25C a d -15C.
- Ref ge a : P   a g, f  a a  f 120 h  (5 da ), he acc e  a  be
ed a  e e a e  be ee  2C a d 8C.
I  add   he de e  e e e , he g e e  c ce ed h he afe  a d
eff cac  f he acc e. The  e e e   he a a  b  he FDA.
5.2 Food and D g Admini a ion (FDA)
The a  c a  e  b  he FDA  he afe a d effec e e  f he acc e. The
FDA  e  a  Ad  C ee a d h d a  FDA dec  e a d   e e  he da a
f  c ca  a  1/2/3. The a a  f he acc e  ba ed  he FDA c e  dec  a
 he he  he afe  a d effec e e  f he acc e e gh a c a ed 23.
I  add , he FDA  c ca  c ce ed h he de-effec  ha  c d e  f
he acc e. A h gh a  de-effec  a e a e e e , he  a e a a  c ce  
he FDA a a  ce .
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5.2 Pa ien  e i emen
The a  c a  e  b  he a e  h  be ece g he acc e a e he afe
a d a a ab  f he d c . Wh e f  he FDA he a ce f afe  e   he de h a d
a a  f he c ca  da a, f  he a e  he e gh   aced  he c ea  a d d ec
c ca  a eg  h h ch he  a e ade a a e f he afe  f he acc e.
I  e  f a a ab , a e  a e c ce ed h he ad a  f acc e  a d he
ca  f acc a  ce e . The e  a c ca e e e  f  a  a a ab  f d e e
ce e   ce e a  a  e e a  b e  ece e he acc e h ea e. H e e , h
 c ed b  he acc e age e e e .
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6. C i ical- o- ali  (CTQ) Va iable
N/A
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7. P od c  Conce
N/A
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8. S e io  P od c  Conce
N/A
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9. Com e i i e (Pa en ) Anal i
G e  RNA acc e  a e a e  ech g , he e   g e a e  f  he ce
 a e he e d  a da d . A  a  f h ,  g e c a  h d  he a e  f  he
a fac g ce .  I  g h  a fac g ce , a e  e e e e ed f
ec f c d d a  a  f he a fac g ce ch a  he f ca  f RNA g
Ta ge a  F  F a  de ce  a d he f a f he L d Na a c e  g a
M c f d c  ch .
The f  a e  c de ed  f  he f ca f RNA f  a In Vitro Transcription
g a TFF de ce. Th  a e  a  f ed h he I e a a  P b ca  N be  WO
2016/193206 A   201625. The a e  c de  he de a  f  f g RNA h gh a
a ge a  f  f a  de ce a d a h d a a e ch a g a h  e . I  a  gge , a
ed  h  ce , ha   a  he  ha  b ffe a  a e added  he TFF ce .
The ed f a  f LNP e  a a e  f ed  2016 f  he c
a fac g ce  f LNP . Th  a e   e he f a e a  f 3:1 f RNA 
d   e ha  h ch  he a  ed  he a fac g ce 27.
The he  a e  ha  e e c de ed a e he d a e  he d b  A b . I  fac ,
M de a  c e   a d e h A b  e A b  a e  gh  f he  de e
e 26. M de a had a c ac a  ag ee e  h A b   2016 he    he
c ac a  gh .
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10. P elimina  P oce  S n he i
The ce   he e RNA acc e   a e  de e e  f  h ch he e  
d  a da d, ha g  bee  de e ed b  M de a a d Pf e . I  c  f f  a
a  f  h ch he e  b a e e ea ch a d de e e . Pa  1  he a f ca  a d
e a a  f he a d f In Vitro T a c . Pa  2  he he  a d f ca  f
RNA. Pa  3  he f a  f LNP  e ca a f RNA. Pa  4  Q a  C  a d
Pac ag g.
Fig e 10.1. B c  D ag a  f  Ma fac g P ce
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10.1 P e a a ion of DNA em la e
The d f ed e e ge  RNA  d ced f  a a d DNA e a e h ch  g
E.Coli ce . A  d c ed  ec  2.2.2, he a d DNA  eed he ge e c f a
f  he a a ed eg  (UTR ), e  ead g f a e (ORF) c d g f  e (S) e  f
he SARS-C V-2 , a d  (A) a  (dec  d    d c ed a e   ec  10.2.3).
The a d DNA ca  be e a ed -h e  ced  a h d a  h ch 
he   he f ed DNA. If he a d  e a ed -h e, he a  a e a  eeded f
he ce  a e he Ge e f I e e  (GOI) a d he a d h ch a e cha ed f  e .
The GOI eed   c a  he de ed ge e c f a a d he e c  e  f  he
e c  e e  ha   be ed  c  he ge e. S a , he a d eed   c a  he
a e e c  e   ha  he a a e e c e e  ca  b d a d c  he a d a
he e ac  ca  a  h ch he GOI  be e ed. The a d  a  c a  a ge e f
a c  e a ce h ch  be ed  e  he he he E.Coli ce  ha e he a d e .
The f  e   h  ce   f  he GOI be a f ed h gh a PCR eac .
F g h ,   b ec ed  a e c  e e d ge  a   he a d. B h a  a e
ed  a ga  e  h DNA ga e  ge e a e he d f ed a d DNA. The e  e
 he a f a  a d a g f he a d E.Coli DH5-a ha ce . The ce  a e he
g   a  LB B h a d e a a ed h M e . I  de   de e e he he  he GOI a d
a d e e b h e  e ed, c e  f he a e  be e  f  ge e e e c g.
U  a da  f he c ec  GOI a d a d e , h e c e   he  be a f ed
a d a ed f  a ec d e. Th e c e  be g  E.Coli DH5-a ha ce  a d a
Ma e   he  be ed f  e a a  f he a d. I  e a a  f  he IVT eac , he
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a d  he  be ea ed g E d c ea e Re c  D ge . A ce f ga  e
 f   a e he a d.
I a , h  a fac g ce  acc ed f he ab e de a ed e   e a e he
DNA. The ad a age  f h  e e he a  e gh f he DNA e a a  ce  a d he
 c  f e a g he DNA -h e e  c g he d c . The d ad a age
e e ha  h  ce  e ed h g add a e e  a d added e  a d eac   he
ce . Th  c ca ed he a fac g ce h  add g g f ca  a e ce he
ce   e a e DNA  a da d ed ac  he d  a d ca  be afe  ced. A  a
e ,  a  ch e   ce he DNA ce  a h d- a  e d . I  h  a e , he
a fac g ce , e  a d e e  de a ed  h  ed e  e DNA a  a
a g a e a  a d he IVT eac  a  he f e   he ce .
A ca  h a B g c  B e  De e e  a  E ge ec a  he d ea  Ma ch 2021 
de a d he  ce   d ce DNA a d  ece e a e f  he ce. The f g
de a ed f a  a  a  ga he ed a  a  f he ca . E ge ec e  he d  a da d
f  he GMP Ma fac g P d c  f a d DNA f  RNA-IVT eac . The a
eed   be ded  he c a  f  he a d e e . The ce  a  h a
e ea ch ce  ba . E ge ec ha  1000  2000 L fe e  a  he  a a ab  a d e ec  a
e f  each de  ba ed  he e ed e d f he d c . The a fac g e e  a d
f e d  eg a  ec ed b  he FDA a d f a  a da d eg a . The fe e a
ce  e  DH108  DH5-a ha E.Coli ce  a d he fe e a  e d  a  f  400 g/L
 1200 g/L.
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F  h  ed ce , E ge ec  d ce he 144 g a  f a d DNA
eeded f  he IVT eac  ha  d ce 200  d e  f he acc e. A g a e d f
0.2 g a /L, he B e  De e e  ed g a 350 L fe e . The d c   be
d ced a  he  fac e   Be g  a d h ed  he U ed S a e   he a  ed 
h  e . The d c   f ec ab e g ade a a d chec ed f  de ,  a d afe .
Th gh  he ce  Q a  C   e ed h he e f e c  a g a d
e e c g a d e d  (LAL ) e .
The e ece ed f  he ce   1M e  h ch  1.2M d a . Th  c  
e a e   c a ed  he c  f e e  a d e e  he c  e ed f  he 
e e e a  a e a  e he Ca  A a g a d T7 RNA e a e. I  add  
c g he ce   f c  he a fac g ce   e  f g IVT, he e a e
e e e c  a  a g c e a  dec d g  ce DNA.
10.2 mRNA S n he i  and P ifica ion
10.2.1 Selec ion of mRNA Se ence
The e (S) e   SARS-C V-2 a  a  e e a e  a g he  
e e  ce . The b d g f he e e   he ACE2 ece   ce   ha  a e  he
ce  ha  a  he   e e  ce . Th , he e e  a  ch e  b  e ea che  
be he e  f e e  ha  d be e c ded b RNA  he RNA acc e. The ec f c
eg  f he e e  ha   e b e f b d g  ACE2  he ece -b d g
d a  (RBD) h ch  f d  he N- e a  f c ea age f ag e  (S1 d a )28. Th
a e  he e  f he he    a  RNA acc e ha  e c de   he RBD d be
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effec e. Pf e  a d B NTech e ed RNA acc e  ha  e c ded b h he RBD a d he
f - e g h e e ; he e  a e ed he  c a e   ch e he ca d da e
acc e ha  e c ded he f - e g h e e 28. Th  dec  a  d e  he d ffe e ce  
e e e  a d e ab  be ee  he acc e . Ea  c ca  a  e ea ed be e
e ab  f he RNA acc e e c d g he f - e g h e e . Add a , he
RNA acc e e c d g he f - e g h e e ed  T ce  e e  aga  he RBD a
e  a  he  eg  f he e e  ha  e e  c ded  he RBD-  acc e
ca d da e29. The e  f he e e a  c ca d e  d e b  Pf e  a d B NTech e e
he a  ea  RNA e c d g he f - e g h e e  a  ch e  f  he acc e.
10.2.2 5  Ca  Addi ion
A  e  d c ed, he 5  ca   he 5  e d f RNA  h gh  a  f  he
a  f a a  f he de ed e ; f  h  ec , ha  e   he e (S) e
f he SARS-C V-2 . If RNA  d ced g in vitro a c , he e a e  a
 h ch he 5  ca  ca  be added  he RNA. The 5  ca  ca  e he  be added
c - a c a   - a c a  g ca g e e . The e a e ad a age  a d
d ad a age   b h e h d , a d a e , c - a c a ca g a  de e ed  be a
be e  f  f  h  ec .
C - a c a  ca g cc  d g he in vitro a c  ce . A ca  a a g
 added  he in vitro a c  eac  a d  be c a ed a  he 5  e d f he RNA
d g he eac . Th  e h d f add g he 5 ca   e a e  e a d d e   e e
add g a he  e   he e a  ce . O e c ce h c - a c a  ca g  he
37
ca g eff c e c ;  a  f he RNA d ced  ha e a ca . S e ca  a a g  ha e e
eff c e c e  ch a  a - e e e-Ca -a a g (ARCA) h ch ha  a ca g eff c e c  be ee
60-80%4. H e e , e e  ca  a a g  ch a  C ea Ca  ca  ach e e ca g eff c e c e
be ee  90-99%, a g c - a c a  ca g a e ab e 4. Add a , e e
d ge  af e  a in vitro a c  eac ca  be ed  deg ade ca ed RNA.
A he  d ad a age a c a ed h c - a c a ca g  ha  ca  a a g  ca  be e
c 30. N e he e , c - a c a  ca g a e  e, a d h   e  a  f a
acc e eed   be d ced c   a a de c a . The eff c e c  f
c - a c a  ca g  a e  h  h e h d a  ch e  f  he ce .
E a c ca g cc af e a in vitro a c eac a d h add e
he e a ce . Wh e he e - a c a e a c eac a e a chea e
a e a e, h e h d e eff c e . Th d c ce de g ed d ce a
RNA acc e a e a e f a a de c, a d h , eff c e c a .
C - a c a ca g a de e ed be he be f eff c e c e . The
ca g e h d  a e h   F g e 10.2.
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Fig e 10.2. Me h d  f 5  ca  add 9.
10.2.3 Pol  (A) Tail Addi ion
The  (A) a   ca ed  he 3  e d f he RNA, a d  g a  he e d f
a a . The e a e  a  a  he  (A) a  ca  be c a ed in vitro
a c bed RNA. The  (A) a  ca  be c a ed  he DNA e a e e e ce, a d
h  he  (A) a   be c a ed  he RNA b  T7 RNA e a e d g in vitro
a c . Th  e h d f  (A) a  add a  f  ec e c  e  he e g h f
he  (A) a  h ch  a  ce he e g h f he  (A) a  ca  ha e a  effec   he
eff c e c  f a a  f he e e 9. Th e h d a  a  f  he  (A) a   be
added c - a c a  a d d e   e e add a e  af e  a c 9. The
eff c e c  a c a ed h c a g he (A) a   he DNA e a e de g  
a e  h  h  e h d a  ch e  f  h  ce .
A  a e a e e h d f   (A) a  add e  add g he a
- a c a  h gh a  e a c eac . Th  e a c ade a  f in vitro
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a c bed RNA e  he e e  (A) e a e. Th  ce   e ea  a d e,
b  e d ad a age  ha   add  a  e a e  he e a  ce . A he  c ce
a c a ed h h  e h d f  (A) a  add  ha  he e  fa  e  c  e  he
e g  (A) a  e g h9. Th   a e d ad a age a  a f   (A) a  e g h 
eeded; he  (A) a  ca  affec  he a a eff c e c  f RNA. Th , d e  he
eff c e c  a d e g h c  a c a ed h c a g he  (A) a   he DNA
e a e de g , h  e h d a  ch e  f  h  ce .
10.2.4 Selec ion of In Vitro T an c i ion Reac o T e
The in vitro a c  (IVT) eac   a ba ch ce  a d h  e e  a ba ch
eac . The e e e d ffe e   c de ed f he eac  e. A a e  ee  ba ch
eac  a  a  c de ed; he a e a  d ab e a d    a d  h  ab e f
ha ace ca  a ca . H e e , h  eac  ha e  be c ea ed a d e ed be ee
ba che  h ch  ed  a d add  add a  c a d ab . Af e  d c  h d a
c a ,  a  de e ed ha  a WAVE B eac e  d be be  f  h  ce .
The WAVE B eac  e  c  f a c e  h ch d ab e a c b eac  bag
a e aced. Th  a  dea  f   ce  d e he fac  ha  af e  each IVT eac , he eac
bag  d ca ded a d a e , e e bag ca  be ed f  he e  . The WAVE B eac
e  ca  ha d e g e  ha  f  he e e e f  IVT eac , a d he e
e  a e e e a e c ed h ch  a a  he IVT eac   cc  a  37℃.
Th , a WAVE B eac  e  a  ch e  f  h ce . A  age f a WAVE B eac
e  ca  be f d  F g e 10.3.
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Fig e 10.3. WAVE B eac  e 31,32.
10.2.5 Rec cle of T7 RNA Pol me a e
Phage T7 RNA P e a e  be ed  he IVT eac a  he e e  a e
RNA f  DNA. A  a  f h  a fac g ce ,  a  c de ed he he  he T7
RNA e a e h d be ec c ed af e  each ee h ba ch d c  f RNA. The
ad a age f h  d be he dec ea ed c  f eed g  cha e e  T7 RNA e a e.
Th  d be a c a  c  ad a age  ce T7 RNA e a e  he e he 
e e e a  a e a  (a   be de a ed  Tab e 11.1). I  fac , T7 RNA e a e acc
f  e  40% f he a  a  a e a  c .
De e he c  ad a age ,  a  ch e   ec c e T7 RNA e a e g e  he
e e  ha f- fe a d ac a . The ha f- fe f T7 RNA e a e d ca ed  e a e
e e  a e  b  a  c c de  a a e  he de  f h . A  a c e b hed 
B ech g  B e g ee g J a   2001 e e c de g a d a  
a a e he a a e e  f T7 RNA e a e. Th a c e c e  he ha f- fe f T7 RNA
e a e a  50 e 33. A he  a c e b hed b  Na e  1999 c e  he ha f- fe f T7
RNA e a e a  24 h  a  de e ed b  e e e h ch ea e he e e  ac
a  a f c  f e af e  ea e 34.  F g ca  h e e  ad g c a ,  a
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e a ed he ha f- fe f T7 RNA e a e  a  IVT eac   a d 5 h . G e  he
 ha f- fe, he T7 RNA e a e ca  be ec c ed. Each IVT eac  a e  5 h  
he T7 RNA e a e   be ac e f  e ba ch  h f RNA d c .
10.2.6 mRNA P ifica ion Me hod Selec ion
D ffe e   e e c de ed  f e   eage f  he IVT eac  a  e  a
 acc h b ffe  e cha ge  a e   he ce . F  he e e , a ge a  f  f a
(TFF)  d a  c d be ed. TFF a  e ec ed  f e   IVT eage  a  e f he
eage  a e a ge  e . H e e , f  he b ffe e cha ge e , b h TFF a d d a  e e
c de ed. TFF a  ch e  f  b h b ffe  e cha ge e  a ge  beca e d a  e e
e  a ge a  f b ffe  a d ca  a e a e  g e d e  he fac  ha  he d g f ce
f he b ffe  e cha ge   d ff 35. Add a , TFF a  f  a e c ce a
h ch ca  be ach e ed h d a , a d e f he b ffe  e cha ge e    ce  a
e e  a e c ce a .
D g he in vitro a c  eac  ed ge e a e he g e- a ded RNA ha
 be ed  he acc e, a  de ed de- d c  ge e a ed. Th  de ed d c  
d b e- a ded RNA  d RNA. d RNA ca  ca e de ed e e e  ha  a e
ead  g ea  ed ced a a  f RNA4. Th , d RNA  be e ed f g he in
vitro a c  eac . d RNA e a  ca  be ach e ed g a ch a g a h  e , a d
he e a e  a  ch a g a h   ha  e e c de ed f  h  ce .
I - a ed e e e ha e h gh e f a ce d ch a g a h  (HPLC) a
c de ed f  he e a  f d RNA. HPLC ca  eff c e e e d RNA, b  he e a e e
e  h HPLC ha  a e   a ab e f  h  ec . The e e  eeded  e
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c  a d ca  be ca ed   a c -effec e a , he ace e eeded f  h  e  
e e e  c, he f ca  e  e g, a d he e   ab  50% RNA ec e
ach e ed4.
The ch a g a h  e h d ch e  e e  a  f he e  a c a ed h HPLC
f ca  f in vitro a c bed RNA. The e h d ch e   a ce e-ba ed fa  e
d ch a g a h  (FPLC). Th  ce  e  e ec e b d g f d RNA  ce e  a
e ha -ba ed b ffe ; he d RNA  e a  b d  he ce e a d he de ed d c ,
g e- a ded RNA,  f  h gh he c 4. Th  e h d ca  e e e  95% f
d RNA e e   a 36. Ce e ch a g a h e e  a fa e , chea e , a d e
c ce  f  he e a  f d RNA, a d h  a e  h  h  ch a g a h  e h d
a  ch e 4.
10.3 Li id Nano a icle S n he i  and P ifica ion
A  e  e ed, d a a c e  a e ed  de e  he RNA  a
d d a  ce . The e a e d ffe e  e h d  f he g he e d a a c e , b
c f d c ch  de ce  e e ch e  a  he  e e he be  f  f  h  ec . A ef ed
e c e e h d ca  be ed  d ce LNP  c a g RNA. The ef ed e c e e h d
e  f  d g he d   e ha  a d he  h d a g he d  b  g h a
a e  b ffe . The d  a e he  e ded h gh f e   ach e e a de ed e. The  RNA
 a  a e  b ffe  h e ha   added a  a ec f c f  a e h g; h  e  ef
f  e e  a  f  he RNA  be e ca a ed b  he LNP 37. The ef ed e c e
e h d a   ch e  a  h  e h d  e ed a d e c g c a ed h
c f d c g de ce .
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M c f d c ch  de ce  e e a he  de g   ha  a  c de ed, a d h  
a  a e  ch e . M c f d c g de ce f  he ce  f a g LNP  he
c a ed h he ef ed e c e e h d. The e agge ed he gb e c f d c (SHM)
g de ce  a  f  he f a  f LNP  a ec d e ca e. The e de ce  ha e
 e  ea  ha  ee  a d g  h gh a g cha e  he e he LNP  a e f ed
c a g he e ca a ed RNA38. The g e e ea  h  c a  he RNA
e ca a ed b  he LNP . The c  f h  ce a  a a  ea  h   a  ch e ,
a d he fac  ha  h  ce  ca  be ca ed b  a a e g a  ch   a  a  ad a age.
F g e 10.4 h  b h he ef ed e c e e h d a d he c f d c g e h d.
Fig e 10.4. D ffe e  e h d  f a a c e he .39
11. A embl  of Da aba e
O e a g c d  e e ba ed  e g RNA a fac g g de e . Safe  a d
ha d g f a e a  e e ba ed  a a ab e Ma e a Safe  Da a Shee  h ch a e ca ed 
44
A e d  I. E e  a d a e a  c  e e e a ed g e g ech g ca
e  a d d c .
11.1 Co  of Ra  Ma e ial
Tab e 12.1 a e  he a  a  a e a eeded f  h  ce  h he
e ec e ce  e  g a  (g). N e ha  he e ce a e ef ec e f b g each a e a  
b  a d a e he ef e e  ha  b g  a a a  ba . B  P ce  e e b a ed
d ec  f  c ac g a  e d  a d/  h he he  f he C a  a d D .
D a d.
Table 11.1. P ce  f Ra  Ma e a  Needed f  P a O e a
Ma e ial Name Co
($USD/g am)
Pla mid DNA $6,944.44
T7 RNA Pol me a e $1,128,000
Adeno ine 5'-T i ho ha e N cleo ide (ATP) $19.31
G ano ine-5'-T i ho ha e N cleo ide (GTP) $18.69
C idine T i ho ha e N cleo ide (CTP) $19.93
U idine-5 -T i ho ha e N cleo ide (UTP) $127.58
RNA Ca  Analog $9,267
T i  H d ochlo ide $0.32
Magne i m Chlo ide $0.27
1,4-Di hio h ei ol $9.46
S e midine $11.58
T i on X-100 $0.033
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DNa e I $114,000
Alkaline Pho ha a e $113,000
Cell lo e $0.025
HEPES $0.15
E h lenediamine e aace ic acid (EDTA) $0.197
Sodi m Chlo ide (NaCl) $0.0028
E hanol $0.026
Sodi m Ace a e $0.091
ALC-0315
((4-h d o b l)a anedi l)bi (he ane-6,1-di l)bi (2-he ldecanoa e)
$1,730
ALC-0159 (2-[( ol e h lene gl col)-2000]-N,N-di e adec lace amide) $158.21
DSPC (1,2-di ea o l- n-gl ce o-3- ho hocholine) $150
Chole e ol $0.96
PBS $1.35
S c o e $0.0081
Sodi m h d o ide $1.09
The ce e  g a  f T  H d ch de, Mag e Ch de, 1,4-D h h e ,
S e d e, T  X-100, DNa e I, A a e Ph ha a e, Ce e, HEPES, EDTA, NaC ,
E ha , a d S d  Ace a e a  b a ed f  he e d  S g a A d ch. The ce e  g a
f each c e de (ATP, GTP, CTP, a d UTP) a d S d H d de a  b a ed f  he
e d  The  F he  Sc e f c. The ce e  g a f T7 RNA P e a e a  b a ed f
Ne  E g a d B Lab  a d he ce e  g a  f he Ca  A a g a  b a ed f  T L
B ech g e . I  add , he ce e  g a  f c g he d c  f a d DNA
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a  b a ed f  he e d  E ge ec. The ce e  g a  f he d  DSPC a d
Ch e e  a  b a ed f  M e S g a. La , he ce e  g a  f he  a
d  ALC-0315 a d ALC-0159 a  b a ed f  he e d  A a  P a  L d .
11.3 T an c i ional Ac i i  of T7 RNA Pol me a e
L e a e a  ed  de e e he a e f a c g he e e T7 RNA









he e s n(d)  he a e f he  f RNA  g a e  e  e  e, vma  he a
a c  a e, KTS  he DNA c ce a  f he ha f- a a  a c  a e, a d d
he c ce a  f DNA. Th  e a  acc  f he a e f RNA he   he a e
f RNA e a e deg ada . F  e a e a  de e ed ha vma e a  10.4 M/
a d KTS e a 4.4 M f  T7 RNA P e a e. I  a fac g ce , he c ce a
f DNA (d) h  he IVT eac  a  de e ed be 21.5 M 40. U g he e a  ab e
a d he ec f ed ce  a ab e , he a e f T7 RNA P e a e a c , s n(d), a
ca c a ed  be 1.07E-05 g a  e  e  e  f   ce . I  he  d , he a e f
he  f RNA cc ed a  a a e f 1.07E-05 g L-1 -1.
11.5 Pha macokine ic /Chemical P o e ie  of Li id
The L d Na Pa c e , h ch e ca a e he RNA a d, a e ade f  f
d ffe e  e  f d . Th , he acc e c a f  d , f h ch  a e ed 
47
a ed ed c a  d c  -- ch e e  a d 1,2-d ea - -g ce -3- h h ch e,
he eaf e  e ed DSPC. A d he e a g  a e c de ed e  a  he  ha e  bee  ed
 a  a h ed ed c a  d c : ALC-0315
((4-h d b )a a ed )b (he a e-6,1-d )b (2-he deca a e)) a d ALC-0159
(2-[( e h e e g c )-2000]-N,N-d e adec ace a de). D e  he e  f ALC-0315
a d ALC-0159, ed f a  ega d g he e d  a e a a ab e. Tab e 11.2 a e
he f  d  eeded f  h  ce  h he e e a  Pha ac e c e e 41 42.
Table 11.2. Pha ac e c  f L d  Needed f P a  O e a 43.
Li id Name Chemical Fo m la Mola  Ma  (g am /mole) Ka
ALC-0315 C48H95NO5 766.29 6.09
ALC-0159 (C2H4O) C31H63NO2 2,000 6.94
Chole e ol C27H46O 386.65 7.01
DSPC C44H88NO8P 790.10 5.92
A  ee   F g e 11.1, ALC-0315  a ca c d c a g a e a  a e a d 
e e  e e , ((4- h d b )a a ed )b (he a e-6,1-d )b (2-he deca a e). I
add , ALC-0315 ha  a KA f 6.09. W h  he LNP , ALC-0315 he  eg a e he
e d a  e ea e f he RNA. Th  cc  beca e he d c  f he e ha c d
e c a g ALC-0315  a  RNA  a a ec f c H  e   a  e ec a c
e ac  be ee  he ega e  cha ged RNA bac b e a d he e  cha ged ca c
d. Th  e ec a c e ac  e   he e ca a  f he RNA a a c e f a
41 42.
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Fig e 11.1. ALC-0315 L d S c e41
The he  e  e c e , ALC-0159  a PEG a ed L d a  efe ed  a  2
[( e h e e g c )-2000]-N,Nd e adec ace a de, a  ee   F g e 11.2.  ALC-0159 ha  a
KA f 6.94. The PEG a ed d ALC-1059  e b e f  f g a ec e h d h c
a e  ha  e ca  ab e  he LNP. Th  a e c b e   age ab  a d ed ce
ec f c b d g  e 41 42.
Fig e 11.2. ALC-0159 L d S c e41
Ch e e   a c a  d  a  h   F g e 11.3. The d ha  a Ka f 7.01.
Ch e e '  a  f c     b a e c e   he LNP a d a   de
b  f he d c e  h  he LNP c e 41 42.
49
Fig e 11.3. Ch e e  L d S c e41
The f a  d h  he LNP c e  DSCP a d  c e  ded  F g e
11.4. Th  d  a  efe ed  a  1,2-D ea - -g ce -3- h h ch e a d   a  a
h ha d ch e h ea  ( c adeca ) ac g  ha   de ed f  a
c adeca c ac d. The Ka f DSCP  5.92. DSCP a h h d c e  ha  de  a
ab e b a e -f g c e  ba a ce he -b a e e  f  he ca c d 41 42.
Fig e 11.4. DSCP L d S c e41
11.5 De ailed Ma  of he mRNA S and U ed In he Vaccine
A  a ed e , he e e  f SARS-C V-2 a  a e  e  he ece
ec g  a d ce  e b a e f  ce . The ef e, he RNA a d ed  he RNA
acc e e c de  f  he f - e g h e e . We c ea ed a de a ed a  f h  f - e g h
e e  g he f a e S a Ge e, h  F g e 11.5.
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Fig e 11.5. Ma  f F -Le g h S e P e  ed  RNA Vacc e
The e g h f he f - e g h e  1,237 a ac d . A  h   F g e 11.5, he
S e e  c e  b h he S1 b  (14 685 e d e ), a d he S2 b  (686 1273
e d e ). The S1 b   e b e f  b d g  he h  ce  h e he S2 b  ed a e
a  ce  e b a e f . W h  he S1 b he e  a  N- e a  d a , abe ed NTD,
(14-205 e d e ) a d a ece -b d g d a , abe ed RBD, (319-541 e d e ). The
ece -b d g d a  h  he S1 b  ec g e a d b d   he h  ece . W h
he S2 b  he e  he f  e de, abe ed FP, (788 806 e d e ), he a e de e ea
e e ce 1, abe ed HR1, (912 984 e d e ), HR2 (1163 1213 e d e ), TM d a
(1213 1237 e d e ), a d c a  d a  (1237 1273 e d e ). A  c e  h  he
S2 b  a  a e  e  a  f  a d e  h  ce 44.
12. P oce  Flo  Shee  Diag am (PFD) and Ma e ial Balance
O e a  a d de a ed ce  f  d ag a  f  ed RNA a fac g
ce  a e de a ed  h  ec . Add a  de a d g he ch ce f e e ,
de g  ec f ca , a d c  ca  be f d  ec 13, 15, 16, a d 17 f h  e .
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12.1 O e all P oce
The ce  f  d ag a  f  he e e a fac g ce  f he RNA acc e 
de a ed  F g e 12.1. The ce  beg  h d c f RNA g -
a c . The RNA  he  f ed g f a e . M c f d c  de ce  a e he
ed  e e ha  he RNA ge  e ca a ed b d a a c e . Th  LNP-RNA d c
 he  f ed a d d ed g a b ffe   a e he f a  RNA acc e d c . F a , he
RNA acc e g e  h gh a ac ag g ce . The f a  f a   he  h ed 
a ed acc e d b  ce e . Tab e 12.1 a d Tab e 12.2 de a  a  ce   a d
age a  h   F g e 12.1 a d he  a de g  ec f ca .
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Fig e 12.1. O e a  P ce  F  D ag a  f  RNA Ma fac g P ce
Table 12.1. P ce  U  S ec f ca  Shee
E i men  ID E i men  Name P e e Tem e a e
PU 1 IVT Wa e B eac 1 a 37℃
PU 2 Ta ge a  F
F a  De ce 1
1 a 4℃
PU 3 Ce e
Ch a g a h
C
1 a 4℃
PU 4 Ta ge a  F
FI a  De ce 2
1 a 4℃
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PU 5 S e e F e  1 1 a 4℃
PU 6 M c f d c  De ce 1 a 4℃
PU 7 Ta ge a  F
FI a  De ce 3
1 a 4℃
PU 8 S e e F e  2 1 a 4℃
Table 12.2. S age Ta  S ec f ca  Shee
S o age ID S o age Tank Name P e e Tem e a e
STOR 1 T  B ffe  S age 1 a 4℃
STOR 2 IVT P d c  S age 1 a 4℃
STOR 3 TFF1 Wa e S age 1 a 4℃
STOR 4 TFF 1 Re e a e
S age
1 a 4℃
STOR 5 Ch a g a h
B ffe  S age Ta
1 a 4℃
STOR 6 Ce e Re
S age Ta
1 a 4℃
STOR 7 E ed d RNA Wa e
Ta
1 a 4℃
STOR 8 Rec e ed P d c
f
Ch a g a h
C  S age Ta
1 a 4℃
STOR 9 S d  Ace a e
B ffe  S age Ta
1 a 4℃
STOR 10 TTF 2 Pe ea e
Wa e S age Ta
1 a 4℃




STOR 12 D  1 a  f
RNA
1 a 4℃
STOR 13 E ha  S age Ta 1 a 4℃
STOR 14 L d  a d E ha
S  S age
Ta
1 a 4℃
STOR 15 M c f d c  d c
age a
1 a 4℃
STOR 16 1X PBS S age 1 a 4℃
STOR 17 TT3 Pe ea e Wa e
S age Ta
1 a 4℃
STOR 18 TFF 3 Re e a e
S age
1 a 4℃
STOR 19 D  2 S age
Ta
1 a 4℃
STOR 20 PBS a d S c e




12.2 S n he i  and P ifica ion of mRNA
A de a ed ce  f  d ag a  f  he he  a d f ca  f RNA ca  be f d 
F g e 12.2. I  add , a ea  ec f ca  hee a d a  ba a ce  f  h  a  f he
a fac g ce  ca  be f d be .
Fig e 12.2. P ce  F  D ag a : S he  a d P f ca f RNA
Table 12.3. S ea  S ec f ca  Shee : S he a d P f ca  f RNA
S eam
ID
S eam De c i ion P e e Tem e a e
S-100 Ra  a e a   IVT Reac : NTP, DNA, T7
RNA e a e
A  5 h : DNA e, Ph ha a e
1 a 4℃
S-101 T  b ffe  fed  IVT eac 1 a 4℃
S-102 IVT d c   age a 1 a 37℃
S-103 IVT d c  f  age a   TFF 1 1 a 4℃
S-104 Wa e  ed a  b ffe   TFF 1 1 a 4℃
S-105 Pe ea e f  TFF 1  a e a 1 a 4℃
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S-106 Re e a e f  TFF 1  age a 1 a 4℃
S-107 Ch a g a h  b ffe  fed  age a  h
RNA  d e RNA
1 a 4℃
S-108 Ch a g a h  b ffe  fed  ce e age a
 a e he ch a g a h  e
1 a 4℃
S-109 Ce e fed  ce e e  age a 1 a 4℃
S-110 Re  fed  ch a g a h  c 1 a 4℃
S-111 B ffe   a h c 1 a 4℃
S-112 Re e a e f  TFF 1 a d ch a g a h  b ffe
fed  ch a g a h  c
1 a 4℃
S-113 Wa e  ed  e e d RNA b d  c 1 a 4℃
S-114 E ed d RNA fed  a e age a 1 a 4℃
S-115 Rec e ed d c  ( RNA) fed  age a 1 a 4℃
S-116 S d  Ace a e B ffe  added  TFF 2 1 a 4℃
S-117 P d c  f  ch a g a h  c  fed f
age a   TFF 2
1 a 4℃
S-118 Pe ea e f  TFF 2  a e a 1 a 4℃
S-119 Re a e f  TFF 2  age a 1 a 4℃
S-120 P d c  f  TFF 2 fed  e e f e  1 1 a 4℃
S-121 P d c  f  e e f e  1 fed  age a f
RNA d  bef e M c f d c
1 a 4℃
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Table 12.4 (a) (b) (c) (d). Ma e a  Ba a ce: S he a d P f ca  f RNA
(a)
S eam ID S-100 S-101 S-102 S-103 S-104 S-105 S-106
Ma  (g) 35,780.57 402.56 36,182.61 36,182.61 1,103,223 1,105,631.18 33,741.21
Com onen  Ma e ial Balance (g)
T i
H d ochlo ide 0 402.56 402.56 402.56 0 402.56 0
Magne i m
Chlo ide
40.38 0 40.38 40.38 0 40.38 0
1,4-Di hio h ei
ol (DTT)
170.87 0 170.87 170.87 0 170.87 0
S e midine 32.18 0 32.18 32.18 0 32.18 0
0.01% ( / )
T i on X-100
11.85 0 11.85 11.85 0 11.85 0
ATP 280.91 0 109.29 109.29 0 109.29 0
GTP 289.77 0 189.43 189.43 0 189.43 0
CTP 267.62 0 162.53 162.53 0 162.53 0
UTP 268.17 0 91.39 91.39 0 91.39 0
Ca  Analog
(Clean Ca ) 11.08 0 1158.59 1158.59 0 1158.59 0
mRNA 0 0 520.62 520.62 0 10.41 510.21
DNA
Tem la e 11.08 0 11.08 11.08 0 11.08 0
T7 RNA
Pol me a e 1,159.10 0 11.08 11.08 0 11.08 0
DNa e I 6.33 0 6.32 6.32 0 6.32 0
Pho ha a e 0.22 0 0.22 0.22 0 0.22 0
Addi ional
WFI 33,231 0 33,231 33,231 1,103,223 1,103,223 33,231
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(b)
S eam ID S-107 S-108 S-109 S-110 S-111 S-112
Ma  (g) 207,116.73 15,158,953.04 275,000 15,433,953.04 9,695,369.88 9,902,996.82
Com onen  Ma e ial Balance (g)
HEPES 38,786.23 3,669,838.48 0 3,669,838.48 2,347,156.92 2,385,943.15
EDTA 475.65 45,004.96 0 45,004.96 28,784.29 29,259.95
NaCl 118,897.19 11,249,700.00 0 11,249,700.00 7,195,088.09 7,313,985.28
E hanol 2,054.70 194,409.60 0 194,409.60 124,340.58 126,395.28
Wa e -Fo -Injec ion 46,902.96 0 0 0 46,902.96 46,902.96
d RNA 0 0 0 0 0 5.10
mRNA 0 0 0 0 0 505.10
Cell lo e 0 0 275,000 275,000 0 0
(c)
S eam ID S-113 S-114 S-115 S-116 S-117 S-118
Ma  (g) 987,839.79 987,844.90 9,902,991.97 5,179 9,902,991.97 9,860,255.297
Com onen  Ma e ial Balance
HEPES 0 0 2,385,943.15 0 2,385,943.15 2,385,943.15
EDTA 0 0 29,259.95 0 29,259.95 29,259.95
NaCl 0 0 7,313,985.28 0 7,313,985.28 7,313,985.28
E hanol 0 0 126,395.28 0 126,395.28 126,395.28
Wa e -Fo -Injec ion 987,839.79 987,839.79 46902.96 0 46,902.96 0
d RNA 0 5.10 0.26 0 0.26 0
mRNA 0 0 505.10 0 505.10 10.10
Cell lo e 0 0 0 0 0 0
50 mM Sodi m
Ace a e
0 0 0 5,179 0 4,661.54
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(d)
S eam ID S-119 S-120
Ma  (g) 47,915.91 47,915.91




E hanol 0 0
Wa e -Fo -Injec ion 46,902.96 46,902.96
d RNA 0 0
mRNA 495.00 495.00
Cell lo e 0 0
50 mM Sodi m Ace a e
517.95 517.95
12.3 Fo m la ion of Li id NanoPa icle -Enca la ion of mRNA
A de a ed ce  f  d ag a  f  he f a f LNP  ca  be f d  F g e 12.3. I
add , a ea  ec f ca  hee  a d a  ba a ce f  h  a  f he ce  ca  be f d
be .
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Fig e 12.3 P ce  F  D ag a : F a  f LNP E ca a  f RNA
Table 12.5. S ea  S ec f ca  Shee : F a f LNP  E ca a  f RNA
S eam
ID
S eam De c i ion P e e Tem e a e
S-121 S e e d c  fed  a  f  e a a  f
M c f d c
1 a 4℃
S-122 E ha   fed  a  f  e a a  h
d
1 a 4℃
S-123 L d  fed  a  f  e a a  h e ha 1 a 4℃
S-124 S d  ace a e f  age  d  h RNA 1 a 4℃
S-125 S  f d   e ha  fed  M c f d c 1 a 4℃
S-126 RNA d ed  d  ace a e fed 
M c f d c
1 a 4℃
S-127 LNP d c  f  M c f d c  fed  age a 1 a 4℃
S-128 LNP f  age a  fed  TFF 3 1 a 4℃
S-129 1X PBS  fed f  age a   TFF 3 1 a 4℃
S-130 Pe ea e fed f  TFF 3  a e age a 1 a 4℃
S-131 Re e a e f  TFF 3 fed  e e a e age a 1 a 4℃
S-132 Re e a e fed  e e f e  2 1 a 4℃
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S-133 P d c  f  e e f e  fed  f a  d 1 a 4℃
S-134 PBS a d c e  fed  f a  d 1 a 4℃
S-135 P d c  f  f a  d 1 a 4℃
Table 12.6 (a) (b) (c). Ma e a  Ba a ce: F a f LNP  E ca a  f RNA
(a)
S eam ID S-121 S-122 S-123 S-124 S-125 S-126
Vol me ic Flo
(mL/min)
- - - - 3 9
Ma  (g) 47,915.90 973,440.30 14,215.38 14,663.70 987,655.69 62,579.61
Com onen  Ma e ial Balance (g)
mRNA 495.00 0 0 0 0 495.00
Sodi m Ace a e 517.95 0 0 14,663.70 0 15,181.65
Addi ional WFI 46,902.96 0 0 0 0 46,902.96
ALC-0315 0 0 7,938.46 0 7,938.46 0
ALC-0159 0 0 923.08 0 923.08 0
DSPC 0 0 1,661.54 0 1,661.54 0
Chole e ol 0 0 3,692.31 0 3,692.31 0
E hanol 0 973,440.30 0 0 973,440.30 0
1X PBS 0 0 0 0 0 0
S c o e 0 0 0 0 0 0
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(b)
S eam ID S-127 S-128 S-129 S-130 S-131 S-132
Vol me ic Flo
(mL/min)
12 - - - - -
Ma  (g) 1,050,235.30 1,050,235.30 333,574.81 1,365,505.55 18,304.56 18,304.56
Com onen  Ma e ial Balance (g)
mRNA 495.00 495.00 0 9.90 485.10 485.10
Sodi m Ace a e 15,181.65 15,181.65 0 15,181.65 0 0
Addi ional WFI 46,902.96 46,902.96 0 46,902.96 0 0
ALC-0315 7,938.46 7,938.46 0 158.77 7,779.69 7,779.69
ALC-0159 923.08 923.08 0 18.46 904.61 904.61
DSPC 1,661.54 1,661.54 0 33.23 1,628.31 1,628.31
Chole e ol 3,692.31 3,692.31 0 73.85 3,618.46 3,618.46
E hanol 973,440.30 973,440.30 0 973,440.30 0 0
1X PBS 0 0 333,574.81 329,686.43 3,888.38 3,888.38
S c o e 0 0 0 0 0 0
(c)
S eam ID S-133 S-134 S-135
Vol me ic Flo  (mL/min) - - -
Ma  (g) 18,304.56 92,307.69 110,612.25
Com onen  Ma e ial Balance (g)
mRNA 485.10 0 485.10
Sodi m Ace a e 0 0 0
Addi ional WFI 0 0 0
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ALC-0315 7,779.69 0 7,779.69
ALC-0159 904.61 0 904.61
DSPC 1,628.31 0 1,628.31
Chole e ol 3,618.46 0 3,618.46
E hanol 0 0 0
1X PBS 3,888.38 6,923.08 6,923.08
S c o e 0 89,273.00 89,273.00
12.4 Packing
Fig e 12.4 P ce  F  D ag a : Pac ag g RNA acc e
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13. P oce  De c i ion
13.1 P e a a ion of DNA
A  d c ed  he P e a  P ce  S he ec , he d c  f he DNA
 be ced  a h d a . The ed ce  f  he d c  f RNA acc e
 a  h he d f ed DNA fed  he In Vitro Transcription eac  f  he he  f
RNA.
13.2 S n he i  and P ifica ion of mRNA
13.2.1 S n he i  of mRNA: In Vitro T an c i ion
The he  f RNA  be d e  a ce -f ee a e  h gh a ce  ca ed in
vitro a c . D g IVT, a  e e ca ed T7 RNA e a e he e  a a d f
RNA g f ee c e de ba e  f  a c e e a DNA e a e. Th  ce  
cc   a WAVE B eac TM 200 e  h ch c f a c e   h ch a d ab e
a c b eac  bag  aced. A 200 L bag be ed f  each IVT eac  ha  cc , a d
110 L f h  bag  be cc ed a  110 L  he eac  e. P   ad g he bag, he
bag  be hea ed  he eac  e e a e f 37℃. Ne , 99 L f he eac  c e
 be ed  he bag; h  99 L c  f he eac  b ffe  (T -HC , MgC 2,
d h h e  (DTT), e d e, a d T  X-100), DNA e a e, c e de ba e , ca
a a g f  c - a c a  ca g a  d c ed  Sec  10.2.2, a d a e  f  ec
(WFI). The 11 L f T7 RNA e a e  be ed  a   ha  he eac   
beg   a  eac  c e  ha e bee  ed  he bag. The H   be ed
 e e ha  he H  8.1. O ce a  c e ha e bee  aded  he bag, he c g a e
65
 be e   4 c  e  e, a d he c g a g e  be e   2   a d e ce e
ha g f he eac  c e . The IVT eac   f  5 h .
F g he IVT eac , e e d ge  a e ece a   a d  he deg ada  f
a ed c e . Af e  he IVT eac  ha  f  5 h , DNa e I  be added 
deg ade he DNA e a e ha  e a  af e  he IVT eac 45. Ph ha a e  a  be added
af e  he 5 h ; h ha a e  de h h a e he 5  e d f ca ed RNA , h
a g he   be b e e  deg aded 46. Af e b h e e  a e added, he c ba  
he WAVE B eac   cc  f  30 e  a  he a e e e a e, H, a d c g
c d . F g he c e  f he IVT eac a d b e e  e e d ge , he
c e  f he bag  be ed  a age a . F  ha  age a , he  
he  be ed  he f  a ge a  f  f a e .
13.2.2 P ifica ion of mRNA: Tangen ial Flo  Fil a ion Befo e Ch oma og a h
The  c g  f he IVT eac  c a a  de ab e e e e  ha  a e
 eeded  he f a  ha ace ca  f a c d g: d b e a ded RNA, DNA e,
h ha e, a d DNA, c a ed NTP , T -X-100, T7 RNA P e a e, Ca
A a g, Mag e  Ch de, T  B ffe , S e d e, a d d h h e . The ef e,  
ece a   f e  h    de   e e he de ed e e e . A b hed a e
ha  f c e   he f ca  f RNA ha  gge ed he f a a ge a  f  f a
f ed b  a ch a g a h  c  f ed b  a he a ge a  f  f a  e  
e e a  f he a ed c a a , ea g e g e a ded RNA25. Rea
f  h  de g  ch ce  d e  he fac  ha  TFF d   ega e  affec  he ab  f RNA
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c a ed  he  f a  ce e . I  fac , RNA a  de c ea ed age ab  af e
a  ea  e e  f TFF c a ed  he age ab f he RNA  he IVT- .
Th , f g he IVT eac , he d c   a  f ed h a
Ta ge a  F  F a  de ce, a  efe ed a  TFF1   ce . The e f h
 e a    e e a  e e e  e ce  f RNA f  he IVT d c  . TFF1
 a d af a  e  ha   cc   a Pa Ce a a  100 SAT S e  aded h Ce a a
100 ca e e  a d a P e he f e Me b a e. I de   e e ha  RNA  f ed, a
af a  e b a e h a M ec a  We gh  C Off (MWCO) f 100 Da  ch e . Th
e e  ha  he RNA ca  a  h gh he f e d e   e. The b ffe  ed f  h
ce   ch e   be a e  a   b ffe  e cha ge a  eeded bef e he ch a g a h
c . I  add , ch g a e  a  he b ffe e a e  a a    ch e c .
A  gge ed b  he a e , TFF1  be e f ed g 10 d  e  (DV) f a e .
S ce he e f he IVT d c   110 L, h ea  ha  he e f a e  eeded a  a
b ffe  f  h  ce  g he 10 DV  be 1100L. The e e a e f TFF1 c a  RNA
(b h g e a d d b e a ded) a d a e . The e e a e e  ch e   be 110 L a  e
a ed  e  he e f IVT d c   e a  he e f he e e a e ( .e. h
TFF1   ea   d af e  a d  c ce a e he e a  ). I  , h  ea  ha
he e ea e e f TFF1  990 L. The e ea e f TFF1 c a : DNA e, h ha e,
a d DNA, c a ed NTP , T -X-100, T7 RNA P e a e, Ca  A a g,
Mag e  Ch de, T  B ffe , S e d e, a d d h h e . The f  f TFF1  e   be
70 L/h/ 2 a  gge ed b  he a e  (CITE). I  add , he ce  e  e   be 2.5 h .
F  he ec f ed ce  a ab e , he e b a e a ea  ca c a ed  be 6.29 2 a d he f
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a e  ca c a ed  be 440 L/h . The a e  e  h  98% f RNA  be ec e ed 
he e e a e  a d h  a  fac ed  ce  de g . Th  ea  ha  520 g a  f
RNA a  f   he TFF1 b   510 g a  a ec e ed  he e e a e. I  h  e ,
RNA bec e  c ce a ed f  0.5 g a  e  e  5 g a  e  e .
13.2.3 P ifica ion of mRNA: Ch oma og a h
The d c  f  TFF1  fed  he ce e-ba ed fa  e  d ch a g a h
(FPLC) ha  b d  he d RNA. The de ed d RNA ha a e e  ha  a    b d
 he ce e e . The a a e e  f  h  c e e ca c a ed ba ed  a ca e-  f he
ce e-ch a g a h  c    a  a c e b hed  2019  M ec a  The  f
N c e c Ac d 36.
The ce  e  he ch a g a h  b ffe   a e he ce e e  a d  d e he
RNA ha   fed  he c . The b ffe   ed  he Ch a g a h  B ffe  S age
Ta  a d  c a  16% e ha  b  e f a e , NaC , EDTA a d HEPES. The
c  f 16% e ha   c ca  a  e ea ch e ea  ha  a h ghe  c ce a  ead  
b h d RNA a d RNA b d g  he c 36 . The e   e a ed h 275 g f ce e
a d 1540 L f b ffe   a e a h ge e  . The e   fed  he c  a d
a ed  e e b  g a .
P   e, he FPLC ch a g a h  c   a hed h a e-c  e f
b ffe . The c   he  fed h he 110 L f RNA f  TFF1 d ed  16 L f
ch a g a h  c . A  he RNA f  h gh he c , e ha  96% f he d RNA
b d   he ce e c 36. Af e  e e, he ch a g a h  c   a hed h
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c ea e-f ee a e   e a a  f  a e  . F  c e a  h e e  c a , 
a  dec ded ha  he e   be e ed a  he a e ec e  a e.
Th  ce   e f ed a  4C. L e a e e e d ca e ha  a  h ghe  e e a e
he e ce  f RNA ec e ed e a  cha ged e he e ce  f d RNA ha  e a
b d c ea e 36. G e  h  a d he add a c  c ed  a g he e e a e, he
ce   cc  a   e e a e.
FPLC  effec e  e g d RNA ha  a ge  e be ee  21 a d 500 b . The
c  ca  be ed  e e d RNA f d ffe e  e a d f d ffe e  c e de
c . Th  ce  d e   c e he eg  f he RNA  a c ca  
ce a  de e a   he RNA ca ed b  he ce e d ha e ca  f  he
e a g f he a fac g ce  a d c d e e be a afe  c ce .
13.2.4 P ifica ion of mRNA: Tangen ial Flo  Fil a ion Af e  Ch oma og a h
A  a ed ab e, f g he ch a g a h  e , he a ed d b e a ded RNA
 e ed f  he ce  , ea g he de ab e d c : g e a ded RNA.
H e e ,    ece a   e e a ed c a a ha  a ea ed  he  d e
 he ch a g a h  e 47. The a ed c a a ha   be e ed f  he
 f g  f he ch a g a h  c , a  he  d   a ea   he f a
ha ace ca  f a  c de: HEPES, EDTA, S d Ch de, a d E ha . S a  
ha  a  d e f g he IVT eac , a a ge a f  f a  e   ece a   e e
he e c a a  f  he g e a ded RNA . The de g  ch ce f ac g a
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Ta ge a  F  F a  S e  gh  af e  he ch a g a h  c , a che  h ha  
a ed  he a e  ha   e ed  ec 13.2.2.
Th , f g he Ch a g a h  c , he d c   a  f ed
h a Ta ge a  F  F a  de ce, a  efe ed  a  TFF2   ce . The e f
h   e a    e e a  e e e  e ce f  RNA f  he ch a g a h  d c
 a d  e f  a b ffe  e cha ge. TFF2 a d af a  e  ha   cc   a Pa
Ce a a  100 SAT S e  aded h Ce a a  100 ca e e  a d a P e he f e
Me b a e. I  de   e e ha  RNA  f ed, a  af a  e b a e h a
M ec a  We gh  C  Off (MWCO) f 100 Da  ch e . Th  e e  ha  he RNA ca
a  h gh he f e  d e   e. The b ffe ed f  h  ce   ch e   be 50 M f
S d  Ace a e a  h   e a e he RNA f  he LNP f a  ce  ha
cc  d ea . A  gge ed b  he a e , TFF2  be e f ed g 10 d
e  (DV) f d  ace a e. S ce he e f he ch a g a h  d c   ab  126
L, h  ea  ha  he e f d  ace a e eeded a  a b ffe  f  h  ce  g he 10
DV  be 1262 L. The e e a e f TFF2 c a g e a ded RNA a d d  ace a e.
The e e a e e  ch e   be 126 L a  e a ed  e  he e f ch a g a h
d c   e a   he e f he e e a e ( .e. h  TFF2   ea   d af e  a d
 c ce a e he e a  ). I  , h ea  ha  he e ea e e f TFF2 
ab  1136 L. The e ea e f TFF2 c a : HEPES, EDTA, S d  Ch de, E ha , a d
d  ace a e. The f  f TFF2  e   be 82.5 L/h/ 2 a  gge ed b  he a e 25. I
add , he ce  e  e   be 2.5 h . F  he ec f ed ce  a ab e , he
e b a e a ea  ca c a ed  be 6.12 2 a d he f  a e  ca c a ed  be 505 L/h . The
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a e  e  h  98% f RNA  be ec e ed  he e e a e  a d h  a
fac ed   ce  de g . Th  ea  ha 505 g a  f RNA a  f   he TFF2
b   495 g a  a  ec e ed  he e e a e. I  h  e , RNA bec e  c ce a ed
f  0.4 g a  e  e   4 g a  e  e .
13.2.5 P ifica ion of mRNA: S e ile Fil a ion
Af e  he RNA  ea e  he ec d a ge a f  f a  e   
ce ,  he  ge  f e ed g a e e f a de ce. Th  e e f a  f he 
e e  a  he a  f ca  e  bef e e e g he ec d eg   ce  h ch  he
f a  f LNP . The e f e e f a   e e ha  he RNA d c  
e e b  e g a  bac e a  a d c b a  c a a f  he a e be g f e ed. I
h  e  f he a fac g ce , he RNA d c  be d ec  f e ed  he f a
age c a e  g a 0.2   e b a e ca dge , a  efe ed  a  O ca S e e XLTµ
10 M e E e f e . The e f e  a e d ab e a d d e  he d e  f he f e
each ba ch h f RNA d c  ea g TFF2 e e ac  e f e . The f e  a e
e ec ed  ec e  100% f he d c .
13.3 Fo m la ion of LNP  Enca la ion of mRNA
13.3.1 P e a a ion fo  Mic ofl idic
Each c f d c de ce ed ha   e  ea ; e e  ea  c a  RNA 
a  a e  b ffe , a d he he  e  ea  c a d  d ed  e ha . The
c ce a  f c e   each ea  a e a f  e g d a a c e (LNP)
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e a  e  a  f  eff c e  RNA e ca a . Th , he e a a  f he e   a
a  e  ha   cc    he c f d c e .
The e a a  f he d  e  d g 14 g a  f he f  d
(ALC-0315, ALC-0159, DSPC, a d ch e e )  1200 L f e ha , e g  a 
h a d c ce a  f 10 g/ L.
The RNA   ha e g e h gh a  f he RNA f ca  e  a d 
h  be  a 50 M d  ace a e ;  ece a  f  he RNA  be  a  ac d c
b ffe  ch a  d  ace a e a  h  e e  RNA e ca a 48. H e e , he RNA
 ha  e  f  he RNA f ca  e c a  RNA a  a c ce a  ha  
 h gh f  he e  c f d c  e . Th , he RNA  d ed h a  add a  3600 L f
50 M d  ace a e  ach e e he de ed c ce a f  c f d c  h ch  0.13
g/ L.
13.3.2 Fo m la ion of LNP: Mic ofl idic
S agge ed he gb e c f d c g de ce  be ed  d ce he
RNA-c a g LNP ; a  age f e f he e de ce ca  be f d  F g e 13.1. O e
e  ea   RNA  a  ac d c b ffe , a d he he  e  ea   d  d ed  e ha .
The  e  ea  ee  a  a g cha e  he e g a d LNP f a  cc   he
de  f c ec d . The e  f he e c f d c ch  de ce  c  f 25 e  f 16
a a e ed ch ,  25 16X e 48. The f d  be ed f  age a  f he
a e  RNA a d he d    each c f d c de ce.
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T  e e RNA ab  h gh  he ce , h  c f d c  e   cc  a
4℃. The RNA  f   h gh e f he e  ea  a  a c ce a  f 0.13 g/ L
 a 50 M d  ace a e b ffe  a  H 4.0; he f a e f he RNA ea   be 9 L/
f  a g e de ce. Add a , he d  f   a  a c ce a  f 10 g/ L 
e ha , a d he d ea  f  a e  be 3 L/  f  a g e de ce. Th  e e e  a
f  a e a  (FRR) f 3:1 ( RNA: d ) h ch ec e ded b  he e a e 48. The
ea   ee  a  he g cha e , he e g  cc  e  he c e f 3
ec d , a d a g e ea   e  a  a f a e f 12 L/  f  a g e de ce. I  
a e 19 h    e ee  h f d c  ( e ba ch  500 g a  f RNA) h gh
he e de ce .
Fig e 13.1. S agge ed he gb e c f d c g de ce. Ma  f he e de ce  ca  be
a a e ed h  a g h  ce  ca ab e.49
13.3.3 P ifica ion of LNP: Tangen ial Flo  Fil a ion
F g he c f d c  de ce, he RNA a d a e  e ca a ed b  LNP .
H e e ,    ece a   e e a ed c a a ha  a ea ed  he  d e
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 he c f d c  e . The a ed c a a  ha   be e ed f  he 
f g  f he ch a g a h  c , a  he d   a ea   he f a  ha ace ca
f a  c de: E ha  a d S d  Ace a e. S a  ha  a  d e f g he IVT
eac  a d ch a g a h  c , a a ge a  f f a  e   ece a   e e he e
c a a  f  he LNP-RNA d c .
Th , f g he c f d c  de ce, he d c   a  f ed h a
Ta ge a  F  F a  de ce, a  efe ed a  TFF3   ce . The e f h
 e a    e e a  e e e  e ce  f LNP- NA d c  a d a   e f  a
b ffe  e cha ge. TFF3  a d af a  e  ha  cc   a Pa Ma a e S e  aded
h Ma e e 100 ca e e  a d a P e he f e Me b a e. I  de   e e ha
LNP-RNA d c   f ed, a  af a  e b a e h a M ec a  We gh  C  Off
(MWCO) f 100 Da  ch e . Th  e e  ha  he LNP-RNA d c  ca  a  h gh he
f e  d e  he e f he e   he e b a e ch e . The b ffe  ed f  h  ce  
ch e   be 1X PBS B ffe , a  h   e a e he LNP-RNA  f  he f a  d
ce  ha  cc  d ea . I  add , PBS b ffe   he f a  f a  f he acc e
a d  h   a he  ea  h  PBS a  ch e  a he TFF3 b ffe . The PBS b ffe   ade
f : P a  Ch de, M ba c a  h ha e, S d  Ch de, a d D ba c
S d  Ph ha e H d a e. A  gge ed b  he a e  ec  13.2.4, TFF3  be
e f ed g 10 d  e  (DV) f PBS25. S ce he e f he d c  
f g  f he c f d c  de ce  ab  4,935 L, h  ea  ha  he e f d
ace a e eeded a  a b ffe  f  h  ce  g he 10 DV  be 49,350 L. The e e a e f
TFF3 c a  L d , RNA, a d PBS. The e e a e e  ch e   be 626 L a  e
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a ed  c ce a e he RNA  bef e  e e   he f a  d  ce . I  ,
h  ea  ha  he e ea e e f TFF2  ab 53,035 L. The e ea e f TFF2 c a :
S d  Ace a e, E ha , a d PBS. The f  f TFF2  e   be 82.5 L/h/ 2 a  gge ed b  he
a e 25. I  add , he ce  e  e  be 7.5 h . TFF3  ce g e  ge
ha  he ce g f  TFF1 a d TFF2 d e  he a ge a  f e eeded  be
ce ed. F  he ec f ed ce  a ab e , he e b a e a ea  ca c a ed  be 86.72 2
a d he f  a e  ca c a ed  be 7,155 L/h . I  add ,   a ed ha  98% f LNP-RNA
d c   be ec e ed  he e e a e . Th  ea  ha  495 g a  f RNA a
f   he TFF2 b   485 g a  a  ec e ed  he e e a e. I  h  e , RNA
bec e  c ce a ed f  0.0092 g a  e  e  2.65 g a  e  e .
13.3.4 P ifica ion of LNP: S e ile Fil a ion
Af e  he LNP- RNA  ea e  he h d a ge a f  f a  e   
ce ,  he  ge  f e ed g a e e f a de ce. Th  e e f a  f he 
e e  a  he a  f ca  e   he e e ce . The e f e e f a   
e e ha  he LNP- RNA d c   e e b  e g a  bac e a  a d c b a
c a a  f  he a e be g f e ed. Th e e f a  e   e  a  a  
e e  ha   f a  d c   c de ed e e h ch  ece a  a    be ec ed 
h a . I  h  e  f he a fac g ce , he RNA d c   be d ec  f e ed 
he f a  age c a e  g a 0.2   e b a e ca dge , a  efe ed  a  O caµ
S e e XLT 10 M e E e f e . The e f e a e d ab e a d d e  he d e
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f he f e  each ba ch h f LNP- RNA d c  ea g TFF3  e e ac  e f e .
The f e  a e e ec ed  ec e  100% f he d c .
13.4 Q ali  Con ol
13.4.1 De e mina ion of Leng h of mRNA P od c
The RNA ha  h d be e e   he f a  f a f he acc e h d be he
e ac  RNA e e ce ha  a  de g ed; he e e ce h d c de he 5  ca , b h he 5
a d 3  UTR , he  ha  c de  f  he f - e g h e e , a d he  (A) a . The
f  RNA e e ce h ch ca  be f d  A e d E  e ac  4079 ba e   e g h.
I   e e a  ha  he e be a e  h ch  e e ha  he RNA be g d ced  he
f - e g h RNA  e e he h ghe  b e a a eff c e c . T  acc h h , a
a e  be a e  f  he d c  f each in vitro a c  eac , a d RNA ge
e ec h e   be e f ed  he d c  g RNA ge  e ec h e  . D g ge
e ec h e , he e  be a  e ec c c e e e  h ch  ca e ega e -cha ged
RNA  e a d he a de50. Sh e  RNA f ag e  g a e fa he  ha  ge
RNA f ag e ,  h  ce  ca  be ed  de e e he he    he RNA d c
f  he in vitro a c  eac   f - e g h50. The ge  h d h   e  ha
90% f - e g h RNA. A a e ge  ca  be f d F g e 13.2. A he   d be 
e e ce he RNA d c ; h e e , h  d be  e c g a d e e e, a d ge
e ec h e   ab e  e ea  he de ed e .
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Fig e 13.2. RNA ge  e ec h e . The ba d  e e e RNA ha   a ec f c e g h 50.
13.4.2 De e mina ion of Si e of Li id Nano a icle
De e g he e f he d a a c e  (LNP )  h gh  a ; he LNP
eed  be a a e  80   de  f  a eff cac  f he acc e. T  de e e he
e f he LNP  be g d ced   c f d c de ce , d a c gh  ca e g (DLS)
 be ed. DLS e  ca e ed gh   de e e he e f a g e  a c e51.  DLS  be
e f ed 4 d ffe e  e  d g he c e f he c f d c  e .
13.4.3 Mea emen  of Endo o in Le el
A  ha ace ca  d c  d ced a e e ed b  a  eg a  age c e
d de  de g  a e   de e e e d e e   he ha ace ca  d c 52.
G a - ega e bac e a ha e e d , a d he e e d  a e e  c  h a 52. T
e e ha  he acc e   c a a ed h e d , a  a eb c e a e (LAL)
a a   be e f ed f g he f a  d e   he ce . The LAL a a   a
a da d a a  a d  ec g ed a  a d b  he FDA, a d  ea e  e d  e e 53. F
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he e ea , he LAL a a  a  ch e  a  he e h d f  e d  ea e e . Acce ab e
e e  f e d  f  RNA acc e  h d be e ha  10 e d   (EU)/ L54.
13.5 Packaging and o age of od c
The d c , af e  he f a  d  a d a c  e ,  be ac aged  a .
Each 2 L g a  a   c a  .45 L f he f e e  f d c . Acc d g 
Pf e  c e  a fac g ce , each a  ea ed h a b b  bbe  e  a d
a  a  ea  h f - ff a c ca . The a  be e   he a  h g c a e
acc d g  FDA eg a 55. Each c a e  h d 5 a  f acc e  h each a
h d g 195 a , e a e   1,170 d e . The ed a fac g ce  e d  a a
f 200  d e  h a ee  d c  f 15.4  d e . Th   e a e   a
ee  d c  f 2  a  a d a ee 2,100 ac aged he a  c a e  (Refe  
A e d  D). The ce   ac age he a  be a  f a echa ca  e g ee g a eg
ha    f c e f  h  ec .
The he a  h g c a e   eed  be ed a d h ed  acc da ce h
FDA eg a . A  e ed  C e  Re e e , he acc e   e e a-c d
f ee e  (be ee  -80C a d -60C), f ee e  f  a a f  ee  (be ee  -25C a d
-15C), a d ef ge a  f  a a  f 120 h , 5 da , (be ee  2C a d 8C).
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14. Ene g  Balance and U ili  Re i emen
D e  he a ce f a a g RNA ab a d e e g RNA deg ada
h gh  he ce ,  d c  fac  eed  be a a ed a  4℃ a  RNA 
e ab e a  e  e e a e . The ea  c f e ec c   a a  he a a e
10,000 f 2 fac  a  4℃  $500,000, a d h  he a ge   c . T  b a  add a
e ec ca  c  a c a ed h e e e  f  ce ch a  hea g he IVT WAVE
B eac , e a  gh g, a d d g hea g a d c g f  ff ce ace  h ch 
cc  a  add a  5,000 f 2, a  add a  20% ($100,000) a  added  he a  e ec ca
c . Add a , a e   ed  a  e h gh  he ce ; h ,  a  ece a
 a e  acc  he ea  c  a c a ed h g a e   he a e  f ca
e  a  he fac . The c  f a e   $10,000 e  ea . The e a e  a e a ed 
Tab e 14.1 be .
Table 14.1. S a  f Yea  U e  C
U ili Yea l  Co
Elec ici  - Cooling Facili $500,000
Elec ici  - Addi ional $100,000
P oce  Wa e $10,000
To al: $610,000
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15. E i men  Li  and Uni  De c i ion
15.1 P e a a ion of DNA
S ce he he  f he DNA h he GOI be ced,  e e   be
ed  he e a a  f DNA.
15.2 S n he i  and P ifica ion of mRNA
15.2.1 T i  B ffe  S o age Tank
La ge a e  f T  H d ch de b ffe  eeded f  he IVT eac . Th  b ffe
 be ed  a  IBC a e  ee  304 a a d  be cha ed f  he e d  The
Ca  C a . Th  a e  ee  d ha d g a  fea e  a e- ece ed b  ha
a  f  c e e d a age, a e e e e g de ce, 10 ga ge a e  ee  IBC
c c  h 2B f h a d a 2  b g e g. The b ffe   be cha ed e e  3
ee  ba  ( .e. e  3 ba che  ba ), he ef e e g he age a  h d    280 e
f T  b ffe . Af e  c  efe e c g h a da d e  f a  ha  he e d  d ce , 
a  de e ed ha  a 379 e  a   be cha ed  h d he T  b ffe . L ea
e a g cha e c  da a ed f  he e d , he cha e c  f he age a  
$1,859 a d he a  ba e d e c   $7,437 ( ee A e d  C f  de a ed cha g
ca c a ).
15.2.2 WAVE Bio eac o
The in vitro a c  (IVT) eac   be   a WAVE B eac TM 200 e
f  C a ( e  GE Hea hca e L fe Sc e ce ). The WAVE B eac TM e  c
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f a c g a a a   h ch a a c d ab e b eac  bag  aced. The eac
c e  a e ed  he bag, a d h   he e he eac   a e ace. The WAVE
B eac TM e  c de  a e e a e c e a d H ; b h f he e e e e
a e a  a  he IVT eac   cc  a  37℃ a d a  a H f 8.1. Th  e  a
acc da e  200 L d ab e b eac  bag  h g e  f   100 L h ch 
dea  a   IVT eac  e e  a eac  e f c e  100 L.
The IVT eac  a  e  a  he DNa e I a d h ha a e ea e   a e ace 
h  b eac  e . The IVT eac   f  5 h , a d af e  h  5 h  e e d,
DNa e I a d h ha a e  be added. The DNa e I a d h ha a e d ge   ceed f
a  add a  30 e . B h f he e ce e  a e ace a  37℃ a d H 8.1. O ce h
5.5 h  e e d ha  a ed, he IVT eac a d e e d ge  c e   be ed
 he IVT d c  age a , a d he e  ed b eac  bag  be d ed f.
Th ee  ba ch eac   eed  be   a WAVE B eac TM e . T  a d
g e  he e e  ha  a eac  d b ea d   a bag d b ea , 2 b eac  a d
26 d ab e a c b eac  bag  e e cha ed. The cha e c  f a WAVE
B eac TM 200 e   $400,000, a d he cha e c  f a 200 L a c d ab e
b eac  bag  $709. We dec ded  cha e 2 b eac a d 26 a c d ab e b eac
bag , a d he a  ba e d e c  f  he e e  $1,636,900.
15.2.3 IVT P od c  S o age Tank
The  ha   ed a e  ec e ed f  he IVT eac   be ed  a  IBC
a e  ee  304 a  ha   be cha ed f he e d  The Ca  C a . Th
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a e  ee  d ha d g a  fea e  a e- ece ed b  ha  a  f  c e e
d a age, a e e e e g de ce, 10 ga ge a e ee  IBC c c  h 2B f h
a d a 2  b g e g. The  eeded  be ed  be  a e  ee  ba  ( .e. e
ba ch ba ), he ef e e g he age a h d    110 e  f d c  . Af e
c  efe e c g h a da d e  f a  ha he e d  d ce ,  a  de e ed ha  a
110 e  a   be cha ed  h d he IVT d c . L ea  e a g cha e
c  da a ed f  he e d , he cha e c f he age a   $1,727 a d he a
ba e d e c   $6,909 ( ee A e d  C f  de a ed cha g ca c a ).
15.2.4 Tangen ial Flo  Fil a ion De ice 1
The d af a  ce   cc   a Ce a a 100 AT ca e e h de . The h de  
ed h a TFF e  a d a e ab e ca e e e b a e. Th  ca e e ha  a e b a e a ea
ha  ca  a ge f  0.9  18.6 a e e e . The e b a e ed  h  TFF de ce  be 6.3
a e e e . The e  ha  ca  e a  c  f  UV, H, c d c ,
a a   a d a .
Th  b ec e f h  Ta ge a  F  F a de ce   e e he e e , DNA
a d c a ed ba e . The e f RNA fed  h  de ce  he 100 L f  he
IVT eac . Th   c b ed  a a  f 1:10 a  gge ed b  he a e  h 1100 L f Wa e
F  I ec   acc  f  a a  f a e e f 1100 L ( efe   a e d  f  de a ed
ca c a ). The f  f h  TFF  70 LMH h ch  he a e age f he  a d h gh a ge
gge ed b  he a e . The e f  he f a ce  a  a ed  be 2.5 h . Th
a  de e ed h gh a e a e e e   h ch a e  a d ce e  gge ed a e f 5
h  a d a d c  h he c a   h ch he e a  dec ea ed  e he
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e  a e  f  he RNA  be f ed g e    ab . The f  a e f  h  ce  
400 L e  h  a d a  de e ed f  he a  f a e e a d he e ec f ed  be 2.5
h . The d c  ea  f h  TFF eac  a e he 110 L f e e a e a d he 990 L f
e ea e.
15.2.5 TFF1 Pe mea e Wa e Tank
The e ea e e ha  f e  h gh he e b a e  he TFF1 e   ec e ed
 he TFF1 Pe ea e Wa e Ta . Th    eeded f  he f a  d c  a d h  
ed  h  a   be d ed f a a e  he ea  f e. Th  a e   be
ed  a  IBC a e  ee  304 a  ha  be cha ed f  he e d  The Ca
C a . Th  a e  ee  d ha d g a fea e  a e- ece ed b  ha  a
f  c e e d a age, a e e e e g de ce, 10 ga ge a e  ee  IBC c c  h
2B f h a d a 2  b g e g. The e ea e a e  eeded  be ed  be  a
e  ee  ba  ( .e. e  ba ch ba ), he ef e e g he age a  h d    990 e
f d c  . Af e  c  efe e c g h a da d e  f a  ha  he e d  d ce ,
 a  de e ed ha  a 1,000 e  a   be cha ed  h d he e ea e . L ea
e a g cha e c  da a ed f  he e d , he cha e c  f he age a  
$2,187 a d he a  ba e d e c   $8,747 ( ee A e d  C f  de a ed cha g
ca c a ).
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15.2.6 TFF1 Re en a e S o age Tank
The e e a e e ha  d e   ge  f e ed h gh he e b a e  he TFF1 e
 ec e ed  he TFF1 Re e a e S age Ta . Th    eeded f  he f a  d c  a
 c a  he RNA d c . Th  e e a e  be ed  a  IBC a e  ee  304
a  ha   be cha ed f  he e d  The Ca C a . Th  a e  ee  d
ha d g a  fea e  a e- ece ed b  ha a  f  c e e d a age, a e e
e e g de ce, 10 ga ge a e  ee  IBC c c h 2B f h a d a 2  b g
e g. The e e a e  eeded  be ed  be  a e  ee  ba  ( .e. e  ba ch
ba ), he ef e e g he age a  h d   110 e  f d c  . Af e  c
efe e c g h a da d e  f a  ha  he e d  d ce ,  a  de e ed ha  a 110
e  a   be cha ed  h d he e e a e . L ea  e a g cha e c
da a ed f  he e d , he cha e c  f he age a   $1,727 a d he a  ba e
d e c   $6,909 ( ee A e d  C f  de a ed cha g ca c a ).
15.2.7 Cell lo e Ch oma og a h  Col mn
Th  ce  e  a 1000 L ce e ch a g a h c . The a a e e  f he
c  e e ca ed f  he 780 L ce e ch a g a h c  ed h a c a
e c  f  he a c e b hed  M ec a  The a N c e c Ac d  c g D . Ka a  Ka
(A Fac e Me h d). The e c  ed  he a - ca e c  a d a a ed  he a ge- ca e
c  ed  h  ce   21.54 c /h . The c  ha  a he gh  f 0.40 e e , a
d a e e  f 1.8 e e  a d a c - ec  a ea f 2.5 a e e e  efe   a e d  f
de a ed ca c a ). A a ge  d a e e  ha  he gh a  ed a  ad ed b  he c a  
de   ach e e he ca ed-  e h e ee g he e c  c a  a d he a a e
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ce  e. The ce  e a  ca c a ed f  he f - a e h ch a    e  b  he
f ed e c  a d he c - ec a  a ea. W h h , he f - a e f  he c   8,800 L
e  e. I  , he ce  e  110 e . U g c g e h d  f  Se de  e  a .
( ee A e d  C f  e de a ), he cha e c f  he c   $124,314 e   a d he
a  ba e d e c   $517,146. The ed ce   e e e  f  he
d c  f 200  d e .
15.2.8 Ch oma og a h  B ffe  S o age Tank
The ch a g a h  b ffe  ha   eeded   he ch a g a h  c   be
ed  a  IBC a e  ee  304 a  ha  be cha ed f  he e d  The Ca
C a . Th  a e  ee  d ha d g a fea e  a e- ece ed b  ha  a
f  c e e d a age, a e e e e g de ce, 10 ga ge a e  ee  IBC c c  h
2B f h a d a 2  b g e g. The ch a g a h b ffe   eeded  be ed 
be  a e  6.5 ee  ba  ( .e. e  6.5 ba che ba ), he ef e e g he age a  h d
  6,508 e  f d c  . Af e  c efe e c g h a da d e  f a  ha  he
e d  d ce ,  a  de e ed ha  a 6,510 e a   be cha ed  h d he
ch a g a h  b ffe  . L ea  e a g cha e c  da a ed f  he
e d , he cha e c  f he age a   $5,443 a d he a  ba e d e c   $21,772
( ee A e d  C f  de a ed cha g ca c a ).
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15.2.9 Cell lo e Re in S o age Tank
The ce e e  f  he ch a g a h  c  be ade a d ed  a  IBC
a e  ee  304 a  ha   be cha ed f  he e d  The Ca  C a . Th
a e  ee  d ha d g a  fea e  a e- ece ed b  ha  a  f  c e e
d a age, a e e e e g de ce, 10 ga ge a e ee  IBC c c  h 2B f h
a d a 2  b g e g. The ce e e   e ab e a d h ,  e c  h f
e   be eeded  be ade a d ed  he a , he ef e e g he age a  h d
  1,540 e  f d c  . Af e  c efe e c g h a da d e  f a  ha  he
e d  d ce ,  a  de e ed ha  a 1,540 e a   be cha ed  h d he ce e
e  . L ea  e a g cha e c da a ed f  he e d , he cha e
c  f he age a   $2,556 a d he a  ba e d e c   $10,223 ( ee A e d  C f
de a ed cha g ca c a ).
15.2.10 Reco e ed P od c  f om Ch oma og a h  Col mn S o age Tank
The  ha  d e   b d  he ch a g a h c   ec e ed a d ed 
a  IBC a e  ee  304 a  ha   be cha ed f  he e d  The Ca  C a . Th
a e  ee  d ha d g a  fea e  a e- ece ed b  ha  a  f  c e e
d a age, a e e e e g de ce, 10 ga ge a e ee  IBC c c  h 2B f h
a d a 2  b g e g. The ch a g a h  d c  eeded  be ed  be  a
e  ee  ba  ( .e. e  ba ch ba ), he ef e e g he age a  h d    126 e
f d c  . Af e  c  efe e c g h a da d e  f a  ha  he e d  d ce ,
 a  de e ed ha  a 130 e  a   be cha ed  h d he ch a g a h  d c
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. L ea  e a g cha e c  da a ed f  he e d , he cha e c  f
he age a   $1,764 a d he a  ba e d e c   $7,056 ( ee A e d  C f  de a ed
cha g ca c a ).
15.2.11 El ed Do ble S anded RNA Wa e Tank
The d b e a ded RNA  ha  d e  b d  he ch a g a h  c  
e ed f  he c  a d ed  a  IBC a e ee  304 Wa e a  ha   be
cha ed f  he e d  The Ca  C a . Th a e  ee  d ha d g a  fea e
a e- ece ed b  ha  a  f  c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B f h a d a 2  b g e g. The d RNA
a e  eeded  be ed  be  a e ee  ba  ( .e. e  ba ch ba ), he ef e
e g he age a  h d    985 e f d c  . Af e  c  efe e c g h
a da d e  f a  ha  he e d  d ce ,  a  de e ed ha  a 1,000 e  a   be
cha ed  h d he ch a g a h  d c  . L ea  e a g cha e c  da a
ed f  he e d , he cha e c  f he age a   $2,187 a d he a  ba e
d e c   $8,747 ( ee A e d  C f  de a ed cha g ca c a ).
15.2.12 Tangen ial Flo  Fil a ion De ice 2
Th  d af a  ce   e a Ce a a 100 SAT h a e b a e a ea f 6.12
a e e e . Th  de ce  be he a e a  he e ed f  TFF 1 (Refe   ec  f  TFF 1
f  ec f c   e a  ha   a  f he de ce).
87
The b ec e f h  Ta ge a  F  F a  de ce   e e he e ha  f  he
ce e ch a g a h  c  a d  d  a b ffe  e cha ge  e a a  f  he
M c f d c  de ce. The e  f h  TFF 2  he d c  f he ce e ch a g a h
c . Th  d c  ha  a e f 126 L a d be d ed h 1,262 L f  50 M d
ace a e f  a a  e f 1,262 L ( efe   A e d B f  ca c a ). S d  ace a e a
ch e  ce h   he d e  ed  he LNP a e ed  efe e ce f  he de g  f he
M c f d c  e  ( efe  A e d  J f  a e  f a ). The RNA ,  d c  f
he ch a g a h  c , a d he d  ace a e a e c b ed  a a  f  1:10 a
gge ed. The f  f h  TFF  82.5 LMH a d he e f  he f a  ce  a  a ed
 be 2.5 h  ( he a e e a  f  TFF1). The f a e f  h  ce   505 L e  h .
The e  f he TFF a e he e ea e a d he e e a e d c  ea . A e f
126.26 L  e ec ed f  he f e  a d fed  he e e a e age a . Th   he RNA
 ha   g  h gh a e e f a a d he   he M c f d c  de ce. The
e f e ea e  1136.49 L a d h   he e ha   d ca ded  he a e a .
15.2.13 Sodi m Ace a e B ffe  S o age Tank
La ge a e  f S d  Ace a e b ffe   eeded f  he TFF2 e . Th  b ffe
 be ed  a  IBC a e  ee  304 a a d  be cha ed f  he e d  The
Ca  C a . Th  a e  ee  d ha d g a  fea e  a e- ece ed b  ha
a  f  c e e d a age, a e e e e g de ce, 10 ga ge a e  ee  IBC
c c  h 2B f h a d a 2  b g e g. The b ffe   be cha ed e e  ee
ba  ( .e. e  ba ch ba ), he ef e e g he age a  h d    1,263 e  f d
ace a e b ffe . Af e  c  efe e c g h a da d e  f a  ha  he e d  d ce , 
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a  de e ed ha  a 1,325 e  a   be cha ed  h d he d  ace a e b ffe .
L ea  e a g cha e c  da a ed f  he e d , he cha e c  f he
age a   $2,233 a d he a  ba e d e c  $8,932 ( ee A e d  C f  de a ed
cha g ca c a ).
15.2.14 TFF2 Re en a e S o age Tank
The e e a e e ha  d e   ge  f e ed h gh he e b a e  he TFF2 e
 ec e ed  he TFF2 Re e a e S age Ta . Th   eeded f  he f a  d c  a
 c a  he RNA d c . Th  e e a e  be ed  a  IBC a e  ee  304
a  ha   be cha ed f  he e d  The Ca C a . Th  a e  ee  d
ha d g a  fea e  a e- ece ed b  ha a  f  c e e d a age, a e e
e e g de ce, 10 ga ge a e  ee  IBC c c h 2B f h a d a 2  b g
e g. The e e a e  eeded  be ed  be  a e  ee  ba  ( .e. e  ba ch
ba ), he ef e e g he age a  h d   126 e  f d c  . Af e  c
efe e c g h a da d e  f a  ha  he e d  d ce ,  a  de e ed ha  a 130
e  a   be cha ed  h d he e e a e . L ea  e a g cha e c
da a ed f  he e d , he cha e c  f he age a   $1,764 a d he a  ba e
d e c   $7,056 ( ee A e d  C f  de a ed cha g ca c a ).
15.2.15 TFF2 Pe mea e Wa e Tank
The e ea e e ha  f e  h gh he e b a e  he TFF2 e   ec e ed
 he TFF2 Pe ea e Wa e Ta . Th    eeded f  he f a  d c  a d h  
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ed  h  a   be d ed f a a e   he ea  f e. Th  a e   be
ed  a  IBC a e  ee  304 a  ha  be cha ed f  he e d  The Ca
C a . Th  a e  ee  d ha d g a fea e  a e- ece ed b  ha  a
f  c e e d a age, a e e e e g de ce, 10 ga ge a e  ee  IBC c c  h
2B f h a d a 2  b g e g. The e ea e a e  eeded  be ed  be  a
e  ee  ba  ( .e. e  ba ch ba ), he ef e e g he age a  h d    1,136
e  f d c  . Af e  c  efe e c g h a da d e  f a  ha  he e d
d ce ,  a  de e ed ha  a 1,325 e  a  be cha ed  h d he e ea e
. L ea  e a g cha e c  da a ed f  he e d , he cha e c  f
he age a   $2,233 a d he a  ba e d e c   $8,932 ( ee A e d  C f  de a ed
cha g ca c a ).
15.2.16 S e ile Fil e  1
O ca S e e XLT 10 M e E e f e  be ed f g he ec d
a ge a  f  f a  ed  he RNA f ca ce . O e O ca f e   be
ed f  each ba ch ( e ba ch e d  a a e 500 g a  f RNA). The e O ca
f e  a e e e f e  a d h  ha e a e e f 0.2 ; h  e e  effec e 
e e g bac e a a d he  c ga  f a g h gh he f e . The e b a e
a ea f he O ca f e   0.54 2, a d he f  7 L/ /c 2 56. Each O ca f e  
ha e 126 L f RNA  f e ed h gh , he e e f a  e f  e ba ch 
be 3 e . The cha e c  f e O ca S e e XLT 10 M e E e f e  
$575.00, a d he a  ba e d e c  f 13 f e  $14,950.00.
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15.3 Fo m la ion of LNP  Enca la ion of mRNA
15.3.1 Dil ion 1 Tank
I a  h  a   e b e f  h d g he RNA  c g  f he S e e
F a  1 U  O e a . Add a , a d f he RNA  h 50 M f
S d  Ace a e  e f ed h  h  a   he M c f d c  De ce. Th  d ed
  be ed  a  IBC a e  ee 304 a  ha   be cha ed f  he e d
The Ca  C a . Th  a e  ee  d ha d g a  fea e  a e- ece ed b
ha  a  f  c e e d a age, a e e e e g de ce, 10 ga ge a e  ee  IBC
c c  h 2B f h a d a 2  b g e g. The d ed  eeded  be ed
 be  a e  ee  ba  ( .e. e  ba ch ba ), he ef e e g he age a  h d  
 3,701 e  f d c  . Af e  c  efe e c g h a da d e  f a  ha  he
e d  d ce ,  a  de e ed ha  a 3,785 e a   be cha ed  h d he d ed
. L ea  e a g cha e c  da a ed f  he e d , he cha e c  f
he age a   $3,557 a d he a  ba e d e c   $14,228 ( ee A e d  C f  de a ed
cha g ca c a ).
15.3.2 E hanol S o age Tank
La ge a e  f E ha    eeded f he d  f d  bef e he
c f d c  de ce. Th  b ffe   be ed a  IBC a e  ee  304 a  a d  be
cha ed f  he e d  The Ca  C a . Th a e  ee  d ha d g a  fea e
a e- ece ed b  ha  a  f  c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B f h a d a 2  b g e g. The e ha  
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be cha ed e e  ee  ba  ( .e. e  ba ch ba ), he ef e e g he age a  h d  
 1,234 e  f e ha . Af e  c  efe e c g h a da d e  f a  ha  he e d
d ce ,  a  de e ed ha  a 1,325 e  a  be cha ed  h d he e ha  .
L ea  e a g cha e c  da a ed f  he e d , he cha e c  f he
age a   $2,233 a d he a  ba e d e c  $8,932 ( ee A e d  C f  de a ed
cha g ca c a ).
15.3.3 Li id and E hanol Sol ion S o age Tank
L d  ge  ed h e ha   a d h  a e e  ed  a age
a  ha   be fed  he c f d c  de ce. The d-e ha    ed  a  IBC
a e  ee  304 a  a d  be cha ed f he e d  The Ca  C a . Th
a e  ee  d ha d g a  fea e  a e- ece ed b  ha  a  f  c e e
d a age, a e e e e g de ce, 10 ga ge a e ee  IBC c c  h 2B f h
a d a 2  b g e g. The d-e ha   be ade e e  ee  ba  ( .e. e
ba ch ba ), he ef e e g he age a h d    1,234 e  f d-e ha . Af e
c  efe e c g h a da d e  f a  ha he e d  d ce ,  a  de e ed ha  a
1,325 e  a   be cha ed  h d he d-e ha . L ea  e a g
cha e c  da a ed f  he e d , he cha e c  f he age a   $2,233 a d
he a  ba e d e c   $8,932 ( ee A e d C f  de a ed cha g ca c a ).
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15.3.4 Mic ofl idic  De ice
S agge ed he gb e c f d c g de ce ba ed  h e ed  he P ec
Na e  Na A e b TM P a f   be ed  f  he LNP  ha   e ca a e he
RNA. The 0.13 g/ L RNA  50 M d  ace a e a  a H f 4.0 e e  h gh he
a e  ea  a  a f  a e f 9 L/  f  a g e de ce h   F g e 15.1, a d he 10
g/ L d   e ha  e e   he he  e a  a f  a e f 3 L/  f  a g e de ce,
a  h   F g e 15.1. Ra d g cc  e 3 ec d , a d he e g
RNA-c a g LNP  e  a  a f  a e f 12 L/ f  a g e de ce.
Fig e 15.1. D ag a  f a g e agge ed he gb e c f d c g de ce57.
The e de ce   be a a e ed  e  f 16, a d 25 f he e 16X e   be ed.
F g e 15.2 h  5 f he e 16X e   g e a ge e a  dea f h  he ga a  .
The RNA a d d   be ed  each de ce, he ec d g  cc ,
a d he  he e g LNP   be d ec ed  he M c f d c  P d c  S age Ta  d c ed
 he f g ec . O e 16X e  f c f d c de ce  c  $13,000, a d he a  ba e
d e c  f 25 f he 16X e   $650,000.
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Fig e 15.2. Pa a e ed c f d c de ce . T e -f e e  f 16 a a e ed de ce  
be ed  he ce .49
15.3.5 Mic ofl idic  P od c  S o age Tank
The d-RNA  f g  f he c f d c de ce  ec e ed a d h
ed  a  IBC a e  ee  304 a  a d be cha ed f  he e d  The Ca
C a . Th  a e  ee  d ha d g a fea e  a e- ece ed b  ha  a
f  c e e d a age, a e e e e g de ce, 10 ga ge a e  ee  IBC c c  h
2B f h a d a 2  b g e g. The d-RNA   be ade e e  ee  ba  ( .e.
e  ba ch ba ), he ef e e g he age a  h d    4,935 e  f d-RNA
. Af e  c  efe e c g h a da d e f a  ha  he e d  d ce ,  a
de e ed ha  a 5,678 e  a   be cha ed  h d he d-RNA . L ea
e a g cha e c  da a ed f  he e d , he cha e c  f he age a  
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$4,500 a d he a  ba e d e c   $18,000 ( ee A e d  C f  de a ed cha g
ca c a ).
15.3.6 Tangen ial Flo  Fil a ion De ice 3
Th  d af a  e   be acc hed h a Ma e e 100 AT ca e e h de ,
ca e e e b a e a d e . Th  ca e e h de  ca  ed f  a ge- ca e ce e
a d ca   h e b a e a ea  a g g f  5.6  92.9 a e e e . The e b a e a ea
ed  h  ce   86.7 a e e e . The Ma e e ca e e  a e de g ed h a ge
a h e g h  ed ce he e e a e f  a e a d he ce e e a a e  .  The ca e e
h de  ca  e a e h a a  e a g e e f 6 ba .
The b ec e f h  Ta ge a  F  F a  de ce   e e he e ha  f  he
d  fed  he M c f d c  de ce a d  d  a b ffe  e cha ge h PBS. The b ffe
ed  h  TFF  be 49,350 L f PBS. Th  be ed h he LNP  e g he
M c f d c  de ce h ch ha  a e f 4,935 L f  a a  f a e e f 53,660 L. The
f  ed  h  ce   be 82.5 LMH h ch f  h gh a e b a e a ea f 87
a e e e  ( efe   A e d  B f  de a ed ca c a ).
Th  TFF de ce  ec e  626 L f LNP  h ch  g   he e e a e
age a  a d a e   he a  e e f e bef e he f a  d . The de ce  f e
53,034 L,  c g f e ha  a d PBS b ffe h ch  be d ca ded  a age a .
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15.3.7 PBS B ffe  S o age Tank
La ge a e  f PBS b ffe  a e eeded f  he TFF3 e . Th  b ffe   be ed
 a  IBC a e  ee  304 a  a d  be cha ed f  he e d  The Ca  C a .
Th  a e  ee  d ha d g a  fea e a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10 ga ge a e  ee  IBC c c  h 2B
f h a d a 2  b g e g. The b ffe   be cha ed e e  ee  ba  ( .e. e  ba ch
ba ), he ef e e g he age a  h d   49,351 e  f PBS b ffe . Af e  c
efe e c g h a da d e  f a  ha  he e d  d ce ,  a  de e ed ha  a
56,781 e  a   be cha ed  h d he PBS b ffe . L ea  e a g cha e c
da a ed f  he e d , he cha e c  f he age a   $29,965 a d he a  ba e
d e c   $119,860 ( ee A e d  C f  de a ed cha g ca c a ).
15.3.8 TFF3 Re en a e S o age Tank
The e e a e e ha  d e   ge  f e ed h gh he e b a e  he TFF3 e
 ec e ed  he TFF3 Re e a e S age Ta . Th   eeded f  he f a  d c  a
 c a  he RNA e ca a ed  a LNP. Th  e e a e   be ed  a  IBC
a e  ee  304 a  ha   be cha ed f he e d  The Ca  C a . Th
a e  ee  d ha d g a  fea e  a e- ece ed b  ha  a  f  c e e
d a age, a e e e e g de ce, 10 ga ge a e ee  IBC c c  h 2B f h
a d a 2  b g e g. The e e a e  eeded  be ed  be  a e  ee
ba  ( .e. e  ba ch ba ), he ef e e g he age a  h d    626 e  f d c
. Af e  c  efe e c g h a da d e f a  ha  he e d  d ce ,  a
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de e ed ha  a 686 e  a   be cha ed  h d he e e a e . L ea
e a g cha e c  da a ed f  he e d , he cha e c  f he age a  
$2,087 a d he a  ba e d e c   $8,347 ( ee A e d  C f  de a ed cha g
ca c a ).
15.3.9 TFF3 Pe mea e Wa e Tank
The e ea e e ha  f e  h gh he e b a e  he TFF3 e   ec e ed
 he TFF3 Pe ea e Wa e Ta . Th    eeded f  he f a  d c  a d h  
ed  h  a   be d ed f a a e  he ea  f e. Th  a e   be
ed  a  IBC a e  ee  304 a  ha  be cha ed f  he e d  The Ca
C a . Th  a e  ee  d ha d g a fea e  a e- ece ed b  ha  a
f  c e e d a age, a e e e e g de ce, 10 ga ge a e  ee  IBC c c  h
2B f h a d a 2  b g e g. The e ea e a e  eeded  be ed  be  a
e  ee  ba  ( .e. e  ba ch ba ), he ef e e g he age a  h d    53,035
e  f d c  . Af e  c  efe e c g h a da d e  f a  ha  he e d
d ce ,  a  de e ed ha  a 56,781 e  a  be cha ed  h d he e ea e
. L ea  e a g cha e c  da a ed f  he e d , he cha e c  f
he age a   $29,965 a d he a  ba e d e c   $119,860 ( ee A e d  C f
de a ed cha g ca c a ).
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15.3.10 S e ile Fil e  2
O ca S e e XLT 10 M e E e f e  be ed f g he h d
a ge a  f  f a  ed  f  he d a a c e  (LNP ) af e  he  ha e bee
he ed. O e O ca f e   be ed f each ba ch ( e ba ch e d  a a e  500
g a  f RNA). The e O ca f e  a e e e f e  a d h  ha e a e e f 0.2 ;
h  e e  effec e  e e g bac e a a d he  c ga  f  a g h gh
he f e . The e b a e a ea f he O ca f e  0.54 2, a d he f   7 L/ /c 2 56.
Each O ca f e   ha e 626 L f RNA-c a g LNP  f e ed h gh , 
he e e f a  e f  e ba ch  be 17 e . The cha e c  f e O ca
S e e XLT 10 M e E e f e   $575.00, a d he a  ba e d e c  f 13 f e  
$14,950.00.
15.3.11 PBS and S c o e Sol ion S o age Tank
La ge a e  f 30% S c e  PBS B ffe   eeded f  he f a  d  f
he LNP-RNA d c  bef e ac ag g. Th  b ffe  be ed  a  IBC a e  ee  304
a  a d  be cha ed f  he e d  The Ca C a . Th  a e  ee  d
ha d g a  fea e  a e- ece ed b  ha a  f  c e e d a age, a e e
e e g de ce, 10 ga ge a e  ee  IBC c c h 2B f h a d a 2  b g
e g. The e ha   be cha ed e e  ee ba  ( .e. e  ba ch ba ), he ef e
e g he age a  h d    298 e f c e  PBS b ffe  . Af e  c
efe e c g h a da d e  f a  ha  he e d  d ce ,  a  de e ed ha  a 379
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e  a   be cha ed  h d he c e  PBS b ffe  . L ea  e a g
cha e c  da a ed f  he e d , he cha e c  f he age a   $1,859
a d he a  ba e d e c   $7,437 ( ee A e d C f  de a ed cha g ca c a ).
15.3.12 Dil ion 2 S o age Tank
I a  h  a   e b e f  h d g he LNP- RNA  c g  f he
S e e F a  2 U  O e a . Add a , a d  f h  LNP- RNA  h
30% S c e  PBS B ffe   e f ed h  h a    he Pac ag g S e . Th
d ed   be ed  a  IBC a e ee  304 a  ha   be cha ed f  he
e d  The Ca  C a . Th  a e  ee  d ha d g a  fea e  a e- ece ed
b  ha  a  f  c e e d a age, a e e e e g de ce, 10 ga ge a e  ee
IBC c c  h 2B f h a d a 2  b g e g. The d ed  eeded  be
ed  be  a e  ee  ba  ( .e. e  ba ch ba ), he ef e e g he age a
h d    923 e  f d c  . Af e c  efe e c g h a da d e  f a
ha  he e d  d ce ,  a  de e ed ha  a 946 e  a   be cha ed  h d he
d ed . L ea  e a g cha e c  da a ed f  he e d , he cha e
c  f he age a   $2,167 a d he a  ba e d e c   $8,675 ( ee A e d  C f
de a ed cha g ca c a ).
99
15.5 O he
15.5.1 F ee e
A 25 a e f  f ee e  f  The F he   be ed  e a e a  eeded
h gh  he ce . The f ee e   be ade  f a e  ee  a d e a D g a
M c ce   c  he e e a e a d he a a e e . The F he  e  he e
f ee e   f  e e da  e  a ab a  e g58. The f ee e   ha  a c  f $8,264, a
e a e   c  g e  he c  f he e e ch a  TFF eac  ed  he
a fac g ce . G e  he c   c de ed e a e  , a 25 a e f  f ee e  
be cha ed a h gh   e  ha   ch age ace  be ed.
I  h  ed a fac g ce , he f ee e  a  be ed  e he
150 g a  f DNA  a e f 20 L h ch  be cha ed  b  a  he a  f he
ce  a d be ed  a ee  ba . The f ee e  a  be ed  e he  a  a e a
ch a  he NTP  ed  he IVT eac .
15.5.2 Wa e  P ifica ion S em
D e  he fac  ha  h  ce  d ce  a acc e ha   be ec ed  h a , he
a e  ed h gh  h  ce   be e e e e. Th  e e e  e a e   be
ed  d e a  a e a  a d  be added  e a  h gh  he ce .
M c a  a  a e   be ed  he a e  f ca e  ca ed   fac . The
a  a e   be f e ed  a e a e  f ec  (WFI). Th  f ed a e  ca  he  be
ed    e a  a  e  a  f  d g a d e a g a  a e a . Tab e 15.1 de a
he a  f a e  ha   be eeded e  ba ch d ced. O  a e  f ca  e  ha
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e a e cha g  ha e he ca ac   d ce 17,500 L e  ee . A M eS g a
a e a e  f a  e  ha  d a f  ee  a e  e e e  ha  a cha e
c  f $175,000 a d a a  ba e d e c  f $350,000.
I  Tab e 15.1, he a  f e e a e  ha  eed  be added d ec   ce a  
e a   h . Th  a  a  d b ed  acc f  a e  eeded  d e a d e a e
a  a e a  a  e  a  f  a e  eeded  c ea a d e e  e a  af e  e.
Table 15.1 A  f S e e Wa e  Needed Pe  Ba ch f he Ma fac g P ce
P oce Wa e  Needed Pe  Week (L)
IVT Reac ion 30
TFF1 1100
Cell lo e Ch oma og a h 1800
TFF2 0
Dil ion Befo e Mic ofl idic 0
LNP Fo ma ion/Mic ofl idic 0
TFF3 0
Final Dil ion 0
Ini ial To al 2,930
Final To al (do bled o acco n  fo
dil ion / e a a ion  of a  ma e ial)
5,860
15.5.3 Pe i al ic P m
I  de   a fe  a e a  h gh he e e ce , e a c  ha e bee
a ed. S ec f ca , e a c  ha e bee de g ed  a  a e a  
a d f  a    he ce . The  a  ha e e e e d  a d e
101
e e e  ba ed  he a e a  a d f  a e he  a e e b e f  a g. F  he
e e a fac g ce  35 e a c  be a ed. The 825 Se e  Pe a c
P   be cha ed f  he e d  Wa -Ma . The cha e c  f e 825 Se e
Pe a c P   $3,000, a d he a  cha e d e c  f 35   $105,000. I
add , he a  ba e d e c  f 35 e a c   $346,500.
102
16. S ecifica ion Shee
16.1 T i  B ffe  S o age Tank
De c i ion and
F nc ion
H d T  H d ch de b ffe    IVT eac . Th  age
a  h d  3 ba che  h f T  B ffe  f  he IVT eac .
N mbe  Re i ed 1.0
Vendo The Ca  C a
O e a ion Ba ch
Ma e ial  Handled Inle  (g/ba ch) O le  (g/ba ch)
T i  B ffe 402.56 402.56
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g
a  fea e  a e- ece ed b  ha
a  f  c e e d a age, a e e
e e g de ce, 10 ga ge a e  ee  IBC
c c  h 2B f h a d a 2  b g
e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 379
Wo king Vol me (L) 265
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $1,859.23 e  
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16.2 WAVE Bio eac o TM 200 em
De c i ion and
F nc ion
The WAVE B eac   be ed   he in vitro a c
(IVT) eac . The WAVE B eac  h d  d ab e b eac
bag  he e he eac  a e  ace. The b eac bag  ch e  a e
200 L bag  h a g e a ge f 10 - 100 L, a d each 
f he IVT eac  e e  a g e f c e  100 L. T
WAVE B eac  a e  be cha ed  acc  f b e
b ea d  f e f he eac . Add a , ce 13 ba che  
be , 26 bag  a e  be cha ed f  a  ea .
Vendo
WAVE Bio eac o
GE Hea hca e L fe
Sc e ce  (
C a)
Di o able Bag
O e a ion Ba ch
Ma e ial  Handled In  (g/ba ch) O  (g/ba ch)
T i  H d ochlo ide 402.56 402.56
Magne i m Chlo ide 40.38 40.38
1,4-Di hio h ei ol
(DTT)
170.87 170.87
S e midine 32.18 32.18




5'-T i ho ha e
N cleo ide (ATP)
280.90 109.29
G ano ine-5'-T i h




T i ho ha e
N cleo ide (CTP)
267.62 162.53
U idine-5 -T i ho








DNA Tem la e 11.08 11.08
T7 RNA Pol me a e 11.08 11.08
DNa e I 6.32 6.32
Pho ha a e 0.22 0.22
Wa e -fo -Injec ion 33,231 33,231
Cha ac e i ic Model Read T P ce TM WAVE B eac TM 200
S e
Dimen ion Ba e : 1852   1096   1120 
Rocking Ra e 4 - 25 c /
Rocking Angle 2  - 9
Bag Si e 200 L
S e ili a ion P a c g e- e d ab e b eac  bag
O e a ion
Condi ion
Tem e a e 37℃
P e e 1 a
H 8.1
Re idence Time 5 h
P cha e Co $400,000.00 e  
$709.00 e  bag
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16.3 IVT P od c  S o age Tank
De c i ion and
F nc ion
H d IVT d c    TFF1.
N mbe  Re i ed 1.0
Vendo The Ca  C a
O e a ion Ba ch
Ma e ial  Handled Inle  (g/ba ch) O le  (g/ba ch)
T i  H d ochlo ide 402.56 402.56
Magne i m Chlo ide 40.38 40.38
1,4-Di hio h ei ol
(DTT)
170.87 170.87
S e midine 32.18 32.18




5'-T i ho ha e
N cleo ide (ATP)
109.29 109.29
G ano ine-5'-T i h




T i ho ha e
N cleo ide (CTP)
162.53 162.53
U idine-5 -T i ho
ha e N cleo ide
(UTP)
91.39 91.39




DNA Tem la e 11.08 11.08
106
T7 RNA Pol me a e 11.08 11.08
DNa e I 6.32 6.32
Pho ha a e 0.22 0.22
Wa e -fo -Injec ion 33,231 33,231
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g
a  fea e  a e- ece ed b  ha
a  f  c e e d a age, a e e
e e g de ce, 10 ga ge a e  ee  IBC
c c  h 2B f h a d a 2  b g
e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 110
Wo king Vol me (L) 110
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $1,727.19 e  
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16.4 Tangen ial Flo  Fil a ion 1 (TFF1)
De c i ion and
F nc ion
The a ge a  f  f a  de ce  ed  f he IVT d c
  ha   RNA  e a g h  he e e a e. Th
d af a  e   e a f e  h a  100 D ec a  e gh  c - ff.
E e  e e, a , a d he  ec e  a e ab e f  h gh he f e
a d ge  ca ed a  he e ea e. The RNA a d TFF b ffe  ca  a
h gh he e b a e. The  a e ef  a  e e a e a d a e ec e ed  he
d c   h ch  fed  he e  ce . The TFF e  ha















T i  H d ochlo ide 402.56 0 402.56
Magne i m Chlo ide 40.38 0 40.38




S e midine 32.18 0 32.18





5'-T i ho ha e
N cleo ide (ATP)
109.29 0 109.29
G ano ine-5'-T i h




T i ho ha e
N cleo ide (CTP)
162.53 0 162.53
108
U idine-5 -T i ho
ha e N cleo ide
(UTP)
91.39 0 91.39
Ca  Analog (Clean
Ca )
1,158.59 0 1,158.59
mRNA 520.62 510.21 10.41
DNA Tem la e 11.08 0 11.08
T7 RNA
Pol me a e
11.08 0 11.08
DNa e I 6.32 0 6.32
Pho ha a e 0.22 0 0.22
Wa e -fo -Injec ion 1,136,454 33,231 1,103,223
Cha ac e i ic Model Ce a a  100 SAT TFF S e
Ma e ial of
Con c ion
S a e  S ee  304
Memb ane Fil e
Ma e ial
PES ( e he f e)
Memb ane i e (m2) 6.29
MWCO 100 Da
Flo  Ra e (L/ho ) 440
Fl  (l/h /m2) 70
B ffe  T e Wa e -F -I ec
To al Fil a e
Vol me (L)
1100
Vol me of mRNA
Sol ion (L)
110










P e e D o  (a m) 0.7
O e a ion
Condi ion
Tem e a e 4℃
P cha e Co $150,000 e   ( c de  e b a e, ca e e , a d c  e )
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16.5 TFF1 Pe mea e Wa e Tank
De c i ion and
F nc ion
H d he Pe ea e V e f  TFF1 a  h   a a e d c  ha  
 eeded f  he ce . E e a  h   be d ed f
a a e .
N mbe  Re i ed 1.0
Vendo The Ca  C a
O e a ion Ba ch
Ma e ial  Handled Inle  (g/ba ch) O le  (g/ba ch)
T i  H d ochlo ide 402.56 402.56
Magne i m Chlo ide 40.38 40.38
1,4-Di hio h ei ol
(DTT) 170.87 170.87
S e midine 32.18 32.18
0.01% ( / ) T i on
X-100 11.85 11.85
Adeno ine
5'-T i ho ha e
N cleo ide (ATP)
109.29 109.29
G ano ine-5'-T i h




T i ho ha e
N cleo ide (CTP)
162.53 162.53
U idine-5 -T i ho
ha e N cleo ide
(UTP)
91.39 91.39
Ca  Analog (Clean
Ca ) 1,158.59 1,158.59
mRNA 10.41 10.41
111
DNA Tem la e 11.08 11.08
T7 RNA Pol me a e 11.08 11.08
DNa e I 6.32 6.32
Pho ha a e 0.22 0.22
Wa e -fo -Injec ion 1,103,223 1,103,223
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g
a  fea e  a e- ece ed b  ha
a  f  c e e d a age, a e e
e e g de ce, 10 ga ge a e  ee  IBC
c c  h 2B f h a d a 2  b g
e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 1000
Wo king Vol me (L) 990
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $2,186.78 e  
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16.6 TFF1 Re en a e S o age Tank
De c i ion and
F nc ion
H d he Re e a e V e f  TFF1   he Ch a g a h
C . Th   c a  he RNA a d  ha  be f he
ce ed d ea .
N mbe  Re i ed 1.0
Vendo The Ca  C a
O e a ion Ba ch
Ma e ial  Handled Inle  (g/ba ch) O le  (g/ba ch)
mRNA 510.21 510.21
Wa e -fo -Injec ion 33,231 33,231
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g
a  fea e  a e- ece ed b  ha
a  f  c e e d a age, a e e
e e g de ce, 10 ga ge a e  ee  IBC
c c  h 2B f h a d a 2  b g
e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 110
Wo king Vol me (L) 110
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $1,727.19 e  
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16.7 Cell lo e Ch oma og a h  Col mn
De c i ion and
F nc ion
The ce e ch a g a h  c   ed  b d d RNA  e e 



















HEPES 2,385,943.15 0 2,385,943.15
EDTA 29,259.95 0 29,259.95
NaCl 7,313,985.28 0 7,313,985.28
E hanol 126,395.28 0 126,395.28
WFI 46,902.96 0 46,902.96
WFI ( a h e
onl )
827,361.26 0 827,361.26
Cha ac e i ic Model Ic  Sc e f c
Ma e ial of
Con c ion
S a e  S ee
C o - ec ional
a ea (m2)
2.46
Heigh  (m) 0.4
Diame e  (m) 1.77
114
Veloci  (cm/h ) 21.54
Flo  Ra e
(L/ho )
7,154.69
Fl  (l/h /m2) 82.5
O e a ion
Condi ion
Tem e a e 4℃
P cha e Co $374,400.00 e   ( c de  FPLC c  e )
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16.8 Ch oma og a h  B ffe  S o age Tank
De c i ion and
F nc ion
H d he Ch a g a h  B ffe    he Ch a g a h
C . Th  a  h d  6.5 ba che  h f Ch a g a h b ffe .
Th , h  a   be f ed a  he beg g f e a  h 6.5
ba che  h f b ffe .
N mbe  Re i ed 1.0
Vendo The Ca  C a
O e a ion Ba ch




E hanol 126,395.28 126,395.28
HEPES 2,385,943.15 2,385,943.15
Wa e -Fo -Injec ion 46,902.96 46,902.96
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g
a  fea e  a e- ece ed b  ha
a  f  c e e d a age, a e e
e e g de ce, 10 ga ge a e  ee  IBC
c c  h 2B f h a d a 2  b g
e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 6,510
Wo king Vol me (L) 6,508
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $5,443.20 e  
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16.9 Cell lo e Re in S o age Tank
De c i ion and
F nc ion
H d he Ce e Re  eeded f  he Ch a g a h C .
Th  e  ca  be e ed a d    eed   be ade ce.
N mbe  Re i ed 1.0
Vendo The Ca  C a
O e a ion Ba ch
Ma e ial  Handled Inle O le
Cell lo e (g) 275,000 275,000
Ch oma og a h
B ffe  (L) 1,540 1,540
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g
a  fea e  a e- ece ed b  ha
a  f  c e e d a age, a e e
e e g de ce, 10 ga ge a e  ee  IBC
c c  h 2B f h a d a 2  b g
e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 1,540
Wo king Vol me (L) 1,540
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $2,555.81 e  
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16.10 Reco e ed P od c  f om Ch oma og a h  Col mn S o age Tank
De c i ion and
F nc ion
H d he Rec e ed RNA  f h gh f he




Vendo The Ca  C a










E hanol 126,395.28 126,395.28
Single S anded
mRNA ( RNA) 505.10 505.10
Do ble S anded
mRNA (d RNA) 0.26 0.26
Wa e -Fo -Injec ion 46,902.96 46,902.96
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g a
fea e  a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B
f h a d a 2  b g e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 130
Wo king Vol me
(L)
126
O e a ion
Condi ion
Tem e a e 4℃
118
P e e 1 a
P cha e Co $1,763.92 e  
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16.11 El ed Do ble S anded RNA Wa e Tank
De c i ion and
F nc ion
H d he e ed d b e a ded RNA (d RNA) f h gh
f  he Ch a g a h  C . Th    a e a    
eeded f  he f a  d c  a d h   ed a a e a . E e a




Vendo The Ca  C a




Do ble S anded
mRNA (d RNA)
(g/ba ch) 4.85 4.85
Ch oma og a h
B ffe  (L) 984.95 984.95
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g a
fea e  a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B f h
a d a 2  b g e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 1,000
Wo king Vol me
(L)
985
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $2,186.78 e  
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16.12 Tangen ial Flo  Fil a ion 2
De c i ion and
F nc ion
The a ge a  f  f a  de ce (TFF2)  ed f  a b ffe  e cha ge
f g he ch a g a h  c   ge  d f he b ffe  f  he
ch a g a h  h ch c a ed e ha , EDTA, HEPES, NaC . Th
d af a  e   e a f e  h a  100 D ec a  e gh  c - ff.
The TFF e  ha  a ca e e h de  a d a f e . Th  TFF   e

















50 mM Sodi m
Ace a e
5,179.49 517.95 4,661.54
HEPES 2,385,943.15 0 2,385,943.15
EDTA 29,259.95 0 29,259.95
NaCl 7,313,985.28 0 7,313,985.28
E hanol 126,395.28 0 126,395.28
WFI 46,902.96 46,902.96 0
Cha ac e i ic Model Ce a a  100 SAT TFF S e
Ma e ial of
Con c ion
S a e  S ee  304
Memb ane Fil e
Ma e ial
PES ( e he f e)





Flo  Ra e
(L/ho )
505
Fl  (l/h /m2) 82.5
B ffe  T e 50 M S d  Ace a e
To al Fil a e
Vol me (L)
1,263.76
Vol me of mRNA
Sol ion (L)
126.28
Re en a e Vol me
(L)
126.27






P e e D o
(a m)
0.7
O e a ion
Condi ion
Tem e a e 4℃
P cha e Co $150,000 e   ( c de  e b a e, ca e e , a d c  e )
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16.13 Sodi m Ace a e B ffe  S o age Tank
De c i ion and
F nc ion
H d he S d  Ace a e B ffe    TFF2. Th b ffe  ac  a  he




Vendo The Ca  C a
O e a ion Ba ch
Ma e ial
Handled
Inle  (g/ba ch) O le  (g/ba ch)
Sodi m Ace a e 5,179 5,179
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g a
fea e  a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B f h
a d a 2  b g e g.
Ma e ial of
Con c ion
S a e  S ee  304




O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $2,233.09 e  
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16.14 TFF2 Re en a e S o age Tank
De c i ion and
F nc ion
H d he Re e a e V e f  TFF2   he S e e F a  1
S e . Th   c a  he RNA a d  ha  be f he




Vendo The Ca  C a





O le  (g/ba ch)
Single S anded
mRNA ( RNA) 495.00 495.00
Sodi m Ace a e 517.95 517.95
Wa e -Fo -Injec ion 46,902.96 46,902.96
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g a
fea e  a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B
f h a d a 2  b g e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 130
Wo king Vol me
(L)
126
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $1,763.92 e  
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16.15 TFF2 Pe mea e Wa e Tank
De c i ion and
F nc ion
H d he Pe ea e V e f  TFF2 a  h   a a e d c  ha   
eeded f  he ce . E e a  h   be d ed f




Vendo The Ca  C a









E hanol 126,395.28 126,395.28
Single S anded
mRNA ( RNA) 10.10 10.10
Sodi m Ace a e 4,661.54 4,661.54
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g a
fea e  a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B f h
a d a 2  b g e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 1,325
Wo king Vol me
(L)
1,136
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
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P cha e Co $2,233.09 e  
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16.16 S e ile Fil e  1
De c i ion and
F nc ion
S e e f e  e e bac e a  c ga , a d he e f e  ha e a
e e f 0.2 . U  ed  e a a  f M c f d c de ce  




Vendo M eS g a





O le  (g/ba ch)
Single S anded
mRNA ( RNA) 495.00 495.00
Sodi m Ace a e 517.95 517.95
Wa e -Fo -Injec ion 4,6902.96 4,6902.96
Cha ac e i ic Model O ca  S e e XLT 10 M e E e . The
de   a ca e h a 0.2  f e  ha  e a
d ffe e a  e e f 6.9 ba   f e  h gh
b g ca  e .
Ma e ial of
Con c ion
P e e/P f e
Memb ane A ea 0.54 2
Fl 7 L/ /c 2
Vol me 130 L
Wo king Vol me 126 L
S e ili a ion D ab e f e
O e a ion
Condi ion
Tem e a e 4℃
P e e 6.2 ba
P cha e Co $1,150 e  
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16.17 Dil ion 1 Tank
De c i ion and
F nc ion
I a  h  a   e b e f  h d g he RNA  c g 
f he S e e F a  1 U  O e a . A d f h  RNA 
h 50 M f S d  Ace a e  e f ed h  h a    he




Vendo The Ca  C a






O le  Po -Dil ion (g/ba ch)
Single S anded
mRNA ( RNA) 495.00 495.00
Sodi m Ace a e 517.95 15,181.65
Wa e -Fo -Injec ion 46,902.96 46,902.96
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g a
fea e  a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B
f h a d a 2  b g e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 3,785
Wo king Vol me
(L)
3,701
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $3,556.90 e  
128
16.18 E hanol S o age Tank
De c i ion and
F nc ion
H d  e ba ch h f E ha  eeded f  he d f L d  bef e




Vendo The Ca  C a
O e a ion Ba ch
Ma e ial
Handled
Inle  (g/ba ch) O le  (g/ba ch)
E hanol 973,440.30 973,440.30
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g a
fea e  a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B f h
a d a 2  b g e g.
Ma e ial of
Con c ion
S a e  S ee  304




O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $2,233.09 e  
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16.19 Li id and E hanol Sol ion S o age Tank
De c i ion and
F nc ion
H d  e ba ch h f L d -E ha    he M c f d c
De ce. D ea  h  a , h    be fed  he




Vendo The Ca  C a
O e a ion Ba ch
Ma e ial
Handled
Inle  (g/ba ch) O le  (g/ba ch)




Chole e ol 3,692.31 3,692.31
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g a
fea e  a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B f h
a d a 2  b g e g.
Ma e ial of
Con c ion
S a e  S ee  304




O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $2,233.09 e  
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16.20 Mic ofl idic De ice
De c i ion and
F nc ion
The c f d c g de ce   be ed  e ca a e he RNA 
d a a c e  (LNP ). The e agge ed he gb e c f d c
e  de ce   be a a e ed  25 e  f 16 c f d c ch
de ce , a d   be ed  c  he f a e  each de ce.
The de ce  ha e  e ; e e   d  d ed  e ha , a d he
he  e   RNA  a  a e  b ffe . The e de ce a  f  a d
g h gh a g cha e   he de  f c ec d h ch ead
 he e ca a  f RNA a d he f a  f LNP .
Vendo P ec  Na e
O e a ion C
Ma e ial
Handled
In  (g/ba ch) O  (g/ba ch)
mRNA 495.00 495.00




Chole e ol 3,692.31 3,692.31
E hanol 973,440.30 973,440.30
Cha ac e i ic Model (ba ed
on) Na A e b TM P a f
Dimen ion Mi ing Channel 200  b  79 
He ingbone S c e 31  h gh, 50  h c
Con c ion
Ma e ial
P d e h a e (PDMS)
S e ili a ion Ne  ch  ca  be cha ed; f ca  e  f
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
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H Sodi m Ace a e B ffe 4.0
Re idence Time 3 
Flo  Ra e e
De ice
mRNA in Sodi m
Ace a e
9 L/
Li id  in E hanol 3 L/
To al 12 L/
P cha e Co $13,000 e  16X e
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16.21 Mic ofl idic  P od c  S o age Tank
De c i ion and
F nc ion






The Ca  C a
O e a ion Ba ch
Ma e ial
Handled
Inle  (g/ba ch) O le  (g/ba ch)




Chole e ol 3,692.31 3,692.31
Wa e -Fo -Injec ion 46,902.96 46,902.96
mRNA ( ingle
anded) 495.00 495.00
50 mM Sodi m
Ace a e 15,181.65 15,181.65
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g a
fea e  a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B
f h a d a 2  b g e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 5,678
Wo king Vol me 4,935
133
(L)
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $4,500.05 e  
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16.21 Tangen ial Flo  Fil a ion 3
De c i ion and
F nc ion
The a ge a  f  f a  de ce  ed  d a b ffe  e cha ge  he
d c  f he M c f d c  h PBS  add he a eeded  he
ha ace ca  f a . Th  d af a  e  e a f e  h a
100 D ec a  e gh  c - ff.
The TFF e  ha  a ca e e h de  a d a f e . Th  TFF   e

















50 mM Sodi m
Ace a e
15,181.65 0.00 15,181.65
Li id 14,215.38 13,931.08 284.31
E hanol 973,440.30 0.00 973,440.30




o a i m
ho ha e
6,745.58 78.63 6,666.94
Sodi m Chlo ide 264,436.87 3,082.46 261,354.40
Diba ic odi m
ho ha e h d a e
54,461.64 634.84 53,826.80
WFI 46,902.96 0 46,902.96
Cha ac e i ic Model Ma e e 100 AT TFF S e
Ma e ial of S a e  S ee  304
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Con c ion
Memb ane Fil e
Ma e ial
PES ( e he f e)




Flo  Ra e
(L/ho )
7,154.69
Fl  (l/h /m2) 82.5
B ffe  T e Ph ha e B ffe ed Sa e (PBS)
To al Fil a e
Vol me (L)
53,660.14
Vol me of LNP
Sol ion (L)
4,935.06
Re en a e Vol me
(L)
625.50






P e e D o
(a m)
0.7
O e a ion
Condi ion
Tem e a e 4℃
P cha e Co $150,000 e   ( c de  e b a e, ca e e , a d c  e )
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16.22 PBS B ffe  S o age Tank
De c i ion and
F nc ion
H d he PBS B ffe    TFF3. Th  b ffe  ac a  he b ffe  




Vendo The Ca  C a
O e a ion Ba ch
Ma e ial
Handled
Inle  (g/ba ch) O le  (g/ba ch)
PBS B ffe 333,574.81 333,574.81
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g a
fea e  a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B f h
a d a 2  b g e g.
Ma e ial of
Con c ion
S a e  S ee  304




O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $29,965.10 e  
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16.23 TFF3 Re en a e S o age Tank
De c i ion and
F nc ion
H d he Re e a e V e f  TFF3   he S e e F a  2
S e . Th   c a  he RNA a d  ha  be f he




Vendo The Ca  C a
O e a ion Ba ch
Ma e ial
Handled
Inle  (g/ba ch) O le  (g/ba ch)
mRNA (Single
S anded) 485.10 485.10
50 mM Sodi m
Ace a e 0.00 0.00
Li id 13,931.08 13,931.08
E hanol 0.00 0.00
Po a i m Chlo ide 92.45 92.45
Monoba ic
o a i m ho ha e 78.63 78.63
Sodi m Chlo ide 3,082.46 3,082.46
Diba ic odi m
ho ha e h d a e 634.84 634.84
Wa e -Fo -Injec ion 0.00 0.00
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g a
fea e  a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B
f h a d a 2  b g e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 682
138
Wo king Vol me
(L)
626
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $2,086.71 e  
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16.24 TFF3 Pe mea e Wa e Tank
De c i ion and
F nc ion
H d he Pe ea e V e f  TFF3 a  h   a a e d c  ha   
eeded f  he ce . E e a  h   be d ed f




Vendo The Ca  C a
O e a ion Ba ch
Ma e ial
Handled
Inle  (g/ba ch) O le  (g/ba ch)
mRNA (Single
S anded) 9.90 9.90
50 mM Sodi m Ace a e 15,181.65 15,181.65
Li id 284.31 284.31
E hanol 973,440.30 973,440.30
Po a i m Chlo ide 7,838.28 7,838.28
Monoba ic o a i m
ho ha e 6,666.94 6,666.94
Sodi m Chlo ide 261,354.40 261,354.40
Diba ic odi m
ho ha e h d a e 53,826.80 53,826.80
Wa e -Fo -Injec ion 46,902.96 46,902.96
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g
a  fea e  a e- ece ed b  ha
a  f  c e e d a age, a e e
e e g de ce, 10 ga ge a e  ee  IBC
c c  h 2B f h a d a 2  b g
e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 56,781
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Wo king Vol me (L) 53,035
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $29,965.10 e  
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16.25 S e ile Fil a ion 2
De c i ion and
F nc ion
S e e f e  e e bac e a  c ga , a d he e f e  ha e a
e e f 0.2 . U  ed  e a a  f M c f d c de ce  




Vendo M eS g a
O e a ion Ba ch
Ma e ial
Handled
Inle  (g/ba ch) O le  (g/ba ch)
mRNA (Single
S anded) 485.10 485.10
50 mM Sodi m
Ace a e 0.00 0.00
Li id 13,931.08 13,931.08
E hanol 0.00 0.00
Po a i m Chlo ide 92.45 92.45
Monoba ic o a i m
ho ha e 78.63 78.63
Sodi m Chlo ide 3,082.46 3,082.46
Diba ic odi m
ho ha e h d a e 634.84 634.84
Wa e -Fo -Injec ion 0.00 0.00
Cha ac e i ic Model O ca  S e e XLT 10 M e E e . The
de   a ca e h a 2 c  f e  ha  e
a d ffe e a  e e f 6.9 ba   f e  h gh
b g ca  e .
Ma e ial of
Con c ion
P e e/P f e
Memb ane A ea 0.54 2
Fl 7 L/ /c 2
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Vol me 130 L
Wo king Vol me 126 L
S e ili a ion D ab e f e
O e a ion
Condi ion
Tem e a e 4℃
P e e 6.2 ba
P cha e Co $1,150 e  
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16.26 PBS and S c o e Sol ion S o age Tank
De c i ion and
F nc ion
H d he 30% S c e  PBS B ffe    D 2. Th  a  h d




Vendo The Ca  C a




S c o e
(g/ba ch) 89,273.00 89,273.00
PBS (L) 297.58 297.58
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g a
fea e  a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B f h
a d a 2  b g e g.
Ma e ial of
Con c ion
S a e  S ee  304




O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $1,859.23 e  
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16.27 Dil ion 2 S o age Tank
De c i ion and
F nc ion
I a  h  a   e b e f  h d g he LNP- RNA 
c g  f he S e e F a  2 U  O e a . A d  f h
LNP- RNA  h 30% S c e  PBS B ffe  e f ed h




Vendo The Ca  C a
O e a ion Ba ch
Ma e ial
Handled
Inle  (g/ba ch) O le  (g/ba ch)
mRNA (Single
S anded) 485.10 485.10
Li id 13,931.08 13,931.08
Po a i m
Chlo ide 92.45 153.85
Monoba ic
o a i m
ho ha e 78.63 153.85
Sodi m Chlo ide 3082.46 5,538.46
Diba ic odi m
ho ha e
h d a e 634.84 1,076.92
30% S c o e in
PBS 89,273.00 89,273.00
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g a
fea e  a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B f h
a d a 2  b g e g.
Ma e ial of
Con c ion
S a e  S ee  304





O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $2,168.67 e  
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16.28 Wa e  P ifica ion S em
De c i ion and
F nc ion
The a e a e  f ca  e   a e c a  a  a e
a d f   ch ha   ca  be ed  a e a ha ace ca d c
ha   afe f  ec   h a . The a e a e   be ed
 d g a d e a g a  a e a  a  e  a  a  f he 
e a   h  ce
Vendo M eS g a
O e a ion Ba ch
Ma e ial  Handled In  (L/ eek) O  (L/ eek)
M nici al Wa e 17,500 17,500
Cha ac e i ic Model (ba ed on) M eS g a S e -Q P  Wa e
P f ca  S e
Dimen ion 81 c   115 c   22 c
Ma im m Dail
P od c  Wa e
U age
8000 L
S e ili a ion P f ca  e
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $175,000.00
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16.29 Pe i al ic P m
De c i ion and
F nc ion
Pe a c P  ha e bee  de g ed  a a e a  
a d f  a    he ce . The  a  ha e e
e e d  a d e  e e e  ba ed  he a e a  a d
f  a e he  a e e b e f  a g.
Vendo Wa -Ma
O e a ion Ba ch
Ma e ial  Handled Va  Ma e a
Cha ac e i ic Model 825 e e
P m  Head
Ma e ial
A  a
S o  and F ame
Ma e ial
304 S a e  S ee
S e ili a ion P f ca  e
Ma im m Flo
Ra e
33 L/
Ma im m P e e 3.5 a
S e ili a ion CIP, SIP
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
Flo  Ra e Va ab e
P cha e Co $3,000 e  
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17. E i men  Co  S mma
Tab e 17.1 de a  he cha e c  f each ece f e e  eeded  he
a fac g ce . The ab e a  c de  he a fac e  f each ece f e e
he  a cab e, he ba e d  fac  ed f each ece f e e , a d he a  ba e
d e c  f  a g e ece f ha  e e . The ba e d e fac  acc  f  a
add a  c  a c a ed h g, g, e ec ca  f da , a a , e g ee g
de g , e c. Whe  a cab e, he ba e d e fac e e a e  f  Tab e 16.11  Se de , e .
a . I  add , a ba e d e fac  f 4.0 a  ed f  a  he age a d a e a  a d a
ba e d e fac  f 3.3 a  ed f  he , a  ad ed b  he c e c . F  he
e a g e e , a ba e d e fac  f 2.0 a ed a  h  a  ad ed   b
P fe  V a a. Wh e he fac  f  a ca  che ca e g ee g a   a e age  a d
3.21, a gh  e  fac  f 2.0 a e  e e f h  ce  beca e  f he e e  
h gh  ec a ed f  b ha ace ca  a ca a d e e e e. Th , he e a g
e e  a  ced g a ba e d e fac  f 2.0.
Table 17.1. E e  C  f  A  U  O e a U ed I  Ma fac g P ce















S n he i  and P ifica ion of mRNA
IVT F ee e N/A The  F he
Sc e f c
$8,264 1 2.0 $16,528
IVT Wa e
Bio eac o
PU-1 C a L fe
Sc e ce
$409,225 2 2.0 $3,273,800
T i  B ffe STOR-1 The Ca $1,859 1 4.0 $7,437
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S o age Tank C a
IVT P od c
S o age Tank
STOR-2 The Ca
C a
$1,727 1 4.0 $6,909
Tangen ial
Flo  Fil a ion
1
PU-2 Pa $150,000 1 2.0 $300,000




$2,187 1 4.0 $8,747
TFF1 Re en a e
S o age Tank
STOR-4 The Ca
C a
$1,727 1 4.0 $6,909
Cell lo e
Ch oma og a
h  Col mn
PU-3 Pa $124,314 1 4.16 $517,146
Ch oma og a
h  B ffe
S o age Tank
STOR-5 The Ca
C a
$5,443 1 4.0 $21,772
Cell lo e Re in
S o age Tank
STOR-6 The Ca
C a
$2,556 1 4.0 $10,223
Reco e ed
P od c  f om
Ch oma og a
h  Col mn
S o age Tank
STOR-8 The Ca
C a
$1,764 1 4.0 $7,056





$2,187 1 4.0 $8,747
Tangen ial
Flo  Fil a ion
2
PU-4 Pa $150,000 1 2.0 $300,000
Sodi m Ace a e




$2,233 1 4.0 $8,932
TFF2 Re en a e STOR-1 The Ca $1,764 1 4.0 $7,056
150
S o age Tank 1 C a






$2,233 1 4.0 $8,932
S e ile Fil e PU-5 M e S g a $575 13 2.0 $14,950
Fo m la ion of LNP




$3,557 1 4.0 $14,228
E hanol



















$13,000 25 2.0 $650,000
Mic ofl idic
P od c





$4,500 1 4.0 $18,000
Tangen ial
Flo  Fil a ion
3
PU-7 N/A $1,000,000 1 2.0 $2,000,000
PBS B ffe





$29,965 1 4.0 $119,860
TFF3 Re en a e





$2,087 1 4.0 $8,347







S e ile Fil e PU-8 M e S g a $575 13 2.0 $14,950
Dil ion 2





$2,167 1 4.0 $8,675
PBS and STOR-2 The Ca $1,859 1 4.0 $7,437
151
S c o e
Sol ion
S o age Tank
0 C a




N/A M e S g a $175,000 1 2.0 $350,000
Pe i al ic
P m
N/A Wa -Ma $105,000 35 3.3 $346,500
To al $6,556,530
A  e e  cha e c  e e ca c a ed e he b  g e a  ded 
Product and Process Design Principles  a e e e  f  he a  e d  ed
ab e  Tab e 17.1 59. S ec f c ce  f  each e e  c  a d he a  c  ca c a
ca  be f d  A e d  C. F g e 17.1 de a  a b ea d  f he c  f  each ca eg  f
e e  ed  he a fac g ce .
Fig e 17.1. E e  C  B ea d  b  E e T e
152
A  h   F g e 17.1, he a ge a  f  f a e  (TFF ) acc  f  he
a ge  c  f he e a  e e , a  TFF  a e  40% f a  e e  c . Th  a  
be ed c ed a  a ge a  f  f a  e a e e e e e beca e he  c a  a
a  c d g a e b a e, ca e e , a , , a d . S ec f ca  h  h
ce  he e a e 3 TFF   a  ( abe ed TFF1, TFF2, a d TFF3) ha  a e fa  a ge  e, a
he  ha e a e b a e e f 6 2, 6 2, a d 87 2 , e ec f . Th , he TFF  e e e ec ed
 ha e a a ge cha e c , h TFF3 ha g he  e e e cha e c  f $2 
USD. I     ha  he e c  a e a ge f ed a  each TFF ha   f  h gh a
a e e f d  de   e  f e  c a a  a d a ed e e e .
Pe ha   he e  f h  a  a    he f a  e     ed ce he c ,
h e e , he c   e   be f a ag de d e  he a ge ce g e
ha  eed  be f e ed. The ec d g f ca  e e c  ed c ab  c e f  he Wa e
B eac  ha   ed f  he I -V  T a c ce . Wa e B eac  a e h gh
ec a ed b ce g e e  a d d e  h ec f c  e   a h gh cha g ce.
T ge he  b h he TFF  a d he Wa e B eac  acc f  e ha  50% f he a
e e  c .
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18. Fi ed Ca i al In e men  S mma
The P f ab  A a  4.0 ead hee , ha  a ded f  h  c e, a  ed 
c e de a ed f a c a  f  h  a fac g a . I    be a ed
h gh  h  ec  f he e . N e ha  he f a c a  e e de ed f  15 ea  f a
e a .
18.1 E i men  Co
The d d a  e e  c  ha  e e de a ed  Tab e 17.1 a  e ed  he
f ab  a a  a d each ece f e e a  a a  c a f ed a  e he  ce
ach e , fab ca ed e e , a e , age,  he . Eff  a  ade  c a f  each ece
f e e  acc d g , h e e  he e c a f ca h d  be a e   c c e e . The
a  ba e d e c , h ch acc  f  b h cha e a d a a  f f ed e e ,
a  ca c a ed  be $6,556,530 b  add g a  he d d a  e e  c  ge he  f  he
ce . A a  f he a  ba e d e c b  e e  ca eg  ca  be ee   F g e
18.1. I  h  f g e, a  he ce  e e  c a f ed  he ca eg e  ha  e e a a ab e
 he f ab  ead hee  a  e ed ab e.
Fig e 18.1. T a  Ba e M d e C  f  P ce
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18.2 To al Pe manen  In e men
The e  f a c a  ha  ca  be ca c a ed  he T a  Pe a e  I e e  (TPI) f  he
a . The f ab  a a  ead hee  ca c a e he TPI b  g G h e  fac -c
e h d h ch a  e  c e he c  f ce a c e  b  a g   be e
 f he a  ba e d e c . The e ec f ed  f  he a  ca  be ee  
F g e 18.2.
Fig e 18.2. G h e  Fac ed-C  Me h d f  T a Pe a e  I e e
N  e ce age a e  e e cha ged f  he defa e g   he f ab  ead hee .  I
add , he a ca ed c  f  a  a d e a ed fac e  a  e a ed  be $4,185,400.
I  de   a fac e he RNA acc e, he a eed   be e a ed a  4 deg ee  ce .
We e a ed ha   a  d be 10,000 f 2 e. The e a ed a ca ed c  f 
a  a d e a ed fac e  f $4,185,400 acc f  he c  f b d g a 10,000 f 2 c d 
a  4 deg ee  ce . Th  c d   a  ha   ed  he f d a fac g d .
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The a c a ed c  f b d g he a  a d cha g he e e   ee  h  
c d a  e a ed f  h ca  f d d  c 60. Th  c  a  a  a ed b  
ad  D . D a d. I  add ,  a  ec e ded b  D . D a d  ha e a $5,000,000
a  e e e. W h a  he e fac , he a e a e  e e - ad ed f  h  a
 $20,063,046. D e  he ca  f he a  be g  M b e, PA, a e fac  f 1.10 f
he N hea  ca  eed   be c de ed59. Af e  ad g f  he e fac , he a
e a e  e e  f  h  a   ab a ed be $22,069,351. A de a ed b ea d  f he
a  e a e  e e  c  ca  be ee   F g e 18.3.
Fig e 18.3. T a  Pe a e  I e e  f  P a
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19. O e a ing Co  - Co  of Man fac e
19.1 Ra  Ma e ial
Tab e 19.1 de a  he c  f  each f he a a e a  eeded f  h  ce  
d ce 200  d e  f he acc e h a 20 e ce  afe  fac . I  add , h  ab e
de a  he c  f a  a e a  eeded e  d e f RNA acc e. The ce  a ed f  each
a  a e a  a e d c e ed  Tab e 11.1.
Table 19.1. C  f Ra  Ma e a  U ed I  Ma fac g P ce
Ma e ial Co  fo  P od cing
200 million do e
i h a 20% Safe
Fac o  ($USD)
Co  ($USD/do e of mRNA
accine)
Pla mid DNA $1,000,000 $5.00E-03
T7 RNA Pol me a e $162,433,128 $8.12E-01
Adeno ine 5'-T i ho ha e
N cleo ide (ATP) $27,445 $1.37E-04
G ano ine-5'-T i ho ha e
N cleo ide (GTP) $46,024 $2.30E-04
C idine T i ho ha e N cleo ide
(CTP) $42,117 $2.11E-04
U idine-5 -T i ho ha e
N cleo ide (UTP) $151,574 $7.58E-04
RNA Ca  Analog $139,583,190 $6.98E-01
T i  H d ochlo ide $1,675 $8.37E-06
Magne i m Chlo ide $141 $7.03E-07
1,4-Di hio h ei ol $21,013 $1.05E-04
S e midine $4,844 $2.42E-05
T i on X-100 $4.81 $2.40E-08
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DNa e I $9,380,637 $4.69E-02
Alkaline Pho ha a e $325,442 $1.63E-03
Cell lo e $6,875 $3.44E-05
HEPES $4,761,150 $2.38E-02
E h lenediamine e aace ic acid
(EDTA) $37,467 $1.87E-04
Sodi m Chlo ide (NaCl) $270,032 $1.35E-03
E hanol $699,221 $3.50E-03
Sodi m Ace a e $1,812 $9.06E-06
ALC-0315
((4-h d o b l)a anedi l)bi (he
ane-6,1-di l)bi (2-he ldecanoa e
) $44,634,000 $2.23E-01
ALC-0159 (2-[( ol e h lene
gl col)-2000]-N,N-di e adec lace
amide) $474,630 $2.37E-03
DSPC
(1,2-di ea o l- n-gl ce o-3- ho
hocholine) $3,240,000 $1.62E-02
Chole e ol $46,000 $2.30E-04
PBS $5,889,513 $2.94E-02
S c o e $723,111 $3.62E-03
Sodi m h d o ide $134,350 $6.72E-04
Af e  g he e c ,  a  de e ed ha  d ce 200  d e  h a
20% afe  fac , he a  e d  $373,935,395 a  a e a . Pe  d e f RNA acc e
d ced, he a  e d  $1.87  a  a e a . Th  ce e  d e  a  a e  ha  he
e g ce f $15 d a  e  d e. I  , h f eca  ha  a fac g he RNA
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acc e  h gh  c a e. The a ge  c  f a  he a  a e a   T7 RNA P e a e. If
h  a  e e   f  a  ea , he e he e a c d b d a e a h  h he
e d , e d e ec  ha  he b - c g c f T7 RNA P e a e d be e  ha
ha  e e a ed   be, he ef e dec ea g he c  f T7 RNA P e a e a a . Th
  d ed ce he c  f a  a  a e a eeded e  d e. I  add , he c  f
cha g he RNA Ca  A a g a  he ec d e e e a  a e a . Th  a
e ec ed a  he RNA Ca  A a g  a h gh  ec f c b g ca  e e e  f h gh .
19.2 U ili ie
Tab e 19.2 de a  he c  f  e  eeded f  h  ce   d ce 200 
d e  f he acc e h a 20 e ce  afe  fac . I  add , h  ab e de a  he c  f
e  eeded e  d e f RNA acc e.  The ce a ed f  each  a e d c e ed
 Tab e 14.1 a d a e de a ed b ea d  f each  eeded  ded  Sec  14 f
h  e .
Table 19.2. C  f U e  U ed I  Ma fac g P ce
U ili Co  fo  P od cing 200
million do e  i h a 20%
Safe  Fac o  ($USD)
Co  ($USD/do e of mRNA
accine)
P oce  Wa e $10,000 $5.00E-05
Elec ici $600,000 $3.00E-03
T  d ce 200  d e  f he RNA acc e h a 20% afe  fac , he a  e d




I   e a ed ha  he a  d eed 30 e a e  h f . I  a  a ed e  da
ha  he e d be 5 h f . Acc d g  Se de e . a ., a  e a   a ed  a e $40
d a  e  h . Th ,  a  a  e a   e ec ed  a e $60,000/ ea .
19.4 Remaining Fi ed Co
The e a g f ed c  a e ca c a ed g G h e fac ed-c  e h d . The
a a e e  f  he e f ed c  a e de a ed  F g e 19.1 be .
Fig e 19.1. Re a g F ed C  Fac  U ed I Ma fac g P ce
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A g de he e a a e e   a  e a ed ha  he e a  fee  f he a  ace d be
$1,000,000 a a  f  a a  ca ed  M b e, PA. We e f ed h  c  e a e h
he he  f D . D a d. I  add , a  f he fee a c a ed h ac ag g a e ed 
he a a  M ce a e  c . Pac ag g f  h ce  c de  a e c f g, abe g,
f ee g, a d age ac ag g a d h e . W h he he  f D . D a d, e e a ed he
a a  ac ag g c   be $300,000,000. Pac ag g  e  c    a e  e e ha  h
c   a   he a fac g c  a a .
19.5 Wo king Ca i al
The g ca a  c e  e a g c  e ed f  he beg g e a  f he
a  a d  c de  he c  f he e  a d a  f d  eeded  c e  acc  ece ab e.
S a   he e a g f ed c , he g ca a   c ed g he fac ed-c
e h d. The a a e e  f  h  e h d a e ed  F g e 19.2. A  fac  a e he a e a  he
defa   he f ab  a a  ead hee e ce  f  RNA acc e I e  a d Ra
Ma e a . B h he RNA I e  a d Ra  Ma e a e e e   be 7 da  a  e e ec  ha
he a   c a  a  a    e a ee ' h f e  a d d c .
Fig e 19.2. Fac -C  Pa a e e  f  W g Ca a
F g e 19.3 c a  a de a ed c a a  b ea d f he g ca a  f  he
a  e a . The a  e a e  e e , h ch a  ca c a ed  F g e 18.3, ed
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h he g ca a  g e  he a  ca a  e e . F  h  ce , he a  a
ca a  e e   $745,950,447.
Fig e 19.3. W g Ca a  C a  B ea d
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20. P ofi abili  Anal i  - B ine  Ca e
20.1 Ba eline Ca h Flo  S mma  and P ofi abili
The f ab  f he a fac g ce  a a a ed e  a 15 ea  e d. F
he ba e e ce  d c ed  h  ec , a d c  ce f $15.00 e  acc e d e a
ch e . Th   a   b  gh  e  ha he ce e  d e ha  he U ed S a e
g e e  a d f  100  d e  f he Pf e -B NTech RNA acc e; The U.S.
g e e  a d Pf e  $1.95 b  f  100 d e  a d h  a d $19.50 e  d e61.
R a e  e e e  a  $5,000,000  c e  ce g c  ch a  h e a c a ed h g he
e  ca c d (ALC-0315) a d he e  PEG a ed d (ALC-0159).
P f ab  a a  f he ce  e ea  ha   h gh  f ab e. The I e a  Ra e
f Re  (IRR) f  he ce   448.80%, he Ne P e e  Va e (NPV)  2021 f  he ce
 $19.6 b , a d he Re   I e e  (ROI) af e  he h d ea  f d c  
475.30% f  he ce . The fac  ha  h  ce  e  f ab e a e  ha  he ce  
e a  f ab e e e   he f a e e e  f a ba ch fa e  e e  b ea d . The
ca h f  a  f  h  ce  e  a 15 ea e d ca  be f d  F g e 20.1.
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Fig e 20.1. Ca h f  a  f  d c . De a  f  a  RNA acc e f  COVID-19
e  a 15 ea  e d h a ce e  acc e d e f $15.00. The a a  d e  b a  h
f a  a  c e ed g he P f ab A a  4.0 S ead hee .
20.2 P ice Pe  Do e Sen i i i  Anal i
A  d c ed  he e  ec , h  ce  e e e  f ab e. A  a
ea  f  h   he ecede ed de a d f  COVID-19 acc e  ha  cc ed beca e f he
c e  COVID-19 a de c. Af e  he a de c  e ,  a  be he ca e ha  COVID-19
acc a   be eeded a a  a   a f  acc e62. I  h  - a de c a ,
he e  be de a d f  COVID-19 acc e , b  he de a d  e  be ch e  ha   
c e . Se  a a  f h  ce  e ea ha  h  ce    f ab e a  a ce
e  d e f ch e  ha  $15.00; aga , a e ce e  d e  e  be ece a  f
- a de c a a  COVID-19 acc e . F g e 20.2 e ea  ha  h  ce  ca   be
f ab e a  a ce e  d e a   a  $6.00 h ch e e e  a 60% dec ea e f  he $15.00
e  d e ed f  h  ec  a d a 70% dec ea e f  he $19.50 e  d e ha  he U.S.
g e e  a d  Pf e -B NTech.
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Fig e 20.2. Se  A a  ce e  d e f he COVID-19 RNA acc e. The ba e e
ce f $15.00 e  d e  h   b e. Th  ce   h gh  f ab e e e  a  $6.00 e
d e. Ba e e a ab e c  e e ed.
20.3 Va iable Co  Sen i i i  Anal i
A  e  e ed, RNA acc e  f  COVID-19  e   be eeded 
he c g ea  b   eed  be d a  e c  e  d e he  c a ed h he c
e  d e be g ed c e . U g he ba e e a ab e c ,  a  h   he e
ec  ha  he c  e  d e c d be e ed e 60% f  he $15.00 e  d e e ec ed f
h  ec , a d he ce  d e a  f ab e. A a   a a  f ab  h e
f he  e g he ce e  d e  e g a ab e c  a c a ed h a fac g he
acc e. L e g a ab e c  ca  be d e b  e g he ce  f a  a e a  ed 
d c . The b  ce  f a  a e a  e e de e ed ba ed  h ee h  f
d c   a e 200  d e  f a  RNA acc e, a d b  ce  f  ea
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d c  d e  be e . Add a , e f he e e  eeded  he in vitro
a c  (IVT) eac  a d b e e  e e d ge  c d be ade -h e h ch
a  a e  a  a e a  c . M e e , b d g be e  e a h  h e d  e  e
 e  e   dec ea ed a ab e c . I he c e  COVID-19 a de c, a e  a e d e
b  he h gh de a d a d he e    he ha d  f he e  h he a a ab e a  a e a .
The e d a c  a e a c a  e ce   he U ed S a e  g e e  a g f  he
acc e, a  e  h ch ha  a g ea e  f a c a  d  a  ha  d a a e   e e  a
a ce c a . P - a de c,   e  he e  be a h f   eg a g e  a d
a fac g fac e  ce a  a e a  e  ha e e ce  a e a  f he  c e
d c g a  he e e  f he a de c.
F g e 20.3 h  IRR a  a f c  f e g ce f  h ee d ffe e  a ab e c .
The e  f a ge da a  e e e  a a  a ab e c  f a a e  $2.1 b , a 19%
dec ea e f  he ba e e a ab e c  h ch a  $2.6 b . The e  f ed da a 
e e e  a a  a ab e c  f a a e $1.6 b , a 38% dec ea e f  he ba e e
a ab e c . I  b h ca e  he e a ab e c a e ed ced, he ce  bec e  f ab e a
a e  e g ce c a ed  he ba e e ca e. S ec f ca , f  he ca e f 38% ed c  
a ab e c , he ce   f ab e a  $3.00 e  d e.
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Fig e 20.3. Se  a a  f he ce e d e a d a ab e c  f he COVID-19
RNA acc e. The ba e e ce f $15.00 e  d e  h   b e. Red c   a ab e
c  ca  a  f  he ce   be f ab e a  $3.00 e  d e.
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21. O he  Im o an  Con ide a ion
21.1 U e of od c
P   ec , each a  eed   be d ed h 1.8 L f 0.9% S d  Ch de
I ec . Th  d e    c ded a  a  f h  a fac g ce  a d  be ced
e e he e h a  e ac  c ce a  f 0.9%. Acc d g  he FDA Fac  Shee  f
Hea hca e de , Af e  d , he a  eed  be ed be ee  2 C a d 25 C a d  ed
h  6 h . I  h  age e d, he a eed  be e ed  a   gh  a d
a d UV  gh  e e. The a  c e  be e a a ed  0.3 L acc e . F  f
acc a , each a e  eed   ece e  d e f h  a c a  acc a  3 ee
a a .
21.2 FDA Reg la o  Fac o
A  a  ec ab e d c , he acc e f he ed a fac g ce   eed
FDA Reg a  A a . G e  he c e  COVID-19 a de c, he acc e ca  be
a h ed h gh a  E e ge c  U e A h a a  a  f O e a  Wa  S eed (OWS).
OWS  a a e h  be ee  he De a e  f Hea h a d H a  Se ce  (HHS), he
De a e  f Defe e (DOD) a d he a e ec 22. The g a  f OWS   acce e a e he
ce  f acc e a a  b  e e g a ec  f FDA eg a  h gh a a a e  ce .
I  de   ga  a h a , he acc e  eed  a  Pha e I, Pha e II a d Pha e III
c ca  a .
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The f  fac   be f g he I e ga a  Ne  D g a ca  (IND) f  Pha e I
d e . A  h  ea  , OWS a e   a  e a g he e a  a d e f  Pha e
III eff cac  a . F g Pha e I, he ce  e  Pha e II a d a  Pha e III
a . OWS e  a a ge  e f  Pha e III a h 30,000  50,000 a c a  h  c ea e
he a a ab  f da a  de   a a e e afe  da a de e d g   a  acce e a ed
e d f e55.
21.3 E i men  Reg la o  Fac o
A  ce   a d age a  ed  he a fac g ce   be cha ed 
acc da ce h c e  G d Ma fac g P ac ce (cGMP). Whe  a g he dec  
ce he DNA d c , g ea  ca e a d de a a  a e   e e he e ,
E ge ec, e  e e  a ed b  he FDA a d f  GMP h gh  he  d c
ce e . The he  ece  f e e   be cha ed f  e ab e c a e  e
The f he  a d Pa , a g he . S a , he dec  f ch g  e a a e
b eac  a  acc ed f  he eg a fac  f he a e b eac .
21.4 En i onmen al fac o
The ce   ge e a e a e  be a e   f ed b ffe , a  a d
e e . The a e f  each eac    be ed  a a e a  a d he a   be
c ed  b  S e c c e. S e c c e  a c a  ha ec a e   afe  c ec g a d
d g a e f  ed ca  ce e , a g he . C ac g S e c c e, h  ed
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ce  e e  a  a e  be e  d ca ded acc d g  c  d  a d
eg a  ac ce .  S e c c e ha  a  fac ca   Pe a a h ch  he a e
 h ch he a   be ca ed. Th  ge g a h c   be a  ad a age add g a a e
f afe  b  a g f  e f e b   ched g a e c ec .
21.5 Em lo ee afe , heal h, elfa e fac o
W h he e f he RNA ech g , h ce  d e   e e he ha d g f a e
 a e a ed . Th  a e  he a fac g ce  afe f  e ee afe   fac   
afe  ha  he a fac g ce  f  he  acc e e . The e a e a   b g ca
eac   ce  ed h gh  he ce . The c d e e a e  a d eac  c d
a  e e  he c ea  f bac e a c e .
Be d he e , a  e ee   ea a a e c h g a d PPE d c  
b h f  COVID-19 eg a  a d f  afe  c ce . A  e ee   be a ed f  he
afe a d e  e f e e . The g e a d a  de g   f   a
c  a e  a d e ee    be a ed h he Q a  C  e . The
 be a ed f  he afe e f he RNA Ge  E ec h e a d E d  A a  K .
21.6 Plan  loca ion fac o
The fac   be b   Me b e, PA. Th ca  a  ch e  f  h ee a
ea . F ,   e   a  a  h b b ha g c e   Ph ade h a
I e a a  A  a  e  a  he a   he Ne  Je e  a d Ne  Y  eg . Sec d , 
  a  a ea h e b ech g  c a e . Th   fac a e h e  f
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e . Th d ,   h g ha  h  a fac g ce   be  a d ffe e  a e
ha  M de a  a d Pf e . Th   f a ce ce  h  a de c a  h ee c a e
ha e he b ec e f acc a g a  a  e e a  b e  he h e  a  f e.
Ge g a h c d e f ca , e e  f  b  a e ead f c   c e , ed ce  he
ac  f a   f  a a a  d a e   he d a  e e  cc g  e a c a
a e.
The c  a e  ed  he f ab  a a f  he c c  f he a  a e
ba ed  c  a e  f  M b e, Pe a a. Add a , he c ac ed a e d a
c a , S e c c e, e a e   ha  a ea a d E ge ec, he e  f he DNA,  h
he d c   he a   M b e.
21.7 Global, c l e and ocial fac o
The acc e  f  be a h ed f e  he U ed S a e  h he E e ge c  U e
A h a . S a e , he acc e  ee a h a   he E ea  U  h
he E ea  Med c e  Age c  (EMA). The e a e a c a ed g ba  c ce . The
a fac g ce   e  e ha  a  e  a -a ae b c ce . A  a e , he
d c  ca  be ed b  M  c e  h  d be ab e  e h  d c  f he
a fac g ce  had c ded a  a ae b c fe e a e .
N e be  18 h 2020, he A e ca  Acade  f Med c e h ed a eb a
 COVID-19 c e a  h a e  e D . Ja e  H d e h (P e de  a d CEO, Meha
Med ca  C ege), D . La  C e  (P e de  a d D ec E e ), D . Ma  G be
(D ec , Off ce f Vacc e Re ea ch a d Re e , Ce e  f  B g c  E a a  a d
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Re ea ch, U.S. F d a d D g Ad a ) a d D . Ja  B e  (De  D ec  f
I fec  D ea e , Ce e  f  D ea e C  a d P e e ). Pa  f he c e a
f c ed  he a  a ec  f c de g he a e g f he acc e. The e e  a e
ed he e  a ce a  a ehe   acc e  he U ed S a e , e ec a   
g . D . Ja e  H d e h dec a ed, "I   ha d e a e he a ehe  a d  h ch
 c  a g   g  aga  ed c e." He d c ed he a ce f ha g
ed e e ge ,  ad ca e f  he e f he acc e. A g h he  eade  f he US
COVID-19 e e, he ed  de f  fa h eade a d c  ga e  h  a e
g  ea  f  he acc e. Th   c ca ce ce a   g  a e e
ed ed  ge  COVID-19. W h  he ed e e ge , D . H d e h a  he e  h
eed  he  a e he ea  e   ge  he acc e 64.
21.8 E hical fac o
The a fac g ce  d e   e he ha d g f a  a a a  ce . The
a  e h ca  c ce  d be he c g f he acc e. I  he a fac g ce  f he
COVID-19 acc e , he d c   be g cha ed b  he U ed S a e  g e e  h gh
O e a  Wa  S eed. The ag ee e  be ee  he a fac g c a  a d he US
g e e  a  acc  f  he he  ded b he g e e   b d he a  a d  f d
he c ca  a  g e  he e e ge c  a de c65. G e  h , he e   c ce  h he
c g f he acc e f  h  ec f c ce  ce he e  be  c e  ce b  ead
a  ag ee e  h a g e e  ha   acc  f fac  he  ha  he ce f he acc e.
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Th  a fac g ce  ca  be ed f  he d c  f he  acc e   he f e.
I  fac , RNA acc e  ha e he e a   be ed  ea g a a a a d ca ce . A  a c e
b hed  Na e  2020 d c e  he e  a ach f RNA ech g e   a a a
acc e . The d c  f h  e a  a a a acc e  he  d eed a a fac g
ce  e he e ed  h  a e . F  ch a a , g ea  ca e a d de a  d eed
 be a d  he e h ca  fac  f c g he acc e.
21.9 Ba ch Sched le
The d c   be b e  d   13 ba che h each ba ch c e ed e  a
7-da  e d. Each ba ch a  h he IVT Reac h ch  cc   a ba ch ce  a d
a e 5 h . The d c   he  c  f h gh he RNA f ca  ce ,
M c f d c , LNP P f ca  a d Pac ag g a d F ee g. I   a e a a e  2 da
f  a h e ee  h f d c   g  h gh he RNA f ca  ce . Th  c de
he e  a e   e a e he a  a e a , d e he c e  bef e he ce  ,
ad he a e a  f  he age a   he ce   a d he  f  he ce  
 he b e e  age a . I  a  c de he e  e -  he e e  a d  c ea
a d e e he e e  af e  e e  e. I  he RNA f ca  ce , each a ge a
f  f a    a e 2.5 h  a d he ce e ch a g a h  e   a e
a a e  2 h .
I   a e a a e  e da   f  a  e e ba ch f d c  h gh he
c f d c  ch . I   a e 19 h  f  he ac a  ce  a d he e a g e  be
eeded f  he d . A  e  he e e  c a ad ce, he c f d c ch   
173
eed  be c ea ed af e  e e  ba ch ce he d c   a e  a e  . Th  
e ed h he e  e e f a  e . G e  h , he a  ce  e f  he
c f d c  e    he ac a   e f he ce .
The LNP f ca  ce   a e a a e 1 da . Th   acc  f  he 2.5
h  a e  f  he a ge a  f  f a  a e  a  he e f  he e e f a  e . The
ac a   e f  he ce   be  he de f a fe  h  a d he e a g e
ched g f  h  e   be ed  e a e he a  a e a , d e he c e  a d
c ea  he e e  af e  e. A f ac  f e  a  be ed f  a  c ; d a c
gh  ca e g (DLS)  be ed  chec  he e f he LNP  f g he h d a ge a
f  f a  e , a d he LAL a a   be ed  ea e e d  e e  f g he
f a  d  a  d c ed  Sec  13.4.. The a  a  f he ce   ac ag g a d f ee g
h ch  a e a a e  2 da . Th  c de he e   a  a d abe  he a  a  e
a  he f ee g f he a .
A a e f a ee  ched e ca  be f d  F g e 21.1. A  e  e ed,
e ba ch  h f acc e  d ced e  a 7 da  e d. F g e 21.1 b ea  d  he 7 da
e d  he 5 a  a  d c ed e ; he e a  c de he IVT eac , RNA
f ca , c f d c , LNP f ca , a d ac ag g a d f ee g. The e f  each f
he a  c de  he e   he  e a  ha  a  a  e  a  he e a a  f a
a e a , ad g f a  a e a    e a , e g d c  f  he 
e a , a d c ea g he  e a . F g e 21.2 h  he e a  ba ch ched e f  he
13 ba che  ha   be   d ce he e ed 200  d e . The e  ba ch  be
a ed  he e e h da  f he e  ba ch. Th  a  d e  ee  he g a  f d c g
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200  d e   a a e  3 h . The ched e  F g e 21.2 h  ha  he 200
 d e  ca  be ade  gh  de  3 h , a d  he e e  f a  a c a ed
de a , he ce  h d a e  e ha  3 h . F g e 21.2 a  h  ha  he 200
 d e  ca  ac a  be d ced  a h e e d f e ha  ha   h . I  
b e ha  he e  ba ch ca  be a ed ea e ha  he e e h da  f he e  ba ch, h
g ea  ed c g he e  d ce 200  d e . We h   F g e 21.2 ha  200 
d e  ca  ea  be d ced  3 h  a d ha h  e e ca  be h e ed f  f e
d c .
Fig e 21.1. Ba ch ched e f  1 ba ch. Each ba ch a e  7 da   c e e a d g e  h gh a
5 a  ce : IVT Reac , RNA P f ca , M c f d c , LNP P f ca  a d
Pac ag g a d F ee g.
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Fig e 21.2. C e e ba ch ched e f  a  13 ba che . Each ba ch f  he a e ce  a
h   he de a   he e  age.
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22. Concl ion  and Recommenda ion
RNA acc e  a e a e  a d e c g acc e e h e a c a ed a fac g
ce   c ea , e e e, a d h gh  f ab e. The e h d f RNA he  ed  h
a fac g ce , in vitro a c  (IVT),  a ce -f ee b che ca  eac ; he fac
ha  he e e a fac g ce   ce -f ee ea  fe e  c a a   a e  eed  be
e ed, h  f g he b e e  f ca e . The ce -f ee a e f h  ce
a  a  f  he ce   be e a e  e e e he  c a ed h he  acc e
a fac g ce e . A  d c ed  Sec  20, h  ce   e e e  f ab e a  he
e ec ed e g ce f $15.00 e  d e f RNA acc e. H e e , e ec g e ha  he
de a d f  RNA acc e  f  COVID-19  e dec ea e  he c g ea  e e  f
a a  d e  bec e ece a . Se  a a a  d e  h  ha  h  ce  ca  
be f ab e h a e g ce f de  $6.00 e  d e f RNA acc e h ch e e e
e ha  a 60% dec ea e  e g ce.
O g he a fac g ce  f  a  RNA acc e f  COVID-19  h gh
a  a  c a e  he  ha  Pf e , B NTech a d M de a a  a   d ce RNA
acc e  f  COVID-19. Th  ce  ca  be e ca ed h ea e a d ca  be ca ed   d
 ee  a  ga a  ec f c eed . Add a , de c b g h  ce   a  f  he
f e f RNA acc e   ge e a . P   he c e COVID-19 a de c, RNA acc e
e e  de e e  f  he  e  ch a  he Z a 66. M e e , RNA acc e  ha e
bee  d ed a  e a  ca ce  he a e c . Th ce  ca  be ed  a e RNA acc e
f  a  e; he  h g ha   cha ge be ee RNA acc e e   he a ge  f
ch ce e c ded b  he RNA. The a ge  f ch ce f  h  ec   he SARS-C V-2 e
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(S) e . The a ge   ea  cha ged b  a a g he DNA e a e e e ce h ch
a  he RNA he ed f  h  DNA e a e  he IVT eac   c a  he a ge
f ch ce. The e a de  f he e   he RNA a fac g ce  e a  cha ged.
RNA acc e  ha e he e a   bec e a e a  e f acc e a ge  d e  he
a  be ef  f he a c a ed a fac g ce d c ed a  e g h h gh  h  e .
The a fac g ce  d c ed  h  e  ce -f ee, e a e  e e e, a d ca  be
ed  a e acc e  f  he  d ea e  d e  he fac  ha  he e a  ce   de e de  f
he a ge  ch e  f  he acc e.
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23. Ackno ledgemen
We d f  e  ha   ec  a h a d ad , D . Sc  D a d, f  h
e e e  a ab e  a d e e e h gh h  ec . H  e e e edge f
b g ca  e g ee g a d he ha ace ca  d ed g ea  a ab e f   ec .
Th gh  he c e f he e e e , he e  c e e  a e g  e  a d
g d g  a d  he edge a d  eeded  c e e h  ec . We a e ed b
he  he ded a d a ed b  he e e d b e   a   edge 
ha e a  ac  h ch he h ed  h gh h  ec .
We d a  e  ha  P fe  B ce V a a f  h  a ab e  e  he c e
 h  ec . I  add , e d e  ha he d a  c a  f  d g a
a ab e d  e ec e ha  he ed  h gh he e e e . I  a c a , e d e
 ha  A h  E che  f  a g he e  f h  b  ched e  ee  h  a d de
h  d a  e e e  he c f d c  de ce . W g  h  ec   h
ecede ed e a  a cha e ge; e a e ha f f  he ded ca ed c a  h  ade 
b e b  ha g he  e a d g da ce. F a , e d e  ha  he e e Che ca
a d B ec a  de a e  f he U e  f Pe a a. The edge ha  e ha e
b a ed f  he fe  a d fac  h  he de a e  h gh  he e a  ea  ha
a ed   c e e h  ec . We a e f e e g a ef  f  he  g da ce a d e .
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Appendi  A - Pharmace tical Form lation
Pfi e  ha mace ical f m la a  de i ed f m a Heal hca e P ide  Fac  hee .
G ea  ca e need   be aken hen l king a  he ma e beca e he d e i  dil ed a  he
accina i n i e, changing he c ncen a i n  f he c m nen . Gi en hi , c ncen a i n  ill
be efe ed  a  e-dil i n ( he c ncen a i n f he d c  f hi  man fac ing ce )
and -dil i n ( he c ncen a i n  f he accine af e  dil i n a  he accina i n i e). Pa ien
a e injec ed i h he dil ed f m f he accine and i h mRNA e en  a  he -dil i n
c ncen a i n.
Table A.1: Pfi e  Pha mace ical F m la i n P e-dil i n
Component Concentration / dose
(mg/mL)
Mass / dose (mg) Total mass (20%
safet  factor)  (g)
mRNA 0.5 0.03 7,200
All lipids 12.83 0.77 184,800
Li id:
(4-h d o b l)a anedi l)bi (he
ane-6,1-di l)bi (2-he ldecano
a e) 7.17 0.43
103,200
Li id: 2[( ol e h lene
gl col)-2000]-
N,N-di e adec lace amide 0.83 0.05
12,000
Li id:
1,2-di ea o l- n-gl ce o-3- ho
hocholine 1.5 0.09
21,600
Li id: chole e ol 3.33 0.2 48,000






(pre-dil tion) 6 0.36 864,000
Dibasic sodi m
phosphate h drate 1.17 0.07
16,800
186
S crose 100 6 1,440,000
Table A.2: Pfi e  Pha mace ical F m la i n P -dil i n (ma  di m chl ide acc n  f
ma  f m man fac ing ce  and f m dil i n)
Component Concentration / dose
(mg/mL)
Mass / dose (mg)
mRNA 0.1 0.03
All lipids 2.57 0.77
Li id:
(4-h d o b l)a anedi l)bi (he ane-6,1-di
l)bi (2-he ldecanoa e)
1.43 0.43
Li id: 2[( ol e h lene gl col)-2000]-
N,N-di e adec lace amide
0.167 0.05
Li id:
1,2-di ea o l- n-gl ce o-3- ho hocholine
0.3 0.09
Li id: chole e ol 0.667 0.2




Sodi m chloride (total) 8.4 2.52
Dibasic sodi m phosphate
h drate
0.233 0.07
S crose 20 6
M de na  ha mace ical f m la i n a  de i ed f m a Heal hca e P ide  Fac
Shee  bli hed b  he FDA. The fac hee  a  ed  calc la e he c ncen a i n e  d e
ing he l me f .5 mL e  d e men i ned in he d c men . The ma  e  d e a  li ed in
he d c men  and a  m l i lied b  200 milli n calc la e he ma  f  all accine  and b  a
20% fac   acc n  f  afe  c n ide a i n .
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Table A.3: M de na Pha mace ical F m la i n
Component Concentration / dose
(mg/mL)
Mass / dose (mg) Total mass (20%
safet  factor) (g)
mRNA 0.2 0.10 24,000
All lipids 3.86 1.93 463,200




Acetic acid 0.086 0.043 10,320
Sodi m acetate 0.24 0.12 28,800
S crose 87 43.5 10,440,000
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Appendi  B - Eq ipment Si ing Calc lations
In vitro Transcription Reactor
The in i o an c i i n (IVT) eac i n ill ake lace in a WAVE Bi eac TM em
in di able la ic bi eac  bag . T  de e mine he king l me and he bag i e needed,
a lab a  cale IVT eac i n a  caled . The am n  f mRNA  be d ced e  ba ch
a  calc la ed ba ed n he fac  ha  13 ba che ld be n and ha  200 milli n d e  f
mRNA accine needed  be d ced e  h e 13 ba che . The Pfi e -Bi NTech
ha mace ical f m la i n a  e ed b  he FDA indica ed ha  he e a e 30 g f mRNA in a
ingle d e f accine. The am n  f mRNA needed e  ba ch a  h  calc la ed ing he e
kn n an i ie , and he calc la i n i  h n bel . A 20% afe  fac  a  incl ded 
acc n  f  he fac  ha  me mRNA ill be l  h gh he ce  a  ell a   acc n  f
aking am le  f  ali  c n l e .
Total mRNA needed: 200, 000, 000 𝑑𝑜𝑠𝑒𝑠 · 30 µ𝑔 𝑚𝑅𝑁𝐴𝑑𝑜𝑠𝑒 = 6, 000 𝑔 𝑚𝑅𝑁𝐴 
mRNA needed per batch: 6,000 𝑔 𝑚𝑅𝑁𝐴13 𝑏𝑎𝑡𝑐ℎ𝑒𝑠 · 1. 2 = 553. 85 𝑔 𝑚𝑅𝑁𝐴/𝑏𝑎𝑡𝑐ℎ
Li e a e di c ing IVT mRNA indica ed ha  in he e ence f T7 RNA l me a e, 1
g f DNA em la e a  fficien   gene a e 50 g f mRNA in a 10 L eac i n l me68. A
caling fac  a  calc la ed and ed  de e mine he eac i n l me e i ed. Thi
calc la i n i  h n bel .
Scaling factor: 553.85 𝑔 𝑚𝑅𝑁𝐴
50×10−6𝑔 𝑚𝑅𝑁𝐴
= 11, 077, 000
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Reaction Vol me: 10 × 10−6 𝐿 · 11, 077, 000 = 110. 77 𝐿
Th , he eac i n l me f  ne ba ch i  110.77 L. I  a  de e mined ha  hi  king
l me c ld be acc mm da ed b  a 200 L la ic di able bi eac  bag. The WAVE
Bi eac TM 200 em a  ch en a  i  can acc mm da e 200 L bag . The e e l  a e
mma i ed in Table B.1.
Table B.1. S mma  f IVT Reac  Pa ame e
Parameter Val e
mRNA Prod ced per Batch (g) 553.85
Reaction Vol me per Batch (L) 110.77
Disposable Bioreactor Bag Si e (L) 200
Tangential Flo  Filtration De ices
In de   a ia el  i e he angen ial fl fil a i n em , a a en  a  ili ed
ha  de ail  he ifica i n ce  f mRNA  d ced b  IVT.  Tangen ial Fl  Fil a i n
de ice  e e ili ed in h ee di inc  lace  in  ce : igh  af e  he IVT eac i n, igh
af e  he ch ma g a h  c l mn, and igh  af e  he mic fl idic  de ice. The e h ee fil a i n
ce e  a e labeled a  TFF1, TFF2, and TFF3, e ec i el .
Tangential Flo  Filtration De ice 1
The a en  hel ed  ch e e e al ke  ce  a iable . A  gge ed b  he a en ,
TFF1 ill be e f med ing 10 dil i n l me  (DV) f a e . Since he l me f he IVT
d c  i  110 L, hi  mean  ha  he l me f a e needed a  a b ffe  f  hi  ce  ing
he 10 DV ill be 1100L (a  1100L = 10*110L). The e en a e f TFF1 c n ain  mRNA (b h
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ingle and d ble anded) and a e . The e en a e l me i  ch en  be 110 L a  e an ed
 e  he l me f IVT d c  l i n e al he l me f he e en a e (i.e. hi  TFF1 i
nl  mean   diafil e  and n  c ncen a e he e all l i n). The al fil a e l me i  e al
 he fil a e l me f m he diafil a i n e l  he fil a e l me f m he c ncen a i n
e . We calc la ed he al fil a e l me f TFF1 a  f ll :
.𝑇𝑜𝑡𝑎𝑙 𝐹𝑖𝑙𝑡𝑟𝑎𝑡𝑒 =  1100 𝐿 + (110 𝐿 − 110 𝐿) = 1100𝐿
Once e f nd he al fil a e l me, e calc la ed he l me f he
e mea e a  f ll :
𝑃𝑒𝑟𝑚𝑒𝑎𝑡𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 = 𝑇𝑜𝑡𝑎𝑙 𝐹𝑖𝑙𝑡𝑟𝑎𝑡𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 −  𝑅𝑒𝑡𝑒𝑛𝑡𝑎𝑡𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 =  1100𝐿 − 110𝐿 = 990𝐿
.
Th , he e mea e l me f TFF1 i  990 L. T  a ia el i e he TFF, e needed 
de e mine he memb ane a ea f he fil e . The memb ane a ea a  calc la ed ing he e a i n
bel :
he e A= memb ane a ea (m2), V= l me f fil a e gene a ed (li e ),𝐴 = 𝑉𝐽*𝑇
J = fil a e fl  a e (li e /m2/h ), and T = ce ime (h ).
Af e  di c ing i h D . Diam nd and he Ind ial C n l an , e de e mined ha  e an ed
 e   ce  ime f  TFF1  be 2.5 h . In addi i n he a en  hel ed  de e mine ha
he fl  f  hi  ce  ill be e   70 li e /m2/h . U ing he e a ame e , e calc la ed
he memb ane a ea f  he fil e  a  f ll :




The la  ce  a iable f  hi  ni  e a i n calc la ed a  he fl  a e. The fl  a e a
calc la ed a  f ll :
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= 440 L/h .𝐹𝑙𝑜𝑤 𝑅𝑎𝑡𝑒 = 1100𝐿2.5 ℎ𝑟
Tangential Flo  Filtration De ice 2
Simila   TFF1, he a en  hel ed  ch e e e al ke  ce  a iable  f  TFF2. A
gge ed b  he a en , TFF2 ill be e f med ing 10 dil i n l me  (DV) f di m
ace a e. Since he l me f he ch ma g a h  d c i  ab  126 L, hi  mean  ha  he
l me f di m ace a e needed a  a b ffe  f  hi ce  ing he 10 DV ill be 1,262 L.
The e en a e f TFF2 c n ain  ingle anded mRNA and di m ace a e. The e en a e l me
i  ch en  be 126 L a  e an ed  e  he l me f ch ma g a h  d c  l i n e al
 he l me f he e en a e (i.e. hi  TFF2 i nl  mean   diafil e  and n  c ncen a e he
e all l i n).  The al fil a e l me i  e al  he fil a e l me f m he diafil a i n
e  l  he fil a e l me f m he c ncen a i n e . We calc la ed he al fil a e l me
f  TFF1 a  f ll :
.𝑇𝑜𝑡𝑎𝑙 𝐹𝑖𝑙𝑡𝑟𝑎𝑡𝑒 =  1262 𝐿 + (126 𝐿 − 126 𝐿) = 1262𝐿
Once e f nd he al fil a e l me, e calc la ed he l me f he e mea e a  f ll :
𝑃𝑒𝑟𝑚𝑒𝑎𝑡𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 = 𝑇𝑜𝑡𝑎𝑙 𝐹𝑖𝑙𝑡𝑟𝑎𝑡𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 −  𝑅𝑒𝑡𝑒𝑛𝑡𝑎𝑡𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 =  1262𝐿 − 126𝐿 = 1136𝐿
.
Th , he e mea e l me f TFF2 i  1,136 L. T  a ia el i e he TFF, e needed 
de e mine he memb ane a ea f he fil e . The memb ane a ea a  calc la ed ing he e a i n
bel :
he e A= memb ane a ea (m2), V= l me f fil a e gene a ed (li e ),𝐴 = 𝑉𝐽*𝑇
J = fil a e fl  a e (li e /m2/h ), and T = ce ime (h ).
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Af e  di c ing i h D . Diam nd and he Ind ial C n l an , e de e mined ha  e an ed
 e   ce  ime f  TFF2  be 2.5 h . In addi i n he a en  hel ed  de e mine ha
he fl  f  hi  ce  ill be e   82.5 li e /m2/h . U ing he e a ame e , e calc la ed
he memb ane a ea f  he fil e  a  f ll :




The la  ce  a iable f  hi  ni  e a i n calc la ed a  he fl  a e. The fl  a e a
calc la ed a  f ll :
= 505 L/h .𝐹𝑙𝑜𝑤 𝑅𝑎𝑡𝑒 = 1136𝐿2.5 ℎ𝑟
Tangential Flo  Filtration De ice 3
Simila   TFF1 and TFF2, he a en  hel ed  ch e e e al ke  ce  a iable  f
TFF3. A  gge ed b  he a en  in ec i n, TFF3 ill be e f med ing 10 dil i n l me
(DV) f PBS. Since he l me f he d c  l i n fl ing  f he mic fl idic  de ice i
ab  4,935 L, hi  mean  ha  he l me f di m ace a e needed a  a b ffe  f  hi  ce
ing he 10 DV ill be 49,350 L. The e en a e f TFF3 c n ain  Li id , mRNA, and PBS. The
e en a e l me i  ch en  be 626 L a  e an ed  c ncen a e he mRNA l i n bef e i
en e  in  he final dil i n ce .  The al fil a e l me i  e al  he fil a e l me
f m he diafil a i n e  l  he fil a e l me f m he c ncen a i n e . We calc la ed he
al fil a e l me f  TFF1 a  f ll :
.𝑇𝑜𝑡𝑎𝑙 𝐹𝑖𝑙𝑡𝑟𝑎𝑡𝑒 =  49350 𝐿 + (4935 𝐿 − 626 𝐿) = 53, 660𝐿
Once e f nd he al fil a e l me, e calc la ed he l me f he e mea e a  f ll :
𝑃𝑒𝑟𝑚𝑒𝑎𝑡𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 = 𝑇𝑜𝑡𝑎𝑙 𝐹𝑖𝑙𝑡𝑟𝑎𝑡𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 −  𝑅𝑒𝑡𝑒𝑛𝑡𝑎𝑡𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 =  53, 660𝐿 − 626𝐿 = 53, 034 𝐿.
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Th , he e mea e l me f TFF2 i  53,034 L. T  a ia el  i e he TFF, e needed 
de e mine he memb ane a ea f he fil e . The memb ane a ea a  calc la ed ing he e a i n
bel :
he e A= memb ane a ea (m2), V= l me f fil a e gene a ed (li e ),𝐴 = 𝑉𝐽*𝑇
J = fil a e fl  a e (li e /m2/h ), and T = ce ime (h ).
Af e  di c ing i h D . Diam nd and he Ind ial C n l an , e de e mined ha  e an ed
 e   ce  ime f  TFF3  be 7.5 h . In addi i n he a en  hel ed  de e mine ha
he fl  f  hi  ce  ill be e   82.5 li e /m2/h . U ing he e a ame e , e calc la ed
he memb ane a ea f  he fil e  a  f ll :




The la  ce  a iable f  hi  ni  e a i n calc la ed a  he fl  a e. The fl  a e a
calc la ed a  f ll :
= 7,155 L/h .𝐹𝑙𝑜𝑤 𝑅𝑎𝑡𝑒 = 53,660𝐿7.5 ℎ𝑟
Cell lose Chromatograph  Col mn
The a ame e  f he ch ma g a h  c l mn e e de e mined b  caling he cell l e
ch ma g a h  c l mn men i ned in a li e a e a icle i en b  cien i  incl ding D .
Ka ik . Thi  ch ma g a h  c l mn a  ed  ce 100 mL f mRNA a  a c ncen a i n
f 1 mg/mL in he ch ma g a h  b ffe . A  hi  c ncen a i n, a  e  he c n l an ' h gh ,
he c l mn f 780 mL ed in he li e a e e a  likel  n a a ed b  he b nd f ac i n
f d RNA. Since he am n  f mRNA needed  ce in hi  man fac ing ce  i  n he
de  f magni de f 1000 ime  he ne ed in he mall- cale c l mn, he calc la i n  e e
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e f med ing  minimi e he i e f he c l mn f  hi  ce . Gi en hi , an mRNA
c ncen a i n f 4 mg/mL a  ed in ead f 1 mg/mL.
The c l mn l me f  hi  ce  a  calc la ed b  fi  de e mining he l me f
mRNA and b ffe  l i n needed  ha e he mRNA a a c ncen a i n f 1 mg/mL. Thi
l me a  calc la ed  be 126.28 L. A a i  f hi l me  he 100 mL ce ed in he
mall- cale c l mn a  ed  calc la e he i e f he c l mn ed in hi  ce : 985.95 L.
A  e  he c n l an  ad ice, a 1000 L c l mn ill be cha ed. I  a  n ed in he
calc la i n  ha  he mall- cale c l mn men i ned in he li e a e e ie  a  likel  n
a a ed ince he f ac i n f d RNA i  mall. H e e , i  a  ill ch en  cale he c l mn
acc ding  l me ince a 1000 L c l mn i  c mm n in ind  and he la ge i e ill all
f  he ce   cc  a  a fa e  a e.
The emaining a ame e  f  he ce  (c l mn diame e , fl  a e, ime f  ce )
e e de e mined b  caling he c l mn i h a c n an el ci . The heigh  a  e   be 0.4
me e . Thi  al e a  fi  ed  calc la e he c - ec i nal a ea f he c l mn.
𝐶𝑟𝑜𝑠𝑠 − 𝑠𝑒𝑐𝑡𝑖𝑜𝑛𝑎𝑙 𝑎𝑟𝑒𝑎 =  0.9849549 𝑚30.4 𝑚 =  2. 46 𝑚
2
The fl - a e a  hen calc la ed b  ing he el ci and he c - ec i nal a ea.
𝐹𝑙𝑜𝑤 𝑟𝑎𝑡𝑒 =  0. 00359 𝑚/𝑚𝑖𝑛 * 2. 46 𝑚2 =  . 00884 𝑚3/𝑚𝑖𝑛  
Thi  al e a  hen ed  calc la e he ime f he ce  b  acc n ing f  he fl  a e and
he l me f he c l mn.
𝑇𝑖𝑚𝑒 𝑓𝑜𝑟 𝑝𝑟𝑜𝑐𝑒𝑠𝑠 =  984953.88 𝑚𝐿8839.33 𝑚𝐿/𝑚𝑖𝑛  =  111. 4 𝑚𝑖𝑛 =  1. 86 ℎ𝑜𝑢𝑟𝑠
Table B.2. C l mn Pa ame e  f Small-Scale C l mn U ed  De e mine Si e
Parameter Val e
Col mn Vol (mL) 780
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Col mn Vol (m3) 0.00078
Height (cm) 56
Height (m) 0.56
Col mn Cross-sectional area (m2) 0.0014
Flo  rate (mL/min) 5
Flo  rate (m3/min) 5.00E-06
Velocit  (m/min) 0.0036
Col mn Diameter (m) 0.042
Table B.3. S mma  f 1000 L C l mn Pa ame e
Parameter Val e
Col mn ol me (L) 1000
Sol tion ol me (L) 984.96
Col mn Vol (m3) 0.98
Height (cm) 40
Height (m) 0.4
Col mn Cross-sectional area (m2) 2.46
Flo  rate (mL/min) 8,839.33
Flo  rate (m3/min) 8.84E-03
Velocit  (m/min) 0.0036
Velocit  (cm/hr) 21.54
Col mn Diameter (m) 1.77
Time for process (min) 111.43
Time for process (hr) 1.86
The ame 16% e han l b ffe  a  ed in he li e a e e ie  i  ed in he de ign f hi
c l mn. The am n  f e han l needed  e a e he b ffe  a  linea l  caled. The he
c m nen  e e ed i h he f ll ing m la i ie : 0.01 HEPES, 0.0001 EDTA, 0.125 NaCl.
The ch ma g a h  b ffe  i  ed  a h he c l mn and dil e he mRNA e e  ba ch and 
make he cell l e e in hich ill be ed f  he ce . The e in i  effec i e a  binding e
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95% f he d RNA. A  e  di c i n  i h he c n l an  n he nde a a i n f he e in
i h each ba ch, he e in ill nl  be made nce in he ce .
The e in i  made i h cell l e and ch ma g a h b ffe . The e i ed ma  f
cell l e a  linea l  caled f m he 250 g am  ed in he mall- cale c l mn  he 275,000
g am  ed in hi  ed ce .
Pre-Microfl idics Dil tions and Microfl idics De ices
Calc la i n  e e c m le ed  de e mine he c ncen a i n f mRNA and li id  needed
f  he mic fl idic  de ice  a  ell a  he n mbe f mic fl idic  de ice  needed. Li e a e a
ell a  P eci i n Nan S em  a en ed mic fl idic echn l g  e e ed  c m le e he e
calc la i n .
A  di c ed in Sec i n 15.3.4, he mic fl idic de ice ha e  inle  eam ; ne inle
c n ain  li id  di l ed in e han l, and he he c n ain  mRNA in an acidic b ffe . Li e a e
indica ed ha  f  he e e  f mic fl idic  ce e , he li id  h ld be di l ed in e han l
a  a al li id c ncen a i n f 10 mg/mL38. I  i al  im an   e  a fl  a e a i  (FRR) f
he mRNA eam  he li id  eam; an a ia e a i  f   ce  a  de e mined ba ed
n li e a e  be 3:1 (mRNA:li id )38.
The c ncen a i n f mRNA needed in he a e  inle eam a  de e mined ba ed n
he FRR, he li id  c ncen a i n in he e han l l i n, and he ma  a i  f mRNA  li id  in
he final ha mace ical f m la i n. In a ingle d e f he accine, he e a e 30 g f mRNA
and 770 g f li id . The calc la i n  d ne  de e mine he mRNA c ncen a i n in he a e
eam a e h n bel , and hi  c ncen a i n a ed  de e mine he am n  f di m
ace a e needed f  he dil i n f he mRNA i  he mic fl idic  e .
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Mass ratio of mRNA to lipids: 30 µ𝑔 𝑚𝑅𝑁𝐴770 µ𝑔 𝑙𝑖𝑝𝑖𝑑𝑠 = 0. 039
Concentration of mRNA in aq eo s stream:
10 𝑚𝑔 𝑙𝑖𝑝𝑖𝑑𝑠
𝑚𝐿 𝑒𝑡ℎ𝑎𝑛𝑜𝑙 𝑠𝑜𝑙𝑛 ·
0.039 𝑚𝑔 𝑚𝑅𝑁𝐴
𝑚𝑔 𝑙𝑖𝑝𝑖𝑑𝑠 ·
1 𝑚𝐿 𝑒𝑡ℎ𝑎𝑛𝑜𝑙 𝑠𝑜𝑙𝑛/𝑚𝑖𝑛
3 𝑚𝐿 𝑚𝑅𝑁𝐴 𝑠𝑜𝑙𝑛/𝑚𝑖𝑛 = 0. 13 
𝑚𝑔 𝑚𝑅𝑁𝐴
𝑚𝐿 𝑚𝑅𝑁𝐴 𝑠𝑜𝑙𝑛
The c ncen a i n f mRNA in a e  l i n i  he e-mic fl idic  dil i n
e  i  3.92 mg/mL in a 126 L di m ace a e l i n; he de ailed ma  balance  a nd each
maj  ce  e  can be f nd in A endi  D. The am n  f addi i nal di m ace a e added
 dil e he mRNA  a c ncen a i n f 0.13 mg/mL a  calc la ed a  h n bel .
Additional sodi m acetate: f di m ace a e added3.92 𝑔 𝑚𝑅𝑁𝐴/𝐿 ·126.28 𝐿0.133 𝑔 𝑚𝑅𝑁𝐴/𝐿 = 3701. 29 𝐿
Elemen  f P eci i n Nan em  a en ed mic fl idic echn l g  e e ed in he
de ign f he mic fl idic  de ice  f  hi  ce . The fl  a e e  de ice e  b  he a en
a  ch en a  he fl  a e e  de ice f   de ign; hi  fl  a e i  12 mL/min. U ing he 3:1
FRR di c ed ab e, hi  mean  ha  he mRNA l i n fl  a e ld be 9 mL/min and he
li id  l i n fl  a e ld be 3 mL/min. A  e i l di c ed in Sec i n 15.3.4, he e
ill c n i  f 25 e  f 16 a alleli ed mic fl idic de ice ; hi  am n   400 al
mic fl idic  de ice . U ing he ch en fl  a e e  de ice, i  a  de e mined ha  ne 16X
e  can ce  192 mL/min  11.52 L/h . The g al a   ce  ne ba ch  h f
mRNA in a  m  ne da . A ima el  5000 L al f mRNA and li id  c m i e ne
ba ch  h,  hi  l me ill need  be ce ed b  he de ice  in nde  a da . Gi en he
a e e  16X e  f 11.52 L/h , e de e mined ha 25 f he e 16X e  ld be fficien .
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If e e 25 f he 16X e , he 5000 L can be ce ed in j  e  17 h . Thi
calc la i n i  de ailed bel , and im an  e l a e mma i ed in Table B.2.
Time to process one batch s orth of mRNA and lipids:
4935.46 𝐿
11.52 𝐿ℎ𝑟·𝑑𝑒𝑣𝑖𝑐𝑒 · 25 𝑑𝑒𝑣𝑖𝑐𝑒𝑠
= 17. 14 ℎ𝑜𝑢𝑟𝑠
Table B.4. S mma  f Mic fl idic  Pa ame e
Parameter Val e
Lipids in Ethanol Concentration (mg/mL) 10
mRNA in Sodi m Acetate Concentration
(mg/mL)
0.13
Lipids in Ethanol Flo  Rate per De ice
(mL/min)
3
mRNA in Sodi m Acetate Flo  Rate per
De ice (mL/min)
9
Total Flo  Rate per De ice (mL/min) 12
N mber of 16X Set ps 25
Total N mber of Microfl idics De ices 400




The e a e  e ile fil a i n e  in he e all ce ; ne cc  a  he final mRNA
ifica i n e , and he he  cc  f ll ing he hi d angen ial fl  fil a i n (TFF) e .
O ica Ⓡ S e ile XLT 10 Milli e E e Ⓡ fil e ill be ed f  b h e . The e ile fil e
ha  e e  a  he final e  f mRNA ifica i n (S e ile Fil e  1) ill need  ce
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a ima el  126 L f mRNA l i n. The e e ile fil e  ha e a memb ane a ea f 0.54 m 2
and a fl  f 7 mL/min/cm2,  he ime  fil e ill be a ima el  3 min e . The e ile
fil e  ha  cc  f ll ing he hi d TFF e  ill need  ce  a ima el  626 L f
mRNA-c n aining LNP l i n. U ing he ame memb ane a ea and fl , he ime  fil e  f
hi  fil e  ill be a ima el  17 min e . The calc la i n  a e h n bel , and he im an
e l  a e mma i ed in Table B.3.




= 3. 34 𝑚𝑖𝑛




= 16. 55 𝑚𝑖𝑛
Table B.5. S mma  f S e ile Fil a i n Pa ame e
Parameter Val e
Filter 1 Time to Filter (min) 3.34
Filter 2 Time to Filter (min) 16.55
Final Dil tion
The final dil i n i  ed  en e he final c ncen a i n i  me  f  e e  c m nen .
The inle   he age ank i  he le  f TFF 3 and hi  eam i  mi ed i h a ec nd eam
ha  i  30% c e in PBS. The ma  calc la i n f  eam 2 e e e f med b  back- acking
f m he e i ed final c ncen a i n . The fi a  f hi  i  calc la ing he l me e  d e f
he final d c . Thi  i  diffe en  f m he 0.3 mL f he d e nce i  i  admini e ed  he
a ien  a  he accina i n i e ince he ial  a e nl  dil ed a  he accina i n i e i h di m
chl ide.
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A fac  f ial   d e  a  calc la ed ing he inf ma i n f m he FDA Heal hca e
ide  fac  hee . Righ  i   admini e ing he accine, he ial  ha e a al l me f
0.45 mL and 1.8 mL (f m he added di m chl ide), ielding a al 2.25 mL. Thi  di ided b
he 0.3 mL e  d e gi e  7.5 hich i  he a i  f ial   d e .
Thi  a i  a  ed  calc la e he l me f each d e in he final d c  f hi
man fac ing ce  b  di iding he l me f each ial hich i  0.45 mL b  he a i  f 7.5.
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑑𝑜𝑠𝑒 𝑓𝑖𝑛𝑎𝑙 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 =  0.45 𝑚𝐿 7.5 =  0. 06 𝑚𝐿 
Thi  l me f 0.06 mL a  m l i lied b  he n mbe f d e  d ced e  eek 
calc la e he al l me ha  need   e i  he age ank in hich he final dil i n ill be
e f med.
𝐹𝑖𝑛𝑎𝑙 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑉𝑜𝑢𝑡 =  0. 06 𝑚𝐿 *  15, 384, 615 =  923, 076. 92 𝑚𝐿 
The le  ma  f m he final dil i n f each c m nen a  calc la ed b  m l i l ing
he ma  e  d e in he final ha mace ical f m la i n (incl ded in A endi  A) and he
d e  e  eek. In he final dil i n, PBS i  in b h inc ming eam : in eam 1 c ming f m
he TFF 3 eac  he e i  a  ed a  a b ffe  and in eam 2 hich i  30% c e in PBS.
The am n  f PBS in eam 2 a  calc la ed b  de e mining he l me needed  acc n  f
he e i ed ma  f c e. The am n  f each c m nen f PBS in eam 2 a  hen
calc la ed b  ing he m la i  f h e c m nen in anda d 1X PBS. The ma  f PBS in
eam 1 a  calc la ed b  d ing he ma  f ha c m nen  in he le  eam min  he ma
f ha  c m nen  in eam 2.
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Appendi  C - Eq ipment Costing Calc lations
In vitro Transcription Reactor
A  e i l  a ed, he WAVE Bi eac TM 200 em ill be ed  n he in i o
an c i i n (IVT) eac i n. The em c n i f a cking em i h a i  c n l
elemen  ch a  a em e a e c n lle  and H m ni , and 200 L di able la ic
bi eac  bag  a e laced n  he cke . The IVT eac i n ill be n 13 ime   d ce he
de i ed am n  f mRNA f  he accine. T  e en l  f ime in he e en  ha  a bag b eak
 a eac  b eak  d n, i  a  de e mined ha  WAVE Bi eac TM 200 em  and 26
di able bi eac  bag  ld be cha ed. Each WAVE Bi eac TM 200 em c
$400,000, and each bag c  $709. The al cha e c  a cia ed i h he IVT eac i n i
h  $809,217. The e al e  a e mma i ed in Table C.1.
Table C.1. IVT Reac  P cha e C
Component Cost
WAVE BioreactorTM 200 s stem (2) $800,000
200 L Disposable Bioreactor Bags (26) $9,217
Total $809,217
Tangential Flo  Filtration De ices
Af e  mee ing i h D . Diam nd, i  a  de e mined ha  a TFF em ha  incl de
memb ane , ca e e , m , and m ni  ld c $150,000 each f  b h TFF1 and TFF2.
F  TFF3, hich i  m ch la ge  in i e, he em a  de e mined  ha e a cha e c  f
$1,000,000.
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Cell lose Chromatograph  Col mn
The c  f he ch ma g a h  c l mn a  calc la ed ing e a i n  ided in
P od c  and P oce  De ign P inci le , hile he FPLC em a  b ained f m a end . F
he c l mn c  e ima e, a CE c inde  f 607 a ed67. The c l mn a  iced a  a e ical
e el made f m 304 ainle  eel. F m A endi B, he c l mn ha  a diame e  f 69.7
inche  and he leng h f he c l mn i  15.7 inche . In addi i n, i  a  e ima ed ha  he c l mn
ha  a all hickne  ( ) f 0.44 inche . Bel  incl de a able ha  mma i e  he e
a ame e :
Table C.2. Ch ma g a h  C l mn Pa ame e
Parameters Val e
Densit  of Stainless Steel (⍴) 0.285 lb/in3
Diameter of Col mn (D) 69.7 in
Length of Col mn (L) 15.7 in
Wall Thickness (ts) 0.44 in
FM (304 Stainless Steel) 1.7
In de   calc la e he cha e c  f he c l mn, he eigh  f he c l mn fi  ha   be
calc la ed ing he f ll ing e a i n:
.𝑊 =  π(𝐷𝑖 +  𝑡𝑠)(𝐿 +  0. 8𝐷𝑖)𝑡𝑠⍴
The ef e, he eigh  f he ch ma g a h  c l mn a  calc la ed a  ch:
𝑊 =  π(69. 7 𝑖𝑛 +  0. 44 𝑖𝑛)(15. 7 𝑖𝑛 +  0. 8 * 69. 7 𝑖𝑛)0. 44 𝑖𝑛 * 0. 285 𝑙𝑏/𝑖𝑛3 = 1966 𝑙𝑏
.
N  ha  e f nd he eigh  f he c l mn  be 1,966 lb, he f. .b cha e c  a  a CE inde
f 567, C , a  calc la ed a  f ll :
𝐶
𝑣
 =  𝑒𝑥𝑝 7. 1390 +  0. 18255 𝑙𝑛(𝑊)  +   0. 02297 𝑙𝑛(𝑊) 2
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                                = 𝑒𝑥𝑝 7. 1390 +  0. 18255 𝑙𝑛(1966)  +   0. 02297 𝑙𝑛(1966) 2 = $18, 855.
Ne  he ma e ial c  a  aken in  acc n  a  ch:
𝐶
𝑝
= 𝐹𝑀 * 𝐶
𝑣
= 1. 7 * $18, 855 = $32, 053.
La l , he CE inde  f 607 a  aken in  acc n a  ch:
𝐶𝑜𝑠𝑡 =  𝐵𝑎𝑠𝑒 𝐶𝑜𝑠𝑡 (𝐼/𝐼
𝑏𝑎𝑠𝑒
) = $32, 053(607/567) = $ 34, 314.
The ef e, he cha e c  f j  he c l mn i $34,314. In addi i n, e b ained a e f
he FPLC em f m Ic n Scien ific. The ed c f  he FPLC em a  $90,000.
The ef e, he al cha e c  f he c l mn and FPLC i :
.𝑇𝑜𝑡𝑎𝑙 𝑃𝑢𝑟𝑐ℎ𝑎𝑠𝑒 𝐶𝑜𝑠𝑡 𝑜𝑓 𝐶𝑜𝑙𝑢𝑚𝑛 𝑎𝑛𝑑 𝐹𝑃𝐿𝐶 𝑆𝑦𝑠𝑡𝑒𝑚 = $34, 314 + $90, 000 = $ 124, 314
Th , he al cha e c  f he ch ma g a h c l mn incl ding he FPLC em i
$124,314.
Microfl idics De ices
I  a  de e mined ha  25 e  f 16 a alleli ed agge ed he ingb ne mic fl idic
mi ing de ice  ld be cha ed. The P eci i n Nan S em a en  di c e  he
a alleli a i n f 8 mic fl idic mi ing de ice  and h  hi  c e can be caled , ci ing
he a alleli a i n f 16 de ice  a  fea ible. The 16X e  a  h  ch en f  hi  jec .
Th gh di c i n i h  jec  a h  and ad i , D . Sc  Diam nd, i  a  de e mined
ha  ne e  f 16 a alleli ed de ice  ld c $13,000. Th , he al cha e c  i
$325,000. Thi  i  mma i ed in Table C.2.
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Table C.3. Mic fl idic  De ice  P cha e C
Component Cost
Single 16X Set p $13,000
Total (25 16X Set ps) $325,000
Sterile Filters
O ica Ⓡ S e ile XLT 10 Milli e E e Ⓡ fil e e e ed f  b h f he e ile
fil a i n e . Each O ica Ⓡ S e ile XLT 10 Milli e E e Ⓡ fil e  ha  a cha e c  f
$575. Since he e fil e  a e ingle e and di able and 13 n  a e e i ed f  each fil e , 26
fil e  ill be cha ed. Thi  b ing  he al cha e c   $14,950 f  b h e ile fil a i n
e . Thi  i  mma i ed in Table C.3.
Table C.4. S e ile Fil a i n P cha e C
Component Cost
Single Sterile Filter $575
Total (26 Filters) $14.950
Storage Tanks
Se e al IBC ainle  eel 304 age ank  f m he end  The Ca  C m an  ill
be ed h gh   ce . In de   main ain c n i enc  i h icing, all ank  e e
ba ed ff f cha e ice  li ed n The Ca  C m an eb i e. Thi  end  did n  eadil
ha e all he ice  f  all he i e  f ank  needed, a  nl  a elec  fe  e e li ed n hei
eb i e. In de   acc a el  ice he ank  i h c ing inf ma i n n  eadil  li ed, e
linea l  in e la ed he a ailable da a  find a line. Thi  line a  hen ed  calc la e he
ice  f ank  ha  e e nkn n. The a ailable ice da a i  de ailed in Table C.5 and he linea
in e la i n f ch da a can be een d n bel in Fig e C.1.
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Table C.5. A ailable Da a f  C  f S age Tank  F m Vend






Fig re C.1. Linea  In e la i n f he A ailable S age Tank C  Da a
The ice  f each indi id al age and a e ank ed in  ce  can be f nd in ec i n
17.
Cold Room
Wi h he hel  f D . Diam nd, i  a  e ima ed ha he man fac ing lan  ld be
10,000 f 2. In de   en e ha  he mRNA emain able h gh  he ce , i  a
de e mined ha   d c i n facili  ld need  be a  4℃.  Li e a e e ima e  ha  he
c  f b ilding a c ld m ha  ha  he e  in la i n  be $250/f 2 60. The ef e, he c  f
b ilding  10,000 f 2 c ld m ld be:
𝐶𝑜𝑠𝑡 𝑜𝑓 𝐵𝑢𝑖𝑙𝑑𝑖𝑛𝑔 𝐶𝑜𝑙𝑑 𝑅𝑜𝑜𝑚 = 10, 000 𝑓𝑡2( $250
𝑓𝑡2
) = $2, 500, 000.
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In addi i n  he b ilding c , e al  e ima ed he c  f in alling 10 fan  ha  ld hel
en e ha  he b ilding emain  a  4℃. Thi  c e ima i n a  d ne ing he e i men
c ing ead hee  ided b  he c e in c . I  a  e ima ed ha  he al ba e m d le
c  f in alling 10 fan  i hin he lan  ld be $1,685,400. The ef e, he al c  f
b ilding a c ld m a  4℃ i :
𝐶𝑜𝑠𝑡 𝑜𝑓 𝐵𝑢𝑖𝑙𝑑𝑖𝑛𝑔 𝐶𝑜𝑙𝑑 𝑃𝑙𝑎𝑛𝑡 = $2, 500, 000 + $1, 685, 400 = $4, 185, 400.
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Appendi  D - Detailed Process Mass Balances
The ed man fac ing ce  a  ed  d ce 200 milli n d e   accina e
100 milli n e le. The able bel  de ail  he eekl d c i n. P -dil i n, he l me f a
ial i  he 0.45 mL f LNP hich e e filled a  he man fac ing i e and he 1.8 f 0.9%
S di m Chl ide f m he dil i n, ielding a al l me f 2.25 mL. Thi  l me i  di ided
in  d e  f 0.3 mL hich gi e  a ial  d e  a i f 7.5. Thi  a i  a  ed  calc la e he
n mbe  f ial  f m he eekl  d c i n f d e . Each a  e  CDC g ideline  each a  ha
195 ial  and each he mal c n aine  ha  5 a . Thi  a  ed  calc la e he n mbe  f
he mal c n aine .
Table D.1. Weekl  P d c i n Q an i ie
Component Weekl  Val e
D e 2,051,282.05
Vial 10.519.40
The mal c n aine 2,103.88
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Table D.2. In i o T an c i i n (IVT) Reac i n and P -IVT En me Dige i n Ma  Balance










Tris HCl 402.56 402.56 0 0 0
MgCl2 40.38 40.38 0 0 0
Dithiothreitol
(DTT)
170.87 170.87 0 0 0
Spermidine 32.18 32.18 0 0 0
Triton X-100 11.85 11.85 0 0 0
ATP 280.91 109.29 0 171.62 0
GTP 289.77 189.43 0 100.34 0
CTP 267.62 162.53 0 105.09 0
UTP 268.17 91.39 0 176.78 0
DNA
template
11.08 0 0 11.08 0
mRNA 0 520.62 553.85 33.23 0
T7 RNA
Pol merase
11.08 11.08 0 0 0
Cap Analog
(Clean Cap)
1,159.10 1,158.59 0 0.51 0
DNase I* 6.33 6.33 0 0 0





33,231.00 33,231.00 0 0 0
TOTAL 2,952.12 2,907.32 553.85 598.65 0
*added af e  he IVT eac i n (+5 h )
**Thi  i addi ional e a e  added af e  all he eac i n c m nen  ha e been added. Thi  i  n he al am n  f a e  in he eac i n.
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Table D.3. IVT Reac i n Final C ncen a i n























*T al eac i n l me = 110.8 L li e  
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Table D.4. Tangen ial Fl  Fil a i n (TFF) 1 Ma  Balance
Component Mass in (g) Mass o t inretentate (g)
Mass o t in
filtrate (g)
Mass
acc m lated (g)
mRNA 520.62 510.21 10.41 0
Tris HCl 402.56 0 402.56 0
MgCl2 40.38 0 40.38 0
Dithiothreitol
(DTT)
170.87 0 170.87 0
Spermidine 32.18 0 32.18 0
Triton X-100 11.85 0 11.85 0
ATP 280.91 0 280.91 0
GTP 289.77 0 289.77 0
CTP 267.62 0 267.62 0
UTP 268.17 0 268.17 0
T7 RNAP 11.08 0 11.08 0
CAP analog 1,158.59 0 1,158.59 0
DNase I 6.33 0 6.33 0
Phosphatase 0.22 0 0.22 0
Additional
WFI
1,136,454.00 33,231.00 1,103,223.00 0
TOTAL 1,139,372.38 33,741.21 1,105,631.17 0
Table D.5. TFF 1 Re en a e C ncen a i n
Component Concentration O t (g/L)*
mRNA 3.63
*T al e en a e l me = 110.8 L li e  
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Table D.6. Cell l e Ch ma g a h  Ma  Balance
Component Mass in (g)
Mass o t in
flo  thro gh
(g)
Mass bo nd to
col mn (g)
Mass
acc m lated (g)
HEPES 2,385,943.15 2,385,943.15 0 0
EDTA 29,259.95 29,259.95 0 0
NaCl 7,313,985.28 7,313,985.28 0 0
Ethanol 126,395.28 126,395.28 0 0
mRNA 505.10 505.10 0 0
dsRNA* 5.10 0.26 4.85 0
Additional WFI 874,264.22 874,264.22 0 0
TOTAL 10,730,358.08 10,730,353.23 4.85 0
*d RNA = d ble- anded RNA
Table D.7. Cell l e Ch ma g a h  Fl  Th gh C ncen a i n







*T al l me = 1001.23 L li e  
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Table D.8. TFF 2 Ma  Balance
Component Mass in (g) Mass o t inretentate (g)
Mass o t in
filtrate (g)
Mass
acc m lated (g)
mRNA 505.10 495.00 10.10 0
Sodi m
Acetate 5,179.49 517.95 4,661.54 0
HEPES 2,385,943.15 0 2,385,943.15 0
EDTA 29,259.95 0 29,259.95 0
NaCl 7,313,985.28 0 7,313,985.28 0
Ethanol 126,395.28 0 126,395.28 0
TOTAL 9,861,268.25 1,012.95 9,860,255.30 0
Table D.9. TFF 2 Re en a e C ncen a i n




*T al l me = 126.28 L li e  
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Mass o t (g) Massacc m lated (g)
mRNA 495.00 0 495.00 0
Sodi m
Acetate 517.95 14,663.70 15,181.65 0
TOTAL 1,012.95 14,663.70 15,676.66 0
Table D.11. P -Dil i n C ncen a i n




*T al l me = 3827.57 L li e  
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Mass o t (g) Massacc m lated (g)
mRNA 495.00 0 495.00 0
Sodi m
Acetate 15,181.65 0 15,181.65 0
Ethanol 0 973,440.30 973,440.30 0
ALC-0315 0 7,938.46 7,938.46 0
ALC-0159 0 923.08 923.08 0
DSPC 0 1,661.54 1,661.54 0
Cholesterol 0 3,692.31 3,692.31 0
TOTAL 15,676.66 987,655.69 1,003,332.34 0
Table D.13. P -Mic fl idic  C ncen a i n









*T al l me = 4935.06 L li e  
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Table D.14. TFF 3 Ma  Balance
Component Mass in (g) Mass o t inretentate (g)
Mass o t in
filtrate (g)
Mass
acc m lated (g)
mRNA 495.00 485.10 9.90 0
Sodi m
Acetate 15,181.65 0 15,181.65 0
Ethanol 973,440.30 0 973,440.30 0
ALC-0315 7,938.46 7,779.69 158.77 0
ALC-0159 923.08 904.62 18.46 0
DSPC 1,661.54 1,628.31 33.23 0






333,574.81 3,888.38 329,686.43 0
TOTAL 1,336,907.15 18,304.56 1,318,602.59 0
*1X PBS c n ain  a i m chl ide, m n ba ic a i m h ha e, di m chl ide, and diba ic di m h ha e h d a e
Table D.15. TFF 3 Re en a e C ncen a i n







*T al l me = 625.50 L li e  
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PBS and s crose
(g)
Mass o t (g) Massacc m lated (g)
mRNA 485.10 0 485.10 0
ALC-0315 7,779.69 0 7,779.69 0
ALC-0159 904.62 0 904.62 0
DSPC 1,628.31 0 1,628.31 0
Cholesterol 3,618.46 0 3,618.46 0
1X PBS 3,888.38 3,034.70 6,923.08 0
S crose 0 89,273.00 89,273.00 0
TOTAL 18,304.56 92,307.69 110,612.25 0
Table D.17. P -Final Dil i n C ncen a i n








*T al l me = 923.08 L li e  
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Appendi  E - Additional mRNA Seq ence Information
A  di c ed in Sec i n 2.1.2, mRNA ha  f  main c m nen : a 5  ca , n an la ed
egi n  (UTR ), an en eading f ame (ORF), and a l  (A) ail. We de igned he mRNA f
 accine ch ha  e ha e de e mined an e ac e ence  be ed in he accine. Thi
mRNA e ence incl de  he 5  UTR, he ORF, he 3 UTR, and he l  (A) ail. Thi  e ence
i  h n in Fig e E.1 i h a legend ha  ma  he egi n  f he e ence. The e ence i
4,079 ba e  l ng and ha  a m lec la  eigh  f 1306.23 kDa. Addi i nall , he b lded and
highligh ed egi n in Fig e E.1 hich an  6 ba e e e en   m a i n  ha  e e made
f m he ild- e ike ein. A  men i ned in Sec i n 2.1.2, he ORF i  he egi n ha  c de
f  he an igen f ch ice hich i  he SARS-C V-2 ike ein f  hi  accine. The i  ba e
highligh ed in he ORF egi n e e en   amin acid  (l ine and aline) ha  e e m a ed 
line ; he e m a i n  e e efe ed  a  K986P (l ine  line) and V987P ( aline 
line). The m a i n  e e made in he Pfi e -Bi NTech BNT162b2 mRNA accine again
COVID-19  main ain he ike ein in he e c nf ma i n. BNT162b2 al  c n ain  a
l  (A) ail ha  i  100 n cle ide  l ng,  ha l  (A) ail leng h a  ch en f  hi
e ence28. F he m e, he UTR e ence  e e b ained f m an mRNA accine candida e
f  he Zika i 66. Im an  al e  ega ding he mRNA e ence a e mma i ed in Table
E.1.
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Fig re E.1. E ac  mRNA e ence  be incl ded in he accine. Thi  e ence c n ain  he 5  UTR, he ORF, he
3  UTR, and he l  (A) ail.
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Table E.1. S mma  f mRNA Se ence Inf ma i n
Parameter Val e
Total Seq ence Length (bases) 4,079
Molec lar Weight of F ll Seq ence (kDa) 1,306.23
Length of Pol  (A) Tail (bases) 100
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Appendi  F- Process Flo sheet Diagrams
Thi  a endi  c e  he de el men  f he PFD and incl de  a  d af . F  cla i ,
nl  main d af  i e a i n  ill be e en ed in hi a endi  ince each i e a i n had m l i le
d af  and e i n  ha  e e c n ide ed.
Fig re F.1. D af  1 f PFD
The fi  d af  f he PFD incl ded he e   e a e and am lif  he DNA. Thi  e  i
em ed in f e e i i n  ince i  a  decided ha he DNA e a a i n ld be
ced. Thi  d af  al  incl de  he T7 RNA l me a e ec cle hich a  em ed ince
he half-life f he en me made i  in al able ec cle i . I  al  em e  he e   e a a e
T7 RNA l me a e ince hi  i  acc m li hed in he TFF. The c l mn in hi  d af  i  an i n
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e change c l mn hich a  la e  ecified  be a cell l e ch ma g a h  c l mn. Thi  d af
al  incl de  a dial i  e  af e  mic fl idic . Thi  e  a  em ed in f e d af  ince i  i
m e al able  en e he l i n in  he mic fl idic i  c m le el  a e  han  en e
hi  af e  he de ice. Thi  i  d ne in f e d af b  adding a e ile fil e  bef e mic fl idic
and ne igh  bef e ackaging.
Fig re F.2. D af  2 f PFD
Thi  d af  h  a change in he fi  a  f he ce , he am lifica i n and
e a a i n f la mid f  IVT. In hi  i e a i n, he e a a i n f DNA i  ced b  he
am lifica i n ha en  a  a  f he man fac ing ce . I  a  la e  decided ha  he
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am lifica i n ld al  be ced. Thi  i  beca e hi  a  f he ce  i  an ind
anda d and a ma e  f f ll ing c l. D ing he DNA am lifica i n in-h e d e  n
add al e  he man fac ing ce  ince i  i f ll ing an ind  anda d. Thi  d af
h  he e f a cell l e c l mn and he e f  TFF  and a e ile fil e   if  he
mRNA. In hi  d af , he inle   he fi  TFF i KCl b ffe , hi  b ffe  a  changed  be a e
ince he chl ide al  ld he i e need  be em ed in TFF 2. The bjec i e f he fi
TFF i   em e he en me  ed in he IVT ce and a e  can be ed a  a b ffe  f  hi
ce .
Fig re F.3. D af  3 f PFD
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Thi  d af  i e a i n h  he deci i n  ce he fi  a  f he ce  hich i
he am lifica i n and ifica i n f he la mid DNA. I  al  h  all f he ce  ni  and
he b ffe  ed in he final d af . I  h  MgCl2 a  a al  e i ing TFF2 b  hi  i  c ec ed in
la e  d af  ince i h a e  a  a b ffe  in TFF 1 in ead f KCl he al  i  n  l nge  d ced.
Thi  d af  h  he e f a ch ma g a h  b ffe  a h he cell l e c l mn,  dil e he
mRNA i   he c l mn and  make he cell l e e in. Thi  d af  h  he e f 5 16X
mic fl idic  de ice  in a allel  d  he LNP f m la i n e . Thi  n mbe  i  changed  25
16X mic fl idic  e  in he final ce   make he ce  ime l e .
Fig re F.4. D af  4 f PFD
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Thi  d af  f he PFD h  he ce  ni  in he ame manne  a  he final d af . The
nl  diffe ence i  ha  i  i  mi ing he ecifica i n f ce ain age ank  ed  e he
b ffe  f he TFF eac . In diffe ence  D af 3, i  ma k  ha  25 16X mic fl idic  de ice
ill be ed in a allel f  he LNP f m la i n.
Fig re F.5. Final D af  f PFD
The final d af  f he PFD i  he ne incl ded in he e . I  incl de  all he age
ank . I  al  incl de  he f mali ie  f n mbe ing e e  ce  ni  and age and a e
ank. I  incl de  a ma k n hen ali  c n l ill cc  b  ing he mb l f a a  and
incl de  he legend f  hi .
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There has been considerable discussion in the literature
recently pertaining to the Bacterial Endotoxins Test, its
significance and interpretation, and its comparison to the
USP rabbit test. The topic was previously briefly addressed
via Inspection Technical Guide No. 32, dated 1/12/79, with
the subject: Pyrogens, Still a Danger.
Because of the increased acceptance and use of the Bacterial
Endotoxins Test, ITG No. 32 is being updated.
The USP now recognizes two tests - The Pyrogen Test
conducted with rabbits and the Bacterial Endotoxins Test,
also termed the Limulus Amebocyte Lysate (LAL) Test.
DEPT. OF HEALTH, EDUCATION,
AND 
WELFARE PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
*ORA/ORO/DEIO/IB*
Date: 3/20/85 Number: 40 
Related Program Areas:
Drugs and Devices
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Additionally, the agency has approved the use of the
Bacterial Endotoxins Test for many drug and device
products. This ITG will focus on the significance and
interpretation of pyrogen/endotoxin testing. Also sources
and methods of depyrogenation will be discussed. The
limitations of the rabbit pyrogen test should be recognized
when reviewing systems during inspections of sterile drug
and device manufacturers.
History
The Federal Register, January 18, 1980, proposed guidelines
for determining endotoxins with the Limulus Amebocyte
Lysate Test (LAL). Subsequently, the draft guideline was
revised and reissued in 1983. The USP XX, 5th supplement,
revised the Bacterial Endotoxins Test. However, unlike the
FDA draft guideline, no retest provisions were included.
Most manufacturers are at some stage of validating the
Bacterial Endotoxin Test for their products.
The USP's subcommittee responsible for revisions of
compendial test methods and/or product monographs has,
in the past few years, made some significant changes in the
bacterial endotoxin test and product monograph
requirements. In 1984, five USP water products were given
specific bacterial endotoxin limits. Water for Injection,
Sterile Water for Injection and Sterile Water for Irrigation
have an allowable endotoxin limit of 0.25 Endotoxin Units
(EU)/ml. (EU=Unit of measurement for endotoxin activity).
However, Bacteriostatic Water for Injection and Sterile
Water for Inhalation have been given a slightly higher
bacterial endotoxin limit of 0.5 EU/ml (USP - Supplement
4a - 1984). The agency has recognized the benefits of the
Bacterial Endotoxins Test, particularly with respect to
sensitivity, reproducibility, scope and simplicity.
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Additionally, both FDA inspections and FDA testing
programs have identified objectionable levels of endotoxin in
drugs and devices.
Some finished products tested, although not found
actionable because of the low dose of product to be
administered, could be indicative of pyrogen problems in
other systems, such as a Water for Injection System. For
example, a particular product such as Cyanocobalamin Inj.,
can have an endotoxin concentration of 10 EU/ml and be
considered as in compliance. However, one could question
the manufacturer's Water for Injection (WFI) System since
the WFI System should have a level of .25 EU/ml.
There is considerable discussion in the literature pertaining
to endotoxicity versus pyrogenicity. Many of the FDA
investigators and reviewers of inspection reports are
unaware of the limitations of the USP rabbit test as an
endotoxin test. For example, Elin, in the Annual Review of
Medicine, commented that "The repeated administration of
lipopolysaccharide (LPS), the chemical name used
synonymously with bacterial endotoxins, to experimental
animals results in a progressive diminution of some of the
biological effects, especially fever. The precise mechanism of
this phenomenon, termed endotoxin tolerance, is unknown".
Also, some studies have shown that the endotoxin of the
Legionnaires' bacillus has a different spectrum of toxicity
than the more common gram-negative organisms. In
particular the Legionnaires' endotoxin was not very
pyrogenic (by the rabbit test), but was very active in the LAL
- 1,000 fold difference between the two tests. In this
situation, the rabbit test is inadequate for determining the
potency of the toxins present.
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The USP pyrogen test has additional limitations besides
endotoxin tolerance and low reactivity to legionnaires'
endotoxin. Among these are its variability in test results
when compared to the same preparation of standardized
endotoxin. This condition is influenced by seasonal
variation, interlaboratory factors, rabbit species to species
characteristics, and other biological influences. The test is
inadequate for certain classes of drugs including
radiopharmaceuticals, cancer chemotherapeutic agents,
hypnotics and narcotics, vitamins, steroids and certain
antibiotics. It has been found that apparent pyrogens in the
product can be "masked" by the physio-chemical activity of
the therapeutic drug components. In addition, the rabbit test
is insufficiently sensitive for endotoxin detection in
intrathecal drug products.
There is also little recognition of the clinical significance of
endotoxin. Possibly this is because the most emphasized
pathogenic effect of gram negative disease is the production
of fever, and of all of the effects of endotoxin, fever is
probably the least important biologically and clinically.
Although many manufacturers are working with LAL, there
are still some manufacturers who are reluctant to employ
LAL because it is too sensitive.
In addition to the sensitivity of the test, greater numbers of
dosage units/devices can be tested using LAL. For example,
a sterile critical device was found to have an acceptable
endotoxin level from a pooled sample. (Note: The USP
pyrogen test is performed on a pooled sample.) However,
when extracts of units were LAL tested individually,
occasional failures were noted. A similar situation occurred
in a sample of Bacteriostatic Water for Injection. A pooled
sample from a number of units was found to have endotoxin
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levels of less than 0.5 EU/ml. However, some specific dosage
units were found to exceed this 0.5 EU/ml USP limit and
Regulatory Action was taken.
Characteristics of Bacterial Endotoxin
"Microbial pyrogen" as opposed to "gram negative bacterial
endotoxin" has become a general descriptive term for many
different substances. However, pyrogenic substances can be
produced by some gram positive bacteria, mycobacteria,
fungi and also viruses, but the pyrogens produced by gram
negative bacteria, i.e., the endotoxins, are of significance to
the pharmaceutical industry.
Bacterial endotoxins, found in the outer membrane of gram-
negative bacteria are members of a class of phospholipids
called lipopolysaccharides (LPS). LPS are not exogenous
products of gram negative bacteria. The release of LPS from
bacteria takes place after death and lysis of the cell. Good
examples of pyrogen producing gram- negative bacteria are
Escherichia coli, Proteus, Pseudomonas, Enterobacter and
Klebsiella.
Formula Used to Calculate the Endotoxin Limit for
Individual Drug Products
The effects of endotoxin are related to the amount of
endotoxin in the product dose administered to a patient.
Because the dose varies from product to product, the
endotoxin limit is expressed as K/M. K is 5.0 EU/kilogram
(kg.), which represents the approximate threshold pyrogen
dose for humans and rabbits. That is the level at which a
product is adjudged pyrogenic or non-pyrogenic. M
represents the rabbit pyrogen test dose or the maximum
human dose per kilogram that would be administered in a
single one hour period, whichever is larger. If a product is
labeled for intrathecal injection, then K is 0.2 EU/kg.
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However, there are 5 water products (previously discussed)
which, because of the large volumes that can be
administered and absence of dose limitation, have specific
endotoxin limits per ml.
Example 1 - A non-intrathecal drug product that has a
maximum human dose of 10 ml/kg.
Endotoxin limit = K 5 EU/kg - = ------- = 0.5 EU/ml M 10
ml/kg
Example 2 - Product: Cyanocobalamin Inj. Potency: 1000
mcg/ml
Maximum Dose/kg 14.3 mcg/kg (see product labeling)
Endotoxin Tolerance Limit = 5.0 EU/kg - non-intrathecal
drug
Endotoxin Limit = K 5.0 EU/kg - = --------- = 0.35 EU/mcg
M 14.3 mcg/kg
This value (0.35 EU/mcg) is expressed in Endotoxin Units
per mcg of product. In order to convert this value to a
endotoxin unit concentration per ml, multiply it (0.35
EU/mcg) by the product potency (see below).
1000 mcg/ml x 0.35 EU/mcg = 350 EU/ml
This determined value means that if a parenteral drug
manufacturer is using the LAL method for endotoxin testing
of Cyanocobalamin Inj., the product can have no more than
350 EU/ml of product.
LAL Methods - Some Inherent Weaknesses
The FDA and USP have recognized the validity of various
approaches to using LAL for endotoxin testing. There are
four basic methods commercially available and currently
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approved by FDA for end-product release testing: (i) the gel-
clot; (ii) the turbidimetric (spectrophotometric); (iii) the
colorimetric (Lowry protein); and (iv) the chromogenic
assay. The LAL reagents used in these methods must be
obtained from an FDA-licensed manufacturer and must be
designed specifically for the method chosen. Many of the
other LAL methods appearing in the literature are
modifications of the gel-clot or turbidimetric test and some
have been designed to use less LAL than the basic method.
Certain products have been known to interfere with the
LAL's ability to react with endotoxin. These factors may be
chemical or physical. Chemical inhibitors cause chelation of
divalent cations necessary for the LAL reaction (i.e. EDTA),
protein denaturation (i.e. fluorescein), or pH disruption (i.e.
pH outside 6.0 - 7.5 range). Physical inhibitors include
adsorption of endotoxin, or product viscosity. Most will
affect all methods although the degree of inhibition may
vary. However, most of the inhibition can be overcome by
dilution of the product. Other factors such as the shape and
type of glassware used in the gel-clot test can also affect the
validity of the test. For example, siliconized glassware as well
as plastic can inhibit gel-clot formation or prevent accurate
spectrophotometric readings of the reaction mixture end
point.
Turbidimetric and chromogenic methods cannot be used
with certain turbid or colored products. Additionally,
precipitate formation, although inhibitory, may be mistaken
for a positive response in these methods. One problem
associated with the use of the chromogenic method is the
formation of a precipitate following the addition of acid to
stop color development. Products that require a neutral or
basic pH for solubility are most likely to cause this problem.
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The necessity to validate the reliability and accuracy of the
LAL method for each product tested cannot be over-
emphasized. Manufacturers can demonstrate this by
inoculating the product with low levels of endotoxin and
assay for their recovery. The endotoxin concentrations used
should be within the lower range of the lysate sensitivity. In
addition, several researchers have found that even the
selection of lysate reagent source (i.e., the manufacturer of
the lysate) can contribute to variability in test results.
Therefore, if any change in reagent source is made, the test
must be re-validated.
There have been several revisions to the analytical
procedures outlined in the bacterial endotoxin test since it
was first issued in 1980. These changes have enabled the
LAL method to be more reliable as a compendial referee test.
The significant changes are (i) After dilution of endotoxin
through a parallel set of solutions, one containing water and
the other pH adjusted product, the end point for the reaction
mixtures between the two sets should not differ by greater
than a two-fold difference; (ii) If the product affects the
lysate test mixture, then any dilution between the inhibition
endpoint and the MVD can be used; (iii) The maximum a
product may be diluted for testing is to be determined using
the maximum valid dilution (MVD) formulae. The formula is
based upon the product dosage, endotoxin tolerance limit
and the lysate sensitivity. Product dilution beyond this
determined factor will render a negative result meaningless.
Harmful endotoxin concentrations may be diluted below the
detectable range of the lysate; (iv) Vague procedures for
washing bacterial endotoxins from medical device products.
Careful attention for not using excessive volumes for product
rinsing is mentioned.
Sources
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There can be several sources of pyrogens in parenteral and
medical device products. Usual sources are: the water used
as the solvent or in the processing; packaging components;
the chemicals, raw materials or equipment used in the
preparation of the product. Good practice would include
control of the microbiological and endotoxin levels of
contamination in the potential sources mentioned above.
For parenteral products, inspections have shown that where
pyrogen problems were found in dosage forms, and when
the source was one of the raw materials, it was the active
drug substance. This was particularly true for drug
substances in which process water was used at some late
stage in the synthesis process. Endotoxin levels of the drug
substance were subsequently lowered when the
microbiological levels of the process water were lowered and
the process water system was controlled.
Additionally, if the drug substance is biologically produced,
the incomplete removal of the microorganism during
purification can result in the drug substance having high
endotoxin levels. Examples include antibiotics produced by
fermentation or the by-products of gram negative bacteria
used to produce genetically engineered drug products. The
potential use of yeast in this area is being evaluated to
eliminate this problem.
General processing procedures for physical components of
parenteral products such as stoppers and vials, provide for
washing these components with pyrogen-free water prior to
sterilization. Good practice would include minimal handling
of the component after washing and prompt sterilization
particularly if sterilized by steam. Storing non-sterile wet
stoppers could lead to an increase in microorganisms and
possibly endotoxin levels.
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Another source of endotoxins is the Water for Injection
(WFI) or pyrogen-free water system. As a general comment,
circulating hot water systems (above 75 C) provide the
environment least conducive to microbial growth and
endotoxin formation. Circulating Water for Injection
Systems at lowered temperatures (at approximately 60 C)
are somewhat (marginally) controlled by the temperature of
the system. There is some concern that there can be some
pathogenic gram negative organisms, such as Legionella
pneumophilia, that will survive and grow at 57 C. There is
considerable information on the presence of L.
pneumophilia in hospital hot water systems. Literature has
shown that periodically raising the temperature of these hot
water systems to 75 - 80 C has eliminated the organism.
Generally, ambient temperature WFI systems present the
greatest problem. Many of the objectionable microorganisms
which are good sources of endotoxins grow well in cold WFI
systems. This is particularly true of Reverse Osmosis (RO)
systems. It has been recognized that since Reverse Osmosis
filters are not absolute, it may be necessary to have them in
series in order to manufacture pyrogen-free WFI.
As previously discussed, the growth of some types of
microorganisms contributes to increased levels of endotoxin.
Non-sterile bulk inprocess or formulated solutions,
particularly the preservative-free solutions, are a good
environment for microbial growth. It is not common practice
for manufacturers to perform endotoxin testing on these
solutions. Most perform microbiological testing in order to
determine the microbiological level (Bio-burden) prior to
subjecting the solution to a sterilization process. However, in
order to determine the potential for high endotoxin levels, it
would be advisable to perform microbiological testing prior
to performing any sterilizing steps. For example, if a product
is formulated and filtered prior to a final sterilization,
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microbiological testing of the Bio-burden after filtration will
provide some useful information for the determination of
the adequacy of the sterilization process. However, it will
provide little, if any, information pertaining to the adequacy
of the process with respect to minimizing endotoxin
contamination. Since endotoxins result from high levels of
microorganisms, and are not removed by sterilizing or
microbiological filters, the subsequent reduction of a high
microbiological level will not be associated with a similar
reduction of high endotoxin level.
As with parenteral drug products, sterile devices have
occasionally been shown to be contaminated with
endotoxins. Sources have been water which somehow
entered into the manufacturing process. For example, the
washing of components such as filter media to be used for
the manufacture of filters, or the washing/rinsing of tubing
or other plastic devices prior to subsequent sterilization are
potential sources of endotoxins.
Depyrogenation
It is difficult to remove endotoxins from products once
present. It is far better to keep finished products and
components relatively endotoxin-free rather than have to
remove it once present.
The most common depyrogenation procedures for physical
components include incineration and removal by washing,
also termed dilution. The literature has shown other
procedures, such as filtration, irradiation and ethylene oxide
treatment to have limited effect in reducing
pyrogen/endotoxin levels. For Water for Injection systems,
the two acceptable ways of manufacture are distillation and
Reverse Osmosis.
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Distillation has been shown to be effective and the most
reliable method in removing endotoxin from contaminated
water samples. Isolated problems related to splashing in the
still and subsequent distillate contamination have been
identified. Similarly, isolated problems with condensers or
heat exchangers have been known to occur. Refer to ITG NO.
34, dated 7/31/79, for an additional discussion of heat
exchangers.
As with most processes and pieces of equipment, it is good
pratice to know the limitations and/or capabilities of
equipment. For example, stills with high levels of endotoxins
in feed water have occasionally been shown to yield WFI of
unacceptable quality ( >.25 EU/ml). More so, when WFI is
produced by Reverse Osmosis (RO), the endotoxin level of
feed water should be known. Since RO filters are not
absolute, it may be necessary to have them in series in order
to manufacture pyrogen-free WFI. Whichever system is
employed, good practice would include the ability to isolate
and evaluate each piece of equipment in a WFI system. Refer
to ITG No. 36, dated 10/21/80, for a discussion of Reverse
Osmosis.
For physical components, such as stoppers and tubing,
rinsing or dilution with pyrogen-free water systems is most
common. Some manufacturers, such as LVP manufacturers,
are employing dilution to remove endotoxin from glass
containers which are then sterilized by other means. As with
validation for sterility, validation for endotoxin reduction
should include a knowledge of the endotoxin burden and a
satisfactory endotoxin challenge. It should be pointed out
that due to the lack of sensitivity of the USP pyrogen test
conducted on rabbits, "challenge" testing should be
conducted employing the Limulus Amebocyte Lysate Test.
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Although there is no guide in this area, it would be expected
that there be at least a 3 log reduction below the endotoxin
challenge when the dilution process is employed.
Historically, vials or glass components have been rendered
pyrogen-free by dry heat sterilization at high temperatures.
Some texts have recommended the depyrogenation of
glassware and equipment by heating at a temperature of 250
C for 45 minutes. It has been reported that 650 C for 1
minute or 180 C for 4 hours, likewise, will destroy pyrogens.
Studies by Tsuji et al, published in 1978, have shown that at
lower temperatures (of 170 C), thermal destruction follows
second-order rate, and a 3 log reduction of endotoxin levels
at lower temperatures might not be practical.
There are other less common methods employed for
removing endotoxins. In the manufacture of sterile powders,
crystallization or purification is commonly employed to
remove endotoxins. Some manufacturers have occasionally
resorted to less acceptable methods such as washing or
rinsing the crystal or powder with a solvent in order to
remove endotoxins.
NOTE: Using dilution or rinsing is acceptable for a physical
component such as a stopper or vial which is not going to be
injected. However, when employing it for a chemical
component, it is only of limited value. There can be only
assurance that the endotoxin level on the outer surface of the
powder is reduced and not throughout the crystal.
Other less generally acceptable methods include ethylene
oxide treatment and irradiation. It has been shown that
reductions of approximately 80% in the pyrogenicity of E.
coli endotoxin in dialyzers have occurred after exposure to
ethylene oxide.
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With respect to manufacturing equipment and transfer lines,
depyrogenation by dilution has usually been the method of
choice. Utilization of strong alkali or oxidizing solution has
occasionally been employed to reduce pyrogens in these
storage/delivery systems. However, it should be followed by
rinsing with Water for Injection. Residues in the rinse
solution of less than 1 part per million (ppm) can be
achieved and have been accepted.
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  Store vaccine in an ultra-cold freezer, thermal shipping 
container, freezer, or refrigerator. See guidance below  
for each storage unit. 
  Follow the manufacturer’s instructions for returning  
the thermal shipping container. 
  Each thermal shipping container holds up to  
5 trays of vaccine.
 » Each tray contains 195 multidose vials (1,170 doses).
 » A vaccine tray is approximately  9 in x 9 in x 1.5 in.
  Check and record storage unit temperatures each 
workday. See guidance below for each type of storage 
unit. Save storage records for 3 years, unless your 
jurisdiction requires a longer time period.
 !Deliveries
Vaccine
Use CDC's Delivery Checklist for P"zer-BioNTech Vaccine when accepting a delivery and unpacking vaccine.  
When vaccine is delivered:                         
1. Open the thermal shipping container. Press the stop 
shipment button on the temperature monitoring 
device for 5 seconds. 
2. The LED indicator light will change to a solid color and a 
temperature status report will be e-mailed to the person 
who ordered the vaccine.
3. Proceed based on the color of the LED indicator light: 
No color or red: Wait for the status report.  
Green: Unpack the vaccine. 
4. Follow the manufacturer's guidance for unpacking the 
vaccine. Inspect the trays.    
 » Do not open the vial trays or remove vials until ready to 
thaw/use the vaccine.
 » If storing the vaccine at ultra-cold temperatures, return 
vaccine to frozen storage within 5 minutes.
Dry Ice Safety
1. Dry ice is needed to maintain proper temperatures in 
the thermal shipping container. 
2. Ensure sta# has proper PPE and is trained to handle 
dry ice safely.  
3. Do not use or store dry ice in con"ned areas, walk-
in refrigerators, environmental chambers, or rooms 
without ventilation. A leak in such an area could cause 
a depletion of oxygen in the atmosphere, which may 
lead to asphyxiation. 
Ancillary Supply Kit
An ancillary supply kit will be delivered separately from the vaccine and includes:  
  Mixing supplies: Diluent, needles, syringes, and sterile 
alcohol prep pads 
 » Mixing supplies are packaged separately with a green 
identi"cation label.
 » Do NOT use mixing supplies to administer vaccine.
  Administration supplies: Needles, syringes, sterile alcohol 
prep pads, vaccination record cards, and some PPE.      
Each ancillary supply kit contains enough supplies to mix and administer 1 tray of vaccine.
Pfizer-BioNTech COVID-19 Vaccine




Storage and Handling Summary
03/03/2021 CS321570-I
 !Thermal Shipping Container 
CDC recommends providers consider using the thermal shipping container for temporary storage only. The container requires 
signi"cant support to store vaccine at proper temperatures, including trained sta#, a regular supply of dry ice, and standard operating 
procedures for regular maintenance. 
Use the Controlant temperature monitoring device (TMD) 
included with the thermal shipping container to monitor  
the temperature. 
  Review contact information.  
 » If the contact for your order (inVTrckS) is not valid, you  
will NOT be noti"ed in the event of a temperature  
excursion. Contact your jurisdiction's immunization  
program for assistance.
 » If your contact is valid and you are not receiving e-mails 
or cannot load email hyperlinks, refer to Controlant for 
troubleshooting (https://in.controlant.com/onsitemonitoring).
 » Identify up to 4 contacts to receive e-mails and text alerts on 
the container's temperature status.
  Review DAILY e-mails on the status of the container.
  Click the link in daily e-mails to access and download 
all temperature data. Save the Excel "le summarizing all 
temperature data for at least 3 years.
  Save the return shipping label provided in your shipping 
container at delivery. Use the shipping label to return the 
thermal shipping container with Controlant TMD after 30 days.
  Replenish dry ice pellets (10 mm to 16 mm) within 24 hours 
of delivery and every 5 days thereafter. Follow manufacturer’s 
guidance for adding dry ice.
  Dry ice will be sent for the "rst re-icing unless you opt out when 
placing the vaccine order.
  Additional dry ice shipments will NOT be provided. Arrange  
for dry ice to maintain the temperature of the container after the 
"rst re-ice. 
Removing vaccine vials/doses for use: 
  Determine the number of vials needed before opening the 
thermal shipping container. 
  Open the thermal shipping container no more than 2 times per 
day for up to 3 minutes each time. Use packaging tape  
to reseal the outer carton after each entry.
   Store vaccine vials upright in the tray and protect from light.
 !Ultra-Cold Freezer
Before mixing, the vaccine may be stored in an ultra-cold freezer between  
-80°C and -60°C (-112°F and -76°F).
  Store vaccine vials upright in  
the tray. 
  Protect from light.
  Vaccine may be stored until the  
expiration date. 
 » As the expiration date approaches, 
contact the manufacturer to 
determine if it has been extended.  
Do not discard vaccine without 
ensuring the expiration date has 
passed. 
 !Freezer
Before mixing, the vaccine may be stored in the freezer between -25°C and -15°C (-13°F to 5°F) for up to 2 weeks. The total time vials 
are stored at these temperatures should be tracked and should not exceed 2 weeks. 
  These temperatures are within the appropriate range for  
routinely recommended vaccines, BUT the temperature range 
for this vaccine is tighter. 
  If storing the vaccine in a freezer with routinely recommended 
vaccines, carefully adjust the freezer temperature to the correct 
temperature range for this vaccine. 
  Use CDC’s freezer storage temperature log for COVID-19 
vaccine to document storage unit temperatures.
  Monitor how long the vaccine has been in the freezer  
using CDC’s beyond-use date labels for P"zer-BioNTech  
COVID-19 vaccine. 
 » Vaccine stored in the freezer can be transferred to 
refrigerator storage for an additional 120 hours (5 days). 
  Store the vaccine in the tray.
  Protect from light. 
  Do not use dry ice for freezer storage.
  Vials stored in the freezer may be returned one time to ultra-
cold temperature storage (-80ºC to -60ºC [-112ºF to -76ºF]).
  Once returned to ultra-cold storage, the 2-week time frame  
is suspended. 
Store vaccine in the FREEZER between -25°C and -15°C 





Today’s date: ____/____/_______ Time:
 
 
Date: ____/____/_______ Time:  
 
*If the 2-week deadline is met, move any  
remaining vials to refrigerated storage for an  
additional 120 hours (5 days). Use a refrigerator  
beyond-use date (BUD) label to 















3For additional information, refer to the manufacturer's website at www.cvdvaccine.com
Pfizer-BioNTech COVID-19 Vaccine
Storage and Handling Summary
03/03/2021 CS321570-I
 !Refrigerator 
Before mixing, the vaccine may be stored in the refrigerator between 2°C and 8°C (36°F and 46°F) for up to 120 hours (5 days). After 120 
hours (5 days), contact the manufacturer for guidance. If directed to discard any remaining vials, follow the manufacturer's and your 
jurisdiction's guidance for proper disposal.
  Monitor how long the vaccine has been in the  
refrigerator using CDC’s beyond-use date labels for  
P"zer-BioNTech COVID-19 vaccine. 
  Store the vaccine in the tray.
  Protect from light. 
  Do NOT refreeze thawed vaccine.
 !Temperature Monitoring 
Ultra-cold freezer, freezer, refrigerator: Storage unit temperatures must be monitored regularly, checked, and recorded at the 
beginning of the workday to determine if any temperature excursions have occurred since the last temperature check. For accurate 
temperature monitoring, use a digital data logger (DDL) with a detachable probe that best re$ects vaccine temperatures. 
  Ultra-cold temperatures: Use a probe designed speci"cally to 
measure ultra-cold temperatures.
  Frozen and refrigerated storage: Use a probe bu#ered with 
glycol, glass beads, sand, or Te$on®.
Check and record the temperature daily using CDC’s temperature log. Use one of the options below:
  Option 1 (preferred): Minimum/Maximum  
(Min/Max) Temperature  
Most DDLs display min/max temperatures. Check and record  
the min/max temperatures at the start of each workday.
  Option 2: Current Temperature  
If the DDL does not display min/max temperatures, check and 
record the current temperature at the start and end of the 
workday. Review the continuous DDL temperature data daily.
Thermal Shipping Container: Use the Controlant temperature monitoring device (TMD) included with the thermal shipping 
container to monitor the temperature. See thermal shipping container information above.  
 !Diluent 
0.9% sodium chloride (normal saline, preservative-free) diluent is included in the ancillary supply kits. Follow the manufacturer’s 
guidance for storing the diluent. 
 !Mixed Vaccine
  Once mixed, vaccine can be left at room temperature  
(2°C to 25°C [35°F to 77°F]) for up to 6 hours. 
  Discard any remaining vaccine after 6 hours.
  Mixed vaccine should NOT be returned to freezer storage. 
  Mixed vaccine does not need to be protected from light. 
 
CDC's P!zer-BioNTech COVID-19 Vaccine materials https://www.cdc.gov/vaccines/covid-19/info-by-product/p"zer/index.html
CDC's Vaccine Storage and Handling Toolkit https://www.cdc.gov/vaccines/hcp/admin/storage/toolkit/storage-handling-toolkit.pdf
CDC's P!zer Beyond-Use Date (BUD) labels https://www.cdc.gov/vaccines/covid-19/info-by-product/p"zer/downloads/bud-tracking-labels.pdf
CDC's Delivery Checklist https://www.cdc.gov/vaccines/covid-19/info-by-product/p"zer/downloads/delivery-checklist.pdf
CDC's Freezer and Refrigerator Temperature Logs https://www.cdc.gov/vaccines/covid-19/info-by-product/p"zer/index.html
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FACT SHEET FOR HEALTHCARE PROVIDERS ADMINISTERING 
VACCINE (VACCINATION PROVIDERS) 
EMERGENCY USE AUTHORIZATION (EUA) OF 
THE MODERNA COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019 
(COVID-19) 
 
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization 
(EUA) to permit the emergency use of the unapproved product, MODERNA COVID-19 
VACCINE, for active immunization to prevent COVID-19 in individuals 18 years of age and 
older. 
 
SUMMARY OF INSTRUCTIONS FOR COVID-19 VACCINATION PROVIDERS 
Vaccination providers enrolled in the federal COVID-19 Vaccination Program must report all 
vaccine administration errors, all serious adverse events, cases of Multisystem Inflammatory 
Syndrome (MIS) in adults, and cases of COVID-19 that result in hospitalization or death 
following administration of the Moderna COVID-19 Vaccine. See “MANDATORY 
REQUIREMENTS FOR MODERNA COVID-19 VACCINE ADMINISTRATION UNDER 
EMERGENCY USE AUTHORIZATION” for reporting requirements. 
 
The Moderna COVID-19 Vaccine is a suspension for intramuscular injection administered as a 
series of two doses (0.5 mL each) 1 month apart. 
 
See this Fact Sheet for instructions for preparation and administration. This Fact Sheet may have 
been updated. For the most recent Fact Sheet, please see www.modernatx.com/covid19vaccine-
eua. 
 
For information on clinical trials that are testing the use of the Moderna COVID-19 Vaccine for 
active immunization against COVID-19, please see www.clinicaltrials.gov. 
 
DESCRIPTION OF COVID-19 
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the novel coronavirus, 
SARS-CoV-2, that appeared in late 2019. It is predominantly a respiratory illness that can affect 
other organs. People with COVID-19 have reported a wide range of symptoms, ranging from 
mild symptoms to severe illness. Symptoms may appear 2 to 14 days after exposure to the virus. 
Symptoms may include: fever or chills; cough; shortness of breath; fatigue; muscle and body 
aches; headache; new loss of taste or smell; sore throat; congestion or runny nose; nausea or 
vomiting; diarrhea. 
 
DOSAGE AND ADMINISTRATION 
 
Storage and Handling 
The information in this Fact Sheet supersedes the information on the vial and carton labels.  
 
During storage, minimize exposure to room light. 
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Data are not available to assess the effects of Moderna COVID-19 Vaccine on the breastfed 
infant or on milk production/excretion.  
 
11.3  Pediatric Use 
Safety and effectiveness have not been assessed in persons less than 18 years of age. Emergency 
Use Authorization of Moderna COVID-19 Vaccine does not include use in individuals younger 
than 18 years of age.  
 
11.4 Geriatric Use 
Clinical studies of Moderna COVID-19 Vaccine included participants 65 years of age and older 
receiving vaccine or placebo, and their data contribute to the overall assessment of safety and 
efficacy. In an ongoing Phase 3 clinical study, 24.8% (n=7,520) of participants were 65 years of 
age and older and 4.6% (n=1,399) of participants were 75 years of age and older. Vaccine 
efficacy in participants 65 years of age and older was 86.4% (95% CI 61.4, 95.2) compared to 
95.6% (95% CI 90.6, 97.9) in participants 18 to <65 years of age [see Clinical Trial Results and 
Supporting Data for EUA (18)]. Overall, there were no notable differences in the safety profiles 
observed in participants 65 years of age and older and younger participants [see Overall Safety 




Moderna COVID-19 Vaccine is provided as a white to off-white suspension for intramuscular 
injection. Each 0.5 mL dose of Moderna COVID-19 Vaccine contains 100 mcg of nucleoside-
modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of 
SARS-CoV-2 virus. 
 
Each dose of the Moderna COVID-19 Vaccine contains the following ingredients: a total lipid 
content of 1.93 mg (SM-102, polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG], 
cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]), 0.31 mg tromethamine, 
1.18 mg tromethamine hydrochloride, 0.043 mg acetic acid, 0.20 mg sodium acetate trihydrate, 
and 43.5 mg sucrose. 
 
Moderna COVID-19 Vaccine does not contain a preservative.  
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DECLARATION OF CONFORMITY 







iThe system mentioned above is manufactured in Millipore S.A.S. - 67120 Molsheim - 
FRANCE - facilities whose quality management system is approved by an accredited 
registering body to the ISO9001 Quality System Standards. 
 
iWe certify that these Lab Water Systems are designed and manufactured in application of 
the following European Council directives :  
 
- 89/336/CEE relating to Electromagnetic compatibility 
- 73/23/CEE relating to electrical equipment designed for use within certain 
voltage limits 
 
i Standards to which conformity is declared as applicable are the following : 
 
EN 50082-1 Edition 1992 : Electromagnetic compatibility : generic 
immunity standard 
EN 55022 Edition 1987: Limits and method of radio-disturbance 
characteristics of information technology equipments. 
EN 61326-1 Edition 1997 / A1 Edition 1998: Electrical equipment for 
measurement, control and laboratory use - EMC requirements. 
EN 61000-3-2 / A1 and A2 Edition 1998 / A14 Edition 2000 : Limits 
for harmonic current emissions (equipment input current up to and 
including 16A per phase) 
EN 61010-1 : 1993 / A2 : 1995 : Safety requirements for electrical 
equipment for measurement, control and laboratory use. 
 
 






 Quality Assurance Manager 
 Millipore S.A.S. 
 



































The Millipore Super-Q Water Systems are modular systems designed to provide the “final 
polish” to water that has been pre-treated by purification methods such as reverse osmosis 
(RO), deionization (DI) or distillation. Super-Q Systems can produce up to 12 L/min of high 
purity water; free of ionic contamination up to 18 megohm-cm resistivity level, and free from 
particulate and microbiological contamination to an absolute size level determined by the 
pore size of the Millipore filter element used. With the appropriate cartridges installed in the 
proper configuration, a level of down to 20 ppb TOC may be achieved for organic removal. 
 
 
Super-Q Systems produce water that is pure enough for critical applications such as atomic 
absorption (AA) spectrophotometry, high performance liquid chromatography (HPLC), tissue 
culture media preparation, electronics rinse water, and total organic carbon (TOC) analysis. 
They are designed to produce water that exceeds C.A.P. (College of America Pathologists), 
A.S.T.M. (American Society for Testing and Materials), N.C.C.L.S. (National Committee for 
Clinical Laboratory Standards), and A.C.S. (American Chemical Society) standards for Type 
I Reagent Grade Water. 
 
 
Super-Q product water is intended for immediate use because such high quality water 
deteriorates when stored, or exposed to the environment. 
 
 
There are both Standard and Plus (Recirculating) Models. The recirculating Super-Q Plus 
System includes a pump and is recommended for single point-of-use applications with 
intermittent demands. The Standard, non-recirculating system, which requires additional 
accessories, is designed for multiple point-of-use applications. 




All Super-Q Systems consist of a series of three or four housings, each of which holds a 
disposable cartridge. Each cartridge provides a particular function such as prefiltration, 
organic adsorption, deionization and final Millipore membrane filtration to particle retention 
levels ranging to 0.22 µm. The full flow of feed water passes from the various cartridges 
through a temperature-compensated (25°C) resistivity sensor that monitors ionic purity over 
an effective range from 1.5 to 18.2 megohm-cm. 
 
 
For Technical assistance with your system, please contact your local representative or 









Super-Q Systems Specifications 
 
 
 Component    Materials of Construction 
 Support bracket   Stainless steel 
 Meg-O-Meter housing  Vacuum-formed plastic 
 PL housing and heads   Polypropylene, nylon 
 Hardware 
 (Screws, nuts, washers)  Stainless steel 
 Sensor housing   White polypropylene 
 
 Connections 
 Inlet :  1/2” NPTF F&T fitting 
 Outlet : 1/2” NPTF F& T fitting 
 
 Dimensions   
 
    3 BOWLS    4 BOWLS 
 Height :  800 mm (26.6 ft)   800 mm (26.6 ft) 
 Width :  945 mm (31.5 ft)   1 150 mm (38.3 ft) 
 Depth :  220 mm (7.3 ft)   220 mm (7.3 ft) 
 
 Electrical Requirements 
 The system must be electrically connected to an earth grounded power supply. 
 220V / 50Hz, 2A  Fuse : 2AT 250V  5 x 20mm 
 115V / 60Hz, 5 A  Fuse : 5AT 250V  5 x 20mm 
 
 Feed Water Requirements 
 Operating Temperature : 5°C - 40°C (41°F - 104°F) 
 Feed Water Pressure :  Minimum : 0.5 psi (0.03 bar). 
     Maximum : 
      Super-Q Plus Systems : 
       15 psi (1 bar). If greater, please use a 
       pressure regulator. 
      Standard Super-Q Systems : 
       depends upon pump specifications, not to 
       exceed maximum system pressure of 80 
       psi (5.5 bar). 
 
 Environmental conditions : 
 Ambient storage temperature : 10°C - 40°C (50°F - 104°F). 





 Typical System Performance 
 Resistivity  : 18.2 Megohms-cm at 25°C. 
 Organic  : < 20 ppb (*). 
 Microorganisms : < 10 cfu/ml (**) 
 
 (*) When an Organex-Q™ cartridge is used and the system is fed with Reverse 
  Osmosis water. 
 
 (**) With 0.22 µm final filtration immediately prior to the point-of-use. 







 Expendable*      Catalogue Nbrs 
 
 Milligard TP Prefilter cartridge, 20”, 3/pk  CWSC02TP3 
 Super-C Carbon cartridge, 22”, 3/pk   CDFC02203 
 Ion-Ex Cartridge component, 22”, 2/pk  CPMB02202 
 Durapore TP 0.22µ Cartridge, 20”, 1/pk  CVDI02TP1 
 Organex-Q Cartridge, 22”, 1/pk   CPEX02201 
 
* Cartridges are not shipped as part of the system and must be ordered separately. 
 
NOTE : Effluent quality will rapidly degrade if stored outside of the Super-Q System. 
Such high quality water will be contaminated by the atmosphere and by contact 




















































 Super-Q Plus Systems are shipped with the support bracket and cartridge housings 
head manifold completely assembled in the same container with the housing bowls 
and other accessories. Each system requires cartridges, that are not provided with the 
preassembled hardware and must be ordered and shipped separately. Standard Super-
Q Systems require additional components that must be ordered separately. Please 
consult the Ordering Information Section of this manual or Technical Service to 
choose the most appropriate cartridge configuration and accessories to meet the water 





 All systems require a clearance of 2 ft (60 cm) below the bowls for cartridge 
installation and replacement. The unit must be mounted on a surface and with bolts 





 All Super-Q Systems require one grounded electrical outlet, either 115V or 220V, 
depending upon your particular system. The systems have a power consumption 
capacity of 5A for 115V systems and 2A for 220V systems. 
 
 
Feed Water Requirements 
 
 Most municipal tap water supplies contain a very high concentration of suspended 
particulate, colloids, dissolved organic and inorganic materials. These should be 
removed by the appropriate pre-treatment methods to prolong the useful life of 
cartridges, and enhance the product water purity. Reverse Osmosis (RO) or 
distillation treatment is ideal. If deionization of the water is preferred, this type of 
water should be prefiltered prior to feeding to the Super-Q Systems to remove some 













 A minimum feed water pressure of 0.5 psi (1 foot head) is required. The maximum 
feed water pressure to the Super-Q Plus Systems is 15 psi (1 bar). A pressure 
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regulator is required with these systems to maintain feed water pressure within these 
limits. 
 
 Feed water temperature should not exceed 40°C (104°F). 
 
 A shut-off valve on the feed water line is recommended to facilitate cartridge 





 Use the following procedure to level and secure the system to a suitable wall. 
 
1. Mark a horizontal line on the mounting surface at least 1400 cm (55”) above 
the floor. Using all four mounting bolt holes as a guide, mark locations for the 
bolts. Predrill the necessary holes. 
 
2. Using fasteners (not supplied) that are strong enough to hold the Super-Q 
System when it is full of water (at least 63 kg - 140 lbs), secure the housing 
assembly to the mounting surface. 
 
 
Pipe and Tube Connections 
 
 Complete any extra piping with polypropylene or polyethylene piping. Joints should 
be solvent cemented or sealed with Teflon-taped threads. Make threaded connections 
by wrapping the male thread with a double overlapping layer of Teflon thread-sealing 
tape to prevent leaks and facilitate removal. 
 
 DO NOT use pipe-thread compound. It will contaminate the water stream making it 





 The feed water source (Reverse Osmosis, deionized or distilled water supply) is 












Pressure Regulator Installation 
 
 If the feed water pressure to the Super-Q Plus Systems exceeds 15 psi (1 bar), install a 
pressure regulator (to be ordered separately) upstream of the Super-Q Plus inlet, 
maintaining the proper flow direction. The pressure regulator can have 1/2” NPTF 
inlet and outlet connections so you can install the regulator with a 1/2” NPTM to 1/2” 
O.D. tube fittings. 
 






 On Super-Q Plus Systems, the outlet of the system has a 1/2” female tube fitting 
located on the production valve.  
 The Standard Super-Q Systems’ outlet is 1/2” NPTF. 
 
 If an outlet delivery tube is required, use inert tubing to maintain the water quality. 
 
 
Installation of Accessories to a Standard Super-Q System 
 
 If a recirculating system with multiple points-of-use is required, a customized unit to 
meet your high purity water needs can be installed using a Standard Super-Q System. 
Call Technician Service for assistance in sizing the proper components for your 
application because a properly designed system must meet the following 
specifications including maximum system pressure and flow rate while still providing 





  Operating Temperature :  5°C - 40°C (41°F - 104°) 
 
  Feed water Pressure :   Minimum : 055 psi (0.03 bar). 
       Maximum : depends upon pump 
         specifications. 
 
  Flow Rate :    Not to exceed 12 L/min. 
 
  Maximum System Pressure :  80 psi (5,5 bars). 
 
NOTE :  It is highly recommended to use Polypropylene or Polyethylene tubing 
 throughout and wrap threaded connections with Teflon thread-sealing tape. 




























A. Function of Components 
 
 
 Head and Housing Assemblies 
 
 All cartridge housings are of identical modular design, consisting of a molded 
head with detachable cylindrical bowl. The heads and housings hold the various 
filter cartridges such that, when properly selected, combine to yield the highest 
quality product water available. 
 
 Use of an ultrafilter cartridge in the final bowl requires additional parts which 




 Pump (Super-Q Plus Systems) * 
 
 The Super-Q Plus Systems include a positive pressure gear-pump that directs 
the feed water, under pressure, through the system. This selected magnetic drive 
gear pump is used to eliminate problems of seal replacement, priming, and 
leakage. It produces a maximum flow of 12 L/min (3 gpm), at a maximum 
pressure of 55 psi (3.8 bar). 
 
 
CAUTION : Although the pump is self-priming, never start the pump 
without ensuring that a proper water supply is connected and 
available to the pump. 
 
 The feed water pressure to the pump should not exceed 15 psi 
(1 bar). If necessary, a pressure regulator should be installed in 
the feed line, upstream of the pump, to control the feed water 
pressure. 
 
* The Standard Super-Q System must have a pump (not included) that is 
properly sized for the application. 
 
 
 Pressure Regulator 
 
 Placed in the inlet feed water line, the pressure regulator controls the feed water 
pressure to the Super-Q Plus System. It should be set to a level between the 
minimum 0.5 psi (0.03 bar) pressure required, and the maximum permitted 






 Meg-O-Meter Assembly 
 
 This water quality meter provides an accurate, in-line measurement of the 
Super-Q product water resistivity. The meter scale is graduated from 2 to 18 
megohm-cm. The unit is internally temperature-compensated to normalize 
readings at 25°C (77°F) for water temperature between 5°C and 40°C (40°F to 
104°F). 
 
 On Super-Q Plus Systems the assembly is equipped with an autorecirculation 
feature that allows water to recirculate when the Main Power Switch is in the 
ON-1 position, and the Pump Control Switch is in the “Standby” mode. This 
recirculation, caused by periodic operation (in the “Standby” mode) permits the 





 The sensor, located just after the last housing, is electrically connected to the 
Meg-O-Meter Assembly. In operation, the sensor continually measures the 
product water resistivity as it exits the last housing. 
 
 
 Main Power Switch (Super-Q Plus Systems) 
 
 This power switch, located on the right side of the Meg-O-Meter panel, has both 
ON-1, OFF-0 positions. The switch, when turned to the ON-1 position, operates 
the pump, and provides power to the circuit. 
 
 
 Main Power Light (Super-Q Plus Systems) 
 
 This green power light is located on the face of the Meg-O-Meter Assembly and 
is illuminated when the switch is in the ON-1 position. 
 
 
 Operation Control Switch (Super-Q Plus Systems) 
 
 This switch, located on the face of the Meg-O-Meter Assembly, controls the 
operation of the pump. To function, the Main Power Switch must be in the ON-
1 position. 
Operate position : In this position, the pump operates continually. Depending 
upon the position of the production valve, product water is 
sent either to the point-of-use, or is continually recirculated. 
 
Standby position : In the standby position, the pump operates only during 
automatically timed flush cycles, once every one and a half 
hour for 41/2 minutes. 
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 Test Button 
 
 The Test Button is used to check if the Meg-O-Meter Assembly is functioning 
correctly. When the Test button is pushed, the Meg-O-Meter Assembly should 
read 10 megohm-cm. For Super-Q Plus Systems, perform the test when the 
Operation Control Switch is in the “Operate” position. 
 
 
 Production Valve (Super-Q Plus Systems) 
 
 This manually operated valve, located to the right of the sensor, directs the 
product water flow in either of two directions : to the point-of-use, or to the 
system’s recirculation loop. Standard Systems that require a recirculation loop 
must include a similar valve. The valve is open when the knob is turned 
anticlockwise to Product position, allowing water to flow to the final filter or 
point-of-use. The valve is closed when the knob is pointed up, to Recirculation 
position allowing water to recirculate through the system so that water quality is 
maintained at a high level.  
 
 NOTE:  If, at anytime, the valve is disassembled, ensure that it is reassembled  
  in the proper orientation. 
 
 
 Pressure Gauge 
 
 The pressure gauge is used to monitor pump discharge pressure. The maximum 
pressure limitation of the system is 80 psi (5.5 bar). Do not overtighten the 
pressure gauge into the housing head. To ensure a tight seal, the threads should 
be wrapped with on or two turns of Teflon tape. 
 
 
 Vent Valve 
 
 This manually-operated vent valve, located at the inlet side of the final housing 
head, is used to remove air from the housing bowls that might prevent total 















B. Function of Expendables 
 
 
 Expendable cartridges are not provided with the preassembly hardware. The 
cartridges must be chosen based upon specific water quality requirements. 
Consult the Ordering Information Section of this manual, or Technical Service 
for the optimum combination required to meet your needs. 
 
 
 Milligard TP Cartridge 
 
 Milligard TP (thermoplastic) cartridges are high-retention-membrane-filter 
cartridge allowing to remove high particle loads from feed water. They are 
designed for clarification and prefiltration of fluids that require final filtering 
through 0.45 µm or 0.22 µm filters. The manufacturing process obviates the use 
of thermal sealing adhesives that could cause contamination of the product 
water. Flow through the Milligard-TP cartridge is from the exterior toward the 
central collecting tube. The arrow marked on the housing head should point to 
the right for correct flow through this cartridge. 
 
 
 Super-C Carbon Cartridge 
 
 Dissolved organic contaminants and residual chlorine are removed by activated 
carbon adsorption within the Super-C cartridge. The Super-C cartridge is always 
installed upstream of the deionizing (Ion-Ex Cartridge) elements to prevent 
organic-fouling of the ion-exchange resins. The possibility of dissolved minerals 
from the carbon entering the effluent stream and degrading final water quality 
will also be eliminated. Flow through the Super-C cartridge is from the exterior 
of the cartridge into the central collecting tube. The arrow marked on the 
housing head points to the right for proper flow through this cartridge. 
 
 
 Ion-Ex Cartridge 
 
 The disposable Ion-Ex Cartridge filter removes dissolved inorganic 
contaminants by ion-exchange in a highly efficient mixed bed of strong acid and 
strong base resins. This element is designed and constructed such as to prevent 
channelling through the resins. The cartridge is used to “polish” water to an 18 
megohm-cm level of purity. 
 
 A series of two identical deionizing cartridge elements must always be located 






 Organex-Q Cartridge (optional) 
 
 The Organex-Q cartridge is a unique mixture of ion-exchange resins and 
synthetic activated carbon for removal of trace organics. The Organex-Q 
cartridge is required when very low levels of organic in the water is desired. The 
cartridge is normally placed in the last housing bowl. This organic scavenging 
cartridge, composed of both mixed-bed resins and carbon, removes dissolved 
trace organic contaminants. 
 
 
 Durapore - TP 0.22µ Cartridge 
 
 The Durapore-TP cartridge is designed specifically as a “final filter” for the 
removal of particles above 0.22µm and micro-organisms. The thermoplastic seal 
construction eliminates contamination from adhesive seals used in the 
construction of some cartridges. Flow through Durapore cartridges is from the 




































C. Standard Cartridge Installation 
(Super-C, Ion-Ex, Milligard-TP and Durapore-TP cartridges) 
 
 
1. Determine the proper cartridge configuration for your application. 
 
2. Lightly lubricate the O-Ring on the first housing head with water. 
 
3. Open the plastic wrapper of the Super-C cartridge and expose the 
cartridge-to-housing connection. Holding the cartridge by the wrapper, 
guide it into the housing head. Turn the cartridge about 1/4 turn and 
push firmly until the O-Rings are securely seated. Remove the plastic 
wrapper. The cartridge should be secured to the housing head. 
 
4. Raise one of the housing bowls over the cartridge to the large O-Ring 
on the housing. With both hands, firmly grasp the bowl, push up and 
turn clockwise until the bowl is completely tightened and cannot be 
turned further. 
 
5. Install and secure the V-clamp. Make sure that the knob is positioned 
to the side of the bowl so that it can be tightened completely without 
overtightening. 
 
6. Secure the remaining bowls to the housing heads without installing 
cartridges. Ensure that they are tightly secured to the housings head 
assembly. 
 
7. Plug the main power cord into the appropriate wall receptacle required, 
and open the feed water supply valve. Connect a length of flexible 
tubing to the outlet of the 3-way product valve and direct to drain. 
 
8. Turn Pump Control switch to the “Operate” position, then turn main 
power switch to ON-1. Allow system to flush for 2 or 3 minutes to 
remove any superficial carbon fines from the Super-C cartridge. 
 
9. Shut off main switch and turn the Pump Control switch to the 
“Standby” mode. Open bleed valve on head 4 to reduce pressure in 
system. 
 
10. Remove, and empty, the last bowls and insert the other purification 
elements.  
 






NOTE : If an Organex-Q cartridge is to be installed, please follow the 
installation procedure next page. 
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D. Organex-Q Cartridge Installation (into 4 bowls systems) 
 
 For applications requiring the use of the Organex-Q cartridge, this element is 




1. Install the Organex-Q cartridge in the last housing bowl. (refer to steps 
3 to 5 of the Standard Cartridge Installation Procedure). 
 
2. Open the valve to the “Product” position (handle towards you), and 
return the Pump Control switch to “Operate”, and flush the system for 
fifteen minutes. 
 
3. Flick the Pump Control switch to “Standby” ; turn off the Main Power 
switch ; and allow the system to stand idle for a minimum of at least 
one hour to hydrate the cartridge (better resistivity can be obtained if 
the system remains idle overnight). 
 
4. The next morning (or after one hour), turn on the Main Power switch ; 
flick the Pump Control switch to “Operate” mode to start the pump, 
leaving the production valve in “Recirculation” position to allow water 
to recirculate. 
 The time required to reach high resistivity and organic-free water will 
vary, depending upon the condition of the cartridges, the pre-treated 




















NOTE : To ensure the highest quality of water during operation, flush the 
system for five minutes after any recirculation period (as in standby) of 
over 12 hours. 
 It is advised to store non-used Ionex and Organex cartridges at 4°C and 
































A Super-Q system can be kept in excellent operating condition with very little maintenance. 
Performance problems are, for the most part, due to improper cleaning and sanitization, or 




A. Cartridge Replacement 
 
 
 The frequency with which cartridge elements require replacement depends 
essentially on the quality of the feed water to the system, the total and also 
relative amounts of particulate, organic, and ionic contaminants the system must 
remove. Since operating conditions vary so widely, no fixed general rule can be 
recommended. Practically speaking, the user should be guided by (a) the degree 
of plugging of the prefilter cartridge (if installed) and the final membrane 
cartridge ; (b) the level of resistivity obtained in the product water ; and (c) the 
level of organic removal achieved. 
 
 For optimum performance of the Super-Q System, and convenience, all 
cartridges should be replaced at the same time. 
 
 When ascertaining the degree of clogging of prefilter and membrane cartridges, 
it is necessary to record the pressure gauge readings (mounted on the top of the 
Super-Q heads) and the flow rate at the time all new cartridges are installed in 
the Super-Q System. Readings should be taken when the system is in the 
“Operate” mode. This is your baseline level and from pressure differential 
changes noted after operation, an evaluation of the need to change these filters 
can be made. It is important to note however that the Super-C, Ion-Ex cartridges 
and Organex-Q cartridges will be exhausted before they would be clogged. 
Therefore these elements are changed on the basis of their ionic, or organic 
removal performance only. The following guide should prove helpful for 






















 The cartridges should be changed : 
 
 
1. When the Meg-O-Meter scale indicator falls below 10 M:-cm or the 
desired resistivity level to a point unsatisfactory for your particular 
use. Purification media should not be left in the system for more than a 
year. 
 
2. When the organic level in the product water exceeds that required for 
your particular use. 
 
3. When a prefilter cartridge is installed in Bowl 1, and the pressure 
differential between the first and second gauges exceeds 10 psi (gauge 
1 increases, gauge 2 remains the same). The prefilter is clogged. 
 
4. With a membrane cartridge installed in Bowl 4, and the pressure 
differential between 3 exceeds 10 psi (gauge 1 and 2 will rise 







NOTE 1 : When it is necessary to add a prefilter to the system, the cartridge 
may be installed in a separate holder (such as the Millipore PL 
Housing) or in the first bowl of your system, followed by a Super-C 
cartridge and Ion-Ex cartridge units, and a disposable membrane filter 
unit (such as a Millipak) connected to the outlet of your system. In the 
former case, install a pressure gauge on the upstream side of the 
housing, and read both this gauge and the next gauge of the system to 
ascertain the pressure differential across the prefilter. In the latter 




NOTE 2: One pressure gauge is delivered with the system. Any other pressure 















 Cartridge Changing Procedure 
 
 Before proceeding, make sure the system is in “Standby” mode : 
 
 
1. Turn off electrical power to the system. 
 
2. To reduce the internal pressure, turn off the feed water flow and open 
the outlet valve, that has been diverted to drain. 
 
3. Open the purge valve at the bottom of each housing to purge the 
system. 
 
4. Remove the housing bowls by releasing the clamp, and twisting or 
rocking the bowl. Carefully lower the bowls from the cartridges. 
 
5. Pull the cartridges straight down and discard them. 
 
6. After cleaning the housing bowls (using the procedure that follows), 
replace the cartridges referring to the Cartridge Installation Procedure 
described in the Operation Section. Replace the elements in the proper 







 When the cartridges are changed, examine the inside of the housing bowls for 
residues deposited on the walls. Clean the insides of the bowls with a non-
abrasive detergent and a sponge or cloth. Thoroughly wash the inner surfaces of 
the bowls and the support structures. Rinse with clean water several times to 





















 Sanitization should be done regularly to both the ultrafiltration cartridge (if 
used) and the system hardware (bowls and heads without cartridges).  
 Ion-Ex, Organex and Super-C cartridges CANNOT be sanitized. 
 
 
 The sanitization process includes : 
 
1. Injection of a sanitant. 
 
2. Soaking or recirculating the unit. 
 
3. Flushing the residual chemicals. 
 
4. Testing for complete removal of residual chemicals. 
 
5. Recovery of water quality. 
 
 
 Super-Q Housing Sanitization 
 
 If slime deposits are detected inside the bowls and heads when cartridges are 
replaced, the entire system should be sanitized. This is especially important if a 
UF cartridge is used. It is also helpful to prevent premature microbial fouling of 
the cartridges. 
 
 To sanitize the bowls and heads : 
 
1. Remove all bowls and cartridges. 
 
2. Discard cartridges (except UF cartridge) and thoroughly clean all 
bowls and heads, following previous instructions in this manual. 
 
3. Replace all bowls except one, without installing cartridges. Make sure 
all purge valves are closed. 
 
4. Place 140 mL of household chlorine bleach (5,25% strength) in the 
remaining empty bowl, and secure this bowl to the final housing head. 
 
5. Open the feed water supply valve and the production valve (if closed). 
 
6. Start the pump. 
 
7. When water begins to flow at the outlet, close the production valve and 
recirculate water for ten minutes. 
 
8. Turn off the pump, close the feed water supply valve, and allow the 
system to stand idle for at least one hour. The water in the system 
should now have a chlorine level of about 200 ppm. 
 
9. Purge all bowls. 
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10. Open the feed water and the production valve. When water begins to 
flow at the outlet, close the production valve and recirculate water 
through the system for two or three minutes. 
 
11. Open the production valve and flush for approximately five minutes to 
remove residual bleach. Check the chlorine level of the water*. 
 
12. When the chlorine level in the flush water is reduced to < 0,1 ppm (or 
the level of the feed water), shut off the system. Open the vent valve to 
allow the internal pressure to drop to zero. Purge and remove the 



































* High chlorine levels can be determined by using the DPD free-chlorine 
test kit, catalogue number : ZLCL000AH. 
 
 Low chlorine levels (0 - 3.5 ppm) can be determined by using the DPD 

































 Description       Catalogue Number 
 
  V 115V-60Hz 
 
    3-Bowl Super-Q System    ZFSQ 115 03 
 
    4-Bowl Super-Q System    ZFSQ 115 04 
 
    4-Bowl Super-Q Plus System   ZFSQ 115 P4 
  (with Pump) 
 
 
  V 220V-50Hz 
 
    3-Bowl Super-Q System    ZFSQ 240 03 
 
    4-Bowl Super-Q System    ZFSQ 240 04 
 
    4-Bowl Super-Q Plus System   ZFSQ 240 P4 





 Description       Catalogue Number 
 
   Milligard TP Cartridge, 3/pk    CWSC 02T P3 
   Super-C Carbon Cartridge, 3/pk   CDFC 022 03 
   Ion-Ex TP Cartridge, 2/pk    CPMB 022 02 
   Organex-Q TP Cartridge, 1/pk   CPEX 022 01 
   Durapore TP Cartridge, 1/pk    CVDI 02T PE 




 Chlorine Test Kits 
 
 High levels of Chlorine 
   DPD Free-Chlorine Test Kit    ZLCL 000 AH 
 
 Low levels of Chlorine (0-3.5 ppm) 













Maximate™ and Maxisette™ Cassettes
For Development, Pilot-Scale and Production in Ultrafiltration and Microfiltration Processes
USD 2450
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Ultrafiltration and Microfiltration TFF – Cassette Membranes
Membranes for UF and MF TFF
Pall Omega™ ultrafiltration (UF) membranes
have been developed and manufactured
to give consistent performance. Products
are available for laboratory, development,
pilot, and production-scale TFF
applications.
Pall Supor® TFF microfiltration (MF)
membranes are optimized for product
clarification and recovery in biotechnology
and pharmaceutical applications.
Pall membranes provide superior
performance and stability to meet the
challenges of each unique TFF application.
Each membrane is available in a broad
range of cassette types and configurations.
Omega Membrane
Omega polyethersulfone (PES) membranes
have been specifically modified to minimize
protein binding to the surface and interstitial
structure of the membrane. This polymeric
membrane is stable against biological and
physical degradation due to the unique
chemical properties of PES.
Omega membranes are cast on a highly
porous, non-woven polyolefin support. They
have an anisotropic structure, a thin skin-
like top layer with a highly porous underlying
support. The structure of the skin
determines the porosity and permeability
characteristics of the membrane.
Anisotropic membranes have higher water
permeability and can typically be cleaned
quicker and easier than membranes with a
uniform, sub-micron depth structure.
Damage to the skin of anisotropic
membranes is easily detected with an
integrity test. This may not be the case for
membranes with sub-micron porous
underlayers.
Supor TFF Membrane
Supor TFF membrane is a modified
polyethersulfone membrane with a uniform
depth structure. The membrane porosity
is optimized for microfi ltration TFF
applications including harvest,
concentration and clarification of cell
cultures and fermentation broths. Use
Supor TFF membranes to harvest bacterial,
mammalian, and insect cells; separate red
blood cells from hemoglobin; and clarify
yeast broth and bacterial lysates.
Characteristics of Omega and Supor
TFF membranes
• Low affinity and adsorption
characteristics resulting in higher
product recovery
• Available in a wide variety of cassette
configurations, for easy and direct
scale-up/scale-down
• Greatest selection of ultrafiltration
membrane rating available: 
650 Da – 1000 kDa to fit specific
application needs
• Wide range of membrane pore sizes to
optimize the process
• Compatible with acids, bases and a
variety of other cleaning agents to
optimize cleaning procedures.
Top: Maxisette Membrane Cassettes
Bottom: Centrasette Membrane Cassettes
Pall offers a comprehensive selection of tangential flow filtration (TFF) products to
meet the increasing diversity of biological and biopharmaceutical processes and
applications. Pall® membrane cassettes and their associated hardware and systems
are the preferred choice in applications that require gentle processing and
characteristics tailored to the application.
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Tangential Flow Filtration Membrane Cassettes
Centramate™, Centrasette™, Maximate™, and Maxisette™ Cassettes
Centramate Cassettes
Centramate cassettes are perfect for
laboratory scale and development
applications in TFF. Small area formats with
0.009 m2 and 0.018 m2 may be used with
the Centramate LV holder for process
volumes of a few liters down to a few
milliliters. The 0.09 m2 format is used with
the Centramate Stainless Steel or
Centramate PE holders. Centramate
cassettes are available in a range of channel
formats and membranes to meet every
application requirement. The cassettes are
supplied with the same membrane and
construction materials as used in the
Centrasette Membrane cassettes.
Applications developed on a Centramate
cassette can be easily scaled up by adding
cassettes to a Centramate holder or by
switching to the Centrasette cassette
format with identical path length and
channel format.
Centrasette and Centrasette II
Cassettes
Centrasette cassettes, available in the
same range of membrane and screen
formats as the Centramate cassettes, have
been widely used for years in various
process applications including
concentration and diafiltration by the
biopharmaceutical industry. Centrasette
cassettes are available with membrane
areas of 0.46, 1.9, and 2.3 m2 (5, 20, and
25 ft2). Larger cassette areas simplify
installation in large TFF systems, reducing
the number of gaskets required and
minimizing risk of leakage.
Pall continues to improve membrane
cassettes to meet the more rigid
requirements of today’s applications.
The Centrasette II membrane cassette
uses the same components as in the
original Centrasette cassette. Therefore
revalidation may not be necessary.
Feed ports in the Centrasette II have been
enlarged to twice the size of the
Centrasette cassette and membrane area
has been increased by about 10%. The
larger fluid port design will enhance the
membrane’s performance by:
• Improving fluid flow distribution
between and through cassettes
• Allowing more efficient cleaning
• Reducing the pressure profile across
the feed/retentate channels
Both types of Centrasette cassettes are
available with 3 different membrane area
options to meet small scale and larger
process volume requirements. The
Centrasette cassettes fit in a variety of
Centrasette holders as well as similar
holders from other manufacturers.
Top: Centramate Membrane Cassettes
Bottom: Centrasette Cassette




The Maximate membrane cassette offers the opportunity to simulate
the performance of the larger Maxisette membrane cassette on a
smaller scale. The path length in Maximate membrane cassettes
is identical to that used in the Maxisette format but the membrane
surface area and hold up volume are proportionately lower, meaning
that processing and optimization studies may be performed on
smaller batches. 
Maxisette Cassettes
The Maxisette format has some distinct benefits that make it
advantageous for large volume processes. Most important is that
the volumetric flow rate required is 40 % lower compared to cassette
formats like the Centrasette. This translates to a smaller pump
and piping diameter being required for the same membrane area
with a corresponding reduction in energy cost. The larger porting
in the Maxisette (almost 50% larger feed and retentate ports than
the Centrasette II Cassette) provides lower resistance to high feed
flow rates which results in lower pressure drops and easier cleaning.
Membrane Cassette General Information
There are four cassette formats for UF and MF applications –
Centramate, Centrasette, Maximate and Maxisette. 
Pall TFF membrane cassettes are available in a range of molecular
weight cut-offs from 650 Da to 1000 kDa and pore sizes from 0.1 µm
to 0.65 µm to meet every application requirement. Featured
membrane types include:
• Omega










Cassettes pass current USP biological safety tests for Class VI plastics at 70 °C (158 °F).
Operating Specifications
Cassette Maximum Operating Maximum 
Format Temperature Recommended 
Operating Pressure
Centramate 50 °C (122 °F) 5 bar (75 psi)
Centrasette 50 °C (122 °F) 5 bar (75 psi)
Maximate 50 °C (122 °F) 5 bar (75 psi)
Maxisette 50 °C (122 °F) 5 bar (75 psi)
* Do not exceed maximum pressure rating of any component in the system.
Cassette Channel Configurations
Cassettes are available in fine, medium and suspended screen
channel formats to best meet the specific requirements of each
application.
Select a cassette channel configuration based on the following
criteria:
Channel Configuration Selection Criteria
Fine Screen Clarified, dilute solutions
Final concentration below 2% 
(20 mg/mL)
MWCO below 300K
Medium Screen Clarified solutions; low – medium 
viscosity
Final concentration < 30% (300 mg/mL)
Suspended Screen/ Particles/cells/cell debris in solution
Open Channel High viscosity
Storage Agents
Omega, and Supor TFF cassettes are shipped wet, in liquid
containing a humectant and bactericidal storage solution. This
solution consists of 15 – 20% glycerin and 0.05 – 0.1% sodium azide. 
The storage solution must be removed and the cassette flushed well
with water prior to use to prevent product contamination.
Cassettes are also available with circa 0.3N sodium hydroxide as
the storage agent.
Traceability
Each membrane cassette has a unique serial number for full
traceability. Each cassette is supplied with:
• Certificate of Test
• Membrane Cassette Care and Use Procedures
• Material Safety Data Sheet (MSDS) for cassette preservative
• Two platinum cured silicone gaskets
Tangential Flow Filtration Membrane Cassettes
Centramate™, Centrasette™, Maximate™, and Maxisette™ Cassettes
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Table 4 – Cassette and Screen Formats
Cassette Format Nominal Area Fine Screen Code1 Medium Screen Code Suspended Screen Code
Centramate 0.01 m2 (0.1 ft2) – C12P1 –
0.02 m2 (0.2 ft2) – C12P2 C11P2
0.1 m2 (1.0 ft2) C10 C12 C11
Centrasette 0.46 m2 (5.0 ft2) C05 C06 C07
1.86 m2 (20 ft2) C20 C21 C22
2.32 m2 (25 ft2) C25 C26 C27
Centrasette II 0.5 m2 (5.4 ft2) F05 F06 F07
2.0 m2 (22 ft2) F20 F21 F22
2.5 m2 (27 ft2) F25 F26 F27
Maximate 0.04 m2 (0.4 ft2) – G01P2 G02P2
0.19 m2 (2.0 ft2) G10 G01 G02
Maxisette 2.8 m2 (30 ft2) C50 C51 C52
1 Fine Screen channel not available in any MWCOs greater than 200 kDa.
Tangential Flow Filtration Membrane Cassettes
Ordering Information
How to Order Membrane Cassettes
1. Choose a membrane type from Table 1 (e.g. OS, or PS).
2. Choose a MWCO from Table 2 or a µm rating code from Table
3, as appropriate (e.g. 010 = 10 kD, M20 = 0.2 µm).
3. Choose a format code from Table 4 (e.g. C10, C11, or C12).
Table 1 – Membrane Type
Code Membrane Comments
OS Omega Low protein-binding
modified polyethesulfone
PS Supor TFF Microfiltration-optimized 
polyethersulfone
Table 2 – Available MWCOs for Omega Ultrafiltration
Membranes
Code D65 001 003 005 010 030 050 070 100 200 300 500 990
MWCO
(kD) 0.65 1 3 5 10 30 50 70 100 200 300 500 1000
Table 3 – Available Micron Ratings for Supor Microfiltration
Membranes
Code (µm) M10 M20 M45 M65
Pore Size 0.1 0.2 0.45 0.65
(µm)




Feed Channel Suspended 
Screen
Area 0.18 m2 (2 ft2)
Special Format None




Feed Channel Medium Screen
Area 0.5 m2 (5.4 ft2)
Special Format 0.3N NaOH 
Storage Agent
Typical Examples:
Tangential Flow Filtration Membrane Cassette Holders
Choosing a Cassette Holder





Centramate 500 S unit
Operators must use calibrated torque
wrenches (supplied with the holder) to effect
required compression of cassettes and
gaskets in a manual torque cassette holder.
Auto-torque cassette holders automatically
compensate for cassette compression and
temperature reduction.
They also eliminate variability in technique
between operators. Auto-torque cassette
holders are recommended for process-scale
validated processes.
Sanitary stainless steel holders may be
sterilized by steam or autoclaving without
cassettes installed.
Complete fittings kits consisting of pressure
gauges, valves, filtrate manifold, connectors,
gaskets and clamps are available for most
cassette holders. Ordering a complete fitting
kit with the cassette holder simplifies
installation into a system and avoids
potential delays in starting your process
due to missing parts.
Designed for optimum performance and
product recovery Pall TFF cassette holders
are available in a variety of sizes to meet
every application requirement. This way
applications that are developed on a small
system using a Centramate or Maximate
cassette can be easily scaled up, either by
adding additional cassettes to the holder
or by scaling into a larger cassette format
and holder configuration with identical flow
path like the Centrasette/Centrastak™ or
Maxisette holders.
TFF cassette holders for the medium and
large-scale production environment have
a small footprint, yet still are capable of
holding large areas of membrane. All
stainless steel holders are engineered to
precise specifications with a high standard
internal and external surface finish and are
available with either manual torque (MT) or




Choosing a Cassette Holder
The following table lists cassette holders with relative area capacities (screen channel cassettes) and working volumes1.
The Minimate™ TFF Capsule is also included to complete the range of lab scale products.
Product Membrane Area (Nominal)1 Working Volumes2
Lab and Development Scale 
(Scale-up and Scale-down studies) Starting Final
Minimate TFF Capsule 0.005 m2 0.05 ft2 25 – 500 mL 15 mL
Centramate LV 0.01 – 0.04 m2 0.1 – 0.4 ft2 25 – 4,000 mL 15 mL
Centramate PE 0.01 – 0.37 m2 1 – 4 ft2 0.5 – 80 L 150 mL
Centramate 0.01 – 0.46 m2 1 – 5 ft2 0.5 – 100 L 150 mL
Maximate 0.19 – 1.11 m2 2 – 12 ft2 1 – 250 L 350 mL
Pilot Scale (Process Development)
Centrasette LV 0.46 – 2.0 m2 5 – 22 ft2 2.5 – 500 L 400 mL
Centrasette P 0.46 – 2.0 m2 5 – 22 ft2 2.5 – 500 L 400 mL
Centrasette 5 0.46 – 4.6 m2 5 – 50 ft2 2.5 – 1,000 L 1,000 mL
Process Scale (Production)
Centrastak 100 0.9 – 20.0 m2 10 – 215 ft2 10 – 4,000 4 L
Centrastak 200 1.85 – 40.0 m2 20 – 430 ft2 20 – 8,000 10 L
Centrastak 300 2.8 – 60.0 m2 30 – 645 ft2 30 – 12,000 15 L
Centrastak 400 3.7 – 80.0 m2 40 – 860 ft2 40 – 16,000 20 L
Maxisette 25 2.8 – 27.9 m2 30 – 300 ft2 30 – 6,000 15 L
Maxisette 50 5.6 – 55.8 m2 60 – 600 ft2 60 – 12,000 30 L
Maxisette 100 5.6 – 92.9 m2 60 – 1,000 ft2 60 – 20,000 40 L
1 Fewer suspended screen cassettes will fit due to increased thickness. Some holders can fit more membrane area than can be operated at required cross flow rates due to high pressure drops.
Do not use more than the recommended area in these holders. Manual (MT) and auto-torque (AT) version holders are available for Pilot and Process Scale applications.
2 Working Volumes are based on an average filtrate flux rate of about 50 LMH and process time of 5 hours. Starting Range covers minimum to maximum area installed for screen channel
cassettes. Final process volume represents final concentration volume or minimum working volume for the system. Actual volumes depend on system hold-up volume and operating
parameters. Piping (tubing) lengths and internal diameters significantly affect the final volume.
Maxisette 25 AT Holder
Tangential Flow Filtration Membrane Cassette Holders
Choosing a Cassette Holder
Centrasette 200 AT Holder
Pall Corporation has offices and plants throughout the world in locations including:
Argentina, Australia, Austria, Belgium, Brazil, Canada, China, France, Germany, India,
Indonesia, Ireland, Italy, Japan, Korea, Malaysia, Mexico, the Netherlands, New Zealand,
Norway, Poland, Puerto Rico, Russia, Singapore, Spain, South Africa, Sweden, Switzerland,
Taiwan, Thailand, United Kingdom, United States and Venezuela. 
Distributors are located in all major industrial areas of the world.
New York - USA
+1 516 484 5400 phone
+1 516 801 9548 fax
pharmafilter@pall.com  e-mail
Portsmouth - Europe
+44 (0)23 9230 3303  phone
+44 (0)23 9230 2506  fax
BioPharmUK@europe.pall.com  e-mail
Because of developments in technology these data or procedures may be subject to change. Consequently we advise
users to review their continuing validity annually.,         , Pall, Centramate, Centrasette, Centrastak, Maximate,
Maxisette, Omega, Minimate and Supor are trademarks of Pall Corporation. 
Filtration. Separation. Solution. and UpScale are service marks of Pall Corporation.
Part numbers quoted above are protected by the Copyright of Pall Corporation.
® indicates a Pall trademark registered in the USA.
© 2007, Pall Europe Limited.
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Visit us on the web at www.pall.com /biopharmaceutical
Pall has the most comprehensive 
family of scalable separation products.
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Tangential Flow Filtration Systems
Pre-Designed Systems for Scalable Processing Pall offers scalable, pre-designed
systems to suit your specific process needs. Pall Standard systems are ready-to-
use, engineered systems with integrated recipe management tools to expedite
your approval processes and reduce your time to market.
The pilot system includes the flexibility of both semi and full automation, a UV
detector, a pH monitor, an Integrity Analyzer, and an integrated tank. The
system expedites the development and scale-up of filtration processes in
accordance with FDA cGMP regulations and guidelines.
 
      
Top: Centramate Pilot Automated Development and Optimization System
Pall Pre-designed Pilot Tangential Flow
Filtration Systems
Pall offers a range of pre-designed systems to meet your process goals.
These include:
Centramate 0.1 – 0.5 m  (1 – 5 ft )
Maximate 0.2 – 0.9 m  (2 – 10 ft )
Centrasette(1) 0.5 – 7.0 m  (5 – 75 ft )
Centrastak(1) 0.9 – 18.6 m  (10 – 200 ft )
(1) Autotorque hardware included and optional Instrumentation for UV, pH, Conductivity,
Integrity, and Auxiliary Pump. Tanks also available.
Features
Intuitive Automated Control System
Fully scalable design and components
Complete validation package with comprehensive IQ/OQ
documentation 
Compact sanitary ergonomic design for enhanced cleanability,
portability, and accessibility
Optional AutoTorque™ (AT) hardware provides uniform cassette sealing
Comprehensive Recipe Management
Adheres to ASME BPE, ANSI ISA, and cGMP standards
Time-saving
Process Automation
Puts Control in the Hands of your Process Engineers
User-friendly recipe management tools include a suite of default recipes for
pre-production, production, and post-production operations. Your process
experts can make applications work without waiting for programmers to sift
through cryptic proprietary software code.
The flexible software design enables users to build recipes and develop
processes without PLC programming expertise. Our software is ideal for use in a





Our recipes are configured from modules which are tested configuration-based
sequences that reduce the number of validation steps.
Operations
From a touch screen,any authorized user can create and store recipes so an
operator can run process tasks simply, easily, and accurately. Pall’s pre-
programmed recipes can be used to automatically sanitize, concentrate,
recover product, and clean in place.
Data Storage
21 CFR Part 11 compliant data-handling
Convenient data storage and retrieval





Exports common text and table formats




Tangential Flow Filtration Systems
Pre-Designed Systems for Scalable Processing Pall offers scalable, pre-designed systems to suit your specific process needs. Pall Standard
systems are ready-to-use, engineered systems with integrated recipe management tools to expedite your approval processes and reduce
your time to market.
The pilot system includes the flexibility of both semi and full automation, a UV detector, a pH monitor, an Integrity Analyzer, and an
integrated tank. The system expedites the development and scale-up of filtration processes in accordance with FDA cGMP regulations and
guidelines.
 
      
Top: Centramate Pilot Automated Development and Optimization System
Pall Pre-designed Pilot Tangential Flow Filtration Systems
Pall offers a range of pre-designed systems to meet your process goals.
These include:
Centramate 0.1 – 0.5 m  (1 – 5 ft )
Maximate 0.2 – 0.9 m  (2 – 10 ft )
Centrasette(1) 0.5 – 7.0 m  (5 – 75 ft )
Centrastak(1) 0.9 – 18.6 m  (10 – 200 ft )
(1) Autotorque hardware included and optional Instrumentation for UV, H, Conductivity, Integri y, and Auxiliary Pump. Tanks also available.
Features
Intuitive Automated Control System
Fully scalable design and components
Complete validation package with comprehensive IQ/OQ documentation 
Compact sanitary ergonomic design for enhanced cleanability, portability, and accessibility
Optional AutoTorque™ (AT) hardware provides uniform cassette sealing
Comprehensive Recipe Management
Adheres to ASME BPE, ANSI ISA, and cGMP standards
Time-saving
Process Automation
Puts Control in the Hands of your Process Engineers
User-friendly recipe management tools include a suite of default recipes for pre-production, production, and post-production operations.
Your process experts can make applications work without waiting for pr grammers to sift through cryptic proprietary software code.
The flexible software design enables users to build recipes and develop processes without PLC programming expertise. Our software is ideal





Our recipes are configured from modules which are tested configuration-based sequences that reduce the number of validation steps.
Operations
From a touch screen,any authorized user can create and store recip s so an operator can run process tasks simply, easily, and accurately.
Pall’s pre-programmed recipes can be used to automatically sanitize, concentrate, r cover product, and clean in place.
Data Storage
21 CFR Part 11 compliant data-handling
Convenient data storage and retrieval





Exports common text and table formats
View additional Tangential Flow Filtration Systems and Components.        
Engineered Solutions
Pall engineers are available to help you design and build systems to accommodate your specific process needs.
Decades of experience in the BioProcess Industry has proven our ability to provide innovative, cost-effective
solutions.
Our team of process engineers and design specialists work with you every step of the way to ensure that systems
meet your application needs and delivery requirements.
 
Top: Centrastak 600 System, Bottom: Centrastak 200 System
Design
Our patented designs provide higher process efficiency, enhanced process control, lower pressure drops, and
minimized holdup volumes to ensure:
Maximum yield
Cleanability and Recovery
Compact cost-effective systems – more membrane area per square-foot of floor space
Autotorque device offers consistent pressure for a reliable seal on cassettes to ensure batch process repeatability
with minimal labor overhead
Process Design
Making your process work reliably and repeatably is our goal. Pall Process engineers are available to work with you throughout the entire








To ensure that our entire project team understands your needs, our Process Engineers will manage your project throughout the entire
design, build, and commissioning cycle. Our process engineers will direct the project team to meet your process requirements on time
every time.
View additional Tangential Flow Filtration Systems and Components.
Pre-Engineered Systems
  Centramate Pilot Maximate Pilot Centrasette 5 SAT Centrastak 100 SAT
Feed Flow Range (L/Min) @ 60
psig
7 7 65 120
Membrane Area 0.1 –0.5 m
(1 – 5 ft )
0.2 – 0.9 m
(2 – 10 ft )
0.5 – 7.0 m
(5 – 75 ft )
0.9 – 18.6 m
(10 – 200 ft )
Connections 1⁄2 in. Sanitary Flange 1⁄2 in. Sanitary Flange 11⁄2 in. Sanitary Flange 11⁄2 in. Sanitary Flange
Membrane Holder Manual Torque Manual Torque Auto Torque Auto Torque




UV, pH, Conductivity, Integrity, Auxiliary Pump,
Tanks
UV, pH, Conductivity, Integrity, Auxiliary Pump,
Tanks
Hold-up Volume 275 mL 275 mL < 2.5 L < 3.5 L
View additional Tangential Flow Filtration Systems and Components.
TFF Systems
Please contact your Pall representative for a quote.
View additional Tangential Flow Filtration Systems and Components.
Pall's standard tangential flow filtration systems are ready-to-use, engineered systems with integrated recipe management tools to expedite
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Product image is a representative example for




Choosing a Cassette Holder
Designed for optimum performance and product recovery Pall TFF cassette
holders are available in a variety of sizes to meet every application requirement.
This way applications that are developed on a small system using a Centramate
or Maximate cassette can be easily scaled up, either by adding additional
cassettes to the holder or by scaling into a larger cassette format and holder
configuration with identical flow path like the Centrasette/Centrastak™ or
Maxisette holders.  
Holder Sizes
TFF cassette holders for the medium and large-scale production environment
have a small footprint, yet still are capable of holding large areas of membrane.  
All stainless steel holders are engineered to precise specifications with a high
standard internal and external surface finish and are available with either
manual torque (MT) or auto torque (AT) compression systems for ease of use.  
Operators must use calibrated torque wrenches (supplied with the holder) to
effect required compression of cassettes and gaskets in a manual torque
cassette holder.  
Auto-torque Feature
Auto-torque cassette holders automatically compensate for cassette
compression and temperature reduction. They also eliminate variability in
technique between operators. Auto-torque cassette holders are recommended
for process-scale validated processes. 
Sanitary stainless steel holders may be sterilized by steam or autoclaving
without cassettes installed.  
Fittings Kits
Complete fittings kits consisting of pressure gauges, valves, filtrate manifold,
connectors, gaskets and clamps are available for most cassette
holders.Ordering a complete fitting kit with the cassette holder simplifies
installation into a system and avoids potential delays in starting your process
due to missing parts. 





Choosing a Cassette Holder
Designed for optimum performance and product recovery Pall TFF cassette holders are available in a variety of sizes to meet every
application requirement. This way applications that are developed on a small system using a Centramate or Maximate cassette can be easily
scaled up, either by adding additional cassettes to the holder or by scaling into a larger cassette format and holder configuration with
identical flow path like the Centrasette/Centrastak™ or Maxisette holders.  
Holder Sizes
TFF cassette holders for the medium and large-scale production environment have a small footprint, yet still are capable of holding large
areas of membrane.   All stainless steel holders are engineered to precise specifications with a high standard internal and external surface
finish and are available with either manual torque (MT) or auto torque (AT) compression systems for ease of use.   Operators must use
calibrated torque wrenches (supplied with the holder) to effect required compression of cassettes and gaskets in a manual torque cassette
holder.  
Auto-torque Feature
Auto-torque cassette holders automatically compensate for cassette compression and temperature reduction. They also eliminate variability
in technique between operators. Auto-torque cassette holders are recommended for process-scale validated processes. 
Sanitary stainless steel holders may be sterilized by steam or autoclaving without cassettes installed.  
Fittings Kits
Complete fittings kits consisting of pressure gauges, valves, filtrate manifold, connectors, gaskets and clamps are available for most cassette
holders.Ordering a complete fitting kit with the cassette holder simplifies installation into a system and avoids potential delays in starting
your process due to missing parts. 
View additional Tangential Flow Filtration Systems and Components.
TFF Membrane Cassette Holder Information
Selection of Holders
Technical Specifications
TFF Membrane Cassette Holder Information
The following tables list cassette holders with relative area capacities (screen channel cassettes) and working volumes .
The Minimate™ TFF Capsule is also included to complete the range of lab scale products.
Lab and Development Scale Holders
 
Product Membrane Area (Nominal
m )
MembraneArea (Nominal







0.005 m 0.05 ft 25 - 500 mL 15 mL
Centramate LV 0.01 - 0.04 m 0.1 - 0.4 ft 25 - 4,000 mL 15 mL
Centramate PE 0.01 - 0.37 m 1 - 4 ft 0.5 - 80 L 150 mL
Centramate 0.1 - 0.5 m 1 - 5 ft 0.5 - 100 L 150 mL
Maximate 0.19 - 1.11 m 2 - 12 ft 1 - 250 L 350 mL
 
Pilot Scale (Process Development)
 
Product Membrane Area (Nominal m ) MembraneArea (Nominal ft ) Working Volume Start Working Volume Final
Centrasette LV 0.46 - 2.0 m 5 - 22 ft 2.5 - 500 L 400 mL 
Centrasette P 0.46 - 2.0 m 5 - 22 ft 2.5 - 500 L 400 mL




Product Membrane Area (Nominal m ) MembraneArea (Nominal ft ) Working Volume Start Working Volume Final
Centrastak 100 0.9 - 20.0 m 10 - 215 ft 10 - 4,000 L 4 L
Centrastak 200 1.85 - 40.0 m 20 - 430 ft 20 - 8,000 L 10 L
Centrastak 300 2.8 - 60.0 m 30 - 645 ft 30 - 12,000 L 15 L
Centrastak 400 3.7 - 80.0 m 40 - 860 ft 40 - 16,000 L 20 L
Maxisette 25 2.8 - 27.9 m 30 - 300 ft 30 - 6,000 L 15 L
Maxisette 50 5.6 - 55.8 m 60 - 600 ft 60 - 12,000 L 30 L
Maxisette 100 5.6 - 92.9 m 60 - 1,000 ft 60 - 20,000 L 40 L
 
!. Fewer suspended screen cassettes will fit due to increased thickness. Some holders can fit more membrane area than can be operated at
required cross flow rates due to high pressure drops. Do not use more than the recommended area in these holders. Manual (MT) and
auto-torque (AT) version holders are available for Pilot and Process Scale applications.
". Working Volumes are based on an average filtrate flux rate of about 50 LMH and process time of 5 hours. Starting Range covers minimum
to maximum area installed for screen channel cassettes. Final process volume represents final concentration volume or minimum
working volume for the system. Actual volumes depend on system hold-up volume and operating parameters. Piping (tubing) lengths and
internal diameters significantly affect the final volume.
Selection of Holders
Centramate LV Holder
The Centramate LV holder is fabricated from Stainless Steel (316L) with female luer fittings for use with 0.01 m
(0.1 ft ) and 0.02 m  (0.2 ft ) Centramate cassettes. The holder can accommodate up to 0.04 m  (0.4 ft ) of screen
channel or 0.02 m  (0.2 ft ) of open channel Centramate cassettes at recommended cross flow rates. A range of
luer fittings and valves are available as well as pressure gauges or transducers to set-up a complete TFF system.
 
Centramate PE Holder
The Centramate PE holder has a polyethylene manifold with # in. NPT threaded ports
sandwiched between 304 stainless steel outer plates for support. It accommodates
up to 4 screen channel (3 suspended screen channel) 0.09 m  (1 ft ) cassettes. The use
of spacers on the tie rods makes it easy to apply and tighten the nuts with minimal
threading if only one cassette is installed. As additional cassettes are added, spacers
can be removed. The Centramate PE holder is recommended for use in applications
where metal contact must be avoided. A plastic, NPT threaded fitting kit, with either 2
or 3 pressure gauges is available. 
Centramate Stainless Steel Holder
The Centramate stainless steel cassette holder (316L) comes with $ in. sanitary flanges on feed and filtrate
ports. The holder is supplied with surface and weld certification. Up to 5 screen channel (4 suspended screen
channel) 0.09 m  (1 ft ) cassettes can be accommodated. Holder is supplied with both 1 in. and 2 in. spacers on
the tie rods to simplify cassette installation and to apply the required torque. Spacers can be removed to
compensate for the height difference as additional cassettes are added to the holder. Sanitary fitting kits with
either 2 or 3 pressure gauges are available.    
Centrasette P Holder
The Centrasette P Holder has a polypropylene center manifold and end plate,for use when product contact with
metal is not desirable or prohibited by your application; for example when processing certain metal sensitive
enzymes or oligonucleotides. The manifold and end plate are housed between stainless steel plates to supply the
necessary rigidity when operating at higher pressures. Luer fittings on the % in. sanitary polypropylene ports can
be used for connection to plastic pressure transducers for monitoring pressures, again without metal contact.
The low-cost plastic manifold and end plate can be replaced to avoid cleaning validation or dedicated to a
specific application along with a set of cassettes to prevent any risk of cross-contamination. The Centrasette P
holder like the Centrasette LV holder is intended for use with Centrasette cassettes when total membrane area
will be less than 2.5 m  (27 ft ) of screen channel cassettes or 1.5 m  (16 ft ) of suspended screen cassettes. 
Centrasette LV Holder
The Centrasette LV Holder is manufactured using highly polished 316L stainless steel. This holder has % in. sanitary fractional fitting on the
feed/retentate and permeate ports which minimizes the hold-up volume. it is ideal for use in systems that use Centrasette cassettes when
total membrane area will be less than 2.5 m2 (27 ft2) of screen channel cassettes or 1.5m2 (16 ft2) of suspended screen cassettes.Centrasette 5
and Centrasette 5AT Holders
The Centrasette 5 holder is intended for use in pilot and process scale applications with up to 5 m  (54 ft ) screen
channel Centrasette or Centrasette II cassettes or 4 m  (43 ft ) of suspended screen cassettes. The feed/retentate
channels have tapered bores engineered to maintain uniform cross flow and pressure drops across the
membrane cassettes. Two permeate ports, one near the feed and the other near the retentate, are designed to
reduce backpressure on the permeate side of the membrane. This is especially important when operating at
high flux rates. Pressure on the permeate side effectively reduces transmembrane pressure and lowers filtrate
flux rates. The highly polished 316L stainless steel unit has ports that mate up with 1 in. sanitary connectors. A
calibrated torque wrench and socket is supplied with the holder, as it is with other manual torque holders. 
Centrastak Holders
Processes developed at bench scale on Centramate and Centrasette cassettes can be scaled up to process volumes in excess of 10,000 L
using a Centrastak system. The Centrastak range of cassette holders have been designed for optimal performance in large-scale production
environment. The small footprint makes them ideal for use in process skids and manufacturing suites where space is at a premium. Each
level in a Centrastak holder can hold up to 10 m  (107 ft ) of Centrasette cassettes on each side of a central manifold or effectively 20 m  (215
ft  per level. A single center-manifold significantly reduces hold-up volumes. Feed flow direction is from bottom to top allowing air to be
easily expelled from the system.
All Centrastak holders are available in auto-torque format with a hydraulic system,including stainless steel pistons and pump, Centramate
for maintaining optimal and uniform compression on the installed cassettes. A pressurized air supply is required to operate the hydraulic
pump (60 psi minimum, 125 psi maximum). All wetted surfaces are electropolished, 316L stainless steel. Holder is supplied with surface and
weld certification to support I/Q validation. 
Maximate Holders
Maximate holders are designed for use with Maximate membrane cassettes. The 316L stainless steel holder has % in. sanitary feed/retentate
ports and $ in. permeate ports. Up to 6 screen channel cassettes (4 suspended screen channel cassettes), 0.19m  (2ft ) will fit into the holder
accommodating process fluid volumes from a few hundred milliliters up to over a hundred liters.
Maximate cassettes are chosen for scale-up studies when process-scale volumes will be processed using a Maxisette system that has the
same feed/retentate channel path length.
Maxisette Holders
The Maxisette holder has been designed for optimal performance in a large-scale production environment. The longer path length of a
Maxisette cassette compared with a Centrasette cassette allows a 40 % reduction in cross flow rate (retentate flow rate), therefore requiring a
smaller pump with a corresponding reduction in heating, energy costs and space requirements. The small footprint makes it ideal for use in
process skids and manufacturing suites where space is at a premium. 
Feed flow direction is from bottom to top allowing air to be easily expelled from the system. Port design in the Maxisette cassette results in a
significant reduction in pressure drops and a more uniform pressure profile at operating cross flow rates compared to other cassette
formats. This results in higher performance during production and more efficient cleaning. 
Processes developed at bench scale on Maximate cassettes can be efficiently scaled up to process volumes in excess of 10,000 L. Maxisette
holders are available in auto-torque format with a hydraulic system, including six pistons and a pump, for maintaining optimal and uniform
compression on the installed cassettes. A pressurized air supply is required to operate the hydraulic pump (60 psi [4.1 bar] minimum, 125 psi





Cassette Holder Centramate LV Holder Centramate PE Holder Centramate Holder
Feed and retentate ports Female luer SS # in. NPT Fitting (female) $ in. sanitary, 9.6 mm (0.38 in.) bore





0.04 m  (0.4 ft )
0.02 m  (0.2 ft )
 -
0.37 m  (4 ft )
0.28 m (3 ft )
 -
0.46 m (5 ft )
0.37 m (4 ft )
Nominal dimensions
(Width x Length x Depth)
 12 x 23 6.6 cm
(4$  x 9 x  2$  in.)
9.4 x 24 x 19 cm
(3% x 9# x 7$ in.)
13 x 23 x 16 cm
(5# x 9 x 6# in.)
Weight 4 kg (8.75 lbs) 8.6 kg (19  lbs) 6.4 kg (14 lbs)
Maximum operating temperature 50 °C 80 °C 80 °C




Cassette Holder Centrasette LV Holder Centrasette P Holder Centrasette 5*,  5AT* Holder,
Feed and retentate ports % in. sanitary SS % in. sanitary PP 1 in. sanitary SS





2.0  m  (22  ft )
1.5  m  (16  ft )
 -
2.0  m  (22  ft )
1.5  m  (16  ft )
-
5  m  (54  ft )
4  m  (43  ft )
Nominal dimensions
(Width x Length x Depth)
26 x 25 x 21 cm
(10#  x 10 x  8$  in.)
30 x 20 x 34 cm
(12 x 8 x 13$ in.)
26 x 25 x 27 cm
(10# x 10 x 10% in.)
Weight 28 kg (62 lbs) 25 kg (55 lbs) 30 kg (66 lbs)
Maximum operating temperature 80 °C 50 °C 80 °C
Maximum operating pressure 6  bar (90 psi) 5 bar (75 psi) 6  bar (90 psi)
 












Feed and retentate ports 2 in. .sanitary 2 in. .sanitary 2 in. .sanitary 2 in. .sanitary





20  m  (216  ft )
15  m  (161  ft )
 -
40  m  (430  ft )
30  m  (323  ft )
 -
60  m  (645  ft )
45  m  (484  ft )
 -
80  m  (860  ft )
60  m  (645  ft )
Nominal dimensions
(Width x Length x Depth)
39 x 91 x 59 cm
(15$ x 36 x 23# in.)
39 x 91 x 59 cm
(15$ x 36 x 37$ in.) 
39 x 91 x 107 cm
(15$ x 36 x 42 in.)
39 x 91 x 120 cm
(15$  x 36 x 47$ in.)
Weight 155 kg (340 lbs) 255 kg (560 lbs) 314 kg (690 lbs) 409 kg (900 lbs)
Maximum operating
temperature
80 °C 80 °C 80 °C 80 °C
Maximum operating pressure 6  bar (90 psi) 6  bar (90 psi) 6  bar (90 psi) 6  bar (90 psi)
 
!. Cassette blocks (2 m2 (21.6 ft2) or 2.5 m2 (26.9 ft2) are recommended. If 0.5 m2 (5.3 ft2) cassettes are used, stabilizer plates must be used
between every 5 cassettes (fine/medium screen) or 3 cassettes suspended screen.
". Maximum operating temperature may be restricted by cassette operating temperature limit.
&. Holder may be steamed with compatible cassettes, or without cassettes at up to 142 °C.
Maximate and Maxisette Cassette Holders
 
Cassette Holder Maximate Holder Maxisette 25 Holder Maxisette 50 Holder Maxisette 100 Holder
Feed and retentate ports % in. sanitary 2 in. sanitary 2$ in. sanitary 2$ in. sanitary





1.1  m  (12  ft )
0.74  m  (8  ft )
 -
28  m  (300  ft )
28  m  (300  ft )
 -
56  m  (600  ft )
56  m  (600  ft )
-
89  m  (960  ft )
56  m  (600  ft )
Nominal dimensions
(Width x Length x Depth)
16 x 44 x 22 cm
(6# x 17$ x 8% in.)
 47 x 105 x 57 cm
(18$ x 41$ x 22$ in.)
47 x 105 x 97 cm
(18$  x 41$  x 38 in.)
 47 x 105 x 117 cm
(18$  x 41$  x 46 in.)
Weight 13.3 kg (29.2 lbs) 455 kg (1000 lbs) 566 kg (1245 lbs) 566 kg (1245 lbs)
Maximum operating temperature 80 °C 80 °C 80 °C 80 °C
maximum operating pressure 6  bar (87 psi) 6  bar (87 psi) 6  bar (87 psi) 6  bar (87 psi)
 
!. Cassette blocks (2 m2 (21.6 ft2) or 2.5 m2 (26.9 ft2) are recommended. If 0.5 m2 (5.3 ft2) cassettes are used, stabilizer plates must be used
between every 5 cassettes (fine/medium screen) or 3 cassettes suspended screen.
". Maximum operating temperature may be restricted by cassette operating temperature limit.
&. Holder may be steamed with compatible cassettes, or without cassettes at up to 142 °C.
Materials of Construction for Wetted Parts
 
Holder Centramate PE Centramate LV Centramate/Maximate Centrasette P Centrasette Maxisette
Plates UHMW polyethylene 316L stainless steel 316L stainless steel Polypropylene 316L stainless steel
Flow distribution
manifold
UHMW polyethylene 316L stainless steel 316L stainless steel Polypropylene 316L stainless steel
Other components  EPDM o-ring on SS 
threaded luer connector




View additional Tangential Flow Filtration Systems and Components.
TFF Holders and Accessories
Ordering Information
The following table lists individual cassette holders as well as holders sold in combination with fittings packages. Additional combinations
and a variety of other accessories are available. For complete descriptions and additional offerings, contact your Pall representative.
 
Description Part Number
Centramate PE Holder, including torque wrench and socket FS002K10
Centramate PE Holder, including fittings package with 3 pressure gauges FS013K10
Centramate LV Holder, including torque wrench and socket CM018LV
Centramate SS Holder, including torque wrench and socket FS001K10
Centramate SS Holder, including torque wrench, fittings package with 3 pressure gauges, 
2 diaphragm valves
FS011K10
Centrasette 5 manual torque, including torque wrench and socket FS001K05
Centrasette P Holder, including torque wrench and socket FS039K05
Centrasette LV Holder, including torque wrench and socket FS044K05
Centrasette LV Holder, including torque wrench and socket, fittings package with 3 pressure gauges, 
2 diaphragm valves
FS046K05
Centrasette 5 Holder, including torque wrench and socket FS001K05
Centrasette 5 Holder, including torque wrench and socket, fittings package with 3 pressure gauges, 
2 diaphragm valves
FS014K05
Centrasette 5AT Holder FS020K05
Centrasette 5AT Holder, including torque wrench and socket, fittings package with 3 pressure gauges, 
2 diaphragm valves
FS022K05
Centrastak 100 AT Holder FS050K05
Centrastak 200 AT Holder FS034K05
Centrastak 300 AT Holder FS036K05
Centrastak 400 AT Holder FS038K05
Maximate Holder, including torque wrench and socket FS001G01
Maximate Holder, including torque wrench and socket, fittings package with 3 pressure gauges, 
2 diaphragm valves
FS003G01
Maxisette 25 AT Holder FS009K50 
Maxisette 50 AT Holder FS013K50
Maxisette 100 AT Holder FS016K50
 
View additional Tangential Flow Filtration Systems and Components.
Designed for optimum performance and product recovery, Pall's TFF cassette holders are available in a variety of sizes to meet every
application requirement. Applications developed on a small system using a Centramate or Maximate cassette can be easily scaled up, either
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Millipore Express® SHC (Sterile, High Capacity) 
¿OWHUVSURYLGHVXSHULRUWKURXJKSXWDQGFDSDFLW\LQ










• Validated sterilizing-grade performance


























































































































































































































































































4XDQWLWDWLYHUHWHQWLRQRI&)8FP Brevundimonas diminuta$7&&®SHU$670® methodology
Bacterial Endotoxin
$TXHRXVH[WUDFWLRQFRQWDLQV(8P/DVGHWHUPLQHGXVLQJWKH/LPXOXV$PHERF\WH/\VDWH/$/WHVW





















































































































































































































































































































































































































Opticap® XL 3 
Capsules
Opticap® XL 5 
Capsules
Opticap® XL 10 
Capsules
Opticap® XLT 10 
Capsules
Opticap® XLT 20 
Capsules




























































FFPLQ FFPLQ FFPLQ FFPLQ FFPLQ FFPLQ
%DFWHULDO5HWHQWLRQ
4XDQWLWDWLYHUHWHQWLRQRI&)8FP Brevundimonas diminuta$7&&®SHU$670® methodology
Bacterial Endotoxin
$TXHRXVH[WUDFWLRQFRQWDLQV(8P/DVGHWHUPLQHGE\WKH/LPXOXV$PHERF\WH/\VDWH/$/7HVW
TOC/Conductivity at 25 °C
$XWRFODYHG¿OWHUHIÀXHQWPHHWVWKH:),UHTXLUHPHQWVRI863!IRU7RWDO2UJDQLF&DUERQDQG863!IRU:DWHU
&RQGXFWLYLW\DIWHUD:),ÀXVKRI
5.5 L / / / 40 L /
Oxidizable Substances
0HHWVWKH8632[LGL]DEOH6XEVWDQFHV7HVWUHTXLUHPHQWVIRUVWHULOHSXUL¿HGZDWHUDIWHUDZDWHUÀXVKRI





































































4XDQWLWDWLYHUHWHQWLRQRI&)8FP Brevundimonas diminuta$7&&®SHU$670® methodology
Bacterial Endotoxin
$TXHRXVH[WUDFWLRQFRQWDLQV(8P/DVGHWHUPLQHGE\WKH/LPXOXV$PHERF\WH/\VDWH/$/7HVW
TOC/Conductivity at 25 °C
*DPPDVWHULOL]HG¿OWHUHIÀXHQWPHHWVWKH:),UHTXLUHPHQWVRI863!IRU7RWDO2UJDQLF
&DUERQDQG863!IRU:DWHU&RQGXFWLYLW\DIWHUDZDWHUÀXVKRI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Opticap® XL 3 
Capsules
Opticap® XL 5 
Capsules
Opticap® XL 10 
Capsules
Per 10” Standard Area 
Opticap® XLT Capsule





























































FFPLQ FFPLQ FFPLQ FFPLQ FFPLQ
%DFWHULDO5HWHQWLRQ
4XDQWLWDWLYHUHWHQWLRQRI&)8FP Brevundimonas diminuta$7&&®SHU$670® methodology
Bacterial Endotoxin
$TXHRXVH[WUDFWLRQFRQWDLQV(8P/DVGHWHUPLQHGXVLQJWKH/LPXOXV$PHERF\WH/\VDWH/$/WHVW
TOC/Conductivity at 25 °C
*DPPDVWHULOL]HG¿OWHUPHHWVWKH:),UHTXLUHPHQWVRI863!IRU7RWDO2UJDQLF&DUERQDQG863!IRU:DWHU&RQGXFWLYLW\
DIWHUD:),ÀXVKRI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HH =  14 mm (LQKRVHEDUELQOHWDQGRXWOHW












































015 = Opticap® XL 150
 2SWLFDS®;/
 2SWLFDS®;/













 SN2SWLFDS® XL 
RQO\
 SN2SWLFDS® XL 5 
and XL 10 only)
K H G E
&DSVXOH6L]H
 2SWLFDS®;/
05 = Opticap® XL 5
10 = Opticap® XL 10
&RQQHFWLRQ7\SH
77 PP1LQVDQLWDU\ÀDQJHLQOHWDQGRXWOHW









































































C H G E
Description Qty/pk Catalogue Number
















In the U.S. and Canada, call toll-free
1(800)-645-5476
For other countries across Europe, call
+44 (0) 115 943 0840
For other countries across Europe  
and the world, please visit  
ZZZHPGPLOOLSRUHFRPRɡFHV
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Caution: Product has not been fully validated for medical applications. For research use only.
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SAFETY DATA SHEET 
Version 5.1 Revision Date 05/16/2018 
Print Date 11/16/2018 
A  P  L , I . 700 I  P  D , A , AL 35007,USA  (800) 227-0651  (205) 663-2494 
F (800) 229-1004 (205) 663-0756  E-  O : @ .   E-mail Inquiries: info@avantilipids.com
E-mail Tech  Q : @ .   V  . .
1. PRODUCT AND COMPANY IDENTIFICATION
1.1 Product identifiers 
Product name : 1,2-stearoyl-3-trimethylammonium-propane 
(chloride salt) 
Product Number : 890880C 
Brand : AVANTI 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 







1.4 Emergency telephone number 
Emergency Phone # : &+(075(&
2. HAZARDS IDENTIFICATION
2.1 Classification of the substance or mixture 
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) 
Acute toxicity, Oral (Category 4), H302 
Acute toxicity, Inhalation (Category 3), H331 
Skin irritation (Category 2), H315 
Eye irritation (Category 2A), H319 
Carcinogenicity (Category 2), H351 
Reproductive toxicity (Category 2), H361d 
Specific target organ toxicity - single exposure (Category 3), Central nervous system, H336 
Specific target organ toxicity - repeated exposure (Category 1), Liver, Kidney, H372 
Acute aquatic toxicity (Category 3), H402 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
2.2 GHS Label elements, including precautionary statements 
Pictogram 
Signal word Danger 
Hazard statement(s) 
H302 Harmful if swallowed. 
H315 Causes skin irritation. 
H319 Causes serious eye irritation. 
Lipid structurally similar to ALC-0159 used in the proposed manufacturing process
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H331 Toxic if inhaled. 
H336 May cause drowsiness or dizziness. 
H351 Suspected of causing cancer. 
H361d Suspected of damaging the unborn child. 
H372 Causes damage to organs (Liver, Kidney) through prolonged or repeated 
exposure. 
H402 Harmful to aquatic life. 
 
Precautionary statement(s) 
P201 Obtain special instructions before use. 
P202 Do not handle until all safety precautions have been read and 
understood. 
P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray. 
P264 Wash skin thoroughly after handling. 
P270 Do not eat, drink or smoke when using this product. 
P271 Use only outdoors or in a well-ventilated area. 
P273 Avoid release to the environment. 
P280 Wear protective gloves/ protective clothing/ eye protection/ face 
protection. 
P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. 
Rinse mouth. 
P302 + P352 IF ON SKIN: Wash with plenty of soap and water. 
P304 + P340 + P311 IF INHALED: Remove person to fresh air and keep comfortable for 
breathing. Call a POISON CENTER/doctor. 
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove 
contact lenses, if present and easy to do. Continue rinsing. 
P308 + P313 IF exposed or concerned: Get medical advice/ attention. 
P332 + P313 If skin irritation occurs: Get medical advice/ attention. 
P337 + P313 If eye irritation persists: Get medical advice/ attention. 
P362 Take off contaminated clothing and wash before reuse. 
P403 + P233 Store in a well-ventilated place. Keep container tightly closed. 
P405 Store locked up. 
P501 Dispose of contents/ container to an approved waste disposal plant. 
 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.2 Mixtures 
Synonyms : 18:0 TAP 
 
Molecular weight : 119.38 g/mol 
 
Hazardous components 










Acute Tox. 4; Acute Tox. 3; 
Skin Irrit. 2; Eye Irrit. 2A; Carc. 
2; Repr. 2; STOT SE 3; STOT 
RE 1; Aquatic Acute 3; H302, 
H315, H319, H331, H336, 
H351, H361d, H372, H402 
90 - 100 % 
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4. FIRST AID MEASURES 
4.1 Description of first aid measures 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician. 
In case of eye contact 
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
No data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Wear respiratory protection. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Evacuate personnel to 
safe areas. 
For personal protection see section 8. 
6.2 Environmental precautions 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the environment 
must be avoided. 
6.3 Methods and materials for containment and cleaning up 
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable, closed containers for 
disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully resealed 
and kept upright to prevent leakage.  
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Recommended storage temperature -25 - -15 °C 
Storage class (TRGS 510): 6.1D: Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous materials 
causing chronic effects 
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Component CAS-No. Value Control 
parameters 
Basis 
Chloroform 67-66-3 TWA 10 ppm  
 
USA. ACGIH Threshold Limit Values 
(TLV) 
 Remarks Central Nervous System impairment 
Liver damage 
Embryo/fetal damage 
Confirmed animal carcinogen with unknown relevance to humans 
  ST 2 ppm  
9.78 mg/m3 
USA. NIOSH Recommended 
Exposure Limits 
  Potential Occupational Carcinogen 
See Appendix A 
  C 50 ppm  
240 mg/m3 
USA. Occupational Exposure Limits 
(OSHA) - Table Z-1 Limits for Air 
Contaminants 
  The value in mg/m3 is approximate. 
Ceiling limit is to be determined from breathing-zone air samples. 
  PEL 2 ppm  
9.78 mg/m3 
California permissible exposure 
limits for chemical contaminants 
(Title 8, Article 107) 
8.2 Exposure controls 
Appropriate engineering controls 
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product. 
Personal protective equipment 
Eye/face protection 
Face shield and safety glasses Use equipment for eye protection tested and approved under appropriate 
government standards such as NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Body Protection 
Complete suit protecting against chemicals, The type of protective equipment must be selected according to 
the concentration and amount of the dangerous substance at the specific workplace. 
Respiratory protection 
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with multi-
purpose combination (US) or type AXBEK (EN 14387) respirator cartridges as a backup to engineering 
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators 
and components tested and approved under appropriate government standards such as NIOSH (US) or CEN 
(EU). 
Control of environmental exposure 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the 
environment must be avoided. 
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9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: liquid 
Colour: colourless 
b) Odour sweet 
c) Odour Threshold No data available 
d) pH No data available 
e) Melting point/freezing 
point 
Melting point: -63.5 °C (-82.3 °F) at 1,013 hPa (760 mmHg) 
f) Initial boiling point and 
boiling range 
61.2 °C (142.2 °F) at 1,013 hPa (760 mmHg) 
g) Flash point  - DIN 51755 Part 1does not flash 
h) Evaporation rate No data available 




No data available 
k) Vapour pressure 210 hPa (158 mmHg) at 20 °C (68 °F) 
l) Vapour density 4.12 - (Air = 1.0) 
m) Relative density 1.49 g/cm3 
n) Water solubility 8.7 g/l at 23 °C (73 °F) - OECD Test Guideline 105 
o) Partition coefficient: n-
octanol/water 
log Pow: 1.97 at 25 °C (77 °F) - (ECHA), Bioaccumulation is not expected. 
p) Auto-ignition 
temperature 
> 600 °C (> 1,112 °F) at 1,013 hPa (760 mmHg) - DIN 51794 
q) Decomposition 
temperature 
Distillable in an undecomposed state at normal pressure. 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
 Solubility in other 
solvents 
organic solvent  at 20 °C (68 °F) - miscible 
 Surface tension 27.1 mN/m at 20.0 °C (68.0 °F) 
 Relative vapour density 4.12 - (Air = 1.0) 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
Contains the following stabiliser(s): 
Ethanol (0.5 %) 
10.3 Possibility of hazardous reactions 
No data available 
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10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong oxidizing agents, Strong bases, Magnesium, Sodium/sodium oxides, Lithium, various plastics 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Hydrogen chloride gas 
Other decomposition products - No data available 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 




IARC: 2B - Group 2B: Possibly carcinogenic to humans (Chloroform) 
NTP: RAHC - Reasonably anticipated to be a human carcinogen (Chloroform) 
OSHA: N              0.1%   OSHA  
list of regulated carcinogens. 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: Not available 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. 
 
Stomach - Irregularities - Based on Human Evidence 
Stomach - Irregularities - Based on Human Evidence 
Stomach - Irregularities - Based on Human Evidence (Ethanol) 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
No data available 
12.2 Persistence and degradability 
No data available 
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12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
An environmental hazard cannot be excluded in the event of unprofessional handling or disposal. 
Harmful to aquatic life. 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste 
disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a 
chemical incinerator equipped with an afterburner and scrubber.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
UN number: 1888 Class: 6.1 Packing group: III 
Proper shipping name: Chloroform, solution 
Reportable Quantity (RQ): 10 lbsReportable Quantity (RQ): 10 lbs 
Poison Inhalation Hazard: No 
 
IMDG 
UN number: 1888 Class: 6.1 Packing group: III EMS-No: F-A, S-A 




UN number: 1888 Class: 6.1 Packing group: III 
Proper shipping name: Chloroform, solution 
 
15. REGULATORY INFORMATION 







SARA 313 Components 







SARA 311/312 Hazards 
Acute Health Hazard, Chronic Health Hazard 
 :  
Reportable Quantity  D022 lbs 
 














California Prop. 65 Components 
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, which is/are known to the State of California to cause cancer 
and birth defects or other reproductive harm. For more 









16. OTHER INFORMATION 
Full text of H-Statements referred to under sections 2 and 3. 
Acute Tox. Acute toxicity 
Aquatic Acute Acute aquatic toxicity 
Carc. Carcinogenicity 
Eye Irrit. Eye irritation  
H302 Harmful if swallowed. 
H315 Causes skin irritation. 
H319 Causes serious eye irritation. 
H331 Toxic if inhaled. 
H336 May cause drowsiness or dizziness. 
H351 Suspected of causing cancer. 
H361d Suspected of damaging the unborn child. 
H372 Causes damage to organs through prolonged or repeated exposure. 
H402 Harmful to aquatic life. 
Repr. Reproductive toxicity 
Skin Irrit. Skin irritation 
STOT RE Specific target organ toxicity - repeated exposure  
STOT SE Specific target organ toxicity - single exposure 
HMIS Rating 
Health hazard: 2 
Chronic Health Hazard: * 
Flammability: 0 
Physical Hazard 0 
NFPA Rating 
Health hazard: 2 
Fire Hazard: 0 
Reactivity Hazard: 0 
Further information 
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 




Product Safety  Americas Region 
1-800-521-8956 
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SAFETY DATA SHEET 
 
Version 6.2 
Revision Date 01/15/2020 
Print Date 11/20/2020 
 
SECTION 1: Identification of the substance/mixture and of the company/undertaking 
1.1 Product identifiers 
Product name : Cholesterol 
 
Product Number : C8667 
Brand : Sigma 
CAS-No. : 57-88-5 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich Inc. 
3050 Spruce Street 
ST. LOUIS MO  63103 
UNITED STATES 
 
Telephone : +1 314 771-5765 
Fax : +1 800 325-5052 
1.4 Emergency telephone number 
Emergency Phone # : 800-424-9300 CHEMTREC (USA) +1-703-
527-3887 CHEMTREC (International) 24 
Hours/day; 7 Days/week 
 
 
SECTION 2: Hazards identification 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 




SECTION 3: Composition/information on ingredients 
3.1 Substances 
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Formula : C27H46O 
Molecular weight : 386.65 g/mol 
CAS-No. : 57-88-5 
EC-No. : 200-353-2 
 




SECTION 4: First aid measures 
4.1 Description of first aid measures 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
In case of skin contact 
Wash off with soap and plenty of water. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 
2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 




SECTION 5: Firefighting measures 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
Carbon oxides 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 




SECTION 6: Accidental release measures 
6.1 Personal precautions, protective equipment and emergency procedures 
Avoid dust formation. Avoid breathing vapours, mist or gas. 
For personal protection see section 8. 
6.2 Environmental precautions 
No special environmental precautions required. 
6.3 Methods and materials for containment and cleaning up 
Sweep up and shovel. Keep in suitable, closed containers for disposal. 
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6.4 Reference to other sections 




SECTION 7: Handling and storage 
7.1 Precautions for safe handling 
Further processing of solid materials may result in the formation of combustible dusts. The 
potential for combustible dust formation should be taken into consideration before 
additional processing occurs. 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Recommended storage temperature -20 °C 
 Keep in a dry place.  
Storage class (TRGS 510): 13: Non Combustible Solids 
7.3 Specific end use(s) 




SECTION 8: Exposure controls/personal protection 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
General industrial hygiene practice. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate 
government standards such as NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove 
removal technique (without touching glove's outer surface) to avoid skin contact 
with this product. Dispose of contaminated gloves after use in accordance with 
applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
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data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail 
sales@kcl.de, test method: EN374 
If used in solution, or mixed with other substances, and under conditions which 
differ from EN 374, contact the supplier of the CE approved gloves. This 
recommendation is advisory only and must be evaluated by an industrial hygienist 
and safety officer familiar with the specific situation of anticipated use by our 




Choose body protection in relation to its type, to the concentration and amount of 
dangerous substances, and to the specific work-place., The type of protective 
equipment must be selected according to the concentration and amount of the 
dangerous substance at the specific workplace. 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of 
dusts are desired, use type N95 (US) or type P1 (EN 143) dust masks. Use 
respirators and components tested and approved under appropriate government 
standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
No special environmental precautions required. 
 
 
SECTION 9: Physical and chemical properties 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: powder 
Colour: white 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH No data available 
e) Melting 
point/freezing point 
Melting point/range: 147 - 149 °C (297 - 300 °F) 
f) Initial boiling point 
and boiling range 
360 °C 680 °F 
g) Flash point  ()No data available 
h) Evaporation rate No data available 
i) Flammability (solid, 
gas) 




No data available 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density 1.067 g/mL at 25 °C (77 °F) 
n) Water solubility 0.00003 g/l at 20 °C (68 °F) - OECD Test Guideline 105 - 
insoluble 
o) Partition coefficient: No data available 
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No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 




SECTION 10: Stability and reactivity 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides 
Other decomposition products - No data available 




SECTION 11: Toxicological information 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - male and female - > 2,000 mg/kg 
(OECD Test Guideline 401) 
LD50 Dermal - Rat - male and female - > 2,000 mg/kg 
(OECD Test Guideline 402) 
Remarks: Limit Test 
No data available 
Skin corrosion/irritation 
Skin - In vitro study 
Result: No skin irritation 
(OECD Test Guideline 439) 
Serious eye damage/eye irritation 
Eyes - Rabbit 
Result: No eye irritation 
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(OECD Test Guideline 405) 
Respiratory or skin sensitisation 
Sensitisation test: - Mouse 
Result: negative 
(OECD Test Guideline 429) 
Germ cell mutagenicity 
No data available 
Ames test 




IARC: 3 - Group 3: Not classifiable as to its carcinogenicity to humans (Cholesterol) 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is 
identified as a carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is 
on OSHA  li  of eg la ed ca cinogens. 
Reproductive toxicity 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 





To the best of our knowledge, the chemical, physical, and toxicological properties have not 
been thoroughly investigated. 
 
No  toxic  effects  are  to  be  expected  when  the  product is handled appropriately. 
Substance which occurs in the human body under physiological conditions. 





SECTION 12: Ecological information 
12.1 Toxicity 
12.2 Persistence and degradability 
Biodegradability aerobic  - Exposure time 28 d 
Result: 74 % - Inherently biodegradable.  
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12.3 Bioaccumulative potential 
12.4 Mobility in soil 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not 
conducted 




SECTION 13: Disposal considerations 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 




SECTION 14: Transport information 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 




SECTION 15: Regulatory information 
 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, 
Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that 
exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 
313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 






New Jersey Right To Know Components 
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California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, 




SECTION 16: Other information 
Further information 
Copyright 2020 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies 
for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive 
and shall be used only as a guide. The information in this document is based on the 
present state of our knowledge and is applicable to the product with regard to 
appropriate safety precautions. It does not represent any guarantee of the properties of 
the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any 
damage resulting from handling or from contact with the above product. See 
www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional 
terms and conditions of sale. 
 
The branding on the header and/or footer of this document may temporarily not visually 
match the product purchased as we transition our branding. However, all of the 
information in the document regarding the product remains unchanged and matches the 
product ordered. For further information please contact mlsbranding@sial.com. 
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SECTION 1: Identification of the substance/mixture and of the company/undertaking 
1.1 Product identifiers 
Product name : 1,2-distearoyl-sn-glycero-3-phosphocholine 
 
Product Number : 850365P 
Brand : Avanti 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich Inc. 
3050 Spruce Street 
ST. LOUIS MO  63103 
UNITED STATES 
 
Telephone : +1 314 771-5765 
Fax : +1 800 325-5052 
1.4 Emergency telephone number 
Emergency Phone # : 800-424-9300 CHEMTREC (USA) +1-703-
527-3887 CHEMTREC (International) 24 
Hours/day; 7 Days/week 
 
 
SECTION 2: Hazards identification 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 




SECTION 3: Composition/information on ingredients 
3.1 Substances 
Synonyms : 18:0 PC (DSPC) 
 












SECTION 4: First aid measures 
4.1 Description of first aid measures 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
In case of skin contact 
Wash off with soap and plenty of water. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 
2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 




SECTION 5: Firefighting measures 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
Carbon oxides, Nitrogen oxides (NOx), Oxides of phosphorus 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 




SECTION 6: Accidental release measures 
6.1 Personal precautions, protective equipment and emergency procedures 
Avoid dust formation. Avoid breathing vapours, mist or gas. 
For personal protection see section 8. 
6.2 Environmental precautions 
No special environmental precautions required. 
6.3 Methods and materials for containment and cleaning up 
Sweep up and shovel. Keep in suitable, closed containers for disposal. 
6.4 Reference to other sections 




SECTION 7: Handling and storage 
7.1 Precautions for safe handling 
Further processing of solid materials may result in the formation of combustible dusts. The 
potential for combustible dust formation should be taken into consideration before 
additional processing occurs. 
 
 





Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Recommended storage temperature -20 °C 
Storage class (TRGS 510): 13: Non Combustible Solids 
7.3 Specific end use(s) 




SECTION 8: Exposure controls/personal protection 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
General industrial hygiene practice. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate 
government standards such as NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove 
removal technique (without touching glove's outer surface) to avoid skin contact 
with this product. Dispose of contaminated gloves after use in accordance with 
applicable laws and good laboratory practices. Wash and dry hands. 
 
Body Protection 
Choose body protection in relation to its type, to the concentration and amount of 
dangerous substances, and to the specific work-place., The type of protective 
equipment must be selected according to the concentration and amount of the 
dangerous substance at the specific workplace. 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of 
dusts are desired, use type N95 (US) or type P1 (EN 143) dust masks. Use 
respirators and components tested and approved under appropriate government 
standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
No special environmental precautions required. 
 
 
SECTION 9: Physical and chemical properties 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: powder 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH No data available 
e) Melting 
point/freezing point 
No data available 
 
 





f) Initial boiling point 
and boiling range 
No data available 
g) Flash point  ()No data available 
h) Evaporation rate No data available 
i) Flammability (solid, 
gas) 




No data available 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density No data available 
n) Water solubility slightly soluble 
o) Partition coefficient: 
n-octanol/water 
No data available 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 




SECTION 10: Stability and reactivity 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen 
oxides (NOx), Oxides of phosphorus 











SECTION 11: Toxicological information 
11.1 Information on toxicological effects 
Acute toxicity 
No data available 
Inhalation: No data available 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 
No data available 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
NTP: No component of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is 
 OSHA    lated carcinogens. 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: Not available 
 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not 





SECTION 12: Ecological information 
12.1 Toxicity 
No data available 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
 
 





12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not 
conducted 
12.6 Other adverse effects 




SECTION 13: Disposal considerations 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 




SECTION 14: Transport information 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 




SECTION 15: Regulatory information 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, 
Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that 
exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 
313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
















New Jersey Right To Know Components 
 
 












California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, 




SECTION 16: Other information 
Further information 
Copyright 2018 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies 
for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive 
and shall be used only as a guide. The information in this document is based on the 
present state of our knowledge and is applicable to the product with regard to 
appropriate safety precautions. It does not represent any guarantee of the properties of 
the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any 
damage resulting from handling or from contact with the above product. See 
www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional 
terms and conditions of sale. 
 
The branding on the header and/or footer of this document may temporarily not visually 
match the product purchased as we transition our branding. However, all of the 
information in the document regarding the product remains unchanged and matches the 
product ordered. For further information please contact mlsbranding@sial.com. 
 





Identification of the substance/preparation  
24 hour Emergency Response (Transport): 866-536-0631
301-431-8585
Outside of the U.S. +1-301-431-8585
Product code
For research use only. Not intended for human or animal diagnostic or therapeutic uses.
Revision Date
18330019
Product name  ATP
Company/Undertaking Identification  
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5791 VAN ALLEN WAY
PO BOX 6482
CARLSBAD, CA 92008
+1 760 603 7200
4 . F i r s t  a i d  m e a s u r e s
Principle Routes of Exposure/
Potential Health effects  
GHS - Classification 
Eyes May cause eye irritation with susceptible persons.
Signal Word
not hazardous
Skin May cause skin irritation in susceptible persons.
Inhalation May be harmful by inhalation.
Ingestion May be harmful if swallowed.
3 . C o m p o s i t i o n /i n f o r m a t i o n  o n  i n g r e d i e n t s
The product contains no substances which at their given concentration, are considered to be hazardous to health. We













Product name  ATP











Prevent further leakage or spillage if safe to do so.
Treat symptomatically.
Respiratory protection In case of insufficient ventilation wear suitable respiratory equipment.
Skin contact
See Section 12 for additional information.
Rinse with plenty of water. If symptoms arise, call a physician.
Hand protection Impervious gloves.
Ingestion
Eye protection Safety glasses with side-shields.
7 . H a n d l i n g  a n d  s t o r a g e
6 . A c c i d e n t a l  r e l e a s e  m e a s u r e s
Skin and body protection. Lightweight protective clothing.
Never give anything by mouth to an unconscious person. If symptoms persist, call
a physician. Do not induce vomiting without medical advice.
Hygiene measures Handle in accordance with good industrial hygiene and safety practice.
5 . F i r e -f i g h t i n g  m e a s u r e s




Prevent product from entering drains.
Storage Keep in a dry, cool and well-ventilated place.
Personal precautions Use personal protective equipment.
_____________________________________________________________________________________________
Inhalation
8 . E x p o s u r e  c o n t r o l s/p e r s o n a l  p r o t e c t i o n
Methods for cleaning up Soak up with inert absorbent material.
Move to fresh air. If symptoms persist, call a physician. If not breathing, give
artificial respiration.
Suitable extinguishing media
Exposure limits  
Revision Date
Water spray. Carbon dioxide (CO2). Foam. Dry chemical.
Product name  ATP
Eye contact
Page  3 / 6
Exposure limits We are not aware of any national exposure limit.
Environmental precautions  
29-Nov-2011
Rinse immediately with plenty of water, also under the eyelids, for at least 15
minutes. If symptoms persist, call a physician.
Engineering measures 
www.lifetechnologies.com
Ensure adequate ventilation, especially in confined areas.
Special protective equipment for firefighters
Product code


















None under normal use
Target Organ Effects None under normal use conditions
polymerization Hazardous polymerisation does not occur.
9 . P h y s i c a l  a n d  c h e m i c a l  p r o p e r t i e s
1 2 . E c o l o g i c a l  i n f o r m a t i o n
1 1 . T o x i c o l o g i c a l  i n f o r m a t i o n
Ecotoxicity effects No information available.
Oxidizing properties




Acute toxicity  
Bioaccumulation Does not bioaccumulate.
Water solubility soluble
No information available
Acute toxicity not hazardous
Principle Routes of Exposure/
Potential Health effects 
Eyes May cause eye irritation with susceptible persons.
_____________________________________________________________________________________________
General Information 
Skin May cause skin irritation in susceptible persons.
1 0 . S t a b i l i t y  a n d  r e a c t i v i t y
Odor
Inhalation May be harmful by inhalation.
Revision Date
Product name  ATP
Ingestion
Page  4 / 6
May be harmful if swallowed.
°F  no data available
Melting point/range
29-Nov-2011
°C  no data available
Autoignition temperature
www.lifetechnologies.com
°C  no data available
Boiling Point/Range
Product code
°F  no data available
Flash point
°C  no data available
°F  no data available
18330019
°C  no data available
°F  no data available
Proper shipping name Not classified as dangerous in the meaning of transport regulations
The above information was acquired by diligent search and/or investigation and the recommendations are based on
prudent application of professional judgment.  The information shall not be taken as being all inclusive and is to be
used only as a guide.  All materials and mixtures may present unkown hazards and should be used with caution.
Since the Company cannot control the actual methods, volumes, or conditions of use, the Company shall not be held
liable for any damages or losses resulting from the handling or from contact with the product as described herein.
THE INFORMATION IN THIS MSDS DOES NOT CONSTITUTE A WARRENTY, EXPRESSED OR IMPLIED,
INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PUPOSE.
1 3 . D i s p o s a l  c o n s i d e r a t i o n s
Hazard class none
End of Safety Data Sheet
Subsidiary Class none
1 6 . O t h e r  i n f o r m a t i o n
Packing group none
IATA 
Reason for Revision Initial Release.
UN-No None
Dispose of in accordance with local regulations.
1 4 . T r a n s p o r t  i n f o r m a t i o n
For research use only. Not intended for human or animal diagnostic or therapeutic uses.
_____________________________________________________________________________________________
SARA 313
This product is not regulated by SARA.
1 5 . R e g u l a t o r y  i n f o r m a t i o n
U.S. Federal Regulations 
Revision Date
Product name  ATP
California Proposition 65
This product does not contain chemicals listed under Proposition 65
Page  5 / 6
Clean Air Act, Section 112 Hazardous Air Pollutants (HAPs) (see 40 CFR 61)






This product has been classified according to the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR




Identification of the substance/preparation  
24 hour Emergency Response (Transport): 866-536-0631
301-431-8585
Outside of the U.S. +1-301-431-8585
Product code
For research use only. Not intended for human or animal diagnostic or therapeutic uses.
Revision Date
18331017
Product name  CTP
Company/Undertaking Identification  
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5791 VAN ALLEN WAY
PO BOX 6482
CARLSBAD, CA 92008
+1 760 603 7200
Safety Data Sheet
___________________________________________________________________________________________________________________
S E C T I O N  1 : I d e n t i f i c a t i o n  o f  t h e  s u b s t a n c e / m i x t u r e  a n d  o f  t h e  c o m p a n y/u n d e r t a k i n g
Identification of the substance or mixture  
Product code 18333013
Product name UTP
Company/undertaking identification  
24 hour Emergency Response for Hazardous Materials
[or Dangerous Goods] Incident. Spill, Leak, Fire,
Exposure, or Accident. Call CHEMTREC
Within the USA + Canada: 1-800-424-9300 and +1
703-527-3887
Outside the USA + Canada: +1 703-741-5970
Country Specific Emergency Number (if available):
For Research Use Only. Not for use in diagnostic procedures.
S E C T I O N  2 : H a z a r d s  i d e n t i f i c a t i o n











5781 Van Allen Way
PO Box 6482
Carlsbad, CA 92008
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S E C T I O N  3 : C o m p o s i t i o n /i n f o r m a t i o n  o n  i n g r e d i e n t s
The product contains no substances which at their given concentration, are considered to be hazardous to health. We
recommend handling all chemicals with caution.
S E C T I O N  4 : F i r s t  a i d  m e a s u r e s
Description of first aid measures
Skin contact Rinse with plenty of water . Immediate medical attention is not required.
Eye contact Rinse cautiously with water for several minutes. Remove contact lenses, if present
and easy to do.
Ingestion Not expected to present a significant ingestion hazard under anticipated conditions
of normal use. If you feel unwell, seek medical advice.
Inhalation Not expected to be an inhalation hazard under anticipated conditions of normal
use of this material. Consult a physician if necessary.
Notes to Physician Treat symptomatically.
Most important symptoms and effects, both acute and delayed
Not Applicable
Indication of any immediate medical attention and special treatment needed
None.
___________________________________________________________________________________________________________________
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Product code 18333013 Product name  UTP
www.thermofisher.com
S E C T I O N  8 : E x p o s u r e  c o n t r o l s /p e r s o n a l  p r o t e c t i o n
Control parameters 
Exposure Limits Contains no substances with occupational exposure limit values.
Engineering measures Ensure adequate ventilation, especially in confined areas.
Exposure controls 
Personal Protective Equipment
Respiratory protection In case of insufficient ventilation wear respirators and components tested and
approved under appropriate government standards.
S E C T I O N  5 : F i r e f i g h t i n g  m e a s u r e s
Extinguishing media
Suitable extinguishing media Water spray. Carbon dioxide (CO2). Foam. Dry chemical.
Unsuitable extinguishing media No information available.
Special hazards arising from the substance or mixture
Not known.
Advice for fire-fighters
Standard procedure for chemical fires.
S E C T I O N  6 : A c c i d e n t a l  r e l e a s e  m e a s u r e s
Personal precautions, protective equipment and emergency procedures
Ensure adequate ventilation. Always wear recommended Personal Protective Equipment. Use personal protection
equipment. See Section 8 for more detail.
Environmental precautions
No special environmental precautions required.
Methods and material for containment and cleaning up
Soak up with inert absorbent material.
Reference to other sections
See section 8 for more information.
S E C T I O N  7 : H a n d l i n g  a n d  s t o r a g e
Precautions for safe handling
Use personal protective equipment as required. No special handling advices are necessary.
Conditions for safe storage, including any incompatibilities
Keep in a dry, cool and well-ventilated place. Keep in properly labeled containers.
Specific end use(s)
For research use only.
___________________________________________________________________________________________________________________
Revision date 07-Dec-2017 Page  3 / 7
Product code 18333013 Product name  UTP
www.thermofisher.com
Hand protection Wear suitable gloves. Glove material: Compatible chemical-resistant gloves.
Eye protection Tight sealing safety goggles.
Skin and Body Protection Wear suitable protective clothing.
Hygiene measures Handle in accordance with good industrial hygiene and safety practice
Environmental exposure controls
No special environmental precautions required.
S E C T I O N  9 : P h y s i c a l  a n d  c h e m i c a l  p r o p e r t i e s
Information on basic physical and chemical properties
Appearance liquid
Odor No data available
Evaporation rate No data available
Flammability (solid, gas) No data available
Upper explosion limit Mixture has not been tested
Lower explosion limit Mixture has not been tested
Vapor Pressure Mixture has not been tested
Relative density Mixture has not been tested
Specific gravity No data available




Explosive properties Mixture has not been tested
Other information
No data available.
S E C T I O N  1 0 : S t a b i l i t y  a n d  r e a c t i v i t y
Reactivity None known.
Chemical stability Stable under normal conditions.
Possibility of hazardous
reactions
Hazardous reaction has not been reported.
Conditions to avoid No information available.




Melting point / melting range °C  Mixture has not been tested °F  Mixture has not been tested
Boiling point / boiling range °C  Mixture has not been tested °F  Mixture has not been tested
Flash point °C  Mixture has not been tested °F  Mixture has not been tested
Autoignition Temperature °C  Mixture has not been tested °F  Mixture has not been tested
Decomposition temperature °C  Mixture has not been tested °F  Mixture has not been tested
___________________________________________________________________________________________________________________
Revision date 07-Dec-2017 Page  4 / 7
Product code 18333013 Product name  UTP
www.thermofisher.com
S E C T I O N  1 1 : T o x i c o l o g i c a l  i n f o r m a t i o n
Information on toxicological effects
There is no evidence available indicating acute toxicity.
Principal Routes of Exposure
Irritation Conclusive but not sufficient for classification
 .
Corrosivity Conclusive but not sufficient for classification
Sensitization Conclusive but not sufficient for classification
 .
STOT - Single Exposure Conclusive but not sufficient for classification
STOT - Repeated Exposure Conclusive but not sufficient for classification
Carcinogenicity Conclusive but not sufficient for classification
Mutagenicity Conclusive but not sufficient for classification
 .
Reproductive toxicity Conclusive but not sufficient for classification
 .
Aspiration hazard Conclusive but not sufficient for classification
S E C T I O N  1 2 : E c o l o g i c a l  i n f o r m a t i o n
Toxicity
Contains no substances known to be hazardous to the environment or not degradable in waste water treatment
plants.
Persistence and degradability No information available.
Bioaccumulative potential No information available.
Results of PBT and vPvB assessment
This mixture does not contain any substances that are assessed to be a PBT or a vPvB.
Other adverse effects No information available.
S E C T I O N  1 3 : D i s p o s a l  c o n s i d e r a t i o n s
Waste treatment methods
The generation of waste should be avoided or minimized wherever possible. Empty containers or liners may retain
some product residues. This material and its container must be disposed of in according to approved disposal
technique. Disposal of this product, its solutions or of any by-products, shall comply with the requirements of all
applicable local, regional or national/federal regulations.
___________________________________________________________________________________________________________________
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Product code 18333013 Product name  UTP
www.thermofisher.com
S E C T I O N  1 6 : O t h e r  i n f o r m a t i o n
Reason for revision SDS sections updated.
Revision number 2
Revision date 07-Dec-2017
S E C T I O N  1 4 : T r a n s p o r t  i n f o r m a t i o n
IATA / ADR / DOT-US / IMDG
Not regulated in the meaning of transport regulations.
UN number Not Applicable
UN proper shipping name Not Applicable
Transport hazard class(es) Not Applicable
Packing group Not Applicable
Environmental hazards
Not Applicable
Special precautions for user
Not Applicable
Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not Applicable.
S E C T I O N  1 5 : R e g u l a t o r y  i n f o r m a t i o n
US Federal Regulations 
SARA 313
This product is not regulated by SARA.
Clean Air Act, Section 112 Hazardous Air Pollutants (HAPs) (see 40 CFR 61)
This product does not contains HAPs.
US State Regulations 
California Proposition 65
This product does not contain any Proposition 65 chemicals.
WHMIS Hazard Class
Non-controlled
This product has been classified in accordance with the hazard criteria of the Controlled Products Regulations (CPR)
and the SDS contains all the information required by the CPR.
___________________________________________________________________________________________________________________
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Product code 18333013 Product name  UTP
www.thermofisher.com






"The above information was acquired by diligent search and/or investigation and the recommendations are based on
prudent application of professional judgment. The information shall not be taken as being all inclusive and is to be
used only as a guide. All materials and mixtures may present unknown hazards and should be used with caution.
Since the Company cannot control the actual methods, volumes, or conditions of use, the Company shall not be held
liable for any damages or losses resulting from the handling or from contact with the product as described herein.
THE INFORMATION IN THIS SDS DOES NOT CONSTITUTE A WARRANTY, EXPRESSED OR
IMPLIED,INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR
PURPOSE"
End of Safety Data Sheet
___________________________________________________________________________________________________________________
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Identification of the substance/preparation  
24 hour Emergency Response (Transport): 866-536-0631
301-431-8585





Company/Undertaking Identification  
Product name  GTP
For research use only. Not intended for human or animal diagnostic or therapeutic uses.
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5791 VAN ALLEN WAY
PO BOX 6482
CARLSBAD, CA 92008
+1 760 603 7200
4 . F i r s t  a i d  m e a s u r e s
Principle Routes of Exposure/
Potential Health effects  
GHS - Classification 
Eyes May cause eye irritation with susceptible persons.
Signal Word
not hazardous
Skin May cause skin irritation in susceptible persons.
Inhalation May be harmful by inhalation.
Ingestion May be harmful if swallowed.
3 . C o m p o s i t i o n /i n f o r m a t i o n  o n  i n g r e d i e n t s
The product contains no substances which at their given concentration, are considered to be hazardous to health. We
















Product name  GTP
Reactivity








Personal protective equipment 
Eye contact
See Section 12 for additional information.
Rinse immediately with plenty of water, also under the eyelids, for at least 15
minutes. If symptoms persist, call a physician.
Respiratory protection In case of insufficient ventilation wear suitable respiratory equipment.
5 . F i r e -f i g h t i n g  m e a s u r e s
6 . A c c i d e n t a l  r e l e a s e  m e a s u r e s
Inhalation
7 . H a n d l i n g  a n d  s t o r a g e
Move to fresh air. If symptoms persist, call a physician. If not breathing, give
artificial respiration.
Hand protection Impervious gloves.
Eye protection Safety glasses with side-shields.
Skin contact
Skin and body protection. Lightweight protective clothing.
Handling Always wear reccommended Personal Protective Equipment. No special handling
advice required.
Hygiene measures Handle in accordance with good industrial hygiene and safety practice.
Personal precautions Use personal protective equipment.
Storage Keep in a dry, cool and well-ventilated place.
Environmental exposure 
controls 
Prevent product from entering drains.
Rinse with plenty of water. If symptoms arise, call a physician.
Suitable extinguishing media
Methods for cleaning up Soak up with inert absorbent material.
8 . E x p o s u r e  c o n t r o l s/p e r s o n a l  p r o t e c t i o n
Water spray. Carbon dioxide (CO2). Foam. Dry chemical.
_____________________________________________________________________________________________
Notes to physician
Exposure limits  
Treat symptomatically.
Special protective equipment for firefighters
Environmental precautions  
Wear self-contained breathing apparatus and protective
suit.
18332015
We are not aware of any national exposure limit.
Revision Date
Ingestion
Product name  GTP
Page  3 / 5
Never give anything by mouth to an unconscious person. If symptoms persist, call
a physician. Do not induce vomiting without medical advice.
27-Dec-2011
Engineering measures Ensure adequate ventilation, especially in confined areas.
www.lifetechnologies.com
Prevent further leakage or spillage if safe to do so.
Product code
No information available
Ingestion May be harmful if swallowed.











None under normal use
polymerization
Target Organ Effects No known effects under normal use conditions.
Hazardous polymerisation does not occur.
9 . P h y s i c a l  a n d  c h e m i c a l  p r o p e r t i e s
1 2 . E c o l o g i c a l  i n f o r m a t i o n
1 1 . T o x i c o l o g i c a l  i n f o r m a t i o n
Oxidizing properties
Ecotoxicity effects No information available.
No information available.
Mobility No information available.
Appearance
Acute toxicity  
Biodegradation Inherently biodegradable
Water solubility




Principle Routes of Exposure/




May cause eye irritation with susceptible persons.
1 0 . S t a b i l i t y  a n d  r e a c t i v i t y
Odor
Skin May cause skin irritation in susceptible persons.
Inhalation
18332015
May be harmful by inhalation.
Revision Date
°F  no data available
Product name  GTP
°F  no data available
Page  4 / 5
Melting point/range °C  no data available
Autoignition temperature
°C  no data available
27-Dec-2011
Boiling Point/Range °F  no data available
www.lifetechnologies.com
Flash point
°C  no data available
Product code
°F  no data available
°C  no data available
1 4 . T r a n s p o r t  i n f o r m a t i o n
For research use only. Not intended for human or animal diagnostic or therapeutic uses.
Proper shipping name Not classified as dangerous in the meaning of transport regulations
The above information was acquired by diligent search and/or investigation and the recommendations are based on
prudent application of professional judgment.  The information shall not be taken as being all inclusive and is to be
used only as a guide.  All materials and mixtures may present unkown hazards and should be used with caution.
Since the Company cannot control the actual methods, volumes, or conditions of use, the Company shall not be held
liable for any damages or losses resulting from the handling or from contact with the product as described herein.
THE INFORMATION IN THIS MSDS DOES NOT CONSTITUTE A WARRENTY, EXPRESSED OR IMPLIED,
INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PUPOSE.
1 3 . D i s p o s a l  c o n s i d e r a t i o n s
Hazard class none
End of Safety Data Sheet
Subsidiary Class none
1 6 . O t h e r  i n f o r m a t i o n
Packing group none
IATA 
Reason for Revision (M)SDS sections updated.
UN-No None
Dispose of in accordance with local regulations.
This product has been classified according to the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR
_____________________________________________________________________________________________
U.S. State Regulations 
SARA 313
This product is not regulated by SARA.
1 5 . R e g u l a t o r y  i n f o r m a t i o n




This product does not contain chemicals listed under Proposition 65
Product name  GTP
Page  5 / 5
Clean Air Act, Section 112 Hazardous Air Pollutants (HAPs) (see 40 CFR 61)










N-7113 Page 1 of 6 
1. IDENTIFICATION






Uses advised against: 
CleanCap™ Reagent $*   
N-7113
Not applicable.
Laboratory chemicals, manufacture of substances. 
No Information Available 
1.3 Details of the Supplier of the Safety Data Sheet 
Supplier address: TriLink BioTechnologies, Inc. 
9955 Mesa Rim Road 






1.4 Emergency Telephone Number 
Emergency Phone: 858-546-0004
800-863-6801 (toll free)
7 am – 5 pm PST, Monday-Friday
2. HAZARD IDENTIFICATION
2.1 Classification 
Not a dangerous substance or mixture 
2.2 Label Elements 
Not a hazardous substance or mixture. 




No ingredients are hazardous according to OSHA criteria. No components need to be disclosed 
according to the applicable regulations. 
4. FIRST AID MEASURES
4.1 First Aid Measures 
Eye contact: Immediately flush eyes with copious amounts of water for at 
least 15 minutes, lifting lower and upper eyelids. Consult a 
physician. 
Skin contact: Immediately wash skin with soap and water. 
Inhalation: Remove to fresh air. 
Ingestion: If swallowed, wash out mouth with water provided person is 
conscious. Consult a physician. 
4.2 Most Important Symptoms and Effects, both Acute and Delayed 
N-7113  Page 2 of 6 
No information available. 
 
4.3 Indication of any Immediate Medical Attention and Special Treatment Needed 
No information available. 
 
5. FIRE-FIGHTING MEASURE 
5.1 Extinguishing Media 
Suitable Media: Use water spray, alcohol-resistant foam, dry chemical or carbon 
dioxide. 
 
5.2 Special Hazards Arising from Product 
No information available. 
 
5.3 Advice for Firefighters 
As in any fire, wear self-contained breathing apparatus pressure-demand, MSHA/NIOSH 
(approved or equivalent) and full protective gear. 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal Precautions, Protective Equipment and Emergency Procedures 
Ensure adequate ventilation. Avoid breathing vapors, mists or gas. See Section 8 for personal 
protection. 
 
6.2 Environmental Precautions 
See Section 12 for additional ecological information. 
 
6.3 Methods and Materials for Containment and Clean Up 
Prevent further leakage or spillage if safe to do so. Soak up with inert absorbent material. Pick up 
and transfer to properly labeled containers. This material and its container must be disposed of 
as hazardous waste. 
 
7. HANDLING & STORAGE 
7.1 Precautions for Safe Handling 
Ensure adequate ventilation. Avoid breathing vapors, mists or gas. See Section 8 for personal 
protection. 
 
7.2 Conditions for Safe Storage 
Keep/store only in original container. Storage Temperature: -20°C or below. 
 
7.3 Incompatibilities  
None known based on information supplied. 
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control Parameters 
This product, as supplied, does not contain any hazardous materials with occupational exposure 
limits established by the region specific regulatory bodies. 
 
8.2 Appropriate Engineering Controls 
General industrial hygiene practices. 
 
8.3 Individual Protection Measures 
Eye/Face Protection: Wear safety glasses with side shields (or goggles). 
Skin/Body Protection: Wear suitable protective clothing and gloves. 
N-7113  Page 3 of 6 
Respiratory Protection: Use in well ventilated areas. 
General: Handle in accordance with good industrial hygiene and safety 
practice. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on Basic Physical and Chemical Properties 
Physical state: Liquid 
Appearance: Colorless 
Odor: Mild 
pH: Refer to trilinkbiotech.com for specific information. 
Melting Point/Freezing Point: No information available 
Boiling Point/Boiling Range: No information available 
Flash Point: No information available 
Evaporation Rate: No information available 
Flammability (solid, gas): No information available 
Upper/Lower Flammability 
Limits: 
No information available 
Vapor Pressure: No information available 
Vapor Density: No information available 
Relative Density: No information available 
Specific Density: No information available 
Water Solubility: No information available 
Partition Coefficient: No information available 
Autoignition Temperature: No information available 
Decomposition Temperature: No information available 
Viscosity: No information available 
Oxidizing Properties: No information available 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No information available. 
 
10.2 Chemical stability 
Stable under normal conditions. 
 
10.3 Possibility of hazardous reactions 
Can react briskly with oxidizers, danger of explosion. 
 
10.4 Conditions to avoid 
Incompatible materials. Ignition sources. Heat. 
 
10.5 Incompatible materials 
Strong oxidizing agents. 
 
10.6 Hazardous decomposition products 
Thermal decomposition can lead to release of irritating and toxic gases and vapors. Carbon 
monoxide. Carbon dioxide (CO2). 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on likely routes of exposure 
Inhalation Avoid breathing vapors or mists. May cause irritation of 
respiratory tract. 
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Eye contact Redness. May cause slight irritation. 
Skin contact Prolonged contact may cause redness and irritation. Repeated 
exposure may cause skin dryness or cracking. 
Ingestion May cause drowsiness or dizziness. Ingestion causes burns of the 
upper digestive and respiratory tracts. Symptoms include burning 
sensation, coughing, wheezing, shortness of breath, headache, 
nausea, and vomiting. 
 
11.2 Information on toxicological effects 
Symptoms No information available. 
 
11.3 Delayed and immediate effects as well as chronic effects from short and long-term 
exposure 
Skin corrosion/Irritation: Mild 
Serious Eye Damage/Eye Mild 
Irritation: 
Skin or Respiratory Sensitization: No information available 
Germ Cell Mutagenicity: No information available 
Carcinogenicity: No information available 
Reproductive Toxicity: No information available 
Developmental Toxicity: No information available 
Teratogenicity: No information available 
STOT – Single Exposure: No information available 
STOT – Repeated Exposure: No information available 
Target Organs: Kidneys, eyes, skin, respiratory system 
Chronic Toxicity: No information available 
Subchronic Toxicity: No information available 
Neurological Effects: No information available 
Aspiration Hazard: No information available 
Other Adverse Effects: No information available 
 
12. ECOLOGICAL INFORMATION 
12.1 Marine pollutant 
No information available 
 
12.2 Ecotoxicity 
No information available 
 
12.3 Persistence and degradability 
No information available 
 
12.4 Bioaccumulation 
No information available 
 
12.5 Mobility 
No information available 
 
12.6 Other adverse effects 
Ozone: No information available 
Ozone Depletion Potential: No information available 
 
13. DISPOSAL CONSIDERATIONS 
N-7113  Page 5 of 6 
13.1 Waste treatment methods 
Relevant Information: Keep out of drains, sewers, ditches and waterways. 
 
Disposal Method:  Use a licensed professional waste disposal service to dispose of 
this product. Product may be dissolved in a combustible solvent 
or absorbed onto a combustible material and burned by a 
chemical incinerator. 
Contaminated Packaging: Dispose of as unused product. 
 
14. TRANSPORT INFORMATION 
Dot:  Not dangerous goods. 
 
15. REGULATORY INFORMATION 
15.1 US Federal Regulations 
Clean Water Act (CWA): This product does not contain any substances regulated as 
pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 
40 CFR 122.42). 
CERCLA: This material, as supplied, does not contain any substances 
regulated as hazardous substances under the Comprehensive 
Environmental Response Compensation and Liability Act 
(CERCLA) (40 CFR 302) or the Superfund Amendments and 
Reauthorization Act (SARA) (40 CFR 355). There may be specific 
reporting requirements at the local, regional, or state level 
pertaining to releases of this material. 
 
15.2 US State Regulations 
California Proposition 65: This product does not contain any Proposition 65 chemicals. 
  
16. OTHER INFORMATION 
16.1 HMIS Rating 
Health Hazard:  0 
Flammability:  0 
Physical Hazard:  0 
Chronic Health Hazard:  0 
 
16.2 NFPA Rating 
Health Hazard:  0 
Fire Hazard:  0 
Reactivity Hazard:  0 
 
16.3 Preparation Information 
Prepared By: TriLink BioTechnologies, Inc. 
  858-546-0004 
Issue Date:  2016-05-31 
Version:  3 
 
16.4 Further Information 
Copyright 2016 TriLink BioTechnologies, inc. License granted to make unlimited paper copies for 
internal use only. The above information is believed to be accurate, but not necessarily all 
inclusive, and thus should only be used as a guide in the handling and use of this material.  The 
data in this SDS relates only to the specific material designated herein and does not relate to use 
in combination with any other material or in any process.  TriLink BioTechnologies, Inc. shall not 
N-7113  Page 6 of 6 
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SAFETY DATA SHEET 
 
Version 6.2 
Revision Date 10/07/2020 
Print Date 11/20/2020 
 
SECTION 1: Identification of the substance/mixture and of the company/undertaking 
1.1 Product identifiers 
Product name : -Cellulose 
 
Product Number : C8002 
Brand : Sigma 
CAS-No. : 9004-34-6 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich Inc. 
3050 Spruce Street 
ST. LOUIS MO  63103 
UNITED STATES 
 
Telephone : +1 314 771-5765 
Fax : +1 800 325-5052 
1.4 Emergency telephone 
Emergency Phone # : 800-424-9300 CHEMTREC (USA) +1-703-
527-3887 CHEMTREC (International) 24 
Hours/day; 7 Days/week 
 
 
SECTION 2: Hazards identification 
2.1 Classification of the substance or mixture 
 
 
2.2 GHS Label elements, including precautionary statements 
Pictogram none 
 
Signal word Warning 
 
Hazard statement(s) 






2.3 Hazards not otherwise classified (HNOC) or not covered by GHS 
Combustible dust 
May form explosible dust-air mixture if dispersed. 
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SECTION 3: Composition/information on ingredients 
3.1 Substances 
CAS-No. : 9004-34-6 
EC-No. : 232-674-9 
 
Component Classification Concentration 
cellulose 





SECTION 4: First aid measures 
4.1 Description of first-aid measures 
If inhaled 
After inhalation: fresh air. 
In case of skin contact 
In case of skin contact: Take off immediately all contaminated clothing. Rinse skin with 
water/ shower. 
In case of eye contact 
After eye contact: rinse out with plenty of water. Remove contact lenses. 
If swallowed 
After swallowing: make victim drink water (two glasses at most). Consult doctor if feeling 
unwell. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 
2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 




SECTION 5: Firefighting measures 
5.1 Extinguishing media 
Suitable extinguishing media 
Water Foam Carbon dioxide (CO2) Dry powder 
Unsuitable extinguishing media 
For this substance/mixture no limitations of extinguishing agents are given. 
5.2 Special hazards arising from the substance or mixture 
Nature of decomposition products not known. 
Combustible. 
Development of hazardous combustion gases or vapours possible in the event of fire. 
5.3 Advice for firefighters 
In the event of fire, wear self-contained breathing apparatus. 
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5.4 Further information 





SECTION 6: Accidental release measures 
6.1 Personal precautions, protective equipment and emergency procedures 
Advice for non-emergency personnel: Avoid inhalation of dusts. Evacuate the danger 
area, observe emergency procedures, consult an expert. 
For personal protection see section 8. 
6.2 Environmental precautions 
Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Cover drains. Collect, bind, and pump off spills. Observe possible material restrictions 
(see sections 7 and 10). Take up dry. Dispose of properly. Clean up affected area. Avoid 
generation of dusts. 
6.4 Reference to other sections 




SECTION 7: Handling and storage 
7.1 Precautions for safe handling 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
No data available 
7.3 Specific end use(s) 




SECTION 8: Exposure controls/personal protection 
8.1 Control parameters 
Ingredients with workplace control parameters 







TWA 10 mg/m3 USA. ACGIH Threshold Limit 
Values (TLV) 
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  TWA 15 mg/m3 USA. OSHA - TABLE Z-1 Limits 
for Air Contaminants - 
1910.1000 
  TWA 5 mg/m3 USA. OSHA - TABLE Z-1 Limits 
for Air Contaminants - 
1910.1000 
  TWA 5 mg/m3 USA. NIOSH Recommended 
Exposure Limits 
  TWA 10 mg/m3 USA. NIOSH Recommended 
Exposure Limits 
  TWA 15 mg/m3 USA. Occupational Exposure 
Limits (OSHA) - Table Z-1 
Limits for Air Contaminants 
  TWA 5 mg/m3 USA. Occupational Exposure 
Limits (OSHA) - Table Z-1 
Limits for Air Contaminants 
  PEL 10 mg/m3 California permissible exposure 
limits for chemical 
contaminants (Title 8, Article 
107) 
  PEL 5 mg/m3 California permissible exposure 
limits for chemical 
contaminants (Title 8, Article 
107) 
  The concentration and percentage of the particulate used 
for this limit are determined from the fraction passing a size 
selector with the following characteristics:  Aerodynamic 
Diameter in Micrometers (unit density sphere)................. 
Percent Passing Selector  0 
.................................................. 100  1 
.................................................. 97  2 
.................................................. 91  3 
................................................... 74  4 
................................................... 50  5 
................................................... 30  6 
................................................... 17  7 
................................................... 9  8 
................................................... 5  10 
.................................................... 1 
8.2 Exposure controls 
Appropriate engineering controls 
Change contaminated clothing. Wash hands after working with substance. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate 
government standards such as NIOSH (US) or EN 166(EU). Safety glasses 
Skin protection 
This recommendation applies only to the product stated in the safety data sheet, 
supplied by us and for the designated use. When dissolving in or mixing with other 
substances and under conditions deviating from those stated in EN374 please 
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Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:KCL 741 Dermatril® L  
This recommendation applies only to the product stated in the safety data sheet, 
supplied by us and for the designated use. When dissolving in or mixing with other 
substances and under conditions deviating from those stated in EN374 please 
contact the supplier of CE-approved gloves (e.g. KCL GmbH, D-36124 Eichenzell, 
Internet: www.kcl.de). 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.4 mm 
Break through time: 480 min 
Material tested:Camatril® (KCL 730 / Aldrich Z677442, Size M)  
Respiratory protection 
required when dusts are generated. 
Our recommendations on filtering respiratory protection are based on the following 
standards: DIN EN 143, DIN 14387 and other accompanying standards relating to 
the used respiratory protection system. 
 
Control of environmental exposure 
Do not let product enter drains. 
 
 
SECTION 9: Physical and chemical properties 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: fibers 
Color: white 
b) Odor No data available 
c) Odor Threshold No data available 
d) pH No data available 
e) Melting 
point/freezing point 
No data available 
f) Initial boiling point 
and boiling range 
No data available 
g) Flash point  ()Not applicable 
h) Evaporation rate No data available 
i) Flammability (solid, 
gas) 




No data available 
k) Vapor pressure No data available 
l) Vapor density No data available 
m) Relative density No data available 
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n) Water solubility No data available 
o) Partition coefficient: 
n-octanol/water 
No data available 
p) Autoignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 




SECTION 10: Stability and reactivity 
10.1 Reactivity 
The following applies in general to flammable organic substances and mixtures: in 
correspondingly fine distribution, when whirled up a dust explosion potential may generally 
be assumed. 
10.2 Chemical stability 
The product is chemically stable under standard ambient conditions (room temperature) . 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
no information available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Nature of decomposition 
products not known. 
Other decomposition products - No data available 




SECTION 11: Toxicological information 
11.1 Information on toxicological effects 
Acute toxicity 
No data available 
Inhalation: No data available 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
No data available 
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Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitization 
No data available 
Germ cell mutagenicity 
No data available 
Carcinogenicity 
IARC: No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
NTP: No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is 
on OSHA’s list of regulated carcinogens. 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 




To the best of our knowledge, the chemical, physical, and toxicological properties have not 
been thoroughly investigated. 
 





SECTION 12: Ecological information 
12.1 Toxicity 
No data available 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not 
conducted 
12.6 Other adverse effects 
No data available 
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SECTION 13: Disposal considerations 
13.1 Waste treatment methods 
Product 
Waste material must be disposed of in accordance with the national and loc No mixing 
with other waste. Handle uncleaned containers like the product See 
www.retrologistik.com for processes regarding the return of chemicals and containers, or 




SECTION 14: Transport information 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 
Not dangerous goods 
 
Further information 




SECTION 15: Regulatory information 
 
SARA 302 Components 
This material does not contain any components with a section 302 EHS TPQ. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that 
exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 
313. 
SARA 311/312 Hazards 
No SARA Hazards 










No components are subject to the Massachusetts Right to Know Act. 






New Jersey Right To Know Components 
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SECTION 16: Other information 
Further information 
The above information is believed to be correct but does not purport to be all inclusive 
and shall be used only as a guide. The information in this document is based on the 
present state of our knowledge and is applicable to the product with regard to 
appropriate safety precautions. It does not represent any guarantee of the properties of 
the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any 
damage resulting from handling or from contact with the above product. See 
www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional 
terms and conditions of sale. 
 
Copyright 2020 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies 
for internal use only. 
The branding on the header and/or footer of this document may temporarily not visually 
match the product purchased as we transition our branding. However, all of the 
information in the document regarding the product remains unchanged and matches the 
product ordered. For further information please contact mlsbranding@sial.com. 
 




S E C T I O N  1 : I d e n t i f i c a t i o n  o f  t h e  s u b s t a n c e / m i x t u r e  a n d  o f  t h e  c o m p a n y/u n d e r t a k i n g
Identification of the substance or mixture  
Product code 18047019
Product name DEOXYRIBONUCLEASE I
Company/undertaking identification  
24 hour Emergency Response for Hazardous Materials
[or Dangerous Goods] Incident. Spill, Leak, Fire,
Exposure, or Accident. Call CHEMTREC
Within the USA + Canada: 1-800-424-9300 and +1
703-527-3887
Outside the USA + Canada: +1 703-741-5970
Country specific Emergency Number (if available):
For Research Use Only. Not for use in diagnostic procedures.
S E C T I O N  2 : H a z a r d s  i d e n t i f i c a t i o n











5781 Van Allen Way
PO Box 6482
Carlsbad, CA 92008
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S E C T I O N  3 : C o m p o s i t i o n /i n f o r m a t i o n  o n  i n g r e d i e n t s
Component CAS-No EINECS-No Weight %
Glycerol
 56-81-5 ( 60-100 )
56-81-5 200-289-5 60-100
Ethyl alcohol
 64-17-5 ( 0.1-0.49 )
64-17-5 200-578-6 0.1-0.49
The product contains no substances which at their given concentration, are considered to be hazardous to health.
S E C T I O N  4 : F i r s t  a i d  m e a s u r e s
Description of first aid measures
Skin contact Rinse with plenty of water . Immediate medical attention is not required.
Eye contact Rinse cautiously with water for several minutes. Remove contact lenses, if present
and easy to do
 .
Ingestion Not expected to present a significant ingestion hazard under anticipated conditions
of normal use. If you feel unwell, seek medical advice.
Inhalation Not expected to be an inhalation hazard under anticipated conditions of normal
use of this material. Consult a physician if necessary.
Notes to Physician Treat symptomatically.
Most important symptoms and effects, both acute and delayed
___________________________________________________________________________________________________________________
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Product code 18047019 Product name  DEOXYRIBONUCLEASE I
www.thermofisher.com
Indication of any immediate medical attention and special treatment needed
None.
S E C T I O N  8 : E x p o s u r e  c o n t r o l s /p e r s o n a l  p r o t e c t i o n
Control parameters 




Ethyl alcohol 1000 ppm
1900 mg/m3
None None 1000 ppm
Engineering measures Ensure adequate ventilation, especially in confined areas
Exposure controls 
Personal Protective Equipment
Respiratory protection In case of insufficient ventilation wear respirators and components tested and
approved under appropriate government standards.
S E C T I O N  5 : F i r e f i g h t i n g  m e a s u r e s
Extinguishing media
Suitable extinguishing media Water spray. Carbon dioxide (CO2). Foam. Dry chemical.
Unsuitable extinguishing media No information available.
Special hazards arising from the substance or mixture Not known.
Advice for fire-fighters Standard procedure for chemical fires.
S E C T I O N  6 : A c c i d e n t a l  r e l e a s e  m e a s u r e s
Personal precautions, protective equipment and emergency procedures
Ensure adequate ventilation. Always wear recommended Personal Protective Equipment. Use personal protection
equipment. See Section 8 for more detail.
Environmental precautions
No special environmental precautions required. Avoid discharge into drains and waterways whenever possible.
Methods and material for containment and cleaning up
Soak up with inert absorbent material.
Reference to other sections
See section 8 for more information.
S E C T I O N  7 : H a n d l i n g  a n d  s t o r a g e
Precautions for safe handling
Use personal protective equipment as required. No special handling advices are necessary.
Conditions for safe storage, including any incompatibilities
Keep in a dry, cool and well-ventilated place. Keep in properly labeled containers.
Specific end use(s)
___________________________________________________________________________________________________________________
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For research use only.
Hand protection Wear suitable gloves Glove material: Compatible chemical-resistant gloves.
Eye protection Tight sealing safety goggles
Skin and Body Protection Wear suitable protective clothing
Hygiene measures Handle in accordance with good industrial hygiene and safety practice
Environmental exposure controls
No special environmental precautions required.
S E C T I O N  9 : P h y s i c a l  a n d  c h e m i c a l  p r o p e r t i e s
Information on basic physical and chemical properties
Appearance liquid
Odor No data available
Evaporation rate No data available
Flammability (solid, gas) No data available
Upper explosion limit Mixture has not been tested
Lower explosion limit Mixture has not been tested
Vapor Pressure Mixture has not been tested
Relative density Mixture has not been tested
Specific gravity No data available




Explosive properties Mixture has not been tested
Other information No data available
S E C T I O N  1 0 : S t a b i l i t y  a n d  r e a c t i v i t y
Reactivity None known.
Chemical stability Stable under normal conditions.
Possibility of hazardous
reactions
Hazardous reaction has not been reported.
Conditions to avoid No information available.




Melting point / melting range °C  Mixture has not been tested °F  Mixture has not been tested
Boiling point / boiling range °C  Mixture has not been tested °F  Mixture has not been tested
Flash point °C  Mixture has not been tested °F  Mixture has not been tested
Autoignition Temperature °C  Mixture has not been tested °F  Mixture has not been tested
Decomposition temperature °C  Mixture has not been tested °F  Mixture has not been tested
___________________________________________________________________________________________________________________
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S E C T I O N  1 1 : T o x i c o l o g i c a l  i n f o r m a t i o n
Information on toxicological effects
Chemical Name LD50 (oral,rat/mouse) LD50 (dermal,rat/rabbit) LC50 (inhalation,rat/mouse)
Glycerol = 12600 mg/kg Oral No data available >570mg/m3(Rat)
Ethyl alcohol = 7060 mg/kg (Rat) No data available =124.7mg/L(Rat)
Principal Routes of Exposure
Irritation Conclusive but not sufficient for classification
Corrosivity Conclusive but not sufficient for classification
Sensitization Conclusive but not sufficient for classification
STOT - Single Exposure Conclusive but not sufficient for classification
STOT - Repeated Exposure Conclusive but not sufficient for classification
Carcinogenicity Conclusive but not sufficient for classification
Mutagenicity Conclusive but not sufficient for classification
Reproductive toxicity May cause adverse reproductive effects - such as birth defect, miscarriages, or
infertility
Aspiration hazard Conclusive but not sufficient for classification
S E C T I O N  1 2 : E c o l o g i c a l  i n f o r m a t i o n
Toxicity
The environmental impact of this product has not been fully investigated.
Chemical Name Freshwater Algae
Data
Water Flea Data Freshwater Fish
Species Data
Microtox Data log Pow
Glycerol No data available Daphnia magna
EC50>500 mg/L (24
h)
No data available No data available logPow-1.76
Ethyl alcohol No data available Daphnia magna
EC50=10800 mg/L (24
h) Daphnia magna




No data available No data available logPow-0.32
Persistence and degradability No information available.
Bioaccumulative potential No information available.
Results of PBT and vPvB assessment
No information available.
Other adverse effects No information available.
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S E C T I O N  1 3 : D i s p o s a l  c o n s i d e r a t i o n s
Waste treatment methods
The generation of waste should be avoided or minimized wherever possible. Empty containers or liners may retain
some product residues. This material and its container must be disposed of in according to approved disposal
technique. Disposal of this product, its solutions or of any by-products, shall comply with the requirements of all
applicable local, regional or national/federal regulations
S E C T I O N  1 4 : T r a n s p o r t  i n f o r m a t i o n
IATA / ADR / DOT-US / IMDG
Not regulated in the meaning of transport regulations.
UN number Not Applicable
UN proper shipping name Not Applicable
Transport hazard class(es) Not Applicable
Packing group Not Applicable
Environmental hazards Not Applicable
Special precautions for user Not Applicable
___________________________________________________________________________________________________________________
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Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not Applicable.
S E C T I O N  1 6 : O t h e r  i n f o r m a t i o n
Reason for revision SDS sections updated.
Revision number 2
Revision date 24-May-2017






"The above information was acquired by diligent search and/or investigation and the recommendations are based on
prudent application of professional judgment. The information shall not be taken as being all inclusive and is to be
used only as a guide. All materials and mixtures may present unknown hazards and should be used with caution.
Since the Company cannot control the actual methods, volumes, or conditions of use, the Company shall not be held
liable for any damages or losses resulting from the handling or from contact with the product as described herein.
THE INFORMATION IN THIS SDS DOES NOT CONSTITUTE A WARRANTY, EXPRESSED OR
IMPLIED,INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR
PURPOSE"
End of Safety Data Sheet
S E C T I O N  1 5 : R e g u l a t o r y  i n f o r m a t i o n
Component US TSCA
Glycerol
 56-81-5 ( 60-100 )
Listed
Ethyl alcohol
 64-17-5 ( 0.1-0.49 )
Listed
US Federal Regulations 
SARA 313
This product is not regulated by SARA.
Clean Air Act, Section 112 Hazardous Air Pollutants (HAPs) (see 40 CFR 61)
This product does not contains HAPs.
US State Regulations 
California Proposition 65
This product contains the following Proposition 65 chemicals.
Chemical Name CAS-No Weight % Category 




This product has been classified in accordance with the hazard criteria of the Controlled Products Regulations (CPR) and the
MSDS contains all the information required by the CPR.
___________________________________________________________________________________________________________________
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SECTION 1. IDENTIFICATION 
Product name 
 





Manufacturer or supplier's details 
Company name of supplier 
 








Telephone : +496217590 
Telefax : +496217592890 
Emergency telephone 
In case of emergencies: : CHEMTREC 
 
+1 703-741-5970 / 
1-800-424-9300 
Recommended use of the chemical and restrictions on use 
Restrictions on use 
 
: For professional users only. 
 
 
SECTION 2. HAZARDS IDENTIFICATION 
GHS classification in accordance with 29 CFR 1910.1200 
Acute toxicity (Oral) 
 
: Category 4 
Skin irritation 
 
: Category 2 
Eye irritation 
 
: Category 2A 




















: H302 Harmful if swallowed. 
H315 Causes skin irritation. 




: Prevention:  
P264 Wash skin thoroughly after handling. 
P270 Do not eat, drink or smoke when using this product. 
P280 Wear protective gloves/ eye protection/ face protection. 
Response:  
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P301 + P312 + P330 IF SWALLOWED: Call a POISON 
CENTER/doctor if you feel unwell. Rinse mouth. 
P302 + P352 IF ON SKIN: Wash with plenty of soap and water. 
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water 
for several minutes. Remove contact lenses, if present and easy 
to do. Continue rinsing. 
P332 + P313 If skin irritation occurs: Get medical advice/ atten-
tion. 
P337 + P313 If eye irritation persists: Get medical advice/ atten-
tion. 
P362 Take off contaminated clothing and wash before reuse. 
Disposal:  






SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS 
Substance / Mixture 
 
:  Mixture 
Components 
Chemical name CAS-No. Concentration (% w/w) 
2,3-Butanediol, 1,4-dimercapto-, 
(2R,3R)-rel- 
3483-12-3  <= 100.0 
Actual concentration is withheld as a trade secret 
 
SECTION 4. FIRST AID MEASURES 
General advice 
 
: Move out of dangerous area. 
Show this material safety data sheet to the doctor in atten-
dance. 




: Move to fresh air. 
If unconscious, place in recovery position and seek medical 
advice. 
If symptoms persist, call a physician. 
 
In case of skin contact 
 
: If skin irritation persists, call a physician. 
If on skin, rinse well with water. 
If on clothes, remove clothes. 
 
In case of eye contact 
 
: Immediately flush eye(s) with plenty of water. 
Remove contact lenses. 
Protect unharmed eye. 
Keep eye wide open while rinsing. 
If eye irritation persists, consult a specialist. 
 
If swallowed : Clean mouth with water and drink afterwards plenty of water. 
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 Keep respiratory tract clear. 
Do not give milk or alcoholic beverages. 
Never give anything by mouth to an unconscious person. 
If symptoms persist, call a physician. 
 
Most important symptoms 
and effects, both acute and 
delayed 
 
: Harmful if swallowed. 
Causes skin irritation. 
Causes serious eye irritation. 
 
Notes to physician 
 
: The first aid procedure should be established in consultation 
with the doctor responsible for industrial medicine. 
 
 
SECTION 5. FIRE-FIGHTING MEASURES 
Suitable extinguishing media 
 
: Use extinguishing measures that are appropriate to local cir-





: High volume water jet 
 
Specific hazards during fire 
fighting 
 





:  No hazardous combustion products are known 
 
Further information : Standard procedure for chemical fires. 
Use extinguishing measures that are appropriate to local cir-
cumstances and the surrounding environment. 
 
Special protective equipment 
for fire-fighters 
 
: Wear self-contained breathing apparatus for firefighting if 
necessary. 
 
SECTION 6. ACCIDENTAL RELEASE MEASURES 
Personal precautions, protec-
tive equipment and emer-
gency procedures 
 
: Use personal protective equipment. 
Avoid dust formation. 




: Prevent further leakage or spillage if safe to do so. 
If the product contaminates rivers and lakes or drains inform 
respective authorities. 
 
Methods and materials for 
containment and cleaning up 
 
: Keep in suitable, closed containers for disposal. 
 
SECTION 7. HANDLING AND STORAGE 
Advice on protection against 
fire and explosion 
 
:  Avoid dust formation. 
Provide appropriate exhaust ventilation at places where dust 
is formed. 
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Advice on safe handling 
 
: Avoid formation of respirable particles. 
Do not breathe vapors/dust. 
Avoid contact with skin and eyes. 
For personal protection see section 8. 
Smoking, eating and drinking should be prohibited in the ap-
plication area. 
Dispose of rinse water in accordance with local and national 
regulations. 
 
Conditions for safe storage 
 
: Keep container tightly closed in a dry and well-ventilated pla-
ce. 
Electrical installations / working materials must comply with 
the technological safety standards. 
 
Further information on stor-
age conditions 
 
: See label, package insert or internal guidelines 
 
Further information on stor-
age stability 
 
:  No decomposition if stored and applied as directed. 
 
SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
Ingredients with workplace control parameters 
Contains no substances with occupational exposure limit values. 
Engineering measures : No data available 
 




: Wear appropriate protective gloves to prevent skin contact. 
Replace torn or punctured gloves promptly. 
Eye protection 
 
: Eye wash bottle with pure water 
Tightly fitting safety goggles 
Wear face-shield and protective suit for abnormal processing 
problems. 
 
Skin and body protection 
 
: Choose body protection according to the amount and con-




: When using do not eat or drink. 
When using do not smoke. 
Wash hands before breaks and at the end of workday. 
 










:  characteristic 
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Odor Threshold 
 




: 5.1 (20 °C / 20 °C)  




: 40 - 44 °C / 40 - 44 °C  
 
Boiling point/boiling range 
 




: > 110 °C / 110 °C 
Evaporation rate 
 
:  No data available  
 
Flammability (solid, gas) 
 




: Sustains combustion 
 
Self-ignition : No data available  
 
Upper explosion limit / Upper 
flammability limit 
 
: No data available  
 
Lower explosion limit / Lower 
flammability limit 
 




: No data available  
 
Relative vapor density 
 









: 1,500 g/l soluble  (20 °C / 20 °C) 
 
Solubility in other solvents 
 





: Remarks: No data available 
Autoignition temperature 
 





















: 154.25 g/mol 
 
SECTION 10. STABILITY AND REACTIVITY 
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Reactivity 
 




:  Stable under normal conditions. 
 
Possibility of hazardous reac-
tions 
 
: Keep away from heat and sources of ignition. 
Reacts with the following substances: 
Oxidizing agents 
No decomposition if stored and applied as directed. 
 
Conditions to avoid 
 
: Exposure to moisture. 








:   In case of fire hazardous decomposition products may be 




SECTION 11. TOXICOLOGICAL INFORMATION 
Acute toxicity 
Harmful if swallowed. 
Components: 
2,3-Butanediol, 1,4-dimercapto-, (2R,3R)-rel-: 
Acute oral toxicity :  LD50 Oral (Rat): 400 mg/kg  
 
Acute toxicity (other routes of 
administration) 
:    




Causes skin irritation. 
Product: 
Remarks : May cause skin irritation in susceptible persons. 
 
Components: 
2,3-Butanediol, 1,4-dimercapto-, (2R,3R)-rel-: 
Result : Irritating to skin. 
 
Serious eye damage/eye irritation 
Causes serious eye irritation. 
Product: 
Remarks : May cause irreversible eye damage. 
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Components: 
2,3-Butanediol, 1,4-dimercapto-, (2R,3R)-rel-: 
Result : Irritating to eyes. 
 
Respiratory or skin sensitization 
Skin sensitization 
Not classified based on available information. 
Respiratory sensitization 
Not classified based on available information. 
Germ cell mutagenicity 
Not classified based on available information. 
Carcinogenicity 
Not classified based on available information. 
IARC No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
 
OSHA No component of this product present at levels greater than or equal to 0.1% is 
on OSHA  li  of eg la ed ca cinogen . 
 
NTP No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
 
Reproductive toxicity 
Not classified based on available information. 
STOT-single exposure 
Not classified based on available information. 
STOT-repeated exposure 
Not classified based on available information. 
Aspiration toxicity 
Not classified based on available information. 




Toxicity Data on Soil 
 
:  Not expected to adsorb on soil. 
 
Other organisms relevant to 
the environment 
 
:  No data available 
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Components: 
2,3-Butanediol, 1,4-dimercapto-, (2R,3R)-rel-: 
Ecotoxicology Assessment 
Acute aquatic toxicity 
 
:  This product has no known ecotoxicological effects. 
 
Chronic aquatic toxicity 
 
:  This product has no known ecotoxicological effects. 
 
Toxicity Data on Soil 
 
:  Not expected to adsorb on soil. 
 
Other organisms relevant to 
the environment 
 
:  No data available 
 
Persistence and degradability 
No data available 
Bioaccumulative potential 
Components: 




: log Pow: ca. -0.48 
 
Mobility in soil 
No data available 




: Regulation: 40 CFR Protection of Environment; Part 82 Pro-
tection of Stratospheric Ozone - CAA Section 602 Class I 
Substances 
Remarks: This product neither contains, nor was manufac-
tured with a Class I or Class II ODS as defined by the U.S. 
Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B). 
 
 
SECTION 13. DISPOSAL CONSIDERATIONS 
Disposal methods 
Waste from residues : Do not contaminate ponds, waterways or ditches with chemi-
cal or used container. 
Send to a licensed waste management company. 
 
Contaminated packaging : Empty remaining contents. 
Dispose of as unused product. 
Empty containers should be taken to an approved waste 
handling site for recycling or disposal. 
Do not re-use empty containers. 
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SECTION 14. TRANSPORT INFORMATION 
International Regulations 
UNRTDG  
Not regulated as a dangerous good 
IATA-DGR  
Not regulated as a dangerous good 
IMDG-Code  
Not regulated as a dangerous good 
Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code 
Not applicable 
Domestic regulation 
49 CFR  
Not regulated as a dangerous good 
 
SECTION 15. REGULATORY INFORMATION 
EPCRA - Emergency Planning and Community Right-to-Know 
CERCLA Reportable Quantity 
This material does not contain any components with a CERCLA RQ. 
SARA 304 Extremely Hazardous Substances Reportable Quantity 
This material does not contain any components with a section 304 EHS RQ. 
SARA 302 Extremely Hazardous Substances Threshold Planning Quantity 
Components CAS-No. Component TPQ (lbs) 
SARA 311/312 Hazards 
 
:  Acute toxicity (any route of exposure) 
Skin corrosion or irritation 
Serious eye damage or eye irritation 
 
Clean Air Act 
This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by 
the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B). 
This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean 
Air Act Section 112 (40 CFR 61). 
This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for 
Accidental Release Prevention (40 CFR 68.130, Subpart F). 
This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 
SOCMI Intermediate or Final VOC's (40 CFR 60.489). 
Clean Water Act 
This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, 
Section 311, Table 116.4A. 
This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, 
Section 311, Table 117.3. 
This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 
307 
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US State Regulations 
Massachusetts Right To Know 
Pennsylvania Right To Know 
 2,3-Butanediol, 1,4-dimercapto-, (2R,3R)-rel- 3483-12-3 
Maine Chemicals of High Concern 
Vermont Chemicals of High Concern 
Washington Chemicals of High Concern 
The ingredients of this product are reported in the following inventories: 
DSL 
 




































: All substances listed as active on the TSCA inventory 
 
TSCA list 
No substances are subject to a Significant New Use Rule. 
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SECTION 16. OTHER INFORMATION 
Further information 
























HMIS® ratings are based on a 0-4 rating 
scale, with 0 representing minimal haz-
ards or risks, and 4 representing signifi-
cant hazards or risks. The "*" represents 
a chronic hazard, while the "/" represents 




3050 Spruce Street 
SAINT LOUIS 
MO 63103 USA 
Full text of other abbreviations 
 
AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of 
Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, 
and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the 
German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Sub-
stances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Haz-
ardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; 
ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with 
x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized Sys-
tem; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - 
International Agency for Research on Cancer; IATA - International Air Transport Association; IBC 
- International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals 
in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organiza-
tion; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime 
Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health 
Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemi-
cals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 
50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Pre-
vention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Oth-
erwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) 
Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable 
Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of 
Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office 
of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic sub-
stance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quanti-
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REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concern-
ing the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable 
Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amend-
ments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance 
Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - 
United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent 




Revision Date :  04-17-2019 
 
 
The information provided in this Material Safety Data Sheet is correct to the best of our 
knowledge, information and belief at the date of its publication. The information given is designed 
only as a guidance for safe handling, use, processing, storage, transportation, disposal and re-
lease and is not to be considered a warranty or quality specification. The information relates only 
to the specific material designated and may not be valid for such material used in combination 
with any other materials or in any process, unless specified in the text. 
 
US / Z8 / 1805 
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SAFETY DATA SHEET 
 
Version 6.2 
Revision Date 01/13/2020 
Print Date 11/20/2020 
 
SECTION 1: Identification of the substance/mixture and of the company/undertaking 
1.1 Product identifiers 
Product name : Ethylenediaminetetraacetic acid 
 
Product Number : E6758 
Brand : Sigma 
Index-No. : 607-429-00-8 
CAS-No. : 60-00-4 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich Inc. 
3050 Spruce Street 
ST. LOUIS MO  63103 
UNITED STATES 
 
Telephone : +1 314 771-5765 
Fax : +1 800 325-5052 
1.4 Emergency telephone number 
Emergency Phone # : 800-424-9300 CHEMTREC (USA) +1-703-
527-3887 CHEMTREC (International) 24 
Hours/day; 7 Days/week 
 
 
SECTION 2: Hazards identification 
2.1 Classification of the substance or mixture 
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) 
Eye irritation (Category 2A), H319 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
2.2 GHS Label elements, including precautionary statements 
Pictogram 
  
Signal word Warning 
 
Hazard statement(s) 
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P264 Wash skin thoroughly after handling. 
P280 Wear eye protection/ face protection. 
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. 
Remove contact lenses, if present and easy to do. Continue 
rinsing. 
P337 + P313 If eye irritation persists: Get medical advice/ attention. 
 




SECTION 3: Composition/information on ingredients 
3.1 Substances 





Formula : C10H16N2O8 
Molecular weight : 292.24 g/mol 
CAS-No. : 60-00-4 
EC-No. : 200-449-4 
Index-No. : 607-429-00-8 
 
Component Classification Concentration 
Edetic acid 
   Eye Irrit. 2A; Aquatic 
Acute 3; H319, H402 
<= 100 % 
 




SECTION 4: First aid measures 
4.1 Description of first aid measures 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of 
dangerous area. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Consult a physician. 
In case of eye contact 
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. 
If swallowed 
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4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 
2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 




SECTION 5: Firefighting measures 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
Carbon oxides, Nitrogen oxides (NOx) 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 




SECTION 6: Accidental release measures 
6.1 Personal precautions, protective equipment and emergency procedures 
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist 
or gas. Ensure adequate ventilation. Avoid breathing dust. 
For personal protection see section 8. 
6.2 Environmental precautions 
Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in 
suitable, closed containers for disposal. 
6.4 Reference to other sections 




SECTION 7: Handling and storage 
7.1 Precautions for safe handling 
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.Further processing 
of solid materials may result in the formation of combustible dusts. The potential for 
combustible dust formation should be taken into consideration before additional processing 
occurs. 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Storage class (TRGS 510): 13: Non Combustible Solids 
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7.3 Specific end use(s) 




SECTION 8: Exposure controls/personal protection 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
Hazardous components without workplace control parameters 
8.2 Exposure controls 
Appropriate engineering controls 
Handle in accordance with good industrial hygiene and safety practice. Wash hands 
before breaks and at the end of workday. 
Personal protective equipment 
Eye/face protection 
Safety glasses with side-shields conforming to EN166 Use equipment for eye 
protection tested and approved under appropriate government standards such as 
NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove 
removal technique (without touching glove's outer surface) to avoid skin contact 
with this product. Dispose of contaminated gloves after use in accordance with 
applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail 
sales@kcl.de, test method: EN374 
If used in solution, or mixed with other substances, and under conditions which 
differ from EN 374, contact the supplier of the CE approved gloves. This 
recommendation is advisory only and must be evaluated by an industrial hygienist 
and safety officer familiar with the specific situation of anticipated use by our 




Impervious clothing, The type of protective equipment must be selected according 
to the concentration and amount of the dangerous substance at the specific 
workplace. 
Respiratory protection 
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle 
respirator.For higher level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU 
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EN 143) respirator cartridges. Use respirators and components tested and approved 
under appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Do not let product enter drains. 
 
 
SECTION 9: Physical and chemical properties 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: crystalline 
Colour: white 
b) Odour odourless 
c) Odour Threshold No data available 
d) pH 2.5 at 10 g/l at 23 °C (73 °F) 
e) Melting 
point/freezing point 
Melting point/range: 250 °C (482 °F) - dec. 
f) Initial boiling point 
and boiling range 
No data available 
g) Flash point  ()No data available 
h) Evaporation rate No data available 
i) Flammability (solid, 
gas) 




No data available 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density 1.46 g/cm3 at 20 °C (68 °F) 
n) Water solubility 0.4 g/l at 20 °C (68 °F) 
o) Partition coefficient: 
n-octanol/water 
log Pow: 8.85 - 10.44 at 20 °C (68 °F) 
p) Auto-ignition 
temperature 
> 400 °C (> 752 °F) at 1,013 hPa 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
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SECTION 10: Stability and reactivity 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen 
oxides (NOx) 
Other decomposition products - No data available 




SECTION 11: Toxicological information 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - male and female - 4,500 mg/kg 
(OECD Test Guideline 401) 
Inhalation: No data available 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
Skin - Rabbit 
Result: No skin irritation - 20 h 
Remarks: (ECHA) 
Serious eye damage/eye irritation 
Eyes - Rabbit 
Result: Eye irritation 
Remarks: (ECHA) 
Respiratory or skin sensitisation 
Maximisation Test - Guinea pig 
Result: negative 
(OECD Test Guideline 406) 
Remarks: (in analogy to similar products) 
Maximisation Test - Rabbit 
Result: Does not cause skin sensitisation. 
Germ cell mutagenicity 
No data available 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
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NTP: No component of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is 
on OSHA  li  of eg la ed ca cinogen . 
Reproductive toxicity 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 




To the best of our knowledge, the chemical, physical, and toxicological properties have not 





SECTION 12: Ecological information 
12.1 Toxicity 
 




Toxicity to daphnia 
and other aquatic 
invertebrates 
static test EC50 - Daphnia magna (Water flea) - 625 mg/l  - 24 h 
(DIN 38412) 
12.2 Persistence and degradability 
Biodegradability aerobic  - Exposure time 20 d 
Result: 0 - 20 % - Not readily biodegradable.  
Remarks: (ECHA) 
 
Ratio BOD/ThBOD < 1 % 
Remarks: (IUCLID) 
12.3 Bioaccumulative potential 
Bioaccumulation Lepomis macrochirus - 28 d 
at 21 °C - 80 µg/l(Edetic acid) 
 
Bioconcentration factor (BCF): 1.8 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
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12.6 Other adverse effects 





SECTION 13: Disposal considerations 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a 
licensed professional waste disposal service to dispose of this material.  
Contaminated packaging 




SECTION 14: Transport information 
DOT (US) 
UN number: 3077 Class: 9 Packing group: III 
Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Edetic acid) 
Reportable Quantity (RQ): 5000 lbs 
Poison Inhalation Hazard: No 
 
IMDG 
Not dangerous goods 
 
IATA 




SECTION 15: Regulatory information 
 
SARA 302 Components 
This material does not contain any components with a section 302 EHS TPQ. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that 
exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 
313. 
SARA 311/312 Hazards 
Acute Health Hazard 









Pennsylvania Right To Know Components 





California Prop. 65 Components 
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This product does not contain any chemicals known to State of California to cause cancer, 




SECTION 16: Other information 
Further information 
Copyright 2020 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies 
for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive 
and shall be used only as a guide. The information in this document is based on the 
present state of our knowledge and is applicable to the product with regard to 
appropriate safety precautions. It does not represent any guarantee of the properties of 
the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any 
damage resulting from handling or from contact with the above product. See 
www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional 
terms and conditions of sale. 
 
The branding on the header and/or footer of this document may temporarily not visually 
match the product purchased as we transition our branding. However, all of the 
information in the document regarding the product remains unchanged and matches the 
product ordered. For further information please contact mlsbranding@sial.com. 
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SAFETY DATA SHEET 
 
Version 6.4 
Revision Date 05/11/2020 
Print Date 11/20/2020 
 
SECTION 1: Identification of the substance/mixture and of the company/undertaking 
1.1 Product identifiers 
Product name : Ethyl alcohol, pure 
 
Product Number : E7023 
Brand : SIGALD 
Index-No. : 603-002-00-5 
CAS-No. : 64-17-5 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich Inc. 
3050 Spruce Street 
ST. LOUIS MO  63103 
UNITED STATES 
 
Telephone : +1 314 771-5765 
Fax : +1 800 325-5052 
1.4 Emergency telephone number 
Emergency Phone # : 800-424-9300 CHEMTREC (USA) +1-703-
527-3887 CHEMTREC (International) 24 
Hours/day; 7 Days/week 
 
 
SECTION 2: Hazards identification 
2.1 Classification of the substance or mixture 
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) 
Flammable liquids (Category 2), H225 
Eye irritation (Category 2A), H319 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
2.2 GHS Label elements, including precautionary statements 
Pictogram 
  
Signal word Danger 
 
Hazard statement(s) 
H225 Highly flammable liquid and vapour. 
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H319 Causes serious eye irritation. 
 
Precautionary statement(s) 
P210 Keep away from heat/sparks/open flames/hot surfaces. No 
smoking. 
P233 Keep container tightly closed. 
P240 Ground/bond container and receiving equipment. 
P241 Use explosion-proof electrical/ ventilating/ lighting equipment. 
P242 Use only non-sparking tools. 
P243 Take precautionary measures against static discharge. 
P264 Wash skin thoroughly after handling. 
P280 Wear protective gloves/ eye protection/ face protection. 
P303 + P361 + P353 IF ON SKIN (or hair): Take off immediately all contaminated 
clothing. Rinse skin with water/shower. 
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. 
Remove contact lenses, if present and easy to do. Continue 
rinsing. 
P337 + P313 If eye irritation persists: Get medical advice/ attention. 
P370 + P378 In case of fire: Use dry sand, dry chemical or alcohol-resistant 
foam to extinguish. 
P403 + P235 Store in a well-ventilated place. Keep cool. 
P501 Dispose of contents/ container to an approved waste disposal 
plant. 
 




SECTION 3: Composition/information on ingredients 
3.1 Substances 
Synonyms : Absolute alcohol 
 
Formula : C2H6O 
Molecular weight : 46.07 g/mol 
CAS-No. : 64-17-5 
EC-No. : 200-578-6 
Index-No. : 603-002-00-5 
 
Component Classification Concentration 
ethanol 
   Flam. Liq. 2; Eye Irrit. 2A; 
H225, H319 
<= 100 % 
 




SECTION 4: First aid measures 
4.1 Description of first aid measures 
General advice 
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If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Consult a physician. 
In case of eye contact 
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. 
If swallowed 
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse 
mouth with water. Consult a physician. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 
2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 




SECTION 5: Firefighting measures 
5.1 Extinguishing media 
Suitable extinguishing media 
Dry powder Dry sand 
Unsuitable extinguishing media 
Do NOT use water jet. 
5.2 Special hazards arising from the substance or mixture 
Carbon oxides 
Combustible. 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 




SECTION 6: Accidental release measures 
6.1 Personal precautions, protective equipment and emergency procedures 
Use personal protective equipment. Avoid breathing vapours, mist or gas. Ensure 
adequate ventilation. Remove all sources of ignition. Evacuate personnel to safe areas. 
Beware of vapours accumulating to form explosive concentrations. Vapours can 
accumulate in low areas. 
For personal protection see section 8. 
6.2 Environmental precautions 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Contain spillage, and then collect with non-combustible absorbent material, (e.g. sand, 
earth, diatomaceous earth, vermiculite) and place in container for disposal according to 
local / national regulations (see section 13). 
 
 




The life science business of Merck KGaA, Darmstadt, Germany 






6.4 Reference to other sections 




SECTION 7: Handling and storage 
7.1 Precautions for safe handling 
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist. 
Use explosion-proof equipment.Keep away from sources of ignition - No smoking.Take 
measures to prevent the build up of electrostatic charge. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place. Containers which are 
opened must be carefully resealed and kept upright to prevent leakage.  
Hygroscopic.  
Storage class (TRGS 510): 3: Flammable liquids 
7.3 Specific end use(s) 




SECTION 8: Exposure controls/personal protection 
8.1 Control parameters 
Components with workplace control parameters 







TWA 1,000 ppm  
1,900 mg/m3 
USA. OSHA - TABLE Z-1 Limits 
for Air Contaminants - 
1910.1000 
  TWA 1,000 ppm  
1,900 mg/m3 
USA. Occupational Exposure 
Limits (OSHA) - Table Z-1 
Limits for Air Contaminants 
 Remarks The value in mg/m3 is approximate. 
  STEL 1,000 ppm  
 
USA. ACGIH Threshold Limit 
Values (TLV) 
  Upper Respiratory Tract irritation 
Confirmed animal carcinogen with unknown relevance to 
humans 
  TWA 1,000 ppm  
1,900 mg/m3 
USA. NIOSH Recommended 
Exposure Limits 
  PEL 1,000 ppm  
1,900 mg/m3 
California permissible exposure 
limits for chemical 
contaminants (Title 8, Article 
107) 
8.2 Exposure controls 
Appropriate engineering controls 
Handle in accordance with good industrial hygiene and safety practice. Wash hands 
before breaks and at the end of workday. 
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Personal protective equipment 
Eye/face protection 
Face shield and safety glasses Use equipment for eye protection tested and 
approved under appropriate government standards such as NIOSH (US) or EN 
166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove 
removal technique (without touching glove's outer surface) to avoid skin contact 
with this product. Dispose of contaminated gloves after use in accordance with 




Minimum layer thickness: 0.3 mm 
Break through time: 480 min 
Material tested:Butoject® (KCL 897 / Aldrich Z677647, Size M)  
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.2 mm 
Break through time: 38 min 
Material tested:Dermatril® P (KCL 743 / Aldrich Z677388, Size M)  
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail 
sales@kcl.de, test method: EN374 
If used in solution, or mixed with other substances, and under conditions which 
differ from EN 374, contact the supplier of the CE approved gloves. This 
recommendation is advisory only and must be evaluated by an industrial hygienist 
and safety officer familiar with the specific situation of anticipated use by our 
customers. It should not be construed as offering an approval for any specific use 
scenario.  
Body Protection 
Impervious clothing, Flame retardant antistatic protective clothing., The type of 
protective equipment must be selected according to the concentration and amount 
of the dangerous substance at the specific workplace. 
Respiratory protection 
Where risk assessment shows air-purifying respirators are appropriate use a full-
face respirator with multi-purpose combination (US) or type ABEK (EN 14387) 
respirator cartridges as a backup to engineering controls. If the respirator is the sole 
means of protection, use a full-face supplied air respirator. Use respirators and 
components tested and approved under appropriate government standards such as 
NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. 
 
 
SECTION 9: Physical and chemical properties 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: liquid 
Colour: colourless 
b) Odour pungent 
c) Odour Threshold No data available 
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d) pH 7.0 at 10 g/l at 20 °C (68 °F) 
e) Melting 
point/freezing point 
Melting point/freezing point: -144.0 °C (-227.2 °F) at 1,013.25 
hPa 
f) Initial boiling point 
and boiling range 
78.29 °C 172.92 °F at 1,013 hPa 
g) Flash point 13 °C (55 °F) - closed cup 
h) Evaporation rate No data available 
i) Flammability (solid, 
gas) 




Upper explosion limit: 13.5 %(V) 
Lower explosion limit: 2.5 %(V) 
k) Vapour pressure 0.57 hPa at 19.6 °C (67.3 °F) 
l) Vapour density 1.6 
m) Relative density 0.79 g/cm3 at 20 °C (68 °F) 
n) Water solubility 1,000 g/l at 20 °C (68 °F) - completely miscible 
o) Partition coefficient: 
n-octanol/water 




455 °C (851 °F) at 1,013 hPa - DIN 51794 
q) Decomposition 
temperature 
Distillable in an undecomposed state at normal pressure. 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
 Conductivity < 1 µS/cm 
 Surface tension 72.75 mN/m at 20 °C (68 °F) 






SECTION 10: Stability and reactivity 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
Vapours may form explosive mixture with air. 
10.4 Conditions to avoid 
Heat, flames and sparks. 
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10.5 Incompatible materials 
rubber, various plastics 
10.6 Hazardous decomposition products 
Other decomposition products - No data available 
Hazardous decomposition products formed under fire conditions. - Carbon oxides 




SECTION 11: Toxicological information 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - male and female - 10,470 mg/kg 
(OECD Test Guideline 401) 
LC50 Inhalation - Rat - male and female - 4 h - 124.7 mg/l 
(OECD Test Guideline 403) 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
Skin - Rabbit 
Result: No skin irritation - 24 h 
(OECD Test Guideline 404) 
Serious eye damage/eye irritation 
Eyes - Rabbit 
Result: Causes serious eye irritation. 
(OECD Test Guideline 405) 
Respiratory or skin sensitisation 
Maximisation Test - Guinea pig 
Result: negative 
(OECD Test Guideline 406) 
Remarks: (in analogy to similar products) 
Germ cell mutagenicity 
Ames test 
Salmonella typhimurium  
Result: negative 
In vitro mammalian cell gene mutation test 
mouse lymphoma cells  
Result: negative 
OECD Test Guideline 478 
Mouse - male 
Result: Positive results were obtained in some in vivo tests. 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
NTP: No component of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is 
on OSHA  li  of eg la ed ca cinogen . 
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No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
Repeated dose toxicity - Rat - male - Oral - No observed adverse effect level - 1,730 mg/kg 
- Lowest observed adverse effect level - 3,200 mg/kg 
RTECS: KQ6300000 
 
irritant effects, respiratory paralysis, Dizziness, narcosis, inebriation, euphoria, Nausea, 
Vomiting 
To the best of our knowledge, the chemical, physical, and toxicological properties have not 
been thoroughly investigated. 
 
Stomach - Irregularities - Based on Human Evidence 




SECTION 12: Ecological information 
12.1 Toxicity 
 
Toxicity to fish flow-through test LC50 - Pimephales promelas (fathead minnow) - 
15,300 mg/l  - 96 h 
(US-EPA) 
 
Toxicity to daphnia 
and other aquatic 
invertebrates 




Toxicity to algae static test ErC50 - Chlorella vulgaris (Fresh water algae) - 275 mg/l  
- 72 h 
(OECD Test Guideline 201) 
 
Toxicity to bacteria static test IC50 - activated sludge - > 1,000 mg/l  - 3 h 
(OECD Test Guideline 209) 
12.2 Persistence and degradability 
Biodegradability aerobic  - Exposure time 15 d 
Result: ca.95 % - Readily biodegradable.  











12.3 Bioaccumulative potential 
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12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not 
conducted 








SECTION 13: Disposal considerations 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company. Burn in a 
chemical incinerator equipped with an afterburner and scrubber but exert extra care in 
igniting as this material is highly flammable. Contact a licensed professional waste 
disposal service to dispose of this material.  
Contaminated packaging 




SECTION 14: Transport information 
DOT (US) 
UN number: 1170 Class: 3 Packing group: II 
Proper shipping name: Ethanol 
Reportable Quantity (RQ):   
Poison Inhalation Hazard: No 
 
IMDG 
UN number: 1170 Class: 3 Packing group: II EMS-No: F-E, S-D 
Proper shipping name: ETHANOL 
 
IATA 
UN number: 1170 Class: 3 Packing group: II 
Proper shipping name: Ethanol 
 
 
SECTION 15: Regulatory information 
 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, 
Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that 
exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 
313. 
SARA 311/312 Hazards 
Fire Hazard, Acute Health Hazard, Chronic Health Hazard 
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No components are subject to the Massachusetts Right to Know Act. 






















SECTION 16: Other information 
Further information 
Copyright 2020 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies 
for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive 
and shall be used only as a guide. The information in this document is based on the 
present state of our knowledge and is applicable to the product with regard to 
appropriate safety precautions. It does not represent any guarantee of the properties of 
the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any 
damage resulting from handling or from contact with the above product. See 
www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional 
terms and conditions of sale. 
 
The branding on the header and/or footer of this document may temporarily not visually 
match the product purchased as we transition our branding. However, all of the 
information in the document regarding the product remains unchanged and matches the 
product ordered. For further information please contact mlsbranding@sial.com. 
 




S E C T I O N  2 : H a z a r d s  i d e n t i f i c a t i o n
Not Hazardous
GHS - Classification 
Principle Routes of Exposure 
Potential Health Effects  





For research use only. Not intended for human or animal diagnostic or therapeutic uses.
Not Hazardous
Identification of the substance or mixture  




Outside of the U.S. +1-301-431-8585
Product code 11344041
Company/undertaking identification  
Country specific Emergency Number (if available):
S E C T I O N  1 : I d e n t i f i c a t i o n  o f  t h e  s u b s t a n c e / m i x t u r e  a n d  o f  t h e  c o m p a n y /u n d e r t a k i n g
11344041
Revision date
Product name  HEPES
Product name












5791 Van Allen Way
PO Box 6482
Carlsbad, CA 92008
+1 760 603 7200
CHEMTREC Brazil (Rio De Janeiro)
Specific effects 
S E C T I O N  5 : F i r e f i g h t i n g  m e a s u r e s
Suitable extinguishing media Water spray. Carbon dioxide (CO2). Foam. Dry chemical.
Target Organ Effects No known effects under normal use conditions
Special protective equipment for firefighters Wear self-contained breathing apparatus and protective
suit.
May cause skin irritation in susceptible persons.
S E C T I O N  6 : A c c i d e n t a l  r e l e a s e  m e a s u r e s
Carcinogenic effects None
Personal precautions Use personal protection equipment.
HMIS 
Methods for cleaning up Take up mechanically, placing in appropriate containers for disposal.
Ingestion
Mutagenic effects
Environmental precautions  
None
May be harmful if swallowed.
Prevent further leakage or spillage if safe to do so.
Skin
S E C T I O N  4 : F i r s t  a i d  m e a s u r e s
Reproductive toxicity None
Skin contact Rinse cautiously with water for several minutes. If symptoms occur, obtain medical
advice.
Eye contact Rinse immediately with plenty of water, also under the eyelids, for at least 15
minutes. If symptoms persist, call a physician.
Ingestion Never give anything by mouth to an unconscious person. If symptoms persist, call
a physician. Do not induce vomiting without medical advice.
Sensitization None
inhalation Remove to fresh air. If symptoms persist, call a physician. If not breathing, give
artificial respiration.
inhalation May be harmful by inhalation.
Notes to Physician Treat symptomatically.
60-100
________________________________________________________________________________________________________________
The product contains no substances which at their given concentration, are considered to be hazardous to health.




Product name  HEPES
Health
Page  2 / 5
0










Hand protection Impervious gloves.
None None
Eye protection Wear safety glasses with side shields (or goggles).
None
Skin and Body Protection Lightweight protective clothing.





Oxidizing properties No information available
Prevent product from entering drains.
Ensure adequate ventilation, especially in confined areas.
Water solubility No data available
Keep in a dry, cool and well-ventilated place.
Viscosity No data available
Exposure Limits  
S E C T I O N  7 : H a n d l i n g  a n d  s t o r a g e
See Section 12 for more information.
S E C T I O N  1 0 : S t a b i l i t y  a n d  r e a c t i v i t y
S E C T I O N  9 : P h y s i c a l  a n d  c h e m i c a l  p r o p e r t i e s
Personal Protective Equipment 
Stability Stable under normal conditions.




None under normal use conditions.
Personal Protective Equipment requirements are dependent on the user institution's risk assessment and are specific





Appearance No information available
OSHA PEL (Ceiling)
Odor No data available
________________________________________________________________________________________________________________
Respiratory protection In case of insufficient ventilation, wear suitable respiratory equipment.
Odor Threshold No data available
ACGIH OEL (TWA) ACGIH OEL (STEL)
Always wear reccommended Personal Protective Equipment. No special handling
advices are necessary.
11344041
S E C T I O N  8 : E x p o s u r e  c o n t r o l s /p e r s o n a l  p r o t e c t i o n
Revision date
°C  No data available
Product name  HEPES
°F  No data available
Page  3 / 5
°C  No data available
°F  No data available
°F  No data available
Melting point / melting range
06-Apr-2015
°C  No data available
Autoignition Temperature
www.lifetechnologies.com
°C  No data available
Boiling point / boiling range
Product code
°F  No data available
flash point
May be harmful by inhalation
LD50 (dermal,rat/rabbit)
Bioaccumulation Material does not bioaccumulate
LC50 (inhalation,rat/mouse)
Ingestion May be harmful if swallowed
Acute Toxicity  
HEPES
S E C T I O N  1 3 : D i s p o s a l  c o n s i d e r a t i o n s
No data available
Carcinogenic effects None
Dispose of contents/containers in accordance with local regulations.
No data available No data available
Mutagenic effects











Principle Routes of Exposure 
Potential Health Effects 
UN-No None
Target Organ Effects No known effects under normal use conditions
________________________________________________________________________________________________________________
eyes May cause eye irritation with susceptible persons
Hazardous polymerization does not occur.
S E C T I O N  1 2 : E c o l o g i c a l  i n f o r m a t i o n




Product name  HEPES
May cause skin irritation in susceptible persons
Page  4 / 5
Ecotoxicity No information available
Chemical Name LD50 (oral,rat/mouse)
06-Apr-2015





Reason for revision SDS sections updated.
"The above information was acquired by diligent search and/or investigation and the recommendations are based on
prudent application of professional judgment. The information shall not be taken as being all inclusive and is to be
used only as a guide. All materials and mixtures may present unknown hazards and should be used with caution.
Since the Company cannot control the actual methods, volumes, or conditions of use, the Company shall not be held
liable for any damages or losses resulting from the handling or from contact with the product as described herein.
THE INFORMATION IN THIS SDS DOES NOT CONSTITUTE A WARRENTY, EXPRESSED OR IMPLIED,
INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PUPOSE"
S E C T I O N  1 6 : O t h e r  i n f o r m a t i o n
End of Safety Data Sheet
For research use only. Not intended for human or animal diagnostic or therapeutic uses.
US Federal Regulations 
WHMIS Hazard Class
Non-controlled
S E C T I O N  1 5 : R e g u l a t o r y  i n f o r m a t i o n
This product has been classified in accordance with the hazard criteria of the Controlled Products Regulations (CPR) and the
MSDS contains all the information required by the CPR.
HEPES
 7365-45-9 ( 60-100 )




This product is not regulated by SARA.
Component





Product name  HEPES
-





Clean Air Act, Section 112 Hazardous Air Pollutants (HAPs) (see 40 CFR 61)
This product does not contains HAPs.
Product code
California Proposition 65
This product does not contain any Proposition 65 chemicals.
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SAFETY DATA SHEET 
 
Version 6.5 
Revision Date 04/20/2020 
Print Date 11/20/2020 
 
SECTION 1: Identification of the substance/mixture and of the company/undertaking 
1.1 Product identifiers 
Product name : Magnesium chloride 
 
Product Number : M8266 
Brand : Sigma 
CAS-No. : 7786-30-3 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich Inc. 
3050 Spruce Street 
ST. LOUIS MO  63103 
UNITED STATES 
 
Telephone : +1 314 771-5765 
Fax : +1 800 325-5052 
1.4 Emergency telephone number 
Emergency Phone # : 800-424-9300 CHEMTREC (USA) +1-703-
527-3887 CHEMTREC (International) 24 
Hours/day; 7 Days/week 
 
 
SECTION 2: Hazards identification 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 




SECTION 3: Composition/information on ingredients 
3.1 Substances 
Formula : Cl2Mg 
Molecular weight : 95.21 g/mol 
CAS-No. : 7786-30-3 
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EC-No. : 232-094-6 
 




SECTION 4: First aid measures 
4.1 Description of first aid measures 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
In case of skin contact 
Wash off with soap and plenty of water. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 
2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 




SECTION 5: Firefighting measures 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 




SECTION 6: Accidental release measures 
6.1 Personal precautions, protective equipment and emergency procedures 
Avoid dust formation. Avoid breathing vapours, mist or gas. 
For personal protection see section 8. 
6.2 Environmental precautions 
No special environmental precautions required. 
6.3 Methods and materials for containment and cleaning up 
Sweep up and shovel. Keep in suitable, closed containers for disposal. 
6.4 Reference to other sections 
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SECTION 7: Handling and storage 
7.1 Precautions for safe handling 
Further processing of solid materials may result in the formation of combustible dusts. The 
potential for combustible dust formation should be taken into consideration before 
additional processing occurs. 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Store under inert gas. Hygroscopic.  
Storage class (TRGS 510): 13: Non Combustible Solids 
7.3 Specific end use(s) 




SECTION 8: Exposure controls/personal protection 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
General industrial hygiene practice. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate 
government standards such as NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove 
removal technique (without touching glove's outer surface) to avoid skin contact 
with this product. Dispose of contaminated gloves after use in accordance with 
applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail 
sales@kcl.de, test method: EN374 
If used in solution, or mixed with other substances, and under conditions which 
differ from EN 374, contact the supplier of the CE approved gloves. This 
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recommendation is advisory only and must be evaluated by an industrial hygienist 
and safety officer familiar with the specific situation of anticipated use by our 




Choose body protection in relation to its type, to the concentration and amount of 
dangerous substances, and to the specific work-place., The type of protective 
equipment must be selected according to the concentration and amount of the 
dangerous substance at the specific workplace. 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of 
dusts are desired, use type N95 (US) or type P1 (EN 143) dust masks. Use 
respirators and components tested and approved under appropriate government 
standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
No special environmental precautions required. 
 
 
SECTION 9: Physical and chemical properties 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: crystalline 
Colour: white 
b) Odour odourless 
c) Odour Threshold No data available 
d) pH No data available 
e) Melting 
point/freezing point 
Melting point/range: 714 °C (1317 °F) 
f) Initial boiling point 
and boiling range 
1,412 °C 2,574 °F 
g) Flash point  ()No data available 
h) Evaporation rate No data available 
i) Flammability (solid, 
gas) 




No data available 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density 2.32 g/mL at 25 °C (77 °F) 
n) Water solubility 468.7 g/l at 20 °C (68 °F) - soluble 
o) Partition coefficient: 
n-octanol/water 
No data available 
p) Auto-ignition 
temperature 
> 404 °C (> 759 °F) - Regulation (EC) No. 440/2008, Annex, 
A.16 
q) Decomposition No data available 
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r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 




SECTION 10: Stability and reactivity 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
When mixed with limited amount of water enough heat may be generated to cause 
frothing. Exposure to moisture 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Other decomposition products - No data available 




SECTION 11: Toxicological information 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - female - > 5,000 mg/kg 
(OECD Test Guideline 423) 
Inhalation: No data available 
LD50 Dermal - Rat - male and female - > 2,000 mg/kg 
(OECD Test Guideline 402) 
No data available 
Skin corrosion/irritation 
Skin - In vitro study 
Result: No skin irritation - 15 min 
(Human Skin Model Test) 
Remarks: (for the hexahydrate) 
Serious eye damage/eye irritation 
Eyes - Rabbit 
Result: No eye irritation - 72 h 
(OECD Test Guideline 405) 
Remarks: (for the hexahydrate) 
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Respiratory or skin sensitisation 
Maximisation Test - Guinea pig 
Result: negative 
(OECD Test Guideline 406) 
Germ cell mutagenicity 





IARC: No component of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
NTP: No component of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is 
on OSHA  li  of eg la ed ca cinogen . 
Reproductive toxicity 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
Repeated dose toxicity - Rat - male and female - Oral - No observed adverse effect level - 
> 1,000 mg/kg 
RTECS: OM2800000 
 
Central nervous system depression, Vomiting, Diarrhoea, Abdominal pain, To the best of 
our knowledge, the chemical, physical, and toxicological properties have not been 
thoroughly investigated. 
 
Stomach - Irregularities - Based on Human Evidence 




SECTION 12: Ecological information 
12.1 Toxicity 
 
Toxicity to fish static test LC50 - Pimephales promelas (fathead minnow) - 2,119.3 
mg/l  - 96 h 
(US-EPA) 
 
Toxicity to daphnia 
and other aquatic 
invertebrates 
static test LC50 - Daphnia magna (Water flea) - 548.4 mg/l  - 48 h 
 
Toxicity to algae Growth rate EC50 - Desmodesmus subspicatus (green algae) - > 100 
mg/l  - 72 h 
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(OECD Test Guideline 201) 
 
Toxicity to bacteria static test EC50 - activated sludge - > 900 mg/l  - 3 h 
(OECD Test Guideline 209) 
12.2 Persistence and degradability 
The methods for determining the biological degradability are not applicable to inorganic 
substances. 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not 
conducted 
12.6 Other adverse effects 




SECTION 13: Disposal considerations 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a 
licensed professional waste disposal service to dispose of this material.  
Contaminated packaging 




SECTION 14: Transport information 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 




SECTION 15: Regulatory information 
 
SARA 302 Components 
This material does not contain any components with a section 302 EHS TPQ. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that 
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Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 





New Jersey Right To Know Components 









SECTION 16: Other information 
Further information 
Copyright 2020 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies 
for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive 
and shall be used only as a guide. The information in this document is based on the 
present state of our knowledge and is applicable to the product with regard to 
appropriate safety precautions. It does not represent any guarantee of the properties of 
the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any 
damage resulting from handling or from contact with the above product. See 
www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional 
terms and conditions of sale. 
 
The branding on the header and/or footer of this document may temporarily not visually 
match the product purchased as we transition our branding. However, all of the 
information in the document regarding the product remains unchanged and matches the 
product ordered. For further information please contact mlsbranding@sial.com. 
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SAFETY DATA SHEET 
 
Version 6.5 
Revision Date 10/07/2020 
Print Date 11/20/2020 
 
SECTION 1: Identification of the substance/mixture and of the company/undertaking 
1.1 Product identifiers 
Product name : Sodium chloride 
 
Product Number : S9888 
Brand : SIGALD 
CAS-No. : 7647-14-5 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich Inc. 
3050 Spruce Street 
ST. LOUIS MO  63103 
UNITED STATES 
 
Telephone : +1 314 771-5765 
Fax : +1 800 325-5052 
1.4 Emergency telephone 
Emergency Phone # : 800-424-9300 CHEMTREC (USA) +1-703-
527-3887 CHEMTREC (International) 24 
Hours/day; 7 Days/week 
 
 
SECTION 2: Hazards identification 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 




SECTION 3: Composition/information on ingredients 
3.1 Substances 
Formula : ClNa 
Molecular weight : 58.44 g/mol 
CAS-No. : 7647-14-5 
EC-No. : 231-598-3 
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SECTION 4: First aid measures 
4.1 Description of first-aid measures 
If inhaled 
After inhalation: fresh air. 
In case of skin contact 
In case of skin contact: Take off immediately all contaminated clothing. Rinse skin with 
water/ shower. 
In case of eye contact 
After eye contact: rinse out with plenty of water. Remove contact lenses. 
If swallowed 
After swallowing: make victim drink water (two glasses at most). Consult doctor if feeling 
unwell. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 
2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 




SECTION 5: Firefighting measures 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
Hydrogen chloride gas, Sodium oxides 
Not combustible. 
Ambient fire may liberate hazardous vapours. 
5.3 Advice for firefighters 
In the event of fire, wear self-contained breathing apparatus. 
5.4 Further information 
Suppress (knock down) gases/vapors/mists with a water spray jet. Prevent fire 




SECTION 6: Accidental release measures 
6.1 Personal precautions, protective equipment and emergency procedures 
Advice for non-emergency personnel: Avoid inhalation of dusts. Evacuate the danger 
area, observe emergency procedures, consult an expert. 
For personal protection see section 8. 
6.2 Environmental precautions 
Do not let product enter drains. 
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6.3 Methods and materials for containment and cleaning up 
Cover drains. Collect, bind, and pump off spills. Observe possible material restrictions 
(see sections 7 and 10). Take up dry. Dispose of properly. Clean up affected area. Avoid 
generation of dusts. 
6.4 Reference to other sections 




SECTION 7: Handling and storage 
7.1 Precautions for safe handling 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Tightly closed. Dry. 
Storage class (TRGS 510): 11: Combustible Solids 
7.3 Specific end use(s) 




SECTION 8: Exposure controls/personal protection 
8.1 Control parameters 
Ingredients with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
Change contaminated clothing. Wash hands after working with substance. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate 
government standards such as NIOSH (US) or EN 166(EU). Safety glasses 
Skin protection 
This recommendation applies only to the product stated in the safety data sheet, 
supplied by us and for the designated use. When dissolving in or mixing with other 
substances and under conditions deviating from those stated in EN374 please 
contact the supplier of CE-approved gloves (e.g. KCL GmbH, D-36124 Eichenzell, 
Internet: www.kcl.de). 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:KCL 741 Dermatril® L 
 
This recommendation applies only to the product stated in the safety data sheet, 
supplied by us and for the designated use. When dissolving in or mixing with other 
substances and under conditions deviating from those stated in EN374 please 
contact the supplier of CE-approved gloves (e.g. KCL GmbH, D-36124 Eichenzell, 
Internet: www.kcl.de). 
Splash contact 
Material: Nitrile rubber 
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Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:KCL 741 Dermatril® L 
 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of 
dusts are desired, use type N95 (US) or type P1 (EN 143) dust masks. Use 
respirators and components tested and approved under appropriate government 
standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Do not let product enter drains. 
 
 
SECTION 9: Physical and chemical properties 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: Crystalline solid 
Color: colorless 
b) Odor odorless 
c) Odor Threshold Not applicable 
d) pH 7 
e) Melting 
point/freezing point 
Melting point/range: 801 °C (1474 °F) 
f) Initial boiling point 
and boiling range 
1,413 °C 2,575 °F 
g) Flash point  ()Not applicable 
h) Evaporation rate No data available 
i) Flammability (solid, 
gas) 




No data available 
k) Vapor pressure No data available 
l) Vapor density No data available 
m) Relative density 2.16 g/cm3 at 25 °C (77 °F) 
n) Water solubility 317 g/l at 20 °C (68 °F) - completely soluble 
o) Partition coefficient: 
n-octanol/water 
Not applicable for inorganic substances 
p) Autoignition 
temperature 
No data available 
q) Decomposition 
temperature 
1,000 °C (1,832 °F) -  
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
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9.2 Other safety information 




SECTION 10: Stability and reactivity 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
The product is chemically stable under standard ambient conditions (room temperature) . 
The product is chemically stable under standard ambient conditions (room temperature) . 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
Risk of explosion/exothermic reaction with:Alkali metalsExothermic reaction with:Lithium 
10.4 Conditions to avoid 
no information available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Other decomposition products - No data available 
Hazardous decomposition products formed under fire conditions. - Hydrogen chloride gas, 
Sodium oxides 




SECTION 11: Toxicological information 
11.1 Information on toxicological effects 
Acute toxicity 
No data available 
Inhalation: No data available 
LD50 Dermal - Rabbit - > 10,000 mg/kg 
Remarks: (RTECS) 
No data available 
Skin corrosion/irritation 
Skin - Rabbit 
Result: No skin irritation 
Remarks: (ECHA) 
Serious eye damage/eye irritation 
Eyes - Rabbit 
Result: No eye irritation 
Remarks: (ECHA) 
Respiratory or skin sensitization 
No data available 
Germ cell mutagenicity 
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Escherichia coli/Salmonella typhimurium  
Result: negative 
OECD Test Guideline 475 
Rat - female - Bone marrow 
Result: positive 
Carcinogenicity 
Did not show carcinogenic effects in animal experiments. 
IARC: No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
NTP: No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is 
on OSHA  li  of reg la ed carcinogens. 
Reproductive toxicity 
Did not show teratogenic effects in animal experiments. 
No impairment of reproductive performance suspected. 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 




Vomiting, Diarrhea, Dehydration and congestion may occur in internal organs. Hypertonic 
salt solutions can produce inflammatory reactions in the gastrointestinal tract., Nausea 
To the best of our knowledge, the chemical, physical, and toxicological properties have not 





SECTION 12: Ecological information 
12.1 Toxicity 
 
Toxicity to fish flow-through test LC50 - Lepomis macrochirus (Bluegill) - 5,840 mg/l  
- 96 h 
Remarks: (ECHA) 
 
Toxicity to daphnia 
and other aquatic 
invertebrates 
static test EC50 - Daphnia magna (Water flea) - 874 mg/l  - 48 h 
Remarks: (ECHA) 
 
 static test LC50 - Daphnia magna (Water flea) - 4,136 mg/l  - 48 h 
(OECD Test Guideline 202) 
 
Toxicity to algae static test EC50 - Nitzschia sp. - 2,430 mg/l  - 120 h 
(OECD Test Guideline 201) 
12.2 Persistence and degradability 
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12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not 
conducted 
12.6 Other adverse effects 




SECTION 13: Disposal considerations 
13.1 Waste treatment methods 
Product 
Waste material must be disposed of in accordance with the national and loc No mixing 
with other waste. Handle uncleaned containers like the product See 
www.retrologistik.com for processes regarding the return of chemicals and containers, or 




SECTION 14: Transport information 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 
Not dangerous goods 
 
Further information 




SECTION 15: Regulatory information 
 
SARA 302 Components 
This material does not contain any components with a section 302 EHS TPQ. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that 
exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 
313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
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No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 





New Jersey Right To Know Components 









SECTION 16: Other information 
Further information 
The above information is believed to be correct but does not purport to be all inclusive 
and shall be used only as a guide. The information in this document is based on the 
present state of our knowledge and is applicable to the product with regard to 
appropriate safety precautions. It does not represent any guarantee of the properties of 
the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any 
damage resulting from handling or from contact with the above product. See 
www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional 
terms and conditions of sale. 
 
Copyright 2020 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies 
for internal use only. 
The branding on the header and/or footer of this document may temporarily not visually 
match the product purchased as we transition our branding. However, all of the 
information in the document regarding the product remains unchanged and matches the 
product ordered. For further information please contact mlsbranding@sial.com. 
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SAFETY DATA SHEET 
 
Version 6.1 
Revision Date 06/14/2019 
Print Date 11/20/2020 
 
SECTION 1: Identification of the substance/mixture and of the company/undertaking 
1.1 Product identifiers 
Product name : Phosphate Buffered Saline, pH 7.4, sterile-
filtered, suitable for cell culture 
 
Product Number : 806552 
Brand : Sigma 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich Inc. 
3050 Spruce Street 
ST. LOUIS MO  63103 
UNITED STATES 
 
Telephone : +1 314 771-5765 
Fax : +1 800 325-5052 
1.4 Emergency telephone number 
Emergency Phone # : 800-424-9300 CHEMTREC (USA) +1-703-
527-3887 CHEMTREC (International) 24 
Hours/day; 7 Days/week 
 
 
SECTION 2: Hazards identification 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 




SECTION 3: Composition/information on ingredients 
3.2 Mixtures 
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SECTION 4: First aid measures 
4.1 Description of first aid measures 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
In case of skin contact 
Wash off with soap and plenty of water. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 
2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 




SECTION 5: Firefighting measures 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
Nature of decomposition products not known. 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 




SECTION 6: Accidental release measures 
6.1 Personal precautions, protective equipment and emergency procedures 
Avoid breathing vapours, mist or gas. 
For personal protection see section 8. 
6.2 Environmental precautions 
No special environmental precautions required. 
6.3 Methods and materials for containment and cleaning up 
Keep in suitable, closed containers for disposal. 
6.4 Reference to other sections 
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SECTION 7: Handling and storage 
7.1 Precautions for safe handling 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Storage class (TRGS 510): 12: Non Combustible Liquids 
7.3 Specific end use(s) 




SECTION 8: Exposure controls/personal protection 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
General industrial hygiene practice. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate 
government standards such as NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove 
removal technique (without touching glove's outer surface) to avoid skin contact 
with this product. Dispose of contaminated gloves after use in accordance with 
applicable laws and good laboratory practices. Wash and dry hands. 
 
Body Protection 
Impervious clothing, The type of protective equipment must be selected according 
to the concentration and amount of the dangerous substance at the specific 
workplace. 
Respiratory protection 
Respiratory protection not required. For nuisance exposures use type OV/AG (US) or 
type ABEK (EU EN 14387) respirator cartridges. Use respirators and components 
tested and approved under appropriate government standards such as NIOSH (US) 
or CEN (EU). 
Control of environmental exposure 
No special environmental precautions required. 
 
 
SECTION 9: Physical and chemical properties 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: liquid 
b) Odour No data available 
c) Odour Threshold No data available 
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d) pH No data available 
e) Melting 
point/freezing point 
No data available 
f) Initial boiling point 
and boiling range 
No data available 
g) Flash point  ()No data available 
h) Evaporation rate No data available 
i) Flammability (solid, 
gas) 




No data available 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density No data available 
n) Water solubility No data available 
o) Partition coefficient: 
n-octanol/water 
No data available 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 




SECTION 10: Stability and reactivity 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Nature of decomposition 
products not known. 
 
 




The life science business of Merck KGaA, Darmstadt, Germany 






Other decomposition products - No data available 




SECTION 11: Toxicological information 
11.1 Information on toxicological effects 
Acute toxicity 
No data available 
Inhalation: No data available 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 
No data available 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is 
identified as a carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is 
on OSHA  li  of eg la ed ca cinogen . 
Reproductive toxicity 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: Not available 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not 
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SECTION 12: Ecological information 
12.1 Toxicity 
No data available 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not 
conducted 
12.6 Other adverse effects 




SECTION 13: Disposal considerations 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 




SECTION 14: Transport information 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 




SECTION 15: Regulatory information 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, 
Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that 
exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 
313. 
SARA 311/312 Hazards 
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No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 






Sodium monohydrogen phosphate, heptahydrate 7782-85-6 
 
1993-04-24 






California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, 




SECTION 16: Other information 
Further information 
Copyright 2018 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies 
for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive 
and shall be used only as a guide. The information in this document is based on the 
present state of our knowledge and is applicable to the product with regard to 
appropriate safety precautions. It does not represent any guarantee of the properties of 
the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any 
damage resulting from handling or from contact with the above product. See 
www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional 
terms and conditions of sale. 
 
The branding on the header and/or footer of this document may temporarily not visually 
match the product purchased as we transition our branding. However, all of the 
information in the document regarding the product remains unchanged and matches the 
product ordered. For further information please contact mlsbranding@sial.com. 
 
Version: 6.1 Revision Date: 06/14/2019 Print Date: 11/20/2020 
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SECTION 1. IDENTIFICATION 
Product name 
 





Manufacturer or supplier's details 
Company name of supplier 
 








Telephone : +496217590 
Telefax : +496217592890 
E-mail address : mannheim.umweltschutz@roche.com 
Emergency telephone 
In case of emergencies: : CHEMTREC 
 
+1 703-741-5970 / 
1-800-424-9300 
Recommended use of the chemical and restrictions on use 
Restrictions on use 
 
: For professional users only. 
 
 
SECTION 2. HAZARDS IDENTIFICATION 
GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 
1910.1200) 
The product is a kit consisting of individual ingredients. The classification of the ingredients can 
be obtained from section 3. Section GHS Label elements contains the resulting labelling for the 
kit 
GHS label elements 
Not a hazardous substance or mixture. 
Other hazards 
None known. 
SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS 
Phosphatase, alkaline 
GHS Classification 
Not a hazardous substance or mixture. 
Components 
Chemical name CAS-No. Concentration (% w/w) 
glycerol 56-81-5 >= 50 -  < 70 
Alkaline phosphatase 9001-78-9 >= 1 -  < 5 
Actual concentration is withheld as a trade secret 
 
 
Alkaline Phosphatase Buffer, 10x conc. 
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GHS Classification 
Not a hazardous substance or mixture. 
Components 
No hazardous ingredients 
 
 
SECTION 4. FIRST AID MEASURES 
General advice 
 




: Move to fresh air. 
If unconscious, place in recovery position and seek medical 
advice. 
If symptoms persist, call a physician. 
 
In case of skin contact 
 
: If on skin, rinse well with water. 
 
In case of eye contact 
 
: Immediately flush eye(s) with plenty of water. 
Remove contact lenses. 
Protect unharmed eye. 




: Keep respiratory tract clear. 
Do not give milk or alcoholic beverages. 
Never give anything by mouth to an unconscious person. 
If symptoms persist, call a physician. 
Rinse mouth with water. 
 
Most important symptoms 
and effects, both acute and 
delayed 
 
: No information available. 
 
Notes to physician 
 
: The first aid procedure should be established in consultation 
with the doctor responsible for industrial medicine. 
SECTION 5. FIRE-FIGHTING MEASURES 
Suitable extinguishing media 
 
: Use extinguishing measures that are appropriate to local cir-
cumstances and the surrounding environment. 
 
Specific hazards during fire 
fighting  
 
: No information available. 
 
Further information : Standard procedure for chemical fires. 
Use extinguishing measures that are appropriate to local cir-
cumstances and the surrounding environment. 
 
Special protective equipment 
for fire-fighters 
 
: Wear self-contained breathing apparatus for firefighting if 
necessary. 
 
SECTION 6. ACCIDENTAL RELEASE MEASURES 
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Personal precautions, protec-
tive equipment and emer-
gency procedures 
 




: Local authorities should be advised if significant spillages 
cannot be contained. 
 
Methods and materials for 
containment and cleaning up  
 
: Wipe up with absorbent material (e.g. cloth, fleece). 
Keep in suitable, closed containers for disposal. 
 
SECTION 7. HANDLING AND STORAGE 
Advice on protection against 
fire and explosion 
 
:  Normal measures for preventive fire protection. 
 
Advice on safe handling 
 
: For personal protection see section 8. 
Smoking, eating and drinking should be prohibited in the ap-
plication area. 
 
Conditions for safe storage 
 
: Electrical installations / working materials must comply with 
the technological safety standards. 
 
Further information on stor-
age conditions 
 
:  See label, package insert or internal guidelines 
 
Materials to avoid  
 
: No materials to be especially mentioned. 
 
Further information on stor-
age stability 
 
:  No decomposition if stored and applied as directed. 
SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
Phosphatase, alkaline 
Ingredients with workplace control parameters 




ters / Permissible 
concentration 
Basis 
glycerol 56-81-5 TWA (mist, 
respirable 
fraction) 
5 mg/m3 OSHA Z-1 
  TWA (mist, 
total dust) 
15 mg/m3 OSHA Z-1 
  TWA (Mist - 
total dust) 
10 mg/m3 OSHA P0 
  TWA (Mist - 
respirable 
fraction) 
5 mg/m3 OSHA P0 
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Alkaline Phosphatase Buffer, 10x conc. 
Ingredients with workplace control parameters 
Contains no substances with occupational exposure limit values. 
Engineering measures : No data available 
 
Personal protective equipment 
Respiratory protection 
 




   In case of contact through splashing:  
Material : Nitrile rubber 
Break through time : > 30 min 
Glove thickness : > 0.11 mm 
 
 
   In case of full contact:  
Material : butyl-rubber 
Break through time : > 480 min 




: Wear appropriate protective gloves to prevent skin contact. 
Replace torn or punctured gloves promptly. 
Eye protection 
 
: Safety glasses 
 
Skin and body protection 
 




: Handle in accordance with good industrial hygiene and safety 
practice. 
 




























: No data available  
 
Boiling point/boiling range 
 
 
: No data available  
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Flash point 
 












 The product is not flammable. 
 
Self-ignition : No data available  
 
Upper explosion limit / Upper 
flammability limit 
 
: No data available  
 
Lower explosion limit / Lower 
flammability limit 
 




: No data available  
 
Relative vapor density  
 













: completely miscible  
 
Solubility in other solvents 
 































: The substance or mixture is not classified as oxidizing. 
 
 








:  clear, colorless 
 
 
Odor :  none 
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: No data available  
 
Boiling point/boiling range 
 
 
















 The product is not flammable. 
 
Self-ignition : No data available  
 
Upper explosion limit / Upper 
flammability limit 
 
: No data available  
 
Lower explosion limit / Lower 
flammability limit 
 




: No data available  
 
Relative vapor density  
 













: completely miscible  
 
Solubility in other solvents 
 


























: Not explosive 
 
 
Oxidizing properties : The substance or mixture is not classified as oxidizing. 
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SECTION 10. STABILITY AND REACTIVITY 
Reactivity 
 




:  Stable under normal conditions. 
 
Possibility of hazardous reac-
tions  
 
: No dangerous reaction known under conditions of normal use. 
Stable under recommended storage conditions. 
No hazards to be specially mentioned. 
 
Conditions to avoid 
 








:   No decomposition if stored and applied as directed. 
 
SECTION 11. TOXICOLOGICAL INFORMATION 
Phosphatase, alkaline 
Acute toxicity 
Not classified based on available information. 
Components: 
glycerol: 
Acute oral toxicity 
 




  LD50 Oral (Mouse): 4,090 mg/kg  
 
Acute inhalation toxicity 
 
:  Acute toxicity estimate: > 30 mg/l  
Test atmosphere: vapor 
Method: Expert judgment 
 
Acute dermal toxicity 
 




Acute oral toxicity 
 
:  Acute toxicity estimate: > 5,001 mg/kg  
Method: Expert judgment 
 
Acute inhalation toxicity 
 
:  Acute toxicity estimate: > 30 mg/l  
Test atmosphere: dust/mist 
Method: Expert judgment 
 
Acute dermal toxicity 
 
:  Acute toxicity estimate: > 5,001 mg/kg 
Method: Expert judgment 
 
Skin corrosion/irritation 
Not classified based on available information. 
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Components: 
glycerol: 
Species : Rabbit 
Exposure time : 24 h 
Result : No skin irritation 
GLP : no 
 
Serious eye damage/eye irritation 
Not classified based on available information. 
Components: 
glycerol: 
Species : Rabbit 
Result : No eye irritation 
Exposure time : 7 d 
GLP : no 
 
Respiratory or skin sensitization 
Skin sensitization 
Not classified based on available information. 
Respiratory sensitization 
Not classified based on available information. 
Components: 
glycerol: 
Assessment :  Mild eye irritant, Mild respiratory irritant, No skin irritation 
 
Germ cell mutagenicity 
Not classified based on available information. 
Components: 
glycerol: 
Genotoxicity in vitro 
 
: Test Type: Microbial mutagenesis assay (Ames test) 
Test system: Salmonella typhimurium 
Metabolic activation: with and without metabolic activation 
Result: negative 




 Test Type: In vitro mammalian cell gene mutation test 
Test system: Chinese hamster ovary cells 
Metabolic activation: with and without metabolic activation 
Method: OECD Test Guideline 476 
Result: negative 
GLP: No information available. 
 
Carcinogenicity 
Not classified based on available information. 
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Components: 
glycerol: 
Species : Rat, male and female 
Application Route : Oral 
Exposure time : 2 Years 
Frequency of Treatment : daily 
GLP : No information available. 
Remarks : No ingredient of this product present at levels greater than or 
equal to 0.1% is identified as probable, possible or confirmed 
human carcinogen by IARC. 
 
IARC No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
 
OSHA No component of this product present at levels greater than or equal to 0.1% is 
on OSHA  li  of eg la ed ca cinogen . 
 
NTP No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
 
Reproductive toxicity 
Not classified based on available information. 
Components: 
glycerol: 
Effects on fertility 
 
:  Test Type: Two-generation study 
Species: Rat, male and female 
Application Route: Oral 
Dose: 2000 mg/kg bw/day 
Fertility: NOAEL: 2,000 mg/kg body weight 
GLP: no 
 
Effects on fetal development 
 
:  Species: Rabbit, female 
Application Route: Oral 
Dose: 11.8, 54.8, 254.5, 1180 mg/kg bw/day 
Duration of Single Treatment: 29 d 




Not classified based on available information. 
Components: 
Alkaline phosphatase: 
Assessment : The substance or mixture is not classified as specific target 
organ toxicant, single exposure. 
 
STOT-repeated exposure 
Not classified based on available information. 
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Components: 
Alkaline phosphatase: 
Assessment : The substance or mixture is not classified as specific target 
organ toxicant, repeated exposure. 
 
Repeated dose toxicity 
Components: 
glycerol: 
Species : Rat, male and female 
NOAEL : 4580 mg/kg 
NOAEL : 4,580 mg/kg  
Application Route : Oral 
Exposure time : 90 d 
Number of exposures : daily 
Dose : 4580 - 25,800 mg/kg/day  
GLP : no 
 
Species : Rat, male and female 
Application Route : Inhalation 
Test atmosphere : dust/mist 
Exposure time : 13 Weeks 
Number of exposures : 6 hours/day, 5 days/week 
Dose : 33, 165 and 660 mg/m3  
GLP : No information available. 
 
Species : Rat 
NOAEL : 5040 mg/kg 
NOAEL : 5,040 mg/kg  
Application Route : dermal 
Exposure time : 45 Weeks 
Number of exposures : 8 hours/day, 5 days/week 
Dose : 0.5-4.0 ml/kg  
GLP : no 
 
Repeated dose toxicity - 
Assessment 
 
:  Mild eye irritant, Mild respiratory irritant, No skin irritation 
 
Aspiration toxicity 
Not classified based on available information. 
Components: 
Alkaline phosphatase: 





Remarks : Health injuries are not known or expected under normal use. 
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Alkaline Phosphatase Buffer, 10x conc. 
Acute toxicity 
Not classified based on available information. 
Skin corrosion/irritation 
Not classified based on available information. 
Serious eye damage/eye irritation 
Not classified based on available information. 
Respiratory or skin sensitization 
Skin sensitization 
Not classified based on available information. 
Respiratory sensitization 
Not classified based on available information. 
Germ cell mutagenicity 
Not classified based on available information. 
Carcinogenicity 
Not classified based on available information. 
IARC No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
 
OSHA No component of this product present at levels greater than or equal to 0.1% is 
on OSHA  li  of eg la ed ca cinogen . 
 
NTP No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
 
Reproductive toxicity 
Not classified based on available information. 
STOT-single exposure 
Not classified based on available information. 
STOT-repeated exposure 
Not classified based on available information. 
Aspiration toxicity 
Not classified based on available information. 
 





Toxicity to fish :  LC50 (Oncorhynchus mykiss (rainbow trout)): 54,000 mg/l 
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 End point: mortality 
Exposure time: 96 h 
Test Type: static test 
GLP: no 
 
Toxicity to daphnia and other 
aquatic invertebrates 
 
:  LC50 (Daphnia magna (Water flea)): 1,955 mg/l 
End point: mortality 
Exposure time: 48 h 
Test Type: static test 
Analytical monitoring: no 
GLP: no 
 
Toxicity to algae/aquatic 
plants 
 
:   (Scenedesmus quadricauda (Green algae)): > 10,000 mg/l 
End point: Growth rate 
Exposure time: 8 d 
Test Type: static test 
GLP: no 
 
Toxicity to microorganisms 
 
:  EC50 (Pseudomonas putida): > 10,000 mg/l 
End point: Growth rate 
Exposure time: 16 h 
Test Type: static test 
GLP: No information available. 
 
Ecotoxicology Assessment 
Acute aquatic toxicity 
 
:  This product has no known ecotoxicological effects. 
 
Chronic aquatic toxicity 
 
:  This product has no known ecotoxicological effects. 
 
Toxicity Data on Soil 
 
:  Not expected to adsorb on soil. 
 
Other organisms relevant to 
the environment 
 
:  No data available 
 
Alkaline phosphatase: 
Toxicity to fish 
 
:  LC50: > 100 mg/l 
Exposure time: 96 h 
 
Toxicity to fish (Chronic tox-
icity) 
 
: > 1 mg/l  
 
Ecotoxicology Assessment 
Acute aquatic toxicity 
 




  This product has no known ecotoxicological effects. 
 
Chronic aquatic toxicity 
 




  This product has no known ecotoxicological effects. 
 
Toxicity Data on Soil 
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Other organisms relevant to 
the environment 
 




   
 





:  aerobic 
Inoculum: activated sludge 
Concentration: 226 mg/l 
Result: Readily biodegradable. 
Biodegradation:  94 % 









: log Pow: -1.75 (77 °F / 25 °C) 
pH: 7.4 







: Remarks: No data available 
 
Mobility in soil 
No data available 
Other adverse effects 
 
Alkaline Phosphatase Buffer, 10x conc. 
Ecotoxicity 
No data available 
Persistence and degradability 
No data available 
Bioaccumulative potential 
No data available 
Mobility in soil 
No data available 
Other adverse effects 
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SECTION 13. DISPOSAL CONSIDERATIONS 
Disposal methods 





: Empty containers should be taken to an approved waste 
handling site for recycling or disposal. 
Do not re-use empty containers. 
 
SECTION 14. TRANSPORT INFORMATION 
International Regulations 
UNRTDG  
Not regulated as a dangerous good 
IATA-DGR  
Not regulated as a dangerous good 
IMDG-Code  
Not regulated as a dangerous good 
Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code 
Not applicable 
Domestic regulation 
49 CFR  
Not regulated as a dangerous good 
SECTION 15. REGULATORY INFORMATION 
Phosphatase, alkaline 
CERCLA Reportable Quantity 
Components CAS-No. Component RQ 
(lbs) 
Calculated product RQ 
(lbs) 
Zinc chloride (ZnCl2) 7646-85-7 1000 * 
*: Calculated RQ exceeds reasonably attainable upper limit. 
SARA 304 Extremely Hazardous Substances Reportable Quantity 
This material does not contain any components with a section 304 EHS RQ. 
SARA 302 Extremely Hazardous Substances Threshold Planning Quantity 
This material does not contain any components with a section 302 EHS TPQ. 
SARA 311/312 Hazards 
 




:  This material does not contain any chemical components with 
known CAS numbers that exceed the threshold (De Minimis) 
reporting levels established by SARA Title III, Section 313. 
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Clean Air Act 
This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by 
the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B). 
This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean 
Air Act Section 112 (40 CFR 61). 
This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for 
Accidental Release Prevention (40 CFR 68.130, Subpart F). 
The following chemical(s) are listed under the U.S. Clean Air Act Section 111 SOCMI Intermedi-
ate or Final VOC's (40 CFR 60.489): 
 glycerol 56-81-5 >= 50 - < 70 % 
Clean Water Act 
The following Hazardous Substances are listed under the U.S. CleanWater Act, Section 311, Ta-
ble 116.4A: 
 Zinc chloride (ZnCl2) 7646-85-7 >= 0 - < 0.1 % 
The following Hazardous Chemicals are listed under the U.S. CleanWater Act, Section 311, Table 
117.3: 
 Zinc chloride (ZnCl2) 7646-85-7 >= 0 - < 0.1 % 
This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 
307 
This product does not contain any priority pollutants related to the U.S. Clean Water Act 
US State Regulations 
Massachusetts Right To Know 
 glycerol 56-81-5 
Pennsylvania Right To Know 
 glycerol 56-81-5 
 Water 7732-18-5 
Maine Chemicals of High Concern 
 Product does not contain any listed chemicals 
Vermont Chemicals of High Concern 
 Product does not contain any listed chemicals 
Washington Chemicals of High Concern 
 Product does not contain any listed chemicals 
California Permissible Exposure Limits for Chemical Contaminants 
 glycerol 56-81-5 
The ingredients of this product are reported in the following inventories: 
DSL 
 
: This product contains the following components listed on the 
Canadian NDSL. All other components are on the Canadian 
DSL. 
 
















: Not in compliance with the inventory 
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KECI 
 
















: All substances listed as active on the TSCA inventory 
 
TSCA list 
No substances are subject to a Significant New Use Rule. 
 




Alkaline Phosphatase Buffer, 10x conc. 
CERCLA Reportable Quantity 
This material does not contain any components with a CERCLA RQ. 
SARA 304 Extremely Hazardous Substances Reportable Quantity 
This material does not contain any components with a section 304 EHS RQ. 
SARA 302 Extremely Hazardous Substances Threshold Planning Quantity 
This material does not contain any components with a section 302 EHS TPQ. 
SARA 311/312 Hazards 
 




:  This material does not contain any chemical components with 
known CAS numbers that exceed the threshold (De Minimis) 
reporting levels established by SARA Title III, Section 313. 
 
Clean Air Act 
This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by 
the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B). 
This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean 
Air Act Section 112 (40 CFR 61). 
This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for 
Accidental Release Prevention (40 CFR 68.130, Subpart F). 
This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 
SOCMI Intermediate or Final VOC's (40 CFR 60.489). 
Clean Water Act 
This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, 
Section 311, Table 116.4A. 
This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, 
Section 311, Table 117.3. 
This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 
307 
This product does not contain any priority pollutants related to the U.S. Clean Water Act 
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US State Regulations 
Massachusetts Right To Know 
 No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know 
 Water 7732-18-5 
 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-, hydrochloride 
(1:1) 
1185-53-1 
Maine Chemicals of High Concern 
 Product does not contain any listed chemicals 
Vermont Chemicals of High Concern 
 Product does not contain any listed chemicals 
Washington Chemicals of High Concern 
 Product does not contain any listed chemicals 
The ingredients of this product are reported in the following inventories: 
DSL 
 




































: All substances listed as active on the TSCA inventory 
 
TSCA list 
No substances are subject to a Significant New Use Rule. 
 





GHS label elements 
Not a hazardous substance or mixture. 
Alkaline Phosphatase Buffer, 10x conc. 
GHS label elements 
Not a hazardous substance or mixture. 
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SECTION 16. OTHER INFORMATION 
Further information 















HMIS® ratings are based on a 0-4 rating 
scale, with 0 representing minimal haz-
ards or risks, and 4 representing signifi-
cant hazards or risks. The "*" represents 
a chronic hazard, while the "/" represents 
the absence of a chronic hazard. 
 















HMIS® ratings are based on a 0-4 rating 
scale, with 0 representing minimal haz-
ards or risks, and 4 representing signifi-
cant hazards or risks. The "*" represents 
a chronic hazard, while the "/" represents 




3050 Spruce Street 
SAINT LOUIS 
MO 63103 USA 
Full text of other abbreviations 
 
AICS - Australian Inventory of Chemical Substances; AIIC - Australian Inventory of Industrial 
Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - 
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Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; 
DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concen-
tration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate 
associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical 
Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - 
Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Prac-
tice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research 
on Cancer; IATA - International Air Transport Association; IBC - International Code for the Con-
struction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal in-
hibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Ex-
isting Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - In-
ternational Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - Interna-
tional Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal 
Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Me-
dian Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; 
MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National 
Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - 
No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - Na-
tional Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization 
for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution 
Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Invento-
ry of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relation-
ship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 
1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, 
Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating 
Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - 
Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances 
Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations 
on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative 
 
 
Revision Date :  02-07-2021 
 
 
The information provided in this Safety Data Sheet is correct to the best of our knowledge, infor-
mation and belief at the date of its publication. The information given is designed only as a guid-
ance for safe handling, use, processing, storage, transportation, disposal and release and is not 
to be considered a warranty or quality specification. The information relates only to the specific 
material designated and may not be valid for such material used in combination with any other 
materials or in any process, unless specified in the text. 
 
US / Z8 / 2004
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SAFETY DATA SHEET 
 
Version 6.3 
Revision Date 10/02/2020 
Print Date 11/20/2020 
 
SECTION 1: Identification of the substance/mixture and of the company/undertaking 
1.1 Product identifiers 
Product name : Sodium acetate 
 
Product Number : S5636 
Brand : Sigma 
CAS-No. : 127-09-3 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich Inc. 
3050 Spruce Street 
ST. LOUIS MO  63103 
UNITED STATES 
 
Telephone : +1 314 771-5765 
Fax : +1 800 325-5052 
1.4 Emergency telephone 
Emergency Phone # : 800-424-9300 CHEMTREC (USA) +1-703-
527-3887 CHEMTREC (International) 24 
Hours/day; 7 Days/week 
 
 
SECTION 2: Hazards identification 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 




SECTION 3: Composition/information on ingredients 
3.1 Substances 
Synonyms : Acetic acid sodium salt 
 
Formula : C2H3NaO2 
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Molecular weight : 82.03 g/mol 
CAS-No. : 127-09-3 
EC-No. : 204-823-8 
 




SECTION 4: First aid measures 
4.1 Description of first-aid measures 
General advice 
Consult a physician. Show this material safety data sheet to the doctor in attendance. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Consult a physician. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult 
a physician. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 
2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 




SECTION 5: Firefighting measures 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
Carbon oxides, Sodium oxides 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 




SECTION 6: Accidental release measures 
6.1 Personal precautions, protective equipment and emergency procedures 
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or 
gas. Ensure adequate ventilation. Avoid breathing dust. 
For personal protection see section 8. 
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6.2 Environmental precautions 
Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in 
suitable, closed containers for disposal. 
6.4 Reference to other sections 




SECTION 7: Handling and storage 
7.1 Precautions for safe handling 
Avoid formation of dust and aerosols.Further processing of solid materials may result in the 
formation of combustible dusts. The potential for combustible dust formation should be 
taken into consideration before additional processing occurs. 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Keep in a dry place.  
Storage class (TRGS 510): 13: Non Combustible Solids 
7.3 Specific end use(s) 




SECTION 8: Exposure controls/personal protection 
8.1 Control parameters 
Ingredients with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
Handle in accordance with good industrial hygiene and safety practice. Wash hands 
before breaks and at the end of workday. 
Personal protective equipment 
Eye/face protection 
Safety glasses with side-shields conforming to EN166 Use equipment for eye 
protection tested and approved under appropriate government standards such as 
NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove 
removal technique (without touching glove's outer surface) to avoid skin contact 
with this product. Dispose of contaminated gloves after use in accordance with 
applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
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Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail 
sales@kcl.de, test method: EN374 
If used in solution, or mixed with other substances, and under conditions which 
differ from EN 374, contact the supplier of the EC approved gloves. This 
recommendation is advisory only and must be evaluated by an industrial hygienist 
and safety officer familiar with the specific situation of anticipated use by our 




Choose body protection in relation to its type, to the concentration and amount of 
dangerous substances, and to the specific work-place., The type of protective 
equipment must be selected according to the concentration and amount of the 
dangerous substance at the specific workplace. 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of 
dusts are desired, use type N95 (US) or type P1 (EN 143) dust masks. Use 
respirators and components tested and approved under appropriate government 
standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Do not let product enter drains. 
 
 
SECTION 9: Physical and chemical properties 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: solid, powder 
Color: white 
b) Odor No data available 
c) Odor Threshold No data available 
d) pH 8.5 - 9.9 at 246 g/l at 25 °C (77 °F) 
e) Melting 
point/freezing point 
Melting point/range: > 300 °C (> 572 °F) 
f) Initial boiling point 
and boiling range 
No data available 
g) Flash point > 250 °C (> 482 °F) - closed cup 
h) Evaporation rate No data available 
i) Flammability (solid, 
gas) 




No data available 
k) Vapor pressure No data available 
 
 




The life science business of Merck KGaA, Darmstadt, Germany 






l) Vapor density No data available 
m) Relative density 1.528 g/cm3 
n) Water solubility 246 g/l at 20 °C (68 °F) - completely soluble 
o) Partition coefficient: 
n-octanol/water 
log Pow: -4.22 
p) Autoignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 




SECTION 10: Stability and reactivity 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
Exposure to moisture. 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Sodium 
oxides 
Other decomposition products - No data available 




SECTION 11: Toxicological information 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - male and female - 2,700 mg/kg 
(OECD Test Guideline 401) 
LC50 Inhalation - Rat - male and female - 4 h - > 5.6 mg/l 
(OECD Test Guideline 403) 
LD50 Dermal - Rabbit - female - > 20,000 mg/kg 
(OECD Test Guideline 402) 
No data available 
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Skin - Rabbit 
Result: No skin irritation - 4 h 
(OECD Test Guideline 404) 
Serious eye damage/eye irritation 
Eyes - Rabbit 
Result: No eye irritation - 24 h 
(OECD Test Guideline 405) 
Respiratory or skin sensitization 
No data available 
Germ cell mutagenicity 
 




IARC: No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
NTP: No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is 
on OSHA  li  of reg la ed carcinogens. 
Reproductive toxicity 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 




Abdominal pain, Nausea, Vomiting 
To the best of our knowledge, the chemical, physical, and toxicological properties have not 





SECTION 12: Ecological information 
12.1 Toxicity 
 
Toxicity to fish semi-static test LC50 - Danio rerio (zebra fish) - > 100 mg/l  - 96 h 
(OECD Test Guideline 203) 
 
Toxicity to daphnia 
and other aquatic 
invertebrates 
static test EC50 - Daphnia magna (Water flea) - > 1,000 mg/l  - 48 h 
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Toxicity to algae ErC50 - Skeletonema costatum - > 1,000 mg/l  - 72 h 
(ISO 10253) 
 
Toxicity to bacteria static test EC50 - Pseudomonas putida - 7,200 mg/l  - 16 h 
(DIN 38 412 Part 8) 
12.2 Persistence and degradability 
Biodegradability aerobic Dissolved organic carbon (DOC) - Exposure time 28 d 
Result: 99 % - Readily biodegradable.  
 (Regulation (EC) No. 440/2008, Annex, C.4-A) 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not 
conducted 
12.6 Other adverse effects 




SECTION 13: Disposal considerations 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 




SECTION 14: Transport information 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 
Not dangerous goods 
 
Further information 




SECTION 15: Regulatory information 
 
SARA 302 Components 
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SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that 
exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 
313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 











New Jersey Right To Know Components 





California Prop. 65 Components 
This product does not contain any chemicals known to the State of California to cause 




SECTION 16: Other information 
Further information 
Copyright 2020 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies 
for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive 
and shall be used only as a guide. The information in this document is based on the 
present state of our knowledge and is applicable to the product with regard to 
appropriate safety precautions. It does not represent any guarantee of the properties of 
the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any 
damage resulting from handling or from contact with the above product. See 
www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional 
terms and conditions of sale. 
 
The branding on the header and/or footer of this document may temporarily not visually 
match the product purchased as we transition our branding. However, all of the 
information in the document regarding the product remains unchanged and matches the 
product ordered. For further information please contact mlsbranding@sial.com. 
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SAFETY DATA SHEET 
 
Version 6.3 
Revision Date 04/20/2020 
Print Date 11/20/2020 
 
SECTION 1: Identification of the substance/mixture and of the company/undertaking 
1.1 Product identifiers 
Product name : Spermidine 
 
Product Number : S2626 
Brand : Sigma 
CAS-No. : 124-20-9 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich Inc. 
3050 Spruce Street 
ST. LOUIS MO  63103 
UNITED STATES 
 
Telephone : +1 314 771-5765 
Fax : +1 800 325-5052 
1.4 Emergency telephone number 
Emergency Phone # : 800-424-9300 CHEMTREC (USA) +1-703-
527-3887 CHEMTREC (International) 24 
Hours/day; 7 Days/week 
 
 
SECTION 2: Hazards identification 
2.1 Classification of the substance or mixture 
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) 
Skin corrosion (Category 1B), H314 
Serious eye damage (Category 1), H318 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
2.2 GHS Label elements, including precautionary statements 
Pictogram 
  
Signal word Danger 
 
Hazard statement(s) 
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P264 Wash skin thoroughly after handling. 
P280 Wear protective gloves/ protective clothing/ eye protection/ face 
protection. 
P301 + P330 + P331 IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. 
P303 + P361 + P353 IF ON SKIN (or hair): Take off immediately all contaminated 
clothing. Rinse skin with water/shower. 
P304 + P340 + P310 IF INHALED: Remove person to fresh air and keep comfortable 
for breathing. Immediately call a POISON CENTER/doctor. 
P305 + P351 + P338 + 
P310 
IF IN EYES: Rinse cautiously with water for several minutes. 
Remove contact lenses, if present and easy to do. Continue 
rinsing. Immediately call a POISON CENTER/doctor. 
P363 Wash contaminated clothing before reuse. 
P405 Store locked up. 
P501 Dispose of contents/ container to an approved waste disposal 
plant. 
 




SECTION 3: Composition/information on ingredients 
3.1 Substances 
Synonyms : 1,8-Diamino-4-azaoctane 
N-(3-Aminopropyl)-1,4-diaminobutane 
 
Formula : C7H19N3 
Molecular weight : 145.25 g/mol 
CAS-No. : 124-20-9 
EC-No. : 204-689-0 
 
Component Classification Concentration 
4-Azaoctamethylenediamine 
   Skin Corr. 1B; Eye Dam. 
1; H314, H318 
<= 100 % 
 




SECTION 4: First aid measures 
4.1 Description of first aid measures 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of 
dangerous area. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
Consult a physician. 
In case of skin contact 
Take off contaminated clothing and shoes immediately. Wash off with soap and plenty of 
water. Consult a physician. 
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In case of eye contact 
Rinse thoroughly with plenty of water for at least 15 minutes and consult a 
physician.Continue rinsing eyes during transport to hospital. 
If swallowed 
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse 
mouth with water. Consult a physician. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 
2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 




SECTION 5: Firefighting measures 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
Carbon oxides, Nitrogen oxides (NOx) 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 




SECTION 6: Accidental release measures 
6.1 Personal precautions, protective equipment and emergency procedures 
Use personal protective equipment. Avoid breathing vapours, mist or gas. Ensure 
adequate ventilation. Evacuate personnel to safe areas. 
For personal protection see section 8. 
6.2 Environmental precautions 
Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in 
suitable, closed containers for disposal. 
6.4 Reference to other sections 




SECTION 7: Handling and storage 
7.1 Precautions for safe handling 
Avoid inhalation of vapour or mist. 
For precautions see section 2.2. 
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7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place. Containers which are 
opened must be carefully resealed and kept upright to prevent leakage.  
Store under inert gas. Air sensitive. strongly hygroscopic  
Storage class (TRGS 510): 8A: Combustible, corrosive hazardous materials 
7.3 Specific end use(s) 




SECTION 8: Exposure controls/personal protection 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
Handle in accordance with good industrial hygiene and safety practice. Wash hands 
before breaks and at the end of workday. 
Personal protective equipment 
Eye/face protection 
Tightly fitting safety goggles.  Faceshield (8-inch minimum). Use equipment for eye 
protection tested and approved under appropriate government standards such as 
NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove 
removal technique (without touching glove's outer surface) to avoid skin contact 
with this product. Dispose of contaminated gloves after use in accordance with 
applicable laws and good laboratory practices. Wash and dry hands. 
 
Body Protection 
Complete suit protecting against chemicals, The type of protective equipment must 
be selected according to the concentration and amount of the dangerous substance 
at the specific workplace. 
Respiratory protection 
Where risk assessment shows air-purifying respirators are appropriate use a full-
face respirator with multi-purpose combination (US) or type ABEK (EN 14387) 
respirator cartridges as a backup to engineering controls. If the respirator is the sole 
means of protection, use a full-face supplied air respirator. Use respirators and 
components tested and approved under appropriate government standards such as 
NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Do not let product enter drains. 
 
 
SECTION 9: Physical and chemical properties 
9.1 Information on basic physical and chemical properties 
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b) Odour No data available 
c) Odour Threshold No data available 
d) pH 12.0 - 13.5 at 145 g/l at 25 °C (77 °F) 
e) Melting 
point/freezing point 
22 - 25 °C (72 - 77 °F) 
f) Initial boiling point 
and boiling range 
No data available 
g) Flash point 112 °C (234 °F) - closed cup 
h) Evaporation rate No data available 
i) Flammability (solid, 
gas) 




No data available 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density 0.925 g/mL at 25 °C (77 °F) 
n) Water solubility 145 g/l at 20 °C (68 °F) - completely soluble 
o) Partition coefficient: 
n-octanol/water 
No data available 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 




SECTION 10: Stability and reactivity 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
acids, Acid chlorides, Acid anhydrides, Oxidizing agents 
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10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen 
oxides (NOx) 
Other decomposition products - No data available 




SECTION 11: Toxicological information 
11.1 Information on toxicological effects 
Acute toxicity 
No data available 
Inhalation: Material is extremely destructive to the tissue of the mucous membranes and 
upper respiratory tract. 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 
No data available 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
NTP: No component of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is 
on OSHA  li  of reg la ed carcinogens. 
Reproductive toxicity 
No data available 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 




Material is extremely destructive to tissue of the mucous membranes and upper respiratory 
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SECTION 12: Ecological information 
12.1 Toxicity 
No data available 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not 
conducted 
12.6 Other adverse effects 




SECTION 13: Disposal considerations 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a 
licensed professional waste disposal service to dispose of this material. Dissolve or mix 
the material with a combustible solvent and burn in a chemical incinerator equipped with 
an afterburner and scrubber.  
Contaminated packaging 




SECTION 14: Transport information 
DOT (US) 
UN number: 3259 Class: 8 Packing group: II 
Proper shipping name: Polyamines, solid, corrosive, n.o.s. (4-Azaoctamethylenediamine) 
Reportable Quantity (RQ):   
Poison Inhalation Hazard: No 
 
IMDG 
UN number: 3259 Class: 8 Packing group: II EMS-No: F-A, S-B 




UN number: 3259 Class: 8 Packing group: II 
Proper shipping name: Polyamines, solid, corrosive, n.o.s. (4-Azaoctamethylenediamine) 
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SARA 302 Components 
This material does not contain any components with a section 302 EHS TPQ. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that 
exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 
313. 
SARA 311/312 Hazards 
Acute Health Hazard 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
 
No components are subject to the Massachusetts Right to Know Act. 
















SECTION 16: Other information 
Further information 
Copyright 2020 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies 
for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive 
and shall be used only as a guide. The information in this document is based on the 
present state of our knowledge and is applicable to the product with regard to 
appropriate safety precautions. It does not represent any guarantee of the properties of 
the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any 
damage resulting from handling or from contact with the above product. See 
www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional 
terms and conditions of sale. 
 
The branding on the header and/or footer of this document may temporarily not visually 
match the product purchased as we transition our branding. However, all of the 
information in the document regarding the product remains unchanged and matches the 
product ordered. For further information please contact mlsbranding@sial.com. 
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SAFETY DATA SHEET 
 
Version 6.6 
Revision Date 10/07/2020 
Print Date 11/20/2020 
 
SECTION 1: Identification of the substance/mixture and of the company/undertaking 
1.1 Product identifiers 
Product name : Sucrose 
 
Product Number : S9378 
Brand : Sigma 
CAS-No. : 57-50-1 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich Inc. 
3050 Spruce Street 
ST. LOUIS MO  63103 
UNITED STATES 
 
Telephone : +1 314 771-5765 
Fax : +1 800 325-5052 
1.4 Emergency telephone 
Emergency Phone # : 800-424-9300 CHEMTREC (USA) +1-703-
527-3887 CHEMTREC (International) 24 
Hours/day; 7 Days/week 
 
 
SECTION 2: Hazards identification 
2.1 Classification of the substance or mixture 
 
 
2.2 GHS Label elements, including precautionary statements 
Pictogram none 
 
Signal word Warning 
 
Hazard statement(s) 






2.3 Hazards not otherwise classified (HNOC) or not covered by GHS 
Combustible dust 
May form explosible dust-air mixture if dispersed. 
 
 




The life science business of Merck KGaA, Darmstadt, Germany 









SECTION 3: Composition/information on ingredients 
3.1 Substances 






Formula : C12H22O11 
Molecular weight : 342.30 g/mol 
CAS-No. : 57-50-1 
EC-No. : 200-334-9 
 
Component Classification Concentration 
Saccharose 





SECTION 4: First aid measures 
4.1 Description of first-aid measures 
If inhaled 
After inhalation: fresh air. 
In case of skin contact 
In case of skin contact: Take off immediately all contaminated clothing. Rinse skin with 
water/ shower. 
In case of eye contact 
After eye contact: rinse out with plenty of water. Remove contact lenses. 
If swallowed 
After swallowing: make victim drink water (two glasses at most). Consult doctor if feeling 
unwell. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 
2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 




SECTION 5: Firefighting measures 
5.1 Extinguishing media 
Suitable extinguishing media 
Water Foam Carbon dioxide (CO2) Dry powder 
Unsuitable extinguishing media 
For this substance/mixture no limitations of extinguishing agents are given. 
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5.2 Special hazards arising from the substance or mixture 
Carbon oxides 
Combustible. 
Development of hazardous combustion gases or vapours possible in the event of fire. 
5.3 Advice for firefighters 
In the event of fire, wear self-contained breathing apparatus. 
5.4 Further information 





SECTION 6: Accidental release measures 
6.1 Personal precautions, protective equipment and emergency procedures 
Advice for non-emergency personnel: Avoid inhalation of dusts. Evacuate the danger 
area, observe emergency procedures, consult an expert. 
For personal protection see section 8. 
6.2 Environmental precautions 
Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Cover drains. Collect, bind, and pump off spills. Observe possible material restrictions 
(see sections 7 and 10). Take up dry. Dispose of properly. Clean up affected area. Avoid 
generation of dusts. 
6.4 Reference to other sections 




SECTION 7: Handling and storage 
7.1 Precautions for safe handling 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
No data available 
7.3 Specific end use(s) 




SECTION 8: Exposure controls/personal protection 
8.1 Control parameters 
Ingredients with workplace control parameters 







TWA 10 mg/m3 USA. ACGIH Threshold Limit 
Values (TLV) 
 Remarks Dental erosion 
Not classifiable as a human carcinogen 
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  TWA 5 mg/m3 USA. NIOSH Recommended 
Exposure Limits 
  TWA 10 mg/m3 USA. NIOSH Recommended 
Exposure Limits 
  TWA 15 mg/m3 USA. Occupational Exposure 
Limits (OSHA) - Table Z-1 
Limits for Air Contaminants 
  TWA 5 mg/m3 USA. Occupational Exposure 
Limits (OSHA) - Table Z-1 
Limits for Air Contaminants 
  PEL 10 mg/m3 California permissible exposure 
limits for chemical 
contaminants (Title 8, Article 
107) 
  PEL 5 mg/m3 California permissible exposure 
limits for chemical 
contaminants (Title 8, Article 
107) 
  The concentration and percentage of the particulate used 
for this limit are determined from the fraction passing a size 
selector with the following characteristics:  Aerodynamic 
Diameter in Micrometers (unit density sphere)................. 
Percent Passing Selector  0 
.................................................. 100  1 
.................................................. 97  2 
.................................................. 91  3 
................................................... 74  4 
................................................... 50  5 
................................................... 30  6 
................................................... 17  7 
................................................... 9  8 
................................................... 5  10 
.................................................... 1 
8.2 Exposure controls 
Appropriate engineering controls 
Change contaminated clothing. Wash hands after working with substance. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate 
government standards such as NIOSH (US) or EN 166(EU). Safety glasses 
Skin protection 
This recommendation applies only to the product stated in the safety data sheet, 
supplied by us and for the designated use. When dissolving in or mixing with other 
substances and under conditions deviating from those stated in EN374 please 
contact the supplier of CE-approved gloves (e.g. KCL GmbH, D-36124 Eichenzell, 
Internet: www.kcl.de). 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:KCL 741 Dermatril® L  
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This recommendation applies only to the product stated in the safety data sheet, 
supplied by us and for the designated use. When dissolving in or mixing with other 
substances and under conditions deviating from those stated in EN374 please 
contact the supplier of CE-approved gloves (e.g. KCL GmbH, D-36124 Eichenzell, 
Internet: www.kcl.de). 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:KCL 741 Dermatril® L 
 
Respiratory protection 
required when dusts are generated. 
Our recommendations on filtering respiratory protection are based on the following 
standards: DIN EN 143, DIN 14387 and other accompanying standards relating to 
the used respiratory protection system. 
 
Control of environmental exposure 
Do not let product enter drains. 
 
 
SECTION 9: Physical and chemical properties 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: crystalline 
Color: white 
b) Odor No data available 
c) Odor Threshold No data available 
d) pH 5.5 - 7.5 at 342 g/l at 25 °C (77 °F) 
e) Melting 
point/freezing point 
Melting point/range: 185 - 187 °C (365 - 369 °F) 
f) Initial boiling point 
and boiling range 
697.11 °C 1286.80 °F at 1,013.3 hPa 
g) Flash point  ()Not applicable 
h) Evaporation rate No data available 
i) Flammability (solid, 
gas) 




No data available 
k) Vapor pressure No data available 
l) Vapor density No data available 
m) Relative density 1.59 g/cm3 at 25 °C (77 °F) 
n) Water solubility 342 g/l at 20 °C (68 °F) - completely soluble 
o) Partition coefficient: 
n-octanol/water 
log Pow: -3.277 
p) Autoignition 
temperature 
No data available 
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160 - 165 °C (320 - 329 °F) -  
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 




SECTION 10: Stability and reactivity 
10.1 Reactivity 
The following applies in general to flammable organic substances and mixtures: in 
correspondingly fine distribution, when whirled up a dust explosion potential may generally 
be assumed. 
10.2 Chemical stability 
The product is chemically stable under standard ambient conditions (room temperature) . 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
no information available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Other decomposition products - No data available 
Hazardous decomposition products formed under fire conditions. - Carbon oxides 




SECTION 11: Toxicological information 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - 29,700 mg/kg 
Remarks: Behavioral:Somnolence (general depressed activity). Cyanosis Diarrhea 
Inhalation: No data available 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitization 
No data available 
Germ cell mutagenicity 
No data available 
Mutagenicity (mammal cell test): 
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(National Toxicology Program) 
Carcinogenicity 
IARC: No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
NTP: No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is 
on OSHA  li  of eg la ed carcinogens. 
Reproductive toxicity 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 




To the best of our knowledge, the chemical, physical, and toxicological properties have not 
been thoroughly investigated. 
 
Substances which occur in nature 
Hazardous properties cannot  be excluded but are unlikely when the product is handled 
appropriately. 





SECTION 12: Ecological information 
12.1 Toxicity 
No data available 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not 
conducted 
12.6 Other adverse effects 
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SECTION 13: Disposal considerations 
13.1 Waste treatment methods 
Product 
Waste material must be disposed of in accordance with the national and loc No mixing 
with other waste. Handle uncleaned containers like the product See 
www.retrologistik.com for processes regarding the return of chemicals and containers, or 




SECTION 14: Transport information 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 
Not dangerous goods 
 
Further information 




SECTION 15: Regulatory information 
 
SARA 302 Components 
This material does not contain any components with a section 302 EHS TPQ. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that 
exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 
313. 
SARA 311/312 Hazards 
No SARA Hazards 










No components are subject to the Massachusetts Right to Know Act. 
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SECTION 16: Other information 
Further information 
The above information is believed to be correct but does not purport to be all inclusive 
and shall be used only as a guide. The information in this document is based on the 
present state of our knowledge and is applicable to the product with regard to 
appropriate safety precautions. It does not represent any guarantee of the properties of 
the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any 
damage resulting from handling or from contact with the above product. See 
www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional 
terms and conditions of sale. 
 
Copyright 2020 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies 
for internal use only. 
The branding on the header and/or footer of this document may temporarily not visually 
match the product purchased as we transition our branding. However, all of the 
information in the document regarding the product remains unchanged and matches the 
product ordered. For further information please contact mlsbranding@sial.com. 
 
Version: 6.6 Revision Date: 10/07/2020 Print Date: 11/20/2020 
 
SAFETY DATA SHEET
This safety data sheet was created pursuant to the requirements of:
OSHA 29 CFR 1910.1200
Document Type  US - OSHA GHS Revision date  25-Nov-2019 Version  6
1. Identification
Product identifier 
Product name T7 RNA Polymerase
Other means of identification 
Product No M0251
Recommended use of the chemical and restrictions on use 
Recommended use This product is for research and development only
Restrictions on use No information available
Details of the supplier of the safety data sheet 
Company Phone Number 978-927-5054, 800-632-5227 (toll free)
Telefax 978-921-1350
E-mail address info@neb.com
Emergency telephone number 
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4. First-aid measures
Description of first aid measures
Inhalation Remove to fresh air.
Eye contact Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids.
Consult a physician.
Skin contact Wash skin with soap and water.
Ingestion Clean mouth with water and drink afterwards plenty of water.
2. Hazard(s) identification
Classification 
This chemical is not considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200)





Unknown acute toxicity 50 % of the mixture consists of ingredient(s) of unknown toxicity
0 % of the mixture consists of ingredient(s) of unknown acute oral toxicity
0 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity
50 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas)
50 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor)
50 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist)




The product contains no substances which at their given concentration, are considered to be hazardous to health.
Hazard statements 
Not a hazardous substance or mixture according to the Globally Harmonized System (GHS)
Appearance  Colorless Physical state  Liquid
_____________________________________________________________________________________________
Product name  T7 RNA Polymerase Page  2 / 8 Product No  M0251
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Most important symptoms and effects, both acute and delayed 
Symptoms No information available.
Indication of any immediate medical attention and special treatment needed 
Note to physicians Treat symptomatically.
5. Fire-fighting measures
Suitable Extinguishing Media Use extinguishing measures that are appropriate to local circumstances and the
surrounding environment.
Unsuitable Extinguishing Media CAUTION: Use of water spray when fighting fire may be inefficient.




Sensitivity to mechanical impact None.
Sensitivity to static discharge None.
Special protective equipment for
fire-fighters
Firefighters should wear self-contained breathing apparatus and full firefighting turnout
gear. Use personal protection equipment.
6. Accidental release measures
Personal precautions, protective equipment and emergency procedures 
Personal precautions Ensure adequate ventilation.
Methods and material for containment and cleaning up 
Methods for containment Prevent further leakage or spillage if safe to do so.
Methods for cleaning up Pick up and transfer to properly labeled containers.
7. Handling and storage
Precautions for safe handling
Advice on safe handling Handle in accordance with good industrial hygiene and safety practice.
Conditions for safe storage, including any incompatibilities
Storage Conditions Keep containers tightly closed in a dry, cool and well-ventilated place.
8. Exposure controls/personal protection
Control parameters 
Exposure Limits .
Other information Vacated limits revoked by the Court of Appeals decision in AFL-CIO v. OSHA, 965 F.2d 962
(11th Cir., 1992).
_____________________________________________________________________________________________
Product name  T7 RNA Polymerase Page  3 / 8 Product No  M0251
Appropriate engineering controls
_____________________________________________________________________________________________




Individual protection measures, such as personal protective equipment
Eye/face protection Wear safety glasses with side shields (or goggles).
Skin and body protection Wear suitable protective clothing.
Respiratory protection No protective equipment is needed under normal use conditions. If exposure limits are
exceeded or irritation is experienced, ventilation and evacuation may be required.
General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.
9. Physical and chemical properties




Odor threshold No information available
Other information  
Explosive properties No information available
Oxidizing properties No information available
Softening point No information available
Molecular weight No information available
VOC Content (%) No information available
Liquid Density No information available
Bulk density No information available
10. Stability and reactivity
Reactivity No information available.
Property Values  5HPDUNV0HWKRG
pH No data available None known
Melting point / freezing point No data available None known
Boiling point / boiling range No data available None known
Flash point No data available None known
Evaporation rate No data available None known
Flammability (solid, gas) No data available None known
Flammability Limit in Air None known
Upper flammability or explosive
limits
No data available
Lower flammability or explosive
limits
No data available
Vapor pressure No data available None known
Vapor density No data available None known
Relative density No data available None known
Water solubility No data available None known
Solubility in other solvents No data available None known
Partition coefficient No data available None known
Autoignition temperature No data available None known
Decomposition temperature No data available None known
Kinematic viscosity No data available None known
Dynamic viscosity No data available
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Chemical stability Stable under normal conditions.
Possibility of hazardous reactions None under normal processing.
Conditions to avoid None known based on information supplied.
Incompatible materials None known based on information supplied.
Hazardous decomposition products None known based on information supplied.
11. Toxicological information
Information on likely routes of exposure 
Product Information
Inhalation Specific test data for the substance or mixture is not available.
Eye contact Specific test data for the substance or mixture is not available.
Skin contact Specific test data for the substance or mixture is not available.
Ingestion Specific test data for the substance or mixture is not available.
Symptoms related to the physical, chemical and toxicological characteristics 
Symptoms No information available.
Acute toxicity 
Numerical measures of toxicity
The following values are calculated based on chapter 3.1 of the GHS document  .
ATEmix (oral) 25,200.00  mg/kg
ATEmix (dermal) 20,000.00  mg/kg
Unknown acute toxicity 50 % of the mixture consists of ingredient(s) of unknown toxicity
0 % of the mixture consists of ingredient(s) of unknown acute oral toxicity
0 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity
50 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas)
50 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor)
50 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist)
Delayed and immediate effects as well as chronic effects from short and long-term exposure  
Skin corrosion/irritation No information available.
Serious eye damage/eye irritation No information available.
Respiratory or skin sensitization No information available.
Germ cell mutagenicity No information available.
Carcinogenicity No information available.
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Reproductive toxicity No information available.
STOT - single exposure No information available.
STOT - repeated exposure No information available.
Aspiration hazard No information available.
Other adverse effects No information available.
Interactive effects No information available.
12. Ecological information
Ecotoxicity .
Persistence and degradability No information available.
Bioaccumulation There is no data for this product.
Component Information





Dispose of in accordance with local regulations. Dispose of waste in accordance with
environmental legislation.
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 TSCA  - United States Toxic Substances Control Act Section 8(b) Inventory
 DSL/NDSL  - Canadian Domestic Substances List/Non-Domestic Substances List
 EINECS/ELINCS  - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances
 ENCS  - Japan Existing and New Chemical Substances
 IECSC  - China Inventory of Existing Chemical Substances
 KECL  - Korean Existing and Evaluated Chemical Substances
 PICCS  - Philippines Inventory of Chemicals and Chemical Substances
 AICS  - Australian Inventory of Chemical Substances
US Federal Regulations 
SARA 313
Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA).  This product does not contain any
chemicals which are subject to the reporting requirements of the Act and Title 40 of the Code of Federal Regulations, Part 372.
SARA 311/312 Hazard Categories
Should this product meet EPCRA 311/312 Tier reporting criteria at 40 CFR 370, refer to Section 2 of this SDS for appropriate
classifications.
CWA (Clean Water Act)
This product does not contain any substances regulated as pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 40
CFR 122.42).
CERCLA
This material, as supplied, does not contain any substances regulated as hazardous substances under the Comprehensive
Environmental Response Compensation and Liability Act (CERCLA) (40 CFR 302) or the Superfund Amendments and
Reauthorization Act (SARA) (40 CFR 355).  There may be specific reporting requirements at the local, regional, or state level
pertaining to releases of this material.
US State Regulations 
California Proposition 65
This product does not contain any Proposition 65 chemicals.
U.S. State Right-to-Know Regulations 
U.S. EPA Label Information 
EPA Pesticide Registration Number Not applicable
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16. Other information
Key or legend to abbreviations and acronyms used in the safety data sheet 
Legend  Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION
Key literature references and sources for data used to compile the SDS
Agency for Toxic Substances and Disease Registry (ATSDR)
U.S. Environmental Protection Agency ChemView Database
European Food Safety Authority (EFSA)
EPA (Environmental Protection Agency)
Acute Exposure Guideline Level(s) (AEGL(s))
U.S. Environmental Protection Agency Federal Insecticide, Fungicide, and Rodenticide Act
U.S. Environmental Protection Agency High Production Volume Chemicals
Food Research Journal
Hazardous Substance Database
International Uniform Chemical Information Database (IUCLID)
Japan GHS Classification
Australia National Industrial Chemicals Notification and Assessment Scheme (NICNAS)
NIOSH (National Institute for Occupational Safety and Health)
National Library of Medicine's ChemID Plus (NLM CIP)
National Library of Medicine's PubMed database (NLM PUBMED)
National Toxicology Program (NTP)
New Zealand's Chemical Classification and Information Database (CCID)
Organization for Economic Co-operation and Development Environment, Health, and Safety Publications
Organization for Economic Co-operation and Development High Production Volume Chemicals Program
Organization for Economic Co-operation and Development Screening Information Data Set
RTECS (Registry of Toxic Effects of Chemical Substances)
World Health Organization
Prepared by Environmental, Health and Safety
978-927-5054
Revision date 25-Nov-2019
Revision note SDS is valid 3 years from revision date. Contact info@neb.com for latest revision.
Disclaimer
IMPORTANT:  The information in this SDS is provided in good faith based on our knowledge as of the issue date (or
subsequent revision date, if any), and is to be used only as a guide.  This SDS does not constitute a guarantee (express
or implied) of any kind and we make no warranties or merchantability or fitness for a particular purpose.  This information
relates only to the designated product as shipped and may not be valid if the product is used in combination with any
other materials or is not used in accordance with our instructions.  It is the responsibility of the buyer/user to ensure that
its activities comply with all applicable governmental requirements. Since conditions of use of the product are not under
the control of New England Biolabs, it is the duty of the buyer/user to determine the necessary conditions for the safe use
of the product.  New England Biolabs will not be liable for any damages resulting from handling or contact with the
product.
End of Safety Data Sheet
NFPA  Health hazards  0 Flammability  0 Instability  0 Special Hazard  -
HMIS  Health hazards  0 Flammability  0 Physical hazards  0 Personal protection  X
TWA TWA (time-weighted average) STEL STEL (Short Term Exposure Limit)
Ceiling Maximum limit value *
_____________________________________________________________________________________________
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Manufacturer or supplier's details 
Company name of supplier 
 








Telephone : +496217590 
Telefax : +496217592890 
Emergency telephone 
In case of emergencies: : CHEMTREC 
 
+1 703-741-5970 / 
1-800-424-9300 
Recommended use of the chemical and restrictions on use 
Restrictions on use 
 
: For professional users only. 
 
 
SECTION 2. HAZARDS IDENTIFICATION 
GHS classification in accordance with 29 CFR 1910.1200 
Not a hazardous substance or mixture. 
GHS label elements 




SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS 
Substance / Mixture 
 
:  Substance 
Substance name 
 







No hazardous ingredients 
 
SECTION 4. FIRST AID MEASURES 
General advice 
 
: Do not leave the victim unattended. 
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If inhaled 
 
: Move to fresh air. 
If unconscious, place in recovery position and seek medical 
advice. 
If symptoms persist, call a physician. 
 
In case of skin contact 
 
: If on skin, rinse well with water. 
 
In case of eye contact 
 
: Immediately flush eye(s) with plenty of water. 
Remove contact lenses. 
Protect unharmed eye. 




: Keep respiratory tract clear. 
Do not give milk or alcoholic beverages. 
Never give anything by mouth to an unconscious person. 
If symptoms persist, call a physician. 
Rinse mouth with water. 
 
Most important symptoms 
and effects, both acute and 
delayed 
 
: None known. 
Notes to physician 
 
: The first aid procedure should be established in consultation 
with the doctor responsible for industrial medicine. 
 
 
SECTION 5. FIRE-FIGHTING MEASURES 
Suitable extinguishing media 
 
: Use extinguishing measures that are appropriate to local cir-
cumstances and the surrounding environment. 
 
Specific hazards during fire 
fighting 
 





:  No hazardous combustion products are known 
 
Further information : Standard procedure for chemical fires. 
Use extinguishing measures that are appropriate to local cir-
cumstances and the surrounding environment. 
 
Special protective equipment 
for fire-fighters 
 
: Wear self-contained breathing apparatus for firefighting if 
necessary. 
 
SECTION 6. ACCIDENTAL RELEASE MEASURES 
Personal precautions, protec-
tive equipment and emer-
gency procedures 
 




: Local authorities should be advised if significant spillages 
cannot be contained. 
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Methods and materials for 
containment and cleaning up 
 
: Pick up and arrange disposal without creating dust. 
Sweep up and shovel. 
Keep in suitable, closed containers for disposal. 
 
SECTION 7. HANDLING AND STORAGE 
Advice on protection against 
fire and explosion 
 
:  Provide appropriate exhaust ventilation at places where dust 
is formed. 
 
Advice on safe handling 
 
: For personal protection see section 8. 
Smoking, eating and drinking should be prohibited in the ap-
plication area. 
 
Conditions for safe storage 
 
: Electrical installations / working materials must comply with 
the technological safety standards. 
 
Further information on stor-
age conditions 
 
: See label, package insert or internal guidelines 
 
Materials to avoid 
 
: No materials to be especially mentioned. 
Keep away from oxidizing agents, strongly alkaline and 
strongly acid materials in order to avoid exothermic reactions. 
 
Further information on stor-
age stability 
 
:  No decomposition if stored and applied as directed. 
 
SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
Ingredients with workplace control parameters 
Contains no substances with occupational exposure limit values. 
Personal protective equipment 
Respiratory protection 
 




   In case of full contact:  
Material : Nitrile rubber 
Break through time : 480 min 
Glove thickness : 0.11 mm 
   In case of contact through splashing:  
Material : Nitrile rubber 
Break through time : 480 min 
Glove thickness : 0.11 mm 
Remarks 
 
: Wear appropriate protective gloves to prevent skin contact. 
Replace torn or punctured gloves promptly. 
Eye protection 
 
: Safety glasses 
 
Skin and body protection 
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: 4.2 (20 °C / 20 °C)  
Concentration: 100 g/l 




: 152 °C / 152 °C  
 
Boiling point/boiling range 
 




: Not applicable  
Evaporation rate 
 
:  Not applicable  
 
Flammability (solid, gas) 
 




: Sustains combustion 
 
Self-ignition : No data available  
 
Upper explosion limit / Upper 
flammability limit 
 
: No data available  
 
Lower explosion limit / Lower 
flammability limit 
 




: No data available  
 
Relative vapor density 
 









: soluble  
 
Solubility in other solvents 
 





: Remarks: Not applicable 
Autoignition temperature 
 









: Not applicable  
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Viscosity, kinematic 
 








: 157.6 g/mol 
 
SECTION 10. STABILITY AND REACTIVITY 
Reactivity 
 




:  Stable under normal conditions. 
 
Possibility of hazardous reac-
tions 
 
: No data available 
Stable under recommended storage conditions. 
No hazards to be specially mentioned. 
 
Conditions to avoid 
 









:   No decomposition if stored and applied as directed. 
 
SECTION 11. TOXICOLOGICAL INFORMATION 
Acute toxicity 
Not classified based on available information. 
Skin corrosion/irritation 
Not classified based on available information. 
Serious eye damage/eye irritation 
Not classified based on available information. 
Respiratory or skin sensitization 
Skin sensitization 
Not classified based on available information. 
Respiratory sensitization 
Not classified based on available information. 
Germ cell mutagenicity 
Not classified based on available information. 
Carcinogenicity 
Not classified based on available information. 
IARC No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
 
OSHA No component of this product present at levels greater than or equal to 0.1% is 
on OSHA  li  of eg la ed ca cinogen . 
 
NTP No ingredient of this product present at levels greater than or equal to 0.1% is 
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identified as a known or anticipated carcinogen by NTP. 
 
Reproductive toxicity 
Not classified based on available information. 
STOT-single exposure 
Not classified based on available information. 
STOT-repeated exposure 
Not classified based on available information. 
Aspiration toxicity 
Not classified based on available information. 
SECTION 12. ECOLOGICAL INFORMATION 
Ecotoxicity 
No data available 
Persistence and degradability 
No data available 
Bioaccumulative potential 
No data available 
Mobility in soil 
No data available 




: Regulation: 40 CFR Protection of Environment; Part 82 Pro-
tection of Stratospheric Ozone - CAA Section 602 Class I 
Substances 
Remarks: This product neither contains, nor was manufac-
tured with a Class I or Class II ODS as defined by the U.S. 
Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B). 
 
 
SECTION 13. DISPOSAL CONSIDERATIONS 
Disposal methods 
Waste from residues : Can be disposed as waste water, when in compliance with 
local regulations. 
 
Contaminated packaging : Empty containers should be taken to an approved waste 
handling site for recycling or disposal. 
Do not re-use empty containers. 
 
SECTION 14. TRANSPORT INFORMATION 
International Regulations 
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UNRTDG  
Not regulated as a dangerous good 
IATA-DGR  
Not regulated as a dangerous good 
IMDG-Code  
Not regulated as a dangerous good 
Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code 
Not applicable 
Domestic regulation 
49 CFR  
Not regulated as a dangerous good 
 
SECTION 15. REGULATORY INFORMATION 
EPCRA - Emergency Planning and Community Right-to-Know 
CERCLA Reportable Quantity 
This material does not contain any components with a CERCLA RQ. 
SARA 304 Extremely Hazardous Substances Reportable Quantity 
This material does not contain any components with a section 304 EHS RQ. 
SARA 302 Extremely Hazardous Substances Threshold Planning Quantity 
Components CAS-No. Component TPQ (lbs) 
SARA 311/312 Hazards 
 
:  No SARA Hazards 
 
Clean Air Act 
This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by 
the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B). 
This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean 
Air Act Section 112 (40 CFR 61). 
This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for 
Accidental Release Prevention (40 CFR 68.130, Subpart F). 
This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 
SOCMI Intermediate or Final VOC's (40 CFR 60.489). 
Clean Water Act 
This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, 
Section 311, Table 116.4A. 
This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, 
Section 311, Table 117.3. 
This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 
307 
US State Regulations 
Massachusetts Right To Know 
Pennsylvania Right To Know 
 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-, hydrochloride 1185-53-1 
 







Revision Date:  
04-17-2019 
Date of last issue: 06-19-2018 
Date of first issue: 10-20-2015 
 
 
8 / 10 
(1:1) 
Maine Chemicals of High Concern 
Vermont Chemicals of High Concern 
Washington Chemicals of High Concern 
The ingredients of this product are reported in the following inventories: 
DSL 
 




































: All substances listed as active on the TSCA inventory 
 
TSCA list 
No substances are subject to a Significant New Use Rule. 
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SECTION 16. OTHER INFORMATION 
Further information 
























HMIS® ratings are based on a 0-4 rating 
scale, with 0 representing minimal haz-
ards or risks, and 4 representing signifi-
cant hazards or risks. The "*" represents 
a chronic hazard, while the "/" represents 




3050 Spruce Street 
SAINT LOUIS 
MO 63103 USA 
Full text of other abbreviations 
 
AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of 
Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, 
and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the 
German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Sub-
stances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Haz-
ardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; 
ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with 
x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized Sys-
tem; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - 
International Agency for Research on Cancer; IATA - International Air Transport Association; IBC 
- International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals 
in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organiza-
tion; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime 
Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health 
Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemi-
cals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 
50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Pre-
vention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Oth-
erwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) 
Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable 
Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of 
Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office 
of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic sub-
stance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quanti-































Revision Date:  
04-17-2019 
Date of last issue: 06-19-2018 
Date of first issue: 10-20-2015 
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REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concern-
ing the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable 
Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amend-
ments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance 
Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - 
United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent 
and Very Bioaccumulative 
 
 
Revision Date :  04-17-2019 
 
 
The information provided in this Material Safety Data Sheet is correct to the best of our 
knowledge, information and belief at the date of its publication. The information given is designed 
only as a guidance for safe handling, use, processing, storage, transportation, disposal and re-
lease and is not to be considered a warranty or quality specification. The information relates only 
to the specific material designated and may not be valid for such material used in combination 
with any other materials or in any process, unless specified in the text. 
 
US / Z8 / 1805 
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SAFETY DATA SHEET 
 
Version 6.6 
Revision Date 04/16/2020 
Print Date 08/29/2020 
 
SECTION 1: Identification of the substance/mixture and of the company/undertaking 
1.1 Product identifiers 
Product name : T i  X-100 
 
Product Number : X100 
Brand : Sigma-Aldrich 
CAS-No. : 9002-93-1 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich Inc. 
3050 Spruce Street 
ST. LOUIS MO  63103 
UNITED STATES 
 
Telephone : +1 314 771-5765 
Fax : +1 800 325-5052 
1.4 Emergency telephone number 
Emergency Phone # : 800-424-9300 CHEMTREC (USA) +1-703-
527-3887 CHEMTREC (International) 24 
Hours/day; 7 Days/week 
 
 
SECTION 2: Hazards identification 
2.1 Classification of the substance or mixture 
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) 
Acute toxicity, Oral (Category 4), H302 
Skin irritation (Category 2), H315 
Serious eye damage (Category 1), H318 
Short-term (acute) aquatic hazard (Category 1), H400 
Long-term (chronic) aquatic hazard (Category 1), H410 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
2.2 GHS Label elements, including precautionary statements 
Pictogram 
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H302 Harmful if swallowed. 
H315 Causes skin irritation. 
H318 Causes serious eye damage. 
H410 Very toxic to aquatic life with long lasting effects. 
 
Precautionary statement(s) 
P264 Wash skin thoroughly after handling. 
P270 Do not eat, drink or smoke when using this product. 
P273 Avoid release to the environment. 
P280 Wear protective gloves/ eye protection/ face protection. 
P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/doctor if you feel 
unwell. Rinse mouth. 
P302 + P352 IF ON SKIN: Wash with plenty of soap and water. 
P305 + P351 + P338 + 
P310 
IF IN EYES: Rinse cautiously with water for several minutes. 
Remove contact lenses, if present and easy to do. Continue 
rinsing. Immediately call a POISON CENTER/doctor. 
P332 + P313 If skin irritation occurs: Get medical advice/ attention. 
P362 Take off contaminated clothing and wash before reuse. 
P391 Collect spillage. 
P501 Dispose of contents/ container to an approved waste disposal 
plant. 
 




SECTION 3: Composition/information on ingredients 
3.1 Substances 
Synonyms : t-Octylphenoxypolyethoxyethanol 
4-(1,1,3,3-Tetramethylbutyl)phenyl-polyethylene glycol 
Polyethylene glycol tert-octylphenyl ether 
 
Formula : (C2H4O)nC14H22O 
CAS-No. : 9002-93-1 
 
Component Classification Concentration 
Triton-X-100 
   Acute Tox. 4; Skin Irrit. 2; 
Eye Dam. 1; Aquatic Acute 
1; Aquatic Chronic 1; 
H302, H315, H318, H400, 
H410 
M-Factor - Aquatic Acute: 
10 - Aquatic Chronic: 1 
<= 100 % 
 
Polyethylene glycol, average MW 8,000 
     >= 1 - < 5 % 
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SECTION 4: First aid measures 
4.1 Description of first aid measures 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of 
dangerous area. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Consult a physician. 
In case of eye contact 
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult 
a physician. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 
2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 




SECTION 5: Firefighting measures 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
Carbon oxides 
Combustible. 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 




SECTION 6: Accidental release measures 
6.1 Personal precautions, protective equipment and emergency procedures 
Use personal protective equipment. Avoid breathing vapours, mist or gas. Ensure 
adequate ventilation. Evacuate personnel to safe areas. 
For personal protection see section 8. 
6.2 Environmental precautions 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. 
Discharge into the environment must be avoided. 
 
 




The life science business of Merck KGaA, Darmstadt, Germany 






6.3 Methods and materials for containment and cleaning up 
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in 
suitable, closed containers for disposal. 
6.4 Reference to other sections 




SECTION 7: Handling and storage 
7.1 Precautions for safe handling 
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place. Containers which are 
opened must be carefully resealed and kept upright to prevent leakage.  
Packaged under inert gas.  
Storage class (TRGS 510): 10: Combustible liquids 
7.3 Specific end use(s) 




SECTION 8: Exposure controls/personal protection 
8.1 Control parameters 
Components with workplace control parameters 










TWA 10 mg/m3 USA. Workplace Environmental 
Exposure Levels (WEEL) 
8.2 Exposure controls 
Appropriate engineering controls 
Handle in accordance with good industrial hygiene and safety practice. Wash hands 
before breaks and at the end of workday. 
Personal protective equipment 
Eye/face protection 
Tightly fitting safety goggles.  Faceshield (8-inch minimum). Use equipment for eye 
protection tested and approved under appropriate government standards such as 
NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove 
removal technique (without touching glove's outer surface) to avoid skin contact 
with this product. Dispose of contaminated gloves after use in accordance with 
applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
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Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail 
sales@kcl.de, test method: EN374 
If used in solution, or mixed with other substances, and under conditions which 
differ from EN 374, contact the supplier of the CE approved gloves. This 
recommendation is advisory only and must be evaluated by an industrial hygienist 
and safety officer familiar with the specific situation of anticipated use by our 




Complete suit protecting against chemicals, The type of protective equipment must 
be selected according to the concentration and amount of the dangerous substance 
at the specific workplace. 
Respiratory protection 
Where risk assessment shows air-purifying respirators are appropriate use a full-
face respirator with multi-purpose combination (US) or type ABEK (EN 14387) 
respirator cartridges as a backup to engineering controls. If the respirator is the sole 
means of protection, use a full-face supplied air respirator. Use respirators and 
components tested and approved under appropriate government standards such as 
NIOSH (US) or CEN (EU). 
ABEK-filter 
Control of environmental exposure 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. 
Discharge into the environment must be avoided. 
 
 
SECTION 9: Physical and chemical properties 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: liquid, clear 
Colour: colourlesslight yellow 
b) Odour characteristic 
c) Odour Threshold No data available 
d) pH 9.7 
e) Melting 
point/freezing point 
Melting point: 6 °C (43 °F) 
f) Initial boiling point 
and boiling range 
> 200 °C > 392 °F at 1,013 hPa 
g) Flash point 251 °C (484 °F) - closed cup 
h) Evaporation rate No data available 
i) Flammability (solid, 
gas) 
No data available 
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No data available 
k) Vapour pressure < 1.33 hPa at 20 °C (68 °F) 
l) Vapour density No data available 
m) Relative density 1.065 g/cm3 at 20 °C (68 °F) 
n) Water solubility soluble 
o) Partition coefficient: 
n-octanol/water 
No data available 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 




SECTION 10: Stability and reactivity 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong acids, Strong bases, Strong oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides 
Other decomposition products - No data available 




SECTION 11: Toxicological information 
11.1 Information on toxicological effects 
Acute toxicity 
No data available 
LD50 Oral - Rat - 1,900 - 5,000 mg/kg 
Remarks: (External MSDS) The value is given in analogy to the following substances: 
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Inhalation: No data available 
Inhalation: No data available 
LD50 Dermal - Rabbit - > 3,000 mg/kg 
LD50 Dermal - Rabbit - > 3,000 mg/kg 
Remarks: (External MSDS) The value is given in analogy to the following substances: 
No data available 
No data available 
Skin corrosion/irritation 
No data available 
Skin - Rabbit 
Result: irritating - 4 h 
(OECD Test Guideline 404) 
Remarks: The value is given in analogy to the following substances: 
Serious eye damage/eye irritation 
No data available 
Eyes - Rabbit 
Result: Risk of serious damage to eyes. 
(Draize Test) 
Risk of corneal clouding. 
Respiratory or skin sensitisation 
No data available 
Sensitisation test: - Human 
Result: negative 
Remarks: (External MSDS) The value is given in analogy to the following substances: 
Germ cell mutagenicity 
No data available 
No data available 
Mutagenicity (mammal cell test): 




IARC: No component of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
NTP: No component of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is 
 OSHA  li  f eg la ed ca ci ge . 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
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RTECS: Not available 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not 
been thoroughly investigated. 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not 
been thoroughly investigated. 
 





SECTION 12: Ecological information 
12.1 Toxicity 
 
Toxicity to fish LC50 - Pimephales promelas (fathead minnow) - 4 - 8.9 mg/l  - 96 h 
 
Toxicity to fish semi-static test LC50 - Leuciscus idus (Golden orfe) - 0.26 mg/l  - 96 
h 
(OECD Test Guideline 203) 
Remarks: The value is given in analogy to the following substances: 
 
Toxicity to daphnia 
and other aquatic 
invertebrates 
LC50 - Daphnia magna (Water flea) - 18 - 26 mg/l  - 48 h 
 
Toxicity to daphnia 
and other aquatic 
invertebrates 
static test EC50 - Daphnia magna (Water flea) - 0.011 mg/l  - 48 h 
Remarks: (ECOTOX Database)The value is given in analogy to the 
following substances: 
 
Toxicity to algae static test EC50 - Pseudokirchneriella subcapitata (green algae) - 1.9 
mg/l  - 96 h 
Remarks: (ECHA)The value is given in analogy to the following 
substances: 
12.2 Persistence and degradability 





12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not 
conducted 
12.6 Other adverse effects 
Very toxic to aquatic life with long lasting effects. 
An environmental hazard cannot be excluded in the event of unprofessional handling or 
disposal. 
Causes endocrine disruption. 
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SECTION 13: Disposal considerations 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a 
licensed professional waste disposal service to dispose of this material.  
Contaminated packaging 




SECTION 14: Transport information 
DOT (US) 
Not dangerous goods 
 
IMDG 
UN number: 3082 Class: 9 Packing group: III EMS-No: F-A, S-F 
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. 
(Triton-X-100) 
Marine pollutant : yes 
 
IATA 
UN number: 3082 Class: 9 Packing group: III 
Proper shipping name: Environmentally hazardous substance, liquid, n.o.s. (Triton-X-100) 
Further information 
EHS-Mark required (ADR 2.2.9.1.10, IMDG code 2.10.3) for single packagings and 
combination packagings containing inner packagings with Dangerous Goods > 5L for liquids 




SECTION 15: Regulatory information 
 
SARA 302 Components 
This material does not contain any components with a section 302 EHS TPQ. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that 
exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 
313. 
SARA 311/312 Hazards 
Acute Health Hazard 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
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SECTION 16: Other information 
Further information 
Copyright 2020 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies 
for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive 
and shall be used only as a guide. The information in this document is based on the 
present state of our knowledge and is applicable to the product with regard to 
appropriate safety precautions. It does not represent any guarantee of the properties of 
the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any 
damage resulting from handling or from contact with the above product. See 
www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional 
terms and conditions of sale. 
 
The branding on the header and/or footer of this document may temporarily not visually 
match the product purchased as we transition our branding. However, all of the 
information in the document regarding the product remains unchanged and matches the 
product ordered. For further information please contact mlsbranding@sial.com. 
 
Version: 6.6 Revision Date: 04/16/2020 Print Date: 08/29/2020 
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(54) Title: A METHOD FOR PRODUCING AND PURIFYING RNA, COMPRISING AT LEAST ONE STEP OF TANGENTIALo FLOW FILTRATION
(57) Abstract: The present invention relates to method for producing and purifying RNA comprising the steps of providing DNA
encoding the RNA; transcription of the DNA into RNA; and conditioning and/or purifying of the solution comprising transcribed
RNA by one or more steps of tangential flow filtration (TFF).
A method for producing and purifying RNA, comprising at least one step of
tangential flow filtration
Technical field
The present invention relates to methods of tangential flow filtration (TFF) for
producing and purifying RNA.
Background of the Invention
RNA is emerging as an innovative candidate for a variety of pharmaceutical
applications, but efficient purification is continuing to be a challenge. This is partly
due to the different types and combinations of undesired contaminants in a sample
that need to be separated from a desired RNA species to obtain a pure RNA
sample. Such contaminants are typically components and by-products of any
upstream processes, for example RNA manufacture. Where in vitro transcription is
used to manufacture large RNA, following successful transcription the sample
typically contains the desired RNA species alongside various contaminants such as
undesired RNA species, proteins, spermidine, DNA or fragments thereof,
pyrophosphates, free nucleotides, endotoxins, detergents, and organic solvents.
Commercial downstream applications (e.g. formulation and use as a pharmaceutical
composition and/or vaccine) pose further constrains on any purification method for
RNA requiring (i) a high degree of purity while retaining RNA stability and
functionality; (ii) compatibility with any formulation requirements of the RNA for in
vivo delivery; and (iii) compliance with good manufacturing practices. Furthermore,
in order to facilitate industrial applications, any RNA purification method must enable
consistent, cost- and time-efficient operation (e.g. quick, easy, reproducible, high
Table 8 : Plasmid concentration
The dsDNA concentration in the retentate was photometrically determined to be
1.05 g/l in a final volume of 22 ml. The diafiltration of the linearized pDNA using TFF
yielded 96.6 % of input DNA.
Agarose Gel Electrophoresis:
Only a negligible amount of plasmid DNA is visible in the permeate of the
concentration step and of the diafiltration step.
13.3 - RNA in vitro transcription
800 ml of in vitro transcription mix as described in Example 4 was incubated for 3 h
at 37°C.
Next, CaC and DNase I was added and subsequently incubated for 2 h at 37°C.
13.4 - Diafiltration of the transcription reaction
The TFF system Sartoflow 200 with two PES membranes (Sartorius, 200 cm2, 100
kDa) was used to exchange the buffer of three aliquots (400 ml each) of the
transcription reaction to WFI (process parameters indicated in Table 9). First,
container and tubes were cleaned with ultrapure water, ethanol and WFI. Then the
setup was assembled and the filter cassette was mounted on the Sartocon holder
according to the manufacturer's instructions. The whole system was cleaned with
ultra-pure water. Subsequently, the system was chemically sanitized by a 1 hour
wash with 1 M NaOH. Then, the setup was washed with WFI until a pH of 7 was
measured in the retentate and the system was equilibrated with 500 ml WFI. After
that, 400 ml transcription reaction (see 13.3) were added to the retentate reservoir,
pressures (dp and TMP) were set to 1 bar, and the diafiltration procedure was
started against 10 diafiltration volumes (DFV) water for injection (WFI). After
diafiltration by TFF the RNA concentration was measured photometrically.
Table 9 : TFF parameters used for diafiltration of the transcription reaction
Results:
The final concentration of the RNA after diafiltration was 5 g/l and the total recovery
rate of the RNA after buffer exchange via diafiltration was 98%.
Example 13.5 - RP-HPLC purification of the conditioned transcription reaction
The RNA solution obtained from Example 13.4 was diluted to 100 mM TEAA and a
concentration of 1 g/l by addition of 1 M triethylammonium acetate (TEAA) and WFI.
The RNA was step-wise purified according to Example 5 . The HPLC fractions were
collected, the product-containing fractions were pooled and divided in three pools I
to III.
Moreover, fractions were analyzed for RNA content (UV260/280) and every fraction
was analyzed for RNA integrity.
Results:
Table 10: Determination of RNA concentration and RNA integrity after RP-HPLC
purification
Pools Volume RNA RNA integrity
cone. amount
Pool I Ca. 7.2 L 0.12 g/l Ca. 840 mg 97.8%
Pool I I Ca. 7.3 L 0.12 g/l Ca. 840 mg 97.7%
Pool III Ca. 6.2 L 0.12 g/l Ca. 744 mg 95.7%
Compared to the starting material (TFF conditioned RNA), the integrity could be
increased by >10 % (86.5% RNA integrity before RP-HPLC) by separating aborted
RNA species.
Example 13.6 - Concentration and diafiltration of the RP-HPLC pool via TFF
The three RP-HPLC purified RNA pools were processed separately using an
additional concentration and diafiltration step with TFF to further separate the RNA
from impurities (e.g. spermidine contaminations) and to exchange the solvent.
First, every pool was concentrated from 0.12 g/l to approximately 5 g/l using TFF.
5M NaCI solution was added to the retentate to get a final concentration of 0.2 M
NaCI. Then, a diafiltration was performed against 0.2 M NaCI (10 DFV) to remove
spermidine impurities. Next, the diafiltration solution was exchanged to WFI (10
DFV). The process parameters are shown in Table 11. After TFF RNA concentration
was determined by measuring the absorption at 260 nm. For agarose gel
electrophoresis the indicated amounts of RNA were used for gel electrophoresis.
Table 11: Parameters used for TFF of the RP-HPLC pools
Results:
The yield after the diafiltration was spectrometrically determined to be 94.44%,




Membrane load 0.1 - 0.6 mg DNA/cm2
Feed flowrate [l/h/m2] 750 - 900
Permeate flux rate [l/h/m2] 30 - 100
14.2 - Diafiltration of the RNA IVT reaction by TFF:
RNA in vitro transcription was performed as described in Example 4 . For tangential
flow filtration of the RNA IVT reaction (conducted according to Example 4), a
Hydrosart filter cassette (cellulose based membrane, MWCO 100 kDa, Sartorius)
was used. The conditioning of the RNA IVT reaction was performed as explained
above (see Example 13). The result of the diafiltration of the RNA IVT reaction is
provided in Figure 14. Relevant process parameters are summarized in Table 17.
Table 17: TFF Process parameters of the RNA IVT reaction diafiltration
- Concentration and diafiltration of the RP-HPLC RNA pool
The in vitro transcribed RNA was purified by RP-HPLC as described in Example 5 .
For tangential flow filtration of the RP-HPLC RNA pool, a Hydrosart filter cassette
(cellulose based membrane, MWCO 100 kDa, Sartorius) was used. The
concentration of the RP-HPLC RNA pool was performed as explained above (see
Example 13). The result of the concentration of the RP-HPLC RNA is provided in
Figure 15. The diafiltration of the RNA into 0.2 M NaCI and a further diafiltration of
the RNA into WFI was performed as explained above (see Example 13). The result
of the diafiltration of the RP-HPLC RNA pool is provided in Figure 16. Relevant
process parameters are summarized in Table 18.
Table 18: TFF process parameters of the RP-HPLC RNA concentration and
diafiltration
Embodiment list:
1. A method for producing and purifying RNA, comprising the steps of
A) providing DNA encoding the RNA;
B) transcription of the DNA to yield a solution comprising transcribed RNA; and
C) conditioning and/or purifying of the solution comprising transcribed RNA by one
or more steps of tangential flow filtration (TFF).
2 . The method according to item 1, wherein in step A) plasmid DNA is provided as
DNA encoding the RNA and the method comprises subsequently to step A) the
steps:
A1) linearization of the plasmid DNA in a linearization reaction;
A2) optionally termination of the linearization reaction; and
A3) conditioning and/or purifying of the linearization reaction comprising linearized
plasmid DNA by one or more steps of TFF.
3 . The method according to item 1 or 2 , wherein step C) comprises at least one
diafiltration step and/or at least one concentration step using TFF.
4 . The method according to item 3, wherein the at least one diafiltration step using
TFF in step C) comprises diafiltration with an aqueous salt solution.
5 . The method according to item 4, wherein the aqueous salt solution is a NaCI
solution, preferably an aqueous solution comprising from about 0.1 M NaCI to about
1 M NaCI, more preferably a solution comprising from about 0.2 to about 0.5 M
NaCI.
6 . The method according to item 3, wherein the at least one diafiltration step using
TFF of step C) comprises diafiltration with water.
7 . The method according to any one of items 1 to 6 , wherein the method does not
comprise a step of phenol/chloroform extraction and/or DNA and/or RNA
precipitation.
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peutic material including, but not limited to, lipid nanoparticles and polymer nanoparticles. In certain embodiments, continuous flow
operation and parallelization of microfluidic mixers contribute to increased nanoparticle production volume.
microfluidic mixers arrayed in parallel in a single device illustrated in FIGURE 3
(4X On-Chip). The total flow rates through the microfluidic device are shown in the
legend. Error bars represent the standard deviation of the mean.
In this Example, 0.231 mg/mL siRNA in 50 mM sodium acetate buffer (pH 4.0)
and lipid mix (12.5 mM l,17-bis(2-octylcyclopropyl)heptadecan-9-yl 4-
(dimethylamino)butanoate/DSPC/Chol/PEG-c-DMA at mole ratios of 50:10:38.5:1.5 in
ethanol) in separate syringes were loaded into independent Harvard PHD Ultra syringe
pumps (Harvard Apparatus, Holliston, MA). The siRNA-total lipid ratio was 0.06 wt/wt.
Mixing volumes ratios of siRNA to lipid mix was 3:1, with 5 mL total volume processed
per mixer (i.e., total formulation volumes: IX = 5 mL, 2X = 10 mL, 4X = 20 mL). Flow
rate per mixer was 12 mL/min at siRNA to lipid mix flow rate ratio of 3:1 (i.e., 9 mL/min
siRNA and 3 mL/min lipid mix in IX). The first 2 mL of volume collected from the
mixer outlet at the beginning of each formulation run was discarded as waste, and the
remaining volume was collected as the sample. The 1 mL of the collected sample was
further diluted into 3 mL of Dulbecco's Phosphate Buffered Saline (without calcium and
without magnesium) before particle sizing.
Particle size measurement was performed as follows: siRNA-LNP were diluted to
appropriate concentration with Dulbecco's Phosphate Buffered Saline (without calcium
and without magnesium) and mean particle size (intensity-weighted) was determined by
dynamic light scattering (DLS) using a Malvern Zetasizer Nano ZS two angle particle
sizer (Malvern Instruments Ltd., Malvern, Worcestershire, UK).
Example 2 : siRNA-Lipid Nanoparticles (siRNA-LNP) Manufactured Using Eight Single
Microfluidic Mixer Devices Arrayed in Parallel Using a Manifold
In this example, 520 mL volume of siRNA-LNP was produced using eight single
microfluidic mixer devices arrayed in parallel using an external manifold. Each mixer in
the array was identical, thus the process conditions for forming siRNA-LNP in each
mixer was identical. The purpose of this experiment was to demonstrate the effect of a
large number of parallel mixers on siRNA-LNP size and quality. This example
significantly demonstrates the successful utilization of a large number of microfluidic
mixers used in parallel in the same system to produce a large volume batch of siRNA-
LNP using an exemplary system as disclosed herein.
FIGURE 5 shows particle diameter (nm) and polydispersity index (PDI) for
representative siRNA-Lipid Nanoparticles (siRNA-LNP) as a function of the
manufactured volume. The siRNA-LNP were composed of l,17-bis(2-
octylcyclopropyl)heptadecan-9-yl 4-(dimethylamino)butanoate/DSPC/Chol/PEG-c-DMA
at mole ratios of 50:10:38.5:1.5 and a siRNA-total lipid ratio of 0.06 wt/wt, and the
nanoparticles were produced using the illustrative continuous flow system shown in
FIGURE 2 with eight single microfluidic mixer device arrayed in parallel using a
manifold. Nanoparticles were sampled every 100 mL from 0 mL to 500 mL and the
results compared to a 2 mL preparation of the same siRNA-LNP prepared using the
NanoAssemblr™ Benchtop Instrument. The NanoAssemblr™ Benchtop Instrument is
commercially available laboratory apparatus that uses microfluidics to manufacture fixed
volume batches of nanoparticles. Error bars represent the standard deviation of the mean.
In this Example, 0.231 mg/mL siRNA in 50 mM sodium acetate buffer (pH 4.0)
and lipid mix (12.5 mM l,17-bis(2-octylcyclopropyl)heptadecan-9-yl 4-
(dimethylamino)butanoate/DSPC/Chol/PEG-c-DMA at mole ratios of 50:10:38.5:1.5 in
ethanol) loaded in separate Flash 100 metering pump (Scientific Systems, Inc., State
College, PA). The siRNA-total lipid ratio was 0.06 wt/wt. Mixing volumes ratios of
siRNA to lipid mix was 3:1, with 65 mL total volume processed per mixer (ie: total
formulation volumes in 8X = 520 mL). Flow rate per mixer was 12 mL/min at siRNA to
lipid mix flow rate ratio of 3:1 (total flow rate = 96 ml/min, thus flow rates for siRNA
and lipid mix were 72 mL/min and 24 mL/min respectively). The first 20 mL of volume
collected from the mixer outlet at the beginning the formulation run was discarded as
waste, and the remaining volume was collected as the sample. After the first 20 mL
priming waste was collected, the particle formulation was diluted in-line with Dulbecco's
Phosphate Buffered Saline (without calcium and without magnesium), 1 part particle
solution to 3 part DPBS, driven by a Masterflex L/S peristaltic pump with dual Easy-load
II pump heads (Cole-Parmer Instrument Company, Montreal, QC, Canada). The
resulting particle formulation was collected in aliquots and sized.
While illustrative embodiments have been illustrated and described, it will be
appreciated that various changes can be made therein without departing from the spirit
and scope of the invention.
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1. Ab ac
RNA acc e  a e a e  f e  f ed c e. U e e-e g acc e
ech g e , RNA acc e  e e  he h a  b d h he ge e c f a   a e a
e  h e d c  c e  a a a  e e e. I  h  a e , RNA acc e
c ea e a b d e  a d b d  a d  a h ge e g  he a e ec  a
ad a  acc e  e  h  e e g he b d h he f e g  . A g he a
ad a age  f h  e  ech g   ha  he a fac g ce , a he  ha  be g ec f c 
a   ec b a  e ,  ec f c  RNA. I  h  a e , he ce   de e de
f he ac a  d ea e he acc e a ge  a d  de e de   he b g ca  e e  f a
RNA a d. Th   e e d  ad a age  ce he a e a fac g ce  ca  be
ed f  he RNA a d f a  ge e c a  f a   e e  f  a c e e  d ffe e
a h ge .
Th  a   f  a a fac g ce   d ce 200  e e d e  f a
RNA acc e aga  SARS-C V-2  a 13- ee  e d he eb  acc a g 100 
e e. The ce  e  Pf e  ha ace ca  f a a d a  h a a d DNA ha
c a  he ge e c c de f  he e e a  e (S) g c e . The DNA  fed  a WAVE
b eac  f  a in vitro transcription (IVT) eac ha  d ce  RNA h gh hage T7
RNA e a e. The RNA  f ed h gh  d af a e  h a  100 Da
MWCO, a ch a g a h  c   e e de ed d RNA a d a e e f e   e e
b g ca  e . The f ed RNA  he  d ed  50 M d  ace a e a d fed 
e f he e -f e 16X c f d c  de ce  a g h a e f d   a  e ha
b ffe . W h a f a e a  f 3:1, he RNA e ca a ed  he d e  he
c f d c  de ce   a e d a a c e (LNP ). Th  e   e  ce he d-ba ed
ca e e e  a  a  e e e f  he RNA, he  ec ed  he h a  b d ,  e e  he
ce  c a  h h gh ab  a d h  d eg a . The LNP  a e f ed h gh a
100 Da MWCO d af e   a h d a ge a  f f a  de ce a d a e e f e . The e
f ed LNP  a e d ed h 1X PBS a d c e  ee  he de ed c ce a  f a
c e   he ha ace ca  f a  a d he RNA c ce a  f 0.5 g/ L. Each
ee  h  c  a fac g ce   f d ce 15.4 e e  d e  ha
 be ac aged  2  a . The a  be e    he a  c a e  f g
he eg a  age a d f ee e  c d . Th gh he ce , he a  f he d c
 be e ed h gh he e f e e a d FDA a ed e e , he c  f he e g h
f he RNA d ced f  he IVT eac  a d a  e d e e  e . The ed ce
ha  a  e a  a e f e  f 449%, a e  e e  f 475% a d a e  e e  a e f
$19.6 b  d a . Be d  a ca   he a eg   add e  he c e  COVID-19
g ba  a de c, h  ed ce   be a f h g he f e  f ed c e h he
e  e f RNA acc e .
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2. In od c ion and Objec i e Time Cha
2.1 In od c ion
The e e ge ce f a h gh  c ag  a d a h ge c e  c a   a  e e e
ac e e a  d e c a  2 (SARS-C V-2) a d  a c a ed d ea e, c a
d ea e 2019 (COVID-19), ha  e ed  a d de a de c. The f  ca e  f h  d ea e
e e e ed  Dece be  2019  W ha , Ch a1. The e ha e bee  e  130  ca e  f
COVID-19 a d a  3  COVID-19 e a ed dea h d de2.
SARS-C V-2 f e  ca e  e a  fec  f a g e e   h a 1. The e
a e c e  e a ed ea e  f  COVID-19 c d g a a  d g  ch a
e de 3. H e e , acc e  f  COVID-19 de a g ea e  ad a age ha  he e ea e
d e  he fac  ha  acc e  a ge  ed ce a fec , a d e e   he ca e f fec ,
acc e  f  COVID-19  e e  e e e e . The e a e c e  a  d ffe e  acc e
f  COVID-19 ha  ha e bee  a ed b  eg a age c e  ac  he d, a d a  he
acc e  a e c e   de e e  a d a e de g g c ca  a . RNA acc e  a e a
e a e  e  e f acc e a d a e e g. The RNA e c de  a e ,
ec f ca  a  a ge  a c a ed h a g e  d ea e. Whe  ec ed  h a , ce   he
b d   d ce he a ge , a d a  e e e  be a ed4.
Vacc a g a ge be  f e e d de g ea  c b e  e d g he
c e  COVID-19 a de c. P d c g acc e   ch a a ge ca e  f e  d ff c , a d 
a c a  d ff c   he ca e f RNA acc e a   c e c a  RNA acc e  e e
a a ab e   he COVID-19 a de c4. O g e h d  f  d c g RNA acc e
 a a ge ca e d be e e e  a ab e  f  he c e  a de c b  f  f e
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d ea e  a d he b  f SARS-C V-2 a ; he ce e  e ed  a e RNA
acc e  d   a  ch he  he a ge   a ed4.
2.2 Biological Backg o nd
2.2.1 Co ona i e  and SARS-CoV-2
C a e  a e a fa  f RNA e  ha  ca ca e e - e a  ac
fec  f a g e e 5. C a e  fec h a  a d a a , a d ca  ead f
a a   h a 6. S e c a e  ca e e d e e  ch a  he c  c d,
b  he e ha e bee  h ee ece  b ea  f c a e c d g SARS-C V-2 ha  ha e
e ed  ch e e  e e  a d dea h 5. A ece  b ea  cc g  Ch a 
2002 a  e e e ac e e a  d e (SARS), a d a he  b ea , M dd e Ea
e a  d e (MERS),  ace  2012 Sa d  A ab a 7. The e e  e
g a ed  a a 7.
C a e  a e ab e  e e  ce  d e  he e (S) e . The e e  
ab e  b d  ce  face ece ;  he ca e f SARS-C V-2,  e e  b d   he
ce  face ece  a g e  c e g e e 2 (ACE2). Af e  e e g ce , he ge c
RNA f he   e e ed a d e ca ed, ead g  he d c  f e  c e  f he
6. Th  c c e ca  be ee   F g e 2.1.
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Fig e 2.1. SARS-C V-2 fe c c e.8
2.1.2 mRNA Vaccine
RNA acc e  a e a g e  acc e ech g a d ca  ea  be ad ed f
d ffe e  e  a d a  f a g e  . Th e f acc e ca  c  f RNA
e ca a ed b  d a a c e  (LNP ). The RNA c e  f he acc e ha  f  a
e e e : a 5  ca , a a ed eg  (UTR ), a e  ead g f a e (ORF), a d a  (A)
a . The 5  ca   ca ed  he 5  e d f he RNA a  ee   F g e 2.2 a d  a  f
he b d g f RNA  he e a c a a a  fac  4E (eIF4E). Th  b d g 
ece a  f  ec e  f he b e h ch a e  a  f  he RNA  be
a a ed  he e  ha   e c de . The 5 ca  a  ec  RNA f  deg ada . The
UTR  a e ca ed  e he  de f he ORF a  ee  F g e 2.2 a d a e h  e ed he 5  UTR
a d he 3  UTR. The UTR  f  ec da  c e ha  a e  affec  he e e  f e
e e ; e ec f ca , he 5  UTR a  a a  e  a a  a , a d he
3  UTR a d   a a g RNA ab . The ORF  he eg  c a g he RNA
e e ce ha  c de  f  he de ed e . F a , he  (A) a   ca ed  he 3  e d f
14
he RNA. The  (A) a  g f e  he e d f a a , a d  e g h ca  affec  
e ac  h -A-b d g e  (PABP) a d h  e a  RNA ab 9.
Fig e 2.2. Ke  c e  f RNA e e ce.9
A  e  a ed, he RNA  e ca a ed LNP . The LNP  c ea e he ab
f he RNA, a d h  he , he RNA d be h gh ab e. LNP  a  a  f  he
eff c e  de e  f he RNA  a a e  ce . LNP  a e ab e  e e  ce  a e d c ,
a d h  e e a  ead   a a  f he RNA e ca a ed b  he LNP . F g e 2.3
h  he ce  f LNP  e e g ce .
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Fig e 2.3. E  f RNA acc e   ce .10
LNP  ed f  RNA acc e  a e ge e a  a d 80   e a d c a  f
d ffe e  e  f d : ab e  ca c d ( he a  c e ), e h e e g c
(PEG)-c ga ed d , h ha d ch e d , a d ch e e  . The ab e  ca c
d  a e e  cha ged a  a  ac d c H, a g he   b d h ega e  cha ged
RNA; a  a h g ca  H, h e e , he ab e  ca c d  e a  e a  cha ged.
PEG d  a  f  c  e  he e f he LNP , a d he  a  c ea e he e a  ab
f he a c e a  e  a in vivo ha f fe.11 The  e a g e  f d ,
h ha d ch e a d ch e e , c b e he e a  c e f he LNP 12. The
c e f he LNP ca  be ee   F g e 2.4.
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Fig e 2.4. L d a a c e (LNP) c e.4
A  RNA acc e f  COVID-19  ha e a  f he e  d c ed fea e . The
ORF, h ch c de  f  he a ge  f ch ce,  e c de he f - e g h e (S) e . Whe
h  e e   e e ed  a  d d a e ce  af e  he  ha e ece ed he
acc e, he e e   be de ec ed b  he e e , ca g a  e e e.
A acc a ed d d a   be h gh  ec ed aga f e fec  ce he  ha e a ead
bee  e ed  a c e  f he SARS-C V-2 , ec f ca , he e e 13.
2.2.3 Modified U idine fo  mRNA abili
P e d d e  be ed  c ea e he ab f he RNA a d e d h ghe
a a a  ca ac . Th  dec   ba ed f d g  f  D . Ka a  Ka  a d D . D e
We a  e ea ch. W h - d f ed d e, he RNA  ge c a d  c e  a
e e e  he h a  b d  h ch deg ade  he RNA bef e a a   e .
I  he ea  f e ea ch, D . Ka  a d D . We a ed ha  ec g ce h RNA h
d f ed d e e e ed he dead  f a a ca ed b  - d f ed d e.14  15 Th
ed a fac g ce  g d f ed P e d d e.
17
2.3 Mo i a ion
O e  e ea  ce  a  dec a ed a d de a de c, COVID-19 c e   be a
a  g ba  b e . W de ead acc a  g ea  c b e  e d g he c e
a de c. T  ach e e de ead acc a , a a eg  be ed f  d c g RNA
acc e  f  COVID-19  a  e e e  a ge ca e a  RNA acc e  ha e e e  bee
d ced  h  ca e bef e. I   a  e h  a fac g a eg  beca e
RNA acc e  e e e , ce -f ee d c e  a d a e h  chea e   d ce ha
he  e  f acc e . Add a , f he acc e d eed  be ad ed f  f e
SARS-C V-2 a , he RNA e e ce  a  ha eed   be ad ed; a  f he d c
e  e a  he a e ega d e  f he a ge  e c ded b  he RNA e e ce. Th  a
ea  ha  h  a fac g a eg  ca  be ed  a e RNA acc e  f  he  d ea e .
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2.4 P ojec  Cha e
P ojec  Name: Ma fac g S a eg  f  he P d c  f 200 M  S e e D e  f a
RNA Vacc e f  COVID-19
P ojec  Leade : Sa abe h H ff a , I e e Laba a, A  S
S ecific Goal : The g a  f h  ec    d ce 200  d e  f a  RNA acc e f
COVID-19, he d ea e ha  e  f  he SARS-C V-2 . The d c  f 200 
d e   a  f  he acc a  f 100 e e d e  he fac  ha   d e  f h
acc e a e e ed.
P ojec  Sco e:
In Scope:
● Se ec  f ec f c RNA e e ce  be c ded  he acc e f a
● De a ed de c  f he ha ace ca  f a f he acc e
● De g  f RNA he  ce
● De g  f RNA f ca  ce
● De g  f RNA e ca a / d a a c e (LNP) f a  ce   e e
a  eff cac  f he acc e
● De g  f LNP f ca  ce
● De c  f ac ag g a d age eeded f  he acc e
● Adhe e ce  g d a fac g ac ce  (GMP)
● Ec c a a  f he ec
Out of Scope:
● P e-c ca  e g f he acc e
● De g  f c ca  a  f  he acc e
● Ac g a a  f  he FDA
● De a ed a  f a fac g fac
● D b  f he acc e
Deli e able :
Business Opportunit  Assessment
● Ca  h  ce  be ed  d ce acc e  f  d ffe e d ea e ?
● I  h  ec  f ab e?
Technical Feasibilit  Assessment
● I   b e  d ce 200  d e  f a RNA acc e f  COVID-19 e  a
e d f h ee h ?
Manufacturing Capabilit  Assessment
● Wha   he ca a  e e  f  he d c fac e  be?
● W  he ce  be c e  h FDA a da d ?
Timeline: Th  ce   de g ed  d ce 200  d e  f a  RNA acc e e  a
e d f h ee h .
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2.5 Objec i e Time Cha
Table 2.1. T e Cha  Sh g Ob ec e  C e

































Bac g d acc e a d
b g ca  e ea ch
P e a  ce
de g
RNA he  a d
f ca  ce
de g
LNP f a  ce
a d f ca
Ide f ca  f a
c  (QC) a a e e
Ec c a d
f ab  a a
F a  e  g
2.6 P og e  of P ojec
The e   a da d ce   a fac e RNA acc e  a d Pf e  a d M de a
eff  a e a  f he f  c e c a a  f a  RNA acc e. G e  h , h  a  
 ba ed  a g e a e ed a fac g ce  e h d g . Ra he , h  a  
he c a  f h gh f  dec  ba ed  de e de ece  f c e f c e ea ch a d
da a a d he e e e ce f he ad  c a . I  fac , he de a  f Pf e  a d M de a
ce e  a e e a  a d ha e  bee  e e ed  b hed  he b c. Th  e e ed
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a cha e ge ha  e ed c ea  a d a   he e  e e  de   f a e h
a .
Th  a  a  b  b  f  ha g a  e a ch g de a d g f he ce  
a e he acc e a d he  c c ca  d g a d e a a g a  ce e  
acc h each e . F  each e , d e e a c e a d ce  f e ea ch e e d ed 
de a d he a  e h d g e  a d he  a dec a  a e  a   h ch ce   
 h  a .
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3. Inno a ion Ma
F g e 3.1. I a  Ma
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4. Ma ke  and Com e i i e A e men
4.1 Ma ke  A e men
The b ea  f a e  c a  a d he e g g ba  a de c ha  c ea ed a
c ea ed d de de a d f  acc e . P  he a de c, he g ba  acc e a e  e
a  e  $40 b  (2019) a d  e ec ed  g  a  $60 b  b  202516. Th  a e
 a e a e  a  b e  f he a ge  g ba ha ace ca  a e  h e e a  a ead
e  $1   2019 a d  e ec ed  each $1.5  b  202517. A h gh acc e  a e a
a e  b e  f he ha ace ca  a e , he a e bec g c ea g  a   he
f gh   e d he COVID-19 a de c. Vacc e  a e a e e e  e e a  f  f e a de c
ha  a  cc .
A  e  d c ed, RNA acc e  a e a  e c g e  acc e ech g  ha
ca  be d ced e chea  ha  he  e  f acc e a d ca  be ed  a e acc e  f
a  d ffe e  e  f d ea e  h e e a  cha ge  he a fac g ce . The
f   RNA acc e   e e  he a e  e e RNA acc e  f  COVID-19 a d e e
a fac ed b  Pf e -B NTech a d M de a. B h Pf e  a d M de a  acc e ha  bee
a ed f  e e ge c  e b  a  eg a  age c e d de, a d b h acc e  e e
a ed f  e e ge c  e b  he FDA  Dece be 2020.
4.2 Com e i i e A e men
I  he U ed S a e , he e a e h ee a  acc e f  COVID-19 ha  a e c e  
he a e  a d  add a  acc e  de g g Pha e III c ca  a , he f a  ha e f
c ca  a  bef e a acc e ca  be   he a e 18. The e acc e  a e a ed 
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Tab e 4.1. Add a , he e f e acc e  a e e he  a h ed f  e  a e de g g
c ca  a   a  he  a  ac  he d.








A o al S a  in U.S.




2 E e ge c  e
a h a
mRNA-1273 M de aTX, I c. RNA
acc e




C a e  f
J h  & J h
V a  ec
acc e
1 E e ge c  e
a h a
AZD1222 A aZe eca V a  ec
acc e
2 N  a ed b  he
FDA;  Pha e III
c ca  a
NVX-CoV2373 N a a , I c. Rec b a
a a c e
acc e
2 N  a ed b  he
FDA;  Pha e III
c ca  a
RNA acc e  ha e e a  ad a age  e he  e  f acc e . The
RNA f d  RNA acc e   d ced  a e a e c ea  a e   ha  he RNA
he   d e a a ce -f ee eac ; he ce ed  d ce he RNA  efe ed  a
in vitro a c ,  IVT. U g he e  b che ca IVT eac   d ce RNA
a d  he a  ed  e  ha  d be ed f ce  e e ed  d ce he RNA.
The a  f d c  f  ce  ca  be e c ca ed e ec a  he  he de ed
d c  e e  ha ace ca -g ade . O he COVID-19 acc e e  c d g a
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ec  acc e  ch a  h e be g ade b  Ja e  a d A aZe eca a  e  a  he
ec b a  a a c e acc e be g d ced b N a a  e e ce  a  a  f he
a fac g ce e . The ce -f ee d c f RNA acc e  de  a  add a
ad a age  h  e f acc e  ha    e e e e a d e  e c g  d ce4.
F he e, he e  c e  c ce  ega d g he c c a  f SARS-C V-2 a . S e
f he e a  e cha ge   he c e f he e e  ch ha  he e e
ha  a h ghe  aff  f  he ACE2 ece ; h a  he   e e  ce  e ea ,
a g he a  e fec 20. I  a  be ece a  ede g  COVID-19 acc e   be
e effec e aga  e  SARS-C V-2 a a . L c , RNA acc e  a e e e 
ede g . The  e e e  ha  eed   be ad ed  he RNA e e ce,   he ca e f
COVID-19, he e e  e e ce. Th  ca  be d e b   de g g a e  DNA
e a e ha  ha  he de ed e e  e e ce ce he RNA  he ed f  a DNA
e a e  he IVT eac . O ce he e  DNA e a e ha  bee  de g ed a d d ced, a
he  e   he a fac g ce  e a  e ac he a e. Th   a a  ad a age f
RNA acc e ; h  a fac g ce  ca  be ed f  SARS-C V-2 a a  a  e  a  f
he  fec  d ea e .
Wh e he e a e a  ad a age  f RNA acc e , he a  d ad a age  he fac
ha  h  e f acc e  e a e  e . P  he a de c, RNA acc e  ha e e e
bee  d ced  a a ge ca e. Th , he e ha  bee ed e ea ch f c ed  d c g
RNA acc e   a ge a e . H e e , ce a c ea  ce  ha  bee  ed, RNA
acc e  ha e he e a   de g ea  be ef  a .
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5. C ome  Re i emen
The e a e h ee c e  g   c de   he de e e  f he COVID RNA
acc e: he g e e  h   cha g he acc e , he eg a  b d  h   a g
he acc e a d he a e  h  a e g he acc e. F  h  e , he e h ee g   be
c de ed h a US ce c a ach, c de g he US g e e  a d he FDA eg a
b d - he e c e a a e e c  ha   he c e  a d e  a cab e  he
c e .
G e  he c e  g ba  a de c, he COVID- RNA acc e  b ec   d ffe e
e e e  a d e  ha  ad a  acc e . P c a , he acc e  be b ec  
he e e e  e ab hed b  O e a  Wa  S eed a d  a  acce e a ed eg a  a a
ce . F he e,  d ffe e ce  he  ha ace ca d c , he acc e   be
cha ed b  he U ed S a e  g e e  a d ded f ee f cha ge  e g b e a .
Th  e  ha  he ce f he acc e  a c ce  f  he a e . F he e, 
d ffe e ce  he  d c  de e e  c c e , a ce c a e  a e  a a
a eh de  ce he c  f he acc e   be c e ed b  he g e e . G e  he e
f RNA acc e   he ea e  f he  c d ch a  a a a a d ca ce ,   c ca  
c e  e a a e he e e e  ha  d be a  a   h e d c  a .
5.1 Uni ed S a e  Go e nmen
The a  c a  e  b  he US g e e  a e he de e  e  a d afe . I  he
Dece be  23 d ag ee e  h Pf e , he US g e e c ed he eed f  a de e  f a
add a  100  d e  b  J  2021, a g he be  f a  d e  eeded  200
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 d e 21. The eed f  a c  a d ag e de e  f acc e   a a  c ce  ha
d e he c ea  f O e a  Wa  S eed  acce e a e he ad a  eg a  ce . A
a  f he de e , he US g e e   a c ce ed h he age f acc e . Th
c de  a  adhe e ce  he f g age h g e e e :22
- U a-C d F ee e : P   g, he acc e  be ed a  e e a e  be ee
-80C a d -60C.
- F ee e : P   g, f  a a  f  ee , he acc e  a  be ed a
e e a e  be ee  -25C a d -15C.
- Ref ge a : P   a g, f  a a  f 120 h  (5 da ), he acc e  a  be
ed a  e e a e  be ee  2C a d 8C.
I  add   he de e  e e e , he g e e  c ce ed h he afe  a d
eff cac  f he acc e. The  e e e   he a a  b  he FDA.
5.2 Food and D g Admini a ion (FDA)
The a  c a  e  b  he FDA  he afe a d effec e e  f he acc e. The
FDA  e  a  Ad  C ee a d h d a  FDA dec  e a d   e e  he da a
f  c ca  a  1/2/3. The a a  f he acc e  ba ed  he FDA c e  dec  a
 he he  he afe  a d effec e e  f he acc e e gh a c a ed 23.
I  add , he FDA  c ca  c ce ed h he de-effec  ha  c d e  f
he acc e. A h gh a  de-effec  a e a e e e , he  a e a a  c ce  
he FDA a a  ce .
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5.2 Pa ien  e i emen
The a  c a  e  b  he a e  h  be ece g he acc e a e he afe
a d a a ab  f he d c . Wh e f  he FDA he a ce f afe  e   he de h a d
a a  f he c ca  da a, f  he a e  he e gh   aced  he c ea  a d d ec
c ca  a eg  h h ch he  a e ade a a e f he afe  f he acc e.
I  e  f a a ab , a e  a e c ce ed h he ad a  f acc e  a d he
ca  f acc a  ce e . The e  a c ca e e e  f  a  a a ab  f d e e
ce e   ce e a  a  e e a  b e  ece e he acc e h ea e. H e e , h
 c ed b  he acc e age e e e .
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6. C i ical- o- ali  (CTQ) Va iable
N/A
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7. P od c  Conce
N/A
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8. S e io  P od c  Conce
N/A
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9. Com e i i e (Pa en ) Anal i
G e  RNA acc e  a e a e  ech g , he e   g e a e  f  he ce
 a e he e d  a da d . A  a  f h ,  g e c a  h d  he a e  f  he
a fac g ce .  I  g h  a fac g ce , a e  e e e e ed f
ec f c d d a  a  f he a fac g ce ch a  he f ca  f RNA g
Ta ge a  F  F a  de ce  a d he f a f he L d Na a c e  g a
M c f d c  ch .
The f  a e  c de ed  f  he f ca f RNA f  a In Vitro Transcription
g a TFF de ce. Th  a e  a  f ed h he I e a a  P b ca  N be  WO
2016/193206 A   201625. The a e  c de  he de a  f  f g RNA h gh a
a ge a  f  f a  de ce a d a h d a a e ch a g a h  e . I  a  gge , a
ed  h  ce , ha   a  he  ha  b ffe a  a e added  he TFF ce .
The ed f a  f LNP e  a a e  f ed  2016 f  he c
a fac g ce  f LNP . Th  a e   e he f a e a  f 3:1 f RNA 
d   e ha  h ch  he a  ed  he a fac g ce 27.
The he  a e  ha  e e c de ed a e he d a e  he d b  A b . I  fac ,
M de a  c e   a d e h A b  e A b  a e  gh  f he  de e
e 26. M de a had a c ac a  ag ee e  h A b   2016 he    he
c ac a  gh .
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10. P elimina  P oce  S n he i
The ce   he e RNA acc e   a e  de e e  f  h ch he e  
d  a da d, ha g  bee  de e ed b  M de a a d Pf e . I  c  f f  a
a  f  h ch he e  b a e e ea ch a d de e e . Pa  1  he a f ca  a d
e a a  f he a d f In Vitro T a c . Pa  2  he he  a d f ca  f
RNA. Pa  3  he f a  f LNP  e ca a f RNA. Pa  4  Q a  C  a d
Pac ag g.
Fig e 10.1. B c  D ag a  f  Ma fac g P ce
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10.1 P e a a ion of DNA em la e
The d f ed e e ge  RNA  d ced f  a a d DNA e a e h ch  g
E.Coli ce . A  d c ed  ec  2.2.2, he a d DNA  eed he ge e c f a
f  he a a ed eg  (UTR ), e  ead g f a e (ORF) c d g f  e (S) e  f
he SARS-C V-2 , a d  (A) a  (dec  d    d c ed a e   ec  10.2.3).
The a d DNA ca  be e a ed -h e  ced  a h d a  h ch 
he   he f ed DNA. If he a d  e a ed -h e, he a  a e a  eeded f
he ce  a e he Ge e f I e e  (GOI) a d he a d h ch a e cha ed f  e .
The GOI eed   c a  he de ed ge e c f a a d he e c  e  f  he
e c  e e  ha   be ed  c  he ge e. S a , he a d eed   c a  he
a e e c  e   ha  he a a e e c e e  ca  b d a d c  he a d a
he e ac  ca  a  h ch he GOI  be e ed. The a d  a  c a  a ge e f
a c  e a ce h ch  be ed  e  he he he E.Coli ce  ha e he a d e .
The f  e   h  ce   f  he GOI be a f ed h gh a PCR eac .
F g h ,   b ec ed  a e c  e e d ge  a   he a d. B h a  a e
ed  a ga  e  h DNA ga e  ge e a e he d f ed a d DNA. The e  e
 he a f a  a d a g f he a d E.Coli DH5-a ha ce . The ce  a e he
g   a  LB B h a d e a a ed h M e . I  de   de e e he he  he GOI a d
a d e e b h e  e ed, c e  f he a e  be e  f  ge e e e c g.
U  a da  f he c ec  GOI a d a d e , h e c e   he  be a f ed
a d a ed f  a ec d e. Th e c e  be g  E.Coli DH5-a ha ce  a d a
Ma e   he  be ed f  e a a  f he a d. I  e a a  f  he IVT eac , he
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a d  he  be ea ed g E d c ea e Re c  D ge . A ce f ga  e
 f   a e he a d.
I a , h  a fac g ce  acc ed f he ab e de a ed e   e a e he
DNA. The ad a age  f h  e e he a  e gh f he DNA e a a  ce  a d he
 c  f e a g he DNA -h e e  c g he d c . The d ad a age
e e ha  h  ce  e ed h g add a e e  a d added e  a d eac   he
ce . Th  c ca ed he a fac g ce h  add g g f ca  a e ce he
ce   e a e DNA  a da d ed ac  he d  a d ca  be afe  ced. A  a
e ,  a  ch e   ce he DNA ce  a h d- a  e d . I  h  a e , he
a fac g ce , e  a d e e  de a ed  h  ed e  e DNA a  a
a g a e a  a d he IVT eac  a  he f e   he ce .
A ca  h a B g c  B e  De e e  a  E ge ec a  he d ea  Ma ch 2021 
de a d he  ce   d ce DNA a d  ece e a e f  he ce. The f g
de a ed f a  a  a  ga he ed a  a  f he ca . E ge ec e  he d  a da d
f  he GMP Ma fac g P d c  f a d DNA f  RNA-IVT eac . The a
eed   be ded  he c a  f  he a d e e . The ce  a  h a
e ea ch ce  ba . E ge ec ha  1000  2000 L fe e  a  he  a a ab  a d e ec  a
e f  each de  ba ed  he e ed e d f he d c . The a fac g e e  a d
f e d  eg a  ec ed b  he FDA a d f a  a da d eg a . The fe e a
ce  e  DH108  DH5-a ha E.Coli ce  a d he fe e a  e d  a  f  400 g/L
 1200 g/L.
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F  h  ed ce , E ge ec  d ce he 144 g a  f a d DNA
eeded f  he IVT eac  ha  d ce 200  d e  f he acc e. A g a e d f
0.2 g a /L, he B e  De e e  ed g a 350 L fe e . The d c   be
d ced a  he  fac e   Be g  a d h ed  he U ed S a e   he a  ed 
h  e . The d c   f ec ab e g ade a a d chec ed f  de ,  a d afe .
Th gh  he ce  Q a  C   e ed h he e f e c  a g a d
e e c g a d e d  (LAL ) e .
The e ece ed f  he ce   1M e  h ch  1.2M d a . Th  c  
e a e   c a ed  he c  f e e  a d e e  he c  e ed f  he 
e e e a  a e a  e he Ca  A a g a d T7 RNA e a e. I  add  
c g he ce   f c  he a fac g ce   e  f g IVT, he e a e
e e e c  a  a g c e a  dec d g  ce DNA.
10.2 mRNA S n he i  and P ifica ion
10.2.1 Selec ion of mRNA Se ence
The e (S) e   SARS-C V-2 a  a  e e a e  a g he  
e e  ce . The b d g f he e e   he ACE2 ece   ce   ha  a e  he
ce  ha  a  he   e e  ce . Th , he e e  a  ch e  b  e ea che  
be he e  f e e  ha  d be e c ded b RNA  he RNA acc e. The ec f c
eg  f he e e  ha   e b e f b d g  ACE2  he ece -b d g
d a  (RBD) h ch  f d  he N- e a  f c ea age f ag e  (S1 d a )28. Th
a e  he e  f he he    a  RNA acc e ha  e c de   he RBD d be
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effec e. Pf e  a d B NTech e ed RNA acc e  ha  e c ded b h he RBD a d he
f - e g h e e ; he e  a e ed he  c a e   ch e he ca d da e
acc e ha  e c ded he f - e g h e e 28. Th  dec  a  d e  he d ffe e ce  
e e e  a d e ab  be ee  he acc e . Ea  c ca  a  e ea ed be e
e ab  f he RNA acc e e c d g he f - e g h e e . Add a , he
RNA acc e e c d g he f - e g h e e ed  T ce  e e  aga  he RBD a
e  a  he  eg  f he e e  ha  e e  c ded  he RBD-  acc e
ca d da e29. The e  f he e e a  c ca d e  d e b  Pf e  a d B NTech e e
he a  ea  RNA e c d g he f - e g h e e  a  ch e  f  he acc e.
10.2.2 5  Ca  Addi ion
A  e  d c ed, he 5  ca   he 5  e d f RNA  h gh  a  f  he
a  f a a  f he de ed e ; f  h  ec , ha  e   he e (S) e
f he SARS-C V-2 . If RNA  d ced g in vitro a c , he e a e  a
 h ch he 5  ca  ca  be added  he RNA. The 5  ca  ca  e he  be added
c - a c a   - a c a  g ca g e e . The e a e ad a age  a d
d ad a age   b h e h d , a d a e , c - a c a ca g a  de e ed  be a
be e  f  f  h  ec .
C - a c a  ca g cc  d g he in vitro a c  ce . A ca  a a g
 added  he in vitro a c  eac  a d  be c a ed a  he 5  e d f he RNA
d g he eac . Th  e h d f add g he 5 ca   e a e  e a d d e   e e
add g a he  e   he e a  ce . O e c ce h c - a c a  ca g  he
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ca g eff c e c ;  a  f he RNA d ced  ha e a ca . S e ca  a a g  ha e e
eff c e c e  ch a  a - e e e-Ca -a a g (ARCA) h ch ha  a ca g eff c e c  be ee
60-80%4. H e e , e e  ca  a a g  ch a  C ea Ca  ca  ach e e ca g eff c e c e
be ee  90-99%, a g c - a c a  ca g a e ab e 4. Add a , e e
d ge  af e  a in vitro a c  eac ca  be ed  deg ade ca ed RNA.
A he  d ad a age a c a ed h c - a c a ca g  ha  ca  a a g  ca  be e
c 30. N e he e , c - a c a  ca g a e  e, a d h   e  a  f a
acc e eed   be d ced c   a a de c a . The eff c e c  f
c - a c a  ca g  a e  h  h e h d a  ch e  f  he ce .
E a c ca g cc af e a in vitro a c eac a d h add e
he e a ce . Wh e he e - a c a e a c eac a e a chea e
a e a e, h e h d e eff c e . Th d c ce de g ed d ce a
RNA acc e a e a e f a a de c, a d h , eff c e c a .
C - a c a ca g a de e ed be he be f eff c e c e . The
ca g e h d  a e h   F g e 10.2.
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Fig e 10.2. Me h d  f 5  ca  add 9.
10.2.3 Pol  (A) Tail Addi ion
The  (A) a   ca ed  he 3  e d f he RNA, a d  g a  he e d f
a a . The e a e  a  a  he  (A) a  ca  be c a ed in vitro
a c bed RNA. The  (A) a  ca  be c a ed  he DNA e a e e e ce, a d
h  he  (A) a   be c a ed  he RNA b  T7 RNA e a e d g in vitro
a c . Th  e h d f  (A) a  add a  f  ec e c  e  he e g h f
he  (A) a  h ch  a  ce he e g h f he  (A) a  ca  ha e a  effec   he
eff c e c  f a a  f he e e 9. Th e h d a  a  f  he  (A) a   be
added c - a c a  a d d e   e e add a e  af e  a c 9. The
eff c e c  a c a ed h c a g he (A) a   he DNA e a e de g  
a e  h  h  e h d a  ch e  f  h  ce .
A  a e a e e h d f   (A) a  add e  add g he a
- a c a  h gh a  e a c eac . Th  e a c ade a  f in vitro
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a c bed RNA e  he e e  (A) e a e. Th  ce   e ea  a d e,
b  e d ad a age  ha   add  a  e a e  he e a  ce . A he  c ce
a c a ed h h  e h d f  (A) a  add  ha  he e  fa  e  c  e  he
e g  (A) a  e g h9. Th   a e d ad a age a  a f   (A) a  e g h 
eeded; he  (A) a  ca  affec  he a a eff c e c  f RNA. Th , d e  he
eff c e c  a d e g h c  a c a ed h c a g he  (A) a   he DNA
e a e de g , h  e h d a  ch e  f  h  ce .
10.2.4 Selec ion of In Vitro T an c i ion Reac o T e
The in vitro a c  (IVT) eac   a ba ch ce  a d h  e e  a ba ch
eac . The e e e d ffe e   c de ed f he eac  e. A a e  ee  ba ch
eac  a  a  c de ed; he a e a  d ab e a d    a d  h  ab e f
ha ace ca  a ca . H e e , h  eac  ha e  be c ea ed a d e ed be ee
ba che  h ch  ed  a d add  add a  c a d ab . Af e  d c  h d a
c a ,  a  de e ed ha  a WAVE B eac e  d be be  f  h  ce .
The WAVE B eac  e  c  f a c e  h ch d ab e a c b eac  bag
a e aced. Th  a  dea  f   ce  d e he fac  ha  af e  each IVT eac , he eac
bag  d ca ded a d a e , e e bag ca  be ed f  he e  . The WAVE B eac
e  ca  ha d e g e  ha  f  he e e e f  IVT eac , a d he e
e  a e e e a e c ed h ch  a a  he IVT eac   cc  a  37℃.
Th , a WAVE B eac  e  a  ch e  f  h ce . A  age f a WAVE B eac
e  ca  be f d  F g e 10.3.
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Fig e 10.3. WAVE B eac  e 31,32.
10.2.5 Rec cle of T7 RNA Pol me a e
Phage T7 RNA P e a e  be ed  he IVT eac a  he e e  a e
RNA f  DNA. A  a  f h  a fac g ce ,  a  c de ed he he  he T7
RNA e a e h d be ec c ed af e  each ee h ba ch d c  f RNA. The
ad a age f h  d be he dec ea ed c  f eed g  cha e e  T7 RNA e a e.
Th  d be a c a  c  ad a age  ce T7 RNA e a e  he e he 
e e e a  a e a  (a   be de a ed  Tab e 11.1). I  fac , T7 RNA e a e acc
f  e  40% f he a  a  a e a  c .
De e he c  ad a age ,  a  ch e   ec c e T7 RNA e a e g e  he
e e  ha f- fe a d ac a . The ha f- fe f T7 RNA e a e d ca ed  e a e
e e  a e  b  a  c c de  a a e  he de  f h . A  a c e b hed 
B ech g  B e g ee g J a   2001 e e c de g a d a  
a a e he a a e e  f T7 RNA e a e. Th a c e c e  he ha f- fe f T7 RNA
e a e a  50 e 33. A he  a c e b hed b  Na e  1999 c e  he ha f- fe f T7
RNA e a e a  24 h  a  de e ed b  e e e h ch ea e he e e  ac
a  a f c  f e af e  ea e 34.  F g ca  h e e  ad g c a ,  a
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e a ed he ha f- fe f T7 RNA e a e  a  IVT eac   a d 5 h . G e  he
 ha f- fe, he T7 RNA e a e ca  be ec c ed. Each IVT eac  a e  5 h  
he T7 RNA e a e   be ac e f  e ba ch  h f RNA d c .
10.2.6 mRNA P ifica ion Me hod Selec ion
D ffe e   e e c de ed  f e   eage f  he IVT eac  a  e  a
 acc h b ffe  e cha ge  a e   he ce . F  he e e , a ge a  f  f a
(TFF)  d a  c d be ed. TFF a  e ec ed  f e   IVT eage  a  e f he
eage  a e a ge  e . H e e , f  he b ffe e cha ge e , b h TFF a d d a  e e
c de ed. TFF a  ch e  f  b h b ffe  e cha ge e  a ge  beca e d a  e e
e  a ge a  f b ffe  a d ca  a e a e  g e d e  he fac  ha  he d g f ce
f he b ffe  e cha ge   d ff 35. Add a , TFF a  f  a e c ce a
h ch ca  be ach e ed h d a , a d e f he b ffe  e cha ge e    ce  a
e e  a e c ce a .
D g he in vitro a c  eac  ed ge e a e he g e- a ded RNA ha
 be ed  he acc e, a  de ed de- d c  ge e a ed. Th  de ed d c  
d b e- a ded RNA  d RNA. d RNA ca  ca e de ed e e e  ha  a e
ead  g ea  ed ced a a  f RNA4. Th , d RNA  be e ed f g he in
vitro a c  eac . d RNA e a  ca  be ach e ed g a ch a g a h  e , a d
he e a e  a  ch a g a h   ha  e e c de ed f  h  ce .
I - a ed e e e ha e h gh e f a ce d ch a g a h  (HPLC) a
c de ed f  he e a  f d RNA. HPLC ca  eff c e e e d RNA, b  he e a e e
e  h HPLC ha  a e   a ab e f  h  ec . The e e  eeded  e
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c  a d ca  be ca ed   a c -effec e a , he ace e eeded f  h  e  
e e e  c, he f ca  e  e g, a d he e   ab  50% RNA ec e
ach e ed4.
The ch a g a h  e h d ch e  e e  a  f he e  a c a ed h HPLC
f ca  f in vitro a c bed RNA. The e h d ch e   a ce e-ba ed fa  e
d ch a g a h  (FPLC). Th  ce  e  e ec e b d g f d RNA  ce e  a
e ha -ba ed b ffe ; he d RNA  e a  b d  he ce e a d he de ed d c ,
g e- a ded RNA,  f  h gh he c 4. Th  e h d ca  e e e  95% f
d RNA e e   a 36. Ce e ch a g a h e e  a fa e , chea e , a d e
c ce  f  he e a  f d RNA, a d h  a e  h  h  ch a g a h  e h d
a  ch e 4.
10.3 Li id Nano a icle S n he i  and P ifica ion
A  e  e ed, d a a c e  a e ed  de e  he RNA  a
d d a  ce . The e a e d ffe e  e h d  f he g he e d a a c e , b
c f d c ch  de ce  e e ch e  a  he  e e he be  f  f  h  ec . A ef ed
e c e e h d ca  be ed  d ce LNP  c a g RNA. The ef ed e c e e h d
e  f  d g he d   e ha  a d he  h d a g he d  b  g h a
a e  b ffe . The d  a e he  e ded h gh f e   ach e e a de ed e. The  RNA
 a  a e  b ffe  h e ha   added a  a ec f c f  a e h g; h  e  ef
f  e e  a  f  he RNA  be e ca a ed b  he LNP 37. The ef ed e c e
e h d a   ch e  a  h  e h d  e ed a d e c g c a ed h
c f d c g de ce .
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M c f d c ch  de ce  e e a he  de g   ha  a  c de ed, a d h  
a  a e  ch e . M c f d c g de ce f  he ce  f a g LNP  he
c a ed h he ef ed e c e e h d. The e agge ed he gb e c f d c (SHM)
g de ce  a  f  he f a  f LNP  a ec d e ca e. The e de ce  ha e
 e  ea  ha  ee  a d g  h gh a g cha e  he e he LNP  a e f ed
c a g he e ca a ed RNA38. The g e e ea  h  c a  he RNA
e ca a ed b  he LNP . The c  f h  ce a  a a  ea  h   a  ch e ,
a d he fac  ha  h  ce  ca  be ca ed b  a a e g a  ch   a  a  ad a age.
F g e 10.4 h  b h he ef ed e c e e h d a d he c f d c g e h d.
Fig e 10.4. D ffe e  e h d  f a a c e he .39
11. A embl  of Da aba e
O e a g c d  e e ba ed  e g RNA a fac g g de e . Safe  a d
ha d g f a e a  e e ba ed  a a ab e Ma e a Safe  Da a Shee  h ch a e ca ed 
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A e d  I. E e  a d a e a  c  e e e a ed g e g ech g ca
e  a d d c .
11.1 Co  of Ra  Ma e ial
Tab e 12.1 a e  he a  a  a e a eeded f  h  ce  h he
e ec e ce  e  g a  (g). N e ha  he e ce a e ef ec e f b g each a e a  
b  a d a e he ef e e  ha  b g  a a a  ba . B  P ce  e e b a ed
d ec  f  c ac g a  e d  a d/  h he he  f he C a  a d D .
D a d.
Table 11.1. P ce  f Ra  Ma e a  Needed f  P a O e a
Ma e ial Name Co
($USD/g am)
Pla mid DNA $6,944.44
T7 RNA Pol me a e $1,128,000
Adeno ine 5'-T i ho ha e N cleo ide (ATP) $19.31
G ano ine-5'-T i ho ha e N cleo ide (GTP) $18.69
C idine T i ho ha e N cleo ide (CTP) $19.93
U idine-5 -T i ho ha e N cleo ide (UTP) $127.58
RNA Ca  Analog $9,267
T i  H d ochlo ide $0.32
Magne i m Chlo ide $0.27
1,4-Di hio h ei ol $9.46
S e midine $11.58
T i on X-100 $0.033
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DNa e I $114,000
Alkaline Pho ha a e $113,000
Cell lo e $0.025
HEPES $0.15
E h lenediamine e aace ic acid (EDTA) $0.197
Sodi m Chlo ide (NaCl) $0.0028
E hanol $0.026
Sodi m Ace a e $0.091
ALC-0315
((4-h d o b l)a anedi l)bi (he ane-6,1-di l)bi (2-he ldecanoa e)
$1,730
ALC-0159 (2-[( ol e h lene gl col)-2000]-N,N-di e adec lace amide) $158.21
DSPC (1,2-di ea o l- n-gl ce o-3- ho hocholine) $150
Chole e ol $0.96
PBS $1.35
S c o e $0.0081
Sodi m h d o ide $1.09
The ce e  g a  f T  H d ch de, Mag e Ch de, 1,4-D h h e ,
S e d e, T  X-100, DNa e I, A a e Ph ha a e, Ce e, HEPES, EDTA, NaC ,
E ha , a d S d  Ace a e a  b a ed f  he e d  S g a A d ch. The ce e  g a
f each c e de (ATP, GTP, CTP, a d UTP) a d S d H d de a  b a ed f  he
e d  The  F he  Sc e f c. The ce e  g a f T7 RNA P e a e a  b a ed f
Ne  E g a d B Lab  a d he ce e  g a  f he Ca  A a g a  b a ed f  T L
B ech g e . I  add , he ce e  g a  f c g he d c  f a d DNA
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a  b a ed f  he e d  E ge ec. The ce e  g a  f he d  DSPC a d
Ch e e  a  b a ed f  M e S g a. La , he ce e  g a  f he  a
d  ALC-0315 a d ALC-0159 a  b a ed f  he e d  A a  P a  L d .
11.3 T an c i ional Ac i i  of T7 RNA Pol me a e
L e a e a  ed  de e e he a e f a c g he e e T7 RNA









he e s n(d)  he a e f he  f RNA  g a e  e  e  e, vma  he a
a c  a e, KTS  he DNA c ce a  f he ha f- a a  a c  a e, a d d
he c ce a  f DNA. Th  e a  acc  f he a e f RNA he   he a e
f RNA e a e deg ada . F  e a e a  de e ed ha vma e a  10.4 M/
a d KTS e a 4.4 M f  T7 RNA P e a e. I  a fac g ce , he c ce a
f DNA (d) h  he IVT eac  a  de e ed be 21.5 M 40. U g he e a  ab e
a d he ec f ed ce  a ab e , he a e f T7 RNA P e a e a c , s n(d), a
ca c a ed  be 1.07E-05 g a  e  e  e  f   ce . I  he  d , he a e f
he  f RNA cc ed a  a a e f 1.07E-05 g L-1 -1.
11.5 Pha macokine ic /Chemical P o e ie  of Li id
The L d Na Pa c e , h ch e ca a e he RNA a d, a e ade f  f
d ffe e  e  f d . Th , he acc e c a f  d , f h ch  a e ed 
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a ed ed c a  d c  -- ch e e  a d 1,2-d ea - -g ce -3- h h ch e,
he eaf e  e ed DSPC. A d he e a g  a e c de ed e  a  he  ha e  bee  ed
 a  a h ed ed c a  d c : ALC-0315
((4-h d b )a a ed )b (he a e-6,1-d )b (2-he deca a e)) a d ALC-0159
(2-[( e h e e g c )-2000]-N,N-d e adec ace a de). D e  he e  f ALC-0315
a d ALC-0159, ed f a  ega d g he e d  a e a a ab e. Tab e 11.2 a e
he f  d  eeded f  h  ce  h he e e a  Pha ac e c e e 41 42.
Table 11.2. Pha ac e c  f L d  Needed f P a  O e a 43.
Li id Name Chemical Fo m la Mola  Ma  (g am /mole) Ka
ALC-0315 C48H95NO5 766.29 6.09
ALC-0159 (C2H4O) C31H63NO2 2,000 6.94
Chole e ol C27H46O 386.65 7.01
DSPC C44H88NO8P 790.10 5.92
A  ee   F g e 11.1, ALC-0315  a ca c d c a g a e a  a e a d 
e e  e e , ((4- h d b )a a ed )b (he a e-6,1-d )b (2-he deca a e). I
add , ALC-0315 ha  a KA f 6.09. W h  he LNP , ALC-0315 he  eg a e he
e d a  e ea e f he RNA. Th  cc  beca e he d c  f he e ha c d
e c a g ALC-0315  a  RNA  a a ec f c H  e   a  e ec a c
e ac  be ee  he ega e  cha ged RNA bac b e a d he e  cha ged ca c
d. Th  e ec a c e ac  e   he e ca a  f he RNA a a c e f a
41 42.
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Fig e 11.1. ALC-0315 L d S c e41
The he  e  e c e , ALC-0159  a PEG a ed L d a  efe ed  a  2
[( e h e e g c )-2000]-N,Nd e adec ace a de, a  ee   F g e 11.2.  ALC-0159 ha  a
KA f 6.94. The PEG a ed d ALC-1059  e b e f  f g a ec e h d h c
a e  ha  e ca  ab e  he LNP. Th  a e c b e   age ab  a d ed ce
ec f c b d g  e 41 42.
Fig e 11.2. ALC-0159 L d S c e41
Ch e e   a c a  d  a  h   F g e 11.3. The d ha  a Ka f 7.01.
Ch e e '  a  f c     b a e c e   he LNP a d a   de
b  f he d c e  h  he LNP c e 41 42.
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Fig e 11.3. Ch e e  L d S c e41
The f a  d h  he LNP c e  DSCP a d  c e  ded  F g e
11.4. Th  d  a  efe ed  a  1,2-D ea - -g ce -3- h h ch e a d   a  a
h ha d ch e h ea  ( c adeca ) ac g  ha   de ed f  a
c adeca c ac d. The Ka f DSCP  5.92. DSCP a h h d c e  ha  de  a
ab e b a e -f g c e  ba a ce he -b a e e  f  he ca c d 41 42.
Fig e 11.4. DSCP L d S c e41
11.5 De ailed Ma  of he mRNA S and U ed In he Vaccine
A  a ed e , he e e  f SARS-C V-2 a  a e  e  he ece
ec g  a d ce  e b a e f  ce . The ef e, he RNA a d ed  he RNA
acc e e c de  f  he f - e g h e e . We c ea ed a de a ed a  f h  f - e g h
e e  g he f a e S a Ge e, h  F g e 11.5.
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Fig e 11.5. Ma  f F -Le g h S e P e  ed  RNA Vacc e
The e g h f he f - e g h e  1,237 a ac d . A  h   F g e 11.5, he
S e e  c e  b h he S1 b  (14 685 e d e ), a d he S2 b  (686 1273
e d e ). The S1 b   e b e f  b d g  he h  ce  h e he S2 b  ed a e
a  ce  e b a e f . W h  he S1 b he e  a  N- e a  d a , abe ed NTD,
(14-205 e d e ) a d a ece -b d g d a , abe ed RBD, (319-541 e d e ). The
ece -b d g d a  h  he S1 b  ec g e a d b d   he h  ece . W h
he S2 b  he e  he f  e de, abe ed FP, (788 806 e d e ), he a e de e ea
e e ce 1, abe ed HR1, (912 984 e d e ), HR2 (1163 1213 e d e ), TM d a
(1213 1237 e d e ), a d c a  d a  (1237 1273 e d e ). A  c e  h  he
S2 b  a  a e  e  a  f  a d e  h  ce 44.
12. P oce  Flo  Shee  Diag am (PFD) and Ma e ial Balance
O e a  a d de a ed ce  f  d ag a  f  ed RNA a fac g
ce  a e de a ed  h  ec . Add a  de a d g he ch ce f e e ,
de g  ec f ca , a d c  ca  be f d  ec 13, 15, 16, a d 17 f h  e .
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12.1 O e all P oce
The ce  f  d ag a  f  he e e a fac g ce  f he RNA acc e 
de a ed  F g e 12.1. The ce  beg  h d c f RNA g -
a c . The RNA  he  f ed g f a e . M c f d c  de ce  a e he
ed  e e ha  he RNA ge  e ca a ed b d a a c e . Th  LNP-RNA d c
 he  f ed a d d ed g a b ffe   a e he f a  RNA acc e d c . F a , he
RNA acc e g e  h gh a ac ag g ce . The f a  f a   he  h ed 
a ed acc e d b  ce e . Tab e 12.1 a d Tab e 12.2 de a  a  ce   a d
age a  h   F g e 12.1 a d he  a de g  ec f ca .
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Fig e 12.1. O e a  P ce  F  D ag a  f  RNA Ma fac g P ce
Table 12.1. P ce  U  S ec f ca  Shee
E i men  ID E i men  Name P e e Tem e a e
PU 1 IVT Wa e B eac 1 a 37℃
PU 2 Ta ge a  F
F a  De ce 1
1 a 4℃
PU 3 Ce e
Ch a g a h
C
1 a 4℃
PU 4 Ta ge a  F
FI a  De ce 2
1 a 4℃
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PU 5 S e e F e  1 1 a 4℃
PU 6 M c f d c  De ce 1 a 4℃
PU 7 Ta ge a  F
FI a  De ce 3
1 a 4℃
PU 8 S e e F e  2 1 a 4℃
Table 12.2. S age Ta  S ec f ca  Shee
S o age ID S o age Tank Name P e e Tem e a e
STOR 1 T  B ffe  S age 1 a 4℃
STOR 2 IVT P d c  S age 1 a 4℃
STOR 3 TFF1 Wa e S age 1 a 4℃
STOR 4 TFF 1 Re e a e
S age
1 a 4℃
STOR 5 Ch a g a h
B ffe  S age Ta
1 a 4℃
STOR 6 Ce e Re
S age Ta
1 a 4℃
STOR 7 E ed d RNA Wa e
Ta
1 a 4℃
STOR 8 Rec e ed P d c
f
Ch a g a h
C  S age Ta
1 a 4℃
STOR 9 S d  Ace a e
B ffe  S age Ta
1 a 4℃
STOR 10 TTF 2 Pe ea e
Wa e S age Ta
1 a 4℃




STOR 12 D  1 a  f
RNA
1 a 4℃
STOR 13 E ha  S age Ta 1 a 4℃
STOR 14 L d  a d E ha
S  S age
Ta
1 a 4℃
STOR 15 M c f d c  d c
age a
1 a 4℃
STOR 16 1X PBS S age 1 a 4℃
STOR 17 TT3 Pe ea e Wa e
S age Ta
1 a 4℃
STOR 18 TFF 3 Re e a e
S age
1 a 4℃
STOR 19 D  2 S age
Ta
1 a 4℃
STOR 20 PBS a d S c e




12.2 S n he i  and P ifica ion of mRNA
A de a ed ce  f  d ag a  f  he he  a d f ca  f RNA ca  be f d 
F g e 12.2. I  add , a ea  ec f ca  hee a d a  ba a ce  f  h  a  f he
a fac g ce  ca  be f d be .
Fig e 12.2. P ce  F  D ag a : S he  a d P f ca f RNA
Table 12.3. S ea  S ec f ca  Shee : S he a d P f ca  f RNA
S eam
ID
S eam De c i ion P e e Tem e a e
S-100 Ra  a e a   IVT Reac : NTP, DNA, T7
RNA e a e
A  5 h : DNA e, Ph ha a e
1 a 4℃
S-101 T  b ffe  fed  IVT eac 1 a 4℃
S-102 IVT d c   age a 1 a 37℃
S-103 IVT d c  f  age a   TFF 1 1 a 4℃
S-104 Wa e  ed a  b ffe   TFF 1 1 a 4℃
S-105 Pe ea e f  TFF 1  a e a 1 a 4℃
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S-106 Re e a e f  TFF 1  age a 1 a 4℃
S-107 Ch a g a h  b ffe  fed  age a  h
RNA  d e RNA
1 a 4℃
S-108 Ch a g a h  b ffe  fed  ce e age a
 a e he ch a g a h  e
1 a 4℃
S-109 Ce e fed  ce e e  age a 1 a 4℃
S-110 Re  fed  ch a g a h  c 1 a 4℃
S-111 B ffe   a h c 1 a 4℃
S-112 Re e a e f  TFF 1 a d ch a g a h  b ffe
fed  ch a g a h  c
1 a 4℃
S-113 Wa e  ed  e e d RNA b d  c 1 a 4℃
S-114 E ed d RNA fed  a e age a 1 a 4℃
S-115 Rec e ed d c  ( RNA) fed  age a 1 a 4℃
S-116 S d  Ace a e B ffe  added  TFF 2 1 a 4℃
S-117 P d c  f  ch a g a h  c  fed f
age a   TFF 2
1 a 4℃
S-118 Pe ea e f  TFF 2  a e a 1 a 4℃
S-119 Re a e f  TFF 2  age a 1 a 4℃
S-120 P d c  f  TFF 2 fed  e e f e  1 1 a 4℃
S-121 P d c  f  e e f e  1 fed  age a f
RNA d  bef e M c f d c
1 a 4℃
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Table 12.4 (a) (b) (c) (d). Ma e a  Ba a ce: S he a d P f ca  f RNA
(a)
S eam ID S-100 S-101 S-102 S-103 S-104 S-105 S-106
Ma  (g) 35,780.57 402.56 36,182.61 36,182.61 1,103,223 1,105,631.18 33,741.21
Com onen  Ma e ial Balance (g)
T i
H d ochlo ide 0 402.56 402.56 402.56 0 402.56 0
Magne i m
Chlo ide
40.38 0 40.38 40.38 0 40.38 0
1,4-Di hio h ei
ol (DTT)
170.87 0 170.87 170.87 0 170.87 0
S e midine 32.18 0 32.18 32.18 0 32.18 0
0.01% ( / )
T i on X-100
11.85 0 11.85 11.85 0 11.85 0
ATP 280.91 0 109.29 109.29 0 109.29 0
GTP 289.77 0 189.43 189.43 0 189.43 0
CTP 267.62 0 162.53 162.53 0 162.53 0
UTP 268.17 0 91.39 91.39 0 91.39 0
Ca  Analog
(Clean Ca ) 11.08 0 1158.59 1158.59 0 1158.59 0
mRNA 0 0 520.62 520.62 0 10.41 510.21
DNA
Tem la e 11.08 0 11.08 11.08 0 11.08 0
T7 RNA
Pol me a e 1,159.10 0 11.08 11.08 0 11.08 0
DNa e I 6.33 0 6.32 6.32 0 6.32 0
Pho ha a e 0.22 0 0.22 0.22 0 0.22 0
Addi ional
WFI 33,231 0 33,231 33,231 1,103,223 1,103,223 33,231
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(b)
S eam ID S-107 S-108 S-109 S-110 S-111 S-112
Ma  (g) 207,116.73 15,158,953.04 275,000 15,433,953.04 9,695,369.88 9,902,996.82
Com onen  Ma e ial Balance (g)
HEPES 38,786.23 3,669,838.48 0 3,669,838.48 2,347,156.92 2,385,943.15
EDTA 475.65 45,004.96 0 45,004.96 28,784.29 29,259.95
NaCl 118,897.19 11,249,700.00 0 11,249,700.00 7,195,088.09 7,313,985.28
E hanol 2,054.70 194,409.60 0 194,409.60 124,340.58 126,395.28
Wa e -Fo -Injec ion 46,902.96 0 0 0 46,902.96 46,902.96
d RNA 0 0 0 0 0 5.10
mRNA 0 0 0 0 0 505.10
Cell lo e 0 0 275,000 275,000 0 0
(c)
S eam ID S-113 S-114 S-115 S-116 S-117 S-118
Ma  (g) 987,839.79 987,844.90 9,902,991.97 5,179 9,902,991.97 9,860,255.297
Com onen  Ma e ial Balance
HEPES 0 0 2,385,943.15 0 2,385,943.15 2,385,943.15
EDTA 0 0 29,259.95 0 29,259.95 29,259.95
NaCl 0 0 7,313,985.28 0 7,313,985.28 7,313,985.28
E hanol 0 0 126,395.28 0 126,395.28 126,395.28
Wa e -Fo -Injec ion 987,839.79 987,839.79 46902.96 0 46,902.96 0
d RNA 0 5.10 0.26 0 0.26 0
mRNA 0 0 505.10 0 505.10 10.10
Cell lo e 0 0 0 0 0 0
50 mM Sodi m
Ace a e
0 0 0 5,179 0 4,661.54
59
(d)
S eam ID S-119 S-120
Ma  (g) 47,915.91 47,915.91




E hanol 0 0
Wa e -Fo -Injec ion 46,902.96 46,902.96
d RNA 0 0
mRNA 495.00 495.00
Cell lo e 0 0
50 mM Sodi m Ace a e
517.95 517.95
12.3 Fo m la ion of Li id NanoPa icle -Enca la ion of mRNA
A de a ed ce  f  d ag a  f  he f a f LNP  ca  be f d  F g e 12.3. I
add , a ea  ec f ca  hee  a d a  ba a ce f  h  a  f he ce  ca  be f d
be .
60
Fig e 12.3 P ce  F  D ag a : F a  f LNP E ca a  f RNA
Table 12.5. S ea  S ec f ca  Shee : F a f LNP  E ca a  f RNA
S eam
ID
S eam De c i ion P e e Tem e a e
S-121 S e e d c  fed  a  f  e a a  f
M c f d c
1 a 4℃
S-122 E ha   fed  a  f  e a a  h
d
1 a 4℃
S-123 L d  fed  a  f  e a a  h e ha 1 a 4℃
S-124 S d  ace a e f  age  d  h RNA 1 a 4℃
S-125 S  f d   e ha  fed  M c f d c 1 a 4℃
S-126 RNA d ed  d  ace a e fed 
M c f d c
1 a 4℃
S-127 LNP d c  f  M c f d c  fed  age a 1 a 4℃
S-128 LNP f  age a  fed  TFF 3 1 a 4℃
S-129 1X PBS  fed f  age a   TFF 3 1 a 4℃
S-130 Pe ea e fed f  TFF 3  a e age a 1 a 4℃
S-131 Re e a e f  TFF 3 fed  e e a e age a 1 a 4℃
S-132 Re e a e fed  e e f e  2 1 a 4℃
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S-133 P d c  f  e e f e  fed  f a  d 1 a 4℃
S-134 PBS a d c e  fed  f a  d 1 a 4℃
S-135 P d c  f  f a  d 1 a 4℃
Table 12.6 (a) (b) (c). Ma e a  Ba a ce: F a f LNP  E ca a  f RNA
(a)
S eam ID S-121 S-122 S-123 S-124 S-125 S-126
Vol me ic Flo
(mL/min)
- - - - 3 9
Ma  (g) 47,915.90 973,440.30 14,215.38 14,663.70 987,655.69 62,579.61
Com onen  Ma e ial Balance (g)
mRNA 495.00 0 0 0 0 495.00
Sodi m Ace a e 517.95 0 0 14,663.70 0 15,181.65
Addi ional WFI 46,902.96 0 0 0 0 46,902.96
ALC-0315 0 0 7,938.46 0 7,938.46 0
ALC-0159 0 0 923.08 0 923.08 0
DSPC 0 0 1,661.54 0 1,661.54 0
Chole e ol 0 0 3,692.31 0 3,692.31 0
E hanol 0 973,440.30 0 0 973,440.30 0
1X PBS 0 0 0 0 0 0
S c o e 0 0 0 0 0 0
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(b)
S eam ID S-127 S-128 S-129 S-130 S-131 S-132
Vol me ic Flo
(mL/min)
12 - - - - -
Ma  (g) 1,050,235.30 1,050,235.30 333,574.81 1,365,505.55 18,304.56 18,304.56
Com onen  Ma e ial Balance (g)
mRNA 495.00 495.00 0 9.90 485.10 485.10
Sodi m Ace a e 15,181.65 15,181.65 0 15,181.65 0 0
Addi ional WFI 46,902.96 46,902.96 0 46,902.96 0 0
ALC-0315 7,938.46 7,938.46 0 158.77 7,779.69 7,779.69
ALC-0159 923.08 923.08 0 18.46 904.61 904.61
DSPC 1,661.54 1,661.54 0 33.23 1,628.31 1,628.31
Chole e ol 3,692.31 3,692.31 0 73.85 3,618.46 3,618.46
E hanol 973,440.30 973,440.30 0 973,440.30 0 0
1X PBS 0 0 333,574.81 329,686.43 3,888.38 3,888.38
S c o e 0 0 0 0 0 0
(c)
S eam ID S-133 S-134 S-135
Vol me ic Flo  (mL/min) - - -
Ma  (g) 18,304.56 92,307.69 110,612.25
Com onen  Ma e ial Balance (g)
mRNA 485.10 0 485.10
Sodi m Ace a e 0 0 0
Addi ional WFI 0 0 0
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ALC-0315 7,779.69 0 7,779.69
ALC-0159 904.61 0 904.61
DSPC 1,628.31 0 1,628.31
Chole e ol 3,618.46 0 3,618.46
E hanol 0 0 0
1X PBS 3,888.38 6,923.08 6,923.08
S c o e 0 89,273.00 89,273.00
12.4 Packing
Fig e 12.4 P ce  F  D ag a : Pac ag g RNA acc e
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13. P oce  De c i ion
13.1 P e a a ion of DNA
A  d c ed  he P e a  P ce  S he ec , he d c  f he DNA
 be ced  a h d a . The ed ce  f  he d c  f RNA acc e
 a  h he d f ed DNA fed  he In Vitro Transcription eac  f  he he  f
RNA.
13.2 S n he i  and P ifica ion of mRNA
13.2.1 S n he i  of mRNA: In Vitro T an c i ion
The he  f RNA  be d e  a ce -f ee a e  h gh a ce  ca ed in
vitro a c . D g IVT, a  e e ca ed T7 RNA e a e he e  a a d f
RNA g f ee c e de ba e  f  a c e e a DNA e a e. Th  ce  
cc   a WAVE B eac TM 200 e  h ch c f a c e   h ch a d ab e
a c b eac  bag  aced. A 200 L bag be ed f  each IVT eac  ha  cc , a d
110 L f h  bag  be cc ed a  110 L  he eac  e. P   ad g he bag, he
bag  be hea ed  he eac  e e a e f 37℃. Ne , 99 L f he eac  c e
 be ed  he bag; h  99 L c  f he eac  b ffe  (T -HC , MgC 2,
d h h e  (DTT), e d e, a d T  X-100), DNA e a e, c e de ba e , ca
a a g f  c - a c a  ca g a  d c ed  Sec  10.2.2, a d a e  f  ec
(WFI). The 11 L f T7 RNA e a e  be ed  a   ha  he eac   
beg   a  eac  c e  ha e bee  ed  he bag. The H   be ed
 e e ha  he H  8.1. O ce a  c e ha e bee  aded  he bag, he c g a e
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 be e   4 c  e  e, a d he c g a g e  be e   2   a d e ce e
ha g f he eac  c e . The IVT eac   f  5 h .
F g he IVT eac , e e d ge  a e ece a   a d  he deg ada  f
a ed c e . Af e  he IVT eac  ha  f  5 h , DNa e I  be added 
deg ade he DNA e a e ha  e a  af e  he IVT eac 45. Ph ha a e  a  be added
af e  he 5 h ; h ha a e  de h h a e he 5  e d f ca ed RNA , h
a g he   be b e e  deg aded 46. Af e b h e e  a e added, he c ba  
he WAVE B eac   cc  f  30 e  a  he a e e e a e, H, a d c g
c d . F g he c e  f he IVT eac a d b e e  e e d ge , he
c e  f he bag  be ed  a age a . F  ha  age a , he  
he  be ed  he f  a ge a  f  f a e .
13.2.2 P ifica ion of mRNA: Tangen ial Flo  Fil a ion Befo e Ch oma og a h
The  c g  f he IVT eac  c a a  de ab e e e e  ha  a e
 eeded  he f a  ha ace ca  f a c d g: d b e a ded RNA, DNA e,
h ha e, a d DNA, c a ed NTP , T -X-100, T7 RNA P e a e, Ca
A a g, Mag e  Ch de, T  B ffe , S e d e, a d d h h e . The ef e,  
ece a   f e  h    de   e e he de ed e e e . A b hed a e
ha  f c e   he f ca  f RNA ha  gge ed he f a a ge a  f  f a
f ed b  a ch a g a h  c  f ed b  a he a ge a  f  f a  e  
e e a  f he a ed c a a , ea g e g e a ded RNA25. Rea
f  h  de g  ch ce  d e  he fac  ha  TFF d   ega e  affec  he ab  f RNA
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c a ed  he  f a  ce e . I  fac , RNA a  de c ea ed age ab  af e
a  ea  e e  f TFF c a ed  he age ab f he RNA  he IVT- .
Th , f g he IVT eac , he d c   a  f ed h a
Ta ge a  F  F a  de ce, a  efe ed a  TFF1   ce . The e f h
 e a    e e a  e e e  e ce  f RNA f  he IVT d c  . TFF1
 a d af a  e  ha   cc   a Pa Ce a a  100 SAT S e  aded h Ce a a
100 ca e e  a d a P e he f e Me b a e. I de   e e ha  RNA  f ed, a
af a  e b a e h a M ec a  We gh  C Off (MWCO) f 100 Da  ch e . Th
e e  ha  he RNA ca  a  h gh he f e d e   e. The b ffe  ed f  h
ce   ch e   be a e  a   b ffe  e cha ge a  eeded bef e he ch a g a h
c . I  add , ch g a e  a  he b ffe e a e  a a    ch e c .
A  gge ed b  he a e , TFF1  be e f ed g 10 d  e  (DV) f a e .
S ce he e f he IVT d c   110 L, h ea  ha  he e f a e  eeded a  a
b ffe  f  h  ce  g he 10 DV  be 1100L. The e e a e f TFF1 c a  RNA
(b h g e a d d b e a ded) a d a e . The e e a e e  ch e   be 110 L a  e
a ed  e  he e f IVT d c   e a  he e f he e e a e ( .e. h
TFF1   ea   d af e  a d  c ce a e he e a  ). I  , h  ea  ha
he e ea e e f TFF1  990 L. The e ea e f TFF1 c a : DNA e, h ha e,
a d DNA, c a ed NTP , T -X-100, T7 RNA P e a e, Ca  A a g,
Mag e  Ch de, T  B ffe , S e d e, a d d h h e . The f  f TFF1  e   be
70 L/h/ 2 a  gge ed b  he a e  (CITE). I  add , he ce  e  e   be 2.5 h .
F  he ec f ed ce  a ab e , he e b a e a ea  ca c a ed  be 6.29 2 a d he f
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a e  ca c a ed  be 440 L/h . The a e  e  h  98% f RNA  be ec e ed 
he e e a e  a d h  a  fac ed  ce  de g . Th  ea  ha  520 g a  f
RNA a  f   he TFF1 b   510 g a  a ec e ed  he e e a e. I  h  e ,
RNA bec e  c ce a ed f  0.5 g a  e  e  5 g a  e  e .
13.2.3 P ifica ion of mRNA: Ch oma og a h
The d c  f  TFF1  fed  he ce e-ba ed fa  e  d ch a g a h
(FPLC) ha  b d  he d RNA. The de ed d RNA ha a e e  ha  a    b d
 he ce e e . The a a e e  f  h  c e e ca c a ed ba ed  a ca e-  f he
ce e-ch a g a h  c    a  a c e b hed  2019  M ec a  The  f
N c e c Ac d 36.
The ce  e  he ch a g a h  b ffe   a e he ce e e  a d  d e he
RNA ha   fed  he c . The b ffe   ed  he Ch a g a h  B ffe  S age
Ta  a d  c a  16% e ha  b  e f a e , NaC , EDTA a d HEPES. The
c  f 16% e ha   c ca  a  e ea ch e ea  ha  a h ghe  c ce a  ead  
b h d RNA a d RNA b d g  he c 36 . The e   e a ed h 275 g f ce e
a d 1540 L f b ffe   a e a h ge e  . The e   fed  he c  a d
a ed  e e b  g a .
P   e, he FPLC ch a g a h  c   a hed h a e-c  e f
b ffe . The c   he  fed h he 110 L f RNA f  TFF1 d ed  16 L f
ch a g a h  c . A  he RNA f  h gh he c , e ha  96% f he d RNA
b d   he ce e c 36. Af e  e e, he ch a g a h  c   a hed h
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c ea e-f ee a e   e a a  f  a e  . F  c e a  h e e  c a , 
a  dec ded ha  he e   be e ed a  he a e ec e  a e.
Th  ce   e f ed a  4C. L e a e e e d ca e ha  a  h ghe  e e a e
he e ce  f RNA ec e ed e a  cha ged e he e ce  f d RNA ha  e a
b d c ea e 36. G e  h  a d he add a c  c ed  a g he e e a e, he
ce   cc  a   e e a e.
FPLC  effec e  e g d RNA ha  a ge  e be ee  21 a d 500 b . The
c  ca  be ed  e e d RNA f d ffe e  e a d f d ffe e  c e de
c . Th  ce  d e   c e he eg  f he RNA  a c ca  
ce a  de e a   he RNA ca ed b  he ce e d ha e ca  f  he
e a g f he a fac g ce  a d c d e e be a afe  c ce .
13.2.4 P ifica ion of mRNA: Tangen ial Flo  Fil a ion Af e  Ch oma og a h
A  a ed ab e, f g he ch a g a h  e , he a ed d b e a ded RNA
 e ed f  he ce  , ea g he de ab e d c : g e a ded RNA.
H e e ,    ece a   e e a ed c a a ha  a ea ed  he  d e
 he ch a g a h  e 47. The a ed c a a ha   be e ed f  he
 f g  f he ch a g a h  c , a  he  d   a ea   he f a
ha ace ca  f a  c de: HEPES, EDTA, S d Ch de, a d E ha . S a  
ha  a  d e f g he IVT eac , a a ge a f  f a  e   ece a   e e
he e c a a  f  he g e a ded RNA . The de g  ch ce f ac g a
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Ta ge a  F  F a  S e  gh  af e  he ch a g a h  c , a che  h ha  
a ed  he a e  ha   e ed  ec 13.2.2.
Th , f g he Ch a g a h  c , he d c   a  f ed
h a Ta ge a  F  F a  de ce, a  efe ed  a  TFF2   ce . The e f
h   e a    e e a  e e e  e ce f  RNA f  he ch a g a h  d c
 a d  e f  a b ffe  e cha ge. TFF2 a d af a  e  ha   cc   a Pa
Ce a a  100 SAT S e  aded h Ce a a  100 ca e e  a d a P e he f e
Me b a e. I  de   e e ha  RNA  f ed, a  af a  e b a e h a
M ec a  We gh  C  Off (MWCO) f 100 Da  ch e . Th  e e  ha  he RNA ca
a  h gh he f e  d e   e. The b ffe ed f  h  ce   ch e   be 50 M f
S d  Ace a e a  h   e a e he RNA f  he LNP f a  ce  ha
cc  d ea . A  gge ed b  he a e , TFF2  be e f ed g 10 d
e  (DV) f d  ace a e. S ce he e f he ch a g a h  d c   ab  126
L, h  ea  ha  he e f d  ace a e eeded a  a b ffe  f  h  ce  g he 10
DV  be 1262 L. The e e a e f TFF2 c a g e a ded RNA a d d  ace a e.
The e e a e e  ch e   be 126 L a  e a ed  e  he e f ch a g a h
d c   e a   he e f he e e a e ( .e. h  TFF2   ea   d af e  a d
 c ce a e he e a  ). I  , h ea  ha  he e ea e e f TFF2 
ab  1136 L. The e ea e f TFF2 c a : HEPES, EDTA, S d  Ch de, E ha , a d
d  ace a e. The f  f TFF2  e   be 82.5 L/h/ 2 a  gge ed b  he a e 25. I
add , he ce  e  e   be 2.5 h . F  he ec f ed ce  a ab e , he
e b a e a ea  ca c a ed  be 6.12 2 a d he f  a e  ca c a ed  be 505 L/h . The
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a e  e  h  98% f RNA  be ec e ed  he e e a e  a d h  a
fac ed   ce  de g . Th  ea  ha 505 g a  f RNA a  f   he TFF2
b   495 g a  a  ec e ed  he e e a e. I  h  e , RNA bec e  c ce a ed
f  0.4 g a  e  e   4 g a  e  e .
13.2.5 P ifica ion of mRNA: S e ile Fil a ion
Af e  he RNA  ea e  he ec d a ge a f  f a  e   
ce ,  he  ge  f e ed g a e e f a de ce. Th  e e f a  f he 
e e  a  he a  f ca  e  bef e e e g he ec d eg   ce  h ch  he
f a  f LNP . The e f e e f a   e e ha  he RNA d c  
e e b  e g a  bac e a  a d c b a  c a a f  he a e be g f e ed. I
h  e  f he a fac g ce , he RNA d c  be d ec  f e ed  he f a
age c a e  g a 0.2   e b a e ca dge , a  efe ed  a  O ca S e e XLTµ
10 M e E e f e . The e f e  a e d ab e a d d e  he d e  f he f e
each ba ch h f RNA d c  ea g TFF2 e e ac  e f e . The f e  a e
e ec ed  ec e  100% f he d c .
13.3 Fo m la ion of LNP  Enca la ion of mRNA
13.3.1 P e a a ion fo  Mic ofl idic
Each c f d c de ce ed ha   e  ea ; e e  ea  c a  RNA 
a  a e  b ffe , a d he he  e  ea  c a d  d ed  e ha . The
c ce a  f c e   each ea  a e a f  e g d a a c e (LNP)
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e a  e  a  f  eff c e  RNA e ca a . Th , he e a a  f he e   a
a  e  ha   cc    he c f d c e .
The e a a  f he d  e  d g 14 g a  f he f  d
(ALC-0315, ALC-0159, DSPC, a d ch e e )  1200 L f e ha , e g  a 
h a d c ce a  f 10 g/ L.
The RNA   ha e g e h gh a  f he RNA f ca  e  a d 
h  be  a 50 M d  ace a e ;  ece a  f  he RNA  be  a  ac d c
b ffe  ch a  d  ace a e a  h  e e  RNA e ca a 48. H e e , he RNA
 ha  e  f  he RNA f ca  e c a  RNA a  a c ce a  ha  
 h gh f  he e  c f d c  e . Th , he RNA  d ed h a  add a  3600 L f
50 M d  ace a e  ach e e he de ed c ce a f  c f d c  h ch  0.13
g/ L.
13.3.2 Fo m la ion of LNP: Mic ofl idic
S agge ed he gb e c f d c g de ce  be ed  d ce he
RNA-c a g LNP ; a  age f e f he e de ce ca  be f d  F g e 13.1. O e
e  ea   RNA  a  ac d c b ffe , a d he he  e  ea   d  d ed  e ha .
The  e  ea  ee  a  a g cha e  he e g a d LNP f a  cc   he
de  f c ec d . The e  f he e c f d c ch  de ce  c  f 25 e  f 16
a a e ed ch ,  25 16X e 48. The f d  be ed f  age a  f he
a e  RNA a d he d    each c f d c de ce.
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T  e e RNA ab  h gh  he ce , h  c f d c  e   cc  a
4℃. The RNA  f   h gh e f he e  ea  a  a c ce a  f 0.13 g/ L
 a 50 M d  ace a e b ffe  a  H 4.0; he f a e f he RNA ea   be 9 L/
f  a g e de ce. Add a , he d  f   a  a c ce a  f 10 g/ L 
e ha , a d he d ea  f  a e  be 3 L/  f  a g e de ce. Th  e e e  a
f  a e a  (FRR) f 3:1 ( RNA: d ) h ch ec e ded b  he e a e 48. The
ea   ee  a  he g cha e , he e g  cc  e  he c e f 3
ec d , a d a g e ea   e  a  a f a e f 12 L/  f  a g e de ce. I  
a e 19 h    e ee  h f d c  ( e ba ch  500 g a  f RNA) h gh
he e de ce .
Fig e 13.1. S agge ed he gb e c f d c g de ce. Ma  f he e de ce  ca  be
a a e ed h  a g h  ce  ca ab e.49
13.3.3 P ifica ion of LNP: Tangen ial Flo  Fil a ion
F g he c f d c  de ce, he RNA a d a e  e ca a ed b  LNP .
H e e ,    ece a   e e a ed c a a ha  a ea ed  he  d e
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 he c f d c  e . The a ed c a a  ha   be e ed f  he 
f g  f he ch a g a h  c , a  he d   a ea   he f a  ha ace ca
f a  c de: E ha  a d S d  Ace a e. S a  ha  a  d e f g he IVT
eac  a d ch a g a h  c , a a ge a  f f a  e   ece a   e e he e
c a a  f  he LNP-RNA d c .
Th , f g he c f d c  de ce, he d c   a  f ed h a
Ta ge a  F  F a  de ce, a  efe ed a  TFF3   ce . The e f h
 e a    e e a  e e e  e ce  f LNP- NA d c  a d a   e f  a
b ffe  e cha ge. TFF3  a d af a  e  ha  cc   a Pa Ma a e S e  aded
h Ma e e 100 ca e e  a d a P e he f e Me b a e. I  de   e e ha
LNP-RNA d c   f ed, a  af a  e b a e h a M ec a  We gh  C  Off
(MWCO) f 100 Da  ch e . Th  e e  ha  he LNP-RNA d c  ca  a  h gh he
f e  d e  he e f he e   he e b a e ch e . The b ffe  ed f  h  ce  
ch e   be 1X PBS B ffe , a  h   e a e he LNP-RNA  f  he f a  d
ce  ha  cc  d ea . I  add , PBS b ffe   he f a  f a  f he acc e
a d  h   a he  ea  h  PBS a  ch e  a he TFF3 b ffe . The PBS b ffe   ade
f : P a  Ch de, M ba c a  h ha e, S d  Ch de, a d D ba c
S d  Ph ha e H d a e. A  gge ed b  he a e  ec  13.2.4, TFF3  be
e f ed g 10 d  e  (DV) f PBS25. S ce he e f he d c  
f g  f he c f d c  de ce  ab  4,935 L, h  ea  ha  he e f d
ace a e eeded a  a b ffe  f  h  ce  g he 10 DV  be 49,350 L. The e e a e f
TFF3 c a  L d , RNA, a d PBS. The e e a e e  ch e   be 626 L a  e
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a ed  c ce a e he RNA  bef e  e e   he f a  d  ce . I  ,
h  ea  ha  he e ea e e f TFF2  ab 53,035 L. The e ea e f TFF2 c a :
S d  Ace a e, E ha , a d PBS. The f  f TFF2  e   be 82.5 L/h/ 2 a  gge ed b  he
a e 25. I  add , he ce  e  e  be 7.5 h . TFF3  ce g e  ge
ha  he ce g f  TFF1 a d TFF2 d e  he a ge a  f e eeded  be
ce ed. F  he ec f ed ce  a ab e , he e b a e a ea  ca c a ed  be 86.72 2
a d he f  a e  ca c a ed  be 7,155 L/h . I  add ,   a ed ha  98% f LNP-RNA
d c   be ec e ed  he e e a e . Th  ea  ha  495 g a  f RNA a
f   he TFF2 b   485 g a  a  ec e ed  he e e a e. I  h  e , RNA
bec e  c ce a ed f  0.0092 g a  e  e  2.65 g a  e  e .
13.3.4 P ifica ion of LNP: S e ile Fil a ion
Af e  he LNP- RNA  ea e  he h d a ge a f  f a  e   
ce ,  he  ge  f e ed g a e e f a de ce. Th  e e f a  f he 
e e  a  he a  f ca  e   he e e ce . The e f e e f a   
e e ha  he LNP- RNA d c   e e b  e g a  bac e a  a d c b a
c a a  f  he a e be g f e ed. Th e e f a  e   e  a  a  
e e  ha   f a  d c   c de ed e e h ch  ece a  a    be ec ed 
h a . I  h  e  f he a fac g ce , he RNA d c   be d ec  f e ed 
he f a  age c a e  g a 0.2   e b a e ca dge , a  efe ed  a  O caµ
S e e XLT 10 M e E e f e . The e f e a e d ab e a d d e  he d e
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f he f e  each ba ch h f LNP- RNA d c  ea g TFF3  e e ac  e f e .
The f e  a e e ec ed  ec e  100% f he d c .
13.4 Q ali  Con ol
13.4.1 De e mina ion of Leng h of mRNA P od c
The RNA ha  h d be e e   he f a  f a f he acc e h d be he
e ac  RNA e e ce ha  a  de g ed; he e e ce h d c de he 5  ca , b h he 5
a d 3  UTR , he  ha  c de  f  he f - e g h e e , a d he  (A) a . The
f  RNA e e ce h ch ca  be f d  A e d E  e ac  4079 ba e   e g h.
I   e e a  ha  he e be a e  h ch  e e ha  he RNA be g d ced  he
f - e g h RNA  e e he h ghe  b e a a eff c e c . T  acc h h , a
a e  be a e  f  he d c  f each in vitro a c  eac , a d RNA ge
e ec h e   be e f ed  he d c  g RNA ge  e ec h e  . D g ge
e ec h e , he e  be a  e ec c c e e e  h ch  ca e ega e -cha ged
RNA  e a d he a de50. Sh e  RNA f ag e  g a e fa he  ha  ge
RNA f ag e ,  h  ce  ca  be ed  de e e he he    he RNA d c
f  he in vitro a c  eac   f - e g h50. The ge  h d h   e  ha
90% f - e g h RNA. A a e ge  ca  be f d F g e 13.2. A he   d be 
e e ce he RNA d c ; h e e , h  d be  e c g a d e e e, a d ge
e ec h e   ab e  e ea  he de ed e .
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Fig e 13.2. RNA ge  e ec h e . The ba d  e e e RNA ha   a ec f c e g h 50.
13.4.2 De e mina ion of Si e of Li id Nano a icle
De e g he e f he d a a c e  (LNP )  h gh  a ; he LNP
eed  be a a e  80   de  f  a eff cac  f he acc e. T  de e e he
e f he LNP  be g d ced   c f d c de ce , d a c gh  ca e g (DLS)
 be ed. DLS e  ca e ed gh   de e e he e f a g e  a c e51.  DLS  be
e f ed 4 d ffe e  e  d g he c e f he c f d c  e .
13.4.3 Mea emen  of Endo o in Le el
A  ha ace ca  d c  d ced a e e ed b  a  eg a  age c e
d de  de g  a e   de e e e d e e   he ha ace ca  d c 52.
G a - ega e bac e a ha e e d , a d he e e d  a e e  c  h a 52. T
e e ha  he acc e   c a a ed h e d , a  a eb c e a e (LAL)
a a   be e f ed f g he f a  d e   he ce . The LAL a a   a
a da d a a  a d  ec g ed a  a d b  he FDA, a d  ea e  e d  e e 53. F
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he e ea , he LAL a a  a  ch e  a  he e h d f  e d  ea e e . Acce ab e
e e  f e d  f  RNA acc e  h d be e ha  10 e d   (EU)/ L54.
13.5 Packaging and o age of od c
The d c , af e  he f a  d  a d a c  e ,  be ac aged  a .
Each 2 L g a  a   c a  .45 L f he f e e  f d c . Acc d g 
Pf e  c e  a fac g ce , each a  ea ed h a b b  bbe  e  a d
a  a  ea  h f - ff a c ca . The a  be e   he a  h g c a e
acc d g  FDA eg a 55. Each c a e  h d 5 a  f acc e  h each a
h d g 195 a , e a e   1,170 d e . The ed a fac g ce  e d  a a
f 200  d e  h a ee  d c  f 15.4  d e . Th   e a e   a
ee  d c  f 2  a  a d a ee 2,100 ac aged he a  c a e  (Refe  
A e d  D). The ce   ac age he a  be a  f a echa ca  e g ee g a eg
ha    f c e f  h  ec .
The he a  h g c a e   eed  be ed a d h ed  acc da ce h
FDA eg a . A  e ed  C e  Re e e , he acc e   e e a-c d
f ee e  (be ee  -80C a d -60C), f ee e  f  a a f  ee  (be ee  -25C a d
-15C), a d ef ge a  f  a a  f 120 h , 5 da , (be ee  2C a d 8C).
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14. Ene g  Balance and U ili  Re i emen
D e  he a ce f a a g RNA ab a d e e g RNA deg ada
h gh  he ce ,  d c  fac  eed  be a a ed a  4℃ a  RNA 
e ab e a  e  e e a e . The ea  c f e ec c   a a  he a a e
10,000 f 2 fac  a  4℃  $500,000, a d h  he a ge   c . T  b a  add a
e ec ca  c  a c a ed h e e e  f  ce ch a  hea g he IVT WAVE
B eac , e a  gh g, a d d g hea g a d c g f  ff ce ace  h ch 
cc  a  add a  5,000 f 2, a  add a  20% ($100,000) a  added  he a  e ec ca
c . Add a , a e   ed  a  e h gh  he ce ; h ,  a  ece a
 a e  acc  he ea  c  a c a ed h g a e   he a e  f ca
e  a  he fac . The c  f a e   $10,000 e  ea . The e a e  a e a ed 
Tab e 14.1 be .
Table 14.1. S a  f Yea  U e  C
U ili Yea l  Co
Elec ici  - Cooling Facili $500,000
Elec ici  - Addi ional $100,000
P oce  Wa e $10,000
To al: $610,000
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15. E i men  Li  and Uni  De c i ion
15.1 P e a a ion of DNA
S ce he he  f he DNA h he GOI be ced,  e e   be
ed  he e a a  f DNA.
15.2 S n he i  and P ifica ion of mRNA
15.2.1 T i  B ffe  S o age Tank
La ge a e  f T  H d ch de b ffe  eeded f  he IVT eac . Th  b ffe
 be ed  a  IBC a e  ee  304 a a d  be cha ed f  he e d  The
Ca  C a . Th  a e  ee  d ha d g a  fea e  a e- ece ed b  ha
a  f  c e e d a age, a e e e e g de ce, 10 ga ge a e  ee  IBC
c c  h 2B f h a d a 2  b g e g. The b ffe   be cha ed e e  3
ee  ba  ( .e. e  3 ba che  ba ), he ef e e g he age a  h d    280 e
f T  b ffe . Af e  c  efe e c g h a da d e  f a  ha  he e d  d ce , 
a  de e ed ha  a 379 e  a   be cha ed  h d he T  b ffe . L ea
e a g cha e c  da a ed f  he e d , he cha e c  f he age a  
$1,859 a d he a  ba e d e c   $7,437 ( ee A e d  C f  de a ed cha g
ca c a ).
15.2.2 WAVE Bio eac o
The in vitro a c  (IVT) eac   be   a WAVE B eac TM 200 e
f  C a ( e  GE Hea hca e L fe Sc e ce ). The WAVE B eac TM e  c
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f a c g a a a   h ch a a c d ab e b eac  bag  aced. The eac
c e  a e ed  he bag, a d h   he e he eac   a e ace. The WAVE
B eac TM e  c de  a e e a e c e a d H ; b h f he e e e e
a e a  a  he IVT eac   cc  a  37℃ a d a  a H f 8.1. Th  e  a
acc da e  200 L d ab e b eac  bag  h g e  f   100 L h ch 
dea  a   IVT eac  e e  a eac  e f c e  100 L.
The IVT eac  a  e  a  he DNa e I a d h ha a e ea e   a e ace 
h  b eac  e . The IVT eac   f  5 h , a d af e  h  5 h  e e d,
DNa e I a d h ha a e  be added. The DNa e I a d h ha a e d ge   ceed f
a  add a  30 e . B h f he e ce e  a e ace a  37℃ a d H 8.1. O ce h
5.5 h  e e d ha  a ed, he IVT eac a d e e d ge  c e   be ed
 he IVT d c  age a , a d he e  ed b eac  bag  be d ed f.
Th ee  ba ch eac   eed  be   a WAVE B eac TM e . T  a d
g e  he e e  ha  a eac  d b ea d   a bag d b ea , 2 b eac  a d
26 d ab e a c b eac  bag  e e cha ed. The cha e c  f a WAVE
B eac TM 200 e   $400,000, a d he cha e c  f a 200 L a c d ab e
b eac  bag  $709. We dec ded  cha e 2 b eac a d 26 a c d ab e b eac
bag , a d he a  ba e d e c  f  he e e  $1,636,900.
15.2.3 IVT P od c  S o age Tank
The  ha   ed a e  ec e ed f  he IVT eac   be ed  a  IBC
a e  ee  304 a  ha   be cha ed f he e d  The Ca  C a . Th
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a e  ee  d ha d g a  fea e  a e- ece ed b  ha  a  f  c e e
d a age, a e e e e g de ce, 10 ga ge a e ee  IBC c c  h 2B f h
a d a 2  b g e g. The  eeded  be ed  be  a e  ee  ba  ( .e. e
ba ch ba ), he ef e e g he age a h d    110 e  f d c  . Af e
c  efe e c g h a da d e  f a  ha he e d  d ce ,  a  de e ed ha  a
110 e  a   be cha ed  h d he IVT d c . L ea  e a g cha e
c  da a ed f  he e d , he cha e c f he age a   $1,727 a d he a
ba e d e c   $6,909 ( ee A e d  C f  de a ed cha g ca c a ).
15.2.4 Tangen ial Flo  Fil a ion De ice 1
The d af a  ce   cc   a Ce a a 100 AT ca e e h de . The h de  
ed h a TFF e  a d a e ab e ca e e e b a e. Th  ca e e ha  a e b a e a ea
ha  ca  a ge f  0.9  18.6 a e e e . The e b a e ed  h  TFF de ce  be 6.3
a e e e . The e  ha  ca  e a  c  f  UV, H, c d c ,
a a   a d a .
Th  b ec e f h  Ta ge a  F  F a de ce   e e he e e , DNA
a d c a ed ba e . The e f RNA fed  h  de ce  he 100 L f  he
IVT eac . Th   c b ed  a a  f 1:10 a  gge ed b  he a e  h 1100 L f Wa e
F  I ec   acc  f  a a  f a e e f 1100 L ( efe   a e d  f  de a ed
ca c a ). The f  f h  TFF  70 LMH h ch  he a e age f he  a d h gh a ge
gge ed b  he a e . The e f  he f a ce  a  a ed  be 2.5 h . Th
a  de e ed h gh a e a e e e   h ch a e  a d ce e  gge ed a e f 5
h  a d a d c  h he c a   h ch he e a  dec ea ed  e he
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e  a e  f  he RNA  be f ed g e    ab . The f  a e f  h  ce  
400 L e  h  a d a  de e ed f  he a  f a e e a d he e ec f ed  be 2.5
h . The d c  ea  f h  TFF eac  a e he 110 L f e e a e a d he 990 L f
e ea e.
15.2.5 TFF1 Pe mea e Wa e Tank
The e ea e e ha  f e  h gh he e b a e  he TFF1 e   ec e ed
 he TFF1 Pe ea e Wa e Ta . Th    eeded f  he f a  d c  a d h  
ed  h  a   be d ed f a a e  he ea  f e. Th  a e   be
ed  a  IBC a e  ee  304 a  ha  be cha ed f  he e d  The Ca
C a . Th  a e  ee  d ha d g a fea e  a e- ece ed b  ha  a
f  c e e d a age, a e e e e g de ce, 10 ga ge a e  ee  IBC c c  h
2B f h a d a 2  b g e g. The e ea e a e  eeded  be ed  be  a
e  ee  ba  ( .e. e  ba ch ba ), he ef e e g he age a  h d    990 e
f d c  . Af e  c  efe e c g h a da d e  f a  ha  he e d  d ce ,
 a  de e ed ha  a 1,000 e  a   be cha ed  h d he e ea e . L ea
e a g cha e c  da a ed f  he e d , he cha e c  f he age a  
$2,187 a d he a  ba e d e c   $8,747 ( ee A e d  C f  de a ed cha g
ca c a ).
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15.2.6 TFF1 Re en a e S o age Tank
The e e a e e ha  d e   ge  f e ed h gh he e b a e  he TFF1 e
 ec e ed  he TFF1 Re e a e S age Ta . Th    eeded f  he f a  d c  a
 c a  he RNA d c . Th  e e a e  be ed  a  IBC a e  ee  304
a  ha   be cha ed f  he e d  The Ca C a . Th  a e  ee  d
ha d g a  fea e  a e- ece ed b  ha a  f  c e e d a age, a e e
e e g de ce, 10 ga ge a e  ee  IBC c c h 2B f h a d a 2  b g
e g. The e e a e  eeded  be ed  be  a e  ee  ba  ( .e. e  ba ch
ba ), he ef e e g he age a  h d   110 e  f d c  . Af e  c
efe e c g h a da d e  f a  ha  he e d  d ce ,  a  de e ed ha  a 110
e  a   be cha ed  h d he e e a e . L ea  e a g cha e c
da a ed f  he e d , he cha e c  f he age a   $1,727 a d he a  ba e
d e c   $6,909 ( ee A e d  C f  de a ed cha g ca c a ).
15.2.7 Cell lo e Ch oma og a h  Col mn
Th  ce  e  a 1000 L ce e ch a g a h c . The a a e e  f he
c  e e ca ed f  he 780 L ce e ch a g a h c  ed h a c a
e c  f  he a c e b hed  M ec a  The a N c e c Ac d  c g D . Ka a  Ka
(A Fac e Me h d). The e c  ed  he a - ca e c  a d a a ed  he a ge- ca e
c  ed  h  ce   21.54 c /h . The c  ha  a he gh  f 0.40 e e , a
d a e e  f 1.8 e e  a d a c - ec  a ea f 2.5 a e e e  efe   a e d  f
de a ed ca c a ). A a ge  d a e e  ha  he gh a  ed a  ad ed b  he c a  
de   ach e e he ca ed-  e h e ee g he e c  c a  a d he a a e
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ce  e. The ce  e a  ca c a ed f  he f - a e h ch a    e  b  he
f ed e c  a d he c - ec a  a ea. W h h , he f - a e f  he c   8,800 L
e  e. I  , he ce  e  110 e . U g c g e h d  f  Se de  e  a .
( ee A e d  C f  e de a ), he cha e c f  he c   $124,314 e   a d he
a  ba e d e c   $517,146. The ed ce   e e e  f  he
d c  f 200  d e .
15.2.8 Ch oma og a h  B ffe  S o age Tank
The ch a g a h  b ffe  ha   eeded   he ch a g a h  c   be
ed  a  IBC a e  ee  304 a  ha  be cha ed f  he e d  The Ca
C a . Th  a e  ee  d ha d g a fea e  a e- ece ed b  ha  a
f  c e e d a age, a e e e e g de ce, 10 ga ge a e  ee  IBC c c  h
2B f h a d a 2  b g e g. The ch a g a h b ffe   eeded  be ed 
be  a e  6.5 ee  ba  ( .e. e  6.5 ba che ba ), he ef e e g he age a  h d
  6,508 e  f d c  . Af e  c efe e c g h a da d e  f a  ha  he
e d  d ce ,  a  de e ed ha  a 6,510 e a   be cha ed  h d he
ch a g a h  b ffe  . L ea  e a g cha e c  da a ed f  he
e d , he cha e c  f he age a   $5,443 a d he a  ba e d e c   $21,772
( ee A e d  C f  de a ed cha g ca c a ).
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15.2.9 Cell lo e Re in S o age Tank
The ce e e  f  he ch a g a h  c  be ade a d ed  a  IBC
a e  ee  304 a  ha   be cha ed f  he e d  The Ca  C a . Th
a e  ee  d ha d g a  fea e  a e- ece ed b  ha  a  f  c e e
d a age, a e e e e g de ce, 10 ga ge a e ee  IBC c c  h 2B f h
a d a 2  b g e g. The ce e e   e ab e a d h ,  e c  h f
e   be eeded  be ade a d ed  he a , he ef e e g he age a  h d
  1,540 e  f d c  . Af e  c efe e c g h a da d e  f a  ha  he
e d  d ce ,  a  de e ed ha  a 1,540 e a   be cha ed  h d he ce e
e  . L ea  e a g cha e c da a ed f  he e d , he cha e
c  f he age a   $2,556 a d he a  ba e d e c   $10,223 ( ee A e d  C f
de a ed cha g ca c a ).
15.2.10 Reco e ed P od c  f om Ch oma og a h  Col mn S o age Tank
The  ha  d e   b d  he ch a g a h c   ec e ed a d ed 
a  IBC a e  ee  304 a  ha   be cha ed f  he e d  The Ca  C a . Th
a e  ee  d ha d g a  fea e  a e- ece ed b  ha  a  f  c e e
d a age, a e e e e g de ce, 10 ga ge a e ee  IBC c c  h 2B f h
a d a 2  b g e g. The ch a g a h  d c  eeded  be ed  be  a
e  ee  ba  ( .e. e  ba ch ba ), he ef e e g he age a  h d    126 e
f d c  . Af e  c  efe e c g h a da d e  f a  ha  he e d  d ce ,
 a  de e ed ha  a 130 e  a   be cha ed  h d he ch a g a h  d c
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. L ea  e a g cha e c  da a ed f  he e d , he cha e c  f
he age a   $1,764 a d he a  ba e d e c   $7,056 ( ee A e d  C f  de a ed
cha g ca c a ).
15.2.11 El ed Do ble S anded RNA Wa e Tank
The d b e a ded RNA  ha  d e  b d  he ch a g a h  c  
e ed f  he c  a d ed  a  IBC a e ee  304 Wa e a  ha   be
cha ed f  he e d  The Ca  C a . Th a e  ee  d ha d g a  fea e
a e- ece ed b  ha  a  f  c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B f h a d a 2  b g e g. The d RNA
a e  eeded  be ed  be  a e ee  ba  ( .e. e  ba ch ba ), he ef e
e g he age a  h d    985 e f d c  . Af e  c  efe e c g h
a da d e  f a  ha  he e d  d ce ,  a  de e ed ha  a 1,000 e  a   be
cha ed  h d he ch a g a h  d c  . L ea  e a g cha e c  da a
ed f  he e d , he cha e c  f he age a   $2,187 a d he a  ba e
d e c   $8,747 ( ee A e d  C f  de a ed cha g ca c a ).
15.2.12 Tangen ial Flo  Fil a ion De ice 2
Th  d af a  ce   e a Ce a a 100 SAT h a e b a e a ea f 6.12
a e e e . Th  de ce  be he a e a  he e ed f  TFF 1 (Refe   ec  f  TFF 1
f  ec f c   e a  ha   a  f he de ce).
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The b ec e f h  Ta ge a  F  F a  de ce   e e he e ha  f  he
ce e ch a g a h  c  a d  d  a b ffe  e cha ge  e a a  f  he
M c f d c  de ce. The e  f h  TFF 2  he d c  f he ce e ch a g a h
c . Th  d c  ha  a e f 126 L a d be d ed h 1,262 L f  50 M d
ace a e f  a a  e f 1,262 L ( efe   A e d B f  ca c a ). S d  ace a e a
ch e  ce h   he d e  ed  he LNP a e ed  efe e ce f  he de g  f he
M c f d c  e  ( efe  A e d  J f  a e  f a ). The RNA ,  d c  f
he ch a g a h  c , a d he d  ace a e a e c b ed  a a  f  1:10 a
gge ed. The f  f h  TFF  82.5 LMH a d he e f  he f a  ce  a  a ed
 be 2.5 h  ( he a e e a  f  TFF1). The f a e f  h  ce   505 L e  h .
The e  f he TFF a e he e ea e a d he e e a e d c  ea . A e f
126.26 L  e ec ed f  he f e  a d fed  he e e a e age a . Th   he RNA
 ha   g  h gh a e e f a a d he   he M c f d c  de ce. The
e f e ea e  1136.49 L a d h   he e ha   d ca ded  he a e a .
15.2.13 Sodi m Ace a e B ffe  S o age Tank
La ge a e  f S d  Ace a e b ffe   eeded f  he TFF2 e . Th  b ffe
 be ed  a  IBC a e  ee  304 a a d  be cha ed f  he e d  The
Ca  C a . Th  a e  ee  d ha d g a  fea e  a e- ece ed b  ha
a  f  c e e d a age, a e e e e g de ce, 10 ga ge a e  ee  IBC
c c  h 2B f h a d a 2  b g e g. The b ffe   be cha ed e e  ee
ba  ( .e. e  ba ch ba ), he ef e e g he age a  h d    1,263 e  f d
ace a e b ffe . Af e  c  efe e c g h a da d e  f a  ha  he e d  d ce , 
88
a  de e ed ha  a 1,325 e  a   be cha ed  h d he d  ace a e b ffe .
L ea  e a g cha e c  da a ed f  he e d , he cha e c  f he
age a   $2,233 a d he a  ba e d e c  $8,932 ( ee A e d  C f  de a ed
cha g ca c a ).
15.2.14 TFF2 Re en a e S o age Tank
The e e a e e ha  d e   ge  f e ed h gh he e b a e  he TFF2 e
 ec e ed  he TFF2 Re e a e S age Ta . Th   eeded f  he f a  d c  a
 c a  he RNA d c . Th  e e a e  be ed  a  IBC a e  ee  304
a  ha   be cha ed f  he e d  The Ca C a . Th  a e  ee  d
ha d g a  fea e  a e- ece ed b  ha a  f  c e e d a age, a e e
e e g de ce, 10 ga ge a e  ee  IBC c c h 2B f h a d a 2  b g
e g. The e e a e  eeded  be ed  be  a e  ee  ba  ( .e. e  ba ch
ba ), he ef e e g he age a  h d   126 e  f d c  . Af e  c
efe e c g h a da d e  f a  ha  he e d  d ce ,  a  de e ed ha  a 130
e  a   be cha ed  h d he e e a e . L ea  e a g cha e c
da a ed f  he e d , he cha e c  f he age a   $1,764 a d he a  ba e
d e c   $7,056 ( ee A e d  C f  de a ed cha g ca c a ).
15.2.15 TFF2 Pe mea e Wa e Tank
The e ea e e ha  f e  h gh he e b a e  he TFF2 e   ec e ed
 he TFF2 Pe ea e Wa e Ta . Th    eeded f  he f a  d c  a d h  
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ed  h  a   be d ed f a a e   he ea  f e. Th  a e   be
ed  a  IBC a e  ee  304 a  ha  be cha ed f  he e d  The Ca
C a . Th  a e  ee  d ha d g a fea e  a e- ece ed b  ha  a
f  c e e d a age, a e e e e g de ce, 10 ga ge a e  ee  IBC c c  h
2B f h a d a 2  b g e g. The e ea e a e  eeded  be ed  be  a
e  ee  ba  ( .e. e  ba ch ba ), he ef e e g he age a  h d    1,136
e  f d c  . Af e  c  efe e c g h a da d e  f a  ha  he e d
d ce ,  a  de e ed ha  a 1,325 e  a  be cha ed  h d he e ea e
. L ea  e a g cha e c  da a ed f  he e d , he cha e c  f
he age a   $2,233 a d he a  ba e d e c   $8,932 ( ee A e d  C f  de a ed
cha g ca c a ).
15.2.16 S e ile Fil e  1
O ca S e e XLT 10 M e E e f e  be ed f g he ec d
a ge a  f  f a  ed  he RNA f ca ce . O e O ca f e   be
ed f  each ba ch ( e ba ch e d  a a e 500 g a  f RNA). The e O ca
f e  a e e e f e  a d h  ha e a e e f 0.2 ; h  e e  effec e 
e e g bac e a a d he  c ga  f a g h gh he f e . The e b a e
a ea f he O ca f e   0.54 2, a d he f  7 L/ /c 2 56. Each O ca f e  
ha e 126 L f RNA  f e ed h gh , he e e f a  e f  e ba ch 
be 3 e . The cha e c  f e O ca S e e XLT 10 M e E e f e  
$575.00, a d he a  ba e d e c  f 13 f e  $14,950.00.
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15.3 Fo m la ion of LNP  Enca la ion of mRNA
15.3.1 Dil ion 1 Tank
I a  h  a   e b e f  h d g he RNA  c g  f he S e e
F a  1 U  O e a . Add a , a d f he RNA  h 50 M f
S d  Ace a e  e f ed h  h  a   he M c f d c  De ce. Th  d ed
  be ed  a  IBC a e  ee 304 a  ha   be cha ed f  he e d
The Ca  C a . Th  a e  ee  d ha d g a  fea e  a e- ece ed b
ha  a  f  c e e d a age, a e e e e g de ce, 10 ga ge a e  ee  IBC
c c  h 2B f h a d a 2  b g e g. The d ed  eeded  be ed
 be  a e  ee  ba  ( .e. e  ba ch ba ), he ef e e g he age a  h d  
 3,701 e  f d c  . Af e  c  efe e c g h a da d e  f a  ha  he
e d  d ce ,  a  de e ed ha  a 3,785 e a   be cha ed  h d he d ed
. L ea  e a g cha e c  da a ed f  he e d , he cha e c  f
he age a   $3,557 a d he a  ba e d e c   $14,228 ( ee A e d  C f  de a ed
cha g ca c a ).
15.3.2 E hanol S o age Tank
La ge a e  f E ha    eeded f he d  f d  bef e he
c f d c  de ce. Th  b ffe   be ed a  IBC a e  ee  304 a  a d  be
cha ed f  he e d  The Ca  C a . Th a e  ee  d ha d g a  fea e
a e- ece ed b  ha  a  f  c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B f h a d a 2  b g e g. The e ha  
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be cha ed e e  ee  ba  ( .e. e  ba ch ba ), he ef e e g he age a  h d  
 1,234 e  f e ha . Af e  c  efe e c g h a da d e  f a  ha  he e d
d ce ,  a  de e ed ha  a 1,325 e  a  be cha ed  h d he e ha  .
L ea  e a g cha e c  da a ed f  he e d , he cha e c  f he
age a   $2,233 a d he a  ba e d e c  $8,932 ( ee A e d  C f  de a ed
cha g ca c a ).
15.3.3 Li id and E hanol Sol ion S o age Tank
L d  ge  ed h e ha   a d h  a e e  ed  a age
a  ha   be fed  he c f d c  de ce. The d-e ha    ed  a  IBC
a e  ee  304 a  a d  be cha ed f he e d  The Ca  C a . Th
a e  ee  d ha d g a  fea e  a e- ece ed b  ha  a  f  c e e
d a age, a e e e e g de ce, 10 ga ge a e ee  IBC c c  h 2B f h
a d a 2  b g e g. The d-e ha   be ade e e  ee  ba  ( .e. e
ba ch ba ), he ef e e g he age a h d    1,234 e  f d-e ha . Af e
c  efe e c g h a da d e  f a  ha he e d  d ce ,  a  de e ed ha  a
1,325 e  a   be cha ed  h d he d-e ha . L ea  e a g
cha e c  da a ed f  he e d , he cha e c  f he age a   $2,233 a d
he a  ba e d e c   $8,932 ( ee A e d C f  de a ed cha g ca c a ).
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15.3.4 Mic ofl idic  De ice
S agge ed he gb e c f d c g de ce ba ed  h e ed  he P ec
Na e  Na A e b TM P a f   be ed  f  he LNP  ha   e ca a e he
RNA. The 0.13 g/ L RNA  50 M d  ace a e a  a H f 4.0 e e  h gh he
a e  ea  a  a f  a e f 9 L/  f  a g e de ce h   F g e 15.1, a d he 10
g/ L d   e ha  e e   he he  e a  a f  a e f 3 L/  f  a g e de ce,
a  h   F g e 15.1. Ra d g cc  e 3 ec d , a d he e g
RNA-c a g LNP  e  a  a f  a e f 12 L/ f  a g e de ce.
Fig e 15.1. D ag a  f a g e agge ed he gb e c f d c g de ce57.
The e de ce   be a a e ed  e  f 16, a d 25 f he e 16X e   be ed.
F g e 15.2 h  5 f he e 16X e   g e a ge e a  dea f h  he ga a  .
The RNA a d d   be ed  each de ce, he ec d g  cc ,
a d he  he e g LNP   be d ec ed  he M c f d c  P d c  S age Ta  d c ed
 he f g ec . O e 16X e  f c f d c de ce  c  $13,000, a d he a  ba e
d e c  f 25 f he 16X e   $650,000.
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Fig e 15.2. Pa a e ed c f d c de ce . T e -f e e  f 16 a a e ed de ce  
be ed  he ce .49
15.3.5 Mic ofl idic  P od c  S o age Tank
The d-RNA  f g  f he c f d c de ce  ec e ed a d h
ed  a  IBC a e  ee  304 a  a d be cha ed f  he e d  The Ca
C a . Th  a e  ee  d ha d g a fea e  a e- ece ed b  ha  a
f  c e e d a age, a e e e e g de ce, 10 ga ge a e  ee  IBC c c  h
2B f h a d a 2  b g e g. The d-RNA   be ade e e  ee  ba  ( .e.
e  ba ch ba ), he ef e e g he age a  h d    4,935 e  f d-RNA
. Af e  c  efe e c g h a da d e f a  ha  he e d  d ce ,  a
de e ed ha  a 5,678 e  a   be cha ed  h d he d-RNA . L ea
e a g cha e c  da a ed f  he e d , he cha e c  f he age a  
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$4,500 a d he a  ba e d e c   $18,000 ( ee A e d  C f  de a ed cha g
ca c a ).
15.3.6 Tangen ial Flo  Fil a ion De ice 3
Th  d af a  e   be acc hed h a Ma e e 100 AT ca e e h de ,
ca e e e b a e a d e . Th  ca e e h de  ca  ed f  a ge- ca e ce e
a d ca   h e b a e a ea  a g g f  5.6  92.9 a e e e . The e b a e a ea
ed  h  ce   86.7 a e e e . The Ma e e ca e e  a e de g ed h a ge
a h e g h  ed ce he e e a e f  a e a d he ce e e a a e  .  The ca e e
h de  ca  e a e h a a  e a g e e f 6 ba .
The b ec e f h  Ta ge a  F  F a  de ce   e e he e ha  f  he
d  fed  he M c f d c  de ce a d  d  a b ffe  e cha ge h PBS. The b ffe
ed  h  TFF  be 49,350 L f PBS. Th  be ed h he LNP  e g he
M c f d c  de ce h ch ha  a e f 4,935 L f  a a  f a e e f 53,660 L. The
f  ed  h  ce   be 82.5 LMH h ch f  h gh a e b a e a ea f 87
a e e e  ( efe   A e d  B f  de a ed ca c a ).
Th  TFF de ce  ec e  626 L f LNP  h ch  g   he e e a e
age a  a d a e   he a  e e f e bef e he f a  d . The de ce  f e
53,034 L,  c g f e ha  a d PBS b ffe h ch  be d ca ded  a age a .
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15.3.7 PBS B ffe  S o age Tank
La ge a e  f PBS b ffe  a e eeded f  he TFF3 e . Th  b ffe   be ed
 a  IBC a e  ee  304 a  a d  be cha ed f  he e d  The Ca  C a .
Th  a e  ee  d ha d g a  fea e a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10 ga ge a e  ee  IBC c c  h 2B
f h a d a 2  b g e g. The b ffe   be cha ed e e  ee  ba  ( .e. e  ba ch
ba ), he ef e e g he age a  h d   49,351 e  f PBS b ffe . Af e  c
efe e c g h a da d e  f a  ha  he e d  d ce ,  a  de e ed ha  a
56,781 e  a   be cha ed  h d he PBS b ffe . L ea  e a g cha e c
da a ed f  he e d , he cha e c  f he age a   $29,965 a d he a  ba e
d e c   $119,860 ( ee A e d  C f  de a ed cha g ca c a ).
15.3.8 TFF3 Re en a e S o age Tank
The e e a e e ha  d e   ge  f e ed h gh he e b a e  he TFF3 e
 ec e ed  he TFF3 Re e a e S age Ta . Th   eeded f  he f a  d c  a
 c a  he RNA e ca a ed  a LNP. Th  e e a e   be ed  a  IBC
a e  ee  304 a  ha   be cha ed f he e d  The Ca  C a . Th
a e  ee  d ha d g a  fea e  a e- ece ed b  ha  a  f  c e e
d a age, a e e e e g de ce, 10 ga ge a e ee  IBC c c  h 2B f h
a d a 2  b g e g. The e e a e  eeded  be ed  be  a e  ee
ba  ( .e. e  ba ch ba ), he ef e e g he age a  h d    626 e  f d c
. Af e  c  efe e c g h a da d e f a  ha  he e d  d ce ,  a
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de e ed ha  a 686 e  a   be cha ed  h d he e e a e . L ea
e a g cha e c  da a ed f  he e d , he cha e c  f he age a  
$2,087 a d he a  ba e d e c   $8,347 ( ee A e d  C f  de a ed cha g
ca c a ).
15.3.9 TFF3 Pe mea e Wa e Tank
The e ea e e ha  f e  h gh he e b a e  he TFF3 e   ec e ed
 he TFF3 Pe ea e Wa e Ta . Th    eeded f  he f a  d c  a d h  
ed  h  a   be d ed f a a e  he ea  f e. Th  a e   be
ed  a  IBC a e  ee  304 a  ha  be cha ed f  he e d  The Ca
C a . Th  a e  ee  d ha d g a fea e  a e- ece ed b  ha  a
f  c e e d a age, a e e e e g de ce, 10 ga ge a e  ee  IBC c c  h
2B f h a d a 2  b g e g. The e ea e a e  eeded  be ed  be  a
e  ee  ba  ( .e. e  ba ch ba ), he ef e e g he age a  h d    53,035
e  f d c  . Af e  c  efe e c g h a da d e  f a  ha  he e d
d ce ,  a  de e ed ha  a 56,781 e  a  be cha ed  h d he e ea e
. L ea  e a g cha e c  da a ed f  he e d , he cha e c  f
he age a   $29,965 a d he a  ba e d e c   $119,860 ( ee A e d  C f
de a ed cha g ca c a ).
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15.3.10 S e ile Fil e  2
O ca S e e XLT 10 M e E e f e  be ed f g he h d
a ge a  f  f a  ed  f  he d a a c e  (LNP ) af e  he  ha e bee
he ed. O e O ca f e   be ed f each ba ch ( e ba ch e d  a a e  500
g a  f RNA). The e O ca f e  a e e e f e  a d h  ha e a e e f 0.2 ;
h  e e  effec e  e e g bac e a a d he  c ga  f  a g h gh
he f e . The e b a e a ea f he O ca f e  0.54 2, a d he f   7 L/ /c 2 56.
Each O ca f e   ha e 626 L f RNA-c a g LNP  f e ed h gh , 
he e e f a  e f  e ba ch  be 17 e . The cha e c  f e O ca
S e e XLT 10 M e E e f e   $575.00, a d he a  ba e d e c  f 13 f e  
$14,950.00.
15.3.11 PBS and S c o e Sol ion S o age Tank
La ge a e  f 30% S c e  PBS B ffe   eeded f  he f a  d  f
he LNP-RNA d c  bef e ac ag g. Th  b ffe  be ed  a  IBC a e  ee  304
a  a d  be cha ed f  he e d  The Ca C a . Th  a e  ee  d
ha d g a  fea e  a e- ece ed b  ha a  f  c e e d a age, a e e
e e g de ce, 10 ga ge a e  ee  IBC c c h 2B f h a d a 2  b g
e g. The e ha   be cha ed e e  ee ba  ( .e. e  ba ch ba ), he ef e
e g he age a  h d    298 e f c e  PBS b ffe  . Af e  c
efe e c g h a da d e  f a  ha  he e d  d ce ,  a  de e ed ha  a 379
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e  a   be cha ed  h d he c e  PBS b ffe  . L ea  e a g
cha e c  da a ed f  he e d , he cha e c  f he age a   $1,859
a d he a  ba e d e c   $7,437 ( ee A e d C f  de a ed cha g ca c a ).
15.3.12 Dil ion 2 S o age Tank
I a  h  a   e b e f  h d g he LNP- RNA  c g  f he
S e e F a  2 U  O e a . Add a , a d  f h  LNP- RNA  h
30% S c e  PBS B ffe   e f ed h  h a    he Pac ag g S e . Th
d ed   be ed  a  IBC a e ee  304 a  ha   be cha ed f  he
e d  The Ca  C a . Th  a e  ee  d ha d g a  fea e  a e- ece ed
b  ha  a  f  c e e d a age, a e e e e g de ce, 10 ga ge a e  ee
IBC c c  h 2B f h a d a 2  b g e g. The d ed  eeded  be
ed  be  a e  ee  ba  ( .e. e  ba ch ba ), he ef e e g he age a
h d    923 e  f d c  . Af e c  efe e c g h a da d e  f a
ha  he e d  d ce ,  a  de e ed ha  a 946 e  a   be cha ed  h d he
d ed . L ea  e a g cha e c  da a ed f  he e d , he cha e
c  f he age a   $2,167 a d he a  ba e d e c   $8,675 ( ee A e d  C f
de a ed cha g ca c a ).
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15.5 O he
15.5.1 F ee e
A 25 a e f  f ee e  f  The F he   be ed  e a e a  eeded
h gh  he ce . The f ee e   be ade  f a e  ee  a d e a D g a
M c ce   c  he e e a e a d he a a e e . The F he  e  he e
f ee e   f  e e da  e  a ab a  e g58. The f ee e   ha  a c  f $8,264, a
e a e   c  g e  he c  f he e e ch a  TFF eac  ed  he
a fac g ce . G e  he c   c de ed e a e  , a 25 a e f  f ee e  
be cha ed a h gh   e  ha   ch age ace  be ed.
I  h  ed a fac g ce , he f ee e  a  be ed  e he
150 g a  f DNA  a e f 20 L h ch  be cha ed  b  a  he a  f he
ce  a d be ed  a ee  ba . The f ee e  a  be ed  e he  a  a e a
ch a  he NTP  ed  he IVT eac .
15.5.2 Wa e  P ifica ion S em
D e  he fac  ha  h  ce  d ce  a acc e ha   be ec ed  h a , he
a e  ed h gh  h  ce   be e e e e. Th  e e e  e a e   be
ed  d e a  a e a  a d  be added  e a  h gh  he ce .
M c a  a  a e   be ed  he a e  f ca e  ca ed   fac . The
a  a e   be f e ed  a e a e  f ec  (WFI). Th  f ed a e  ca  he  be
ed    e a  a  e  a  f  d g a d e a g a  a e a . Tab e 15.1 de a
he a  f a e  ha   be eeded e  ba ch d ced. O  a e  f ca  e  ha
100
e a e cha g  ha e he ca ac   d ce 17,500 L e  ee . A M eS g a
a e a e  f a  e  ha  d a f  ee  a e  e e e  ha  a cha e
c  f $175,000 a d a a  ba e d e c  f $350,000.
I  Tab e 15.1, he a  f e e a e  ha  eed  be added d ec   ce a  
e a   h . Th  a  a  d b ed  acc f  a e  eeded  d e a d e a e
a  a e a  a  e  a  f  a e  eeded  c ea a d e e  e a  af e  e.
Table 15.1 A  f S e e Wa e  Needed Pe  Ba ch f he Ma fac g P ce
P oce Wa e  Needed Pe  Week (L)
IVT Reac ion 30
TFF1 1100
Cell lo e Ch oma og a h 1800
TFF2 0
Dil ion Befo e Mic ofl idic 0
LNP Fo ma ion/Mic ofl idic 0
TFF3 0
Final Dil ion 0
Ini ial To al 2,930
Final To al (do bled o acco n  fo
dil ion / e a a ion  of a  ma e ial)
5,860
15.5.3 Pe i al ic P m
I  de   a fe  a e a  h gh he e e ce , e a c  ha e bee
a ed. S ec f ca , e a c  ha e bee de g ed  a  a e a  
a d f  a    he ce . The  a  ha e e e e d  a d e
101
e e e  ba ed  he a e a  a d f  a e he  a e e b e f  a g. F  he
e e a fac g ce  35 e a c  be a ed. The 825 Se e  Pe a c
P   be cha ed f  he e d  Wa -Ma . The cha e c  f e 825 Se e
Pe a c P   $3,000, a d he a  cha e d e c  f 35   $105,000. I
add , he a  ba e d e c  f 35 e a c   $346,500.
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16. S ecifica ion Shee
16.1 T i  B ffe  S o age Tank
De c i ion and
F nc ion
H d T  H d ch de b ffe    IVT eac . Th  age
a  h d  3 ba che  h f T  B ffe  f  he IVT eac .
N mbe  Re i ed 1.0
Vendo The Ca  C a
O e a ion Ba ch
Ma e ial  Handled Inle  (g/ba ch) O le  (g/ba ch)
T i  B ffe 402.56 402.56
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g
a  fea e  a e- ece ed b  ha
a  f  c e e d a age, a e e
e e g de ce, 10 ga ge a e  ee  IBC
c c  h 2B f h a d a 2  b g
e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 379
Wo king Vol me (L) 265
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $1,859.23 e  
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16.2 WAVE Bio eac o TM 200 em
De c i ion and
F nc ion
The WAVE B eac   be ed   he in vitro a c
(IVT) eac . The WAVE B eac  h d  d ab e b eac
bag  he e he eac  a e  ace. The b eac bag  ch e  a e
200 L bag  h a g e a ge f 10 - 100 L, a d each 
f he IVT eac  e e  a g e f c e  100 L. T
WAVE B eac  a e  be cha ed  acc  f b e
b ea d  f e f he eac . Add a , ce 13 ba che  
be , 26 bag  a e  be cha ed f  a  ea .
Vendo
WAVE Bio eac o
GE Hea hca e L fe
Sc e ce  (
C a)
Di o able Bag
O e a ion Ba ch
Ma e ial  Handled In  (g/ba ch) O  (g/ba ch)
T i  H d ochlo ide 402.56 402.56
Magne i m Chlo ide 40.38 40.38
1,4-Di hio h ei ol
(DTT)
170.87 170.87
S e midine 32.18 32.18




5'-T i ho ha e
N cleo ide (ATP)
280.90 109.29
G ano ine-5'-T i h




T i ho ha e
N cleo ide (CTP)
267.62 162.53
U idine-5 -T i ho








DNA Tem la e 11.08 11.08
T7 RNA Pol me a e 11.08 11.08
DNa e I 6.32 6.32
Pho ha a e 0.22 0.22
Wa e -fo -Injec ion 33,231 33,231
Cha ac e i ic Model Read T P ce TM WAVE B eac TM 200
S e
Dimen ion Ba e : 1852   1096   1120 
Rocking Ra e 4 - 25 c /
Rocking Angle 2  - 9
Bag Si e 200 L
S e ili a ion P a c g e- e d ab e b eac  bag
O e a ion
Condi ion
Tem e a e 37℃
P e e 1 a
H 8.1
Re idence Time 5 h
P cha e Co $400,000.00 e  
$709.00 e  bag
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16.3 IVT P od c  S o age Tank
De c i ion and
F nc ion
H d IVT d c    TFF1.
N mbe  Re i ed 1.0
Vendo The Ca  C a
O e a ion Ba ch
Ma e ial  Handled Inle  (g/ba ch) O le  (g/ba ch)
T i  H d ochlo ide 402.56 402.56
Magne i m Chlo ide 40.38 40.38
1,4-Di hio h ei ol
(DTT)
170.87 170.87
S e midine 32.18 32.18




5'-T i ho ha e
N cleo ide (ATP)
109.29 109.29
G ano ine-5'-T i h




T i ho ha e
N cleo ide (CTP)
162.53 162.53
U idine-5 -T i ho
ha e N cleo ide
(UTP)
91.39 91.39




DNA Tem la e 11.08 11.08
106
T7 RNA Pol me a e 11.08 11.08
DNa e I 6.32 6.32
Pho ha a e 0.22 0.22
Wa e -fo -Injec ion 33,231 33,231
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g
a  fea e  a e- ece ed b  ha
a  f  c e e d a age, a e e
e e g de ce, 10 ga ge a e  ee  IBC
c c  h 2B f h a d a 2  b g
e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 110
Wo king Vol me (L) 110
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $1,727.19 e  
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16.4 Tangen ial Flo  Fil a ion 1 (TFF1)
De c i ion and
F nc ion
The a ge a  f  f a  de ce  ed  f he IVT d c
  ha   RNA  e a g h  he e e a e. Th
d af a  e   e a f e  h a  100 D ec a  e gh  c - ff.
E e  e e, a , a d he  ec e  a e ab e f  h gh he f e
a d ge  ca ed a  he e ea e. The RNA a d TFF b ffe  ca  a
h gh he e b a e. The  a e ef  a  e e a e a d a e ec e ed  he
d c   h ch  fed  he e  ce . The TFF e  ha















T i  H d ochlo ide 402.56 0 402.56
Magne i m Chlo ide 40.38 0 40.38




S e midine 32.18 0 32.18





5'-T i ho ha e
N cleo ide (ATP)
109.29 0 109.29
G ano ine-5'-T i h




T i ho ha e
N cleo ide (CTP)
162.53 0 162.53
108
U idine-5 -T i ho
ha e N cleo ide
(UTP)
91.39 0 91.39
Ca  Analog (Clean
Ca )
1,158.59 0 1,158.59
mRNA 520.62 510.21 10.41
DNA Tem la e 11.08 0 11.08
T7 RNA
Pol me a e
11.08 0 11.08
DNa e I 6.32 0 6.32
Pho ha a e 0.22 0 0.22
Wa e -fo -Injec ion 1,136,454 33,231 1,103,223
Cha ac e i ic Model Ce a a  100 SAT TFF S e
Ma e ial of
Con c ion
S a e  S ee  304
Memb ane Fil e
Ma e ial
PES ( e he f e)
Memb ane i e (m2) 6.29
MWCO 100 Da
Flo  Ra e (L/ho ) 440
Fl  (l/h /m2) 70
B ffe  T e Wa e -F -I ec
To al Fil a e
Vol me (L)
1100
Vol me of mRNA
Sol ion (L)
110










P e e D o  (a m) 0.7
O e a ion
Condi ion
Tem e a e 4℃
P cha e Co $150,000 e   ( c de  e b a e, ca e e , a d c  e )
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16.5 TFF1 Pe mea e Wa e Tank
De c i ion and
F nc ion
H d he Pe ea e V e f  TFF1 a  h   a a e d c  ha  
 eeded f  he ce . E e a  h   be d ed f
a a e .
N mbe  Re i ed 1.0
Vendo The Ca  C a
O e a ion Ba ch
Ma e ial  Handled Inle  (g/ba ch) O le  (g/ba ch)
T i  H d ochlo ide 402.56 402.56
Magne i m Chlo ide 40.38 40.38
1,4-Di hio h ei ol
(DTT) 170.87 170.87
S e midine 32.18 32.18
0.01% ( / ) T i on
X-100 11.85 11.85
Adeno ine
5'-T i ho ha e
N cleo ide (ATP)
109.29 109.29
G ano ine-5'-T i h




T i ho ha e
N cleo ide (CTP)
162.53 162.53
U idine-5 -T i ho
ha e N cleo ide
(UTP)
91.39 91.39
Ca  Analog (Clean
Ca ) 1,158.59 1,158.59
mRNA 10.41 10.41
111
DNA Tem la e 11.08 11.08
T7 RNA Pol me a e 11.08 11.08
DNa e I 6.32 6.32
Pho ha a e 0.22 0.22
Wa e -fo -Injec ion 1,103,223 1,103,223
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g
a  fea e  a e- ece ed b  ha
a  f  c e e d a age, a e e
e e g de ce, 10 ga ge a e  ee  IBC
c c  h 2B f h a d a 2  b g
e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 1000
Wo king Vol me (L) 990
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $2,186.78 e  
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16.6 TFF1 Re en a e S o age Tank
De c i ion and
F nc ion
H d he Re e a e V e f  TFF1   he Ch a g a h
C . Th   c a  he RNA a d  ha  be f he
ce ed d ea .
N mbe  Re i ed 1.0
Vendo The Ca  C a
O e a ion Ba ch
Ma e ial  Handled Inle  (g/ba ch) O le  (g/ba ch)
mRNA 510.21 510.21
Wa e -fo -Injec ion 33,231 33,231
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g
a  fea e  a e- ece ed b  ha
a  f  c e e d a age, a e e
e e g de ce, 10 ga ge a e  ee  IBC
c c  h 2B f h a d a 2  b g
e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 110
Wo king Vol me (L) 110
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $1,727.19 e  
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16.7 Cell lo e Ch oma og a h  Col mn
De c i ion and
F nc ion
The ce e ch a g a h  c   ed  b d d RNA  e e 



















HEPES 2,385,943.15 0 2,385,943.15
EDTA 29,259.95 0 29,259.95
NaCl 7,313,985.28 0 7,313,985.28
E hanol 126,395.28 0 126,395.28
WFI 46,902.96 0 46,902.96
WFI ( a h e
onl )
827,361.26 0 827,361.26
Cha ac e i ic Model Ic  Sc e f c
Ma e ial of
Con c ion
S a e  S ee
C o - ec ional
a ea (m2)
2.46
Heigh  (m) 0.4
Diame e  (m) 1.77
114
Veloci  (cm/h ) 21.54
Flo  Ra e
(L/ho )
7,154.69
Fl  (l/h /m2) 82.5
O e a ion
Condi ion
Tem e a e 4℃
P cha e Co $374,400.00 e   ( c de  FPLC c  e )
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16.8 Ch oma og a h  B ffe  S o age Tank
De c i ion and
F nc ion
H d he Ch a g a h  B ffe    he Ch a g a h
C . Th  a  h d  6.5 ba che  h f Ch a g a h b ffe .
Th , h  a   be f ed a  he beg g f e a  h 6.5
ba che  h f b ffe .
N mbe  Re i ed 1.0
Vendo The Ca  C a
O e a ion Ba ch




E hanol 126,395.28 126,395.28
HEPES 2,385,943.15 2,385,943.15
Wa e -Fo -Injec ion 46,902.96 46,902.96
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g
a  fea e  a e- ece ed b  ha
a  f  c e e d a age, a e e
e e g de ce, 10 ga ge a e  ee  IBC
c c  h 2B f h a d a 2  b g
e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 6,510
Wo king Vol me (L) 6,508
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $5,443.20 e  
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16.9 Cell lo e Re in S o age Tank
De c i ion and
F nc ion
H d he Ce e Re  eeded f  he Ch a g a h C .
Th  e  ca  be e ed a d    eed   be ade ce.
N mbe  Re i ed 1.0
Vendo The Ca  C a
O e a ion Ba ch
Ma e ial  Handled Inle O le
Cell lo e (g) 275,000 275,000
Ch oma og a h
B ffe  (L) 1,540 1,540
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g
a  fea e  a e- ece ed b  ha
a  f  c e e d a age, a e e
e e g de ce, 10 ga ge a e  ee  IBC
c c  h 2B f h a d a 2  b g
e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 1,540
Wo king Vol me (L) 1,540
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $2,555.81 e  
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16.10 Reco e ed P od c  f om Ch oma og a h  Col mn S o age Tank
De c i ion and
F nc ion
H d he Rec e ed RNA  f h gh f he




Vendo The Ca  C a










E hanol 126,395.28 126,395.28
Single S anded
mRNA ( RNA) 505.10 505.10
Do ble S anded
mRNA (d RNA) 0.26 0.26
Wa e -Fo -Injec ion 46,902.96 46,902.96
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g a
fea e  a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B
f h a d a 2  b g e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 130
Wo king Vol me
(L)
126
O e a ion
Condi ion
Tem e a e 4℃
118
P e e 1 a
P cha e Co $1,763.92 e  
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16.11 El ed Do ble S anded RNA Wa e Tank
De c i ion and
F nc ion
H d he e ed d b e a ded RNA (d RNA) f h gh
f  he Ch a g a h  C . Th    a e a    
eeded f  he f a  d c  a d h   ed a a e a . E e a




Vendo The Ca  C a




Do ble S anded
mRNA (d RNA)
(g/ba ch) 4.85 4.85
Ch oma og a h
B ffe  (L) 984.95 984.95
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g a
fea e  a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B f h
a d a 2  b g e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 1,000
Wo king Vol me
(L)
985
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $2,186.78 e  
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16.12 Tangen ial Flo  Fil a ion 2
De c i ion and
F nc ion
The a ge a  f  f a  de ce (TFF2)  ed f  a b ffe  e cha ge
f g he ch a g a h  c   ge  d f he b ffe  f  he
ch a g a h  h ch c a ed e ha , EDTA, HEPES, NaC . Th
d af a  e   e a f e  h a  100 D ec a  e gh  c - ff.
The TFF e  ha  a ca e e h de  a d a f e . Th  TFF   e

















50 mM Sodi m
Ace a e
5,179.49 517.95 4,661.54
HEPES 2,385,943.15 0 2,385,943.15
EDTA 29,259.95 0 29,259.95
NaCl 7,313,985.28 0 7,313,985.28
E hanol 126,395.28 0 126,395.28
WFI 46,902.96 46,902.96 0
Cha ac e i ic Model Ce a a  100 SAT TFF S e
Ma e ial of
Con c ion
S a e  S ee  304
Memb ane Fil e
Ma e ial
PES ( e he f e)





Flo  Ra e
(L/ho )
505
Fl  (l/h /m2) 82.5
B ffe  T e 50 M S d  Ace a e
To al Fil a e
Vol me (L)
1,263.76
Vol me of mRNA
Sol ion (L)
126.28
Re en a e Vol me
(L)
126.27






P e e D o
(a m)
0.7
O e a ion
Condi ion
Tem e a e 4℃
P cha e Co $150,000 e   ( c de  e b a e, ca e e , a d c  e )
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16.13 Sodi m Ace a e B ffe  S o age Tank
De c i ion and
F nc ion
H d he S d  Ace a e B ffe    TFF2. Th b ffe  ac  a  he




Vendo The Ca  C a
O e a ion Ba ch
Ma e ial
Handled
Inle  (g/ba ch) O le  (g/ba ch)
Sodi m Ace a e 5,179 5,179
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g a
fea e  a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B f h
a d a 2  b g e g.
Ma e ial of
Con c ion
S a e  S ee  304




O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $2,233.09 e  
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16.14 TFF2 Re en a e S o age Tank
De c i ion and
F nc ion
H d he Re e a e V e f  TFF2   he S e e F a  1
S e . Th   c a  he RNA a d  ha  be f he




Vendo The Ca  C a





O le  (g/ba ch)
Single S anded
mRNA ( RNA) 495.00 495.00
Sodi m Ace a e 517.95 517.95
Wa e -Fo -Injec ion 46,902.96 46,902.96
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g a
fea e  a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B
f h a d a 2  b g e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 130
Wo king Vol me
(L)
126
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $1,763.92 e  
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16.15 TFF2 Pe mea e Wa e Tank
De c i ion and
F nc ion
H d he Pe ea e V e f  TFF2 a  h   a a e d c  ha   
eeded f  he ce . E e a  h   be d ed f




Vendo The Ca  C a









E hanol 126,395.28 126,395.28
Single S anded
mRNA ( RNA) 10.10 10.10
Sodi m Ace a e 4,661.54 4,661.54
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g a
fea e  a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B f h
a d a 2  b g e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 1,325
Wo king Vol me
(L)
1,136
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
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P cha e Co $2,233.09 e  
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16.16 S e ile Fil e  1
De c i ion and
F nc ion
S e e f e  e e bac e a  c ga , a d he e f e  ha e a
e e f 0.2 . U  ed  e a a  f M c f d c de ce  




Vendo M eS g a





O le  (g/ba ch)
Single S anded
mRNA ( RNA) 495.00 495.00
Sodi m Ace a e 517.95 517.95
Wa e -Fo -Injec ion 4,6902.96 4,6902.96
Cha ac e i ic Model O ca  S e e XLT 10 M e E e . The
de   a ca e h a 0.2  f e  ha  e a
d ffe e a  e e f 6.9 ba   f e  h gh
b g ca  e .
Ma e ial of
Con c ion
P e e/P f e
Memb ane A ea 0.54 2
Fl 7 L/ /c 2
Vol me 130 L
Wo king Vol me 126 L
S e ili a ion D ab e f e
O e a ion
Condi ion
Tem e a e 4℃
P e e 6.2 ba
P cha e Co $1,150 e  
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16.17 Dil ion 1 Tank
De c i ion and
F nc ion
I a  h  a   e b e f  h d g he RNA  c g 
f he S e e F a  1 U  O e a . A d f h  RNA 
h 50 M f S d  Ace a e  e f ed h  h a    he




Vendo The Ca  C a






O le  Po -Dil ion (g/ba ch)
Single S anded
mRNA ( RNA) 495.00 495.00
Sodi m Ace a e 517.95 15,181.65
Wa e -Fo -Injec ion 46,902.96 46,902.96
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g a
fea e  a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B
f h a d a 2  b g e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 3,785
Wo king Vol me
(L)
3,701
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $3,556.90 e  
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16.18 E hanol S o age Tank
De c i ion and
F nc ion
H d  e ba ch h f E ha  eeded f  he d f L d  bef e




Vendo The Ca  C a
O e a ion Ba ch
Ma e ial
Handled
Inle  (g/ba ch) O le  (g/ba ch)
E hanol 973,440.30 973,440.30
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g a
fea e  a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B f h
a d a 2  b g e g.
Ma e ial of
Con c ion
S a e  S ee  304




O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $2,233.09 e  
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16.19 Li id and E hanol Sol ion S o age Tank
De c i ion and
F nc ion
H d  e ba ch h f L d -E ha    he M c f d c
De ce. D ea  h  a , h    be fed  he




Vendo The Ca  C a
O e a ion Ba ch
Ma e ial
Handled
Inle  (g/ba ch) O le  (g/ba ch)




Chole e ol 3,692.31 3,692.31
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g a
fea e  a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B f h
a d a 2  b g e g.
Ma e ial of
Con c ion
S a e  S ee  304




O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $2,233.09 e  
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16.20 Mic ofl idic De ice
De c i ion and
F nc ion
The c f d c g de ce   be ed  e ca a e he RNA 
d a a c e  (LNP ). The e agge ed he gb e c f d c
e  de ce   be a a e ed  25 e  f 16 c f d c ch
de ce , a d   be ed  c  he f a e  each de ce.
The de ce  ha e  e ; e e   d  d ed  e ha , a d he
he  e   RNA  a  a e  b ffe . The e de ce a  f  a d
g h gh a g cha e   he de  f c ec d h ch ead
 he e ca a  f RNA a d he f a  f LNP .
Vendo P ec  Na e
O e a ion C
Ma e ial
Handled
In  (g/ba ch) O  (g/ba ch)
mRNA 495.00 495.00




Chole e ol 3,692.31 3,692.31
E hanol 973,440.30 973,440.30
Cha ac e i ic Model (ba ed
on) Na A e b TM P a f
Dimen ion Mi ing Channel 200  b  79 
He ingbone S c e 31  h gh, 50  h c
Con c ion
Ma e ial
P d e h a e (PDMS)
S e ili a ion Ne  ch  ca  be cha ed; f ca  e  f
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
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H Sodi m Ace a e B ffe 4.0
Re idence Time 3 
Flo  Ra e e
De ice
mRNA in Sodi m
Ace a e
9 L/
Li id  in E hanol 3 L/
To al 12 L/
P cha e Co $13,000 e  16X e
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16.21 Mic ofl idic  P od c  S o age Tank
De c i ion and
F nc ion






The Ca  C a
O e a ion Ba ch
Ma e ial
Handled
Inle  (g/ba ch) O le  (g/ba ch)




Chole e ol 3,692.31 3,692.31
Wa e -Fo -Injec ion 46,902.96 46,902.96
mRNA ( ingle
anded) 495.00 495.00
50 mM Sodi m
Ace a e 15,181.65 15,181.65
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g a
fea e  a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B
f h a d a 2  b g e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 5,678
Wo king Vol me 4,935
133
(L)
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $4,500.05 e  
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16.21 Tangen ial Flo  Fil a ion 3
De c i ion and
F nc ion
The a ge a  f  f a  de ce  ed  d a b ffe  e cha ge  he
d c  f he M c f d c  h PBS  add he a eeded  he
ha ace ca  f a . Th  d af a  e  e a f e  h a
100 D ec a  e gh  c - ff.
The TFF e  ha  a ca e e h de  a d a f e . Th  TFF   e

















50 mM Sodi m
Ace a e
15,181.65 0.00 15,181.65
Li id 14,215.38 13,931.08 284.31
E hanol 973,440.30 0.00 973,440.30




o a i m
ho ha e
6,745.58 78.63 6,666.94
Sodi m Chlo ide 264,436.87 3,082.46 261,354.40
Diba ic odi m
ho ha e h d a e
54,461.64 634.84 53,826.80
WFI 46,902.96 0 46,902.96
Cha ac e i ic Model Ma e e 100 AT TFF S e
Ma e ial of S a e  S ee  304
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Con c ion
Memb ane Fil e
Ma e ial
PES ( e he f e)




Flo  Ra e
(L/ho )
7,154.69
Fl  (l/h /m2) 82.5
B ffe  T e Ph ha e B ffe ed Sa e (PBS)
To al Fil a e
Vol me (L)
53,660.14
Vol me of LNP
Sol ion (L)
4,935.06
Re en a e Vol me
(L)
625.50






P e e D o
(a m)
0.7
O e a ion
Condi ion
Tem e a e 4℃
P cha e Co $150,000 e   ( c de  e b a e, ca e e , a d c  e )
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16.22 PBS B ffe  S o age Tank
De c i ion and
F nc ion
H d he PBS B ffe    TFF3. Th  b ffe  ac a  he b ffe  




Vendo The Ca  C a
O e a ion Ba ch
Ma e ial
Handled
Inle  (g/ba ch) O le  (g/ba ch)
PBS B ffe 333,574.81 333,574.81
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g a
fea e  a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B f h
a d a 2  b g e g.
Ma e ial of
Con c ion
S a e  S ee  304




O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $29,965.10 e  
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16.23 TFF3 Re en a e S o age Tank
De c i ion and
F nc ion
H d he Re e a e V e f  TFF3   he S e e F a  2
S e . Th   c a  he RNA a d  ha  be f he




Vendo The Ca  C a
O e a ion Ba ch
Ma e ial
Handled
Inle  (g/ba ch) O le  (g/ba ch)
mRNA (Single
S anded) 485.10 485.10
50 mM Sodi m
Ace a e 0.00 0.00
Li id 13,931.08 13,931.08
E hanol 0.00 0.00
Po a i m Chlo ide 92.45 92.45
Monoba ic
o a i m ho ha e 78.63 78.63
Sodi m Chlo ide 3,082.46 3,082.46
Diba ic odi m
ho ha e h d a e 634.84 634.84
Wa e -Fo -Injec ion 0.00 0.00
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g a
fea e  a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B
f h a d a 2  b g e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 682
138
Wo king Vol me
(L)
626
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $2,086.71 e  
139
16.24 TFF3 Pe mea e Wa e Tank
De c i ion and
F nc ion
H d he Pe ea e V e f  TFF3 a  h   a a e d c  ha   
eeded f  he ce . E e a  h   be d ed f




Vendo The Ca  C a
O e a ion Ba ch
Ma e ial
Handled
Inle  (g/ba ch) O le  (g/ba ch)
mRNA (Single
S anded) 9.90 9.90
50 mM Sodi m Ace a e 15,181.65 15,181.65
Li id 284.31 284.31
E hanol 973,440.30 973,440.30
Po a i m Chlo ide 7,838.28 7,838.28
Monoba ic o a i m
ho ha e 6,666.94 6,666.94
Sodi m Chlo ide 261,354.40 261,354.40
Diba ic odi m
ho ha e h d a e 53,826.80 53,826.80
Wa e -Fo -Injec ion 46,902.96 46,902.96
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g
a  fea e  a e- ece ed b  ha
a  f  c e e d a age, a e e
e e g de ce, 10 ga ge a e  ee  IBC
c c  h 2B f h a d a 2  b g
e g.
Ma e ial of
Con c ion
S a e  S ee  304
Vol me (L) 56,781
140
Wo king Vol me (L) 53,035
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $29,965.10 e  
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16.25 S e ile Fil a ion 2
De c i ion and
F nc ion
S e e f e  e e bac e a  c ga , a d he e f e  ha e a
e e f 0.2 . U  ed  e a a  f M c f d c de ce  




Vendo M eS g a
O e a ion Ba ch
Ma e ial
Handled
Inle  (g/ba ch) O le  (g/ba ch)
mRNA (Single
S anded) 485.10 485.10
50 mM Sodi m
Ace a e 0.00 0.00
Li id 13,931.08 13,931.08
E hanol 0.00 0.00
Po a i m Chlo ide 92.45 92.45
Monoba ic o a i m
ho ha e 78.63 78.63
Sodi m Chlo ide 3,082.46 3,082.46
Diba ic odi m
ho ha e h d a e 634.84 634.84
Wa e -Fo -Injec ion 0.00 0.00
Cha ac e i ic Model O ca  S e e XLT 10 M e E e . The
de   a ca e h a 2 c  f e  ha  e
a d ffe e a  e e f 6.9 ba   f e  h gh
b g ca  e .
Ma e ial of
Con c ion
P e e/P f e
Memb ane A ea 0.54 2
Fl 7 L/ /c 2
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Vol me 130 L
Wo king Vol me 126 L
S e ili a ion D ab e f e
O e a ion
Condi ion
Tem e a e 4℃
P e e 6.2 ba
P cha e Co $1,150 e  
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16.26 PBS and S c o e Sol ion S o age Tank
De c i ion and
F nc ion
H d he 30% S c e  PBS B ffe    D 2. Th  a  h d




Vendo The Ca  C a




S c o e
(g/ba ch) 89,273.00 89,273.00
PBS (L) 297.58 297.58
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g a
fea e  a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B f h
a d a 2  b g e g.
Ma e ial of
Con c ion
S a e  S ee  304




O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $1,859.23 e  
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16.27 Dil ion 2 S o age Tank
De c i ion and
F nc ion
I a  h  a   e b e f  h d g he LNP- RNA 
c g  f he S e e F a  2 U  O e a . A d  f h
LNP- RNA  h 30% S c e  PBS B ffe  e f ed h




Vendo The Ca  C a
O e a ion Ba ch
Ma e ial
Handled
Inle  (g/ba ch) O le  (g/ba ch)
mRNA (Single
S anded) 485.10 485.10
Li id 13,931.08 13,931.08
Po a i m
Chlo ide 92.45 153.85
Monoba ic
o a i m
ho ha e 78.63 153.85
Sodi m Chlo ide 3082.46 5,538.46
Diba ic odi m
ho ha e
h d a e 634.84 1,076.92
30% S c o e in
PBS 89,273.00 89,273.00
Cha ac e i ic Model IBC a . Th  a e  ee  d ha d g a
fea e  a e- ece ed b  ha  a  f
c e e d a age, a e e e e g de ce, 10
ga ge a e  ee  IBC c c  h 2B f h
a d a 2  b g e g.
Ma e ial of
Con c ion
S a e  S ee  304





O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $2,168.67 e  
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16.28 Wa e  P ifica ion S em
De c i ion and
F nc ion
The a e a e  f ca  e   a e c a  a  a e
a d f   ch ha   ca  be ed  a e a ha ace ca d c
ha   afe f  ec   h a . The a e a e   be ed
 d g a d e a g a  a e a  a  e  a  a  f he 
e a   h  ce
Vendo M eS g a
O e a ion Ba ch
Ma e ial  Handled In  (L/ eek) O  (L/ eek)
M nici al Wa e 17,500 17,500
Cha ac e i ic Model (ba ed on) M eS g a S e -Q P  Wa e
P f ca  S e
Dimen ion 81 c   115 c   22 c
Ma im m Dail
P od c  Wa e
U age
8000 L
S e ili a ion P f ca  e
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
P cha e Co $175,000.00
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16.29 Pe i al ic P m
De c i ion and
F nc ion
Pe a c P  ha e bee  de g ed  a a e a  
a d f  a    he ce . The  a  ha e e
e e d  a d e  e e e  ba ed  he a e a  a d
f  a e he  a e e b e f  a g.
Vendo Wa -Ma
O e a ion Ba ch
Ma e ial  Handled Va  Ma e a
Cha ac e i ic Model 825 e e
P m  Head
Ma e ial
A  a
S o  and F ame
Ma e ial
304 S a e  S ee
S e ili a ion P f ca  e
Ma im m Flo
Ra e
33 L/
Ma im m P e e 3.5 a
S e ili a ion CIP, SIP
O e a ion
Condi ion
Tem e a e 4℃
P e e 1 a
Flo  Ra e Va ab e
P cha e Co $3,000 e  
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17. E i men  Co  S mma
Tab e 17.1 de a  he cha e c  f each ece f e e  eeded  he
a fac g ce . The ab e a  c de  he a fac e  f each ece f e e
he  a cab e, he ba e d  fac  ed f each ece f e e , a d he a  ba e
d e c  f  a g e ece f ha  e e . The ba e d e fac  acc  f  a
add a  c  a c a ed h g, g, e ec ca  f da , a a , e g ee g
de g , e c. Whe  a cab e, he ba e d e fac e e a e  f  Tab e 16.11  Se de , e .
a . I  add , a ba e d e fac  f 4.0 a  ed f  a  he age a d a e a  a d a
ba e d e fac  f 3.3 a  ed f  he , a  ad ed b  he c e c . F  he
e a g e e , a ba e d e fac  f 2.0 a ed a  h  a  ad ed   b
P fe  V a a. Wh e he fac  f  a ca  che ca e g ee g a   a e age  a d
3.21, a gh  e  fac  f 2.0 a e  e e f h  ce  beca e  f he e e  
h gh  ec a ed f  b ha ace ca  a ca a d e e e e. Th , he e a g
e e  a  ced g a ba e d e fac  f 2.0.
Table 17.1. E e  C  f  A  U  O e a U ed I  Ma fac g P ce















S n he i  and P ifica ion of mRNA
IVT F ee e N/A The  F he
Sc e f c
$8,264 1 2.0 $16,528
IVT Wa e
Bio eac o
PU-1 C a L fe
Sc e ce
$409,225 2 2.0 $3,273,800
T i  B ffe STOR-1 The Ca $1,859 1 4.0 $7,437
149
S o age Tank C a
IVT P od c
S o age Tank
STOR-2 The Ca
C a
$1,727 1 4.0 $6,909
Tangen ial
Flo  Fil a ion
1
PU-2 Pa $150,000 1 2.0 $300,000




$2,187 1 4.0 $8,747
TFF1 Re en a e
S o age Tank
STOR-4 The Ca
C a
$1,727 1 4.0 $6,909
Cell lo e
Ch oma og a
h  Col mn
PU-3 Pa $124,314 1 4.16 $517,146
Ch oma og a
h  B ffe
S o age Tank
STOR-5 The Ca
C a
$5,443 1 4.0 $21,772
Cell lo e Re in
S o age Tank
STOR-6 The Ca
C a
$2,556 1 4.0 $10,223
Reco e ed
P od c  f om
Ch oma og a
h  Col mn
S o age Tank
STOR-8 The Ca
C a
$1,764 1 4.0 $7,056





$2,187 1 4.0 $8,747
Tangen ial
Flo  Fil a ion
2
PU-4 Pa $150,000 1 2.0 $300,000
Sodi m Ace a e




$2,233 1 4.0 $8,932
TFF2 Re en a e STOR-1 The Ca $1,764 1 4.0 $7,056
150
S o age Tank 1 C a






$2,233 1 4.0 $8,932
S e ile Fil e PU-5 M e S g a $575 13 2.0 $14,950
Fo m la ion of LNP




$3,557 1 4.0 $14,228
E hanol



















$13,000 25 2.0 $650,000
Mic ofl idic
P od c





$4,500 1 4.0 $18,000
Tangen ial
Flo  Fil a ion
3
PU-7 N/A $1,000,000 1 2.0 $2,000,000
PBS B ffe





$29,965 1 4.0 $119,860
TFF3 Re en a e





$2,087 1 4.0 $8,347







S e ile Fil e PU-8 M e S g a $575 13 2.0 $14,950
Dil ion 2





$2,167 1 4.0 $8,675
PBS and STOR-2 The Ca $1,859 1 4.0 $7,437
151
S c o e
Sol ion
S o age Tank
0 C a




N/A M e S g a $175,000 1 2.0 $350,000
Pe i al ic
P m
N/A Wa -Ma $105,000 35 3.3 $346,500
To al $6,556,530
A  e e  cha e c  e e ca c a ed e he b  g e a  ded 
Product and Process Design Principles  a e e e  f  he a  e d  ed
ab e  Tab e 17.1 59. S ec f c ce  f  each e e  c  a d he a  c  ca c a
ca  be f d  A e d  C. F g e 17.1 de a  a b ea d  f he c  f  each ca eg  f
e e  ed  he a fac g ce .
Fig e 17.1. E e  C  B ea d  b  E e T e
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A  h   F g e 17.1, he a ge a  f  f a e  (TFF ) acc  f  he
a ge  c  f he e a  e e , a  TFF  a e  40% f a  e e  c . Th  a  
be ed c ed a  a ge a  f  f a  e a e e e e e beca e he  c a  a
a  c d g a e b a e, ca e e , a , , a d . S ec f ca  h  h
ce  he e a e 3 TFF   a  ( abe ed TFF1, TFF2, a d TFF3) ha  a e fa  a ge  e, a
he  ha e a e b a e e f 6 2, 6 2, a d 87 2 , e ec f . Th , he TFF  e e e ec ed
 ha e a a ge cha e c , h TFF3 ha g he  e e e cha e c  f $2 
USD. I     ha  he e c  a e a ge f ed a  each TFF ha   f  h gh a
a e e f d  de   e  f e  c a a  a d a ed e e e .
Pe ha   he e  f h  a  a    he f a  e     ed ce he c ,
h e e , he c   e   be f a ag de d e  he a ge ce g e
ha  eed  be f e ed. The ec d g f ca  e e c  ed c ab  c e f  he Wa e
B eac  ha   ed f  he I -V  T a c ce . Wa e B eac  a e h gh
ec a ed b ce g e e  a d d e  h ec f c  e   a h gh cha g ce.
T ge he  b h he TFF  a d he Wa e B eac  acc f  e ha  50% f he a
e e  c .
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18. Fi ed Ca i al In e men  S mma
The P f ab  A a  4.0 ead hee , ha  a ded f  h  c e, a  ed 
c e de a ed f a c a  f  h  a fac g a . I    be a ed
h gh  h  ec  f he e . N e ha  he f a c a  e e de ed f  15 ea  f a
e a .
18.1 E i men  Co
The d d a  e e  c  ha  e e de a ed  Tab e 17.1 a  e ed  he
f ab  a a  a d each ece f e e a  a a  c a f ed a  e he  ce
ach e , fab ca ed e e , a e , age,  he . Eff  a  ade  c a f  each ece
f e e  acc d g , h e e  he e c a f ca h d  be a e   c c e e . The
a  ba e d e c , h ch acc  f  b h cha e a d a a  f f ed e e ,
a  ca c a ed  be $6,556,530 b  add g a  he d d a  e e  c  ge he  f  he
ce . A a  f he a  ba e d e c b  e e  ca eg  ca  be ee   F g e
18.1. I  h  f g e, a  he ce  e e  c a f ed  he ca eg e  ha  e e a a ab e
 he f ab  ead hee  a  e ed ab e.
Fig e 18.1. T a  Ba e M d e C  f  P ce
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18.2 To al Pe manen  In e men
The e  f a c a  ha  ca  be ca c a ed  he T a  Pe a e  I e e  (TPI) f  he
a . The f ab  a a  ead hee  ca c a e he TPI b  g G h e  fac -c
e h d h ch a  e  c e he c  f ce a c e  b  a g   be e
 f he a  ba e d e c . The e ec f ed  f  he a  ca  be ee  
F g e 18.2.
Fig e 18.2. G h e  Fac ed-C  Me h d f  T a Pe a e  I e e
N  e ce age a e  e e cha ged f  he defa e g   he f ab  ead hee .  I
add , he a ca ed c  f  a  a d e a ed fac e  a  e a ed  be $4,185,400.
I  de   a fac e he RNA acc e, he a eed   be e a ed a  4 deg ee  ce .
We e a ed ha   a  d be 10,000 f 2 e. The e a ed a ca ed c  f 
a  a d e a ed fac e  f $4,185,400 acc f  he c  f b d g a 10,000 f 2 c d 
a  4 deg ee  ce . Th  c d   a  ha   ed  he f d a fac g d .
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The a c a ed c  f b d g he a  a d cha g he e e   ee  h  
c d a  e a ed f  h ca  f d d  c 60. Th  c  a  a  a ed b  
ad  D . D a d. I  add ,  a  ec e ded b  D . D a d  ha e a $5,000,000
a  e e e. W h a  he e fac , he a e a e  e e - ad ed f  h  a
 $20,063,046. D e  he ca  f he a  be g  M b e, PA, a e fac  f 1.10 f
he N hea  ca  eed   be c de ed59. Af e  ad g f  he e fac , he a
e a e  e e  f  h  a   ab a ed be $22,069,351. A de a ed b ea d  f he
a  e a e  e e  c  ca  be ee   F g e 18.3.
Fig e 18.3. T a  Pe a e  I e e  f  P a
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19. O e a ing Co  - Co  of Man fac e
19.1 Ra  Ma e ial
Tab e 19.1 de a  he c  f  each f he a a e a  eeded f  h  ce  
d ce 200  d e  f he acc e h a 20 e ce  afe  fac . I  add , h  ab e
de a  he c  f a  a e a  eeded e  d e f RNA acc e. The ce  a ed f  each
a  a e a  a e d c e ed  Tab e 11.1.
Table 19.1. C  f Ra  Ma e a  U ed I  Ma fac g P ce
Ma e ial Co  fo  P od cing
200 million do e
i h a 20% Safe
Fac o  ($USD)
Co  ($USD/do e of mRNA
accine)
Pla mid DNA $1,000,000 $5.00E-03
T7 RNA Pol me a e $162,433,128 $8.12E-01
Adeno ine 5'-T i ho ha e
N cleo ide (ATP) $27,445 $1.37E-04
G ano ine-5'-T i ho ha e
N cleo ide (GTP) $46,024 $2.30E-04
C idine T i ho ha e N cleo ide
(CTP) $42,117 $2.11E-04
U idine-5 -T i ho ha e
N cleo ide (UTP) $151,574 $7.58E-04
RNA Ca  Analog $139,583,190 $6.98E-01
T i  H d ochlo ide $1,675 $8.37E-06
Magne i m Chlo ide $141 $7.03E-07
1,4-Di hio h ei ol $21,013 $1.05E-04
S e midine $4,844 $2.42E-05
T i on X-100 $4.81 $2.40E-08
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DNa e I $9,380,637 $4.69E-02
Alkaline Pho ha a e $325,442 $1.63E-03
Cell lo e $6,875 $3.44E-05
HEPES $4,761,150 $2.38E-02
E h lenediamine e aace ic acid
(EDTA) $37,467 $1.87E-04
Sodi m Chlo ide (NaCl) $270,032 $1.35E-03
E hanol $699,221 $3.50E-03
Sodi m Ace a e $1,812 $9.06E-06
ALC-0315
((4-h d o b l)a anedi l)bi (he
ane-6,1-di l)bi (2-he ldecanoa e
) $44,634,000 $2.23E-01
ALC-0159 (2-[( ol e h lene
gl col)-2000]-N,N-di e adec lace
amide) $474,630 $2.37E-03
DSPC
(1,2-di ea o l- n-gl ce o-3- ho
hocholine) $3,240,000 $1.62E-02
Chole e ol $46,000 $2.30E-04
PBS $5,889,513 $2.94E-02
S c o e $723,111 $3.62E-03
Sodi m h d o ide $134,350 $6.72E-04
Af e  g he e c ,  a  de e ed ha  d ce 200  d e  h a
20% afe  fac , he a  e d  $373,935,395 a  a e a . Pe  d e f RNA acc e
d ced, he a  e d  $1.87  a  a e a . Th  ce e  d e  a  a e  ha  he
e g ce f $15 d a  e  d e. I  , h f eca  ha  a fac g he RNA
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acc e  h gh  c a e. The a ge  c  f a  he a  a e a   T7 RNA P e a e. If
h  a  e e   f  a  ea , he e he e a c d b d a e a h  h he
e d , e d e ec  ha  he b - c g c f T7 RNA P e a e d be e  ha
ha  e e a ed   be, he ef e dec ea g he c  f T7 RNA P e a e a a . Th
  d ed ce he c  f a  a  a e a eeded e  d e. I  add , he c  f
cha g he RNA Ca  A a g a  he ec d e e e a  a e a . Th  a
e ec ed a  he RNA Ca  A a g  a h gh  ec f c b g ca  e e e  f h gh .
19.2 U ili ie
Tab e 19.2 de a  he c  f  e  eeded f  h  ce   d ce 200 
d e  f he acc e h a 20 e ce  afe  fac . I  add , h  ab e de a  he c  f
e  eeded e  d e f RNA acc e.  The ce a ed f  each  a e d c e ed
 Tab e 14.1 a d a e de a ed b ea d  f each  eeded  ded  Sec  14 f
h  e .
Table 19.2. C  f U e  U ed I  Ma fac g P ce
U ili Co  fo  P od cing 200
million do e  i h a 20%
Safe  Fac o  ($USD)
Co  ($USD/do e of mRNA
accine)
P oce  Wa e $10,000 $5.00E-05
Elec ici $600,000 $3.00E-03
T  d ce 200  d e  f he RNA acc e h a 20% afe  fac , he a  e d




I   e a ed ha  he a  d eed 30 e a e  h f . I  a  a ed e  da
ha  he e d be 5 h f . Acc d g  Se de e . a ., a  e a   a ed  a e $40
d a  e  h . Th ,  a  a  e a   e ec ed  a e $60,000/ ea .
19.4 Remaining Fi ed Co
The e a g f ed c  a e ca c a ed g G h e fac ed-c  e h d . The
a a e e  f  he e f ed c  a e de a ed  F g e 19.1 be .
Fig e 19.1. Re a g F ed C  Fac  U ed I Ma fac g P ce
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A g de he e a a e e   a  e a ed ha  he e a  fee  f he a  ace d be
$1,000,000 a a  f  a a  ca ed  M b e, PA. We e f ed h  c  e a e h
he he  f D . D a d. I  add , a  f he fee a c a ed h ac ag g a e ed 
he a a  M ce a e  c . Pac ag g f  h ce  c de  a e c f g, abe g,
f ee g, a d age ac ag g a d h e . W h he he  f D . D a d, e e a ed he
a a  ac ag g c   be $300,000,000. Pac ag g  e  c    a e  e e ha  h
c   a   he a fac g c  a a .
19.5 Wo king Ca i al
The g ca a  c e  e a g c  e ed f  he beg g e a  f he
a  a d  c de  he c  f he e  a d a  f d  eeded  c e  acc  ece ab e.
S a   he e a g f ed c , he g ca a   c ed g he fac ed-c
e h d. The a a e e  f  h  e h d a e ed  F g e 19.2. A  fac  a e he a e a  he
defa   he f ab  a a  ead hee e ce  f  RNA acc e I e  a d Ra
Ma e a . B h he RNA I e  a d Ra  Ma e a e e e   be 7 da  a  e e ec  ha
he a   c a  a  a    e a ee ' h f e  a d d c .
Fig e 19.2. Fac -C  Pa a e e  f  W g Ca a
F g e 19.3 c a  a de a ed c a a  b ea d f he g ca a  f  he
a  e a . The a  e a e  e e , h ch a  ca c a ed  F g e 18.3, ed
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h he g ca a  g e  he a  ca a  e e . F  h  ce , he a  a
ca a  e e   $745,950,447.
Fig e 19.3. W g Ca a  C a  B ea d
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20. P ofi abili  Anal i  - B ine  Ca e
20.1 Ba eline Ca h Flo  S mma  and P ofi abili
The f ab  f he a fac g ce  a a a ed e  a 15 ea  e d. F
he ba e e ce  d c ed  h  ec , a d c  ce f $15.00 e  acc e d e a
ch e . Th   a   b  gh  e  ha he ce e  d e ha  he U ed S a e
g e e  a d f  100  d e  f he Pf e -B NTech RNA acc e; The U.S.
g e e  a d Pf e  $1.95 b  f  100 d e  a d h  a d $19.50 e  d e61.
R a e  e e e  a  $5,000,000  c e  ce g c  ch a  h e a c a ed h g he
e  ca c d (ALC-0315) a d he e  PEG a ed d (ALC-0159).
P f ab  a a  f he ce  e ea  ha   h gh  f ab e. The I e a  Ra e
f Re  (IRR) f  he ce   448.80%, he Ne P e e  Va e (NPV)  2021 f  he ce
 $19.6 b , a d he Re   I e e  (ROI) af e  he h d ea  f d c  
475.30% f  he ce . The fac  ha  h  ce  e  f ab e a e  ha  he ce  
e a  f ab e e e   he f a e e e  f a ba ch fa e  e e  b ea d . The
ca h f  a  f  h  ce  e  a 15 ea e d ca  be f d  F g e 20.1.
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Fig e 20.1. Ca h f  a  f  d c . De a  f  a  RNA acc e f  COVID-19
e  a 15 ea  e d h a ce e  acc e d e f $15.00. The a a  d e  b a  h
f a  a  c e ed g he P f ab A a  4.0 S ead hee .
20.2 P ice Pe  Do e Sen i i i  Anal i
A  d c ed  he e  ec , h  ce  e e e  f ab e. A  a
ea  f  h   he ecede ed de a d f  COVID-19 acc e  ha  cc ed beca e f he
c e  COVID-19 a de c. Af e  he a de c  e ,  a  be he ca e ha  COVID-19
acc a   be eeded a a  a   a f  acc e62. I  h  - a de c a ,
he e  be de a d f  COVID-19 acc e , b  he de a d  e  be ch e  ha   
c e . Se  a a  f h  ce  e ea ha  h  ce    f ab e a  a ce
e  d e f ch e  ha  $15.00; aga , a e ce e  d e  e  be ece a  f
- a de c a a  COVID-19 acc e . F g e 20.2 e ea  ha  h  ce  ca   be
f ab e a  a ce e  d e a   a  $6.00 h ch e e e  a 60% dec ea e f  he $15.00
e  d e ed f  h  ec  a d a 70% dec ea e f  he $19.50 e  d e ha  he U.S.
g e e  a d  Pf e -B NTech.
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Fig e 20.2. Se  A a  ce e  d e f he COVID-19 RNA acc e. The ba e e
ce f $15.00 e  d e  h   b e. Th  ce   h gh  f ab e e e  a  $6.00 e
d e. Ba e e a ab e c  e e ed.
20.3 Va iable Co  Sen i i i  Anal i
A  e  e ed, RNA acc e  f  COVID-19  e   be eeded 
he c g ea  b   eed  be d a  e c  e  d e he  c a ed h he c
e  d e be g ed c e . U g he ba e e a ab e c ,  a  h   he e
ec  ha  he c  e  d e c d be e ed e 60% f  he $15.00 e  d e e ec ed f
h  ec , a d he ce  d e a  f ab e. A a   a a  f ab  h e
f he  e g he ce e  d e  e g a ab e c  a c a ed h a fac g he
acc e. L e g a ab e c  ca  be d e b  e g he ce  f a  a e a  ed 
d c . The b  ce  f a  a e a  e e de e ed ba ed  h ee h  f
d c   a e 200  d e  f a  RNA acc e, a d b  ce  f  ea
165
d c  d e  be e . Add a , e f he e e  eeded  he in vitro
a c  (IVT) eac  a d b e e  e e d ge  c d be ade -h e h ch
a  a e  a  a e a  c . M e e , b d g be e  e a h  h e d  e  e
 e  e   dec ea ed a ab e c . I he c e  COVID-19 a de c, a e  a e d e
b  he h gh de a d a d he e    he ha d  f he e  h he a a ab e a  a e a .
The e d a c  a e a c a  e ce   he U ed S a e  g e e  a g f  he
acc e, a  e  h ch ha  a g ea e  f a c a  d  a  ha  d a a e   e e  a
a ce c a . P - a de c,   e  he e  be a h f   eg a g e  a d
a fac g fac e  ce a  a e a  e  ha e e ce  a e a  f he  c e
d c g a  he e e  f he a de c.
F g e 20.3 h  IRR a  a f c  f e g ce f  h ee d ffe e  a ab e c .
The e  f a ge da a  e e e  a a  a ab e c  f a a e  $2.1 b , a 19%
dec ea e f  he ba e e a ab e c  h ch a  $2.6 b . The e  f ed da a 
e e e  a a  a ab e c  f a a e $1.6 b , a 38% dec ea e f  he ba e e
a ab e c . I  b h ca e  he e a ab e c a e ed ced, he ce  bec e  f ab e a
a e  e g ce c a ed  he ba e e ca e. S ec f ca , f  he ca e f 38% ed c  
a ab e c , he ce   f ab e a  $3.00 e  d e.
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Fig e 20.3. Se  a a  f he ce e d e a d a ab e c  f he COVID-19
RNA acc e. The ba e e ce f $15.00 e  d e  h   b e. Red c   a ab e
c  ca  a  f  he ce   be f ab e a  $3.00 e  d e.
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21. O he  Im o an  Con ide a ion
21.1 U e of od c
P   ec , each a  eed   be d ed h 1.8 L f 0.9% S d  Ch de
I ec . Th  d e    c ded a  a  f h  a fac g ce  a d  be ced
e e he e h a  e ac  c ce a  f 0.9%. Acc d g  he FDA Fac  Shee  f
Hea hca e de , Af e  d , he a  eed  be ed be ee  2 C a d 25 C a d  ed
h  6 h . I  h  age e d, he a eed  be e ed  a   gh  a d
a d UV  gh  e e. The a  c e  be e a a ed  0.3 L acc e . F  f
acc a , each a e  eed   ece e  d e f h  a c a  acc a  3 ee
a a .
21.2 FDA Reg la o  Fac o
A  a  ec ab e d c , he acc e f he ed a fac g ce   eed
FDA Reg a  A a . G e  he c e  COVID-19 a de c, he acc e ca  be
a h ed h gh a  E e ge c  U e A h a a  a  f O e a  Wa  S eed (OWS).
OWS  a a e h  be ee  he De a e  f Hea h a d H a  Se ce  (HHS), he
De a e  f Defe e (DOD) a d he a e ec 22. The g a  f OWS   acce e a e he
ce  f acc e a a  b  e e g a ec  f FDA eg a  h gh a a a e  ce .
I  de   ga  a h a , he acc e  eed  a  Pha e I, Pha e II a d Pha e III
c ca  a .
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The f  fac   be f g he I e ga a  Ne  D g a ca  (IND) f  Pha e I
d e . A  h  ea  , OWS a e   a  e a g he e a  a d e f  Pha e
III eff cac  a . F g Pha e I, he ce  e  Pha e II a d a  Pha e III
a . OWS e  a a ge  e f  Pha e III a h 30,000  50,000 a c a  h  c ea e
he a a ab  f da a  de   a a e e afe  da a de e d g   a  acce e a ed
e d f e55.
21.3 E i men  Reg la o  Fac o
A  ce   a d age a  ed  he a fac g ce   be cha ed 
acc da ce h c e  G d Ma fac g P ac ce (cGMP). Whe  a g he dec  
ce he DNA d c , g ea  ca e a d de a a  a e   e e he e ,
E ge ec, e  e e  a ed b  he FDA a d f  GMP h gh  he  d c
ce e . The he  ece  f e e   be cha ed f  e ab e c a e  e
The f he  a d Pa , a g he . S a , he dec  f ch g  e a a e
b eac  a  acc ed f  he eg a fac  f he a e b eac .
21.4 En i onmen al fac o
The ce   ge e a e a e  be a e   f ed b ffe , a  a d
e e . The a e f  each eac    be ed  a a e a  a d he a   be
c ed  b  S e c c e. S e c c e  a c a  ha ec a e   afe  c ec g a d
d g a e f  ed ca  ce e , a g he . C ac g S e c c e, h  ed
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ce  e e  a  a e  be e  d ca ded acc d g  c  d  a d
eg a  ac ce .  S e c c e ha  a  fac ca   Pe a a h ch  he a e
 h ch he a   be ca ed. Th  ge g a h c   be a  ad a age add g a a e
f afe  b  a g f  e f e b   ched g a e c ec .
21.5 Em lo ee afe , heal h, elfa e fac o
W h he e f he RNA ech g , h ce  d e   e e he ha d g f a e
 a e a ed . Th  a e  he a fac g ce  afe f  e ee afe   fac   
afe  ha  he a fac g ce  f  he  acc e e . The e a e a   b g ca
eac   ce  ed h gh  he ce . The c d e e a e  a d eac  c d
a  e e  he c ea  f bac e a c e .
Be d he e , a  e ee   ea a a e c h g a d PPE d c  
b h f  COVID-19 eg a  a d f  afe  c ce . A  e ee   be a ed f  he
afe a d e  e f e e . The g e a d a  de g   f   a
c  a e  a d e ee    be a ed h he Q a  C  e . The
 be a ed f  he afe e f he RNA Ge  E ec h e a d E d  A a  K .
21.6 Plan  loca ion fac o
The fac   be b   Me b e, PA. Th ca  a  ch e  f  h ee a
ea . F ,   e   a  a  h b b ha g c e   Ph ade h a
I e a a  A  a  e  a  he a   he Ne  Je e  a d Ne  Y  eg . Sec d , 
  a  a ea h e b ech g  c a e . Th   fac a e h e  f
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e . Th d ,   h g ha  h  a fac g ce   be  a d ffe e  a e
ha  M de a  a d Pf e . Th   f a ce ce  h  a de c a  h ee c a e
ha e he b ec e f acc a g a  a  e e a  b e  he h e  a  f e.
Ge g a h c d e f ca , e e  f  b  a e ead f c   c e , ed ce  he
ac  f a   f  a a a  d a e   he d a  e e  cc g  e a c a
a e.
The c  a e  ed  he f ab  a a f  he c c  f he a  a e
ba ed  c  a e  f  M b e, Pe a a. Add a , he c ac ed a e d a
c a , S e c c e, e a e   ha  a ea a d E ge ec, he e  f he DNA,  h
he d c   he a   M b e.
21.7 Global, c l e and ocial fac o
The acc e  f  be a h ed f e  he U ed S a e  h he E e ge c  U e
A h a . S a e , he acc e  ee a h a   he E ea  U  h
he E ea  Med c e  Age c  (EMA). The e a e a c a ed g ba  c ce . The
a fac g ce   e  e ha  a  e  a -a ae b c ce . A  a e , he
d c  ca  be ed b  M  c e  h  d be ab e  e h  d c  f he
a fac g ce  had c ded a  a ae b c fe e a e .
N e be  18 h 2020, he A e ca  Acade  f Med c e h ed a eb a
 COVID-19 c e a  h a e  e D . Ja e  H d e h (P e de  a d CEO, Meha
Med ca  C ege), D . La  C e  (P e de  a d D ec E e ), D . Ma  G be
(D ec , Off ce f Vacc e Re ea ch a d Re e , Ce e  f  B g c  E a a  a d
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Re ea ch, U.S. F d a d D g Ad a ) a d D . Ja  B e  (De  D ec  f
I fec  D ea e , Ce e  f  D ea e C  a d P e e ). Pa  f he c e a
f c ed  he a  a ec  f c de g he a e g f he acc e. The e e  a e
ed he e  a ce a  a ehe   acc e  he U ed S a e , e ec a   
g . D . Ja e  H d e h dec a ed, "I   ha d e a e he a ehe  a d  h ch
 c  a g   g  aga  ed c e." He d c ed he a ce f ha g
ed e e ge ,  ad ca e f  he e f he acc e. A g h he  eade  f he US
COVID-19 e e, he ed  de f  fa h eade a d c  ga e  h  a e
g  ea  f  he acc e. Th   c ca ce ce a   g  a e e
ed ed  ge  COVID-19. W h  he ed e e ge , D . H d e h a  he e  h
eed  he  a e he ea  e   ge  he acc e 64.
21.8 E hical fac o
The a fac g ce  d e   e he ha d g f a  a a a  ce . The
a  e h ca  c ce  d be he c g f he acc e. I  he a fac g ce  f he
COVID-19 acc e , he d c   be g cha ed b  he U ed S a e  g e e  h gh
O e a  Wa  S eed. The ag ee e  be ee  he a fac g c a  a d he US
g e e  a  acc  f  he he  ded b he g e e   b d he a  a d  f d
he c ca  a  g e  he e e ge c  a de c65. G e  h , he e   c ce  h he
c g f he acc e f  h  ec f c ce  ce he e  be  c e  ce b  ead
a  ag ee e  h a g e e  ha   acc  f fac  he  ha  he ce f he acc e.
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Th  a fac g ce  ca  be ed f  he d c  f he  acc e   he f e.
I  fac , RNA acc e  ha e he e a   be ed  ea g a a a a d ca ce . A  a c e
b hed  Na e  2020 d c e  he e  a ach f RNA ech g e   a a a
acc e . The d c  f h  e a  a a a acc e  he  d eed a a fac g
ce  e he e ed  h  a e . F  ch a a , g ea  ca e a d de a  d eed
 be a d  he e h ca  fac  f c g he acc e.
21.9 Ba ch Sched le
The d c   be b e  d   13 ba che h each ba ch c e ed e  a
7-da  e d. Each ba ch a  h he IVT Reac h ch  cc   a ba ch ce  a d
a e 5 h . The d c   he  c  f h gh he RNA f ca  ce ,
M c f d c , LNP P f ca  a d Pac ag g a d F ee g. I   a e a a e  2 da
f  a h e ee  h f d c   g  h gh he RNA f ca  ce . Th  c de
he e  a e   e a e he a  a e a , d e he c e  bef e he ce  ,
ad he a e a  f  he age a   he ce   a d he  f  he ce  
 he b e e  age a . I  a  c de he e  e -  he e e  a d  c ea
a d e e he e e  af e  e e  e. I  he RNA f ca  ce , each a ge a
f  f a    a e 2.5 h  a d he ce e ch a g a h  e   a e
a a e  2 h .
I   a e a a e  e da   f  a  e e ba ch f d c  h gh he
c f d c  ch . I   a e 19 h  f  he ac a  ce  a d he e a g e  be
eeded f  he d . A  e  he e e  c a ad ce, he c f d c ch   
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eed  be c ea ed af e  e e  ba ch ce he d c   a e  a e  . Th  
e ed h he e  e e f a  e . G e  h , he a  ce  e f  he
c f d c  e    he ac a   e f he ce .
The LNP f ca  ce   a e a a e 1 da . Th   acc  f  he 2.5
h  a e  f  he a ge a  f  f a  a e  a  he e f  he e e f a  e . The
ac a   e f  he ce   be  he de f a fe  h  a d he e a g e
ched g f  h  e   be ed  e a e he a  a e a , d e he c e  a d
c ea  he e e  af e  e. A f ac  f e  a  be ed f  a  c ; d a c
gh  ca e g (DLS)  be ed  chec  he e f he LNP  f g he h d a ge a
f  f a  e , a d he LAL a a   be ed  ea e e d  e e  f g he
f a  d  a  d c ed  Sec  13.4.. The a  a  f he ce   ac ag g a d f ee g
h ch  a e a a e  2 da . Th  c de he e   a  a d abe  he a  a  e
a  he f ee g f he a .
A a e f a ee  ched e ca  be f d  F g e 21.1. A  e  e ed,
e ba ch  h f acc e  d ced e  a 7 da  e d. F g e 21.1 b ea  d  he 7 da
e d  he 5 a  a  d c ed e ; he e a  c de he IVT eac , RNA
f ca , c f d c , LNP f ca , a d ac ag g a d f ee g. The e f  each f
he a  c de  he e   he  e a  ha  a  a  e  a  he e a a  f a
a e a , ad g f a  a e a    e a , e g d c  f  he 
e a , a d c ea g he  e a . F g e 21.2 h  he e a  ba ch ched e f  he
13 ba che  ha   be   d ce he e ed 200  d e . The e  ba ch  be
a ed  he e e h da  f he e  ba ch. Th  a  d e  ee  he g a  f d c g
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200  d e   a a e  3 h . The ched e  F g e 21.2 h  ha  he 200
 d e  ca  be ade  gh  de  3 h , a d  he e e  f a  a c a ed
de a , he ce  h d a e  e ha  3 h . F g e 21.2 a  h  ha  he 200
 d e  ca  ac a  be d ced  a h e e d f e ha  ha   h . I  
b e ha  he e  ba ch ca  be a ed ea e ha  he e e h da  f he e  ba ch, h
g ea  ed c g he e  d ce 200  d e . We h   F g e 21.2 ha  200 
d e  ca  ea  be d ced  3 h  a d ha h  e e ca  be h e ed f  f e
d c .
Fig e 21.1. Ba ch ched e f  1 ba ch. Each ba ch a e  7 da   c e e a d g e  h gh a
5 a  ce : IVT Reac , RNA P f ca , M c f d c , LNP P f ca  a d
Pac ag g a d F ee g.
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Fig e 21.2. C e e ba ch ched e f  a  13 ba che . Each ba ch f  he a e ce  a
h   he de a   he e  age.
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22. Concl ion  and Recommenda ion
RNA acc e  a e a e  a d e c g acc e e h e a c a ed a fac g
ce   c ea , e e e, a d h gh  f ab e. The e h d f RNA he  ed  h
a fac g ce , in vitro a c  (IVT),  a ce -f ee b che ca  eac ; he fac
ha  he e e a fac g ce   ce -f ee ea  fe e  c a a   a e  eed  be
e ed, h  f g he b e e  f ca e . The ce -f ee a e f h  ce
a  a  f  he ce   be e a e  e e e he  c a ed h he  acc e
a fac g ce e . A  d c ed  Sec  20, h  ce   e e e  f ab e a  he
e ec ed e g ce f $15.00 e  d e f RNA acc e. H e e , e ec g e ha  he
de a d f  RNA acc e  f  COVID-19  e dec ea e  he c g ea  e e  f
a a  d e  bec e ece a . Se  a a a  d e  h  ha  h  ce  ca  
be f ab e h a e g ce f de  $6.00 e  d e f RNA acc e h ch e e e
e ha  a 60% dec ea e  e g ce.
O g he a fac g ce  f  a  RNA acc e f  COVID-19  h gh
a  a  c a e  he  ha  Pf e , B NTech a d M de a a  a   d ce RNA
acc e  f  COVID-19. Th  ce  ca  be e ca ed h ea e a d ca  be ca ed   d
 ee  a  ga a  ec f c eed . Add a , de c b g h  ce   a  f  he
f e f RNA acc e   ge e a . P   he c e COVID-19 a de c, RNA acc e
e e  de e e  f  he  e  ch a  he Z a 66. M e e , RNA acc e  ha e
bee  d ed a  e a  ca ce  he a e c . Th ce  ca  be ed  a e RNA acc e
f  a  e; he  h g ha   cha ge be ee RNA acc e e   he a ge  f
ch ce e c ded b  he RNA. The a ge  f ch ce f  h  ec   he SARS-C V-2 e
177
(S) e . The a ge   ea  cha ged b  a a g he DNA e a e e e ce h ch
a  he RNA he ed f  h  DNA e a e  he IVT eac   c a  he a ge
f ch ce. The e a de  f he e   he RNA a fac g ce  e a  cha ged.
RNA acc e  ha e he e a   bec e a e a  e f acc e a ge  d e  he
a  be ef  f he a c a ed a fac g ce d c ed a  e g h h gh  h  e .
The a fac g ce  d c ed  h  e  ce -f ee, e a e  e e e, a d ca  be
ed  a e acc e  f  he  d ea e  d e  he fac  ha  he e a  ce   de e de  f
he a ge  ch e  f  he acc e.
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23. Ackno ledgemen
We d f  e  ha   ec  a h a d ad , D . Sc  D a d, f  h
e e e  a ab e  a d e e e h gh h  ec . H  e e e edge f
b g ca  e g ee g a d he ha ace ca  d ed g ea  a ab e f   ec .
Th gh  he c e f he e e e , he e  c e e  a e g  e  a d
g d g  a d  he edge a d  eeded  c e e h  ec . We a e ed b
he  he ded a d a ed b  he e e d b e   a   edge 
ha e a  ac  h ch he h ed  h gh h  ec .
We d a  e  ha  P fe  B ce V a a f  h  a ab e  e  he c e
 h  ec . I  add , e d e  ha he d a  c a  f  d g a
a ab e d  e ec e ha  he ed  h gh he e e e . I  a c a , e d e
 ha  A h  E che  f  a g he e  f h  b  ched e  ee  h  a d de
h  d a  e e e  he c f d c  de ce . W g  h  ec   h
ecede ed e a  a cha e ge; e a e ha f f  he ded ca ed c a  h  ade 
b e b  ha g he  e a d g da ce. F a , e d e  ha  he e e Che ca
a d B ec a  de a e  f he U e  f Pe a a. The edge ha  e ha e
b a ed f  he fe  a d fac  h  he de a e  h gh  he e a  ea  ha
a ed   c e e h  ec . We a e f e e g a ef  f  he  g da ce a d e .
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Appendi  A - Pharmace tical Form lation
Pfi e  ha mace ical f m la a  de i ed f m a Heal hca e P ide  Fac  hee .
G ea  ca e need   be aken hen l king a  he ma e beca e he d e i  dil ed a  he
accina i n i e, changing he c ncen a i n  f he c m nen . Gi en hi , c ncen a i n  ill
be efe ed  a  e-dil i n ( he c ncen a i n f he d c  f hi  man fac ing ce )
and -dil i n ( he c ncen a i n  f he accine af e  dil i n a  he accina i n i e). Pa ien
a e injec ed i h he dil ed f m f he accine and i h mRNA e en  a  he -dil i n
c ncen a i n.
Table A.1: Pfi e  Pha mace ical F m la i n P e-dil i n
Component Concentration / dose
(mg/mL)
Mass / dose (mg) Total mass (20%
safet  factor)  (g)
mRNA 0.5 0.03 7,200
All lipids 12.83 0.77 184,800
Li id:
(4-h d o b l)a anedi l)bi (he
ane-6,1-di l)bi (2-he ldecano
a e) 7.17 0.43
103,200
Li id: 2[( ol e h lene
gl col)-2000]-
N,N-di e adec lace amide 0.83 0.05
12,000
Li id:
1,2-di ea o l- n-gl ce o-3- ho
hocholine 1.5 0.09
21,600
Li id: chole e ol 3.33 0.2 48,000






(pre-dil tion) 6 0.36 864,000
Dibasic sodi m
phosphate h drate 1.17 0.07
16,800
186
S crose 100 6 1,440,000
Table A.2: Pfi e  Pha mace ical F m la i n P -dil i n (ma  di m chl ide acc n  f
ma  f m man fac ing ce  and f m dil i n)
Component Concentration / dose
(mg/mL)
Mass / dose (mg)
mRNA 0.1 0.03
All lipids 2.57 0.77
Li id:
(4-h d o b l)a anedi l)bi (he ane-6,1-di
l)bi (2-he ldecanoa e)
1.43 0.43
Li id: 2[( ol e h lene gl col)-2000]-
N,N-di e adec lace amide
0.167 0.05
Li id:
1,2-di ea o l- n-gl ce o-3- ho hocholine
0.3 0.09
Li id: chole e ol 0.667 0.2




Sodi m chloride (total) 8.4 2.52
Dibasic sodi m phosphate
h drate
0.233 0.07
S crose 20 6
M de na  ha mace ical f m la i n a  de i ed f m a Heal hca e P ide  Fac
Shee  bli hed b  he FDA. The fac hee  a  ed  calc la e he c ncen a i n e  d e
ing he l me f .5 mL e  d e men i ned in he d c men . The ma  e  d e a  li ed in
he d c men  and a  m l i lied b  200 milli n calc la e he ma  f  all accine  and b  a
20% fac   acc n  f  afe  c n ide a i n .
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Table A.3: M de na Pha mace ical F m la i n
Component Concentration / dose
(mg/mL)
Mass / dose (mg) Total mass (20%
safet  factor) (g)
mRNA 0.2 0.10 24,000
All lipids 3.86 1.93 463,200




Acetic acid 0.086 0.043 10,320
Sodi m acetate 0.24 0.12 28,800
S crose 87 43.5 10,440,000
188
Appendi  B - Eq ipment Si ing Calc lations
In vitro Transcription Reactor
The in i o an c i i n (IVT) eac i n ill ake lace in a WAVE Bi eac TM em
in di able la ic bi eac  bag . T  de e mine he king l me and he bag i e needed,
a lab a  cale IVT eac i n a  caled . The am n  f mRNA  be d ced e  ba ch
a  calc la ed ba ed n he fac  ha  13 ba che ld be n and ha  200 milli n d e  f
mRNA accine needed  be d ced e  h e 13 ba che . The Pfi e -Bi NTech
ha mace ical f m la i n a  e ed b  he FDA indica ed ha  he e a e 30 g f mRNA in a
ingle d e f accine. The am n  f mRNA needed e  ba ch a  h  calc la ed ing he e
kn n an i ie , and he calc la i n i  h n bel . A 20% afe  fac  a  incl ded 
acc n  f  he fac  ha  me mRNA ill be l  h gh he ce  a  ell a   acc n  f
aking am le  f  ali  c n l e .
Total mRNA needed: 200, 000, 000 𝑑𝑜𝑠𝑒𝑠 · 30 µ𝑔 𝑚𝑅𝑁𝐴𝑑𝑜𝑠𝑒 = 6, 000 𝑔 𝑚𝑅𝑁𝐴 
mRNA needed per batch: 6,000 𝑔 𝑚𝑅𝑁𝐴13 𝑏𝑎𝑡𝑐ℎ𝑒𝑠 · 1. 2 = 553. 85 𝑔 𝑚𝑅𝑁𝐴/𝑏𝑎𝑡𝑐ℎ
Li e a e di c ing IVT mRNA indica ed ha  in he e ence f T7 RNA l me a e, 1
g f DNA em la e a  fficien   gene a e 50 g f mRNA in a 10 L eac i n l me68. A
caling fac  a  calc la ed and ed  de e mine he eac i n l me e i ed. Thi
calc la i n i  h n bel .
Scaling factor: 553.85 𝑔 𝑚𝑅𝑁𝐴
50×10−6𝑔 𝑚𝑅𝑁𝐴
= 11, 077, 000
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Reaction Vol me: 10 × 10−6 𝐿 · 11, 077, 000 = 110. 77 𝐿
Th , he eac i n l me f  ne ba ch i  110.77 L. I  a  de e mined ha  hi  king
l me c ld be acc mm da ed b  a 200 L la ic di able bi eac  bag. The WAVE
Bi eac TM 200 em a  ch en a  i  can acc mm da e 200 L bag . The e e l  a e
mma i ed in Table B.1.
Table B.1. S mma  f IVT Reac  Pa ame e
Parameter Val e
mRNA Prod ced per Batch (g) 553.85
Reaction Vol me per Batch (L) 110.77
Disposable Bioreactor Bag Si e (L) 200
Tangential Flo  Filtration De ices
In de   a ia el  i e he angen ial fl fil a i n em , a a en  a  ili ed
ha  de ail  he ifica i n ce  f mRNA  d ced b  IVT.  Tangen ial Fl  Fil a i n
de ice  e e ili ed in h ee di inc  lace  in  ce : igh  af e  he IVT eac i n, igh
af e  he ch ma g a h  c l mn, and igh  af e  he mic fl idic  de ice. The e h ee fil a i n
ce e  a e labeled a  TFF1, TFF2, and TFF3, e ec i el .
Tangential Flo  Filtration De ice 1
The a en  hel ed  ch e e e al ke  ce  a iable . A  gge ed b  he a en ,
TFF1 ill be e f med ing 10 dil i n l me  (DV) f a e . Since he l me f he IVT
d c  i  110 L, hi  mean  ha  he l me f a e needed a  a b ffe  f  hi  ce  ing
he 10 DV ill be 1100L (a  1100L = 10*110L). The e en a e f TFF1 c n ain  mRNA (b h
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ingle and d ble anded) and a e . The e en a e l me i  ch en  be 110 L a  e an ed
 e  he l me f IVT d c  l i n e al he l me f he e en a e (i.e. hi  TFF1 i
nl  mean   diafil e  and n  c ncen a e he e all l i n). The al fil a e l me i  e al
 he fil a e l me f m he diafil a i n e l  he fil a e l me f m he c ncen a i n
e . We calc la ed he al fil a e l me f TFF1 a  f ll :
.𝑇𝑜𝑡𝑎𝑙 𝐹𝑖𝑙𝑡𝑟𝑎𝑡𝑒 =  1100 𝐿 + (110 𝐿 − 110 𝐿) = 1100𝐿
Once e f nd he al fil a e l me, e calc la ed he l me f he
e mea e a  f ll :
𝑃𝑒𝑟𝑚𝑒𝑎𝑡𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 = 𝑇𝑜𝑡𝑎𝑙 𝐹𝑖𝑙𝑡𝑟𝑎𝑡𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 −  𝑅𝑒𝑡𝑒𝑛𝑡𝑎𝑡𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 =  1100𝐿 − 110𝐿 = 990𝐿
.
Th , he e mea e l me f TFF1 i  990 L. T  a ia el i e he TFF, e needed 
de e mine he memb ane a ea f he fil e . The memb ane a ea a  calc la ed ing he e a i n
bel :
he e A= memb ane a ea (m2), V= l me f fil a e gene a ed (li e ),𝐴 = 𝑉𝐽*𝑇
J = fil a e fl  a e (li e /m2/h ), and T = ce ime (h ).
Af e  di c ing i h D . Diam nd and he Ind ial C n l an , e de e mined ha  e an ed
 e   ce  ime f  TFF1  be 2.5 h . In addi i n he a en  hel ed  de e mine ha
he fl  f  hi  ce  ill be e   70 li e /m2/h . U ing he e a ame e , e calc la ed
he memb ane a ea f  he fil e  a  f ll :




The la  ce  a iable f  hi  ni  e a i n calc la ed a  he fl  a e. The fl  a e a
calc la ed a  f ll :
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= 440 L/h .𝐹𝑙𝑜𝑤 𝑅𝑎𝑡𝑒 = 1100𝐿2.5 ℎ𝑟
Tangential Flo  Filtration De ice 2
Simila   TFF1, he a en  hel ed  ch e e e al ke  ce  a iable  f  TFF2. A
gge ed b  he a en , TFF2 ill be e f med ing 10 dil i n l me  (DV) f di m
ace a e. Since he l me f he ch ma g a h  d c i  ab  126 L, hi  mean  ha  he
l me f di m ace a e needed a  a b ffe  f  hi ce  ing he 10 DV ill be 1,262 L.
The e en a e f TFF2 c n ain  ingle anded mRNA and di m ace a e. The e en a e l me
i  ch en  be 126 L a  e an ed  e  he l me f ch ma g a h  d c  l i n e al
 he l me f he e en a e (i.e. hi  TFF2 i nl  mean   diafil e  and n  c ncen a e he
e all l i n).  The al fil a e l me i  e al  he fil a e l me f m he diafil a i n
e  l  he fil a e l me f m he c ncen a i n e . We calc la ed he al fil a e l me
f  TFF1 a  f ll :
.𝑇𝑜𝑡𝑎𝑙 𝐹𝑖𝑙𝑡𝑟𝑎𝑡𝑒 =  1262 𝐿 + (126 𝐿 − 126 𝐿) = 1262𝐿
Once e f nd he al fil a e l me, e calc la ed he l me f he e mea e a  f ll :
𝑃𝑒𝑟𝑚𝑒𝑎𝑡𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 = 𝑇𝑜𝑡𝑎𝑙 𝐹𝑖𝑙𝑡𝑟𝑎𝑡𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 −  𝑅𝑒𝑡𝑒𝑛𝑡𝑎𝑡𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 =  1262𝐿 − 126𝐿 = 1136𝐿
.
Th , he e mea e l me f TFF2 i  1,136 L. T  a ia el i e he TFF, e needed 
de e mine he memb ane a ea f he fil e . The memb ane a ea a  calc la ed ing he e a i n
bel :
he e A= memb ane a ea (m2), V= l me f fil a e gene a ed (li e ),𝐴 = 𝑉𝐽*𝑇
J = fil a e fl  a e (li e /m2/h ), and T = ce ime (h ).
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Af e  di c ing i h D . Diam nd and he Ind ial C n l an , e de e mined ha  e an ed
 e   ce  ime f  TFF2  be 2.5 h . In addi i n he a en  hel ed  de e mine ha
he fl  f  hi  ce  ill be e   82.5 li e /m2/h . U ing he e a ame e , e calc la ed
he memb ane a ea f  he fil e  a  f ll :




The la  ce  a iable f  hi  ni  e a i n calc la ed a  he fl  a e. The fl  a e a
calc la ed a  f ll :
= 505 L/h .𝐹𝑙𝑜𝑤 𝑅𝑎𝑡𝑒 = 1136𝐿2.5 ℎ𝑟
Tangential Flo  Filtration De ice 3
Simila   TFF1 and TFF2, he a en  hel ed  ch e e e al ke  ce  a iable  f
TFF3. A  gge ed b  he a en  in ec i n, TFF3 ill be e f med ing 10 dil i n l me
(DV) f PBS. Since he l me f he d c  l i n fl ing  f he mic fl idic  de ice i
ab  4,935 L, hi  mean  ha  he l me f di m ace a e needed a  a b ffe  f  hi  ce
ing he 10 DV ill be 49,350 L. The e en a e f TFF3 c n ain  Li id , mRNA, and PBS. The
e en a e l me i  ch en  be 626 L a  e an ed  c ncen a e he mRNA l i n bef e i
en e  in  he final dil i n ce .  The al fil a e l me i  e al  he fil a e l me
f m he diafil a i n e  l  he fil a e l me f m he c ncen a i n e . We calc la ed he
al fil a e l me f  TFF1 a  f ll :
.𝑇𝑜𝑡𝑎𝑙 𝐹𝑖𝑙𝑡𝑟𝑎𝑡𝑒 =  49350 𝐿 + (4935 𝐿 − 626 𝐿) = 53, 660𝐿
Once e f nd he al fil a e l me, e calc la ed he l me f he e mea e a  f ll :
𝑃𝑒𝑟𝑚𝑒𝑎𝑡𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 = 𝑇𝑜𝑡𝑎𝑙 𝐹𝑖𝑙𝑡𝑟𝑎𝑡𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 −  𝑅𝑒𝑡𝑒𝑛𝑡𝑎𝑡𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 =  53, 660𝐿 − 626𝐿 = 53, 034 𝐿.
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Th , he e mea e l me f TFF2 i  53,034 L. T  a ia el  i e he TFF, e needed 
de e mine he memb ane a ea f he fil e . The memb ane a ea a  calc la ed ing he e a i n
bel :
he e A= memb ane a ea (m2), V= l me f fil a e gene a ed (li e ),𝐴 = 𝑉𝐽*𝑇
J = fil a e fl  a e (li e /m2/h ), and T = ce ime (h ).
Af e  di c ing i h D . Diam nd and he Ind ial C n l an , e de e mined ha  e an ed
 e   ce  ime f  TFF3  be 7.5 h . In addi i n he a en  hel ed  de e mine ha
he fl  f  hi  ce  ill be e   82.5 li e /m2/h . U ing he e a ame e , e calc la ed
he memb ane a ea f  he fil e  a  f ll :




The la  ce  a iable f  hi  ni  e a i n calc la ed a  he fl  a e. The fl  a e a
calc la ed a  f ll :
= 7,155 L/h .𝐹𝑙𝑜𝑤 𝑅𝑎𝑡𝑒 = 53,660𝐿7.5 ℎ𝑟
Cell lose Chromatograph  Col mn
The a ame e  f he ch ma g a h  c l mn e e de e mined b  caling he cell l e
ch ma g a h  c l mn men i ned in a li e a e a icle i en b  cien i  incl ding D .
Ka ik . Thi  ch ma g a h  c l mn a  ed  ce 100 mL f mRNA a  a c ncen a i n
f 1 mg/mL in he ch ma g a h  b ffe . A  hi  c ncen a i n, a  e  he c n l an ' h gh ,
he c l mn f 780 mL ed in he li e a e e a  likel  n a a ed b  he b nd f ac i n
f d RNA. Since he am n  f mRNA needed  ce in hi  man fac ing ce  i  n he
de  f magni de f 1000 ime  he ne ed in he mall- cale c l mn, he calc la i n  e e
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e f med ing  minimi e he i e f he c l mn f  hi  ce . Gi en hi , an mRNA
c ncen a i n f 4 mg/mL a  ed in ead f 1 mg/mL.
The c l mn l me f  hi  ce  a  calc la ed b  fi  de e mining he l me f
mRNA and b ffe  l i n needed  ha e he mRNA a a c ncen a i n f 1 mg/mL. Thi
l me a  calc la ed  be 126.28 L. A a i  f hi l me  he 100 mL ce ed in he
mall- cale c l mn a  ed  calc la e he i e f he c l mn ed in hi  ce : 985.95 L.
A  e  he c n l an  ad ice, a 1000 L c l mn ill be cha ed. I  a  n ed in he
calc la i n  ha  he mall- cale c l mn men i ned in he li e a e e ie  a  likel  n
a a ed ince he f ac i n f d RNA i  mall. H e e , i  a  ill ch en  cale he c l mn
acc ding  l me ince a 1000 L c l mn i  c mm n in ind  and he la ge i e ill all
f  he ce   cc  a  a fa e  a e.
The emaining a ame e  f  he ce  (c l mn diame e , fl  a e, ime f  ce )
e e de e mined b  caling he c l mn i h a c n an el ci . The heigh  a  e   be 0.4
me e . Thi  al e a  fi  ed  calc la e he c - ec i nal a ea f he c l mn.
𝐶𝑟𝑜𝑠𝑠 − 𝑠𝑒𝑐𝑡𝑖𝑜𝑛𝑎𝑙 𝑎𝑟𝑒𝑎 =  0.9849549 𝑚30.4 𝑚 =  2. 46 𝑚
2
The fl - a e a  hen calc la ed b  ing he el ci and he c - ec i nal a ea.
𝐹𝑙𝑜𝑤 𝑟𝑎𝑡𝑒 =  0. 00359 𝑚/𝑚𝑖𝑛 * 2. 46 𝑚2 =  . 00884 𝑚3/𝑚𝑖𝑛  
Thi  al e a  hen ed  calc la e he ime f he ce  b  acc n ing f  he fl  a e and
he l me f he c l mn.
𝑇𝑖𝑚𝑒 𝑓𝑜𝑟 𝑝𝑟𝑜𝑐𝑒𝑠𝑠 =  984953.88 𝑚𝐿8839.33 𝑚𝐿/𝑚𝑖𝑛  =  111. 4 𝑚𝑖𝑛 =  1. 86 ℎ𝑜𝑢𝑟𝑠
Table B.2. C l mn Pa ame e  f Small-Scale C l mn U ed  De e mine Si e
Parameter Val e
Col mn Vol (mL) 780
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Col mn Vol (m3) 0.00078
Height (cm) 56
Height (m) 0.56
Col mn Cross-sectional area (m2) 0.0014
Flo  rate (mL/min) 5
Flo  rate (m3/min) 5.00E-06
Velocit  (m/min) 0.0036
Col mn Diameter (m) 0.042
Table B.3. S mma  f 1000 L C l mn Pa ame e
Parameter Val e
Col mn ol me (L) 1000
Sol tion ol me (L) 984.96
Col mn Vol (m3) 0.98
Height (cm) 40
Height (m) 0.4
Col mn Cross-sectional area (m2) 2.46
Flo  rate (mL/min) 8,839.33
Flo  rate (m3/min) 8.84E-03
Velocit  (m/min) 0.0036
Velocit  (cm/hr) 21.54
Col mn Diameter (m) 1.77
Time for process (min) 111.43
Time for process (hr) 1.86
The ame 16% e han l b ffe  a  ed in he li e a e e ie  i  ed in he de ign f hi
c l mn. The am n  f e han l needed  e a e he b ffe  a  linea l  caled. The he
c m nen  e e ed i h he f ll ing m la i ie : 0.01 HEPES, 0.0001 EDTA, 0.125 NaCl.
The ch ma g a h  b ffe  i  ed  a h he c l mn and dil e he mRNA e e  ba ch and 
make he cell l e e in hich ill be ed f  he ce . The e in i  effec i e a  binding e
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95% f he d RNA. A  e  di c i n  i h he c n l an  n he nde a a i n f he e in
i h each ba ch, he e in ill nl  be made nce in he ce .
The e in i  made i h cell l e and ch ma g a h b ffe . The e i ed ma  f
cell l e a  linea l  caled f m he 250 g am  ed in he mall- cale c l mn  he 275,000
g am  ed in hi  ed ce .
Pre-Microfl idics Dil tions and Microfl idics De ices
Calc la i n  e e c m le ed  de e mine he c ncen a i n f mRNA and li id  needed
f  he mic fl idic  de ice  a  ell a  he n mbe f mic fl idic  de ice  needed. Li e a e a
ell a  P eci i n Nan S em  a en ed mic fl idic echn l g  e e ed  c m le e he e
calc la i n .
A  di c ed in Sec i n 15.3.4, he mic fl idic de ice ha e  inle  eam ; ne inle
c n ain  li id  di l ed in e han l, and he he c n ain  mRNA in an acidic b ffe . Li e a e
indica ed ha  f  he e e  f mic fl idic  ce e , he li id  h ld be di l ed in e han l
a  a al li id c ncen a i n f 10 mg/mL38. I  i al  im an   e  a fl  a e a i  (FRR) f
he mRNA eam  he li id  eam; an a ia e a i  f   ce  a  de e mined ba ed
n li e a e  be 3:1 (mRNA:li id )38.
The c ncen a i n f mRNA needed in he a e  inle eam a  de e mined ba ed n
he FRR, he li id  c ncen a i n in he e han l l i n, and he ma  a i  f mRNA  li id  in
he final ha mace ical f m la i n. In a ingle d e f he accine, he e a e 30 g f mRNA
and 770 g f li id . The calc la i n  d ne  de e mine he mRNA c ncen a i n in he a e
eam a e h n bel , and hi  c ncen a i n a ed  de e mine he am n  f di m
ace a e needed f  he dil i n f he mRNA i  he mic fl idic  e .
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Mass ratio of mRNA to lipids: 30 µ𝑔 𝑚𝑅𝑁𝐴770 µ𝑔 𝑙𝑖𝑝𝑖𝑑𝑠 = 0. 039
Concentration of mRNA in aq eo s stream:
10 𝑚𝑔 𝑙𝑖𝑝𝑖𝑑𝑠
𝑚𝐿 𝑒𝑡ℎ𝑎𝑛𝑜𝑙 𝑠𝑜𝑙𝑛 ·
0.039 𝑚𝑔 𝑚𝑅𝑁𝐴
𝑚𝑔 𝑙𝑖𝑝𝑖𝑑𝑠 ·
1 𝑚𝐿 𝑒𝑡ℎ𝑎𝑛𝑜𝑙 𝑠𝑜𝑙𝑛/𝑚𝑖𝑛
3 𝑚𝐿 𝑚𝑅𝑁𝐴 𝑠𝑜𝑙𝑛/𝑚𝑖𝑛 = 0. 13 
𝑚𝑔 𝑚𝑅𝑁𝐴
𝑚𝐿 𝑚𝑅𝑁𝐴 𝑠𝑜𝑙𝑛
The c ncen a i n f mRNA in a e  l i n i  he e-mic fl idic  dil i n
e  i  3.92 mg/mL in a 126 L di m ace a e l i n; he de ailed ma  balance  a nd each
maj  ce  e  can be f nd in A endi  D. The am n  f addi i nal di m ace a e added
 dil e he mRNA  a c ncen a i n f 0.13 mg/mL a  calc la ed a  h n bel .
Additional sodi m acetate: f di m ace a e added3.92 𝑔 𝑚𝑅𝑁𝐴/𝐿 ·126.28 𝐿0.133 𝑔 𝑚𝑅𝑁𝐴/𝐿 = 3701. 29 𝐿
Elemen  f P eci i n Nan em  a en ed mic fl idic echn l g  e e ed in he
de ign f he mic fl idic  de ice  f  hi  ce . The fl  a e e  de ice e  b  he a en
a  ch en a  he fl  a e e  de ice f   de ign; hi  fl  a e i  12 mL/min. U ing he 3:1
FRR di c ed ab e, hi  mean  ha  he mRNA l i n fl  a e ld be 9 mL/min and he
li id  l i n fl  a e ld be 3 mL/min. A  e i l di c ed in Sec i n 15.3.4, he e
ill c n i  f 25 e  f 16 a alleli ed mic fl idic de ice ; hi  am n   400 al
mic fl idic  de ice . U ing he ch en fl  a e e  de ice, i  a  de e mined ha  ne 16X
e  can ce  192 mL/min  11.52 L/h . The g al a   ce  ne ba ch  h f
mRNA in a  m  ne da . A ima el  5000 L al f mRNA and li id  c m i e ne
ba ch  h,  hi  l me ill need  be ce ed b  he de ice  in nde  a da . Gi en he
a e e  16X e  f 11.52 L/h , e de e mined ha 25 f he e 16X e  ld be fficien .
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If e e 25 f he 16X e , he 5000 L can be ce ed in j  e  17 h . Thi
calc la i n i  de ailed bel , and im an  e l a e mma i ed in Table B.2.
Time to process one batch s orth of mRNA and lipids:
4935.46 𝐿
11.52 𝐿ℎ𝑟·𝑑𝑒𝑣𝑖𝑐𝑒 · 25 𝑑𝑒𝑣𝑖𝑐𝑒𝑠
= 17. 14 ℎ𝑜𝑢𝑟𝑠
Table B.4. S mma  f Mic fl idic  Pa ame e
Parameter Val e
Lipids in Ethanol Concentration (mg/mL) 10
mRNA in Sodi m Acetate Concentration
(mg/mL)
0.13
Lipids in Ethanol Flo  Rate per De ice
(mL/min)
3
mRNA in Sodi m Acetate Flo  Rate per
De ice (mL/min)
9
Total Flo  Rate per De ice (mL/min) 12
N mber of 16X Set ps 25
Total N mber of Microfl idics De ices 400




The e a e  e ile fil a i n e  in he e all ce ; ne cc  a  he final mRNA
ifica i n e , and he he  cc  f ll ing he hi d angen ial fl  fil a i n (TFF) e .
O ica Ⓡ S e ile XLT 10 Milli e E e Ⓡ fil e ill be ed f  b h e . The e ile fil e
ha  e e  a  he final e  f mRNA ifica i n (S e ile Fil e  1) ill need  ce
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a ima el  126 L f mRNA l i n. The e e ile fil e  ha e a memb ane a ea f 0.54 m 2
and a fl  f 7 mL/min/cm2,  he ime  fil e ill be a ima el  3 min e . The e ile
fil e  ha  cc  f ll ing he hi d TFF e  ill need  ce  a ima el  626 L f
mRNA-c n aining LNP l i n. U ing he ame memb ane a ea and fl , he ime  fil e  f
hi  fil e  ill be a ima el  17 min e . The calc la i n  a e h n bel , and he im an
e l  a e mma i ed in Table B.3.




= 3. 34 𝑚𝑖𝑛




= 16. 55 𝑚𝑖𝑛
Table B.5. S mma  f S e ile Fil a i n Pa ame e
Parameter Val e
Filter 1 Time to Filter (min) 3.34
Filter 2 Time to Filter (min) 16.55
Final Dil tion
The final dil i n i  ed  en e he final c ncen a i n i  me  f  e e  c m nen .
The inle   he age ank i  he le  f TFF 3 and hi  eam i  mi ed i h a ec nd eam
ha  i  30% c e in PBS. The ma  calc la i n f  eam 2 e e e f med b  back- acking
f m he e i ed final c ncen a i n . The fi a  f hi  i  calc la ing he l me e  d e f
he final d c . Thi  i  diffe en  f m he 0.3 mL f he d e nce i  i  admini e ed  he
a ien  a  he accina i n i e ince he ial  a e nl  dil ed a  he accina i n i e i h di m
chl ide.
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A fac  f ial   d e  a  calc la ed ing he inf ma i n f m he FDA Heal hca e
ide  fac  hee . Righ  i   admini e ing he accine, he ial  ha e a al l me f
0.45 mL and 1.8 mL (f m he added di m chl ide), ielding a al 2.25 mL. Thi  di ided b
he 0.3 mL e  d e gi e  7.5 hich i  he a i  f ial   d e .
Thi  a i  a  ed  calc la e he l me f each d e in he final d c  f hi
man fac ing ce  b  di iding he l me f each ial hich i  0.45 mL b  he a i  f 7.5.
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑑𝑜𝑠𝑒 𝑓𝑖𝑛𝑎𝑙 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 =  0.45 𝑚𝐿 7.5 =  0. 06 𝑚𝐿 
Thi  l me f 0.06 mL a  m l i lied b  he n mbe f d e  d ced e  eek 
calc la e he al l me ha  need   e i  he age ank in hich he final dil i n ill be
e f med.
𝐹𝑖𝑛𝑎𝑙 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑉𝑜𝑢𝑡 =  0. 06 𝑚𝐿 *  15, 384, 615 =  923, 076. 92 𝑚𝐿 
The le  ma  f m he final dil i n f each c m nen a  calc la ed b  m l i l ing
he ma  e  d e in he final ha mace ical f m la i n (incl ded in A endi  A) and he
d e  e  eek. In he final dil i n, PBS i  in b h inc ming eam : in eam 1 c ming f m
he TFF 3 eac  he e i  a  ed a  a b ffe  and in eam 2 hich i  30% c e in PBS.
The am n  f PBS in eam 2 a  calc la ed b  de e mining he l me needed  acc n  f
he e i ed ma  f c e. The am n  f each c m nen f PBS in eam 2 a  hen
calc la ed b  ing he m la i  f h e c m nen in anda d 1X PBS. The ma  f PBS in
eam 1 a  calc la ed b  d ing he ma  f ha c m nen  in he le  eam min  he ma
f ha  c m nen  in eam 2.
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Appendi  C - Eq ipment Costing Calc lations
In vitro Transcription Reactor
A  e i l  a ed, he WAVE Bi eac TM 200 em ill be ed  n he in i o
an c i i n (IVT) eac i n. The em c n i f a cking em i h a i  c n l
elemen  ch a  a em e a e c n lle  and H m ni , and 200 L di able la ic
bi eac  bag  a e laced n  he cke . The IVT eac i n ill be n 13 ime   d ce he
de i ed am n  f mRNA f  he accine. T  e en l  f ime in he e en  ha  a bag b eak
 a eac  b eak  d n, i  a  de e mined ha  WAVE Bi eac TM 200 em  and 26
di able bi eac  bag  ld be cha ed. Each WAVE Bi eac TM 200 em c
$400,000, and each bag c  $709. The al cha e c  a cia ed i h he IVT eac i n i
h  $809,217. The e al e  a e mma i ed in Table C.1.
Table C.1. IVT Reac  P cha e C
Component Cost
WAVE BioreactorTM 200 s stem (2) $800,000
200 L Disposable Bioreactor Bags (26) $9,217
Total $809,217
Tangential Flo  Filtration De ices
Af e  mee ing i h D . Diam nd, i  a  de e mined ha  a TFF em ha  incl de
memb ane , ca e e , m , and m ni  ld c $150,000 each f  b h TFF1 and TFF2.
F  TFF3, hich i  m ch la ge  in i e, he em a  de e mined  ha e a cha e c  f
$1,000,000.
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Cell lose Chromatograph  Col mn
The c  f he ch ma g a h  c l mn a  calc la ed ing e a i n  ided in
P od c  and P oce  De ign P inci le , hile he FPLC em a  b ained f m a end . F
he c l mn c  e ima e, a CE c inde  f 607 a ed67. The c l mn a  iced a  a e ical
e el made f m 304 ainle  eel. F m A endi B, he c l mn ha  a diame e  f 69.7
inche  and he leng h f he c l mn i  15.7 inche . In addi i n, i  a  e ima ed ha  he c l mn
ha  a all hickne  ( ) f 0.44 inche . Bel  incl de a able ha  mma i e  he e
a ame e :
Table C.2. Ch ma g a h  C l mn Pa ame e
Parameters Val e
Densit  of Stainless Steel (⍴) 0.285 lb/in3
Diameter of Col mn (D) 69.7 in
Length of Col mn (L) 15.7 in
Wall Thickness (ts) 0.44 in
FM (304 Stainless Steel) 1.7
In de   calc la e he cha e c  f he c l mn, he eigh  f he c l mn fi  ha   be
calc la ed ing he f ll ing e a i n:
.𝑊 =  π(𝐷𝑖 +  𝑡𝑠)(𝐿 +  0. 8𝐷𝑖)𝑡𝑠⍴
The ef e, he eigh  f he ch ma g a h  c l mn a  calc la ed a  ch:
𝑊 =  π(69. 7 𝑖𝑛 +  0. 44 𝑖𝑛)(15. 7 𝑖𝑛 +  0. 8 * 69. 7 𝑖𝑛)0. 44 𝑖𝑛 * 0. 285 𝑙𝑏/𝑖𝑛3 = 1966 𝑙𝑏
.
N  ha  e f nd he eigh  f he c l mn  be 1,966 lb, he f. .b cha e c  a  a CE inde
f 567, C , a  calc la ed a  f ll :
𝐶
𝑣
 =  𝑒𝑥𝑝 7. 1390 +  0. 18255 𝑙𝑛(𝑊)  +   0. 02297 𝑙𝑛(𝑊) 2
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                                = 𝑒𝑥𝑝 7. 1390 +  0. 18255 𝑙𝑛(1966)  +   0. 02297 𝑙𝑛(1966) 2 = $18, 855.
Ne  he ma e ial c  a  aken in  acc n  a  ch:
𝐶
𝑝
= 𝐹𝑀 * 𝐶
𝑣
= 1. 7 * $18, 855 = $32, 053.
La l , he CE inde  f 607 a  aken in  acc n a  ch:
𝐶𝑜𝑠𝑡 =  𝐵𝑎𝑠𝑒 𝐶𝑜𝑠𝑡 (𝐼/𝐼
𝑏𝑎𝑠𝑒
) = $32, 053(607/567) = $ 34, 314.
The ef e, he cha e c  f j  he c l mn i $34,314. In addi i n, e b ained a e f
he FPLC em f m Ic n Scien ific. The ed c f  he FPLC em a  $90,000.
The ef e, he al cha e c  f he c l mn and FPLC i :
.𝑇𝑜𝑡𝑎𝑙 𝑃𝑢𝑟𝑐ℎ𝑎𝑠𝑒 𝐶𝑜𝑠𝑡 𝑜𝑓 𝐶𝑜𝑙𝑢𝑚𝑛 𝑎𝑛𝑑 𝐹𝑃𝐿𝐶 𝑆𝑦𝑠𝑡𝑒𝑚 = $34, 314 + $90, 000 = $ 124, 314
Th , he al cha e c  f he ch ma g a h c l mn incl ding he FPLC em i
$124,314.
Microfl idics De ices
I  a  de e mined ha  25 e  f 16 a alleli ed agge ed he ingb ne mic fl idic
mi ing de ice  ld be cha ed. The P eci i n Nan S em a en  di c e  he
a alleli a i n f 8 mic fl idic mi ing de ice  and h  hi  c e can be caled , ci ing
he a alleli a i n f 16 de ice  a  fea ible. The 16X e  a  h  ch en f  hi  jec .
Th gh di c i n i h  jec  a h  and ad i , D . Sc  Diam nd, i  a  de e mined
ha  ne e  f 16 a alleli ed de ice  ld c $13,000. Th , he al cha e c  i
$325,000. Thi  i  mma i ed in Table C.2.
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Table C.3. Mic fl idic  De ice  P cha e C
Component Cost
Single 16X Set p $13,000
Total (25 16X Set ps) $325,000
Sterile Filters
O ica Ⓡ S e ile XLT 10 Milli e E e Ⓡ fil e e e ed f  b h f he e ile
fil a i n e . Each O ica Ⓡ S e ile XLT 10 Milli e E e Ⓡ fil e  ha  a cha e c  f
$575. Since he e fil e  a e ingle e and di able and 13 n  a e e i ed f  each fil e , 26
fil e  ill be cha ed. Thi  b ing  he al cha e c   $14,950 f  b h e ile fil a i n
e . Thi  i  mma i ed in Table C.3.
Table C.4. S e ile Fil a i n P cha e C
Component Cost
Single Sterile Filter $575
Total (26 Filters) $14.950
Storage Tanks
Se e al IBC ainle  eel 304 age ank  f m he end  The Ca  C m an  ill
be ed h gh   ce . In de   main ain c n i enc  i h icing, all ank  e e
ba ed ff f cha e ice  li ed n The Ca  C m an eb i e. Thi  end  did n  eadil
ha e all he ice  f  all he i e  f ank  needed, a  nl  a elec  fe  e e li ed n hei
eb i e. In de   acc a el  ice he ank  i h c ing inf ma i n n  eadil  li ed, e
linea l  in e la ed he a ailable da a  find a line. Thi  line a  hen ed  calc la e he
ice  f ank  ha  e e nkn n. The a ailable ice da a i  de ailed in Table C.5 and he linea
in e la i n f ch da a can be een d n bel in Fig e C.1.
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Table C.5. A ailable Da a f  C  f S age Tank  F m Vend






Fig re C.1. Linea  In e la i n f he A ailable S age Tank C  Da a
The ice  f each indi id al age and a e ank ed in  ce  can be f nd in ec i n
17.
Cold Room
Wi h he hel  f D . Diam nd, i  a  e ima ed ha he man fac ing lan  ld be
10,000 f 2. In de   en e ha  he mRNA emain able h gh  he ce , i  a
de e mined ha   d c i n facili  ld need  be a  4℃.  Li e a e e ima e  ha  he
c  f b ilding a c ld m ha  ha  he e  in la i n  be $250/f 2 60. The ef e, he c  f
b ilding  10,000 f 2 c ld m ld be:
𝐶𝑜𝑠𝑡 𝑜𝑓 𝐵𝑢𝑖𝑙𝑑𝑖𝑛𝑔 𝐶𝑜𝑙𝑑 𝑅𝑜𝑜𝑚 = 10, 000 𝑓𝑡2( $250
𝑓𝑡2
) = $2, 500, 000.
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In addi i n  he b ilding c , e al  e ima ed he c  f in alling 10 fan  ha  ld hel
en e ha  he b ilding emain  a  4℃. Thi  c e ima i n a  d ne ing he e i men
c ing ead hee  ided b  he c e in c . I  a  e ima ed ha  he al ba e m d le
c  f in alling 10 fan  i hin he lan  ld be $1,685,400. The ef e, he al c  f
b ilding a c ld m a  4℃ i :
𝐶𝑜𝑠𝑡 𝑜𝑓 𝐵𝑢𝑖𝑙𝑑𝑖𝑛𝑔 𝐶𝑜𝑙𝑑 𝑃𝑙𝑎𝑛𝑡 = $2, 500, 000 + $1, 685, 400 = $4, 185, 400.
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Appendi  D - Detailed Process Mass Balances
The ed man fac ing ce  a  ed  d ce 200 milli n d e   accina e
100 milli n e le. The able bel  de ail  he eekl d c i n. P -dil i n, he l me f a
ial i  he 0.45 mL f LNP hich e e filled a  he man fac ing i e and he 1.8 f 0.9%
S di m Chl ide f m he dil i n, ielding a al l me f 2.25 mL. Thi  l me i  di ided
in  d e  f 0.3 mL hich gi e  a ial  d e  a i f 7.5. Thi  a i  a  ed  calc la e he
n mbe  f ial  f m he eekl  d c i n f d e . Each a  e  CDC g ideline  each a  ha
195 ial  and each he mal c n aine  ha  5 a . Thi  a  ed  calc la e he n mbe  f
he mal c n aine .
Table D.1. Weekl  P d c i n Q an i ie
Component Weekl  Val e
D e 2,051,282.05
Vial 10.519.40
The mal c n aine 2,103.88
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Table D.2. In i o T an c i i n (IVT) Reac i n and P -IVT En me Dige i n Ma  Balance










Tris HCl 402.56 402.56 0 0 0
MgCl2 40.38 40.38 0 0 0
Dithiothreitol
(DTT)
170.87 170.87 0 0 0
Spermidine 32.18 32.18 0 0 0
Triton X-100 11.85 11.85 0 0 0
ATP 280.91 109.29 0 171.62 0
GTP 289.77 189.43 0 100.34 0
CTP 267.62 162.53 0 105.09 0
UTP 268.17 91.39 0 176.78 0
DNA
template
11.08 0 0 11.08 0
mRNA 0 520.62 553.85 33.23 0
T7 RNA
Pol merase
11.08 11.08 0 0 0
Cap Analog
(Clean Cap)
1,159.10 1,158.59 0 0.51 0
DNase I* 6.33 6.33 0 0 0





33,231.00 33,231.00 0 0 0
TOTAL 2,952.12 2,907.32 553.85 598.65 0
*added af e  he IVT eac i n (+5 h )
**Thi  i addi ional e a e  added af e  all he eac i n c m nen  ha e been added. Thi  i  n he al am n  f a e  in he eac i n.
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Table D.3. IVT Reac i n Final C ncen a i n























*T al eac i n l me = 110.8 L li e  
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Table D.4. Tangen ial Fl  Fil a i n (TFF) 1 Ma  Balance
Component Mass in (g) Mass o t inretentate (g)
Mass o t in
filtrate (g)
Mass
acc m lated (g)
mRNA 520.62 510.21 10.41 0
Tris HCl 402.56 0 402.56 0
MgCl2 40.38 0 40.38 0
Dithiothreitol
(DTT)
170.87 0 170.87 0
Spermidine 32.18 0 32.18 0
Triton X-100 11.85 0 11.85 0
ATP 280.91 0 280.91 0
GTP 289.77 0 289.77 0
CTP 267.62 0 267.62 0
UTP 268.17 0 268.17 0
T7 RNAP 11.08 0 11.08 0
CAP analog 1,158.59 0 1,158.59 0
DNase I 6.33 0 6.33 0
Phosphatase 0.22 0 0.22 0
Additional
WFI
1,136,454.00 33,231.00 1,103,223.00 0
TOTAL 1,139,372.38 33,741.21 1,105,631.17 0
Table D.5. TFF 1 Re en a e C ncen a i n
Component Concentration O t (g/L)*
mRNA 3.63
*T al e en a e l me = 110.8 L li e  
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Table D.6. Cell l e Ch ma g a h  Ma  Balance
Component Mass in (g)
Mass o t in
flo  thro gh
(g)
Mass bo nd to
col mn (g)
Mass
acc m lated (g)
HEPES 2,385,943.15 2,385,943.15 0 0
EDTA 29,259.95 29,259.95 0 0
NaCl 7,313,985.28 7,313,985.28 0 0
Ethanol 126,395.28 126,395.28 0 0
mRNA 505.10 505.10 0 0
dsRNA* 5.10 0.26 4.85 0
Additional WFI 874,264.22 874,264.22 0 0
TOTAL 10,730,358.08 10,730,353.23 4.85 0
*d RNA = d ble- anded RNA
Table D.7. Cell l e Ch ma g a h  Fl  Th gh C ncen a i n







*T al l me = 1001.23 L li e  
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Table D.8. TFF 2 Ma  Balance
Component Mass in (g) Mass o t inretentate (g)
Mass o t in
filtrate (g)
Mass
acc m lated (g)
mRNA 505.10 495.00 10.10 0
Sodi m
Acetate 5,179.49 517.95 4,661.54 0
HEPES 2,385,943.15 0 2,385,943.15 0
EDTA 29,259.95 0 29,259.95 0
NaCl 7,313,985.28 0 7,313,985.28 0
Ethanol 126,395.28 0 126,395.28 0
TOTAL 9,861,268.25 1,012.95 9,860,255.30 0
Table D.9. TFF 2 Re en a e C ncen a i n




*T al l me = 126.28 L li e  
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Mass o t (g) Massacc m lated (g)
mRNA 495.00 0 495.00 0
Sodi m
Acetate 517.95 14,663.70 15,181.65 0
TOTAL 1,012.95 14,663.70 15,676.66 0
Table D.11. P -Dil i n C ncen a i n




*T al l me = 3827.57 L li e  
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Mass o t (g) Massacc m lated (g)
mRNA 495.00 0 495.00 0
Sodi m
Acetate 15,181.65 0 15,181.65 0
Ethanol 0 973,440.30 973,440.30 0
ALC-0315 0 7,938.46 7,938.46 0
ALC-0159 0 923.08 923.08 0
DSPC 0 1,661.54 1,661.54 0
Cholesterol 0 3,692.31 3,692.31 0
TOTAL 15,676.66 987,655.69 1,003,332.34 0
Table D.13. P -Mic fl idic  C ncen a i n









*T al l me = 4935.06 L li e  
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Table D.14. TFF 3 Ma  Balance
Component Mass in (g) Mass o t inretentate (g)
Mass o t in
filtrate (g)
Mass
acc m lated (g)
mRNA 495.00 485.10 9.90 0
Sodi m
Acetate 15,181.65 0 15,181.65 0
Ethanol 973,440.30 0 973,440.30 0
ALC-0315 7,938.46 7,779.69 158.77 0
ALC-0159 923.08 904.62 18.46 0
DSPC 1,661.54 1,628.31 33.23 0






333,574.81 3,888.38 329,686.43 0
TOTAL 1,336,907.15 18,304.56 1,318,602.59 0
*1X PBS c n ain  a i m chl ide, m n ba ic a i m h ha e, di m chl ide, and diba ic di m h ha e h d a e
Table D.15. TFF 3 Re en a e C ncen a i n







*T al l me = 625.50 L li e  
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PBS and s crose
(g)
Mass o t (g) Massacc m lated (g)
mRNA 485.10 0 485.10 0
ALC-0315 7,779.69 0 7,779.69 0
ALC-0159 904.62 0 904.62 0
DSPC 1,628.31 0 1,628.31 0
Cholesterol 3,618.46 0 3,618.46 0
1X PBS 3,888.38 3,034.70 6,923.08 0
S crose 0 89,273.00 89,273.00 0
TOTAL 18,304.56 92,307.69 110,612.25 0
Table D.17. P -Final Dil i n C ncen a i n








*T al l me = 923.08 L li e  
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Appendi  E - Additional mRNA Seq ence Information
A  di c ed in Sec i n 2.1.2, mRNA ha  f  main c m nen : a 5  ca , n an la ed
egi n  (UTR ), an en eading f ame (ORF), and a l  (A) ail. We de igned he mRNA f
 accine ch ha  e ha e de e mined an e ac e ence  be ed in he accine. Thi
mRNA e ence incl de  he 5  UTR, he ORF, he 3 UTR, and he l  (A) ail. Thi  e ence
i  h n in Fig e E.1 i h a legend ha  ma  he egi n  f he e ence. The e ence i
4,079 ba e  l ng and ha  a m lec la  eigh  f 1306.23 kDa. Addi i nall , he b lded and
highligh ed egi n in Fig e E.1 hich an  6 ba e e e en   m a i n  ha  e e made
f m he ild- e ike ein. A  men i ned in Sec i n 2.1.2, he ORF i  he egi n ha  c de
f  he an igen f ch ice hich i  he SARS-C V-2 ike ein f  hi  accine. The i  ba e
highligh ed in he ORF egi n e e en   amin acid  (l ine and aline) ha  e e m a ed 
line ; he e m a i n  e e efe ed  a  K986P (l ine  line) and V987P ( aline 
line). The m a i n  e e made in he Pfi e -Bi NTech BNT162b2 mRNA accine again
COVID-19  main ain he ike ein in he e c nf ma i n. BNT162b2 al  c n ain  a
l  (A) ail ha  i  100 n cle ide  l ng,  ha l  (A) ail leng h a  ch en f  hi
e ence28. F he m e, he UTR e ence  e e b ained f m an mRNA accine candida e
f  he Zika i 66. Im an  al e  ega ding he mRNA e ence a e mma i ed in Table
E.1.
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Fig re E.1. E ac  mRNA e ence  be incl ded in he accine. Thi  e ence c n ain  he 5  UTR, he ORF, he
3  UTR, and he l  (A) ail.
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Table E.1. S mma  f mRNA Se ence Inf ma i n
Parameter Val e
Total Seq ence Length (bases) 4,079
Molec lar Weight of F ll Seq ence (kDa) 1,306.23
Length of Pol  (A) Tail (bases) 100
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Appendi  F- Process Flo sheet Diagrams
Thi  a endi  c e  he de el men  f he PFD and incl de  a  d af . F  cla i ,
nl  main d af  i e a i n  ill be e en ed in hi a endi  ince each i e a i n had m l i le
d af  and e i n  ha  e e c n ide ed.
Fig re F.1. D af  1 f PFD
The fi  d af  f he PFD incl ded he e   e a e and am lif  he DNA. Thi  e  i
em ed in f e e i i n  ince i  a  decided ha he DNA e a a i n ld be
ced. Thi  d af  al  incl de  he T7 RNA l me a e ec cle hich a  em ed ince
he half-life f he en me made i  in al able ec cle i . I  al  em e  he e   e a a e
T7 RNA l me a e ince hi  i  acc m li hed in he TFF. The c l mn in hi  d af  i  an i n
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e change c l mn hich a  la e  ecified  be a cell l e ch ma g a h  c l mn. Thi  d af
al  incl de  a dial i  e  af e  mic fl idic . Thi  e  a  em ed in f e d af  ince i  i
m e al able  en e he l i n in  he mic fl idic i  c m le el  a e  han  en e
hi  af e  he de ice. Thi  i  d ne in f e d af b  adding a e ile fil e  bef e mic fl idic
and ne igh  bef e ackaging.
Fig re F.2. D af  2 f PFD
Thi  d af  h  a change in he fi  a  f he ce , he am lifica i n and
e a a i n f la mid f  IVT. In hi  i e a i n, he e a a i n f DNA i  ced b  he
am lifica i n ha en  a  a  f he man fac ing ce . I  a  la e  decided ha  he
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am lifica i n ld al  be ced. Thi  i  beca e hi  a  f he ce  i  an ind
anda d and a ma e  f f ll ing c l. D ing he DNA am lifica i n in-h e d e  n
add al e  he man fac ing ce  ince i  i f ll ing an ind  anda d. Thi  d af
h  he e f a cell l e c l mn and he e f  TFF  and a e ile fil e   if  he
mRNA. In hi  d af , he inle   he fi  TFF i KCl b ffe , hi  b ffe  a  changed  be a e
ince he chl ide al  ld he i e need  be em ed in TFF 2. The bjec i e f he fi
TFF i   em e he en me  ed in he IVT ce and a e  can be ed a  a b ffe  f  hi
ce .
Fig re F.3. D af  3 f PFD
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Thi  d af  i e a i n h  he deci i n  ce he fi  a  f he ce  hich i
he am lifica i n and ifica i n f he la mid DNA. I  al  h  all f he ce  ni  and
he b ffe  ed in he final d af . I  h  MgCl2 a  a al  e i ing TFF2 b  hi  i  c ec ed in
la e  d af  ince i h a e  a  a b ffe  in TFF 1 in ead f KCl he al  i  n  l nge  d ced.
Thi  d af  h  he e f a ch ma g a h  b ffe  a h he cell l e c l mn,  dil e he
mRNA i   he c l mn and  make he cell l e e in. Thi  d af  h  he e f 5 16X
mic fl idic  de ice  in a allel  d  he LNP f m la i n e . Thi  n mbe  i  changed  25
16X mic fl idic  e  in he final ce   make he ce  ime l e .
Fig re F.4. D af  4 f PFD
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Thi  d af  f he PFD h  he ce  ni  in he ame manne  a  he final d af . The
nl  diffe ence i  ha  i  i  mi ing he ecifica i n f ce ain age ank  ed  e he
b ffe  f he TFF eac . In diffe ence  D af 3, i  ma k  ha  25 16X mic fl idic  de ice
ill be ed in a allel f  he LNP f m la i n.
Fig re F.5. Final D af  f PFD
The final d af  f he PFD i  he ne incl ded in he e . I  incl de  all he age
ank . I  al  incl de  he f mali ie  f n mbe ing e e  ce  ni  and age and a e
ank. I  incl de  a ma k n hen ali  c n l ill cc  b  ing he mb l f a a  and
incl de  he legend f  hi .
226
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There has been considerable discussion in the literature
recently pertaining to the Bacterial Endotoxins Test, its
significance and interpretation, and its comparison to the
USP rabbit test. The topic was previously briefly addressed
via Inspection Technical Guide No. 32, dated 1/12/79, with
the subject: Pyrogens, Still a Danger.
Because of the increased acceptance and use of the Bacterial
Endotoxins Test, ITG No. 32 is being updated.
The USP now recognizes two tests - The Pyrogen Test
conducted with rabbits and the Bacterial Endotoxins Test,
also termed the Limulus Amebocyte Lysate (LAL) Test.
DEPT. OF HEALTH, EDUCATION,
AND 
WELFARE PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
*ORA/ORO/DEIO/IB*
Date: 3/20/85 Number: 40 
Related Program Areas:
Drugs and Devices
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Additionally, the agency has approved the use of the
Bacterial Endotoxins Test for many drug and device
products. This ITG will focus on the significance and
interpretation of pyrogen/endotoxin testing. Also sources
and methods of depyrogenation will be discussed. The
limitations of the rabbit pyrogen test should be recognized
when reviewing systems during inspections of sterile drug
and device manufacturers.
History
The Federal Register, January 18, 1980, proposed guidelines
for determining endotoxins with the Limulus Amebocyte
Lysate Test (LAL). Subsequently, the draft guideline was
revised and reissued in 1983. The USP XX, 5th supplement,
revised the Bacterial Endotoxins Test. However, unlike the
FDA draft guideline, no retest provisions were included.
Most manufacturers are at some stage of validating the
Bacterial Endotoxin Test for their products.
The USP's subcommittee responsible for revisions of
compendial test methods and/or product monographs has,
in the past few years, made some significant changes in the
bacterial endotoxin test and product monograph
requirements. In 1984, five USP water products were given
specific bacterial endotoxin limits. Water for Injection,
Sterile Water for Injection and Sterile Water for Irrigation
have an allowable endotoxin limit of 0.25 Endotoxin Units
(EU)/ml. (EU=Unit of measurement for endotoxin activity).
However, Bacteriostatic Water for Injection and Sterile
Water for Inhalation have been given a slightly higher
bacterial endotoxin limit of 0.5 EU/ml (USP - Supplement
4a - 1984). The agency has recognized the benefits of the
Bacterial Endotoxins Test, particularly with respect to
sensitivity, reproducibility, scope and simplicity.
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Additionally, both FDA inspections and FDA testing
programs have identified objectionable levels of endotoxin in
drugs and devices.
Some finished products tested, although not found
actionable because of the low dose of product to be
administered, could be indicative of pyrogen problems in
other systems, such as a Water for Injection System. For
example, a particular product such as Cyanocobalamin Inj.,
can have an endotoxin concentration of 10 EU/ml and be
considered as in compliance. However, one could question
the manufacturer's Water for Injection (WFI) System since
the WFI System should have a level of .25 EU/ml.
There is considerable discussion in the literature pertaining
to endotoxicity versus pyrogenicity. Many of the FDA
investigators and reviewers of inspection reports are
unaware of the limitations of the USP rabbit test as an
endotoxin test. For example, Elin, in the Annual Review of
Medicine, commented that "The repeated administration of
lipopolysaccharide (LPS), the chemical name used
synonymously with bacterial endotoxins, to experimental
animals results in a progressive diminution of some of the
biological effects, especially fever. The precise mechanism of
this phenomenon, termed endotoxin tolerance, is unknown".
Also, some studies have shown that the endotoxin of the
Legionnaires' bacillus has a different spectrum of toxicity
than the more common gram-negative organisms. In
particular the Legionnaires' endotoxin was not very
pyrogenic (by the rabbit test), but was very active in the LAL
- 1,000 fold difference between the two tests. In this
situation, the rabbit test is inadequate for determining the
potency of the toxins present.
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The USP pyrogen test has additional limitations besides
endotoxin tolerance and low reactivity to legionnaires'
endotoxin. Among these are its variability in test results
when compared to the same preparation of standardized
endotoxin. This condition is influenced by seasonal
variation, interlaboratory factors, rabbit species to species
characteristics, and other biological influences. The test is
inadequate for certain classes of drugs including
radiopharmaceuticals, cancer chemotherapeutic agents,
hypnotics and narcotics, vitamins, steroids and certain
antibiotics. It has been found that apparent pyrogens in the
product can be "masked" by the physio-chemical activity of
the therapeutic drug components. In addition, the rabbit test
is insufficiently sensitive for endotoxin detection in
intrathecal drug products.
There is also little recognition of the clinical significance of
endotoxin. Possibly this is because the most emphasized
pathogenic effect of gram negative disease is the production
of fever, and of all of the effects of endotoxin, fever is
probably the least important biologically and clinically.
Although many manufacturers are working with LAL, there
are still some manufacturers who are reluctant to employ
LAL because it is too sensitive.
In addition to the sensitivity of the test, greater numbers of
dosage units/devices can be tested using LAL. For example,
a sterile critical device was found to have an acceptable
endotoxin level from a pooled sample. (Note: The USP
pyrogen test is performed on a pooled sample.) However,
when extracts of units were LAL tested individually,
occasional failures were noted. A similar situation occurred
in a sample of Bacteriostatic Water for Injection. A pooled
sample from a number of units was found to have endotoxin
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levels of less than 0.5 EU/ml. However, some specific dosage
units were found to exceed this 0.5 EU/ml USP limit and
Regulatory Action was taken.
Characteristics of Bacterial Endotoxin
"Microbial pyrogen" as opposed to "gram negative bacterial
endotoxin" has become a general descriptive term for many
different substances. However, pyrogenic substances can be
produced by some gram positive bacteria, mycobacteria,
fungi and also viruses, but the pyrogens produced by gram
negative bacteria, i.e., the endotoxins, are of significance to
the pharmaceutical industry.
Bacterial endotoxins, found in the outer membrane of gram-
negative bacteria are members of a class of phospholipids
called lipopolysaccharides (LPS). LPS are not exogenous
products of gram negative bacteria. The release of LPS from
bacteria takes place after death and lysis of the cell. Good
examples of pyrogen producing gram- negative bacteria are
Escherichia coli, Proteus, Pseudomonas, Enterobacter and
Klebsiella.
Formula Used to Calculate the Endotoxin Limit for
Individual Drug Products
The effects of endotoxin are related to the amount of
endotoxin in the product dose administered to a patient.
Because the dose varies from product to product, the
endotoxin limit is expressed as K/M. K is 5.0 EU/kilogram
(kg.), which represents the approximate threshold pyrogen
dose for humans and rabbits. That is the level at which a
product is adjudged pyrogenic or non-pyrogenic. M
represents the rabbit pyrogen test dose or the maximum
human dose per kilogram that would be administered in a
single one hour period, whichever is larger. If a product is
labeled for intrathecal injection, then K is 0.2 EU/kg.
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However, there are 5 water products (previously discussed)
which, because of the large volumes that can be
administered and absence of dose limitation, have specific
endotoxin limits per ml.
Example 1 - A non-intrathecal drug product that has a
maximum human dose of 10 ml/kg.
Endotoxin limit = K 5 EU/kg - = ------- = 0.5 EU/ml M 10
ml/kg
Example 2 - Product: Cyanocobalamin Inj. Potency: 1000
mcg/ml
Maximum Dose/kg 14.3 mcg/kg (see product labeling)
Endotoxin Tolerance Limit = 5.0 EU/kg - non-intrathecal
drug
Endotoxin Limit = K 5.0 EU/kg - = --------- = 0.35 EU/mcg
M 14.3 mcg/kg
This value (0.35 EU/mcg) is expressed in Endotoxin Units
per mcg of product. In order to convert this value to a
endotoxin unit concentration per ml, multiply it (0.35
EU/mcg) by the product potency (see below).
1000 mcg/ml x 0.35 EU/mcg = 350 EU/ml
This determined value means that if a parenteral drug
manufacturer is using the LAL method for endotoxin testing
of Cyanocobalamin Inj., the product can have no more than
350 EU/ml of product.
LAL Methods - Some Inherent Weaknesses
The FDA and USP have recognized the validity of various
approaches to using LAL for endotoxin testing. There are
four basic methods commercially available and currently
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approved by FDA for end-product release testing: (i) the gel-
clot; (ii) the turbidimetric (spectrophotometric); (iii) the
colorimetric (Lowry protein); and (iv) the chromogenic
assay. The LAL reagents used in these methods must be
obtained from an FDA-licensed manufacturer and must be
designed specifically for the method chosen. Many of the
other LAL methods appearing in the literature are
modifications of the gel-clot or turbidimetric test and some
have been designed to use less LAL than the basic method.
Certain products have been known to interfere with the
LAL's ability to react with endotoxin. These factors may be
chemical or physical. Chemical inhibitors cause chelation of
divalent cations necessary for the LAL reaction (i.e. EDTA),
protein denaturation (i.e. fluorescein), or pH disruption (i.e.
pH outside 6.0 - 7.5 range). Physical inhibitors include
adsorption of endotoxin, or product viscosity. Most will
affect all methods although the degree of inhibition may
vary. However, most of the inhibition can be overcome by
dilution of the product. Other factors such as the shape and
type of glassware used in the gel-clot test can also affect the
validity of the test. For example, siliconized glassware as well
as plastic can inhibit gel-clot formation or prevent accurate
spectrophotometric readings of the reaction mixture end
point.
Turbidimetric and chromogenic methods cannot be used
with certain turbid or colored products. Additionally,
precipitate formation, although inhibitory, may be mistaken
for a positive response in these methods. One problem
associated with the use of the chromogenic method is the
formation of a precipitate following the addition of acid to
stop color development. Products that require a neutral or
basic pH for solubility are most likely to cause this problem.
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The necessity to validate the reliability and accuracy of the
LAL method for each product tested cannot be over-
emphasized. Manufacturers can demonstrate this by
inoculating the product with low levels of endotoxin and
assay for their recovery. The endotoxin concentrations used
should be within the lower range of the lysate sensitivity. In
addition, several researchers have found that even the
selection of lysate reagent source (i.e., the manufacturer of
the lysate) can contribute to variability in test results.
Therefore, if any change in reagent source is made, the test
must be re-validated.
There have been several revisions to the analytical
procedures outlined in the bacterial endotoxin test since it
was first issued in 1980. These changes have enabled the
LAL method to be more reliable as a compendial referee test.
The significant changes are (i) After dilution of endotoxin
through a parallel set of solutions, one containing water and
the other pH adjusted product, the end point for the reaction
mixtures between the two sets should not differ by greater
than a two-fold difference; (ii) If the product affects the
lysate test mixture, then any dilution between the inhibition
endpoint and the MVD can be used; (iii) The maximum a
product may be diluted for testing is to be determined using
the maximum valid dilution (MVD) formulae. The formula is
based upon the product dosage, endotoxin tolerance limit
and the lysate sensitivity. Product dilution beyond this
determined factor will render a negative result meaningless.
Harmful endotoxin concentrations may be diluted below the
detectable range of the lysate; (iv) Vague procedures for
washing bacterial endotoxins from medical device products.
Careful attention for not using excessive volumes for product
rinsing is mentioned.
Sources
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There can be several sources of pyrogens in parenteral and
medical device products. Usual sources are: the water used
as the solvent or in the processing; packaging components;
the chemicals, raw materials or equipment used in the
preparation of the product. Good practice would include
control of the microbiological and endotoxin levels of
contamination in the potential sources mentioned above.
For parenteral products, inspections have shown that where
pyrogen problems were found in dosage forms, and when
the source was one of the raw materials, it was the active
drug substance. This was particularly true for drug
substances in which process water was used at some late
stage in the synthesis process. Endotoxin levels of the drug
substance were subsequently lowered when the
microbiological levels of the process water were lowered and
the process water system was controlled.
Additionally, if the drug substance is biologically produced,
the incomplete removal of the microorganism during
purification can result in the drug substance having high
endotoxin levels. Examples include antibiotics produced by
fermentation or the by-products of gram negative bacteria
used to produce genetically engineered drug products. The
potential use of yeast in this area is being evaluated to
eliminate this problem.
General processing procedures for physical components of
parenteral products such as stoppers and vials, provide for
washing these components with pyrogen-free water prior to
sterilization. Good practice would include minimal handling
of the component after washing and prompt sterilization
particularly if sterilized by steam. Storing non-sterile wet
stoppers could lead to an increase in microorganisms and
possibly endotoxin levels.
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Another source of endotoxins is the Water for Injection
(WFI) or pyrogen-free water system. As a general comment,
circulating hot water systems (above 75 C) provide the
environment least conducive to microbial growth and
endotoxin formation. Circulating Water for Injection
Systems at lowered temperatures (at approximately 60 C)
are somewhat (marginally) controlled by the temperature of
the system. There is some concern that there can be some
pathogenic gram negative organisms, such as Legionella
pneumophilia, that will survive and grow at 57 C. There is
considerable information on the presence of L.
pneumophilia in hospital hot water systems. Literature has
shown that periodically raising the temperature of these hot
water systems to 75 - 80 C has eliminated the organism.
Generally, ambient temperature WFI systems present the
greatest problem. Many of the objectionable microorganisms
which are good sources of endotoxins grow well in cold WFI
systems. This is particularly true of Reverse Osmosis (RO)
systems. It has been recognized that since Reverse Osmosis
filters are not absolute, it may be necessary to have them in
series in order to manufacture pyrogen-free WFI.
As previously discussed, the growth of some types of
microorganisms contributes to increased levels of endotoxin.
Non-sterile bulk inprocess or formulated solutions,
particularly the preservative-free solutions, are a good
environment for microbial growth. It is not common practice
for manufacturers to perform endotoxin testing on these
solutions. Most perform microbiological testing in order to
determine the microbiological level (Bio-burden) prior to
subjecting the solution to a sterilization process. However, in
order to determine the potential for high endotoxin levels, it
would be advisable to perform microbiological testing prior
to performing any sterilizing steps. For example, if a product
is formulated and filtered prior to a final sterilization,
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microbiological testing of the Bio-burden after filtration will
provide some useful information for the determination of
the adequacy of the sterilization process. However, it will
provide little, if any, information pertaining to the adequacy
of the process with respect to minimizing endotoxin
contamination. Since endotoxins result from high levels of
microorganisms, and are not removed by sterilizing or
microbiological filters, the subsequent reduction of a high
microbiological level will not be associated with a similar
reduction of high endotoxin level.
As with parenteral drug products, sterile devices have
occasionally been shown to be contaminated with
endotoxins. Sources have been water which somehow
entered into the manufacturing process. For example, the
washing of components such as filter media to be used for
the manufacture of filters, or the washing/rinsing of tubing
or other plastic devices prior to subsequent sterilization are
potential sources of endotoxins.
Depyrogenation
It is difficult to remove endotoxins from products once
present. It is far better to keep finished products and
components relatively endotoxin-free rather than have to
remove it once present.
The most common depyrogenation procedures for physical
components include incineration and removal by washing,
also termed dilution. The literature has shown other
procedures, such as filtration, irradiation and ethylene oxide
treatment to have limited effect in reducing
pyrogen/endotoxin levels. For Water for Injection systems,
the two acceptable ways of manufacture are distillation and
Reverse Osmosis.
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Distillation has been shown to be effective and the most
reliable method in removing endotoxin from contaminated
water samples. Isolated problems related to splashing in the
still and subsequent distillate contamination have been
identified. Similarly, isolated problems with condensers or
heat exchangers have been known to occur. Refer to ITG NO.
34, dated 7/31/79, for an additional discussion of heat
exchangers.
As with most processes and pieces of equipment, it is good
pratice to know the limitations and/or capabilities of
equipment. For example, stills with high levels of endotoxins
in feed water have occasionally been shown to yield WFI of
unacceptable quality ( >.25 EU/ml). More so, when WFI is
produced by Reverse Osmosis (RO), the endotoxin level of
feed water should be known. Since RO filters are not
absolute, it may be necessary to have them in series in order
to manufacture pyrogen-free WFI. Whichever system is
employed, good practice would include the ability to isolate
and evaluate each piece of equipment in a WFI system. Refer
to ITG No. 36, dated 10/21/80, for a discussion of Reverse
Osmosis.
For physical components, such as stoppers and tubing,
rinsing or dilution with pyrogen-free water systems is most
common. Some manufacturers, such as LVP manufacturers,
are employing dilution to remove endotoxin from glass
containers which are then sterilized by other means. As with
validation for sterility, validation for endotoxin reduction
should include a knowledge of the endotoxin burden and a
satisfactory endotoxin challenge. It should be pointed out
that due to the lack of sensitivity of the USP pyrogen test
conducted on rabbits, "challenge" testing should be
conducted employing the Limulus Amebocyte Lysate Test.
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Although there is no guide in this area, it would be expected
that there be at least a 3 log reduction below the endotoxin
challenge when the dilution process is employed.
Historically, vials or glass components have been rendered
pyrogen-free by dry heat sterilization at high temperatures.
Some texts have recommended the depyrogenation of
glassware and equipment by heating at a temperature of 250
C for 45 minutes. It has been reported that 650 C for 1
minute or 180 C for 4 hours, likewise, will destroy pyrogens.
Studies by Tsuji et al, published in 1978, have shown that at
lower temperatures (of 170 C), thermal destruction follows
second-order rate, and a 3 log reduction of endotoxin levels
at lower temperatures might not be practical.
There are other less common methods employed for
removing endotoxins. In the manufacture of sterile powders,
crystallization or purification is commonly employed to
remove endotoxins. Some manufacturers have occasionally
resorted to less acceptable methods such as washing or
rinsing the crystal or powder with a solvent in order to
remove endotoxins.
NOTE: Using dilution or rinsing is acceptable for a physical
component such as a stopper or vial which is not going to be
injected. However, when employing it for a chemical
component, it is only of limited value. There can be only
assurance that the endotoxin level on the outer surface of the
powder is reduced and not throughout the crystal.
Other less generally acceptable methods include ethylene
oxide treatment and irradiation. It has been shown that
reductions of approximately 80% in the pyrogenicity of E.
coli endotoxin in dialyzers have occurred after exposure to
ethylene oxide.
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With respect to manufacturing equipment and transfer lines,
depyrogenation by dilution has usually been the method of
choice. Utilization of strong alkali or oxidizing solution has
occasionally been employed to reduce pyrogens in these
storage/delivery systems. However, it should be followed by
rinsing with Water for Injection. Residues in the rinse
solution of less than 1 part per million (ppm) can be
achieved and have been accepted.
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  Store vaccine in an ultra-cold freezer, thermal shipping 
container, freezer, or refrigerator. See guidance below  
for each storage unit. 
  Follow the manufacturer’s instructions for returning  
the thermal shipping container. 
  Each thermal shipping container holds up to  
5 trays of vaccine.
 » Each tray contains 195 multidose vials (1,170 doses).
 » A vaccine tray is approximately  9 in x 9 in x 1.5 in.
  Check and record storage unit temperatures each 
workday. See guidance below for each type of storage 
unit. Save storage records for 3 years, unless your 
jurisdiction requires a longer time period.
 !Deliveries
Vaccine
Use CDC's Delivery Checklist for P"zer-BioNTech Vaccine when accepting a delivery and unpacking vaccine.  
When vaccine is delivered:                         
1. Open the thermal shipping container. Press the stop 
shipment button on the temperature monitoring 
device for 5 seconds. 
2. The LED indicator light will change to a solid color and a 
temperature status report will be e-mailed to the person 
who ordered the vaccine.
3. Proceed based on the color of the LED indicator light: 
No color or red: Wait for the status report.  
Green: Unpack the vaccine. 
4. Follow the manufacturer's guidance for unpacking the 
vaccine. Inspect the trays.    
 » Do not open the vial trays or remove vials until ready to 
thaw/use the vaccine.
 » If storing the vaccine at ultra-cold temperatures, return 
vaccine to frozen storage within 5 minutes.
Dry Ice Safety
1. Dry ice is needed to maintain proper temperatures in 
the thermal shipping container. 
2. Ensure sta# has proper PPE and is trained to handle 
dry ice safely.  
3. Do not use or store dry ice in con"ned areas, walk-
in refrigerators, environmental chambers, or rooms 
without ventilation. A leak in such an area could cause 
a depletion of oxygen in the atmosphere, which may 
lead to asphyxiation. 
Ancillary Supply Kit
An ancillary supply kit will be delivered separately from the vaccine and includes:  
  Mixing supplies: Diluent, needles, syringes, and sterile 
alcohol prep pads 
 » Mixing supplies are packaged separately with a green 
identi"cation label.
 » Do NOT use mixing supplies to administer vaccine.
  Administration supplies: Needles, syringes, sterile alcohol 
prep pads, vaccination record cards, and some PPE.      
Each ancillary supply kit contains enough supplies to mix and administer 1 tray of vaccine.
Pfizer-BioNTech COVID-19 Vaccine




Storage and Handling Summary
03/03/2021 CS321570-I
 !Thermal Shipping Container 
CDC recommends providers consider using the thermal shipping container for temporary storage only. The container requires 
signi"cant support to store vaccine at proper temperatures, including trained sta#, a regular supply of dry ice, and standard operating 
procedures for regular maintenance. 
Use the Controlant temperature monitoring device (TMD) 
included with the thermal shipping container to monitor  
the temperature. 
  Review contact information.  
 » If the contact for your order (inVTrckS) is not valid, you  
will NOT be noti"ed in the event of a temperature  
excursion. Contact your jurisdiction's immunization  
program for assistance.
 » If your contact is valid and you are not receiving e-mails 
or cannot load email hyperlinks, refer to Controlant for 
troubleshooting (https://in.controlant.com/onsitemonitoring).
 » Identify up to 4 contacts to receive e-mails and text alerts on 
the container's temperature status.
  Review DAILY e-mails on the status of the container.
  Click the link in daily e-mails to access and download 
all temperature data. Save the Excel "le summarizing all 
temperature data for at least 3 years.
  Save the return shipping label provided in your shipping 
container at delivery. Use the shipping label to return the 
thermal shipping container with Controlant TMD after 30 days.
  Replenish dry ice pellets (10 mm to 16 mm) within 24 hours 
of delivery and every 5 days thereafter. Follow manufacturer’s 
guidance for adding dry ice.
  Dry ice will be sent for the "rst re-icing unless you opt out when 
placing the vaccine order.
  Additional dry ice shipments will NOT be provided. Arrange  
for dry ice to maintain the temperature of the container after the 
"rst re-ice. 
Removing vaccine vials/doses for use: 
  Determine the number of vials needed before opening the 
thermal shipping container. 
  Open the thermal shipping container no more than 2 times per 
day for up to 3 minutes each time. Use packaging tape  
to reseal the outer carton after each entry.
   Store vaccine vials upright in the tray and protect from light.
 !Ultra-Cold Freezer
Before mixing, the vaccine may be stored in an ultra-cold freezer between  
-80°C and -60°C (-112°F and -76°F).
  Store vaccine vials upright in  
the tray. 
  Protect from light.
  Vaccine may be stored until the  
expiration date. 
 » As the expiration date approaches, 
contact the manufacturer to 
determine if it has been extended.  
Do not discard vaccine without 
ensuring the expiration date has 
passed. 
 !Freezer
Before mixing, the vaccine may be stored in the freezer between -25°C and -15°C (-13°F to 5°F) for up to 2 weeks. The total time vials 
are stored at these temperatures should be tracked and should not exceed 2 weeks. 
  These temperatures are within the appropriate range for  
routinely recommended vaccines, BUT the temperature range 
for this vaccine is tighter. 
  If storing the vaccine in a freezer with routinely recommended 
vaccines, carefully adjust the freezer temperature to the correct 
temperature range for this vaccine. 
  Use CDC’s freezer storage temperature log for COVID-19 
vaccine to document storage unit temperatures.
  Monitor how long the vaccine has been in the freezer  
using CDC’s beyond-use date labels for P"zer-BioNTech  
COVID-19 vaccine. 
 » Vaccine stored in the freezer can be transferred to 
refrigerator storage for an additional 120 hours (5 days). 
  Store the vaccine in the tray.
  Protect from light. 
  Do not use dry ice for freezer storage.
  Vials stored in the freezer may be returned one time to ultra-
cold temperature storage (-80ºC to -60ºC [-112ºF to -76ºF]).
  Once returned to ultra-cold storage, the 2-week time frame  
is suspended. 
Store vaccine in the FREEZER between -25°C and -15°C 





Today’s date: ____/____/_______ Time:
 
 
Date: ____/____/_______ Time:  
 
*If the 2-week deadline is met, move any  
remaining vials to refrigerated storage for an  
additional 120 hours (5 days). Use a refrigerator  
beyond-use date (BUD) label to 















3For additional information, refer to the manufacturer's website at www.cvdvaccine.com
Pfizer-BioNTech COVID-19 Vaccine
Storage and Handling Summary
03/03/2021 CS321570-I
 !Refrigerator 
Before mixing, the vaccine may be stored in the refrigerator between 2°C and 8°C (36°F and 46°F) for up to 120 hours (5 days). After 120 
hours (5 days), contact the manufacturer for guidance. If directed to discard any remaining vials, follow the manufacturer's and your 
jurisdiction's guidance for proper disposal.
  Monitor how long the vaccine has been in the  
refrigerator using CDC’s beyond-use date labels for  
P"zer-BioNTech COVID-19 vaccine. 
  Store the vaccine in the tray.
  Protect from light. 
  Do NOT refreeze thawed vaccine.
 !Temperature Monitoring 
Ultra-cold freezer, freezer, refrigerator: Storage unit temperatures must be monitored regularly, checked, and recorded at the 
beginning of the workday to determine if any temperature excursions have occurred since the last temperature check. For accurate 
temperature monitoring, use a digital data logger (DDL) with a detachable probe that best re$ects vaccine temperatures. 
  Ultra-cold temperatures: Use a probe designed speci"cally to 
measure ultra-cold temperatures.
  Frozen and refrigerated storage: Use a probe bu#ered with 
glycol, glass beads, sand, or Te$on®.
Check and record the temperature daily using CDC’s temperature log. Use one of the options below:
  Option 1 (preferred): Minimum/Maximum  
(Min/Max) Temperature  
Most DDLs display min/max temperatures. Check and record  
the min/max temperatures at the start of each workday.
  Option 2: Current Temperature  
If the DDL does not display min/max temperatures, check and 
record the current temperature at the start and end of the 
workday. Review the continuous DDL temperature data daily.
Thermal Shipping Container: Use the Controlant temperature monitoring device (TMD) included with the thermal shipping 
container to monitor the temperature. See thermal shipping container information above.  
 !Diluent 
0.9% sodium chloride (normal saline, preservative-free) diluent is included in the ancillary supply kits. Follow the manufacturer’s 
guidance for storing the diluent. 
 !Mixed Vaccine
  Once mixed, vaccine can be left at room temperature  
(2°C to 25°C [35°F to 77°F]) for up to 6 hours. 
  Discard any remaining vaccine after 6 hours.
  Mixed vaccine should NOT be returned to freezer storage. 
  Mixed vaccine does not need to be protected from light. 
 
CDC's P!zer-BioNTech COVID-19 Vaccine materials https://www.cdc.gov/vaccines/covid-19/info-by-product/p"zer/index.html
CDC's Vaccine Storage and Handling Toolkit https://www.cdc.gov/vaccines/hcp/admin/storage/toolkit/storage-handling-toolkit.pdf
CDC's P!zer Beyond-Use Date (BUD) labels https://www.cdc.gov/vaccines/covid-19/info-by-product/p"zer/downloads/bud-tracking-labels.pdf
CDC's Delivery Checklist https://www.cdc.gov/vaccines/covid-19/info-by-product/p"zer/downloads/delivery-checklist.pdf
CDC's Freezer and Refrigerator Temperature Logs https://www.cdc.gov/vaccines/covid-19/info-by-product/p"zer/index.html
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FACT SHEET FOR HEALTHCARE PROVIDERS ADMINISTERING 
VACCINE (VACCINATION PROVIDERS) 
EMERGENCY USE AUTHORIZATION (EUA) OF 
THE MODERNA COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019 
(COVID-19) 
 
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization 
(EUA) to permit the emergency use of the unapproved product, MODERNA COVID-19 
VACCINE, for active immunization to prevent COVID-19 in individuals 18 years of age and 
older. 
 
SUMMARY OF INSTRUCTIONS FOR COVID-19 VACCINATION PROVIDERS 
Vaccination providers enrolled in the federal COVID-19 Vaccination Program must report all 
vaccine administration errors, all serious adverse events, cases of Multisystem Inflammatory 
Syndrome (MIS) in adults, and cases of COVID-19 that result in hospitalization or death 
following administration of the Moderna COVID-19 Vaccine. See “MANDATORY 
REQUIREMENTS FOR MODERNA COVID-19 VACCINE ADMINISTRATION UNDER 
EMERGENCY USE AUTHORIZATION” for reporting requirements. 
 
The Moderna COVID-19 Vaccine is a suspension for intramuscular injection administered as a 
series of two doses (0.5 mL each) 1 month apart. 
 
See this Fact Sheet for instructions for preparation and administration. This Fact Sheet may have 
been updated. For the most recent Fact Sheet, please see www.modernatx.com/covid19vaccine-
eua. 
 
For information on clinical trials that are testing the use of the Moderna COVID-19 Vaccine for 
active immunization against COVID-19, please see www.clinicaltrials.gov. 
 
DESCRIPTION OF COVID-19 
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the novel coronavirus, 
SARS-CoV-2, that appeared in late 2019. It is predominantly a respiratory illness that can affect 
other organs. People with COVID-19 have reported a wide range of symptoms, ranging from 
mild symptoms to severe illness. Symptoms may appear 2 to 14 days after exposure to the virus. 
Symptoms may include: fever or chills; cough; shortness of breath; fatigue; muscle and body 
aches; headache; new loss of taste or smell; sore throat; congestion or runny nose; nausea or 
vomiting; diarrhea. 
 
DOSAGE AND ADMINISTRATION 
 
Storage and Handling 
The information in this Fact Sheet supersedes the information on the vial and carton labels.  
 
During storage, minimize exposure to room light. 
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Data are not available to assess the effects of Moderna COVID-19 Vaccine on the breastfed 
infant or on milk production/excretion.  
 
11.3  Pediatric Use 
Safety and effectiveness have not been assessed in persons less than 18 years of age. Emergency 
Use Authorization of Moderna COVID-19 Vaccine does not include use in individuals younger 
than 18 years of age.  
 
11.4 Geriatric Use 
Clinical studies of Moderna COVID-19 Vaccine included participants 65 years of age and older 
receiving vaccine or placebo, and their data contribute to the overall assessment of safety and 
efficacy. In an ongoing Phase 3 clinical study, 24.8% (n=7,520) of participants were 65 years of 
age and older and 4.6% (n=1,399) of participants were 75 years of age and older. Vaccine 
efficacy in participants 65 years of age and older was 86.4% (95% CI 61.4, 95.2) compared to 
95.6% (95% CI 90.6, 97.9) in participants 18 to <65 years of age [see Clinical Trial Results and 
Supporting Data for EUA (18)]. Overall, there were no notable differences in the safety profiles 
observed in participants 65 years of age and older and younger participants [see Overall Safety 




Moderna COVID-19 Vaccine is provided as a white to off-white suspension for intramuscular 
injection. Each 0.5 mL dose of Moderna COVID-19 Vaccine contains 100 mcg of nucleoside-
modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of 
SARS-CoV-2 virus. 
 
Each dose of the Moderna COVID-19 Vaccine contains the following ingredients: a total lipid 
content of 1.93 mg (SM-102, polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG], 
cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]), 0.31 mg tromethamine, 
1.18 mg tromethamine hydrochloride, 0.043 mg acetic acid, 0.20 mg sodium acetate trihydrate, 
and 43.5 mg sucrose. 
 
Moderna COVID-19 Vaccine does not contain a preservative.  
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DECLARATION OF CONFORMITY 







iThe system mentioned above is manufactured in Millipore S.A.S. - 67120 Molsheim - 
FRANCE - facilities whose quality management system is approved by an accredited 
registering body to the ISO9001 Quality System Standards. 
 
iWe certify that these Lab Water Systems are designed and manufactured in application of 
the following European Council directives :  
 
- 89/336/CEE relating to Electromagnetic compatibility 
- 73/23/CEE relating to electrical equipment designed for use within certain 
voltage limits 
 
i Standards to which conformity is declared as applicable are the following : 
 
EN 50082-1 Edition 1992 : Electromagnetic compatibility : generic 
immunity standard 
EN 55022 Edition 1987: Limits and method of radio-disturbance 
characteristics of information technology equipments. 
EN 61326-1 Edition 1997 / A1 Edition 1998: Electrical equipment for 
measurement, control and laboratory use - EMC requirements. 
EN 61000-3-2 / A1 and A2 Edition 1998 / A14 Edition 2000 : Limits 
for harmonic current emissions (equipment input current up to and 
including 16A per phase) 
EN 61010-1 : 1993 / A2 : 1995 : Safety requirements for electrical 
equipment for measurement, control and laboratory use. 
 
 






 Quality Assurance Manager 
 Millipore S.A.S. 
 



































The Millipore Super-Q Water Systems are modular systems designed to provide the “final 
polish” to water that has been pre-treated by purification methods such as reverse osmosis 
(RO), deionization (DI) or distillation. Super-Q Systems can produce up to 12 L/min of high 
purity water; free of ionic contamination up to 18 megohm-cm resistivity level, and free from 
particulate and microbiological contamination to an absolute size level determined by the 
pore size of the Millipore filter element used. With the appropriate cartridges installed in the 
proper configuration, a level of down to 20 ppb TOC may be achieved for organic removal. 
 
 
Super-Q Systems produce water that is pure enough for critical applications such as atomic 
absorption (AA) spectrophotometry, high performance liquid chromatography (HPLC), tissue 
culture media preparation, electronics rinse water, and total organic carbon (TOC) analysis. 
They are designed to produce water that exceeds C.A.P. (College of America Pathologists), 
A.S.T.M. (American Society for Testing and Materials), N.C.C.L.S. (National Committee for 
Clinical Laboratory Standards), and A.C.S. (American Chemical Society) standards for Type 
I Reagent Grade Water. 
 
 
Super-Q product water is intended for immediate use because such high quality water 
deteriorates when stored, or exposed to the environment. 
 
 
There are both Standard and Plus (Recirculating) Models. The recirculating Super-Q Plus 
System includes a pump and is recommended for single point-of-use applications with 
intermittent demands. The Standard, non-recirculating system, which requires additional 
accessories, is designed for multiple point-of-use applications. 




All Super-Q Systems consist of a series of three or four housings, each of which holds a 
disposable cartridge. Each cartridge provides a particular function such as prefiltration, 
organic adsorption, deionization and final Millipore membrane filtration to particle retention 
levels ranging to 0.22 µm. The full flow of feed water passes from the various cartridges 
through a temperature-compensated (25°C) resistivity sensor that monitors ionic purity over 
an effective range from 1.5 to 18.2 megohm-cm. 
 
 
For Technical assistance with your system, please contact your local representative or 









Super-Q Systems Specifications 
 
 
 Component    Materials of Construction 
 Support bracket   Stainless steel 
 Meg-O-Meter housing  Vacuum-formed plastic 
 PL housing and heads   Polypropylene, nylon 
 Hardware 
 (Screws, nuts, washers)  Stainless steel 
 Sensor housing   White polypropylene 
 
 Connections 
 Inlet :  1/2” NPTF F&T fitting 
 Outlet : 1/2” NPTF F& T fitting 
 
 Dimensions   
 
    3 BOWLS    4 BOWLS 
 Height :  800 mm (26.6 ft)   800 mm (26.6 ft) 
 Width :  945 mm (31.5 ft)   1 150 mm (38.3 ft) 
 Depth :  220 mm (7.3 ft)   220 mm (7.3 ft) 
 
 Electrical Requirements 
 The system must be electrically connected to an earth grounded power supply. 
 220V / 50Hz, 2A  Fuse : 2AT 250V  5 x 20mm 
 115V / 60Hz, 5 A  Fuse : 5AT 250V  5 x 20mm 
 
 Feed Water Requirements 
 Operating Temperature : 5°C - 40°C (41°F - 104°F) 
 Feed Water Pressure :  Minimum : 0.5 psi (0.03 bar). 
     Maximum : 
      Super-Q Plus Systems : 
       15 psi (1 bar). If greater, please use a 
       pressure regulator. 
      Standard Super-Q Systems : 
       depends upon pump specifications, not to 
       exceed maximum system pressure of 80 
       psi (5.5 bar). 
 
 Environmental conditions : 
 Ambient storage temperature : 10°C - 40°C (50°F - 104°F). 





 Typical System Performance 
 Resistivity  : 18.2 Megohms-cm at 25°C. 
 Organic  : < 20 ppb (*). 
 Microorganisms : < 10 cfu/ml (**) 
 
 (*) When an Organex-Q™ cartridge is used and the system is fed with Reverse 
  Osmosis water. 
 
 (**) With 0.22 µm final filtration immediately prior to the point-of-use. 







 Expendable*      Catalogue Nbrs 
 
 Milligard TP Prefilter cartridge, 20”, 3/pk  CWSC02TP3 
 Super-C Carbon cartridge, 22”, 3/pk   CDFC02203 
 Ion-Ex Cartridge component, 22”, 2/pk  CPMB02202 
 Durapore TP 0.22µ Cartridge, 20”, 1/pk  CVDI02TP1 
 Organex-Q Cartridge, 22”, 1/pk   CPEX02201 
 
* Cartridges are not shipped as part of the system and must be ordered separately. 
 
NOTE : Effluent quality will rapidly degrade if stored outside of the Super-Q System. 
Such high quality water will be contaminated by the atmosphere and by contact 




















































 Super-Q Plus Systems are shipped with the support bracket and cartridge housings 
head manifold completely assembled in the same container with the housing bowls 
and other accessories. Each system requires cartridges, that are not provided with the 
preassembled hardware and must be ordered and shipped separately. Standard Super-
Q Systems require additional components that must be ordered separately. Please 
consult the Ordering Information Section of this manual or Technical Service to 
choose the most appropriate cartridge configuration and accessories to meet the water 





 All systems require a clearance of 2 ft (60 cm) below the bowls for cartridge 
installation and replacement. The unit must be mounted on a surface and with bolts 





 All Super-Q Systems require one grounded electrical outlet, either 115V or 220V, 
depending upon your particular system. The systems have a power consumption 
capacity of 5A for 115V systems and 2A for 220V systems. 
 
 
Feed Water Requirements 
 
 Most municipal tap water supplies contain a very high concentration of suspended 
particulate, colloids, dissolved organic and inorganic materials. These should be 
removed by the appropriate pre-treatment methods to prolong the useful life of 
cartridges, and enhance the product water purity. Reverse Osmosis (RO) or 
distillation treatment is ideal. If deionization of the water is preferred, this type of 
water should be prefiltered prior to feeding to the Super-Q Systems to remove some 













 A minimum feed water pressure of 0.5 psi (1 foot head) is required. The maximum 
feed water pressure to the Super-Q Plus Systems is 15 psi (1 bar). A pressure 
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regulator is required with these systems to maintain feed water pressure within these 
limits. 
 
 Feed water temperature should not exceed 40°C (104°F). 
 
 A shut-off valve on the feed water line is recommended to facilitate cartridge 





 Use the following procedure to level and secure the system to a suitable wall. 
 
1. Mark a horizontal line on the mounting surface at least 1400 cm (55”) above 
the floor. Using all four mounting bolt holes as a guide, mark locations for the 
bolts. Predrill the necessary holes. 
 
2. Using fasteners (not supplied) that are strong enough to hold the Super-Q 
System when it is full of water (at least 63 kg - 140 lbs), secure the housing 
assembly to the mounting surface. 
 
 
Pipe and Tube Connections 
 
 Complete any extra piping with polypropylene or polyethylene piping. Joints should 
be solvent cemented or sealed with Teflon-taped threads. Make threaded connections 
by wrapping the male thread with a double overlapping layer of Teflon thread-sealing 
tape to prevent leaks and facilitate removal. 
 
 DO NOT use pipe-thread compound. It will contaminate the water stream making it 





 The feed water source (Reverse Osmosis, deionized or distilled water supply) is 












Pressure Regulator Installation 
 
 If the feed water pressure to the Super-Q Plus Systems exceeds 15 psi (1 bar), install a 
pressure regulator (to be ordered separately) upstream of the Super-Q Plus inlet, 
maintaining the proper flow direction. The pressure regulator can have 1/2” NPTF 
inlet and outlet connections so you can install the regulator with a 1/2” NPTM to 1/2” 
O.D. tube fittings. 
 






 On Super-Q Plus Systems, the outlet of the system has a 1/2” female tube fitting 
located on the production valve.  
 The Standard Super-Q Systems’ outlet is 1/2” NPTF. 
 
 If an outlet delivery tube is required, use inert tubing to maintain the water quality. 
 
 
Installation of Accessories to a Standard Super-Q System 
 
 If a recirculating system with multiple points-of-use is required, a customized unit to 
meet your high purity water needs can be installed using a Standard Super-Q System. 
Call Technician Service for assistance in sizing the proper components for your 
application because a properly designed system must meet the following 
specifications including maximum system pressure and flow rate while still providing 





  Operating Temperature :  5°C - 40°C (41°F - 104°) 
 
  Feed water Pressure :   Minimum : 055 psi (0.03 bar). 
       Maximum : depends upon pump 
         specifications. 
 
  Flow Rate :    Not to exceed 12 L/min. 
 
  Maximum System Pressure :  80 psi (5,5 bars). 
 
NOTE :  It is highly recommended to use Polypropylene or Polyethylene tubing 
 throughout and wrap threaded connections with Teflon thread-sealing tape. 




























A. Function of Components 
 
 
 Head and Housing Assemblies 
 
 All cartridge housings are of identical modular design, consisting of a molded 
head with detachable cylindrical bowl. The heads and housings hold the various 
filter cartridges such that, when properly selected, combine to yield the highest 
quality product water available. 
 
 Use of an ultrafilter cartridge in the final bowl requires additional parts which 




 Pump (Super-Q Plus Systems) * 
 
 The Super-Q Plus Systems include a positive pressure gear-pump that directs 
the feed water, under pressure, through the system. This selected magnetic drive 
gear pump is used to eliminate problems of seal replacement, priming, and 
leakage. It produces a maximum flow of 12 L/min (3 gpm), at a maximum 
pressure of 55 psi (3.8 bar). 
 
 
CAUTION : Although the pump is self-priming, never start the pump 
without ensuring that a proper water supply is connected and 
available to the pump. 
 
 The feed water pressure to the pump should not exceed 15 psi 
(1 bar). If necessary, a pressure regulator should be installed in 
the feed line, upstream of the pump, to control the feed water 
pressure. 
 
* The Standard Super-Q System must have a pump (not included) that is 
properly sized for the application. 
 
 
 Pressure Regulator 
 
 Placed in the inlet feed water line, the pressure regulator controls the feed water 
pressure to the Super-Q Plus System. It should be set to a level between the 
minimum 0.5 psi (0.03 bar) pressure required, and the maximum permitted 






 Meg-O-Meter Assembly 
 
 This water quality meter provides an accurate, in-line measurement of the 
Super-Q product water resistivity. The meter scale is graduated from 2 to 18 
megohm-cm. The unit is internally temperature-compensated to normalize 
readings at 25°C (77°F) for water temperature between 5°C and 40°C (40°F to 
104°F). 
 
 On Super-Q Plus Systems the assembly is equipped with an autorecirculation 
feature that allows water to recirculate when the Main Power Switch is in the 
ON-1 position, and the Pump Control Switch is in the “Standby” mode. This 
recirculation, caused by periodic operation (in the “Standby” mode) permits the 





 The sensor, located just after the last housing, is electrically connected to the 
Meg-O-Meter Assembly. In operation, the sensor continually measures the 
product water resistivity as it exits the last housing. 
 
 
 Main Power Switch (Super-Q Plus Systems) 
 
 This power switch, located on the right side of the Meg-O-Meter panel, has both 
ON-1, OFF-0 positions. The switch, when turned to the ON-1 position, operates 
the pump, and provides power to the circuit. 
 
 
 Main Power Light (Super-Q Plus Systems) 
 
 This green power light is located on the face of the Meg-O-Meter Assembly and 
is illuminated when the switch is in the ON-1 position. 
 
 
 Operation Control Switch (Super-Q Plus Systems) 
 
 This switch, located on the face of the Meg-O-Meter Assembly, controls the 
operation of the pump. To function, the Main Power Switch must be in the ON-
1 position. 
Operate position : In this position, the pump operates continually. Depending 
upon the position of the production valve, product water is 
sent either to the point-of-use, or is continually recirculated. 
 
Standby position : In the standby position, the pump operates only during 
automatically timed flush cycles, once every one and a half 
hour for 41/2 minutes. 
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 Test Button 
 
 The Test Button is used to check if the Meg-O-Meter Assembly is functioning 
correctly. When the Test button is pushed, the Meg-O-Meter Assembly should 
read 10 megohm-cm. For Super-Q Plus Systems, perform the test when the 
Operation Control Switch is in the “Operate” position. 
 
 
 Production Valve (Super-Q Plus Systems) 
 
 This manually operated valve, located to the right of the sensor, directs the 
product water flow in either of two directions : to the point-of-use, or to the 
system’s recirculation loop. Standard Systems that require a recirculation loop 
must include a similar valve. The valve is open when the knob is turned 
anticlockwise to Product position, allowing water to flow to the final filter or 
point-of-use. The valve is closed when the knob is pointed up, to Recirculation 
position allowing water to recirculate through the system so that water quality is 
maintained at a high level.  
 
 NOTE:  If, at anytime, the valve is disassembled, ensure that it is reassembled  
  in the proper orientation. 
 
 
 Pressure Gauge 
 
 The pressure gauge is used to monitor pump discharge pressure. The maximum 
pressure limitation of the system is 80 psi (5.5 bar). Do not overtighten the 
pressure gauge into the housing head. To ensure a tight seal, the threads should 
be wrapped with on or two turns of Teflon tape. 
 
 
 Vent Valve 
 
 This manually-operated vent valve, located at the inlet side of the final housing 
head, is used to remove air from the housing bowls that might prevent total 















B. Function of Expendables 
 
 
 Expendable cartridges are not provided with the preassembly hardware. The 
cartridges must be chosen based upon specific water quality requirements. 
Consult the Ordering Information Section of this manual, or Technical Service 
for the optimum combination required to meet your needs. 
 
 
 Milligard TP Cartridge 
 
 Milligard TP (thermoplastic) cartridges are high-retention-membrane-filter 
cartridge allowing to remove high particle loads from feed water. They are 
designed for clarification and prefiltration of fluids that require final filtering 
through 0.45 µm or 0.22 µm filters. The manufacturing process obviates the use 
of thermal sealing adhesives that could cause contamination of the product 
water. Flow through the Milligard-TP cartridge is from the exterior toward the 
central collecting tube. The arrow marked on the housing head should point to 
the right for correct flow through this cartridge. 
 
 
 Super-C Carbon Cartridge 
 
 Dissolved organic contaminants and residual chlorine are removed by activated 
carbon adsorption within the Super-C cartridge. The Super-C cartridge is always 
installed upstream of the deionizing (Ion-Ex Cartridge) elements to prevent 
organic-fouling of the ion-exchange resins. The possibility of dissolved minerals 
from the carbon entering the effluent stream and degrading final water quality 
will also be eliminated. Flow through the Super-C cartridge is from the exterior 
of the cartridge into the central collecting tube. The arrow marked on the 
housing head points to the right for proper flow through this cartridge. 
 
 
 Ion-Ex Cartridge 
 
 The disposable Ion-Ex Cartridge filter removes dissolved inorganic 
contaminants by ion-exchange in a highly efficient mixed bed of strong acid and 
strong base resins. This element is designed and constructed such as to prevent 
channelling through the resins. The cartridge is used to “polish” water to an 18 
megohm-cm level of purity. 
 
 A series of two identical deionizing cartridge elements must always be located 






 Organex-Q Cartridge (optional) 
 
 The Organex-Q cartridge is a unique mixture of ion-exchange resins and 
synthetic activated carbon for removal of trace organics. The Organex-Q 
cartridge is required when very low levels of organic in the water is desired. The 
cartridge is normally placed in the last housing bowl. This organic scavenging 
cartridge, composed of both mixed-bed resins and carbon, removes dissolved 
trace organic contaminants. 
 
 
 Durapore - TP 0.22µ Cartridge 
 
 The Durapore-TP cartridge is designed specifically as a “final filter” for the 
removal of particles above 0.22µm and micro-organisms. The thermoplastic seal 
construction eliminates contamination from adhesive seals used in the 
construction of some cartridges. Flow through Durapore cartridges is from the 




































C. Standard Cartridge Installation 
(Super-C, Ion-Ex, Milligard-TP and Durapore-TP cartridges) 
 
 
1. Determine the proper cartridge configuration for your application. 
 
2. Lightly lubricate the O-Ring on the first housing head with water. 
 
3. Open the plastic wrapper of the Super-C cartridge and expose the 
cartridge-to-housing connection. Holding the cartridge by the wrapper, 
guide it into the housing head. Turn the cartridge about 1/4 turn and 
push firmly until the O-Rings are securely seated. Remove the plastic 
wrapper. The cartridge should be secured to the housing head. 
 
4. Raise one of the housing bowls over the cartridge to the large O-Ring 
on the housing. With both hands, firmly grasp the bowl, push up and 
turn clockwise until the bowl is completely tightened and cannot be 
turned further. 
 
5. Install and secure the V-clamp. Make sure that the knob is positioned 
to the side of the bowl so that it can be tightened completely without 
overtightening. 
 
6. Secure the remaining bowls to the housing heads without installing 
cartridges. Ensure that they are tightly secured to the housings head 
assembly. 
 
7. Plug the main power cord into the appropriate wall receptacle required, 
and open the feed water supply valve. Connect a length of flexible 
tubing to the outlet of the 3-way product valve and direct to drain. 
 
8. Turn Pump Control switch to the “Operate” position, then turn main 
power switch to ON-1. Allow system to flush for 2 or 3 minutes to 
remove any superficial carbon fines from the Super-C cartridge. 
 
9. Shut off main switch and turn the Pump Control switch to the 
“Standby” mode. Open bleed valve on head 4 to reduce pressure in 
system. 
 
10. Remove, and empty, the last bowls and insert the other purification 
elements.  
 






NOTE : If an Organex-Q cartridge is to be installed, please follow the 
installation procedure next page. 
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D. Organex-Q Cartridge Installation (into 4 bowls systems) 
 
 For applications requiring the use of the Organex-Q cartridge, this element is 




1. Install the Organex-Q cartridge in the last housing bowl. (refer to steps 
3 to 5 of the Standard Cartridge Installation Procedure). 
 
2. Open the valve to the “Product” position (handle towards you), and 
return the Pump Control switch to “Operate”, and flush the system for 
fifteen minutes. 
 
3. Flick the Pump Control switch to “Standby” ; turn off the Main Power 
switch ; and allow the system to stand idle for a minimum of at least 
one hour to hydrate the cartridge (better resistivity can be obtained if 
the system remains idle overnight). 
 
4. The next morning (or after one hour), turn on the Main Power switch ; 
flick the Pump Control switch to “Operate” mode to start the pump, 
leaving the production valve in “Recirculation” position to allow water 
to recirculate. 
 The time required to reach high resistivity and organic-free water will 
vary, depending upon the condition of the cartridges, the pre-treated 




















NOTE : To ensure the highest quality of water during operation, flush the 
system for five minutes after any recirculation period (as in standby) of 
over 12 hours. 
 It is advised to store non-used Ionex and Organex cartridges at 4°C and 
































A Super-Q system can be kept in excellent operating condition with very little maintenance. 
Performance problems are, for the most part, due to improper cleaning and sanitization, or 




A. Cartridge Replacement 
 
 
 The frequency with which cartridge elements require replacement depends 
essentially on the quality of the feed water to the system, the total and also 
relative amounts of particulate, organic, and ionic contaminants the system must 
remove. Since operating conditions vary so widely, no fixed general rule can be 
recommended. Practically speaking, the user should be guided by (a) the degree 
of plugging of the prefilter cartridge (if installed) and the final membrane 
cartridge ; (b) the level of resistivity obtained in the product water ; and (c) the 
level of organic removal achieved. 
 
 For optimum performance of the Super-Q System, and convenience, all 
cartridges should be replaced at the same time. 
 
 When ascertaining the degree of clogging of prefilter and membrane cartridges, 
it is necessary to record the pressure gauge readings (mounted on the top of the 
Super-Q heads) and the flow rate at the time all new cartridges are installed in 
the Super-Q System. Readings should be taken when the system is in the 
“Operate” mode. This is your baseline level and from pressure differential 
changes noted after operation, an evaluation of the need to change these filters 
can be made. It is important to note however that the Super-C, Ion-Ex cartridges 
and Organex-Q cartridges will be exhausted before they would be clogged. 
Therefore these elements are changed on the basis of their ionic, or organic 
removal performance only. The following guide should prove helpful for 






















 The cartridges should be changed : 
 
 
1. When the Meg-O-Meter scale indicator falls below 10 M:-cm or the 
desired resistivity level to a point unsatisfactory for your particular 
use. Purification media should not be left in the system for more than a 
year. 
 
2. When the organic level in the product water exceeds that required for 
your particular use. 
 
3. When a prefilter cartridge is installed in Bowl 1, and the pressure 
differential between the first and second gauges exceeds 10 psi (gauge 
1 increases, gauge 2 remains the same). The prefilter is clogged. 
 
4. With a membrane cartridge installed in Bowl 4, and the pressure 
differential between 3 exceeds 10 psi (gauge 1 and 2 will rise 







NOTE 1 : When it is necessary to add a prefilter to the system, the cartridge 
may be installed in a separate holder (such as the Millipore PL 
Housing) or in the first bowl of your system, followed by a Super-C 
cartridge and Ion-Ex cartridge units, and a disposable membrane filter 
unit (such as a Millipak) connected to the outlet of your system. In the 
former case, install a pressure gauge on the upstream side of the 
housing, and read both this gauge and the next gauge of the system to 
ascertain the pressure differential across the prefilter. In the latter 




NOTE 2: One pressure gauge is delivered with the system. Any other pressure 















 Cartridge Changing Procedure 
 
 Before proceeding, make sure the system is in “Standby” mode : 
 
 
1. Turn off electrical power to the system. 
 
2. To reduce the internal pressure, turn off the feed water flow and open 
the outlet valve, that has been diverted to drain. 
 
3. Open the purge valve at the bottom of each housing to purge the 
system. 
 
4. Remove the housing bowls by releasing the clamp, and twisting or 
rocking the bowl. Carefully lower the bowls from the cartridges. 
 
5. Pull the cartridges straight down and discard them. 
 
6. After cleaning the housing bowls (using the procedure that follows), 
replace the cartridges referring to the Cartridge Installation Procedure 
described in the Operation Section. Replace the elements in the proper 







 When the cartridges are changed, examine the inside of the housing bowls for 
residues deposited on the walls. Clean the insides of the bowls with a non-
abrasive detergent and a sponge or cloth. Thoroughly wash the inner surfaces of 
the bowls and the support structures. Rinse with clean water several times to 





















 Sanitization should be done regularly to both the ultrafiltration cartridge (if 
used) and the system hardware (bowls and heads without cartridges).  
 Ion-Ex, Organex and Super-C cartridges CANNOT be sanitized. 
 
 
 The sanitization process includes : 
 
1. Injection of a sanitant. 
 
2. Soaking or recirculating the unit. 
 
3. Flushing the residual chemicals. 
 
4. Testing for complete removal of residual chemicals. 
 
5. Recovery of water quality. 
 
 
 Super-Q Housing Sanitization 
 
 If slime deposits are detected inside the bowls and heads when cartridges are 
replaced, the entire system should be sanitized. This is especially important if a 
UF cartridge is used. It is also helpful to prevent premature microbial fouling of 
the cartridges. 
 
 To sanitize the bowls and heads : 
 
1. Remove all bowls and cartridges. 
 
2. Discard cartridges (except UF cartridge) and thoroughly clean all 
bowls and heads, following previous instructions in this manual. 
 
3. Replace all bowls except one, without installing cartridges. Make sure 
all purge valves are closed. 
 
4. Place 140 mL of household chlorine bleach (5,25% strength) in the 
remaining empty bowl, and secure this bowl to the final housing head. 
 
5. Open the feed water supply valve and the production valve (if closed). 
 
6. Start the pump. 
 
7. When water begins to flow at the outlet, close the production valve and 
recirculate water for ten minutes. 
 
8. Turn off the pump, close the feed water supply valve, and allow the 
system to stand idle for at least one hour. The water in the system 
should now have a chlorine level of about 200 ppm. 
 
9. Purge all bowls. 
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10. Open the feed water and the production valve. When water begins to 
flow at the outlet, close the production valve and recirculate water 
through the system for two or three minutes. 
 
11. Open the production valve and flush for approximately five minutes to 
remove residual bleach. Check the chlorine level of the water*. 
 
12. When the chlorine level in the flush water is reduced to < 0,1 ppm (or 
the level of the feed water), shut off the system. Open the vent valve to 
allow the internal pressure to drop to zero. Purge and remove the 



































* High chlorine levels can be determined by using the DPD free-chlorine 
test kit, catalogue number : ZLCL000AH. 
 
 Low chlorine levels (0 - 3.5 ppm) can be determined by using the DPD 

































 Description       Catalogue Number 
 
  V 115V-60Hz 
 
    3-Bowl Super-Q System    ZFSQ 115 03 
 
    4-Bowl Super-Q System    ZFSQ 115 04 
 
    4-Bowl Super-Q Plus System   ZFSQ 115 P4 
  (with Pump) 
 
 
  V 220V-50Hz 
 
    3-Bowl Super-Q System    ZFSQ 240 03 
 
    4-Bowl Super-Q System    ZFSQ 240 04 
 
    4-Bowl Super-Q Plus System   ZFSQ 240 P4 





 Description       Catalogue Number 
 
   Milligard TP Cartridge, 3/pk    CWSC 02T P3 
   Super-C Carbon Cartridge, 3/pk   CDFC 022 03 
   Ion-Ex TP Cartridge, 2/pk    CPMB 022 02 
   Organex-Q TP Cartridge, 1/pk   CPEX 022 01 
   Durapore TP Cartridge, 1/pk    CVDI 02T PE 




 Chlorine Test Kits 
 
 High levels of Chlorine 
   DPD Free-Chlorine Test Kit    ZLCL 000 AH 
 
 Low levels of Chlorine (0-3.5 ppm) 













Maximate™ and Maxisette™ Cassettes
For Development, Pilot-Scale and Production in Ultrafiltration and Microfiltration Processes
USD 2450
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Ultrafiltration and Microfiltration TFF – Cassette Membranes
Membranes for UF and MF TFF
Pall Omega™ ultrafiltration (UF) membranes
have been developed and manufactured
to give consistent performance. Products
are available for laboratory, development,
pilot, and production-scale TFF
applications.
Pall Supor® TFF microfiltration (MF)
membranes are optimized for product
clarification and recovery in biotechnology
and pharmaceutical applications.
Pall membranes provide superior
performance and stability to meet the
challenges of each unique TFF application.
Each membrane is available in a broad
range of cassette types and configurations.
Omega Membrane
Omega polyethersulfone (PES) membranes
have been specifically modified to minimize
protein binding to the surface and interstitial
structure of the membrane. This polymeric
membrane is stable against biological and
physical degradation due to the unique
chemical properties of PES.
Omega membranes are cast on a highly
porous, non-woven polyolefin support. They
have an anisotropic structure, a thin skin-
like top layer with a highly porous underlying
support. The structure of the skin
determines the porosity and permeability
characteristics of the membrane.
Anisotropic membranes have higher water
permeability and can typically be cleaned
quicker and easier than membranes with a
uniform, sub-micron depth structure.
Damage to the skin of anisotropic
membranes is easily detected with an
integrity test. This may not be the case for
membranes with sub-micron porous
underlayers.
Supor TFF Membrane
Supor TFF membrane is a modified
polyethersulfone membrane with a uniform
depth structure. The membrane porosity
is optimized for microfi ltration TFF
applications including harvest,
concentration and clarification of cell
cultures and fermentation broths. Use
Supor TFF membranes to harvest bacterial,
mammalian, and insect cells; separate red
blood cells from hemoglobin; and clarify
yeast broth and bacterial lysates.
Characteristics of Omega and Supor
TFF membranes
• Low affinity and adsorption
characteristics resulting in higher
product recovery
• Available in a wide variety of cassette
configurations, for easy and direct
scale-up/scale-down
• Greatest selection of ultrafiltration
membrane rating available: 
650 Da – 1000 kDa to fit specific
application needs
• Wide range of membrane pore sizes to
optimize the process
• Compatible with acids, bases and a
variety of other cleaning agents to
optimize cleaning procedures.
Top: Maxisette Membrane Cassettes
Bottom: Centrasette Membrane Cassettes
Pall offers a comprehensive selection of tangential flow filtration (TFF) products to
meet the increasing diversity of biological and biopharmaceutical processes and
applications. Pall® membrane cassettes and their associated hardware and systems
are the preferred choice in applications that require gentle processing and
characteristics tailored to the application.
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Tangential Flow Filtration Membrane Cassettes
Centramate™, Centrasette™, Maximate™, and Maxisette™ Cassettes
Centramate Cassettes
Centramate cassettes are perfect for
laboratory scale and development
applications in TFF. Small area formats with
0.009 m2 and 0.018 m2 may be used with
the Centramate LV holder for process
volumes of a few liters down to a few
milliliters. The 0.09 m2 format is used with
the Centramate Stainless Steel or
Centramate PE holders. Centramate
cassettes are available in a range of channel
formats and membranes to meet every
application requirement. The cassettes are
supplied with the same membrane and
construction materials as used in the
Centrasette Membrane cassettes.
Applications developed on a Centramate
cassette can be easily scaled up by adding
cassettes to a Centramate holder or by
switching to the Centrasette cassette
format with identical path length and
channel format.
Centrasette and Centrasette II
Cassettes
Centrasette cassettes, available in the
same range of membrane and screen
formats as the Centramate cassettes, have
been widely used for years in various
process applications including
concentration and diafiltration by the
biopharmaceutical industry. Centrasette
cassettes are available with membrane
areas of 0.46, 1.9, and 2.3 m2 (5, 20, and
25 ft2). Larger cassette areas simplify
installation in large TFF systems, reducing
the number of gaskets required and
minimizing risk of leakage.
Pall continues to improve membrane
cassettes to meet the more rigid
requirements of today’s applications.
The Centrasette II membrane cassette
uses the same components as in the
original Centrasette cassette. Therefore
revalidation may not be necessary.
Feed ports in the Centrasette II have been
enlarged to twice the size of the
Centrasette cassette and membrane area
has been increased by about 10%. The
larger fluid port design will enhance the
membrane’s performance by:
• Improving fluid flow distribution
between and through cassettes
• Allowing more efficient cleaning
• Reducing the pressure profile across
the feed/retentate channels
Both types of Centrasette cassettes are
available with 3 different membrane area
options to meet small scale and larger
process volume requirements. The
Centrasette cassettes fit in a variety of
Centrasette holders as well as similar
holders from other manufacturers.
Top: Centramate Membrane Cassettes
Bottom: Centrasette Cassette




The Maximate membrane cassette offers the opportunity to simulate
the performance of the larger Maxisette membrane cassette on a
smaller scale. The path length in Maximate membrane cassettes
is identical to that used in the Maxisette format but the membrane
surface area and hold up volume are proportionately lower, meaning
that processing and optimization studies may be performed on
smaller batches. 
Maxisette Cassettes
The Maxisette format has some distinct benefits that make it
advantageous for large volume processes. Most important is that
the volumetric flow rate required is 40 % lower compared to cassette
formats like the Centrasette. This translates to a smaller pump
and piping diameter being required for the same membrane area
with a corresponding reduction in energy cost. The larger porting
in the Maxisette (almost 50% larger feed and retentate ports than
the Centrasette II Cassette) provides lower resistance to high feed
flow rates which results in lower pressure drops and easier cleaning.
Membrane Cassette General Information
There are four cassette formats for UF and MF applications –
Centramate, Centrasette, Maximate and Maxisette. 
Pall TFF membrane cassettes are available in a range of molecular
weight cut-offs from 650 Da to 1000 kDa and pore sizes from 0.1 µm
to 0.65 µm to meet every application requirement. Featured
membrane types include:
• Omega










Cassettes pass current USP biological safety tests for Class VI plastics at 70 °C (158 °F).
Operating Specifications
Cassette Maximum Operating Maximum 
Format Temperature Recommended 
Operating Pressure
Centramate 50 °C (122 °F) 5 bar (75 psi)
Centrasette 50 °C (122 °F) 5 bar (75 psi)
Maximate 50 °C (122 °F) 5 bar (75 psi)
Maxisette 50 °C (122 °F) 5 bar (75 psi)
* Do not exceed maximum pressure rating of any component in the system.
Cassette Channel Configurations
Cassettes are available in fine, medium and suspended screen
channel formats to best meet the specific requirements of each
application.
Select a cassette channel configuration based on the following
criteria:
Channel Configuration Selection Criteria
Fine Screen Clarified, dilute solutions
Final concentration below 2% 
(20 mg/mL)
MWCO below 300K
Medium Screen Clarified solutions; low – medium 
viscosity
Final concentration < 30% (300 mg/mL)
Suspended Screen/ Particles/cells/cell debris in solution
Open Channel High viscosity
Storage Agents
Omega, and Supor TFF cassettes are shipped wet, in liquid
containing a humectant and bactericidal storage solution. This
solution consists of 15 – 20% glycerin and 0.05 – 0.1% sodium azide. 
The storage solution must be removed and the cassette flushed well
with water prior to use to prevent product contamination.
Cassettes are also available with circa 0.3N sodium hydroxide as
the storage agent.
Traceability
Each membrane cassette has a unique serial number for full
traceability. Each cassette is supplied with:
• Certificate of Test
• Membrane Cassette Care and Use Procedures
• Material Safety Data Sheet (MSDS) for cassette preservative
• Two platinum cured silicone gaskets
Tangential Flow Filtration Membrane Cassettes
Centramate™, Centrasette™, Maximate™, and Maxisette™ Cassettes
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Table 4 – Cassette and Screen Formats
Cassette Format Nominal Area Fine Screen Code1 Medium Screen Code Suspended Screen Code
Centramate 0.01 m2 (0.1 ft2) – C12P1 –
0.02 m2 (0.2 ft2) – C12P2 C11P2
0.1 m2 (1.0 ft2) C10 C12 C11
Centrasette 0.46 m2 (5.0 ft2) C05 C06 C07
1.86 m2 (20 ft2) C20 C21 C22
2.32 m2 (25 ft2) C25 C26 C27
Centrasette II 0.5 m2 (5.4 ft2) F05 F06 F07
2.0 m2 (22 ft2) F20 F21 F22
2.5 m2 (27 ft2) F25 F26 F27
Maximate 0.04 m2 (0.4 ft2) – G01P2 G02P2
0.19 m2 (2.0 ft2) G10 G01 G02
Maxisette 2.8 m2 (30 ft2) C50 C51 C52
1 Fine Screen channel not available in any MWCOs greater than 200 kDa.
Tangential Flow Filtration Membrane Cassettes
Ordering Information
How to Order Membrane Cassettes
1. Choose a membrane type from Table 1 (e.g. OS, or PS).
2. Choose a MWCO from Table 2 or a µm rating code from Table
3, as appropriate (e.g. 010 = 10 kD, M20 = 0.2 µm).
3. Choose a format code from Table 4 (e.g. C10, C11, or C12).
Table 1 – Membrane Type
Code Membrane Comments
OS Omega Low protein-binding
modified polyethesulfone
PS Supor TFF Microfiltration-optimized 
polyethersulfone
Table 2 – Available MWCOs for Omega Ultrafiltration
Membranes
Code D65 001 003 005 010 030 050 070 100 200 300 500 990
MWCO
(kD) 0.65 1 3 5 10 30 50 70 100 200 300 500 1000
Table 3 – Available Micron Ratings for Supor Microfiltration
Membranes
Code (µm) M10 M20 M45 M65
Pore Size 0.1 0.2 0.45 0.65
(µm)




Feed Channel Suspended 
Screen
Area 0.18 m2 (2 ft2)
Special Format None




Feed Channel Medium Screen
Area 0.5 m2 (5.4 ft2)
Special Format 0.3N NaOH 
Storage Agent
Typical Examples:
Tangential Flow Filtration Membrane Cassette Holders
Choosing a Cassette Holder





Centramate 500 S unit
Operators must use calibrated torque
wrenches (supplied with the holder) to effect
required compression of cassettes and
gaskets in a manual torque cassette holder.
Auto-torque cassette holders automatically
compensate for cassette compression and
temperature reduction.
They also eliminate variability in technique
between operators. Auto-torque cassette
holders are recommended for process-scale
validated processes.
Sanitary stainless steel holders may be
sterilized by steam or autoclaving without
cassettes installed.
Complete fittings kits consisting of pressure
gauges, valves, filtrate manifold, connectors,
gaskets and clamps are available for most
cassette holders. Ordering a complete fitting
kit with the cassette holder simplifies
installation into a system and avoids
potential delays in starting your process
due to missing parts.
Designed for optimum performance and
product recovery Pall TFF cassette holders
are available in a variety of sizes to meet
every application requirement. This way
applications that are developed on a small
system using a Centramate or Maximate
cassette can be easily scaled up, either by
adding additional cassettes to the holder
or by scaling into a larger cassette format
and holder configuration with identical flow
path like the Centrasette/Centrastak™ or
Maxisette holders.
TFF cassette holders for the medium and
large-scale production environment have
a small footprint, yet still are capable of
holding large areas of membrane. All
stainless steel holders are engineered to
precise specifications with a high standard
internal and external surface finish and are
available with either manual torque (MT) or




Choosing a Cassette Holder
The following table lists cassette holders with relative area capacities (screen channel cassettes) and working volumes1.
The Minimate™ TFF Capsule is also included to complete the range of lab scale products.
Product Membrane Area (Nominal)1 Working Volumes2
Lab and Development Scale 
(Scale-up and Scale-down studies) Starting Final
Minimate TFF Capsule 0.005 m2 0.05 ft2 25 – 500 mL 15 mL
Centramate LV 0.01 – 0.04 m2 0.1 – 0.4 ft2 25 – 4,000 mL 15 mL
Centramate PE 0.01 – 0.37 m2 1 – 4 ft2 0.5 – 80 L 150 mL
Centramate 0.01 – 0.46 m2 1 – 5 ft2 0.5 – 100 L 150 mL
Maximate 0.19 – 1.11 m2 2 – 12 ft2 1 – 250 L 350 mL
Pilot Scale (Process Development)
Centrasette LV 0.46 – 2.0 m2 5 – 22 ft2 2.5 – 500 L 400 mL
Centrasette P 0.46 – 2.0 m2 5 – 22 ft2 2.5 – 500 L 400 mL
Centrasette 5 0.46 – 4.6 m2 5 – 50 ft2 2.5 – 1,000 L 1,000 mL
Process Scale (Production)
Centrastak 100 0.9 – 20.0 m2 10 – 215 ft2 10 – 4,000 4 L
Centrastak 200 1.85 – 40.0 m2 20 – 430 ft2 20 – 8,000 10 L
Centrastak 300 2.8 – 60.0 m2 30 – 645 ft2 30 – 12,000 15 L
Centrastak 400 3.7 – 80.0 m2 40 – 860 ft2 40 – 16,000 20 L
Maxisette 25 2.8 – 27.9 m2 30 – 300 ft2 30 – 6,000 15 L
Maxisette 50 5.6 – 55.8 m2 60 – 600 ft2 60 – 12,000 30 L
Maxisette 100 5.6 – 92.9 m2 60 – 1,000 ft2 60 – 20,000 40 L
1 Fewer suspended screen cassettes will fit due to increased thickness. Some holders can fit more membrane area than can be operated at required cross flow rates due to high pressure drops.
Do not use more than the recommended area in these holders. Manual (MT) and auto-torque (AT) version holders are available for Pilot and Process Scale applications.
2 Working Volumes are based on an average filtrate flux rate of about 50 LMH and process time of 5 hours. Starting Range covers minimum to maximum area installed for screen channel
cassettes. Final process volume represents final concentration volume or minimum working volume for the system. Actual volumes depend on system hold-up volume and operating
parameters. Piping (tubing) lengths and internal diameters significantly affect the final volume.
Maxisette 25 AT Holder
Tangential Flow Filtration Membrane Cassette Holders
Choosing a Cassette Holder
Centrasette 200 AT Holder
Pall Corporation has offices and plants throughout the world in locations including:
Argentina, Australia, Austria, Belgium, Brazil, Canada, China, France, Germany, India,
Indonesia, Ireland, Italy, Japan, Korea, Malaysia, Mexico, the Netherlands, New Zealand,
Norway, Poland, Puerto Rico, Russia, Singapore, Spain, South Africa, Sweden, Switzerland,
Taiwan, Thailand, United Kingdom, United States and Venezuela. 
Distributors are located in all major industrial areas of the world.
New York - USA
+1 516 484 5400 phone
+1 516 801 9548 fax
pharmafilter@pall.com  e-mail
Portsmouth - Europe
+44 (0)23 9230 3303  phone
+44 (0)23 9230 2506  fax
BioPharmUK@europe.pall.com  e-mail
Because of developments in technology these data or procedures may be subject to change. Consequently we advise
users to review their continuing validity annually.,         , Pall, Centramate, Centrasette, Centrastak, Maximate,
Maxisette, Omega, Minimate and Supor are trademarks of Pall Corporation. 
Filtration. Separation. Solution. and UpScale are service marks of Pall Corporation.
Part numbers quoted above are protected by the Copyright of Pall Corporation.
® indicates a Pall trademark registered in the USA.
© 2007, Pall Europe Limited.
PELWR/SM/2.2007
Visit us on the web at www.pall.com /biopharmaceutical
Pall has the most comprehensive 
family of scalable separation products.
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Tangential Flow Filtration Systems
Pre-Designed Systems for Scalable Processing Pall offers scalable, pre-designed
systems to suit your specific process needs. Pall Standard systems are ready-to-
use, engineered systems with integrated recipe management tools to expedite
your approval processes and reduce your time to market.
The pilot system includes the flexibility of both semi and full automation, a UV
detector, a pH monitor, an Integrity Analyzer, and an integrated tank. The
system expedites the development and scale-up of filtration processes in
accordance with FDA cGMP regulations and guidelines.
 
      
Top: Centramate Pilot Automated Development and Optimization System
Pall Pre-designed Pilot Tangential Flow
Filtration Systems
Pall offers a range of pre-designed systems to meet your process goals.
These include:
Centramate 0.1 – 0.5 m  (1 – 5 ft )
Maximate 0.2 – 0.9 m  (2 – 10 ft )
Centrasette(1) 0.5 – 7.0 m  (5 – 75 ft )
Centrastak(1) 0.9 – 18.6 m  (10 – 200 ft )
(1) Autotorque hardware included and optional Instrumentation for UV, pH, Conductivity,
Integrity, and Auxiliary Pump. Tanks also available.
Features
Intuitive Automated Control System
Fully scalable design and components
Complete validation package with comprehensive IQ/OQ
documentation 
Compact sanitary ergonomic design for enhanced cleanability,
portability, and accessibility
Optional AutoTorque™ (AT) hardware provides uniform cassette sealing
Comprehensive Recipe Management
Adheres to ASME BPE, ANSI ISA, and cGMP standards
Time-saving
Process Automation
Puts Control in the Hands of your Process Engineers
User-friendly recipe management tools include a suite of default recipes for
pre-production, production, and post-production operations. Your process
experts can make applications work without waiting for programmers to sift
through cryptic proprietary software code.
The flexible software design enables users to build recipes and develop
processes without PLC programming expertise. Our software is ideal for use in a





Our recipes are configured from modules which are tested configuration-based
sequences that reduce the number of validation steps.
Operations
From a touch screen,any authorized user can create and store recipes so an
operator can run process tasks simply, easily, and accurately. Pall’s pre-
programmed recipes can be used to automatically sanitize, concentrate,
recover product, and clean in place.
Data Storage
21 CFR Part 11 compliant data-handling
Convenient data storage and retrieval





Exports common text and table formats




Tangential Flow Filtration Systems
Pre-Designed Systems for Scalable Processing Pall offers scalable, pre-designed systems to suit your specific process needs. Pall Standard
systems are ready-to-use, engineered systems with integrated recipe management tools to expedite your approval processes and reduce
your time to market.
The pilot system includes the flexibility of both semi and full automation, a UV detector, a pH monitor, an Integrity Analyzer, and an
integrated tank. The system expedites the development and scale-up of filtration processes in accordance with FDA cGMP regulations and
guidelines.
 
      
Top: Centramate Pilot Automated Development and Optimization System
Pall Pre-designed Pilot Tangential Flow Filtration Systems
Pall offers a range of pre-designed systems to meet your process goals.
These include:
Centramate 0.1 – 0.5 m  (1 – 5 ft )
Maximate 0.2 – 0.9 m  (2 – 10 ft )
Centrasette(1) 0.5 – 7.0 m  (5 – 75 ft )
Centrastak(1) 0.9 – 18.6 m  (10 – 200 ft )
(1) Autotorque hardware included and optional Instrumentation for UV, H, Conductivity, Integri y, and Auxiliary Pump. Tanks also available.
Features
Intuitive Automated Control System
Fully scalable design and components
Complete validation package with comprehensive IQ/OQ documentation 
Compact sanitary ergonomic design for enhanced cleanability, portability, and accessibility
Optional AutoTorque™ (AT) hardware provides uniform cassette sealing
Comprehensive Recipe Management
Adheres to ASME BPE, ANSI ISA, and cGMP standards
Time-saving
Process Automation
Puts Control in the Hands of your Process Engineers
User-friendly recipe management tools include a suite of default recipes for pre-production, production, and post-production operations.
Your process experts can make applications work without waiting for pr grammers to sift through cryptic proprietary software code.
The flexible software design enables users to build recipes and develop processes without PLC programming expertise. Our software is ideal





Our recipes are configured from modules which are tested configuration-based sequences that reduce the number of validation steps.
Operations
From a touch screen,any authorized user can create and store recip s so an operator can run process tasks simply, easily, and accurately.
Pall’s pre-programmed recipes can be used to automatically sanitize, concentrate, r cover product, and clean in place.
Data Storage
21 CFR Part 11 compliant data-handling
Convenient data storage and retrieval





Exports common text and table formats
View additional Tangential Flow Filtration Systems and Components.        
Engineered Solutions
Pall engineers are available to help you design and build systems to accommodate your specific process needs.
Decades of experience in the BioProcess Industry has proven our ability to provide innovative, cost-effective
solutions.
Our team of process engineers and design specialists work with you every step of the way to ensure that systems
meet your application needs and delivery requirements.
 
Top: Centrastak 600 System, Bottom: Centrastak 200 System
Design
Our patented designs provide higher process efficiency, enhanced process control, lower pressure drops, and
minimized holdup volumes to ensure:
Maximum yield
Cleanability and Recovery
Compact cost-effective systems – more membrane area per square-foot of floor space
Autotorque device offers consistent pressure for a reliable seal on cassettes to ensure batch process repeatability
with minimal labor overhead
Process Design
Making your process work reliably and repeatably is our goal. Pall Process engineers are available to work with you throughout the entire








To ensure that our entire project team understands your needs, our Process Engineers will manage your project throughout the entire
design, build, and commissioning cycle. Our process engineers will direct the project team to meet your process requirements on time
every time.
View additional Tangential Flow Filtration Systems and Components.
Pre-Engineered Systems
  Centramate Pilot Maximate Pilot Centrasette 5 SAT Centrastak 100 SAT
Feed Flow Range (L/Min) @ 60
psig
7 7 65 120
Membrane Area 0.1 –0.5 m
(1 – 5 ft )
0.2 – 0.9 m
(2 – 10 ft )
0.5 – 7.0 m
(5 – 75 ft )
0.9 – 18.6 m
(10 – 200 ft )
Connections 1⁄2 in. Sanitary Flange 1⁄2 in. Sanitary Flange 11⁄2 in. Sanitary Flange 11⁄2 in. Sanitary Flange
Membrane Holder Manual Torque Manual Torque Auto Torque Auto Torque




UV, pH, Conductivity, Integrity, Auxiliary Pump,
Tanks
UV, pH, Conductivity, Integrity, Auxiliary Pump,
Tanks
Hold-up Volume 275 mL 275 mL < 2.5 L < 3.5 L
View additional Tangential Flow Filtration Systems and Components.
TFF Systems
Please contact your Pall representative for a quote.
View additional Tangential Flow Filtration Systems and Components.
Pall's standard tangential flow filtration systems are ready-to-use, engineered systems with integrated recipe management tools to expedite
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Product image is a representative example for




Choosing a Cassette Holder
Designed for optimum performance and product recovery Pall TFF cassette
holders are available in a variety of sizes to meet every application requirement.
This way applications that are developed on a small system using a Centramate
or Maximate cassette can be easily scaled up, either by adding additional
cassettes to the holder or by scaling into a larger cassette format and holder
configuration with identical flow path like the Centrasette/Centrastak™ or
Maxisette holders.  
Holder Sizes
TFF cassette holders for the medium and large-scale production environment
have a small footprint, yet still are capable of holding large areas of membrane.  
All stainless steel holders are engineered to precise specifications with a high
standard internal and external surface finish and are available with either
manual torque (MT) or auto torque (AT) compression systems for ease of use.  
Operators must use calibrated torque wrenches (supplied with the holder) to
effect required compression of cassettes and gaskets in a manual torque
cassette holder.  
Auto-torque Feature
Auto-torque cassette holders automatically compensate for cassette
compression and temperature reduction. They also eliminate variability in
technique between operators. Auto-torque cassette holders are recommended
for process-scale validated processes. 
Sanitary stainless steel holders may be sterilized by steam or autoclaving
without cassettes installed.  
Fittings Kits
Complete fittings kits consisting of pressure gauges, valves, filtrate manifold,
connectors, gaskets and clamps are available for most cassette
holders.Ordering a complete fitting kit with the cassette holder simplifies
installation into a system and avoids potential delays in starting your process
due to missing parts. 





Choosing a Cassette Holder
Designed for optimum performance and product recovery Pall TFF cassette holders are available in a variety of sizes to meet every
application requirement. This way applications that are developed on a small system using a Centramate or Maximate cassette can be easily
scaled up, either by adding additional cassettes to the holder or by scaling into a larger cassette format and holder configuration with
identical flow path like the Centrasette/Centrastak™ or Maxisette holders.  
Holder Sizes
TFF cassette holders for the medium and large-scale production environment have a small footprint, yet still are capable of holding large
areas of membrane.   All stainless steel holders are engineered to precise specifications with a high standard internal and external surface
finish and are available with either manual torque (MT) or auto torque (AT) compression systems for ease of use.   Operators must use
calibrated torque wrenches (supplied with the holder) to effect required compression of cassettes and gaskets in a manual torque cassette
holder.  
Auto-torque Feature
Auto-torque cassette holders automatically compensate for cassette compression and temperature reduction. They also eliminate variability
in technique between operators. Auto-torque cassette holders are recommended for process-scale validated processes. 
Sanitary stainless steel holders may be sterilized by steam or autoclaving without cassettes installed.  
Fittings Kits
Complete fittings kits consisting of pressure gauges, valves, filtrate manifold, connectors, gaskets and clamps are available for most cassette
holders.Ordering a complete fitting kit with the cassette holder simplifies installation into a system and avoids potential delays in starting
your process due to missing parts. 
View additional Tangential Flow Filtration Systems and Components.
TFF Membrane Cassette Holder Information
Selection of Holders
Technical Specifications
TFF Membrane Cassette Holder Information
The following tables list cassette holders with relative area capacities (screen channel cassettes) and working volumes .
The Minimate™ TFF Capsule is also included to complete the range of lab scale products.
Lab and Development Scale Holders
 
Product Membrane Area (Nominal
m )
MembraneArea (Nominal







0.005 m 0.05 ft 25 - 500 mL 15 mL
Centramate LV 0.01 - 0.04 m 0.1 - 0.4 ft 25 - 4,000 mL 15 mL
Centramate PE 0.01 - 0.37 m 1 - 4 ft 0.5 - 80 L 150 mL
Centramate 0.1 - 0.5 m 1 - 5 ft 0.5 - 100 L 150 mL
Maximate 0.19 - 1.11 m 2 - 12 ft 1 - 250 L 350 mL
 
Pilot Scale (Process Development)
 
Product Membrane Area (Nominal m ) MembraneArea (Nominal ft ) Working Volume Start Working Volume Final
Centrasette LV 0.46 - 2.0 m 5 - 22 ft 2.5 - 500 L 400 mL 
Centrasette P 0.46 - 2.0 m 5 - 22 ft 2.5 - 500 L 400 mL




Product Membrane Area (Nominal m ) MembraneArea (Nominal ft ) Working Volume Start Working Volume Final
Centrastak 100 0.9 - 20.0 m 10 - 215 ft 10 - 4,000 L 4 L
Centrastak 200 1.85 - 40.0 m 20 - 430 ft 20 - 8,000 L 10 L
Centrastak 300 2.8 - 60.0 m 30 - 645 ft 30 - 12,000 L 15 L
Centrastak 400 3.7 - 80.0 m 40 - 860 ft 40 - 16,000 L 20 L
Maxisette 25 2.8 - 27.9 m 30 - 300 ft 30 - 6,000 L 15 L
Maxisette 50 5.6 - 55.8 m 60 - 600 ft 60 - 12,000 L 30 L
Maxisette 100 5.6 - 92.9 m 60 - 1,000 ft 60 - 20,000 L 40 L
 
!. Fewer suspended screen cassettes will fit due to increased thickness. Some holders can fit more membrane area than can be operated at
required cross flow rates due to high pressure drops. Do not use more than the recommended area in these holders. Manual (MT) and
auto-torque (AT) version holders are available for Pilot and Process Scale applications.
". Working Volumes are based on an average filtrate flux rate of about 50 LMH and process time of 5 hours. Starting Range covers minimum
to maximum area installed for screen channel cassettes. Final process volume represents final concentration volume or minimum
working volume for the system. Actual volumes depend on system hold-up volume and operating parameters. Piping (tubing) lengths and
internal diameters significantly affect the final volume.
Selection of Holders
Centramate LV Holder
The Centramate LV holder is fabricated from Stainless Steel (316L) with female luer fittings for use with 0.01 m
(0.1 ft ) and 0.02 m  (0.2 ft ) Centramate cassettes. The holder can accommodate up to 0.04 m  (0.4 ft ) of screen
channel or 0.02 m  (0.2 ft ) of open channel Centramate cassettes at recommended cross flow rates. A range of
luer fittings and valves are available as well as pressure gauges or transducers to set-up a complete TFF system.
 
Centramate PE Holder
The Centramate PE holder has a polyethylene manifold with # in. NPT threaded ports
sandwiched between 304 stainless steel outer plates for support. It accommodates
up to 4 screen channel (3 suspended screen channel) 0.09 m  (1 ft ) cassettes. The use
of spacers on the tie rods makes it easy to apply and tighten the nuts with minimal
threading if only one cassette is installed. As additional cassettes are added, spacers
can be removed. The Centramate PE holder is recommended for use in applications
where metal contact must be avoided. A plastic, NPT threaded fitting kit, with either 2
or 3 pressure gauges is available. 
Centramate Stainless Steel Holder
The Centramate stainless steel cassette holder (316L) comes with $ in. sanitary flanges on feed and filtrate
ports. The holder is supplied with surface and weld certification. Up to 5 screen channel (4 suspended screen
channel) 0.09 m  (1 ft ) cassettes can be accommodated. Holder is supplied with both 1 in. and 2 in. spacers on
the tie rods to simplify cassette installation and to apply the required torque. Spacers can be removed to
compensate for the height difference as additional cassettes are added to the holder. Sanitary fitting kits with
either 2 or 3 pressure gauges are available.    
Centrasette P Holder
The Centrasette P Holder has a polypropylene center manifold and end plate,for use when product contact with
metal is not desirable or prohibited by your application; for example when processing certain metal sensitive
enzymes or oligonucleotides. The manifold and end plate are housed between stainless steel plates to supply the
necessary rigidity when operating at higher pressures. Luer fittings on the % in. sanitary polypropylene ports can
be used for connection to plastic pressure transducers for monitoring pressures, again without metal contact.
The low-cost plastic manifold and end plate can be replaced to avoid cleaning validation or dedicated to a
specific application along with a set of cassettes to prevent any risk of cross-contamination. The Centrasette P
holder like the Centrasette LV holder is intended for use with Centrasette cassettes when total membrane area
will be less than 2.5 m  (27 ft ) of screen channel cassettes or 1.5 m  (16 ft ) of suspended screen cassettes. 
Centrasette LV Holder
The Centrasette LV Holder is manufactured using highly polished 316L stainless steel. This holder has % in. sanitary fractional fitting on the
feed/retentate and permeate ports which minimizes the hold-up volume. it is ideal for use in systems that use Centrasette cassettes when
total membrane area will be less than 2.5 m2 (27 ft2) of screen channel cassettes or 1.5m2 (16 ft2) of suspended screen cassettes.Centrasette 5
and Centrasette 5AT Holders
The Centrasette 5 holder is intended for use in pilot and process scale applications with up to 5 m  (54 ft ) screen
channel Centrasette or Centrasette II cassettes or 4 m  (43 ft ) of suspended screen cassettes. The feed/retentate
channels have tapered bores engineered to maintain uniform cross flow and pressure drops across the
membrane cassettes. Two permeate ports, one near the feed and the other near the retentate, are designed to
reduce backpressure on the permeate side of the membrane. This is especially important when operating at
high flux rates. Pressure on the permeate side effectively reduces transmembrane pressure and lowers filtrate
flux rates. The highly polished 316L stainless steel unit has ports that mate up with 1 in. sanitary connectors. A
calibrated torque wrench and socket is supplied with the holder, as it is with other manual torque holders. 
Centrastak Holders
Processes developed at bench scale on Centramate and Centrasette cassettes can be scaled up to process volumes in excess of 10,000 L
using a Centrastak system. The Centrastak range of cassette holders have been designed for optimal performance in large-scale production
environment. The small footprint makes them ideal for use in process skids and manufacturing suites where space is at a premium. Each
level in a Centrastak holder can hold up to 10 m  (107 ft ) of Centrasette cassettes on each side of a central manifold or effectively 20 m  (215
ft  per level. A single center-manifold significantly reduces hold-up volumes. Feed flow direction is from bottom to top allowing air to be
easily expelled from the system.
All Centrastak holders are available in auto-torque format with a hydraulic system,including stainless steel pistons and pump, Centramate
for maintaining optimal and uniform compression on the installed cassettes. A pressurized air supply is required to operate the hydraulic
pump (60 psi minimum, 125 psi maximum). All wetted surfaces are electropolished, 316L stainless steel. Holder is supplied with surface and
weld certification to support I/Q validation. 
Maximate Holders
Maximate holders are designed for use with Maximate membrane cassettes. The 316L stainless steel holder has % in. sanitary feed/retentate
ports and $ in. permeate ports. Up to 6 screen channel cassettes (4 suspended screen channel cassettes), 0.19m  (2ft ) will fit into the holder
accommodating process fluid volumes from a few hundred milliliters up to over a hundred liters.
Maximate cassettes are chosen for scale-up studies when process-scale volumes will be processed using a Maxisette system that has the
same feed/retentate channel path length.
Maxisette Holders
The Maxisette holder has been designed for optimal performance in a large-scale production environment. The longer path length of a
Maxisette cassette compared with a Centrasette cassette allows a 40 % reduction in cross flow rate (retentate flow rate), therefore requiring a
smaller pump with a corresponding reduction in heating, energy costs and space requirements. The small footprint makes it ideal for use in
process skids and manufacturing suites where space is at a premium. 
Feed flow direction is from bottom to top allowing air to be easily expelled from the system. Port design in the Maxisette cassette results in a
significant reduction in pressure drops and a more uniform pressure profile at operating cross flow rates compared to other cassette
formats. This results in higher performance during production and more efficient cleaning. 
Processes developed at bench scale on Maximate cassettes can be efficiently scaled up to process volumes in excess of 10,000 L. Maxisette
holders are available in auto-torque format with a hydraulic system, including six pistons and a pump, for maintaining optimal and uniform
compression on the installed cassettes. A pressurized air supply is required to operate the hydraulic pump (60 psi [4.1 bar] minimum, 125 psi





Cassette Holder Centramate LV Holder Centramate PE Holder Centramate Holder
Feed and retentate ports Female luer SS # in. NPT Fitting (female) $ in. sanitary, 9.6 mm (0.38 in.) bore





0.04 m  (0.4 ft )
0.02 m  (0.2 ft )
 -
0.37 m  (4 ft )
0.28 m (3 ft )
 -
0.46 m (5 ft )
0.37 m (4 ft )
Nominal dimensions
(Width x Length x Depth)
 12 x 23 6.6 cm
(4$  x 9 x  2$  in.)
9.4 x 24 x 19 cm
(3% x 9# x 7$ in.)
13 x 23 x 16 cm
(5# x 9 x 6# in.)
Weight 4 kg (8.75 lbs) 8.6 kg (19  lbs) 6.4 kg (14 lbs)
Maximum operating temperature 50 °C 80 °C 80 °C




Cassette Holder Centrasette LV Holder Centrasette P Holder Centrasette 5*,  5AT* Holder,
Feed and retentate ports % in. sanitary SS % in. sanitary PP 1 in. sanitary SS





2.0  m  (22  ft )
1.5  m  (16  ft )
 -
2.0  m  (22  ft )
1.5  m  (16  ft )
-
5  m  (54  ft )
4  m  (43  ft )
Nominal dimensions
(Width x Length x Depth)
26 x 25 x 21 cm
(10#  x 10 x  8$  in.)
30 x 20 x 34 cm
(12 x 8 x 13$ in.)
26 x 25 x 27 cm
(10# x 10 x 10% in.)
Weight 28 kg (62 lbs) 25 kg (55 lbs) 30 kg (66 lbs)
Maximum operating temperature 80 °C 50 °C 80 °C
Maximum operating pressure 6  bar (90 psi) 5 bar (75 psi) 6  bar (90 psi)
 












Feed and retentate ports 2 in. .sanitary 2 in. .sanitary 2 in. .sanitary 2 in. .sanitary





20  m  (216  ft )
15  m  (161  ft )
 -
40  m  (430  ft )
30  m  (323  ft )
 -
60  m  (645  ft )
45  m  (484  ft )
 -
80  m  (860  ft )
60  m  (645  ft )
Nominal dimensions
(Width x Length x Depth)
39 x 91 x 59 cm
(15$ x 36 x 23# in.)
39 x 91 x 59 cm
(15$ x 36 x 37$ in.) 
39 x 91 x 107 cm
(15$ x 36 x 42 in.)
39 x 91 x 120 cm
(15$  x 36 x 47$ in.)
Weight 155 kg (340 lbs) 255 kg (560 lbs) 314 kg (690 lbs) 409 kg (900 lbs)
Maximum operating
temperature
80 °C 80 °C 80 °C 80 °C
Maximum operating pressure 6  bar (90 psi) 6  bar (90 psi) 6  bar (90 psi) 6  bar (90 psi)
 
!. Cassette blocks (2 m2 (21.6 ft2) or 2.5 m2 (26.9 ft2) are recommended. If 0.5 m2 (5.3 ft2) cassettes are used, stabilizer plates must be used
between every 5 cassettes (fine/medium screen) or 3 cassettes suspended screen.
". Maximum operating temperature may be restricted by cassette operating temperature limit.
&. Holder may be steamed with compatible cassettes, or without cassettes at up to 142 °C.
Maximate and Maxisette Cassette Holders
 
Cassette Holder Maximate Holder Maxisette 25 Holder Maxisette 50 Holder Maxisette 100 Holder
Feed and retentate ports % in. sanitary 2 in. sanitary 2$ in. sanitary 2$ in. sanitary





1.1  m  (12  ft )
0.74  m  (8  ft )
 -
28  m  (300  ft )
28  m  (300  ft )
 -
56  m  (600  ft )
56  m  (600  ft )
-
89  m  (960  ft )
56  m  (600  ft )
Nominal dimensions
(Width x Length x Depth)
16 x 44 x 22 cm
(6# x 17$ x 8% in.)
 47 x 105 x 57 cm
(18$ x 41$ x 22$ in.)
47 x 105 x 97 cm
(18$  x 41$  x 38 in.)
 47 x 105 x 117 cm
(18$  x 41$  x 46 in.)
Weight 13.3 kg (29.2 lbs) 455 kg (1000 lbs) 566 kg (1245 lbs) 566 kg (1245 lbs)
Maximum operating temperature 80 °C 80 °C 80 °C 80 °C
maximum operating pressure 6  bar (87 psi) 6  bar (87 psi) 6  bar (87 psi) 6  bar (87 psi)
 
!. Cassette blocks (2 m2 (21.6 ft2) or 2.5 m2 (26.9 ft2) are recommended. If 0.5 m2 (5.3 ft2) cassettes are used, stabilizer plates must be used
between every 5 cassettes (fine/medium screen) or 3 cassettes suspended screen.
". Maximum operating temperature may be restricted by cassette operating temperature limit.
&. Holder may be steamed with compatible cassettes, or without cassettes at up to 142 °C.
Materials of Construction for Wetted Parts
 
Holder Centramate PE Centramate LV Centramate/Maximate Centrasette P Centrasette Maxisette
Plates UHMW polyethylene 316L stainless steel 316L stainless steel Polypropylene 316L stainless steel
Flow distribution
manifold
UHMW polyethylene 316L stainless steel 316L stainless steel Polypropylene 316L stainless steel
Other components  EPDM o-ring on SS 
threaded luer connector




View additional Tangential Flow Filtration Systems and Components.
TFF Holders and Accessories
Ordering Information
The following table lists individual cassette holders as well as holders sold in combination with fittings packages. Additional combinations
and a variety of other accessories are available. For complete descriptions and additional offerings, contact your Pall representative.
 
Description Part Number
Centramate PE Holder, including torque wrench and socket FS002K10
Centramate PE Holder, including fittings package with 3 pressure gauges FS013K10
Centramate LV Holder, including torque wrench and socket CM018LV
Centramate SS Holder, including torque wrench and socket FS001K10
Centramate SS Holder, including torque wrench, fittings package with 3 pressure gauges, 
2 diaphragm valves
FS011K10
Centrasette 5 manual torque, including torque wrench and socket FS001K05
Centrasette P Holder, including torque wrench and socket FS039K05
Centrasette LV Holder, including torque wrench and socket FS044K05
Centrasette LV Holder, including torque wrench and socket, fittings package with 3 pressure gauges, 
2 diaphragm valves
FS046K05
Centrasette 5 Holder, including torque wrench and socket FS001K05
Centrasette 5 Holder, including torque wrench and socket, fittings package with 3 pressure gauges, 
2 diaphragm valves
FS014K05
Centrasette 5AT Holder FS020K05
Centrasette 5AT Holder, including torque wrench and socket, fittings package with 3 pressure gauges, 
2 diaphragm valves
FS022K05
Centrastak 100 AT Holder FS050K05
Centrastak 200 AT Holder FS034K05
Centrastak 300 AT Holder FS036K05
Centrastak 400 AT Holder FS038K05
Maximate Holder, including torque wrench and socket FS001G01
Maximate Holder, including torque wrench and socket, fittings package with 3 pressure gauges, 
2 diaphragm valves
FS003G01
Maxisette 25 AT Holder FS009K50 
Maxisette 50 AT Holder FS013K50
Maxisette 100 AT Holder FS016K50
 
View additional Tangential Flow Filtration Systems and Components.
Designed for optimum performance and product recovery, Pall's TFF cassette holders are available in a variety of sizes to meet every
application requirement. Applications developed on a small system using a Centramate or Maximate cassette can be easily scaled up, either
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Millipore Express® SHC (Sterile, High Capacity) 
¿OWHUVSURYLGHVXSHULRUWKURXJKSXWDQGFDSDFLW\LQ










• Validated sterilizing-grade performance


























































































































































































































































































4XDQWLWDWLYHUHWHQWLRQRI&)8FP Brevundimonas diminuta$7&&®SHU$670® methodology
Bacterial Endotoxin
$TXHRXVH[WUDFWLRQFRQWDLQV(8P/DVGHWHUPLQHGXVLQJWKH/LPXOXV$PHERF\WH/\VDWH/$/WHVW





















































































































































































































































































































































































































Opticap® XL 3 
Capsules
Opticap® XL 5 
Capsules
Opticap® XL 10 
Capsules
Opticap® XLT 10 
Capsules
Opticap® XLT 20 
Capsules




























































FFPLQ FFPLQ FFPLQ FFPLQ FFPLQ FFPLQ
%DFWHULDO5HWHQWLRQ
4XDQWLWDWLYHUHWHQWLRQRI&)8FP Brevundimonas diminuta$7&&®SHU$670® methodology
Bacterial Endotoxin
$TXHRXVH[WUDFWLRQFRQWDLQV(8P/DVGHWHUPLQHGE\WKH/LPXOXV$PHERF\WH/\VDWH/$/7HVW
TOC/Conductivity at 25 °C
$XWRFODYHG¿OWHUHIÀXHQWPHHWVWKH:),UHTXLUHPHQWVRI863!IRU7RWDO2UJDQLF&DUERQDQG863!IRU:DWHU
&RQGXFWLYLW\DIWHUD:),ÀXVKRI
5.5 L / / / 40 L /
Oxidizable Substances
0HHWVWKH8632[LGL]DEOH6XEVWDQFHV7HVWUHTXLUHPHQWVIRUVWHULOHSXUL¿HGZDWHUDIWHUDZDWHUÀXVKRI





































































4XDQWLWDWLYHUHWHQWLRQRI&)8FP Brevundimonas diminuta$7&&®SHU$670® methodology
Bacterial Endotoxin
$TXHRXVH[WUDFWLRQFRQWDLQV(8P/DVGHWHUPLQHGE\WKH/LPXOXV$PHERF\WH/\VDWH/$/7HVW
TOC/Conductivity at 25 °C
*DPPDVWHULOL]HG¿OWHUHIÀXHQWPHHWVWKH:),UHTXLUHPHQWVRI863!IRU7RWDO2UJDQLF
&DUERQDQG863!IRU:DWHU&RQGXFWLYLW\DIWHUDZDWHUÀXVKRI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Opticap® XL 3 
Capsules
Opticap® XL 5 
Capsules
Opticap® XL 10 
Capsules
Per 10” Standard Area 
Opticap® XLT Capsule





























































FFPLQ FFPLQ FFPLQ FFPLQ FFPLQ
%DFWHULDO5HWHQWLRQ
4XDQWLWDWLYHUHWHQWLRQRI&)8FP Brevundimonas diminuta$7&&®SHU$670® methodology
Bacterial Endotoxin
$TXHRXVH[WUDFWLRQFRQWDLQV(8P/DVGHWHUPLQHGXVLQJWKH/LPXOXV$PHERF\WH/\VDWH/$/WHVW
TOC/Conductivity at 25 °C
*DPPDVWHULOL]HG¿OWHUPHHWVWKH:),UHTXLUHPHQWVRI863!IRU7RWDO2UJDQLF&DUERQDQG863!IRU:DWHU&RQGXFWLYLW\
DIWHUD:),ÀXVKRI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HH =  14 mm (LQ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015 = Opticap® XL 150
 2SWLFDS®;/
 2SWLFDS®;/













 SN2SWLFDS® XL 
RQO\
 SN2SWLFDS® XL 5 
and XL 10 only)
K H G E
&DSVXOH6L]H
 2SWLFDS®;/
05 = Opticap® XL 5
10 = Opticap® XL 10
&RQQHFWLRQ7\SH
77 PP1LQVDQLWDU\ÀDQJHLQOHWDQGRXWOHW









































































C H G E
Description Qty/pk Catalogue Number
















In the U.S. and Canada, call toll-free
1(800)-645-5476
For other countries across Europe, call
+44 (0) 115 943 0840
For other countries across Europe  
and the world, please visit  
ZZZHPGPLOOLSRUHFRPRɡFHV
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Caution: Product has not been fully validated for medical applications. For research use only.
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SAFETY DATA SHEET 
Version 5.1 Revision Date 05/16/2018 
Print Date 11/16/2018 
A  P  L , I . 700 I  P  D , A , AL 35007,USA  (800) 227-0651  (205) 663-2494 
F (800) 229-1004 (205) 663-0756  E-  O : @ .   E-mail Inquiries: info@avantilipids.com
E-mail Tech  Q : @ .   V  . .
1. PRODUCT AND COMPANY IDENTIFICATION
1.1 Product identifiers 
Product name : 1,2-stearoyl-3-trimethylammonium-propane 
(chloride salt) 
Product Number : 890880C 
Brand : AVANTI 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 







1.4 Emergency telephone number 
Emergency Phone # : &+(075(&
2. HAZARDS IDENTIFICATION
2.1 Classification of the substance or mixture 
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) 
Acute toxicity, Oral (Category 4), H302 
Acute toxicity, Inhalation (Category 3), H331 
Skin irritation (Category 2), H315 
Eye irritation (Category 2A), H319 
Carcinogenicity (Category 2), H351 
Reproductive toxicity (Category 2), H361d 
Specific target organ toxicity - single exposure (Category 3), Central nervous system, H336 
Specific target organ toxicity - repeated exposure (Category 1), Liver, Kidney, H372 
Acute aquatic toxicity (Category 3), H402 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
2.2 GHS Label elements, including precautionary statements 
Pictogram 
Signal word Danger 
Hazard statement(s) 
H302 Harmful if swallowed. 
H315 Causes skin irritation. 
H319 Causes serious eye irritation. 
Lipid structurally similar to ALC-0159 used in the proposed manufacturing process
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H331 Toxic if inhaled. 
H336 May cause drowsiness or dizziness. 
H351 Suspected of causing cancer. 
H361d Suspected of damaging the unborn child. 
H372 Causes damage to organs (Liver, Kidney) through prolonged or repeated 
exposure. 
H402 Harmful to aquatic life. 
 
Precautionary statement(s) 
P201 Obtain special instructions before use. 
P202 Do not handle until all safety precautions have been read and 
understood. 
P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray. 
P264 Wash skin thoroughly after handling. 
P270 Do not eat, drink or smoke when using this product. 
P271 Use only outdoors or in a well-ventilated area. 
P273 Avoid release to the environment. 
P280 Wear protective gloves/ protective clothing/ eye protection/ face 
protection. 
P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. 
Rinse mouth. 
P302 + P352 IF ON SKIN: Wash with plenty of soap and water. 
P304 + P340 + P311 IF INHALED: Remove person to fresh air and keep comfortable for 
breathing. Call a POISON CENTER/doctor. 
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove 
contact lenses, if present and easy to do. Continue rinsing. 
P308 + P313 IF exposed or concerned: Get medical advice/ attention. 
P332 + P313 If skin irritation occurs: Get medical advice/ attention. 
P337 + P313 If eye irritation persists: Get medical advice/ attention. 
P362 Take off contaminated clothing and wash before reuse. 
P403 + P233 Store in a well-ventilated place. Keep container tightly closed. 
P405 Store locked up. 
P501 Dispose of contents/ container to an approved waste disposal plant. 
 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.2 Mixtures 
Synonyms : 18:0 TAP 
 
Molecular weight : 119.38 g/mol 
 
Hazardous components 










Acute Tox. 4; Acute Tox. 3; 
Skin Irrit. 2; Eye Irrit. 2A; Carc. 
2; Repr. 2; STOT SE 3; STOT 
RE 1; Aquatic Acute 3; H302, 
H315, H319, H331, H336, 
H351, H361d, H372, H402 
90 - 100 % 
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4. FIRST AID MEASURES 
4.1 Description of first aid measures 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician. 
In case of eye contact 
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
No data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Wear respiratory protection. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Evacuate personnel to 
safe areas. 
For personal protection see section 8. 
6.2 Environmental precautions 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the environment 
must be avoided. 
6.3 Methods and materials for containment and cleaning up 
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable, closed containers for 
disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully resealed 
and kept upright to prevent leakage.  
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Recommended storage temperature -25 - -15 °C 
Storage class (TRGS 510): 6.1D: Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous materials 
causing chronic effects 
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Component CAS-No. Value Control 
parameters 
Basis 
Chloroform 67-66-3 TWA 10 ppm  
 
USA. ACGIH Threshold Limit Values 
(TLV) 
 Remarks Central Nervous System impairment 
Liver damage 
Embryo/fetal damage 
Confirmed animal carcinogen with unknown relevance to humans 
  ST 2 ppm  
9.78 mg/m3 
USA. NIOSH Recommended 
Exposure Limits 
  Potential Occupational Carcinogen 
See Appendix A 
  C 50 ppm  
240 mg/m3 
USA. Occupational Exposure Limits 
(OSHA) - Table Z-1 Limits for Air 
Contaminants 
  The value in mg/m3 is approximate. 
Ceiling limit is to be determined from breathing-zone air samples. 
  PEL 2 ppm  
9.78 mg/m3 
California permissible exposure 
limits for chemical contaminants 
(Title 8, Article 107) 
8.2 Exposure controls 
Appropriate engineering controls 
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product. 
Personal protective equipment 
Eye/face protection 
Face shield and safety glasses Use equipment for eye protection tested and approved under appropriate 
government standards such as NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Body Protection 
Complete suit protecting against chemicals, The type of protective equipment must be selected according to 
the concentration and amount of the dangerous substance at the specific workplace. 
Respiratory protection 
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with multi-
purpose combination (US) or type AXBEK (EN 14387) respirator cartridges as a backup to engineering 
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators 
and components tested and approved under appropriate government standards such as NIOSH (US) or CEN 
(EU). 
Control of environmental exposure 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the 
environment must be avoided. 
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9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: liquid 
Colour: colourless 
b) Odour sweet 
c) Odour Threshold No data available 
d) pH No data available 
e) Melting point/freezing 
point 
Melting point: -63.5 °C (-82.3 °F) at 1,013 hPa (760 mmHg) 
f) Initial boiling point and 
boiling range 
61.2 °C (142.2 °F) at 1,013 hPa (760 mmHg) 
g) Flash point  - DIN 51755 Part 1does not flash 
h) Evaporation rate No data available 




No data available 
k) Vapour pressure 210 hPa (158 mmHg) at 20 °C (68 °F) 
l) Vapour density 4.12 - (Air = 1.0) 
m) Relative density 1.49 g/cm3 
n) Water solubility 8.7 g/l at 23 °C (73 °F) - OECD Test Guideline 105 
o) Partition coefficient: n-
octanol/water 
log Pow: 1.97 at 25 °C (77 °F) - (ECHA), Bioaccumulation is not expected. 
p) Auto-ignition 
temperature 
> 600 °C (> 1,112 °F) at 1,013 hPa (760 mmHg) - DIN 51794 
q) Decomposition 
temperature 
Distillable in an undecomposed state at normal pressure. 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
 Solubility in other 
solvents 
organic solvent  at 20 °C (68 °F) - miscible 
 Surface tension 27.1 mN/m at 20.0 °C (68.0 °F) 
 Relative vapour density 4.12 - (Air = 1.0) 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
Contains the following stabiliser(s): 
Ethanol (0.5 %) 
10.3 Possibility of hazardous reactions 
No data available 
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10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong oxidizing agents, Strong bases, Magnesium, Sodium/sodium oxides, Lithium, various plastics 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Hydrogen chloride gas 
Other decomposition products - No data available 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 




IARC: 2B - Group 2B: Possibly carcinogenic to humans (Chloroform) 
NTP: RAHC - Reasonably anticipated to be a human carcinogen (Chloroform) 
OSHA: N              0.1%   OSHA  
list of regulated carcinogens. 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: Not available 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. 
 
Stomach - Irregularities - Based on Human Evidence 
Stomach - Irregularities - Based on Human Evidence 
Stomach - Irregularities - Based on Human Evidence (Ethanol) 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
No data available 
12.2 Persistence and degradability 
No data available 
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12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
An environmental hazard cannot be excluded in the event of unprofessional handling or disposal. 
Harmful to aquatic life. 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste 
disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a 
chemical incinerator equipped with an afterburner and scrubber.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
UN number: 1888 Class: 6.1 Packing group: III 
Proper shipping name: Chloroform, solution 
Reportable Quantity (RQ): 10 lbsReportable Quantity (RQ): 10 lbs 
Poison Inhalation Hazard: No 
 
IMDG 
UN number: 1888 Class: 6.1 Packing group: III EMS-No: F-A, S-A 




UN number: 1888 Class: 6.1 Packing group: III 
Proper shipping name: Chloroform, solution 
 
15. REGULATORY INFORMATION 







SARA 313 Components 







SARA 311/312 Hazards 
Acute Health Hazard, Chronic Health Hazard 
 :  
Reportable Quantity  D022 lbs 
 














California Prop. 65 Components 
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, which is/are known to the State of California to cause cancer 
and birth defects or other reproductive harm. For more 









16. OTHER INFORMATION 
Full text of H-Statements referred to under sections 2 and 3. 
Acute Tox. Acute toxicity 
Aquatic Acute Acute aquatic toxicity 
Carc. Carcinogenicity 
Eye Irrit. Eye irritation  
H302 Harmful if swallowed. 
H315 Causes skin irritation. 
H319 Causes serious eye irritation. 
H331 Toxic if inhaled. 
H336 May cause drowsiness or dizziness. 
H351 Suspected of causing cancer. 
H361d Suspected of damaging the unborn child. 
H372 Causes damage to organs through prolonged or repeated exposure. 
H402 Harmful to aquatic life. 
Repr. Reproductive toxicity 
Skin Irrit. Skin irritation 
STOT RE Specific target organ toxicity - repeated exposure  
STOT SE Specific target organ toxicity - single exposure 
HMIS Rating 
Health hazard: 2 
Chronic Health Hazard: * 
Flammability: 0 
Physical Hazard 0 
NFPA Rating 
Health hazard: 2 
Fire Hazard: 0 
Reactivity Hazard: 0 
Further information 
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 




Product Safety  Americas Region 
1-800-521-8956 
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SAFETY DATA SHEET 
 
Version 6.2 
Revision Date 01/15/2020 
Print Date 11/20/2020 
 
SECTION 1: Identification of the substance/mixture and of the company/undertaking 
1.1 Product identifiers 
Product name : Cholesterol 
 
Product Number : C8667 
Brand : Sigma 
CAS-No. : 57-88-5 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich Inc. 
3050 Spruce Street 
ST. LOUIS MO  63103 
UNITED STATES 
 
Telephone : +1 314 771-5765 
Fax : +1 800 325-5052 
1.4 Emergency telephone number 
Emergency Phone # : 800-424-9300 CHEMTREC (USA) +1-703-
527-3887 CHEMTREC (International) 24 
Hours/day; 7 Days/week 
 
 
SECTION 2: Hazards identification 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 




SECTION 3: Composition/information on ingredients 
3.1 Substances 
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Formula : C27H46O 
Molecular weight : 386.65 g/mol 
CAS-No. : 57-88-5 
EC-No. : 200-353-2 
 




SECTION 4: First aid measures 
4.1 Description of first aid measures 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
In case of skin contact 
Wash off with soap and plenty of water. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 
2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 




SECTION 5: Firefighting measures 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
Carbon oxides 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 




SECTION 6: Accidental release measures 
6.1 Personal precautions, protective equipment and emergency procedures 
Avoid dust formation. Avoid breathing vapours, mist or gas. 
For personal protection see section 8. 
6.2 Environmental precautions 
No special environmental precautions required. 
6.3 Methods and materials for containment and cleaning up 
Sweep up and shovel. Keep in suitable, closed containers for disposal. 
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6.4 Reference to other sections 




SECTION 7: Handling and storage 
7.1 Precautions for safe handling 
Further processing of solid materials may result in the formation of combustible dusts. The 
potential for combustible dust formation should be taken into consideration before 
additional processing occurs. 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Recommended storage temperature -20 °C 
 Keep in a dry place.  
Storage class (TRGS 510): 13: Non Combustible Solids 
7.3 Specific end use(s) 




SECTION 8: Exposure controls/personal protection 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
General industrial hygiene practice. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate 
government standards such as NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove 
removal technique (without touching glove's outer surface) to avoid skin contact 
with this product. Dispose of contaminated gloves after use in accordance with 
applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
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data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail 
sales@kcl.de, test method: EN374 
If used in solution, or mixed with other substances, and under conditions which 
differ from EN 374, contact the supplier of the CE approved gloves. This 
recommendation is advisory only and must be evaluated by an industrial hygienist 
and safety officer familiar with the specific situation of anticipated use by our 




Choose body protection in relation to its type, to the concentration and amount of 
dangerous substances, and to the specific work-place., The type of protective 
equipment must be selected according to the concentration and amount of the 
dangerous substance at the specific workplace. 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of 
dusts are desired, use type N95 (US) or type P1 (EN 143) dust masks. Use 
respirators and components tested and approved under appropriate government 
standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
No special environmental precautions required. 
 
 
SECTION 9: Physical and chemical properties 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: powder 
Colour: white 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH No data available 
e) Melting 
point/freezing point 
Melting point/range: 147 - 149 °C (297 - 300 °F) 
f) Initial boiling point 
and boiling range 
360 °C 680 °F 
g) Flash point  ()No data available 
h) Evaporation rate No data available 
i) Flammability (solid, 
gas) 




No data available 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density 1.067 g/mL at 25 °C (77 °F) 
n) Water solubility 0.00003 g/l at 20 °C (68 °F) - OECD Test Guideline 105 - 
insoluble 
o) Partition coefficient: No data available 
 
 




The life science business of Merck KGaA, Darmstadt, Germany 









No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 




SECTION 10: Stability and reactivity 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides 
Other decomposition products - No data available 




SECTION 11: Toxicological information 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - male and female - > 2,000 mg/kg 
(OECD Test Guideline 401) 
LD50 Dermal - Rat - male and female - > 2,000 mg/kg 
(OECD Test Guideline 402) 
Remarks: Limit Test 
No data available 
Skin corrosion/irritation 
Skin - In vitro study 
Result: No skin irritation 
(OECD Test Guideline 439) 
Serious eye damage/eye irritation 
Eyes - Rabbit 
Result: No eye irritation 
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(OECD Test Guideline 405) 
Respiratory or skin sensitisation 
Sensitisation test: - Mouse 
Result: negative 
(OECD Test Guideline 429) 
Germ cell mutagenicity 
No data available 
Ames test 




IARC: 3 - Group 3: Not classifiable as to its carcinogenicity to humans (Cholesterol) 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is 
identified as a carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is 
on OSHA  li  of eg la ed ca cinogens. 
Reproductive toxicity 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 





To the best of our knowledge, the chemical, physical, and toxicological properties have not 
been thoroughly investigated. 
 
No  toxic  effects  are  to  be  expected  when  the  product is handled appropriately. 
Substance which occurs in the human body under physiological conditions. 





SECTION 12: Ecological information 
12.1 Toxicity 
12.2 Persistence and degradability 
Biodegradability aerobic  - Exposure time 28 d 
Result: 74 % - Inherently biodegradable.  
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12.3 Bioaccumulative potential 
12.4 Mobility in soil 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not 
conducted 




SECTION 13: Disposal considerations 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 




SECTION 14: Transport information 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 




SECTION 15: Regulatory information 
 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, 
Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that 
exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 
313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 






New Jersey Right To Know Components 
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California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, 




SECTION 16: Other information 
Further information 
Copyright 2020 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies 
for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive 
and shall be used only as a guide. The information in this document is based on the 
present state of our knowledge and is applicable to the product with regard to 
appropriate safety precautions. It does not represent any guarantee of the properties of 
the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any 
damage resulting from handling or from contact with the above product. See 
www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional 
terms and conditions of sale. 
 
The branding on the header and/or footer of this document may temporarily not visually 
match the product purchased as we transition our branding. However, all of the 
information in the document regarding the product remains unchanged and matches the 
product ordered. For further information please contact mlsbranding@sial.com. 
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SECTION 1: Identification of the substance/mixture and of the company/undertaking 
1.1 Product identifiers 
Product name : 1,2-distearoyl-sn-glycero-3-phosphocholine 
 
Product Number : 850365P 
Brand : Avanti 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich Inc. 
3050 Spruce Street 
ST. LOUIS MO  63103 
UNITED STATES 
 
Telephone : +1 314 771-5765 
Fax : +1 800 325-5052 
1.4 Emergency telephone number 
Emergency Phone # : 800-424-9300 CHEMTREC (USA) +1-703-
527-3887 CHEMTREC (International) 24 
Hours/day; 7 Days/week 
 
 
SECTION 2: Hazards identification 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 




SECTION 3: Composition/information on ingredients 
3.1 Substances 
Synonyms : 18:0 PC (DSPC) 
 












SECTION 4: First aid measures 
4.1 Description of first aid measures 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
In case of skin contact 
Wash off with soap and plenty of water. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 
2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 




SECTION 5: Firefighting measures 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
Carbon oxides, Nitrogen oxides (NOx), Oxides of phosphorus 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 




SECTION 6: Accidental release measures 
6.1 Personal precautions, protective equipment and emergency procedures 
Avoid dust formation. Avoid breathing vapours, mist or gas. 
For personal protection see section 8. 
6.2 Environmental precautions 
No special environmental precautions required. 
6.3 Methods and materials for containment and cleaning up 
Sweep up and shovel. Keep in suitable, closed containers for disposal. 
6.4 Reference to other sections 




SECTION 7: Handling and storage 
7.1 Precautions for safe handling 
Further processing of solid materials may result in the formation of combustible dusts. The 
potential for combustible dust formation should be taken into consideration before 
additional processing occurs. 
 
 





Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Recommended storage temperature -20 °C 
Storage class (TRGS 510): 13: Non Combustible Solids 
7.3 Specific end use(s) 




SECTION 8: Exposure controls/personal protection 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
General industrial hygiene practice. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate 
government standards such as NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove 
removal technique (without touching glove's outer surface) to avoid skin contact 
with this product. Dispose of contaminated gloves after use in accordance with 
applicable laws and good laboratory practices. Wash and dry hands. 
 
Body Protection 
Choose body protection in relation to its type, to the concentration and amount of 
dangerous substances, and to the specific work-place., The type of protective 
equipment must be selected according to the concentration and amount of the 
dangerous substance at the specific workplace. 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of 
dusts are desired, use type N95 (US) or type P1 (EN 143) dust masks. Use 
respirators and components tested and approved under appropriate government 
standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
No special environmental precautions required. 
 
 
SECTION 9: Physical and chemical properties 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: powder 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH No data available 
e) Melting 
point/freezing point 
No data available 
 
 





f) Initial boiling point 
and boiling range 
No data available 
g) Flash point  ()No data available 
h) Evaporation rate No data available 
i) Flammability (solid, 
gas) 




No data available 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density No data available 
n) Water solubility slightly soluble 
o) Partition coefficient: 
n-octanol/water 
No data available 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 




SECTION 10: Stability and reactivity 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen 
oxides (NOx), Oxides of phosphorus 











SECTION 11: Toxicological information 
11.1 Information on toxicological effects 
Acute toxicity 
No data available 
Inhalation: No data available 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 
No data available 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
NTP: No component of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is 
 OSHA    lated carcinogens. 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: Not available 
 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not 





SECTION 12: Ecological information 
12.1 Toxicity 
No data available 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
 
 





12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not 
conducted 
12.6 Other adverse effects 




SECTION 13: Disposal considerations 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 




SECTION 14: Transport information 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 




SECTION 15: Regulatory information 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, 
Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that 
exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 
313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
















New Jersey Right To Know Components 
 
 












California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, 




SECTION 16: Other information 
Further information 
Copyright 2018 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies 
for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive 
and shall be used only as a guide. The information in this document is based on the 
present state of our knowledge and is applicable to the product with regard to 
appropriate safety precautions. It does not represent any guarantee of the properties of 
the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any 
damage resulting from handling or from contact with the above product. See 
www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional 
terms and conditions of sale. 
 
The branding on the header and/or footer of this document may temporarily not visually 
match the product purchased as we transition our branding. However, all of the 
information in the document regarding the product remains unchanged and matches the 
product ordered. For further information please contact mlsbranding@sial.com. 
 





Identification of the substance/preparation  
24 hour Emergency Response (Transport): 866-536-0631
301-431-8585
Outside of the U.S. +1-301-431-8585
Product code
For research use only. Not intended for human or animal diagnostic or therapeutic uses.
Revision Date
18330019
Product name  ATP
Company/Undertaking Identification  
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5791 VAN ALLEN WAY
PO BOX 6482
CARLSBAD, CA 92008
+1 760 603 7200
4 . F i r s t  a i d  m e a s u r e s
Principle Routes of Exposure/
Potential Health effects  
GHS - Classification 
Eyes May cause eye irritation with susceptible persons.
Signal Word
not hazardous
Skin May cause skin irritation in susceptible persons.
Inhalation May be harmful by inhalation.
Ingestion May be harmful if swallowed.
3 . C o m p o s i t i o n /i n f o r m a t i o n  o n  i n g r e d i e n t s
The product contains no substances which at their given concentration, are considered to be hazardous to health. We













Product name  ATP











Prevent further leakage or spillage if safe to do so.
Treat symptomatically.
Respiratory protection In case of insufficient ventilation wear suitable respiratory equipment.
Skin contact
See Section 12 for additional information.
Rinse with plenty of water. If symptoms arise, call a physician.
Hand protection Impervious gloves.
Ingestion
Eye protection Safety glasses with side-shields.
7 . H a n d l i n g  a n d  s t o r a g e
6 . A c c i d e n t a l  r e l e a s e  m e a s u r e s
Skin and body protection. Lightweight protective clothing.
Never give anything by mouth to an unconscious person. If symptoms persist, call
a physician. Do not induce vomiting without medical advice.
Hygiene measures Handle in accordance with good industrial hygiene and safety practice.
5 . F i r e -f i g h t i n g  m e a s u r e s




Prevent product from entering drains.
Storage Keep in a dry, cool and well-ventilated place.
Personal precautions Use personal protective equipment.
_____________________________________________________________________________________________
Inhalation
8 . E x p o s u r e  c o n t r o l s/p e r s o n a l  p r o t e c t i o n
Methods for cleaning up Soak up with inert absorbent material.
Move to fresh air. If symptoms persist, call a physician. If not breathing, give
artificial respiration.
Suitable extinguishing media
Exposure limits  
Revision Date
Water spray. Carbon dioxide (CO2). Foam. Dry chemical.
Product name  ATP
Eye contact
Page  3 / 6
Exposure limits We are not aware of any national exposure limit.
Environmental precautions  
29-Nov-2011
Rinse immediately with plenty of water, also under the eyelids, for at least 15
minutes. If symptoms persist, call a physician.
Engineering measures 
www.lifetechnologies.com
Ensure adequate ventilation, especially in confined areas.
Special protective equipment for firefighters
Product code


















None under normal use
Target Organ Effects None under normal use conditions
polymerization Hazardous polymerisation does not occur.
9 . P h y s i c a l  a n d  c h e m i c a l  p r o p e r t i e s
1 2 . E c o l o g i c a l  i n f o r m a t i o n
1 1 . T o x i c o l o g i c a l  i n f o r m a t i o n
Ecotoxicity effects No information available.
Oxidizing properties




Acute toxicity  
Bioaccumulation Does not bioaccumulate.
Water solubility soluble
No information available
Acute toxicity not hazardous
Principle Routes of Exposure/
Potential Health effects 
Eyes May cause eye irritation with susceptible persons.
_____________________________________________________________________________________________
General Information 
Skin May cause skin irritation in susceptible persons.
1 0 . S t a b i l i t y  a n d  r e a c t i v i t y
Odor
Inhalation May be harmful by inhalation.
Revision Date
Product name  ATP
Ingestion
Page  4 / 6
May be harmful if swallowed.
°F  no data available
Melting point/range
29-Nov-2011
°C  no data available
Autoignition temperature
www.lifetechnologies.com
°C  no data available
Boiling Point/Range
Product code
°F  no data available
Flash point
°C  no data available
°F  no data available
18330019
°C  no data available
°F  no data available
Proper shipping name Not classified as dangerous in the meaning of transport regulations
The above information was acquired by diligent search and/or investigation and the recommendations are based on
prudent application of professional judgment.  The information shall not be taken as being all inclusive and is to be
used only as a guide.  All materials and mixtures may present unkown hazards and should be used with caution.
Since the Company cannot control the actual methods, volumes, or conditions of use, the Company shall not be held
liable for any damages or losses resulting from the handling or from contact with the product as described herein.
THE INFORMATION IN THIS MSDS DOES NOT CONSTITUTE A WARRENTY, EXPRESSED OR IMPLIED,
INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PUPOSE.
1 3 . D i s p o s a l  c o n s i d e r a t i o n s
Hazard class none
End of Safety Data Sheet
Subsidiary Class none
1 6 . O t h e r  i n f o r m a t i o n
Packing group none
IATA 
Reason for Revision Initial Release.
UN-No None
Dispose of in accordance with local regulations.
1 4 . T r a n s p o r t  i n f o r m a t i o n
For research use only. Not intended for human or animal diagnostic or therapeutic uses.
_____________________________________________________________________________________________
SARA 313
This product is not regulated by SARA.
1 5 . R e g u l a t o r y  i n f o r m a t i o n
U.S. Federal Regulations 
Revision Date
Product name  ATP
California Proposition 65
This product does not contain chemicals listed under Proposition 65
Page  5 / 6
Clean Air Act, Section 112 Hazardous Air Pollutants (HAPs) (see 40 CFR 61)






This product has been classified according to the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR




Identification of the substance/preparation  
24 hour Emergency Response (Transport): 866-536-0631
301-431-8585
Outside of the U.S. +1-301-431-8585
Product code
For research use only. Not intended for human or animal diagnostic or therapeutic uses.
Revision Date
18331017
Product name  CTP
Company/Undertaking Identification  
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5791 VAN ALLEN WAY
PO BOX 6482
CARLSBAD, CA 92008
+1 760 603 7200
Safety Data Sheet
___________________________________________________________________________________________________________________
S E C T I O N  1 : I d e n t i f i c a t i o n  o f  t h e  s u b s t a n c e / m i x t u r e  a n d  o f  t h e  c o m p a n y/u n d e r t a k i n g
Identification of the substance or mixture  
Product code 18333013
Product name UTP
Company/undertaking identification  
24 hour Emergency Response for Hazardous Materials
[or Dangerous Goods] Incident. Spill, Leak, Fire,
Exposure, or Accident. Call CHEMTREC
Within the USA + Canada: 1-800-424-9300 and +1
703-527-3887
Outside the USA + Canada: +1 703-741-5970
Country Specific Emergency Number (if available):
For Research Use Only. Not for use in diagnostic procedures.
S E C T I O N  2 : H a z a r d s  i d e n t i f i c a t i o n











5781 Van Allen Way
PO Box 6482
Carlsbad, CA 92008
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S E C T I O N  3 : C o m p o s i t i o n /i n f o r m a t i o n  o n  i n g r e d i e n t s
The product contains no substances which at their given concentration, are considered to be hazardous to health. We
recommend handling all chemicals with caution.
S E C T I O N  4 : F i r s t  a i d  m e a s u r e s
Description of first aid measures
Skin contact Rinse with plenty of water . Immediate medical attention is not required.
Eye contact Rinse cautiously with water for several minutes. Remove contact lenses, if present
and easy to do.
Ingestion Not expected to present a significant ingestion hazard under anticipated conditions
of normal use. If you feel unwell, seek medical advice.
Inhalation Not expected to be an inhalation hazard under anticipated conditions of normal
use of this material. Consult a physician if necessary.
Notes to Physician Treat symptomatically.
Most important symptoms and effects, both acute and delayed
Not Applicable
Indication of any immediate medical attention and special treatment needed
None.
___________________________________________________________________________________________________________________
Revision date 07-Dec-2017 Page  2 / 7
Product code 18333013 Product name  UTP
www.thermofisher.com
S E C T I O N  8 : E x p o s u r e  c o n t r o l s /p e r s o n a l  p r o t e c t i o n
Control parameters 
Exposure Limits Contains no substances with occupational exposure limit values.
Engineering measures Ensure adequate ventilation, especially in confined areas.
Exposure controls 
Personal Protective Equipment
Respiratory protection In case of insufficient ventilation wear respirators and components tested and
approved under appropriate government standards.
S E C T I O N  5 : F i r e f i g h t i n g  m e a s u r e s
Extinguishing media
Suitable extinguishing media Water spray. Carbon dioxide (CO2). Foam. Dry chemical.
Unsuitable extinguishing media No information available.
Special hazards arising from the substance or mixture
Not known.
Advice for fire-fighters
Standard procedure for chemical fires.
S E C T I O N  6 : A c c i d e n t a l  r e l e a s e  m e a s u r e s
Personal precautions, protective equipment and emergency procedures
Ensure adequate ventilation. Always wear recommended Personal Protective Equipment. Use personal protection
equipment. See Section 8 for more detail.
Environmental precautions
No special environmental precautions required.
Methods and material for containment and cleaning up
Soak up with inert absorbent material.
Reference to other sections
See section 8 for more information.
S E C T I O N  7 : H a n d l i n g  a n d  s t o r a g e
Precautions for safe handling
Use personal protective equipment as required. No special handling advices are necessary.
Conditions for safe storage, including any incompatibilities
Keep in a dry, cool and well-ventilated place. Keep in properly labeled containers.
Specific end use(s)
For research use only.
___________________________________________________________________________________________________________________
Revision date 07-Dec-2017 Page  3 / 7
Product code 18333013 Product name  UTP
www.thermofisher.com
Hand protection Wear suitable gloves. Glove material: Compatible chemical-resistant gloves.
Eye protection Tight sealing safety goggles.
Skin and Body Protection Wear suitable protective clothing.
Hygiene measures Handle in accordance with good industrial hygiene and safety practice
Environmental exposure controls
No special environmental precautions required.
S E C T I O N  9 : P h y s i c a l  a n d  c h e m i c a l  p r o p e r t i e s
Information on basic physical and chemical properties
Appearance liquid
Odor No data available
Evaporation rate No data available
Flammability (solid, gas) No data available
Upper explosion limit Mixture has not been tested
Lower explosion limit Mixture has not been tested
Vapor Pressure Mixture has not been tested
Relative density Mixture has not been tested
Specific gravity No data available




Explosive properties Mixture has not been tested
Other information
No data available.
S E C T I O N  1 0 : S t a b i l i t y  a n d  r e a c t i v i t y
Reactivity None known.
Chemical stability Stable under normal conditions.
Possibility of hazardous
reactions
Hazardous reaction has not been reported.
Conditions to avoid No information available.




Melting point / melting range °C  Mixture has not been tested °F  Mixture has not been tested
Boiling point / boiling range °C  Mixture has not been tested °F  Mixture has not been tested
Flash point °C  Mixture has not been tested °F  Mixture has not been tested
Autoignition Temperature °C  Mixture has not been tested °F  Mixture has not been tested
Decomposition temperature °C  Mixture has not been tested °F  Mixture has not been tested
___________________________________________________________________________________________________________________
Revision date 07-Dec-2017 Page  4 / 7
Product code 18333013 Product name  UTP
www.thermofisher.com
S E C T I O N  1 1 : T o x i c o l o g i c a l  i n f o r m a t i o n
Information on toxicological effects
There is no evidence available indicating acute toxicity.
Principal Routes of Exposure
Irritation Conclusive but not sufficient for classification
 .
Corrosivity Conclusive but not sufficient for classification
Sensitization Conclusive but not sufficient for classification
 .
STOT - Single Exposure Conclusive but not sufficient for classification
STOT - Repeated Exposure Conclusive but not sufficient for classification
Carcinogenicity Conclusive but not sufficient for classification
Mutagenicity Conclusive but not sufficient for classification
 .
Reproductive toxicity Conclusive but not sufficient for classification
 .
Aspiration hazard Conclusive but not sufficient for classification
S E C T I O N  1 2 : E c o l o g i c a l  i n f o r m a t i o n
Toxicity
Contains no substances known to be hazardous to the environment or not degradable in waste water treatment
plants.
Persistence and degradability No information available.
Bioaccumulative potential No information available.
Results of PBT and vPvB assessment
This mixture does not contain any substances that are assessed to be a PBT or a vPvB.
Other adverse effects No information available.
S E C T I O N  1 3 : D i s p o s a l  c o n s i d e r a t i o n s
Waste treatment methods
The generation of waste should be avoided or minimized wherever possible. Empty containers or liners may retain
some product residues. This material and its container must be disposed of in according to approved disposal
technique. Disposal of this product, its solutions or of any by-products, shall comply with the requirements of all
applicable local, regional or national/federal regulations.
___________________________________________________________________________________________________________________
Revision date 07-Dec-2017 Page  5 / 7
Product code 18333013 Product name  UTP
www.thermofisher.com
S E C T I O N  1 6 : O t h e r  i n f o r m a t i o n
Reason for revision SDS sections updated.
Revision number 2
Revision date 07-Dec-2017
S E C T I O N  1 4 : T r a n s p o r t  i n f o r m a t i o n
IATA / ADR / DOT-US / IMDG
Not regulated in the meaning of transport regulations.
UN number Not Applicable
UN proper shipping name Not Applicable
Transport hazard class(es) Not Applicable
Packing group Not Applicable
Environmental hazards
Not Applicable
Special precautions for user
Not Applicable
Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not Applicable.
S E C T I O N  1 5 : R e g u l a t o r y  i n f o r m a t i o n
US Federal Regulations 
SARA 313
This product is not regulated by SARA.
Clean Air Act, Section 112 Hazardous Air Pollutants (HAPs) (see 40 CFR 61)
This product does not contains HAPs.
US State Regulations 
California Proposition 65
This product does not contain any Proposition 65 chemicals.
WHMIS Hazard Class
Non-controlled
This product has been classified in accordance with the hazard criteria of the Controlled Products Regulations (CPR)
and the SDS contains all the information required by the CPR.
___________________________________________________________________________________________________________________
Revision date 07-Dec-2017 Page  6 / 7
Product code 18333013 Product name  UTP
www.thermofisher.com






"The above information was acquired by diligent search and/or investigation and the recommendations are based on
prudent application of professional judgment. The information shall not be taken as being all inclusive and is to be
used only as a guide. All materials and mixtures may present unknown hazards and should be used with caution.
Since the Company cannot control the actual methods, volumes, or conditions of use, the Company shall not be held
liable for any damages or losses resulting from the handling or from contact with the product as described herein.
THE INFORMATION IN THIS SDS DOES NOT CONSTITUTE A WARRANTY, EXPRESSED OR
IMPLIED,INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR
PURPOSE"
End of Safety Data Sheet
___________________________________________________________________________________________________________________
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Identification of the substance/preparation  
24 hour Emergency Response (Transport): 866-536-0631
301-431-8585





Company/Undertaking Identification  
Product name  GTP
For research use only. Not intended for human or animal diagnostic or therapeutic uses.
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5791 VAN ALLEN WAY
PO BOX 6482
CARLSBAD, CA 92008
+1 760 603 7200
4 . F i r s t  a i d  m e a s u r e s
Principle Routes of Exposure/
Potential Health effects  
GHS - Classification 
Eyes May cause eye irritation with susceptible persons.
Signal Word
not hazardous
Skin May cause skin irritation in susceptible persons.
Inhalation May be harmful by inhalation.
Ingestion May be harmful if swallowed.
3 . C o m p o s i t i o n /i n f o r m a t i o n  o n  i n g r e d i e n t s
The product contains no substances which at their given concentration, are considered to be hazardous to health. We
















Product name  GTP
Reactivity








Personal protective equipment 
Eye contact
See Section 12 for additional information.
Rinse immediately with plenty of water, also under the eyelids, for at least 15
minutes. If symptoms persist, call a physician.
Respiratory protection In case of insufficient ventilation wear suitable respiratory equipment.
5 . F i r e -f i g h t i n g  m e a s u r e s
6 . A c c i d e n t a l  r e l e a s e  m e a s u r e s
Inhalation
7 . H a n d l i n g  a n d  s t o r a g e
Move to fresh air. If symptoms persist, call a physician. If not breathing, give
artificial respiration.
Hand protection Impervious gloves.
Eye protection Safety glasses with side-shields.
Skin contact
Skin and body protection. Lightweight protective clothing.
Handling Always wear reccommended Personal Protective Equipment. No special handling
advice required.
Hygiene measures Handle in accordance with good industrial hygiene and safety practice.
Personal precautions Use personal protective equipment.
Storage Keep in a dry, cool and well-ventilated place.
Environmental exposure 
controls 
Prevent product from entering drains.
Rinse with plenty of water. If symptoms arise, call a physician.
Suitable extinguishing media
Methods for cleaning up Soak up with inert absorbent material.
8 . E x p o s u r e  c o n t r o l s/p e r s o n a l  p r o t e c t i o n
Water spray. Carbon dioxide (CO2). Foam. Dry chemical.
_____________________________________________________________________________________________
Notes to physician
Exposure limits  
Treat symptomatically.
Special protective equipment for firefighters
Environmental precautions  
Wear self-contained breathing apparatus and protective
suit.
18332015
We are not aware of any national exposure limit.
Revision Date
Ingestion
Product name  GTP
Page  3 / 5
Never give anything by mouth to an unconscious person. If symptoms persist, call
a physician. Do not induce vomiting without medical advice.
27-Dec-2011
Engineering measures Ensure adequate ventilation, especially in confined areas.
www.lifetechnologies.com
Prevent further leakage or spillage if safe to do so.
Product code
No information available
Ingestion May be harmful if swallowed.











None under normal use
polymerization
Target Organ Effects No known effects under normal use conditions.
Hazardous polymerisation does not occur.
9 . P h y s i c a l  a n d  c h e m i c a l  p r o p e r t i e s
1 2 . E c o l o g i c a l  i n f o r m a t i o n
1 1 . T o x i c o l o g i c a l  i n f o r m a t i o n
Oxidizing properties
Ecotoxicity effects No information available.
No information available.
Mobility No information available.
Appearance
Acute toxicity  
Biodegradation Inherently biodegradable
Water solubility




Principle Routes of Exposure/




May cause eye irritation with susceptible persons.
1 0 . S t a b i l i t y  a n d  r e a c t i v i t y
Odor
Skin May cause skin irritation in susceptible persons.
Inhalation
18332015
May be harmful by inhalation.
Revision Date
°F  no data available
Product name  GTP
°F  no data available
Page  4 / 5
Melting point/range °C  no data available
Autoignition temperature
°C  no data available
27-Dec-2011
Boiling Point/Range °F  no data available
www.lifetechnologies.com
Flash point
°C  no data available
Product code
°F  no data available
°C  no data available
1 4 . T r a n s p o r t  i n f o r m a t i o n
For research use only. Not intended for human or animal diagnostic or therapeutic uses.
Proper shipping name Not classified as dangerous in the meaning of transport regulations
The above information was acquired by diligent search and/or investigation and the recommendations are based on
prudent application of professional judgment.  The information shall not be taken as being all inclusive and is to be
used only as a guide.  All materials and mixtures may present unkown hazards and should be used with caution.
Since the Company cannot control the actual methods, volumes, or conditions of use, the Company shall not be held
liable for any damages or losses resulting from the handling or from contact with the product as described herein.
THE INFORMATION IN THIS MSDS DOES NOT CONSTITUTE A WARRENTY, EXPRESSED OR IMPLIED,
INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PUPOSE.
1 3 . D i s p o s a l  c o n s i d e r a t i o n s
Hazard class none
End of Safety Data Sheet
Subsidiary Class none
1 6 . O t h e r  i n f o r m a t i o n
Packing group none
IATA 
Reason for Revision (M)SDS sections updated.
UN-No None
Dispose of in accordance with local regulations.
This product has been classified according to the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR
_____________________________________________________________________________________________
U.S. State Regulations 
SARA 313
This product is not regulated by SARA.
1 5 . R e g u l a t o r y  i n f o r m a t i o n




This product does not contain chemicals listed under Proposition 65
Product name  GTP
Page  5 / 5
Clean Air Act, Section 112 Hazardous Air Pollutants (HAPs) (see 40 CFR 61)










N-7113 Page 1 of 6 
1. IDENTIFICATION






Uses advised against: 
CleanCap™ Reagent $*   
N-7113
Not applicable.
Laboratory chemicals, manufacture of substances. 
No Information Available 
1.3 Details of the Supplier of the Safety Data Sheet 
Supplier address: TriLink BioTechnologies, Inc. 
9955 Mesa Rim Road 






1.4 Emergency Telephone Number 
Emergency Phone: 858-546-0004
800-863-6801 (toll free)
7 am – 5 pm PST, Monday-Friday
2. HAZARD IDENTIFICATION
2.1 Classification 
Not a dangerous substance or mixture 
2.2 Label Elements 
Not a hazardous substance or mixture. 




No ingredients are hazardous according to OSHA criteria. No components need to be disclosed 
according to the applicable regulations. 
4. FIRST AID MEASURES
4.1 First Aid Measures 
Eye contact: Immediately flush eyes with copious amounts of water for at 
least 15 minutes, lifting lower and upper eyelids. Consult a 
physician. 
Skin contact: Immediately wash skin with soap and water. 
Inhalation: Remove to fresh air. 
Ingestion: If swallowed, wash out mouth with water provided person is 
conscious. Consult a physician. 
4.2 Most Important Symptoms and Effects, both Acute and Delayed 
N-7113  Page 2 of 6 
No information available. 
 
4.3 Indication of any Immediate Medical Attention and Special Treatment Needed 
No information available. 
 
5. FIRE-FIGHTING MEASURE 
5.1 Extinguishing Media 
Suitable Media: Use water spray, alcohol-resistant foam, dry chemical or carbon 
dioxide. 
 
5.2 Special Hazards Arising from Product 
No information available. 
 
5.3 Advice for Firefighters 
As in any fire, wear self-contained breathing apparatus pressure-demand, MSHA/NIOSH 
(approved or equivalent) and full protective gear. 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal Precautions, Protective Equipment and Emergency Procedures 
Ensure adequate ventilation. Avoid breathing vapors, mists or gas. See Section 8 for personal 
protection. 
 
6.2 Environmental Precautions 
See Section 12 for additional ecological information. 
 
6.3 Methods and Materials for Containment and Clean Up 
Prevent further leakage or spillage if safe to do so. Soak up with inert absorbent material. Pick up 
and transfer to properly labeled containers. This material and its container must be disposed of 
as hazardous waste. 
 
7. HANDLING & STORAGE 
7.1 Precautions for Safe Handling 
Ensure adequate ventilation. Avoid breathing vapors, mists or gas. See Section 8 for personal 
protection. 
 
7.2 Conditions for Safe Storage 
Keep/store only in original container. Storage Temperature: -20°C or below. 
 
7.3 Incompatibilities  
None known based on information supplied. 
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control Parameters 
This product, as supplied, does not contain any hazardous materials with occupational exposure 
limits established by the region specific regulatory bodies. 
 
8.2 Appropriate Engineering Controls 
General industrial hygiene practices. 
 
8.3 Individual Protection Measures 
Eye/Face Protection: Wear safety glasses with side shields (or goggles). 
Skin/Body Protection: Wear suitable protective clothing and gloves. 
N-7113  Page 3 of 6 
Respiratory Protection: Use in well ventilated areas. 
General: Handle in accordance with good industrial hygiene and safety 
practice. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on Basic Physical and Chemical Properties 
Physical state: Liquid 
Appearance: Colorless 
Odor: Mild 
pH: Refer to trilinkbiotech.com for specific information. 
Melting Point/Freezing Point: No information available 
Boiling Point/Boiling Range: No information available 
Flash Point: No information available 
Evaporation Rate: No information available 
Flammability (solid, gas): No information available 
Upper/Lower Flammability 
Limits: 
No information available 
Vapor Pressure: No information available 
Vapor Density: No information available 
Relative Density: No information available 
Specific Density: No information available 
Water Solubility: No information available 
Partition Coefficient: No information available 
Autoignition Temperature: No information available 
Decomposition Temperature: No information available 
Viscosity: No information available 
Oxidizing Properties: No information available 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No information available. 
 
10.2 Chemical stability 
Stable under normal conditions. 
 
10.3 Possibility of hazardous reactions 
Can react briskly with oxidizers, danger of explosion. 
 
10.4 Conditions to avoid 
Incompatible materials. Ignition sources. Heat. 
 
10.5 Incompatible materials 
Strong oxidizing agents. 
 
10.6 Hazardous decomposition products 
Thermal decomposition can lead to release of irritating and toxic gases and vapors. Carbon 
monoxide. Carbon dioxide (CO2). 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on likely routes of exposure 
Inhalation Avoid breathing vapors or mists. May cause irritation of 
respiratory tract. 
N-7113  Page 4 of 6 
Eye contact Redness. May cause slight irritation. 
Skin contact Prolonged contact may cause redness and irritation. Repeated 
exposure may cause skin dryness or cracking. 
Ingestion May cause drowsiness or dizziness. Ingestion causes burns of the 
upper digestive and respiratory tracts. Symptoms include burning 
sensation, coughing, wheezing, shortness of breath, headache, 
nausea, and vomiting. 
 
11.2 Information on toxicological effects 
Symptoms No information available. 
 
11.3 Delayed and immediate effects as well as chronic effects from short and long-term 
exposure 
Skin corrosion/Irritation: Mild 
Serious Eye Damage/Eye Mild 
Irritation: 
Skin or Respiratory Sensitization: No information available 
Germ Cell Mutagenicity: No information available 
Carcinogenicity: No information available 
Reproductive Toxicity: No information available 
Developmental Toxicity: No information available 
Teratogenicity: No information available 
STOT – Single Exposure: No information available 
STOT – Repeated Exposure: No information available 
Target Organs: Kidneys, eyes, skin, respiratory system 
Chronic Toxicity: No information available 
Subchronic Toxicity: No information available 
Neurological Effects: No information available 
Aspiration Hazard: No information available 
Other Adverse Effects: No information available 
 
12. ECOLOGICAL INFORMATION 
12.1 Marine pollutant 
No information available 
 
12.2 Ecotoxicity 
No information available 
 
12.3 Persistence and degradability 
No information available 
 
12.4 Bioaccumulation 
No information available 
 
12.5 Mobility 
No information available 
 
12.6 Other adverse effects 
Ozone: No information available 
Ozone Depletion Potential: No information available 
 
13. DISPOSAL CONSIDERATIONS 
N-7113  Page 5 of 6 
13.1 Waste treatment methods 
Relevant Information: Keep out of drains, sewers, ditches and waterways. 
 
Disposal Method:  Use a licensed professional waste disposal service to dispose of 
this product. Product may be dissolved in a combustible solvent 
or absorbed onto a combustible material and burned by a 
chemical incinerator. 
Contaminated Packaging: Dispose of as unused product. 
 
14. TRANSPORT INFORMATION 
Dot:  Not dangerous goods. 
 
15. REGULATORY INFORMATION 
15.1 US Federal Regulations 
Clean Water Act (CWA): This product does not contain any substances regulated as 
pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 
40 CFR 122.42). 
CERCLA: This material, as supplied, does not contain any substances 
regulated as hazardous substances under the Comprehensive 
Environmental Response Compensation and Liability Act 
(CERCLA) (40 CFR 302) or the Superfund Amendments and 
Reauthorization Act (SARA) (40 CFR 355). There may be specific 
reporting requirements at the local, regional, or state level 
pertaining to releases of this material. 
 
15.2 US State Regulations 
California Proposition 65: This product does not contain any Proposition 65 chemicals. 
  
16. OTHER INFORMATION 
16.1 HMIS Rating 
Health Hazard:  0 
Flammability:  0 
Physical Hazard:  0 
Chronic Health Hazard:  0 
 
16.2 NFPA Rating 
Health Hazard:  0 
Fire Hazard:  0 
Reactivity Hazard:  0 
 
16.3 Preparation Information 
Prepared By: TriLink BioTechnologies, Inc. 
  858-546-0004 
Issue Date:  2016-05-31 
Version:  3 
 
16.4 Further Information 
Copyright 2016 TriLink BioTechnologies, inc. License granted to make unlimited paper copies for 
internal use only. The above information is believed to be accurate, but not necessarily all 
inclusive, and thus should only be used as a guide in the handling and use of this material.  The 
data in this SDS relates only to the specific material designated herein and does not relate to use 
in combination with any other material or in any process.  TriLink BioTechnologies, Inc. shall not 
N-7113  Page 6 of 6 
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SAFETY DATA SHEET 
 
Version 6.2 
Revision Date 10/07/2020 
Print Date 11/20/2020 
 
SECTION 1: Identification of the substance/mixture and of the company/undertaking 
1.1 Product identifiers 
Product name : -Cellulose 
 
Product Number : C8002 
Brand : Sigma 
CAS-No. : 9004-34-6 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich Inc. 
3050 Spruce Street 
ST. LOUIS MO  63103 
UNITED STATES 
 
Telephone : +1 314 771-5765 
Fax : +1 800 325-5052 
1.4 Emergency telephone 
Emergency Phone # : 800-424-9300 CHEMTREC (USA) +1-703-
527-3887 CHEMTREC (International) 24 
Hours/day; 7 Days/week 
 
 
SECTION 2: Hazards identification 
2.1 Classification of the substance or mixture 
 
 
2.2 GHS Label elements, including precautionary statements 
Pictogram none 
 
Signal word Warning 
 
Hazard statement(s) 






2.3 Hazards not otherwise classified (HNOC) or not covered by GHS 
Combustible dust 
May form explosible dust-air mixture if dispersed. 
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SECTION 3: Composition/information on ingredients 
3.1 Substances 
CAS-No. : 9004-34-6 
EC-No. : 232-674-9 
 
Component Classification Concentration 
cellulose 





SECTION 4: First aid measures 
4.1 Description of first-aid measures 
If inhaled 
After inhalation: fresh air. 
In case of skin contact 
In case of skin contact: Take off immediately all contaminated clothing. Rinse skin with 
water/ shower. 
In case of eye contact 
After eye contact: rinse out with plenty of water. Remove contact lenses. 
If swallowed 
After swallowing: make victim drink water (two glasses at most). Consult doctor if feeling 
unwell. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 
2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 




SECTION 5: Firefighting measures 
5.1 Extinguishing media 
Suitable extinguishing media 
Water Foam Carbon dioxide (CO2) Dry powder 
Unsuitable extinguishing media 
For this substance/mixture no limitations of extinguishing agents are given. 
5.2 Special hazards arising from the substance or mixture 
Nature of decomposition products not known. 
Combustible. 
Development of hazardous combustion gases or vapours possible in the event of fire. 
5.3 Advice for firefighters 
In the event of fire, wear self-contained breathing apparatus. 
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5.4 Further information 





SECTION 6: Accidental release measures 
6.1 Personal precautions, protective equipment and emergency procedures 
Advice for non-emergency personnel: Avoid inhalation of dusts. Evacuate the danger 
area, observe emergency procedures, consult an expert. 
For personal protection see section 8. 
6.2 Environmental precautions 
Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Cover drains. Collect, bind, and pump off spills. Observe possible material restrictions 
(see sections 7 and 10). Take up dry. Dispose of properly. Clean up affected area. Avoid 
generation of dusts. 
6.4 Reference to other sections 




SECTION 7: Handling and storage 
7.1 Precautions for safe handling 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
No data available 
7.3 Specific end use(s) 




SECTION 8: Exposure controls/personal protection 
8.1 Control parameters 
Ingredients with workplace control parameters 







TWA 10 mg/m3 USA. ACGIH Threshold Limit 
Values (TLV) 
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  TWA 15 mg/m3 USA. OSHA - TABLE Z-1 Limits 
for Air Contaminants - 
1910.1000 
  TWA 5 mg/m3 USA. OSHA - TABLE Z-1 Limits 
for Air Contaminants - 
1910.1000 
  TWA 5 mg/m3 USA. NIOSH Recommended 
Exposure Limits 
  TWA 10 mg/m3 USA. NIOSH Recommended 
Exposure Limits 
  TWA 15 mg/m3 USA. Occupational Exposure 
Limits (OSHA) - Table Z-1 
Limits for Air Contaminants 
  TWA 5 mg/m3 USA. Occupational Exposure 
Limits (OSHA) - Table Z-1 
Limits for Air Contaminants 
  PEL 10 mg/m3 California permissible exposure 
limits for chemical 
contaminants (Title 8, Article 
107) 
  PEL 5 mg/m3 California permissible exposure 
limits for chemical 
contaminants (Title 8, Article 
107) 
  The concentration and percentage of the particulate used 
for this limit are determined from the fraction passing a size 
selector with the following characteristics:  Aerodynamic 
Diameter in Micrometers (unit density sphere)................. 
Percent Passing Selector  0 
.................................................. 100  1 
.................................................. 97  2 
.................................................. 91  3 
................................................... 74  4 
................................................... 50  5 
................................................... 30  6 
................................................... 17  7 
................................................... 9  8 
................................................... 5  10 
.................................................... 1 
8.2 Exposure controls 
Appropriate engineering controls 
Change contaminated clothing. Wash hands after working with substance. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate 
government standards such as NIOSH (US) or EN 166(EU). Safety glasses 
Skin protection 
This recommendation applies only to the product stated in the safety data sheet, 
supplied by us and for the designated use. When dissolving in or mixing with other 
substances and under conditions deviating from those stated in EN374 please 
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Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:KCL 741 Dermatril® L  
This recommendation applies only to the product stated in the safety data sheet, 
supplied by us and for the designated use. When dissolving in or mixing with other 
substances and under conditions deviating from those stated in EN374 please 
contact the supplier of CE-approved gloves (e.g. KCL GmbH, D-36124 Eichenzell, 
Internet: www.kcl.de). 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.4 mm 
Break through time: 480 min 
Material tested:Camatril® (KCL 730 / Aldrich Z677442, Size M)  
Respiratory protection 
required when dusts are generated. 
Our recommendations on filtering respiratory protection are based on the following 
standards: DIN EN 143, DIN 14387 and other accompanying standards relating to 
the used respiratory protection system. 
 
Control of environmental exposure 
Do not let product enter drains. 
 
 
SECTION 9: Physical and chemical properties 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: fibers 
Color: white 
b) Odor No data available 
c) Odor Threshold No data available 
d) pH No data available 
e) Melting 
point/freezing point 
No data available 
f) Initial boiling point 
and boiling range 
No data available 
g) Flash point  ()Not applicable 
h) Evaporation rate No data available 
i) Flammability (solid, 
gas) 




No data available 
k) Vapor pressure No data available 
l) Vapor density No data available 
m) Relative density No data available 
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n) Water solubility No data available 
o) Partition coefficient: 
n-octanol/water 
No data available 
p) Autoignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 




SECTION 10: Stability and reactivity 
10.1 Reactivity 
The following applies in general to flammable organic substances and mixtures: in 
correspondingly fine distribution, when whirled up a dust explosion potential may generally 
be assumed. 
10.2 Chemical stability 
The product is chemically stable under standard ambient conditions (room temperature) . 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
no information available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Nature of decomposition 
products not known. 
Other decomposition products - No data available 




SECTION 11: Toxicological information 
11.1 Information on toxicological effects 
Acute toxicity 
No data available 
Inhalation: No data available 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
No data available 
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Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitization 
No data available 
Germ cell mutagenicity 
No data available 
Carcinogenicity 
IARC: No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
NTP: No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is 
on OSHA’s list of regulated carcinogens. 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 




To the best of our knowledge, the chemical, physical, and toxicological properties have not 
been thoroughly investigated. 
 





SECTION 12: Ecological information 
12.1 Toxicity 
No data available 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not 
conducted 
12.6 Other adverse effects 
No data available 
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SECTION 13: Disposal considerations 
13.1 Waste treatment methods 
Product 
Waste material must be disposed of in accordance with the national and loc No mixing 
with other waste. Handle uncleaned containers like the product See 
www.retrologistik.com for processes regarding the return of chemicals and containers, or 




SECTION 14: Transport information 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 
Not dangerous goods 
 
Further information 




SECTION 15: Regulatory information 
 
SARA 302 Components 
This material does not contain any components with a section 302 EHS TPQ. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that 
exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 
313. 
SARA 311/312 Hazards 
No SARA Hazards 










No components are subject to the Massachusetts Right to Know Act. 






New Jersey Right To Know Components 
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SECTION 16: Other information 
Further information 
The above information is believed to be correct but does not purport to be all inclusive 
and shall be used only as a guide. The information in this document is based on the 
present state of our knowledge and is applicable to the product with regard to 
appropriate safety precautions. It does not represent any guarantee of the properties of 
the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any 
damage resulting from handling or from contact with the above product. See 
www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional 
terms and conditions of sale. 
 
Copyright 2020 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies 
for internal use only. 
The branding on the header and/or footer of this document may temporarily not visually 
match the product purchased as we transition our branding. However, all of the 
information in the document regarding the product remains unchanged and matches the 
product ordered. For further information please contact mlsbranding@sial.com. 
 




S E C T I O N  1 : I d e n t i f i c a t i o n  o f  t h e  s u b s t a n c e / m i x t u r e  a n d  o f  t h e  c o m p a n y/u n d e r t a k i n g
Identification of the substance or mixture  
Product code 18047019
Product name DEOXYRIBONUCLEASE I
Company/undertaking identification  
24 hour Emergency Response for Hazardous Materials
[or Dangerous Goods] Incident. Spill, Leak, Fire,
Exposure, or Accident. Call CHEMTREC
Within the USA + Canada: 1-800-424-9300 and +1
703-527-3887
Outside the USA + Canada: +1 703-741-5970
Country specific Emergency Number (if available):
For Research Use Only. Not for use in diagnostic procedures.
S E C T I O N  2 : H a z a r d s  i d e n t i f i c a t i o n











5781 Van Allen Way
PO Box 6482
Carlsbad, CA 92008
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S E C T I O N  3 : C o m p o s i t i o n /i n f o r m a t i o n  o n  i n g r e d i e n t s
Component CAS-No EINECS-No Weight %
Glycerol
 56-81-5 ( 60-100 )
56-81-5 200-289-5 60-100
Ethyl alcohol
 64-17-5 ( 0.1-0.49 )
64-17-5 200-578-6 0.1-0.49
The product contains no substances which at their given concentration, are considered to be hazardous to health.
S E C T I O N  4 : F i r s t  a i d  m e a s u r e s
Description of first aid measures
Skin contact Rinse with plenty of water . Immediate medical attention is not required.
Eye contact Rinse cautiously with water for several minutes. Remove contact lenses, if present
and easy to do
 .
Ingestion Not expected to present a significant ingestion hazard under anticipated conditions
of normal use. If you feel unwell, seek medical advice.
Inhalation Not expected to be an inhalation hazard under anticipated conditions of normal
use of this material. Consult a physician if necessary.
Notes to Physician Treat symptomatically.
Most important symptoms and effects, both acute and delayed
___________________________________________________________________________________________________________________
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Product code 18047019 Product name  DEOXYRIBONUCLEASE I
www.thermofisher.com
Indication of any immediate medical attention and special treatment needed
None.
S E C T I O N  8 : E x p o s u r e  c o n t r o l s /p e r s o n a l  p r o t e c t i o n
Control parameters 




Ethyl alcohol 1000 ppm
1900 mg/m3
None None 1000 ppm
Engineering measures Ensure adequate ventilation, especially in confined areas
Exposure controls 
Personal Protective Equipment
Respiratory protection In case of insufficient ventilation wear respirators and components tested and
approved under appropriate government standards.
S E C T I O N  5 : F i r e f i g h t i n g  m e a s u r e s
Extinguishing media
Suitable extinguishing media Water spray. Carbon dioxide (CO2). Foam. Dry chemical.
Unsuitable extinguishing media No information available.
Special hazards arising from the substance or mixture Not known.
Advice for fire-fighters Standard procedure for chemical fires.
S E C T I O N  6 : A c c i d e n t a l  r e l e a s e  m e a s u r e s
Personal precautions, protective equipment and emergency procedures
Ensure adequate ventilation. Always wear recommended Personal Protective Equipment. Use personal protection
equipment. See Section 8 for more detail.
Environmental precautions
No special environmental precautions required. Avoid discharge into drains and waterways whenever possible.
Methods and material for containment and cleaning up
Soak up with inert absorbent material.
Reference to other sections
See section 8 for more information.
S E C T I O N  7 : H a n d l i n g  a n d  s t o r a g e
Precautions for safe handling
Use personal protective equipment as required. No special handling advices are necessary.
Conditions for safe storage, including any incompatibilities
Keep in a dry, cool and well-ventilated place. Keep in properly labeled containers.
Specific end use(s)
___________________________________________________________________________________________________________________
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For research use only.
Hand protection Wear suitable gloves Glove material: Compatible chemical-resistant gloves.
Eye protection Tight sealing safety goggles
Skin and Body Protection Wear suitable protective clothing
Hygiene measures Handle in accordance with good industrial hygiene and safety practice
Environmental exposure controls
No special environmental precautions required.
S E C T I O N  9 : P h y s i c a l  a n d  c h e m i c a l  p r o p e r t i e s
Information on basic physical and chemical properties
Appearance liquid
Odor No data available
Evaporation rate No data available
Flammability (solid, gas) No data available
Upper explosion limit Mixture has not been tested
Lower explosion limit Mixture has not been tested
Vapor Pressure Mixture has not been tested
Relative density Mixture has not been tested
Specific gravity No data available




Explosive properties Mixture has not been tested
Other information No data available
S E C T I O N  1 0 : S t a b i l i t y  a n d  r e a c t i v i t y
Reactivity None known.
Chemical stability Stable under normal conditions.
Possibility of hazardous
reactions
Hazardous reaction has not been reported.
Conditions to avoid No information available.




Melting point / melting range °C  Mixture has not been tested °F  Mixture has not been tested
Boiling point / boiling range °C  Mixture has not been tested °F  Mixture has not been tested
Flash point °C  Mixture has not been tested °F  Mixture has not been tested
Autoignition Temperature °C  Mixture has not been tested °F  Mixture has not been tested
Decomposition temperature °C  Mixture has not been tested °F  Mixture has not been tested
___________________________________________________________________________________________________________________
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S E C T I O N  1 1 : T o x i c o l o g i c a l  i n f o r m a t i o n
Information on toxicological effects
Chemical Name LD50 (oral,rat/mouse) LD50 (dermal,rat/rabbit) LC50 (inhalation,rat/mouse)
Glycerol = 12600 mg/kg Oral No data available >570mg/m3(Rat)
Ethyl alcohol = 7060 mg/kg (Rat) No data available =124.7mg/L(Rat)
Principal Routes of Exposure
Irritation Conclusive but not sufficient for classification
Corrosivity Conclusive but not sufficient for classification
Sensitization Conclusive but not sufficient for classification
STOT - Single Exposure Conclusive but not sufficient for classification
STOT - Repeated Exposure Conclusive but not sufficient for classification
Carcinogenicity Conclusive but not sufficient for classification
Mutagenicity Conclusive but not sufficient for classification
Reproductive toxicity May cause adverse reproductive effects - such as birth defect, miscarriages, or
infertility
Aspiration hazard Conclusive but not sufficient for classification
S E C T I O N  1 2 : E c o l o g i c a l  i n f o r m a t i o n
Toxicity
The environmental impact of this product has not been fully investigated.
Chemical Name Freshwater Algae
Data
Water Flea Data Freshwater Fish
Species Data
Microtox Data log Pow
Glycerol No data available Daphnia magna
EC50>500 mg/L (24
h)
No data available No data available logPow-1.76
Ethyl alcohol No data available Daphnia magna
EC50=10800 mg/L (24
h) Daphnia magna




No data available No data available logPow-0.32
Persistence and degradability No information available.
Bioaccumulative potential No information available.
Results of PBT and vPvB assessment
No information available.
Other adverse effects No information available.
___________________________________________________________________________________________________________________
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S E C T I O N  1 3 : D i s p o s a l  c o n s i d e r a t i o n s
Waste treatment methods
The generation of waste should be avoided or minimized wherever possible. Empty containers or liners may retain
some product residues. This material and its container must be disposed of in according to approved disposal
technique. Disposal of this product, its solutions or of any by-products, shall comply with the requirements of all
applicable local, regional or national/federal regulations
S E C T I O N  1 4 : T r a n s p o r t  i n f o r m a t i o n
IATA / ADR / DOT-US / IMDG
Not regulated in the meaning of transport regulations.
UN number Not Applicable
UN proper shipping name Not Applicable
Transport hazard class(es) Not Applicable
Packing group Not Applicable
Environmental hazards Not Applicable
Special precautions for user Not Applicable
___________________________________________________________________________________________________________________
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Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not Applicable.
S E C T I O N  1 6 : O t h e r  i n f o r m a t i o n
Reason for revision SDS sections updated.
Revision number 2
Revision date 24-May-2017






"The above information was acquired by diligent search and/or investigation and the recommendations are based on
prudent application of professional judgment. The information shall not be taken as being all inclusive and is to be
used only as a guide. All materials and mixtures may present unknown hazards and should be used with caution.
Since the Company cannot control the actual methods, volumes, or conditions of use, the Company shall not be held
liable for any damages or losses resulting from the handling or from contact with the product as described herein.
THE INFORMATION IN THIS SDS DOES NOT CONSTITUTE A WARRANTY, EXPRESSED OR
IMPLIED,INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR
PURPOSE"
End of Safety Data Sheet
S E C T I O N  1 5 : R e g u l a t o r y  i n f o r m a t i o n
Component US TSCA
Glycerol
 56-81-5 ( 60-100 )
Listed
Ethyl alcohol
 64-17-5 ( 0.1-0.49 )
Listed
US Federal Regulations 
SARA 313
This product is not regulated by SARA.
Clean Air Act, Section 112 Hazardous Air Pollutants (HAPs) (see 40 CFR 61)
This product does not contains HAPs.
US State Regulations 
California Proposition 65
This product contains the following Proposition 65 chemicals.
Chemical Name CAS-No Weight % Category 




This product has been classified in accordance with the hazard criteria of the Controlled Products Regulations (CPR) and the
MSDS contains all the information required by the CPR.
___________________________________________________________________________________________________________________
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SECTION 1. IDENTIFICATION 
Product name 
 





Manufacturer or supplier's details 
Company name of supplier 
 








Telephone : +496217590 
Telefax : +496217592890 
Emergency telephone 
In case of emergencies: : CHEMTREC 
 
+1 703-741-5970 / 
1-800-424-9300 
Recommended use of the chemical and restrictions on use 
Restrictions on use 
 
: For professional users only. 
 
 
SECTION 2. HAZARDS IDENTIFICATION 
GHS classification in accordance with 29 CFR 1910.1200 
Acute toxicity (Oral) 
 
: Category 4 
Skin irritation 
 
: Category 2 
Eye irritation 
 
: Category 2A 




















: H302 Harmful if swallowed. 
H315 Causes skin irritation. 




: Prevention:  
P264 Wash skin thoroughly after handling. 
P270 Do not eat, drink or smoke when using this product. 
P280 Wear protective gloves/ eye protection/ face protection. 
Response:  
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P301 + P312 + P330 IF SWALLOWED: Call a POISON 
CENTER/doctor if you feel unwell. Rinse mouth. 
P302 + P352 IF ON SKIN: Wash with plenty of soap and water. 
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water 
for several minutes. Remove contact lenses, if present and easy 
to do. Continue rinsing. 
P332 + P313 If skin irritation occurs: Get medical advice/ atten-
tion. 
P337 + P313 If eye irritation persists: Get medical advice/ atten-
tion. 
P362 Take off contaminated clothing and wash before reuse. 
Disposal:  






SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS 
Substance / Mixture 
 
:  Mixture 
Components 
Chemical name CAS-No. Concentration (% w/w) 
2,3-Butanediol, 1,4-dimercapto-, 
(2R,3R)-rel- 
3483-12-3  <= 100.0 
Actual concentration is withheld as a trade secret 
 
SECTION 4. FIRST AID MEASURES 
General advice 
 
: Move out of dangerous area. 
Show this material safety data sheet to the doctor in atten-
dance. 




: Move to fresh air. 
If unconscious, place in recovery position and seek medical 
advice. 
If symptoms persist, call a physician. 
 
In case of skin contact 
 
: If skin irritation persists, call a physician. 
If on skin, rinse well with water. 
If on clothes, remove clothes. 
 
In case of eye contact 
 
: Immediately flush eye(s) with plenty of water. 
Remove contact lenses. 
Protect unharmed eye. 
Keep eye wide open while rinsing. 
If eye irritation persists, consult a specialist. 
 
If swallowed : Clean mouth with water and drink afterwards plenty of water. 
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 Keep respiratory tract clear. 
Do not give milk or alcoholic beverages. 
Never give anything by mouth to an unconscious person. 
If symptoms persist, call a physician. 
 
Most important symptoms 
and effects, both acute and 
delayed 
 
: Harmful if swallowed. 
Causes skin irritation. 
Causes serious eye irritation. 
 
Notes to physician 
 
: The first aid procedure should be established in consultation 
with the doctor responsible for industrial medicine. 
 
 
SECTION 5. FIRE-FIGHTING MEASURES 
Suitable extinguishing media 
 
: Use extinguishing measures that are appropriate to local cir-





: High volume water jet 
 
Specific hazards during fire 
fighting 
 





:  No hazardous combustion products are known 
 
Further information : Standard procedure for chemical fires. 
Use extinguishing measures that are appropriate to local cir-
cumstances and the surrounding environment. 
 
Special protective equipment 
for fire-fighters 
 
: Wear self-contained breathing apparatus for firefighting if 
necessary. 
 
SECTION 6. ACCIDENTAL RELEASE MEASURES 
Personal precautions, protec-
tive equipment and emer-
gency procedures 
 
: Use personal protective equipment. 
Avoid dust formation. 




: Prevent further leakage or spillage if safe to do so. 
If the product contaminates rivers and lakes or drains inform 
respective authorities. 
 
Methods and materials for 
containment and cleaning up 
 
: Keep in suitable, closed containers for disposal. 
 
SECTION 7. HANDLING AND STORAGE 
Advice on protection against 
fire and explosion 
 
:  Avoid dust formation. 
Provide appropriate exhaust ventilation at places where dust 
is formed. 
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Advice on safe handling 
 
: Avoid formation of respirable particles. 
Do not breathe vapors/dust. 
Avoid contact with skin and eyes. 
For personal protection see section 8. 
Smoking, eating and drinking should be prohibited in the ap-
plication area. 
Dispose of rinse water in accordance with local and national 
regulations. 
 
Conditions for safe storage 
 
: Keep container tightly closed in a dry and well-ventilated pla-
ce. 
Electrical installations / working materials must comply with 
the technological safety standards. 
 
Further information on stor-
age conditions 
 
: See label, package insert or internal guidelines 
 
Further information on stor-
age stability 
 
:  No decomposition if stored and applied as directed. 
 
SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
Ingredients with workplace control parameters 
Contains no substances with occupational exposure limit values. 
Engineering measures : No data available 
 




: Wear appropriate protective gloves to prevent skin contact. 
Replace torn or punctured gloves promptly. 
Eye protection 
 
: Eye wash bottle with pure water 
Tightly fitting safety goggles 
Wear face-shield and protective suit for abnormal processing 
problems. 
 
Skin and body protection 
 
: Choose body protection according to the amount and con-




: When using do not eat or drink. 
When using do not smoke. 
Wash hands before breaks and at the end of workday. 
 










:  characteristic 
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Odor Threshold 
 




: 5.1 (20 °C / 20 °C)  




: 40 - 44 °C / 40 - 44 °C  
 
Boiling point/boiling range 
 




: > 110 °C / 110 °C 
Evaporation rate 
 
:  No data available  
 
Flammability (solid, gas) 
 




: Sustains combustion 
 
Self-ignition : No data available  
 
Upper explosion limit / Upper 
flammability limit 
 
: No data available  
 
Lower explosion limit / Lower 
flammability limit 
 




: No data available  
 
Relative vapor density 
 









: 1,500 g/l soluble  (20 °C / 20 °C) 
 
Solubility in other solvents 
 





: Remarks: No data available 
Autoignition temperature 
 





















: 154.25 g/mol 
 
SECTION 10. STABILITY AND REACTIVITY 
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Reactivity 
 




:  Stable under normal conditions. 
 
Possibility of hazardous reac-
tions 
 
: Keep away from heat and sources of ignition. 
Reacts with the following substances: 
Oxidizing agents 
No decomposition if stored and applied as directed. 
 
Conditions to avoid 
 
: Exposure to moisture. 








:   In case of fire hazardous decomposition products may be 




SECTION 11. TOXICOLOGICAL INFORMATION 
Acute toxicity 
Harmful if swallowed. 
Components: 
2,3-Butanediol, 1,4-dimercapto-, (2R,3R)-rel-: 
Acute oral toxicity :  LD50 Oral (Rat): 400 mg/kg  
 
Acute toxicity (other routes of 
administration) 
:    




Causes skin irritation. 
Product: 
Remarks : May cause skin irritation in susceptible persons. 
 
Components: 
2,3-Butanediol, 1,4-dimercapto-, (2R,3R)-rel-: 
Result : Irritating to skin. 
 
Serious eye damage/eye irritation 
Causes serious eye irritation. 
Product: 
Remarks : May cause irreversible eye damage. 
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Components: 
2,3-Butanediol, 1,4-dimercapto-, (2R,3R)-rel-: 
Result : Irritating to eyes. 
 
Respiratory or skin sensitization 
Skin sensitization 
Not classified based on available information. 
Respiratory sensitization 
Not classified based on available information. 
Germ cell mutagenicity 
Not classified based on available information. 
Carcinogenicity 
Not classified based on available information. 
IARC No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
 
OSHA No component of this product present at levels greater than or equal to 0.1% is 
on OSHA  li  of eg la ed ca cinogen . 
 
NTP No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
 
Reproductive toxicity 
Not classified based on available information. 
STOT-single exposure 
Not classified based on available information. 
STOT-repeated exposure 
Not classified based on available information. 
Aspiration toxicity 
Not classified based on available information. 




Toxicity Data on Soil 
 
:  Not expected to adsorb on soil. 
 
Other organisms relevant to 
the environment 
 
:  No data available 
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Components: 
2,3-Butanediol, 1,4-dimercapto-, (2R,3R)-rel-: 
Ecotoxicology Assessment 
Acute aquatic toxicity 
 
:  This product has no known ecotoxicological effects. 
 
Chronic aquatic toxicity 
 
:  This product has no known ecotoxicological effects. 
 
Toxicity Data on Soil 
 
:  Not expected to adsorb on soil. 
 
Other organisms relevant to 
the environment 
 
:  No data available 
 
Persistence and degradability 
No data available 
Bioaccumulative potential 
Components: 




: log Pow: ca. -0.48 
 
Mobility in soil 
No data available 




: Regulation: 40 CFR Protection of Environment; Part 82 Pro-
tection of Stratospheric Ozone - CAA Section 602 Class I 
Substances 
Remarks: This product neither contains, nor was manufac-
tured with a Class I or Class II ODS as defined by the U.S. 
Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B). 
 
 
SECTION 13. DISPOSAL CONSIDERATIONS 
Disposal methods 
Waste from residues : Do not contaminate ponds, waterways or ditches with chemi-
cal or used container. 
Send to a licensed waste management company. 
 
Contaminated packaging : Empty remaining contents. 
Dispose of as unused product. 
Empty containers should be taken to an approved waste 
handling site for recycling or disposal. 
Do not re-use empty containers. 
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SECTION 14. TRANSPORT INFORMATION 
International Regulations 
UNRTDG  
Not regulated as a dangerous good 
IATA-DGR  
Not regulated as a dangerous good 
IMDG-Code  
Not regulated as a dangerous good 
Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code 
Not applicable 
Domestic regulation 
49 CFR  
Not regulated as a dangerous good 
 
SECTION 15. REGULATORY INFORMATION 
EPCRA - Emergency Planning and Community Right-to-Know 
CERCLA Reportable Quantity 
This material does not contain any components with a CERCLA RQ. 
SARA 304 Extremely Hazardous Substances Reportable Quantity 
This material does not contain any components with a section 304 EHS RQ. 
SARA 302 Extremely Hazardous Substances Threshold Planning Quantity 
Components CAS-No. Component TPQ (lbs) 
SARA 311/312 Hazards 
 
:  Acute toxicity (any route of exposure) 
Skin corrosion or irritation 
Serious eye damage or eye irritation 
 
Clean Air Act 
This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by 
the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B). 
This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean 
Air Act Section 112 (40 CFR 61). 
This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for 
Accidental Release Prevention (40 CFR 68.130, Subpart F). 
This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 
SOCMI Intermediate or Final VOC's (40 CFR 60.489). 
Clean Water Act 
This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, 
Section 311, Table 116.4A. 
This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, 
Section 311, Table 117.3. 
This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 
307 
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US State Regulations 
Massachusetts Right To Know 
Pennsylvania Right To Know 
 2,3-Butanediol, 1,4-dimercapto-, (2R,3R)-rel- 3483-12-3 
Maine Chemicals of High Concern 
Vermont Chemicals of High Concern 
Washington Chemicals of High Concern 
The ingredients of this product are reported in the following inventories: 
DSL 
 




































: All substances listed as active on the TSCA inventory 
 
TSCA list 
No substances are subject to a Significant New Use Rule. 
 








 DTT, 25g 
Version  
1.5 
Revision Date:  
04-17-2019 
Date of last issue: 06-18-2018 
Date of first issue: 08-12-2015 
 
 
11 / 12 
 
 
SECTION 16. OTHER INFORMATION 
Further information 
























HMIS® ratings are based on a 0-4 rating 
scale, with 0 representing minimal haz-
ards or risks, and 4 representing signifi-
cant hazards or risks. The "*" represents 
a chronic hazard, while the "/" represents 




3050 Spruce Street 
SAINT LOUIS 
MO 63103 USA 
Full text of other abbreviations 
 
AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of 
Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, 
and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the 
German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Sub-
stances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Haz-
ardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; 
ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with 
x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized Sys-
tem; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - 
International Agency for Research on Cancer; IATA - International Air Transport Association; IBC 
- International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals 
in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organiza-
tion; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime 
Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health 
Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemi-
cals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 
50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Pre-
vention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Oth-
erwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) 
Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable 
Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of 
Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office 
of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic sub-
stance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quanti-
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REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concern-
ing the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable 
Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amend-
ments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance 
Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - 
United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent 




Revision Date :  04-17-2019 
 
 
The information provided in this Material Safety Data Sheet is correct to the best of our 
knowledge, information and belief at the date of its publication. The information given is designed 
only as a guidance for safe handling, use, processing, storage, transportation, disposal and re-
lease and is not to be considered a warranty or quality specification. The information relates only 
to the specific material designated and may not be valid for such material used in combination 
with any other materials or in any process, unless specified in the text. 
 
US / Z8 / 1805 
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SAFETY DATA SHEET 
 
Version 6.2 
Revision Date 01/13/2020 
Print Date 11/20/2020 
 
SECTION 1: Identification of the substance/mixture and of the company/undertaking 
1.1 Product identifiers 
Product name : Ethylenediaminetetraacetic acid 
 
Product Number : E6758 
Brand : Sigma 
Index-No. : 607-429-00-8 
CAS-No. : 60-00-4 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich Inc. 
3050 Spruce Street 
ST. LOUIS MO  63103 
UNITED STATES 
 
Telephone : +1 314 771-5765 
Fax : +1 800 325-5052 
1.4 Emergency telephone number 
Emergency Phone # : 800-424-9300 CHEMTREC (USA) +1-703-
527-3887 CHEMTREC (International) 24 
Hours/day; 7 Days/week 
 
 
SECTION 2: Hazards identification 
2.1 Classification of the substance or mixture 
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) 
Eye irritation (Category 2A), H319 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
2.2 GHS Label elements, including precautionary statements 
Pictogram 
  
Signal word Warning 
 
Hazard statement(s) 
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P264 Wash skin thoroughly after handling. 
P280 Wear eye protection/ face protection. 
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. 
Remove contact lenses, if present and easy to do. Continue 
rinsing. 
P337 + P313 If eye irritation persists: Get medical advice/ attention. 
 




SECTION 3: Composition/information on ingredients 
3.1 Substances 





Formula : C10H16N2O8 
Molecular weight : 292.24 g/mol 
CAS-No. : 60-00-4 
EC-No. : 200-449-4 
Index-No. : 607-429-00-8 
 
Component Classification Concentration 
Edetic acid 
   Eye Irrit. 2A; Aquatic 
Acute 3; H319, H402 
<= 100 % 
 




SECTION 4: First aid measures 
4.1 Description of first aid measures 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of 
dangerous area. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Consult a physician. 
In case of eye contact 
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. 
If swallowed 
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4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 
2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 




SECTION 5: Firefighting measures 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
Carbon oxides, Nitrogen oxides (NOx) 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 




SECTION 6: Accidental release measures 
6.1 Personal precautions, protective equipment and emergency procedures 
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist 
or gas. Ensure adequate ventilation. Avoid breathing dust. 
For personal protection see section 8. 
6.2 Environmental precautions 
Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in 
suitable, closed containers for disposal. 
6.4 Reference to other sections 




SECTION 7: Handling and storage 
7.1 Precautions for safe handling 
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.Further processing 
of solid materials may result in the formation of combustible dusts. The potential for 
combustible dust formation should be taken into consideration before additional processing 
occurs. 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Storage class (TRGS 510): 13: Non Combustible Solids 
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7.3 Specific end use(s) 




SECTION 8: Exposure controls/personal protection 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
Hazardous components without workplace control parameters 
8.2 Exposure controls 
Appropriate engineering controls 
Handle in accordance with good industrial hygiene and safety practice. Wash hands 
before breaks and at the end of workday. 
Personal protective equipment 
Eye/face protection 
Safety glasses with side-shields conforming to EN166 Use equipment for eye 
protection tested and approved under appropriate government standards such as 
NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove 
removal technique (without touching glove's outer surface) to avoid skin contact 
with this product. Dispose of contaminated gloves after use in accordance with 
applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail 
sales@kcl.de, test method: EN374 
If used in solution, or mixed with other substances, and under conditions which 
differ from EN 374, contact the supplier of the CE approved gloves. This 
recommendation is advisory only and must be evaluated by an industrial hygienist 
and safety officer familiar with the specific situation of anticipated use by our 




Impervious clothing, The type of protective equipment must be selected according 
to the concentration and amount of the dangerous substance at the specific 
workplace. 
Respiratory protection 
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle 
respirator.For higher level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU 
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EN 143) respirator cartridges. Use respirators and components tested and approved 
under appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Do not let product enter drains. 
 
 
SECTION 9: Physical and chemical properties 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: crystalline 
Colour: white 
b) Odour odourless 
c) Odour Threshold No data available 
d) pH 2.5 at 10 g/l at 23 °C (73 °F) 
e) Melting 
point/freezing point 
Melting point/range: 250 °C (482 °F) - dec. 
f) Initial boiling point 
and boiling range 
No data available 
g) Flash point  ()No data available 
h) Evaporation rate No data available 
i) Flammability (solid, 
gas) 




No data available 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density 1.46 g/cm3 at 20 °C (68 °F) 
n) Water solubility 0.4 g/l at 20 °C (68 °F) 
o) Partition coefficient: 
n-octanol/water 
log Pow: 8.85 - 10.44 at 20 °C (68 °F) 
p) Auto-ignition 
temperature 
> 400 °C (> 752 °F) at 1,013 hPa 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
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SECTION 10: Stability and reactivity 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen 
oxides (NOx) 
Other decomposition products - No data available 




SECTION 11: Toxicological information 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - male and female - 4,500 mg/kg 
(OECD Test Guideline 401) 
Inhalation: No data available 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
Skin - Rabbit 
Result: No skin irritation - 20 h 
Remarks: (ECHA) 
Serious eye damage/eye irritation 
Eyes - Rabbit 
Result: Eye irritation 
Remarks: (ECHA) 
Respiratory or skin sensitisation 
Maximisation Test - Guinea pig 
Result: negative 
(OECD Test Guideline 406) 
Remarks: (in analogy to similar products) 
Maximisation Test - Rabbit 
Result: Does not cause skin sensitisation. 
Germ cell mutagenicity 
No data available 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
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NTP: No component of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is 
on OSHA  li  of eg la ed ca cinogen . 
Reproductive toxicity 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 




To the best of our knowledge, the chemical, physical, and toxicological properties have not 





SECTION 12: Ecological information 
12.1 Toxicity 
 




Toxicity to daphnia 
and other aquatic 
invertebrates 
static test EC50 - Daphnia magna (Water flea) - 625 mg/l  - 24 h 
(DIN 38412) 
12.2 Persistence and degradability 
Biodegradability aerobic  - Exposure time 20 d 
Result: 0 - 20 % - Not readily biodegradable.  
Remarks: (ECHA) 
 
Ratio BOD/ThBOD < 1 % 
Remarks: (IUCLID) 
12.3 Bioaccumulative potential 
Bioaccumulation Lepomis macrochirus - 28 d 
at 21 °C - 80 µg/l(Edetic acid) 
 
Bioconcentration factor (BCF): 1.8 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
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12.6 Other adverse effects 





SECTION 13: Disposal considerations 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a 
licensed professional waste disposal service to dispose of this material.  
Contaminated packaging 




SECTION 14: Transport information 
DOT (US) 
UN number: 3077 Class: 9 Packing group: III 
Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Edetic acid) 
Reportable Quantity (RQ): 5000 lbs 
Poison Inhalation Hazard: No 
 
IMDG 
Not dangerous goods 
 
IATA 




SECTION 15: Regulatory information 
 
SARA 302 Components 
This material does not contain any components with a section 302 EHS TPQ. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that 
exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 
313. 
SARA 311/312 Hazards 
Acute Health Hazard 









Pennsylvania Right To Know Components 





California Prop. 65 Components 
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This product does not contain any chemicals known to State of California to cause cancer, 




SECTION 16: Other information 
Further information 
Copyright 2020 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies 
for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive 
and shall be used only as a guide. The information in this document is based on the 
present state of our knowledge and is applicable to the product with regard to 
appropriate safety precautions. It does not represent any guarantee of the properties of 
the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any 
damage resulting from handling or from contact with the above product. See 
www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional 
terms and conditions of sale. 
 
The branding on the header and/or footer of this document may temporarily not visually 
match the product purchased as we transition our branding. However, all of the 
information in the document regarding the product remains unchanged and matches the 
product ordered. For further information please contact mlsbranding@sial.com. 
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SAFETY DATA SHEET 
 
Version 6.4 
Revision Date 05/11/2020 
Print Date 11/20/2020 
 
SECTION 1: Identification of the substance/mixture and of the company/undertaking 
1.1 Product identifiers 
Product name : Ethyl alcohol, pure 
 
Product Number : E7023 
Brand : SIGALD 
Index-No. : 603-002-00-5 
CAS-No. : 64-17-5 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich Inc. 
3050 Spruce Street 
ST. LOUIS MO  63103 
UNITED STATES 
 
Telephone : +1 314 771-5765 
Fax : +1 800 325-5052 
1.4 Emergency telephone number 
Emergency Phone # : 800-424-9300 CHEMTREC (USA) +1-703-
527-3887 CHEMTREC (International) 24 
Hours/day; 7 Days/week 
 
 
SECTION 2: Hazards identification 
2.1 Classification of the substance or mixture 
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) 
Flammable liquids (Category 2), H225 
Eye irritation (Category 2A), H319 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
2.2 GHS Label elements, including precautionary statements 
Pictogram 
  
Signal word Danger 
 
Hazard statement(s) 
H225 Highly flammable liquid and vapour. 
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H319 Causes serious eye irritation. 
 
Precautionary statement(s) 
P210 Keep away from heat/sparks/open flames/hot surfaces. No 
smoking. 
P233 Keep container tightly closed. 
P240 Ground/bond container and receiving equipment. 
P241 Use explosion-proof electrical/ ventilating/ lighting equipment. 
P242 Use only non-sparking tools. 
P243 Take precautionary measures against static discharge. 
P264 Wash skin thoroughly after handling. 
P280 Wear protective gloves/ eye protection/ face protection. 
P303 + P361 + P353 IF ON SKIN (or hair): Take off immediately all contaminated 
clothing. Rinse skin with water/shower. 
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. 
Remove contact lenses, if present and easy to do. Continue 
rinsing. 
P337 + P313 If eye irritation persists: Get medical advice/ attention. 
P370 + P378 In case of fire: Use dry sand, dry chemical or alcohol-resistant 
foam to extinguish. 
P403 + P235 Store in a well-ventilated place. Keep cool. 
P501 Dispose of contents/ container to an approved waste disposal 
plant. 
 




SECTION 3: Composition/information on ingredients 
3.1 Substances 
Synonyms : Absolute alcohol 
 
Formula : C2H6O 
Molecular weight : 46.07 g/mol 
CAS-No. : 64-17-5 
EC-No. : 200-578-6 
Index-No. : 603-002-00-5 
 
Component Classification Concentration 
ethanol 
   Flam. Liq. 2; Eye Irrit. 2A; 
H225, H319 
<= 100 % 
 




SECTION 4: First aid measures 
4.1 Description of first aid measures 
General advice 
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If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Consult a physician. 
In case of eye contact 
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. 
If swallowed 
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse 
mouth with water. Consult a physician. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 
2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 




SECTION 5: Firefighting measures 
5.1 Extinguishing media 
Suitable extinguishing media 
Dry powder Dry sand 
Unsuitable extinguishing media 
Do NOT use water jet. 
5.2 Special hazards arising from the substance or mixture 
Carbon oxides 
Combustible. 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 




SECTION 6: Accidental release measures 
6.1 Personal precautions, protective equipment and emergency procedures 
Use personal protective equipment. Avoid breathing vapours, mist or gas. Ensure 
adequate ventilation. Remove all sources of ignition. Evacuate personnel to safe areas. 
Beware of vapours accumulating to form explosive concentrations. Vapours can 
accumulate in low areas. 
For personal protection see section 8. 
6.2 Environmental precautions 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Contain spillage, and then collect with non-combustible absorbent material, (e.g. sand, 
earth, diatomaceous earth, vermiculite) and place in container for disposal according to 
local / national regulations (see section 13). 
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6.4 Reference to other sections 




SECTION 7: Handling and storage 
7.1 Precautions for safe handling 
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist. 
Use explosion-proof equipment.Keep away from sources of ignition - No smoking.Take 
measures to prevent the build up of electrostatic charge. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place. Containers which are 
opened must be carefully resealed and kept upright to prevent leakage.  
Hygroscopic.  
Storage class (TRGS 510): 3: Flammable liquids 
7.3 Specific end use(s) 




SECTION 8: Exposure controls/personal protection 
8.1 Control parameters 
Components with workplace control parameters 







TWA 1,000 ppm  
1,900 mg/m3 
USA. OSHA - TABLE Z-1 Limits 
for Air Contaminants - 
1910.1000 
  TWA 1,000 ppm  
1,900 mg/m3 
USA. Occupational Exposure 
Limits (OSHA) - Table Z-1 
Limits for Air Contaminants 
 Remarks The value in mg/m3 is approximate. 
  STEL 1,000 ppm  
 
USA. ACGIH Threshold Limit 
Values (TLV) 
  Upper Respiratory Tract irritation 
Confirmed animal carcinogen with unknown relevance to 
humans 
  TWA 1,000 ppm  
1,900 mg/m3 
USA. NIOSH Recommended 
Exposure Limits 
  PEL 1,000 ppm  
1,900 mg/m3 
California permissible exposure 
limits for chemical 
contaminants (Title 8, Article 
107) 
8.2 Exposure controls 
Appropriate engineering controls 
Handle in accordance with good industrial hygiene and safety practice. Wash hands 
before breaks and at the end of workday. 
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Personal protective equipment 
Eye/face protection 
Face shield and safety glasses Use equipment for eye protection tested and 
approved under appropriate government standards such as NIOSH (US) or EN 
166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove 
removal technique (without touching glove's outer surface) to avoid skin contact 
with this product. Dispose of contaminated gloves after use in accordance with 




Minimum layer thickness: 0.3 mm 
Break through time: 480 min 
Material tested:Butoject® (KCL 897 / Aldrich Z677647, Size M)  
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.2 mm 
Break through time: 38 min 
Material tested:Dermatril® P (KCL 743 / Aldrich Z677388, Size M)  
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail 
sales@kcl.de, test method: EN374 
If used in solution, or mixed with other substances, and under conditions which 
differ from EN 374, contact the supplier of the CE approved gloves. This 
recommendation is advisory only and must be evaluated by an industrial hygienist 
and safety officer familiar with the specific situation of anticipated use by our 
customers. It should not be construed as offering an approval for any specific use 
scenario.  
Body Protection 
Impervious clothing, Flame retardant antistatic protective clothing., The type of 
protective equipment must be selected according to the concentration and amount 
of the dangerous substance at the specific workplace. 
Respiratory protection 
Where risk assessment shows air-purifying respirators are appropriate use a full-
face respirator with multi-purpose combination (US) or type ABEK (EN 14387) 
respirator cartridges as a backup to engineering controls. If the respirator is the sole 
means of protection, use a full-face supplied air respirator. Use respirators and 
components tested and approved under appropriate government standards such as 
NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. 
 
 
SECTION 9: Physical and chemical properties 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: liquid 
Colour: colourless 
b) Odour pungent 
c) Odour Threshold No data available 
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d) pH 7.0 at 10 g/l at 20 °C (68 °F) 
e) Melting 
point/freezing point 
Melting point/freezing point: -144.0 °C (-227.2 °F) at 1,013.25 
hPa 
f) Initial boiling point 
and boiling range 
78.29 °C 172.92 °F at 1,013 hPa 
g) Flash point 13 °C (55 °F) - closed cup 
h) Evaporation rate No data available 
i) Flammability (solid, 
gas) 




Upper explosion limit: 13.5 %(V) 
Lower explosion limit: 2.5 %(V) 
k) Vapour pressure 0.57 hPa at 19.6 °C (67.3 °F) 
l) Vapour density 1.6 
m) Relative density 0.79 g/cm3 at 20 °C (68 °F) 
n) Water solubility 1,000 g/l at 20 °C (68 °F) - completely miscible 
o) Partition coefficient: 
n-octanol/water 




455 °C (851 °F) at 1,013 hPa - DIN 51794 
q) Decomposition 
temperature 
Distillable in an undecomposed state at normal pressure. 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
 Conductivity < 1 µS/cm 
 Surface tension 72.75 mN/m at 20 °C (68 °F) 






SECTION 10: Stability and reactivity 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
Vapours may form explosive mixture with air. 
10.4 Conditions to avoid 
Heat, flames and sparks. 
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10.5 Incompatible materials 
rubber, various plastics 
10.6 Hazardous decomposition products 
Other decomposition products - No data available 
Hazardous decomposition products formed under fire conditions. - Carbon oxides 




SECTION 11: Toxicological information 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - male and female - 10,470 mg/kg 
(OECD Test Guideline 401) 
LC50 Inhalation - Rat - male and female - 4 h - 124.7 mg/l 
(OECD Test Guideline 403) 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
Skin - Rabbit 
Result: No skin irritation - 24 h 
(OECD Test Guideline 404) 
Serious eye damage/eye irritation 
Eyes - Rabbit 
Result: Causes serious eye irritation. 
(OECD Test Guideline 405) 
Respiratory or skin sensitisation 
Maximisation Test - Guinea pig 
Result: negative 
(OECD Test Guideline 406) 
Remarks: (in analogy to similar products) 
Germ cell mutagenicity 
Ames test 
Salmonella typhimurium  
Result: negative 
In vitro mammalian cell gene mutation test 
mouse lymphoma cells  
Result: negative 
OECD Test Guideline 478 
Mouse - male 
Result: Positive results were obtained in some in vivo tests. 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
NTP: No component of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is 
on OSHA  li  of eg la ed ca cinogen . 
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No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
Repeated dose toxicity - Rat - male - Oral - No observed adverse effect level - 1,730 mg/kg 
- Lowest observed adverse effect level - 3,200 mg/kg 
RTECS: KQ6300000 
 
irritant effects, respiratory paralysis, Dizziness, narcosis, inebriation, euphoria, Nausea, 
Vomiting 
To the best of our knowledge, the chemical, physical, and toxicological properties have not 
been thoroughly investigated. 
 
Stomach - Irregularities - Based on Human Evidence 




SECTION 12: Ecological information 
12.1 Toxicity 
 
Toxicity to fish flow-through test LC50 - Pimephales promelas (fathead minnow) - 
15,300 mg/l  - 96 h 
(US-EPA) 
 
Toxicity to daphnia 
and other aquatic 
invertebrates 




Toxicity to algae static test ErC50 - Chlorella vulgaris (Fresh water algae) - 275 mg/l  
- 72 h 
(OECD Test Guideline 201) 
 
Toxicity to bacteria static test IC50 - activated sludge - > 1,000 mg/l  - 3 h 
(OECD Test Guideline 209) 
12.2 Persistence and degradability 
Biodegradability aerobic  - Exposure time 15 d 
Result: ca.95 % - Readily biodegradable.  











12.3 Bioaccumulative potential 
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12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not 
conducted 








SECTION 13: Disposal considerations 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company. Burn in a 
chemical incinerator equipped with an afterburner and scrubber but exert extra care in 
igniting as this material is highly flammable. Contact a licensed professional waste 
disposal service to dispose of this material.  
Contaminated packaging 




SECTION 14: Transport information 
DOT (US) 
UN number: 1170 Class: 3 Packing group: II 
Proper shipping name: Ethanol 
Reportable Quantity (RQ):   
Poison Inhalation Hazard: No 
 
IMDG 
UN number: 1170 Class: 3 Packing group: II EMS-No: F-E, S-D 
Proper shipping name: ETHANOL 
 
IATA 
UN number: 1170 Class: 3 Packing group: II 
Proper shipping name: Ethanol 
 
 
SECTION 15: Regulatory information 
 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, 
Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that 
exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 
313. 
SARA 311/312 Hazards 
Fire Hazard, Acute Health Hazard, Chronic Health Hazard 
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No components are subject to the Massachusetts Right to Know Act. 






















SECTION 16: Other information 
Further information 
Copyright 2020 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies 
for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive 
and shall be used only as a guide. The information in this document is based on the 
present state of our knowledge and is applicable to the product with regard to 
appropriate safety precautions. It does not represent any guarantee of the properties of 
the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any 
damage resulting from handling or from contact with the above product. See 
www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional 
terms and conditions of sale. 
 
The branding on the header and/or footer of this document may temporarily not visually 
match the product purchased as we transition our branding. However, all of the 
information in the document regarding the product remains unchanged and matches the 
product ordered. For further information please contact mlsbranding@sial.com. 
 




S E C T I O N  2 : H a z a r d s  i d e n t i f i c a t i o n
Not Hazardous
GHS - Classification 
Principle Routes of Exposure 
Potential Health Effects  





For research use only. Not intended for human or animal diagnostic or therapeutic uses.
Not Hazardous
Identification of the substance or mixture  




Outside of the U.S. +1-301-431-8585
Product code 11344041
Company/undertaking identification  
Country specific Emergency Number (if available):
S E C T I O N  1 : I d e n t i f i c a t i o n  o f  t h e  s u b s t a n c e / m i x t u r e  a n d  o f  t h e  c o m p a n y /u n d e r t a k i n g
11344041
Revision date
Product name  HEPES
Product name












5791 Van Allen Way
PO Box 6482
Carlsbad, CA 92008
+1 760 603 7200
CHEMTREC Brazil (Rio De Janeiro)
Specific effects 
S E C T I O N  5 : F i r e f i g h t i n g  m e a s u r e s
Suitable extinguishing media Water spray. Carbon dioxide (CO2). Foam. Dry chemical.
Target Organ Effects No known effects under normal use conditions
Special protective equipment for firefighters Wear self-contained breathing apparatus and protective
suit.
May cause skin irritation in susceptible persons.
S E C T I O N  6 : A c c i d e n t a l  r e l e a s e  m e a s u r e s
Carcinogenic effects None
Personal precautions Use personal protection equipment.
HMIS 
Methods for cleaning up Take up mechanically, placing in appropriate containers for disposal.
Ingestion
Mutagenic effects
Environmental precautions  
None
May be harmful if swallowed.
Prevent further leakage or spillage if safe to do so.
Skin
S E C T I O N  4 : F i r s t  a i d  m e a s u r e s
Reproductive toxicity None
Skin contact Rinse cautiously with water for several minutes. If symptoms occur, obtain medical
advice.
Eye contact Rinse immediately with plenty of water, also under the eyelids, for at least 15
minutes. If symptoms persist, call a physician.
Ingestion Never give anything by mouth to an unconscious person. If symptoms persist, call
a physician. Do not induce vomiting without medical advice.
Sensitization None
inhalation Remove to fresh air. If symptoms persist, call a physician. If not breathing, give
artificial respiration.
inhalation May be harmful by inhalation.
Notes to Physician Treat symptomatically.
60-100
________________________________________________________________________________________________________________
The product contains no substances which at their given concentration, are considered to be hazardous to health.




Product name  HEPES
Health
Page  2 / 5
0










Hand protection Impervious gloves.
None None
Eye protection Wear safety glasses with side shields (or goggles).
None
Skin and Body Protection Lightweight protective clothing.





Oxidizing properties No information available
Prevent product from entering drains.
Ensure adequate ventilation, especially in confined areas.
Water solubility No data available
Keep in a dry, cool and well-ventilated place.
Viscosity No data available
Exposure Limits  
S E C T I O N  7 : H a n d l i n g  a n d  s t o r a g e
See Section 12 for more information.
S E C T I O N  1 0 : S t a b i l i t y  a n d  r e a c t i v i t y
S E C T I O N  9 : P h y s i c a l  a n d  c h e m i c a l  p r o p e r t i e s
Personal Protective Equipment 
Stability Stable under normal conditions.




None under normal use conditions.
Personal Protective Equipment requirements are dependent on the user institution's risk assessment and are specific





Appearance No information available
OSHA PEL (Ceiling)
Odor No data available
________________________________________________________________________________________________________________
Respiratory protection In case of insufficient ventilation, wear suitable respiratory equipment.
Odor Threshold No data available
ACGIH OEL (TWA) ACGIH OEL (STEL)
Always wear reccommended Personal Protective Equipment. No special handling
advices are necessary.
11344041
S E C T I O N  8 : E x p o s u r e  c o n t r o l s /p e r s o n a l  p r o t e c t i o n
Revision date
°C  No data available
Product name  HEPES
°F  No data available
Page  3 / 5
°C  No data available
°F  No data available
°F  No data available
Melting point / melting range
06-Apr-2015
°C  No data available
Autoignition Temperature
www.lifetechnologies.com
°C  No data available
Boiling point / boiling range
Product code
°F  No data available
flash point
May be harmful by inhalation
LD50 (dermal,rat/rabbit)
Bioaccumulation Material does not bioaccumulate
LC50 (inhalation,rat/mouse)
Ingestion May be harmful if swallowed
Acute Toxicity  
HEPES
S E C T I O N  1 3 : D i s p o s a l  c o n s i d e r a t i o n s
No data available
Carcinogenic effects None
Dispose of contents/containers in accordance with local regulations.
No data available No data available
Mutagenic effects











Principle Routes of Exposure 
Potential Health Effects 
UN-No None
Target Organ Effects No known effects under normal use conditions
________________________________________________________________________________________________________________
eyes May cause eye irritation with susceptible persons
Hazardous polymerization does not occur.
S E C T I O N  1 2 : E c o l o g i c a l  i n f o r m a t i o n




Product name  HEPES
May cause skin irritation in susceptible persons
Page  4 / 5
Ecotoxicity No information available
Chemical Name LD50 (oral,rat/mouse)
06-Apr-2015





Reason for revision SDS sections updated.
"The above information was acquired by diligent search and/or investigation and the recommendations are based on
prudent application of professional judgment. The information shall not be taken as being all inclusive and is to be
used only as a guide. All materials and mixtures may present unknown hazards and should be used with caution.
Since the Company cannot control the actual methods, volumes, or conditions of use, the Company shall not be held
liable for any damages or losses resulting from the handling or from contact with the product as described herein.
THE INFORMATION IN THIS SDS DOES NOT CONSTITUTE A WARRENTY, EXPRESSED OR IMPLIED,
INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PUPOSE"
S E C T I O N  1 6 : O t h e r  i n f o r m a t i o n
End of Safety Data Sheet
For research use only. Not intended for human or animal diagnostic or therapeutic uses.
US Federal Regulations 
WHMIS Hazard Class
Non-controlled
S E C T I O N  1 5 : R e g u l a t o r y  i n f o r m a t i o n
This product has been classified in accordance with the hazard criteria of the Controlled Products Regulations (CPR) and the
MSDS contains all the information required by the CPR.
HEPES
 7365-45-9 ( 60-100 )




This product is not regulated by SARA.
Component





Product name  HEPES
-





Clean Air Act, Section 112 Hazardous Air Pollutants (HAPs) (see 40 CFR 61)
This product does not contains HAPs.
Product code
California Proposition 65
This product does not contain any Proposition 65 chemicals.
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SAFETY DATA SHEET 
 
Version 6.5 
Revision Date 04/20/2020 
Print Date 11/20/2020 
 
SECTION 1: Identification of the substance/mixture and of the company/undertaking 
1.1 Product identifiers 
Product name : Magnesium chloride 
 
Product Number : M8266 
Brand : Sigma 
CAS-No. : 7786-30-3 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich Inc. 
3050 Spruce Street 
ST. LOUIS MO  63103 
UNITED STATES 
 
Telephone : +1 314 771-5765 
Fax : +1 800 325-5052 
1.4 Emergency telephone number 
Emergency Phone # : 800-424-9300 CHEMTREC (USA) +1-703-
527-3887 CHEMTREC (International) 24 
Hours/day; 7 Days/week 
 
 
SECTION 2: Hazards identification 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 




SECTION 3: Composition/information on ingredients 
3.1 Substances 
Formula : Cl2Mg 
Molecular weight : 95.21 g/mol 
CAS-No. : 7786-30-3 
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EC-No. : 232-094-6 
 




SECTION 4: First aid measures 
4.1 Description of first aid measures 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
In case of skin contact 
Wash off with soap and plenty of water. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 
2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 




SECTION 5: Firefighting measures 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 




SECTION 6: Accidental release measures 
6.1 Personal precautions, protective equipment and emergency procedures 
Avoid dust formation. Avoid breathing vapours, mist or gas. 
For personal protection see section 8. 
6.2 Environmental precautions 
No special environmental precautions required. 
6.3 Methods and materials for containment and cleaning up 
Sweep up and shovel. Keep in suitable, closed containers for disposal. 
6.4 Reference to other sections 
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SECTION 7: Handling and storage 
7.1 Precautions for safe handling 
Further processing of solid materials may result in the formation of combustible dusts. The 
potential for combustible dust formation should be taken into consideration before 
additional processing occurs. 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Store under inert gas. Hygroscopic.  
Storage class (TRGS 510): 13: Non Combustible Solids 
7.3 Specific end use(s) 




SECTION 8: Exposure controls/personal protection 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
General industrial hygiene practice. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate 
government standards such as NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove 
removal technique (without touching glove's outer surface) to avoid skin contact 
with this product. Dispose of contaminated gloves after use in accordance with 
applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail 
sales@kcl.de, test method: EN374 
If used in solution, or mixed with other substances, and under conditions which 
differ from EN 374, contact the supplier of the CE approved gloves. This 
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recommendation is advisory only and must be evaluated by an industrial hygienist 
and safety officer familiar with the specific situation of anticipated use by our 




Choose body protection in relation to its type, to the concentration and amount of 
dangerous substances, and to the specific work-place., The type of protective 
equipment must be selected according to the concentration and amount of the 
dangerous substance at the specific workplace. 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of 
dusts are desired, use type N95 (US) or type P1 (EN 143) dust masks. Use 
respirators and components tested and approved under appropriate government 
standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
No special environmental precautions required. 
 
 
SECTION 9: Physical and chemical properties 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: crystalline 
Colour: white 
b) Odour odourless 
c) Odour Threshold No data available 
d) pH No data available 
e) Melting 
point/freezing point 
Melting point/range: 714 °C (1317 °F) 
f) Initial boiling point 
and boiling range 
1,412 °C 2,574 °F 
g) Flash point  ()No data available 
h) Evaporation rate No data available 
i) Flammability (solid, 
gas) 




No data available 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density 2.32 g/mL at 25 °C (77 °F) 
n) Water solubility 468.7 g/l at 20 °C (68 °F) - soluble 
o) Partition coefficient: 
n-octanol/water 
No data available 
p) Auto-ignition 
temperature 
> 404 °C (> 759 °F) - Regulation (EC) No. 440/2008, Annex, 
A.16 
q) Decomposition No data available 
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r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 




SECTION 10: Stability and reactivity 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
When mixed with limited amount of water enough heat may be generated to cause 
frothing. Exposure to moisture 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Other decomposition products - No data available 




SECTION 11: Toxicological information 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - female - > 5,000 mg/kg 
(OECD Test Guideline 423) 
Inhalation: No data available 
LD50 Dermal - Rat - male and female - > 2,000 mg/kg 
(OECD Test Guideline 402) 
No data available 
Skin corrosion/irritation 
Skin - In vitro study 
Result: No skin irritation - 15 min 
(Human Skin Model Test) 
Remarks: (for the hexahydrate) 
Serious eye damage/eye irritation 
Eyes - Rabbit 
Result: No eye irritation - 72 h 
(OECD Test Guideline 405) 
Remarks: (for the hexahydrate) 
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Respiratory or skin sensitisation 
Maximisation Test - Guinea pig 
Result: negative 
(OECD Test Guideline 406) 
Germ cell mutagenicity 





IARC: No component of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
NTP: No component of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is 
on OSHA  li  of eg la ed ca cinogen . 
Reproductive toxicity 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
Repeated dose toxicity - Rat - male and female - Oral - No observed adverse effect level - 
> 1,000 mg/kg 
RTECS: OM2800000 
 
Central nervous system depression, Vomiting, Diarrhoea, Abdominal pain, To the best of 
our knowledge, the chemical, physical, and toxicological properties have not been 
thoroughly investigated. 
 
Stomach - Irregularities - Based on Human Evidence 




SECTION 12: Ecological information 
12.1 Toxicity 
 
Toxicity to fish static test LC50 - Pimephales promelas (fathead minnow) - 2,119.3 
mg/l  - 96 h 
(US-EPA) 
 
Toxicity to daphnia 
and other aquatic 
invertebrates 
static test LC50 - Daphnia magna (Water flea) - 548.4 mg/l  - 48 h 
 
Toxicity to algae Growth rate EC50 - Desmodesmus subspicatus (green algae) - > 100 
mg/l  - 72 h 
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(OECD Test Guideline 201) 
 
Toxicity to bacteria static test EC50 - activated sludge - > 900 mg/l  - 3 h 
(OECD Test Guideline 209) 
12.2 Persistence and degradability 
The methods for determining the biological degradability are not applicable to inorganic 
substances. 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not 
conducted 
12.6 Other adverse effects 




SECTION 13: Disposal considerations 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a 
licensed professional waste disposal service to dispose of this material.  
Contaminated packaging 




SECTION 14: Transport information 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 




SECTION 15: Regulatory information 
 
SARA 302 Components 
This material does not contain any components with a section 302 EHS TPQ. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that 
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Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 





New Jersey Right To Know Components 









SECTION 16: Other information 
Further information 
Copyright 2020 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies 
for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive 
and shall be used only as a guide. The information in this document is based on the 
present state of our knowledge and is applicable to the product with regard to 
appropriate safety precautions. It does not represent any guarantee of the properties of 
the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any 
damage resulting from handling or from contact with the above product. See 
www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional 
terms and conditions of sale. 
 
The branding on the header and/or footer of this document may temporarily not visually 
match the product purchased as we transition our branding. However, all of the 
information in the document regarding the product remains unchanged and matches the 
product ordered. For further information please contact mlsbranding@sial.com. 
 








The life science business of Merck KGaA, Darmstadt, Germany 









SAFETY DATA SHEET 
 
Version 6.5 
Revision Date 10/07/2020 
Print Date 11/20/2020 
 
SECTION 1: Identification of the substance/mixture and of the company/undertaking 
1.1 Product identifiers 
Product name : Sodium chloride 
 
Product Number : S9888 
Brand : SIGALD 
CAS-No. : 7647-14-5 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich Inc. 
3050 Spruce Street 
ST. LOUIS MO  63103 
UNITED STATES 
 
Telephone : +1 314 771-5765 
Fax : +1 800 325-5052 
1.4 Emergency telephone 
Emergency Phone # : 800-424-9300 CHEMTREC (USA) +1-703-
527-3887 CHEMTREC (International) 24 
Hours/day; 7 Days/week 
 
 
SECTION 2: Hazards identification 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 




SECTION 3: Composition/information on ingredients 
3.1 Substances 
Formula : ClNa 
Molecular weight : 58.44 g/mol 
CAS-No. : 7647-14-5 
EC-No. : 231-598-3 
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SECTION 4: First aid measures 
4.1 Description of first-aid measures 
If inhaled 
After inhalation: fresh air. 
In case of skin contact 
In case of skin contact: Take off immediately all contaminated clothing. Rinse skin with 
water/ shower. 
In case of eye contact 
After eye contact: rinse out with plenty of water. Remove contact lenses. 
If swallowed 
After swallowing: make victim drink water (two glasses at most). Consult doctor if feeling 
unwell. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 
2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 




SECTION 5: Firefighting measures 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
Hydrogen chloride gas, Sodium oxides 
Not combustible. 
Ambient fire may liberate hazardous vapours. 
5.3 Advice for firefighters 
In the event of fire, wear self-contained breathing apparatus. 
5.4 Further information 
Suppress (knock down) gases/vapors/mists with a water spray jet. Prevent fire 




SECTION 6: Accidental release measures 
6.1 Personal precautions, protective equipment and emergency procedures 
Advice for non-emergency personnel: Avoid inhalation of dusts. Evacuate the danger 
area, observe emergency procedures, consult an expert. 
For personal protection see section 8. 
6.2 Environmental precautions 
Do not let product enter drains. 
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6.3 Methods and materials for containment and cleaning up 
Cover drains. Collect, bind, and pump off spills. Observe possible material restrictions 
(see sections 7 and 10). Take up dry. Dispose of properly. Clean up affected area. Avoid 
generation of dusts. 
6.4 Reference to other sections 




SECTION 7: Handling and storage 
7.1 Precautions for safe handling 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Tightly closed. Dry. 
Storage class (TRGS 510): 11: Combustible Solids 
7.3 Specific end use(s) 




SECTION 8: Exposure controls/personal protection 
8.1 Control parameters 
Ingredients with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
Change contaminated clothing. Wash hands after working with substance. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate 
government standards such as NIOSH (US) or EN 166(EU). Safety glasses 
Skin protection 
This recommendation applies only to the product stated in the safety data sheet, 
supplied by us and for the designated use. When dissolving in or mixing with other 
substances and under conditions deviating from those stated in EN374 please 
contact the supplier of CE-approved gloves (e.g. KCL GmbH, D-36124 Eichenzell, 
Internet: www.kcl.de). 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:KCL 741 Dermatril® L 
 
This recommendation applies only to the product stated in the safety data sheet, 
supplied by us and for the designated use. When dissolving in or mixing with other 
substances and under conditions deviating from those stated in EN374 please 
contact the supplier of CE-approved gloves (e.g. KCL GmbH, D-36124 Eichenzell, 
Internet: www.kcl.de). 
Splash contact 
Material: Nitrile rubber 
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Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:KCL 741 Dermatril® L 
 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of 
dusts are desired, use type N95 (US) or type P1 (EN 143) dust masks. Use 
respirators and components tested and approved under appropriate government 
standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Do not let product enter drains. 
 
 
SECTION 9: Physical and chemical properties 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: Crystalline solid 
Color: colorless 
b) Odor odorless 
c) Odor Threshold Not applicable 
d) pH 7 
e) Melting 
point/freezing point 
Melting point/range: 801 °C (1474 °F) 
f) Initial boiling point 
and boiling range 
1,413 °C 2,575 °F 
g) Flash point  ()Not applicable 
h) Evaporation rate No data available 
i) Flammability (solid, 
gas) 




No data available 
k) Vapor pressure No data available 
l) Vapor density No data available 
m) Relative density 2.16 g/cm3 at 25 °C (77 °F) 
n) Water solubility 317 g/l at 20 °C (68 °F) - completely soluble 
o) Partition coefficient: 
n-octanol/water 
Not applicable for inorganic substances 
p) Autoignition 
temperature 
No data available 
q) Decomposition 
temperature 
1,000 °C (1,832 °F) -  
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
 
 




The life science business of Merck KGaA, Darmstadt, Germany 






9.2 Other safety information 




SECTION 10: Stability and reactivity 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
The product is chemically stable under standard ambient conditions (room temperature) . 
The product is chemically stable under standard ambient conditions (room temperature) . 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
Risk of explosion/exothermic reaction with:Alkali metalsExothermic reaction with:Lithium 
10.4 Conditions to avoid 
no information available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Other decomposition products - No data available 
Hazardous decomposition products formed under fire conditions. - Hydrogen chloride gas, 
Sodium oxides 




SECTION 11: Toxicological information 
11.1 Information on toxicological effects 
Acute toxicity 
No data available 
Inhalation: No data available 
LD50 Dermal - Rabbit - > 10,000 mg/kg 
Remarks: (RTECS) 
No data available 
Skin corrosion/irritation 
Skin - Rabbit 
Result: No skin irritation 
Remarks: (ECHA) 
Serious eye damage/eye irritation 
Eyes - Rabbit 
Result: No eye irritation 
Remarks: (ECHA) 
Respiratory or skin sensitization 
No data available 
Germ cell mutagenicity 
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Escherichia coli/Salmonella typhimurium  
Result: negative 
OECD Test Guideline 475 
Rat - female - Bone marrow 
Result: positive 
Carcinogenicity 
Did not show carcinogenic effects in animal experiments. 
IARC: No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
NTP: No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is 
on OSHA  li  of reg la ed carcinogens. 
Reproductive toxicity 
Did not show teratogenic effects in animal experiments. 
No impairment of reproductive performance suspected. 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 




Vomiting, Diarrhea, Dehydration and congestion may occur in internal organs. Hypertonic 
salt solutions can produce inflammatory reactions in the gastrointestinal tract., Nausea 
To the best of our knowledge, the chemical, physical, and toxicological properties have not 





SECTION 12: Ecological information 
12.1 Toxicity 
 
Toxicity to fish flow-through test LC50 - Lepomis macrochirus (Bluegill) - 5,840 mg/l  
- 96 h 
Remarks: (ECHA) 
 
Toxicity to daphnia 
and other aquatic 
invertebrates 
static test EC50 - Daphnia magna (Water flea) - 874 mg/l  - 48 h 
Remarks: (ECHA) 
 
 static test LC50 - Daphnia magna (Water flea) - 4,136 mg/l  - 48 h 
(OECD Test Guideline 202) 
 
Toxicity to algae static test EC50 - Nitzschia sp. - 2,430 mg/l  - 120 h 
(OECD Test Guideline 201) 
12.2 Persistence and degradability 
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12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not 
conducted 
12.6 Other adverse effects 




SECTION 13: Disposal considerations 
13.1 Waste treatment methods 
Product 
Waste material must be disposed of in accordance with the national and loc No mixing 
with other waste. Handle uncleaned containers like the product See 
www.retrologistik.com for processes regarding the return of chemicals and containers, or 




SECTION 14: Transport information 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 
Not dangerous goods 
 
Further information 




SECTION 15: Regulatory information 
 
SARA 302 Components 
This material does not contain any components with a section 302 EHS TPQ. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that 
exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 
313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
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No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 





New Jersey Right To Know Components 









SECTION 16: Other information 
Further information 
The above information is believed to be correct but does not purport to be all inclusive 
and shall be used only as a guide. The information in this document is based on the 
present state of our knowledge and is applicable to the product with regard to 
appropriate safety precautions. It does not represent any guarantee of the properties of 
the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any 
damage resulting from handling or from contact with the above product. See 
www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional 
terms and conditions of sale. 
 
Copyright 2020 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies 
for internal use only. 
The branding on the header and/or footer of this document may temporarily not visually 
match the product purchased as we transition our branding. However, all of the 
information in the document regarding the product remains unchanged and matches the 
product ordered. For further information please contact mlsbranding@sial.com. 
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SAFETY DATA SHEET 
 
Version 6.1 
Revision Date 06/14/2019 
Print Date 11/20/2020 
 
SECTION 1: Identification of the substance/mixture and of the company/undertaking 
1.1 Product identifiers 
Product name : Phosphate Buffered Saline, pH 7.4, sterile-
filtered, suitable for cell culture 
 
Product Number : 806552 
Brand : Sigma 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich Inc. 
3050 Spruce Street 
ST. LOUIS MO  63103 
UNITED STATES 
 
Telephone : +1 314 771-5765 
Fax : +1 800 325-5052 
1.4 Emergency telephone number 
Emergency Phone # : 800-424-9300 CHEMTREC (USA) +1-703-
527-3887 CHEMTREC (International) 24 
Hours/day; 7 Days/week 
 
 
SECTION 2: Hazards identification 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 




SECTION 3: Composition/information on ingredients 
3.2 Mixtures 
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SECTION 4: First aid measures 
4.1 Description of first aid measures 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
In case of skin contact 
Wash off with soap and plenty of water. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 
2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 




SECTION 5: Firefighting measures 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
Nature of decomposition products not known. 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 




SECTION 6: Accidental release measures 
6.1 Personal precautions, protective equipment and emergency procedures 
Avoid breathing vapours, mist or gas. 
For personal protection see section 8. 
6.2 Environmental precautions 
No special environmental precautions required. 
6.3 Methods and materials for containment and cleaning up 
Keep in suitable, closed containers for disposal. 
6.4 Reference to other sections 
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SECTION 7: Handling and storage 
7.1 Precautions for safe handling 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Storage class (TRGS 510): 12: Non Combustible Liquids 
7.3 Specific end use(s) 




SECTION 8: Exposure controls/personal protection 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
General industrial hygiene practice. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate 
government standards such as NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove 
removal technique (without touching glove's outer surface) to avoid skin contact 
with this product. Dispose of contaminated gloves after use in accordance with 
applicable laws and good laboratory practices. Wash and dry hands. 
 
Body Protection 
Impervious clothing, The type of protective equipment must be selected according 
to the concentration and amount of the dangerous substance at the specific 
workplace. 
Respiratory protection 
Respiratory protection not required. For nuisance exposures use type OV/AG (US) or 
type ABEK (EU EN 14387) respirator cartridges. Use respirators and components 
tested and approved under appropriate government standards such as NIOSH (US) 
or CEN (EU). 
Control of environmental exposure 
No special environmental precautions required. 
 
 
SECTION 9: Physical and chemical properties 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: liquid 
b) Odour No data available 
c) Odour Threshold No data available 
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d) pH No data available 
e) Melting 
point/freezing point 
No data available 
f) Initial boiling point 
and boiling range 
No data available 
g) Flash point  ()No data available 
h) Evaporation rate No data available 
i) Flammability (solid, 
gas) 




No data available 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density No data available 
n) Water solubility No data available 
o) Partition coefficient: 
n-octanol/water 
No data available 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 




SECTION 10: Stability and reactivity 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Nature of decomposition 
products not known. 
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Other decomposition products - No data available 




SECTION 11: Toxicological information 
11.1 Information on toxicological effects 
Acute toxicity 
No data available 
Inhalation: No data available 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 
No data available 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is 
identified as a carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is 
on OSHA  li  of eg la ed ca cinogen . 
Reproductive toxicity 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: Not available 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not 
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SECTION 12: Ecological information 
12.1 Toxicity 
No data available 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not 
conducted 
12.6 Other adverse effects 




SECTION 13: Disposal considerations 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 




SECTION 14: Transport information 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 




SECTION 15: Regulatory information 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, 
Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that 
exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 
313. 
SARA 311/312 Hazards 
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No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 






Sodium monohydrogen phosphate, heptahydrate 7782-85-6 
 
1993-04-24 






California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, 




SECTION 16: Other information 
Further information 
Copyright 2018 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies 
for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive 
and shall be used only as a guide. The information in this document is based on the 
present state of our knowledge and is applicable to the product with regard to 
appropriate safety precautions. It does not represent any guarantee of the properties of 
the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any 
damage resulting from handling or from contact with the above product. See 
www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional 
terms and conditions of sale. 
 
The branding on the header and/or footer of this document may temporarily not visually 
match the product purchased as we transition our branding. However, all of the 
information in the document regarding the product remains unchanged and matches the 
product ordered. For further information please contact mlsbranding@sial.com. 
 
Version: 6.1 Revision Date: 06/14/2019 Print Date: 11/20/2020 
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SECTION 1. IDENTIFICATION 
Product name 
 





Manufacturer or supplier's details 
Company name of supplier 
 








Telephone : +496217590 
Telefax : +496217592890 
E-mail address : mannheim.umweltschutz@roche.com 
Emergency telephone 
In case of emergencies: : CHEMTREC 
 
+1 703-741-5970 / 
1-800-424-9300 
Recommended use of the chemical and restrictions on use 
Restrictions on use 
 
: For professional users only. 
 
 
SECTION 2. HAZARDS IDENTIFICATION 
GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 
1910.1200) 
The product is a kit consisting of individual ingredients. The classification of the ingredients can 
be obtained from section 3. Section GHS Label elements contains the resulting labelling for the 
kit 
GHS label elements 
Not a hazardous substance or mixture. 
Other hazards 
None known. 
SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS 
Phosphatase, alkaline 
GHS Classification 
Not a hazardous substance or mixture. 
Components 
Chemical name CAS-No. Concentration (% w/w) 
glycerol 56-81-5 >= 50 -  < 70 
Alkaline phosphatase 9001-78-9 >= 1 -  < 5 
Actual concentration is withheld as a trade secret 
 
 
Alkaline Phosphatase Buffer, 10x conc. 
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GHS Classification 
Not a hazardous substance or mixture. 
Components 
No hazardous ingredients 
 
 
SECTION 4. FIRST AID MEASURES 
General advice 
 




: Move to fresh air. 
If unconscious, place in recovery position and seek medical 
advice. 
If symptoms persist, call a physician. 
 
In case of skin contact 
 
: If on skin, rinse well with water. 
 
In case of eye contact 
 
: Immediately flush eye(s) with plenty of water. 
Remove contact lenses. 
Protect unharmed eye. 




: Keep respiratory tract clear. 
Do not give milk or alcoholic beverages. 
Never give anything by mouth to an unconscious person. 
If symptoms persist, call a physician. 
Rinse mouth with water. 
 
Most important symptoms 
and effects, both acute and 
delayed 
 
: No information available. 
 
Notes to physician 
 
: The first aid procedure should be established in consultation 
with the doctor responsible for industrial medicine. 
SECTION 5. FIRE-FIGHTING MEASURES 
Suitable extinguishing media 
 
: Use extinguishing measures that are appropriate to local cir-
cumstances and the surrounding environment. 
 
Specific hazards during fire 
fighting  
 
: No information available. 
 
Further information : Standard procedure for chemical fires. 
Use extinguishing measures that are appropriate to local cir-
cumstances and the surrounding environment. 
 
Special protective equipment 
for fire-fighters 
 
: Wear self-contained breathing apparatus for firefighting if 
necessary. 
 
SECTION 6. ACCIDENTAL RELEASE MEASURES 
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Personal precautions, protec-
tive equipment and emer-
gency procedures 
 




: Local authorities should be advised if significant spillages 
cannot be contained. 
 
Methods and materials for 
containment and cleaning up  
 
: Wipe up with absorbent material (e.g. cloth, fleece). 
Keep in suitable, closed containers for disposal. 
 
SECTION 7. HANDLING AND STORAGE 
Advice on protection against 
fire and explosion 
 
:  Normal measures for preventive fire protection. 
 
Advice on safe handling 
 
: For personal protection see section 8. 
Smoking, eating and drinking should be prohibited in the ap-
plication area. 
 
Conditions for safe storage 
 
: Electrical installations / working materials must comply with 
the technological safety standards. 
 
Further information on stor-
age conditions 
 
:  See label, package insert or internal guidelines 
 
Materials to avoid  
 
: No materials to be especially mentioned. 
 
Further information on stor-
age stability 
 
:  No decomposition if stored and applied as directed. 
SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
Phosphatase, alkaline 
Ingredients with workplace control parameters 




ters / Permissible 
concentration 
Basis 
glycerol 56-81-5 TWA (mist, 
respirable 
fraction) 
5 mg/m3 OSHA Z-1 
  TWA (mist, 
total dust) 
15 mg/m3 OSHA Z-1 
  TWA (Mist - 
total dust) 
10 mg/m3 OSHA P0 
  TWA (Mist - 
respirable 
fraction) 
5 mg/m3 OSHA P0 
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Alkaline Phosphatase Buffer, 10x conc. 
Ingredients with workplace control parameters 
Contains no substances with occupational exposure limit values. 
Engineering measures : No data available 
 
Personal protective equipment 
Respiratory protection 
 




   In case of contact through splashing:  
Material : Nitrile rubber 
Break through time : > 30 min 
Glove thickness : > 0.11 mm 
 
 
   In case of full contact:  
Material : butyl-rubber 
Break through time : > 480 min 




: Wear appropriate protective gloves to prevent skin contact. 
Replace torn or punctured gloves promptly. 
Eye protection 
 
: Safety glasses 
 
Skin and body protection 
 




: Handle in accordance with good industrial hygiene and safety 
practice. 
 




























: No data available  
 
Boiling point/boiling range 
 
 
: No data available  
 
 




 Phosphatase,alkaline(AP),MB grd.(20U/µl) 
Version  
1.8 
Revision Date:  
02-07-2021 
Date of last issue: 09-19-2019 
Date of first issue: 09-17-2015 
 
5 / 19 
Flash point 
 












 The product is not flammable. 
 
Self-ignition : No data available  
 
Upper explosion limit / Upper 
flammability limit 
 
: No data available  
 
Lower explosion limit / Lower 
flammability limit 
 




: No data available  
 
Relative vapor density  
 













: completely miscible  
 
Solubility in other solvents 
 































: The substance or mixture is not classified as oxidizing. 
 
 








:  clear, colorless 
 
 
Odor :  none 
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: No data available  
 
Boiling point/boiling range 
 
 
















 The product is not flammable. 
 
Self-ignition : No data available  
 
Upper explosion limit / Upper 
flammability limit 
 
: No data available  
 
Lower explosion limit / Lower 
flammability limit 
 




: No data available  
 
Relative vapor density  
 













: completely miscible  
 
Solubility in other solvents 
 


























: Not explosive 
 
 
Oxidizing properties : The substance or mixture is not classified as oxidizing. 
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SECTION 10. STABILITY AND REACTIVITY 
Reactivity 
 




:  Stable under normal conditions. 
 
Possibility of hazardous reac-
tions  
 
: No dangerous reaction known under conditions of normal use. 
Stable under recommended storage conditions. 
No hazards to be specially mentioned. 
 
Conditions to avoid 
 








:   No decomposition if stored and applied as directed. 
 
SECTION 11. TOXICOLOGICAL INFORMATION 
Phosphatase, alkaline 
Acute toxicity 
Not classified based on available information. 
Components: 
glycerol: 
Acute oral toxicity 
 




  LD50 Oral (Mouse): 4,090 mg/kg  
 
Acute inhalation toxicity 
 
:  Acute toxicity estimate: > 30 mg/l  
Test atmosphere: vapor 
Method: Expert judgment 
 
Acute dermal toxicity 
 




Acute oral toxicity 
 
:  Acute toxicity estimate: > 5,001 mg/kg  
Method: Expert judgment 
 
Acute inhalation toxicity 
 
:  Acute toxicity estimate: > 30 mg/l  
Test atmosphere: dust/mist 
Method: Expert judgment 
 
Acute dermal toxicity 
 
:  Acute toxicity estimate: > 5,001 mg/kg 
Method: Expert judgment 
 
Skin corrosion/irritation 
Not classified based on available information. 
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Components: 
glycerol: 
Species : Rabbit 
Exposure time : 24 h 
Result : No skin irritation 
GLP : no 
 
Serious eye damage/eye irritation 
Not classified based on available information. 
Components: 
glycerol: 
Species : Rabbit 
Result : No eye irritation 
Exposure time : 7 d 
GLP : no 
 
Respiratory or skin sensitization 
Skin sensitization 
Not classified based on available information. 
Respiratory sensitization 
Not classified based on available information. 
Components: 
glycerol: 
Assessment :  Mild eye irritant, Mild respiratory irritant, No skin irritation 
 
Germ cell mutagenicity 
Not classified based on available information. 
Components: 
glycerol: 
Genotoxicity in vitro 
 
: Test Type: Microbial mutagenesis assay (Ames test) 
Test system: Salmonella typhimurium 
Metabolic activation: with and without metabolic activation 
Result: negative 




 Test Type: In vitro mammalian cell gene mutation test 
Test system: Chinese hamster ovary cells 
Metabolic activation: with and without metabolic activation 
Method: OECD Test Guideline 476 
Result: negative 
GLP: No information available. 
 
Carcinogenicity 
Not classified based on available information. 
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Components: 
glycerol: 
Species : Rat, male and female 
Application Route : Oral 
Exposure time : 2 Years 
Frequency of Treatment : daily 
GLP : No information available. 
Remarks : No ingredient of this product present at levels greater than or 
equal to 0.1% is identified as probable, possible or confirmed 
human carcinogen by IARC. 
 
IARC No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
 
OSHA No component of this product present at levels greater than or equal to 0.1% is 
on OSHA  li  of eg la ed ca cinogen . 
 
NTP No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
 
Reproductive toxicity 
Not classified based on available information. 
Components: 
glycerol: 
Effects on fertility 
 
:  Test Type: Two-generation study 
Species: Rat, male and female 
Application Route: Oral 
Dose: 2000 mg/kg bw/day 
Fertility: NOAEL: 2,000 mg/kg body weight 
GLP: no 
 
Effects on fetal development 
 
:  Species: Rabbit, female 
Application Route: Oral 
Dose: 11.8, 54.8, 254.5, 1180 mg/kg bw/day 
Duration of Single Treatment: 29 d 




Not classified based on available information. 
Components: 
Alkaline phosphatase: 
Assessment : The substance or mixture is not classified as specific target 
organ toxicant, single exposure. 
 
STOT-repeated exposure 
Not classified based on available information. 
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Components: 
Alkaline phosphatase: 
Assessment : The substance or mixture is not classified as specific target 
organ toxicant, repeated exposure. 
 
Repeated dose toxicity 
Components: 
glycerol: 
Species : Rat, male and female 
NOAEL : 4580 mg/kg 
NOAEL : 4,580 mg/kg  
Application Route : Oral 
Exposure time : 90 d 
Number of exposures : daily 
Dose : 4580 - 25,800 mg/kg/day  
GLP : no 
 
Species : Rat, male and female 
Application Route : Inhalation 
Test atmosphere : dust/mist 
Exposure time : 13 Weeks 
Number of exposures : 6 hours/day, 5 days/week 
Dose : 33, 165 and 660 mg/m3  
GLP : No information available. 
 
Species : Rat 
NOAEL : 5040 mg/kg 
NOAEL : 5,040 mg/kg  
Application Route : dermal 
Exposure time : 45 Weeks 
Number of exposures : 8 hours/day, 5 days/week 
Dose : 0.5-4.0 ml/kg  
GLP : no 
 
Repeated dose toxicity - 
Assessment 
 
:  Mild eye irritant, Mild respiratory irritant, No skin irritation 
 
Aspiration toxicity 
Not classified based on available information. 
Components: 
Alkaline phosphatase: 





Remarks : Health injuries are not known or expected under normal use. 
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Alkaline Phosphatase Buffer, 10x conc. 
Acute toxicity 
Not classified based on available information. 
Skin corrosion/irritation 
Not classified based on available information. 
Serious eye damage/eye irritation 
Not classified based on available information. 
Respiratory or skin sensitization 
Skin sensitization 
Not classified based on available information. 
Respiratory sensitization 
Not classified based on available information. 
Germ cell mutagenicity 
Not classified based on available information. 
Carcinogenicity 
Not classified based on available information. 
IARC No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
 
OSHA No component of this product present at levels greater than or equal to 0.1% is 
on OSHA  li  of eg la ed ca cinogen . 
 
NTP No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
 
Reproductive toxicity 
Not classified based on available information. 
STOT-single exposure 
Not classified based on available information. 
STOT-repeated exposure 
Not classified based on available information. 
Aspiration toxicity 
Not classified based on available information. 
 





Toxicity to fish :  LC50 (Oncorhynchus mykiss (rainbow trout)): 54,000 mg/l 
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 End point: mortality 
Exposure time: 96 h 
Test Type: static test 
GLP: no 
 
Toxicity to daphnia and other 
aquatic invertebrates 
 
:  LC50 (Daphnia magna (Water flea)): 1,955 mg/l 
End point: mortality 
Exposure time: 48 h 
Test Type: static test 
Analytical monitoring: no 
GLP: no 
 
Toxicity to algae/aquatic 
plants 
 
:   (Scenedesmus quadricauda (Green algae)): > 10,000 mg/l 
End point: Growth rate 
Exposure time: 8 d 
Test Type: static test 
GLP: no 
 
Toxicity to microorganisms 
 
:  EC50 (Pseudomonas putida): > 10,000 mg/l 
End point: Growth rate 
Exposure time: 16 h 
Test Type: static test 
GLP: No information available. 
 
Ecotoxicology Assessment 
Acute aquatic toxicity 
 
:  This product has no known ecotoxicological effects. 
 
Chronic aquatic toxicity 
 
:  This product has no known ecotoxicological effects. 
 
Toxicity Data on Soil 
 
:  Not expected to adsorb on soil. 
 
Other organisms relevant to 
the environment 
 
:  No data available 
 
Alkaline phosphatase: 
Toxicity to fish 
 
:  LC50: > 100 mg/l 
Exposure time: 96 h 
 
Toxicity to fish (Chronic tox-
icity) 
 
: > 1 mg/l  
 
Ecotoxicology Assessment 
Acute aquatic toxicity 
 




  This product has no known ecotoxicological effects. 
 
Chronic aquatic toxicity 
 




  This product has no known ecotoxicological effects. 
 
Toxicity Data on Soil 
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Other organisms relevant to 
the environment 
 




   
 





:  aerobic 
Inoculum: activated sludge 
Concentration: 226 mg/l 
Result: Readily biodegradable. 
Biodegradation:  94 % 









: log Pow: -1.75 (77 °F / 25 °C) 
pH: 7.4 







: Remarks: No data available 
 
Mobility in soil 
No data available 
Other adverse effects 
 
Alkaline Phosphatase Buffer, 10x conc. 
Ecotoxicity 
No data available 
Persistence and degradability 
No data available 
Bioaccumulative potential 
No data available 
Mobility in soil 
No data available 
Other adverse effects 
 
 




 Phosphatase,alkaline(AP),MB grd.(20U/µl) 
Version  
1.8 
Revision Date:  
02-07-2021 
Date of last issue: 09-19-2019 
Date of first issue: 09-17-2015 
 
14 / 19 
SECTION 13. DISPOSAL CONSIDERATIONS 
Disposal methods 





: Empty containers should be taken to an approved waste 
handling site for recycling or disposal. 
Do not re-use empty containers. 
 
SECTION 14. TRANSPORT INFORMATION 
International Regulations 
UNRTDG  
Not regulated as a dangerous good 
IATA-DGR  
Not regulated as a dangerous good 
IMDG-Code  
Not regulated as a dangerous good 
Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code 
Not applicable 
Domestic regulation 
49 CFR  
Not regulated as a dangerous good 
SECTION 15. REGULATORY INFORMATION 
Phosphatase, alkaline 
CERCLA Reportable Quantity 
Components CAS-No. Component RQ 
(lbs) 
Calculated product RQ 
(lbs) 
Zinc chloride (ZnCl2) 7646-85-7 1000 * 
*: Calculated RQ exceeds reasonably attainable upper limit. 
SARA 304 Extremely Hazardous Substances Reportable Quantity 
This material does not contain any components with a section 304 EHS RQ. 
SARA 302 Extremely Hazardous Substances Threshold Planning Quantity 
This material does not contain any components with a section 302 EHS TPQ. 
SARA 311/312 Hazards 
 




:  This material does not contain any chemical components with 
known CAS numbers that exceed the threshold (De Minimis) 
reporting levels established by SARA Title III, Section 313. 
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Clean Air Act 
This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by 
the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B). 
This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean 
Air Act Section 112 (40 CFR 61). 
This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for 
Accidental Release Prevention (40 CFR 68.130, Subpart F). 
The following chemical(s) are listed under the U.S. Clean Air Act Section 111 SOCMI Intermedi-
ate or Final VOC's (40 CFR 60.489): 
 glycerol 56-81-5 >= 50 - < 70 % 
Clean Water Act 
The following Hazardous Substances are listed under the U.S. CleanWater Act, Section 311, Ta-
ble 116.4A: 
 Zinc chloride (ZnCl2) 7646-85-7 >= 0 - < 0.1 % 
The following Hazardous Chemicals are listed under the U.S. CleanWater Act, Section 311, Table 
117.3: 
 Zinc chloride (ZnCl2) 7646-85-7 >= 0 - < 0.1 % 
This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 
307 
This product does not contain any priority pollutants related to the U.S. Clean Water Act 
US State Regulations 
Massachusetts Right To Know 
 glycerol 56-81-5 
Pennsylvania Right To Know 
 glycerol 56-81-5 
 Water 7732-18-5 
Maine Chemicals of High Concern 
 Product does not contain any listed chemicals 
Vermont Chemicals of High Concern 
 Product does not contain any listed chemicals 
Washington Chemicals of High Concern 
 Product does not contain any listed chemicals 
California Permissible Exposure Limits for Chemical Contaminants 
 glycerol 56-81-5 
The ingredients of this product are reported in the following inventories: 
DSL 
 
: This product contains the following components listed on the 
Canadian NDSL. All other components are on the Canadian 
DSL. 
 
















: Not in compliance with the inventory 
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KECI 
 
















: All substances listed as active on the TSCA inventory 
 
TSCA list 
No substances are subject to a Significant New Use Rule. 
 




Alkaline Phosphatase Buffer, 10x conc. 
CERCLA Reportable Quantity 
This material does not contain any components with a CERCLA RQ. 
SARA 304 Extremely Hazardous Substances Reportable Quantity 
This material does not contain any components with a section 304 EHS RQ. 
SARA 302 Extremely Hazardous Substances Threshold Planning Quantity 
This material does not contain any components with a section 302 EHS TPQ. 
SARA 311/312 Hazards 
 




:  This material does not contain any chemical components with 
known CAS numbers that exceed the threshold (De Minimis) 
reporting levels established by SARA Title III, Section 313. 
 
Clean Air Act 
This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by 
the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B). 
This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean 
Air Act Section 112 (40 CFR 61). 
This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for 
Accidental Release Prevention (40 CFR 68.130, Subpart F). 
This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 
SOCMI Intermediate or Final VOC's (40 CFR 60.489). 
Clean Water Act 
This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, 
Section 311, Table 116.4A. 
This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, 
Section 311, Table 117.3. 
This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 
307 
This product does not contain any priority pollutants related to the U.S. Clean Water Act 
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US State Regulations 
Massachusetts Right To Know 
 No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know 
 Water 7732-18-5 
 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-, hydrochloride 
(1:1) 
1185-53-1 
Maine Chemicals of High Concern 
 Product does not contain any listed chemicals 
Vermont Chemicals of High Concern 
 Product does not contain any listed chemicals 
Washington Chemicals of High Concern 
 Product does not contain any listed chemicals 
The ingredients of this product are reported in the following inventories: 
DSL 
 




































: All substances listed as active on the TSCA inventory 
 
TSCA list 
No substances are subject to a Significant New Use Rule. 
 





GHS label elements 
Not a hazardous substance or mixture. 
Alkaline Phosphatase Buffer, 10x conc. 
GHS label elements 
Not a hazardous substance or mixture. 
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SECTION 16. OTHER INFORMATION 
Further information 















HMIS® ratings are based on a 0-4 rating 
scale, with 0 representing minimal haz-
ards or risks, and 4 representing signifi-
cant hazards or risks. The "*" represents 
a chronic hazard, while the "/" represents 
the absence of a chronic hazard. 
 















HMIS® ratings are based on a 0-4 rating 
scale, with 0 representing minimal haz-
ards or risks, and 4 representing signifi-
cant hazards or risks. The "*" represents 
a chronic hazard, while the "/" represents 




3050 Spruce Street 
SAINT LOUIS 
MO 63103 USA 
Full text of other abbreviations 
 
AICS - Australian Inventory of Chemical Substances; AIIC - Australian Inventory of Industrial 
Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - 
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Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; 
DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concen-
tration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate 
associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical 
Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - 
Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Prac-
tice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research 
on Cancer; IATA - International Air Transport Association; IBC - International Code for the Con-
struction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal in-
hibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Ex-
isting Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - In-
ternational Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - Interna-
tional Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal 
Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Me-
dian Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; 
MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National 
Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - 
No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - Na-
tional Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization 
for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution 
Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Invento-
ry of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relation-
ship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 
1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, 
Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating 
Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - 
Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances 
Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations 
on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative 
 
 
Revision Date :  02-07-2021 
 
 
The information provided in this Safety Data Sheet is correct to the best of our knowledge, infor-
mation and belief at the date of its publication. The information given is designed only as a guid-
ance for safe handling, use, processing, storage, transportation, disposal and release and is not 
to be considered a warranty or quality specification. The information relates only to the specific 
material designated and may not be valid for such material used in combination with any other 
materials or in any process, unless specified in the text. 
 
US / Z8 / 2004
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SAFETY DATA SHEET 
 
Version 6.3 
Revision Date 10/02/2020 
Print Date 11/20/2020 
 
SECTION 1: Identification of the substance/mixture and of the company/undertaking 
1.1 Product identifiers 
Product name : Sodium acetate 
 
Product Number : S5636 
Brand : Sigma 
CAS-No. : 127-09-3 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich Inc. 
3050 Spruce Street 
ST. LOUIS MO  63103 
UNITED STATES 
 
Telephone : +1 314 771-5765 
Fax : +1 800 325-5052 
1.4 Emergency telephone 
Emergency Phone # : 800-424-9300 CHEMTREC (USA) +1-703-
527-3887 CHEMTREC (International) 24 
Hours/day; 7 Days/week 
 
 
SECTION 2: Hazards identification 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 




SECTION 3: Composition/information on ingredients 
3.1 Substances 
Synonyms : Acetic acid sodium salt 
 
Formula : C2H3NaO2 
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Molecular weight : 82.03 g/mol 
CAS-No. : 127-09-3 
EC-No. : 204-823-8 
 




SECTION 4: First aid measures 
4.1 Description of first-aid measures 
General advice 
Consult a physician. Show this material safety data sheet to the doctor in attendance. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Consult a physician. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult 
a physician. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 
2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 




SECTION 5: Firefighting measures 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
Carbon oxides, Sodium oxides 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 




SECTION 6: Accidental release measures 
6.1 Personal precautions, protective equipment and emergency procedures 
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or 
gas. Ensure adequate ventilation. Avoid breathing dust. 
For personal protection see section 8. 
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6.2 Environmental precautions 
Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in 
suitable, closed containers for disposal. 
6.4 Reference to other sections 




SECTION 7: Handling and storage 
7.1 Precautions for safe handling 
Avoid formation of dust and aerosols.Further processing of solid materials may result in the 
formation of combustible dusts. The potential for combustible dust formation should be 
taken into consideration before additional processing occurs. 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Keep in a dry place.  
Storage class (TRGS 510): 13: Non Combustible Solids 
7.3 Specific end use(s) 




SECTION 8: Exposure controls/personal protection 
8.1 Control parameters 
Ingredients with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
Handle in accordance with good industrial hygiene and safety practice. Wash hands 
before breaks and at the end of workday. 
Personal protective equipment 
Eye/face protection 
Safety glasses with side-shields conforming to EN166 Use equipment for eye 
protection tested and approved under appropriate government standards such as 
NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove 
removal technique (without touching glove's outer surface) to avoid skin contact 
with this product. Dispose of contaminated gloves after use in accordance with 
applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
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Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail 
sales@kcl.de, test method: EN374 
If used in solution, or mixed with other substances, and under conditions which 
differ from EN 374, contact the supplier of the EC approved gloves. This 
recommendation is advisory only and must be evaluated by an industrial hygienist 
and safety officer familiar with the specific situation of anticipated use by our 




Choose body protection in relation to its type, to the concentration and amount of 
dangerous substances, and to the specific work-place., The type of protective 
equipment must be selected according to the concentration and amount of the 
dangerous substance at the specific workplace. 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of 
dusts are desired, use type N95 (US) or type P1 (EN 143) dust masks. Use 
respirators and components tested and approved under appropriate government 
standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Do not let product enter drains. 
 
 
SECTION 9: Physical and chemical properties 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: solid, powder 
Color: white 
b) Odor No data available 
c) Odor Threshold No data available 
d) pH 8.5 - 9.9 at 246 g/l at 25 °C (77 °F) 
e) Melting 
point/freezing point 
Melting point/range: > 300 °C (> 572 °F) 
f) Initial boiling point 
and boiling range 
No data available 
g) Flash point > 250 °C (> 482 °F) - closed cup 
h) Evaporation rate No data available 
i) Flammability (solid, 
gas) 




No data available 
k) Vapor pressure No data available 
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l) Vapor density No data available 
m) Relative density 1.528 g/cm3 
n) Water solubility 246 g/l at 20 °C (68 °F) - completely soluble 
o) Partition coefficient: 
n-octanol/water 
log Pow: -4.22 
p) Autoignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 




SECTION 10: Stability and reactivity 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
Exposure to moisture. 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Sodium 
oxides 
Other decomposition products - No data available 




SECTION 11: Toxicological information 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - male and female - 2,700 mg/kg 
(OECD Test Guideline 401) 
LC50 Inhalation - Rat - male and female - 4 h - > 5.6 mg/l 
(OECD Test Guideline 403) 
LD50 Dermal - Rabbit - female - > 20,000 mg/kg 
(OECD Test Guideline 402) 
No data available 
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Skin - Rabbit 
Result: No skin irritation - 4 h 
(OECD Test Guideline 404) 
Serious eye damage/eye irritation 
Eyes - Rabbit 
Result: No eye irritation - 24 h 
(OECD Test Guideline 405) 
Respiratory or skin sensitization 
No data available 
Germ cell mutagenicity 
 




IARC: No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
NTP: No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is 
on OSHA  li  of reg la ed carcinogens. 
Reproductive toxicity 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 




Abdominal pain, Nausea, Vomiting 
To the best of our knowledge, the chemical, physical, and toxicological properties have not 





SECTION 12: Ecological information 
12.1 Toxicity 
 
Toxicity to fish semi-static test LC50 - Danio rerio (zebra fish) - > 100 mg/l  - 96 h 
(OECD Test Guideline 203) 
 
Toxicity to daphnia 
and other aquatic 
invertebrates 
static test EC50 - Daphnia magna (Water flea) - > 1,000 mg/l  - 48 h 
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Toxicity to algae ErC50 - Skeletonema costatum - > 1,000 mg/l  - 72 h 
(ISO 10253) 
 
Toxicity to bacteria static test EC50 - Pseudomonas putida - 7,200 mg/l  - 16 h 
(DIN 38 412 Part 8) 
12.2 Persistence and degradability 
Biodegradability aerobic Dissolved organic carbon (DOC) - Exposure time 28 d 
Result: 99 % - Readily biodegradable.  
 (Regulation (EC) No. 440/2008, Annex, C.4-A) 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not 
conducted 
12.6 Other adverse effects 




SECTION 13: Disposal considerations 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 




SECTION 14: Transport information 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 
Not dangerous goods 
 
Further information 




SECTION 15: Regulatory information 
 
SARA 302 Components 
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SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that 
exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 
313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 











New Jersey Right To Know Components 





California Prop. 65 Components 
This product does not contain any chemicals known to the State of California to cause 




SECTION 16: Other information 
Further information 
Copyright 2020 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies 
for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive 
and shall be used only as a guide. The information in this document is based on the 
present state of our knowledge and is applicable to the product with regard to 
appropriate safety precautions. It does not represent any guarantee of the properties of 
the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any 
damage resulting from handling or from contact with the above product. See 
www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional 
terms and conditions of sale. 
 
The branding on the header and/or footer of this document may temporarily not visually 
match the product purchased as we transition our branding. However, all of the 
information in the document regarding the product remains unchanged and matches the 
product ordered. For further information please contact mlsbranding@sial.com. 
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SAFETY DATA SHEET 
 
Version 6.3 
Revision Date 04/20/2020 
Print Date 11/20/2020 
 
SECTION 1: Identification of the substance/mixture and of the company/undertaking 
1.1 Product identifiers 
Product name : Spermidine 
 
Product Number : S2626 
Brand : Sigma 
CAS-No. : 124-20-9 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich Inc. 
3050 Spruce Street 
ST. LOUIS MO  63103 
UNITED STATES 
 
Telephone : +1 314 771-5765 
Fax : +1 800 325-5052 
1.4 Emergency telephone number 
Emergency Phone # : 800-424-9300 CHEMTREC (USA) +1-703-
527-3887 CHEMTREC (International) 24 
Hours/day; 7 Days/week 
 
 
SECTION 2: Hazards identification 
2.1 Classification of the substance or mixture 
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) 
Skin corrosion (Category 1B), H314 
Serious eye damage (Category 1), H318 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
2.2 GHS Label elements, including precautionary statements 
Pictogram 
  
Signal word Danger 
 
Hazard statement(s) 
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P264 Wash skin thoroughly after handling. 
P280 Wear protective gloves/ protective clothing/ eye protection/ face 
protection. 
P301 + P330 + P331 IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. 
P303 + P361 + P353 IF ON SKIN (or hair): Take off immediately all contaminated 
clothing. Rinse skin with water/shower. 
P304 + P340 + P310 IF INHALED: Remove person to fresh air and keep comfortable 
for breathing. Immediately call a POISON CENTER/doctor. 
P305 + P351 + P338 + 
P310 
IF IN EYES: Rinse cautiously with water for several minutes. 
Remove contact lenses, if present and easy to do. Continue 
rinsing. Immediately call a POISON CENTER/doctor. 
P363 Wash contaminated clothing before reuse. 
P405 Store locked up. 
P501 Dispose of contents/ container to an approved waste disposal 
plant. 
 




SECTION 3: Composition/information on ingredients 
3.1 Substances 
Synonyms : 1,8-Diamino-4-azaoctane 
N-(3-Aminopropyl)-1,4-diaminobutane 
 
Formula : C7H19N3 
Molecular weight : 145.25 g/mol 
CAS-No. : 124-20-9 
EC-No. : 204-689-0 
 
Component Classification Concentration 
4-Azaoctamethylenediamine 
   Skin Corr. 1B; Eye Dam. 
1; H314, H318 
<= 100 % 
 




SECTION 4: First aid measures 
4.1 Description of first aid measures 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of 
dangerous area. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
Consult a physician. 
In case of skin contact 
Take off contaminated clothing and shoes immediately. Wash off with soap and plenty of 
water. Consult a physician. 
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In case of eye contact 
Rinse thoroughly with plenty of water for at least 15 minutes and consult a 
physician.Continue rinsing eyes during transport to hospital. 
If swallowed 
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse 
mouth with water. Consult a physician. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 
2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 




SECTION 5: Firefighting measures 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
Carbon oxides, Nitrogen oxides (NOx) 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 




SECTION 6: Accidental release measures 
6.1 Personal precautions, protective equipment and emergency procedures 
Use personal protective equipment. Avoid breathing vapours, mist or gas. Ensure 
adequate ventilation. Evacuate personnel to safe areas. 
For personal protection see section 8. 
6.2 Environmental precautions 
Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in 
suitable, closed containers for disposal. 
6.4 Reference to other sections 




SECTION 7: Handling and storage 
7.1 Precautions for safe handling 
Avoid inhalation of vapour or mist. 
For precautions see section 2.2. 
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7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place. Containers which are 
opened must be carefully resealed and kept upright to prevent leakage.  
Store under inert gas. Air sensitive. strongly hygroscopic  
Storage class (TRGS 510): 8A: Combustible, corrosive hazardous materials 
7.3 Specific end use(s) 




SECTION 8: Exposure controls/personal protection 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
Handle in accordance with good industrial hygiene and safety practice. Wash hands 
before breaks and at the end of workday. 
Personal protective equipment 
Eye/face protection 
Tightly fitting safety goggles.  Faceshield (8-inch minimum). Use equipment for eye 
protection tested and approved under appropriate government standards such as 
NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove 
removal technique (without touching glove's outer surface) to avoid skin contact 
with this product. Dispose of contaminated gloves after use in accordance with 
applicable laws and good laboratory practices. Wash and dry hands. 
 
Body Protection 
Complete suit protecting against chemicals, The type of protective equipment must 
be selected according to the concentration and amount of the dangerous substance 
at the specific workplace. 
Respiratory protection 
Where risk assessment shows air-purifying respirators are appropriate use a full-
face respirator with multi-purpose combination (US) or type ABEK (EN 14387) 
respirator cartridges as a backup to engineering controls. If the respirator is the sole 
means of protection, use a full-face supplied air respirator. Use respirators and 
components tested and approved under appropriate government standards such as 
NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Do not let product enter drains. 
 
 
SECTION 9: Physical and chemical properties 
9.1 Information on basic physical and chemical properties 
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b) Odour No data available 
c) Odour Threshold No data available 
d) pH 12.0 - 13.5 at 145 g/l at 25 °C (77 °F) 
e) Melting 
point/freezing point 
22 - 25 °C (72 - 77 °F) 
f) Initial boiling point 
and boiling range 
No data available 
g) Flash point 112 °C (234 °F) - closed cup 
h) Evaporation rate No data available 
i) Flammability (solid, 
gas) 




No data available 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density 0.925 g/mL at 25 °C (77 °F) 
n) Water solubility 145 g/l at 20 °C (68 °F) - completely soluble 
o) Partition coefficient: 
n-octanol/water 
No data available 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 




SECTION 10: Stability and reactivity 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
acids, Acid chlorides, Acid anhydrides, Oxidizing agents 
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10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen 
oxides (NOx) 
Other decomposition products - No data available 




SECTION 11: Toxicological information 
11.1 Information on toxicological effects 
Acute toxicity 
No data available 
Inhalation: Material is extremely destructive to the tissue of the mucous membranes and 
upper respiratory tract. 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 
No data available 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
NTP: No component of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is 
on OSHA  li  of reg la ed carcinogens. 
Reproductive toxicity 
No data available 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 




Material is extremely destructive to tissue of the mucous membranes and upper respiratory 
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SECTION 12: Ecological information 
12.1 Toxicity 
No data available 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not 
conducted 
12.6 Other adverse effects 




SECTION 13: Disposal considerations 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a 
licensed professional waste disposal service to dispose of this material. Dissolve or mix 
the material with a combustible solvent and burn in a chemical incinerator equipped with 
an afterburner and scrubber.  
Contaminated packaging 




SECTION 14: Transport information 
DOT (US) 
UN number: 3259 Class: 8 Packing group: II 
Proper shipping name: Polyamines, solid, corrosive, n.o.s. (4-Azaoctamethylenediamine) 
Reportable Quantity (RQ):   
Poison Inhalation Hazard: No 
 
IMDG 
UN number: 3259 Class: 8 Packing group: II EMS-No: F-A, S-B 




UN number: 3259 Class: 8 Packing group: II 
Proper shipping name: Polyamines, solid, corrosive, n.o.s. (4-Azaoctamethylenediamine) 
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SARA 302 Components 
This material does not contain any components with a section 302 EHS TPQ. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that 
exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 
313. 
SARA 311/312 Hazards 
Acute Health Hazard 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
 
No components are subject to the Massachusetts Right to Know Act. 
















SECTION 16: Other information 
Further information 
Copyright 2020 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies 
for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive 
and shall be used only as a guide. The information in this document is based on the 
present state of our knowledge and is applicable to the product with regard to 
appropriate safety precautions. It does not represent any guarantee of the properties of 
the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any 
damage resulting from handling or from contact with the above product. See 
www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional 
terms and conditions of sale. 
 
The branding on the header and/or footer of this document may temporarily not visually 
match the product purchased as we transition our branding. However, all of the 
information in the document regarding the product remains unchanged and matches the 
product ordered. For further information please contact mlsbranding@sial.com. 
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SAFETY DATA SHEET 
 
Version 6.6 
Revision Date 10/07/2020 
Print Date 11/20/2020 
 
SECTION 1: Identification of the substance/mixture and of the company/undertaking 
1.1 Product identifiers 
Product name : Sucrose 
 
Product Number : S9378 
Brand : Sigma 
CAS-No. : 57-50-1 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich Inc. 
3050 Spruce Street 
ST. LOUIS MO  63103 
UNITED STATES 
 
Telephone : +1 314 771-5765 
Fax : +1 800 325-5052 
1.4 Emergency telephone 
Emergency Phone # : 800-424-9300 CHEMTREC (USA) +1-703-
527-3887 CHEMTREC (International) 24 
Hours/day; 7 Days/week 
 
 
SECTION 2: Hazards identification 
2.1 Classification of the substance or mixture 
 
 
2.2 GHS Label elements, including precautionary statements 
Pictogram none 
 
Signal word Warning 
 
Hazard statement(s) 






2.3 Hazards not otherwise classified (HNOC) or not covered by GHS 
Combustible dust 
May form explosible dust-air mixture if dispersed. 
 
 




The life science business of Merck KGaA, Darmstadt, Germany 









SECTION 3: Composition/information on ingredients 
3.1 Substances 






Formula : C12H22O11 
Molecular weight : 342.30 g/mol 
CAS-No. : 57-50-1 
EC-No. : 200-334-9 
 
Component Classification Concentration 
Saccharose 





SECTION 4: First aid measures 
4.1 Description of first-aid measures 
If inhaled 
After inhalation: fresh air. 
In case of skin contact 
In case of skin contact: Take off immediately all contaminated clothing. Rinse skin with 
water/ shower. 
In case of eye contact 
After eye contact: rinse out with plenty of water. Remove contact lenses. 
If swallowed 
After swallowing: make victim drink water (two glasses at most). Consult doctor if feeling 
unwell. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 
2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 




SECTION 5: Firefighting measures 
5.1 Extinguishing media 
Suitable extinguishing media 
Water Foam Carbon dioxide (CO2) Dry powder 
Unsuitable extinguishing media 
For this substance/mixture no limitations of extinguishing agents are given. 
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5.2 Special hazards arising from the substance or mixture 
Carbon oxides 
Combustible. 
Development of hazardous combustion gases or vapours possible in the event of fire. 
5.3 Advice for firefighters 
In the event of fire, wear self-contained breathing apparatus. 
5.4 Further information 





SECTION 6: Accidental release measures 
6.1 Personal precautions, protective equipment and emergency procedures 
Advice for non-emergency personnel: Avoid inhalation of dusts. Evacuate the danger 
area, observe emergency procedures, consult an expert. 
For personal protection see section 8. 
6.2 Environmental precautions 
Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Cover drains. Collect, bind, and pump off spills. Observe possible material restrictions 
(see sections 7 and 10). Take up dry. Dispose of properly. Clean up affected area. Avoid 
generation of dusts. 
6.4 Reference to other sections 




SECTION 7: Handling and storage 
7.1 Precautions for safe handling 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
No data available 
7.3 Specific end use(s) 




SECTION 8: Exposure controls/personal protection 
8.1 Control parameters 
Ingredients with workplace control parameters 







TWA 10 mg/m3 USA. ACGIH Threshold Limit 
Values (TLV) 
 Remarks Dental erosion 
Not classifiable as a human carcinogen 
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  TWA 5 mg/m3 USA. NIOSH Recommended 
Exposure Limits 
  TWA 10 mg/m3 USA. NIOSH Recommended 
Exposure Limits 
  TWA 15 mg/m3 USA. Occupational Exposure 
Limits (OSHA) - Table Z-1 
Limits for Air Contaminants 
  TWA 5 mg/m3 USA. Occupational Exposure 
Limits (OSHA) - Table Z-1 
Limits for Air Contaminants 
  PEL 10 mg/m3 California permissible exposure 
limits for chemical 
contaminants (Title 8, Article 
107) 
  PEL 5 mg/m3 California permissible exposure 
limits for chemical 
contaminants (Title 8, Article 
107) 
  The concentration and percentage of the particulate used 
for this limit are determined from the fraction passing a size 
selector with the following characteristics:  Aerodynamic 
Diameter in Micrometers (unit density sphere)................. 
Percent Passing Selector  0 
.................................................. 100  1 
.................................................. 97  2 
.................................................. 91  3 
................................................... 74  4 
................................................... 50  5 
................................................... 30  6 
................................................... 17  7 
................................................... 9  8 
................................................... 5  10 
.................................................... 1 
8.2 Exposure controls 
Appropriate engineering controls 
Change contaminated clothing. Wash hands after working with substance. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate 
government standards such as NIOSH (US) or EN 166(EU). Safety glasses 
Skin protection 
This recommendation applies only to the product stated in the safety data sheet, 
supplied by us and for the designated use. When dissolving in or mixing with other 
substances and under conditions deviating from those stated in EN374 please 
contact the supplier of CE-approved gloves (e.g. KCL GmbH, D-36124 Eichenzell, 
Internet: www.kcl.de). 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:KCL 741 Dermatril® L  
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This recommendation applies only to the product stated in the safety data sheet, 
supplied by us and for the designated use. When dissolving in or mixing with other 
substances and under conditions deviating from those stated in EN374 please 
contact the supplier of CE-approved gloves (e.g. KCL GmbH, D-36124 Eichenzell, 
Internet: www.kcl.de). 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:KCL 741 Dermatril® L 
 
Respiratory protection 
required when dusts are generated. 
Our recommendations on filtering respiratory protection are based on the following 
standards: DIN EN 143, DIN 14387 and other accompanying standards relating to 
the used respiratory protection system. 
 
Control of environmental exposure 
Do not let product enter drains. 
 
 
SECTION 9: Physical and chemical properties 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: crystalline 
Color: white 
b) Odor No data available 
c) Odor Threshold No data available 
d) pH 5.5 - 7.5 at 342 g/l at 25 °C (77 °F) 
e) Melting 
point/freezing point 
Melting point/range: 185 - 187 °C (365 - 369 °F) 
f) Initial boiling point 
and boiling range 
697.11 °C 1286.80 °F at 1,013.3 hPa 
g) Flash point  ()Not applicable 
h) Evaporation rate No data available 
i) Flammability (solid, 
gas) 




No data available 
k) Vapor pressure No data available 
l) Vapor density No data available 
m) Relative density 1.59 g/cm3 at 25 °C (77 °F) 
n) Water solubility 342 g/l at 20 °C (68 °F) - completely soluble 
o) Partition coefficient: 
n-octanol/water 
log Pow: -3.277 
p) Autoignition 
temperature 
No data available 
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160 - 165 °C (320 - 329 °F) -  
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 




SECTION 10: Stability and reactivity 
10.1 Reactivity 
The following applies in general to flammable organic substances and mixtures: in 
correspondingly fine distribution, when whirled up a dust explosion potential may generally 
be assumed. 
10.2 Chemical stability 
The product is chemically stable under standard ambient conditions (room temperature) . 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
no information available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Other decomposition products - No data available 
Hazardous decomposition products formed under fire conditions. - Carbon oxides 




SECTION 11: Toxicological information 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - 29,700 mg/kg 
Remarks: Behavioral:Somnolence (general depressed activity). Cyanosis Diarrhea 
Inhalation: No data available 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitization 
No data available 
Germ cell mutagenicity 
No data available 
Mutagenicity (mammal cell test): 
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(National Toxicology Program) 
Carcinogenicity 
IARC: No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
NTP: No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is 
on OSHA  li  of eg la ed carcinogens. 
Reproductive toxicity 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 




To the best of our knowledge, the chemical, physical, and toxicological properties have not 
been thoroughly investigated. 
 
Substances which occur in nature 
Hazardous properties cannot  be excluded but are unlikely when the product is handled 
appropriately. 





SECTION 12: Ecological information 
12.1 Toxicity 
No data available 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not 
conducted 
12.6 Other adverse effects 
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SECTION 13: Disposal considerations 
13.1 Waste treatment methods 
Product 
Waste material must be disposed of in accordance with the national and loc No mixing 
with other waste. Handle uncleaned containers like the product See 
www.retrologistik.com for processes regarding the return of chemicals and containers, or 




SECTION 14: Transport information 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 
Not dangerous goods 
 
Further information 




SECTION 15: Regulatory information 
 
SARA 302 Components 
This material does not contain any components with a section 302 EHS TPQ. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that 
exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 
313. 
SARA 311/312 Hazards 
No SARA Hazards 










No components are subject to the Massachusetts Right to Know Act. 
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SECTION 16: Other information 
Further information 
The above information is believed to be correct but does not purport to be all inclusive 
and shall be used only as a guide. The information in this document is based on the 
present state of our knowledge and is applicable to the product with regard to 
appropriate safety precautions. It does not represent any guarantee of the properties of 
the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any 
damage resulting from handling or from contact with the above product. See 
www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional 
terms and conditions of sale. 
 
Copyright 2020 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies 
for internal use only. 
The branding on the header and/or footer of this document may temporarily not visually 
match the product purchased as we transition our branding. However, all of the 
information in the document regarding the product remains unchanged and matches the 
product ordered. For further information please contact mlsbranding@sial.com. 
 
Version: 6.6 Revision Date: 10/07/2020 Print Date: 11/20/2020 
 
SAFETY DATA SHEET
This safety data sheet was created pursuant to the requirements of:
OSHA 29 CFR 1910.1200
Document Type  US - OSHA GHS Revision date  25-Nov-2019 Version  6
1. Identification
Product identifier 
Product name T7 RNA Polymerase
Other means of identification 
Product No M0251
Recommended use of the chemical and restrictions on use 
Recommended use This product is for research and development only
Restrictions on use No information available
Details of the supplier of the safety data sheet 
Company Phone Number 978-927-5054, 800-632-5227 (toll free)
Telefax 978-921-1350
E-mail address info@neb.com
Emergency telephone number 
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4. First-aid measures
Description of first aid measures
Inhalation Remove to fresh air.
Eye contact Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids.
Consult a physician.
Skin contact Wash skin with soap and water.
Ingestion Clean mouth with water and drink afterwards plenty of water.
2. Hazard(s) identification
Classification 
This chemical is not considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200)





Unknown acute toxicity 50 % of the mixture consists of ingredient(s) of unknown toxicity
0 % of the mixture consists of ingredient(s) of unknown acute oral toxicity
0 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity
50 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas)
50 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor)
50 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist)




The product contains no substances which at their given concentration, are considered to be hazardous to health.
Hazard statements 
Not a hazardous substance or mixture according to the Globally Harmonized System (GHS)
Appearance  Colorless Physical state  Liquid
_____________________________________________________________________________________________
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Most important symptoms and effects, both acute and delayed 
Symptoms No information available.
Indication of any immediate medical attention and special treatment needed 
Note to physicians Treat symptomatically.
5. Fire-fighting measures
Suitable Extinguishing Media Use extinguishing measures that are appropriate to local circumstances and the
surrounding environment.
Unsuitable Extinguishing Media CAUTION: Use of water spray when fighting fire may be inefficient.




Sensitivity to mechanical impact None.
Sensitivity to static discharge None.
Special protective equipment for
fire-fighters
Firefighters should wear self-contained breathing apparatus and full firefighting turnout
gear. Use personal protection equipment.
6. Accidental release measures
Personal precautions, protective equipment and emergency procedures 
Personal precautions Ensure adequate ventilation.
Methods and material for containment and cleaning up 
Methods for containment Prevent further leakage or spillage if safe to do so.
Methods for cleaning up Pick up and transfer to properly labeled containers.
7. Handling and storage
Precautions for safe handling
Advice on safe handling Handle in accordance with good industrial hygiene and safety practice.
Conditions for safe storage, including any incompatibilities
Storage Conditions Keep containers tightly closed in a dry, cool and well-ventilated place.
8. Exposure controls/personal protection
Control parameters 
Exposure Limits .
Other information Vacated limits revoked by the Court of Appeals decision in AFL-CIO v. OSHA, 965 F.2d 962
(11th Cir., 1992).
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Appropriate engineering controls
_____________________________________________________________________________________________




Individual protection measures, such as personal protective equipment
Eye/face protection Wear safety glasses with side shields (or goggles).
Skin and body protection Wear suitable protective clothing.
Respiratory protection No protective equipment is needed under normal use conditions. If exposure limits are
exceeded or irritation is experienced, ventilation and evacuation may be required.
General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.
9. Physical and chemical properties




Odor threshold No information available
Other information  
Explosive properties No information available
Oxidizing properties No information available
Softening point No information available
Molecular weight No information available
VOC Content (%) No information available
Liquid Density No information available
Bulk density No information available
10. Stability and reactivity
Reactivity No information available.
Property Values  5HPDUNV0HWKRG
pH No data available None known
Melting point / freezing point No data available None known
Boiling point / boiling range No data available None known
Flash point No data available None known
Evaporation rate No data available None known
Flammability (solid, gas) No data available None known
Flammability Limit in Air None known
Upper flammability or explosive
limits
No data available
Lower flammability or explosive
limits
No data available
Vapor pressure No data available None known
Vapor density No data available None known
Relative density No data available None known
Water solubility No data available None known
Solubility in other solvents No data available None known
Partition coefficient No data available None known
Autoignition temperature No data available None known
Decomposition temperature No data available None known
Kinematic viscosity No data available None known
Dynamic viscosity No data available
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Chemical stability Stable under normal conditions.
Possibility of hazardous reactions None under normal processing.
Conditions to avoid None known based on information supplied.
Incompatible materials None known based on information supplied.
Hazardous decomposition products None known based on information supplied.
11. Toxicological information
Information on likely routes of exposure 
Product Information
Inhalation Specific test data for the substance or mixture is not available.
Eye contact Specific test data for the substance or mixture is not available.
Skin contact Specific test data for the substance or mixture is not available.
Ingestion Specific test data for the substance or mixture is not available.
Symptoms related to the physical, chemical and toxicological characteristics 
Symptoms No information available.
Acute toxicity 
Numerical measures of toxicity
The following values are calculated based on chapter 3.1 of the GHS document  .
ATEmix (oral) 25,200.00  mg/kg
ATEmix (dermal) 20,000.00  mg/kg
Unknown acute toxicity 50 % of the mixture consists of ingredient(s) of unknown toxicity
0 % of the mixture consists of ingredient(s) of unknown acute oral toxicity
0 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity
50 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas)
50 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor)
50 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist)
Delayed and immediate effects as well as chronic effects from short and long-term exposure  
Skin corrosion/irritation No information available.
Serious eye damage/eye irritation No information available.
Respiratory or skin sensitization No information available.
Germ cell mutagenicity No information available.
Carcinogenicity No information available.
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Reproductive toxicity No information available.
STOT - single exposure No information available.
STOT - repeated exposure No information available.
Aspiration hazard No information available.
Other adverse effects No information available.
Interactive effects No information available.
12. Ecological information
Ecotoxicity .
Persistence and degradability No information available.
Bioaccumulation There is no data for this product.
Component Information





Dispose of in accordance with local regulations. Dispose of waste in accordance with
environmental legislation.
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 TSCA  - United States Toxic Substances Control Act Section 8(b) Inventory
 DSL/NDSL  - Canadian Domestic Substances List/Non-Domestic Substances List
 EINECS/ELINCS  - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances
 ENCS  - Japan Existing and New Chemical Substances
 IECSC  - China Inventory of Existing Chemical Substances
 KECL  - Korean Existing and Evaluated Chemical Substances
 PICCS  - Philippines Inventory of Chemicals and Chemical Substances
 AICS  - Australian Inventory of Chemical Substances
US Federal Regulations 
SARA 313
Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA).  This product does not contain any
chemicals which are subject to the reporting requirements of the Act and Title 40 of the Code of Federal Regulations, Part 372.
SARA 311/312 Hazard Categories
Should this product meet EPCRA 311/312 Tier reporting criteria at 40 CFR 370, refer to Section 2 of this SDS for appropriate
classifications.
CWA (Clean Water Act)
This product does not contain any substances regulated as pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 40
CFR 122.42).
CERCLA
This material, as supplied, does not contain any substances regulated as hazardous substances under the Comprehensive
Environmental Response Compensation and Liability Act (CERCLA) (40 CFR 302) or the Superfund Amendments and
Reauthorization Act (SARA) (40 CFR 355).  There may be specific reporting requirements at the local, regional, or state level
pertaining to releases of this material.
US State Regulations 
California Proposition 65
This product does not contain any Proposition 65 chemicals.
U.S. State Right-to-Know Regulations 
U.S. EPA Label Information 
EPA Pesticide Registration Number Not applicable
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16. Other information
Key or legend to abbreviations and acronyms used in the safety data sheet 
Legend  Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION
Key literature references and sources for data used to compile the SDS
Agency for Toxic Substances and Disease Registry (ATSDR)
U.S. Environmental Protection Agency ChemView Database
European Food Safety Authority (EFSA)
EPA (Environmental Protection Agency)
Acute Exposure Guideline Level(s) (AEGL(s))
U.S. Environmental Protection Agency Federal Insecticide, Fungicide, and Rodenticide Act
U.S. Environmental Protection Agency High Production Volume Chemicals
Food Research Journal
Hazardous Substance Database
International Uniform Chemical Information Database (IUCLID)
Japan GHS Classification
Australia National Industrial Chemicals Notification and Assessment Scheme (NICNAS)
NIOSH (National Institute for Occupational Safety and Health)
National Library of Medicine's ChemID Plus (NLM CIP)
National Library of Medicine's PubMed database (NLM PUBMED)
National Toxicology Program (NTP)
New Zealand's Chemical Classification and Information Database (CCID)
Organization for Economic Co-operation and Development Environment, Health, and Safety Publications
Organization for Economic Co-operation and Development High Production Volume Chemicals Program
Organization for Economic Co-operation and Development Screening Information Data Set
RTECS (Registry of Toxic Effects of Chemical Substances)
World Health Organization
Prepared by Environmental, Health and Safety
978-927-5054
Revision date 25-Nov-2019
Revision note SDS is valid 3 years from revision date. Contact info@neb.com for latest revision.
Disclaimer
IMPORTANT:  The information in this SDS is provided in good faith based on our knowledge as of the issue date (or
subsequent revision date, if any), and is to be used only as a guide.  This SDS does not constitute a guarantee (express
or implied) of any kind and we make no warranties or merchantability or fitness for a particular purpose.  This information
relates only to the designated product as shipped and may not be valid if the product is used in combination with any
other materials or is not used in accordance with our instructions.  It is the responsibility of the buyer/user to ensure that
its activities comply with all applicable governmental requirements. Since conditions of use of the product are not under
the control of New England Biolabs, it is the duty of the buyer/user to determine the necessary conditions for the safe use
of the product.  New England Biolabs will not be liable for any damages resulting from handling or contact with the
product.
End of Safety Data Sheet
NFPA  Health hazards  0 Flammability  0 Instability  0 Special Hazard  -
HMIS  Health hazards  0 Flammability  0 Physical hazards  0 Personal protection  X
TWA TWA (time-weighted average) STEL STEL (Short Term Exposure Limit)
Ceiling Maximum limit value *
_____________________________________________________________________________________________
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Manufacturer or supplier's details 
Company name of supplier 
 








Telephone : +496217590 
Telefax : +496217592890 
Emergency telephone 
In case of emergencies: : CHEMTREC 
 
+1 703-741-5970 / 
1-800-424-9300 
Recommended use of the chemical and restrictions on use 
Restrictions on use 
 
: For professional users only. 
 
 
SECTION 2. HAZARDS IDENTIFICATION 
GHS classification in accordance with 29 CFR 1910.1200 
Not a hazardous substance or mixture. 
GHS label elements 




SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS 
Substance / Mixture 
 
:  Substance 
Substance name 
 







No hazardous ingredients 
 
SECTION 4. FIRST AID MEASURES 
General advice 
 
: Do not leave the victim unattended. 
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If inhaled 
 
: Move to fresh air. 
If unconscious, place in recovery position and seek medical 
advice. 
If symptoms persist, call a physician. 
 
In case of skin contact 
 
: If on skin, rinse well with water. 
 
In case of eye contact 
 
: Immediately flush eye(s) with plenty of water. 
Remove contact lenses. 
Protect unharmed eye. 




: Keep respiratory tract clear. 
Do not give milk or alcoholic beverages. 
Never give anything by mouth to an unconscious person. 
If symptoms persist, call a physician. 
Rinse mouth with water. 
 
Most important symptoms 
and effects, both acute and 
delayed 
 
: None known. 
Notes to physician 
 
: The first aid procedure should be established in consultation 
with the doctor responsible for industrial medicine. 
 
 
SECTION 5. FIRE-FIGHTING MEASURES 
Suitable extinguishing media 
 
: Use extinguishing measures that are appropriate to local cir-
cumstances and the surrounding environment. 
 
Specific hazards during fire 
fighting 
 





:  No hazardous combustion products are known 
 
Further information : Standard procedure for chemical fires. 
Use extinguishing measures that are appropriate to local cir-
cumstances and the surrounding environment. 
 
Special protective equipment 
for fire-fighters 
 
: Wear self-contained breathing apparatus for firefighting if 
necessary. 
 
SECTION 6. ACCIDENTAL RELEASE MEASURES 
Personal precautions, protec-
tive equipment and emer-
gency procedures 
 




: Local authorities should be advised if significant spillages 
cannot be contained. 
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Methods and materials for 
containment and cleaning up 
 
: Pick up and arrange disposal without creating dust. 
Sweep up and shovel. 
Keep in suitable, closed containers for disposal. 
 
SECTION 7. HANDLING AND STORAGE 
Advice on protection against 
fire and explosion 
 
:  Provide appropriate exhaust ventilation at places where dust 
is formed. 
 
Advice on safe handling 
 
: For personal protection see section 8. 
Smoking, eating and drinking should be prohibited in the ap-
plication area. 
 
Conditions for safe storage 
 
: Electrical installations / working materials must comply with 
the technological safety standards. 
 
Further information on stor-
age conditions 
 
: See label, package insert or internal guidelines 
 
Materials to avoid 
 
: No materials to be especially mentioned. 
Keep away from oxidizing agents, strongly alkaline and 
strongly acid materials in order to avoid exothermic reactions. 
 
Further information on stor-
age stability 
 
:  No decomposition if stored and applied as directed. 
 
SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
Ingredients with workplace control parameters 
Contains no substances with occupational exposure limit values. 
Personal protective equipment 
Respiratory protection 
 




   In case of full contact:  
Material : Nitrile rubber 
Break through time : 480 min 
Glove thickness : 0.11 mm 
   In case of contact through splashing:  
Material : Nitrile rubber 
Break through time : 480 min 
Glove thickness : 0.11 mm 
Remarks 
 
: Wear appropriate protective gloves to prevent skin contact. 
Replace torn or punctured gloves promptly. 
Eye protection 
 
: Safety glasses 
 
Skin and body protection 
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: 4.2 (20 °C / 20 °C)  
Concentration: 100 g/l 




: 152 °C / 152 °C  
 
Boiling point/boiling range 
 




: Not applicable  
Evaporation rate 
 
:  Not applicable  
 
Flammability (solid, gas) 
 




: Sustains combustion 
 
Self-ignition : No data available  
 
Upper explosion limit / Upper 
flammability limit 
 
: No data available  
 
Lower explosion limit / Lower 
flammability limit 
 




: No data available  
 
Relative vapor density 
 









: soluble  
 
Solubility in other solvents 
 





: Remarks: Not applicable 
Autoignition temperature 
 









: Not applicable  
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Viscosity, kinematic 
 








: 157.6 g/mol 
 
SECTION 10. STABILITY AND REACTIVITY 
Reactivity 
 




:  Stable under normal conditions. 
 
Possibility of hazardous reac-
tions 
 
: No data available 
Stable under recommended storage conditions. 
No hazards to be specially mentioned. 
 
Conditions to avoid 
 









:   No decomposition if stored and applied as directed. 
 
SECTION 11. TOXICOLOGICAL INFORMATION 
Acute toxicity 
Not classified based on available information. 
Skin corrosion/irritation 
Not classified based on available information. 
Serious eye damage/eye irritation 
Not classified based on available information. 
Respiratory or skin sensitization 
Skin sensitization 
Not classified based on available information. 
Respiratory sensitization 
Not classified based on available information. 
Germ cell mutagenicity 
Not classified based on available information. 
Carcinogenicity 
Not classified based on available information. 
IARC No ingredient of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
 
OSHA No component of this product present at levels greater than or equal to 0.1% is 
on OSHA  li  of eg la ed ca cinogen . 
 
NTP No ingredient of this product present at levels greater than or equal to 0.1% is 
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identified as a known or anticipated carcinogen by NTP. 
 
Reproductive toxicity 
Not classified based on available information. 
STOT-single exposure 
Not classified based on available information. 
STOT-repeated exposure 
Not classified based on available information. 
Aspiration toxicity 
Not classified based on available information. 
SECTION 12. ECOLOGICAL INFORMATION 
Ecotoxicity 
No data available 
Persistence and degradability 
No data available 
Bioaccumulative potential 
No data available 
Mobility in soil 
No data available 




: Regulation: 40 CFR Protection of Environment; Part 82 Pro-
tection of Stratospheric Ozone - CAA Section 602 Class I 
Substances 
Remarks: This product neither contains, nor was manufac-
tured with a Class I or Class II ODS as defined by the U.S. 
Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B). 
 
 
SECTION 13. DISPOSAL CONSIDERATIONS 
Disposal methods 
Waste from residues : Can be disposed as waste water, when in compliance with 
local regulations. 
 
Contaminated packaging : Empty containers should be taken to an approved waste 
handling site for recycling or disposal. 
Do not re-use empty containers. 
 
SECTION 14. TRANSPORT INFORMATION 
International Regulations 
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UNRTDG  
Not regulated as a dangerous good 
IATA-DGR  
Not regulated as a dangerous good 
IMDG-Code  
Not regulated as a dangerous good 
Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code 
Not applicable 
Domestic regulation 
49 CFR  
Not regulated as a dangerous good 
 
SECTION 15. REGULATORY INFORMATION 
EPCRA - Emergency Planning and Community Right-to-Know 
CERCLA Reportable Quantity 
This material does not contain any components with a CERCLA RQ. 
SARA 304 Extremely Hazardous Substances Reportable Quantity 
This material does not contain any components with a section 304 EHS RQ. 
SARA 302 Extremely Hazardous Substances Threshold Planning Quantity 
Components CAS-No. Component TPQ (lbs) 
SARA 311/312 Hazards 
 
:  No SARA Hazards 
 
Clean Air Act 
This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by 
the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B). 
This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean 
Air Act Section 112 (40 CFR 61). 
This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for 
Accidental Release Prevention (40 CFR 68.130, Subpart F). 
This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 
SOCMI Intermediate or Final VOC's (40 CFR 60.489). 
Clean Water Act 
This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, 
Section 311, Table 116.4A. 
This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, 
Section 311, Table 117.3. 
This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 
307 
US State Regulations 
Massachusetts Right To Know 
Pennsylvania Right To Know 
 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-, hydrochloride 1185-53-1 
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(1:1) 
Maine Chemicals of High Concern 
Vermont Chemicals of High Concern 
Washington Chemicals of High Concern 
The ingredients of this product are reported in the following inventories: 
DSL 
 




































: All substances listed as active on the TSCA inventory 
 
TSCA list 
No substances are subject to a Significant New Use Rule. 
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SECTION 16. OTHER INFORMATION 
Further information 
























HMIS® ratings are based on a 0-4 rating 
scale, with 0 representing minimal haz-
ards or risks, and 4 representing signifi-
cant hazards or risks. The "*" represents 
a chronic hazard, while the "/" represents 




3050 Spruce Street 
SAINT LOUIS 
MO 63103 USA 
Full text of other abbreviations 
 
AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of 
Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, 
and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the 
German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Sub-
stances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Haz-
ardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; 
ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with 
x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized Sys-
tem; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - 
International Agency for Research on Cancer; IATA - International Air Transport Association; IBC 
- International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals 
in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organiza-
tion; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime 
Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health 
Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemi-
cals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 
50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Pre-
vention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Oth-
erwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) 
Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable 
Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of 
Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office 
of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic sub-
stance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quanti-
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REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concern-
ing the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable 
Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amend-
ments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance 
Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - 
United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent 
and Very Bioaccumulative 
 
 
Revision Date :  04-17-2019 
 
 
The information provided in this Material Safety Data Sheet is correct to the best of our 
knowledge, information and belief at the date of its publication. The information given is designed 
only as a guidance for safe handling, use, processing, storage, transportation, disposal and re-
lease and is not to be considered a warranty or quality specification. The information relates only 
to the specific material designated and may not be valid for such material used in combination 
with any other materials or in any process, unless specified in the text. 
 
US / Z8 / 1805 
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SAFETY DATA SHEET 
 
Version 6.6 
Revision Date 04/16/2020 
Print Date 08/29/2020 
 
SECTION 1: Identification of the substance/mixture and of the company/undertaking 
1.1 Product identifiers 
Product name : T i  X-100 
 
Product Number : X100 
Brand : Sigma-Aldrich 
CAS-No. : 9002-93-1 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich Inc. 
3050 Spruce Street 
ST. LOUIS MO  63103 
UNITED STATES 
 
Telephone : +1 314 771-5765 
Fax : +1 800 325-5052 
1.4 Emergency telephone number 
Emergency Phone # : 800-424-9300 CHEMTREC (USA) +1-703-
527-3887 CHEMTREC (International) 24 
Hours/day; 7 Days/week 
 
 
SECTION 2: Hazards identification 
2.1 Classification of the substance or mixture 
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) 
Acute toxicity, Oral (Category 4), H302 
Skin irritation (Category 2), H315 
Serious eye damage (Category 1), H318 
Short-term (acute) aquatic hazard (Category 1), H400 
Long-term (chronic) aquatic hazard (Category 1), H410 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
2.2 GHS Label elements, including precautionary statements 
Pictogram 
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H302 Harmful if swallowed. 
H315 Causes skin irritation. 
H318 Causes serious eye damage. 
H410 Very toxic to aquatic life with long lasting effects. 
 
Precautionary statement(s) 
P264 Wash skin thoroughly after handling. 
P270 Do not eat, drink or smoke when using this product. 
P273 Avoid release to the environment. 
P280 Wear protective gloves/ eye protection/ face protection. 
P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/doctor if you feel 
unwell. Rinse mouth. 
P302 + P352 IF ON SKIN: Wash with plenty of soap and water. 
P305 + P351 + P338 + 
P310 
IF IN EYES: Rinse cautiously with water for several minutes. 
Remove contact lenses, if present and easy to do. Continue 
rinsing. Immediately call a POISON CENTER/doctor. 
P332 + P313 If skin irritation occurs: Get medical advice/ attention. 
P362 Take off contaminated clothing and wash before reuse. 
P391 Collect spillage. 
P501 Dispose of contents/ container to an approved waste disposal 
plant. 
 




SECTION 3: Composition/information on ingredients 
3.1 Substances 
Synonyms : t-Octylphenoxypolyethoxyethanol 
4-(1,1,3,3-Tetramethylbutyl)phenyl-polyethylene glycol 
Polyethylene glycol tert-octylphenyl ether 
 
Formula : (C2H4O)nC14H22O 
CAS-No. : 9002-93-1 
 
Component Classification Concentration 
Triton-X-100 
   Acute Tox. 4; Skin Irrit. 2; 
Eye Dam. 1; Aquatic Acute 
1; Aquatic Chronic 1; 
H302, H315, H318, H400, 
H410 
M-Factor - Aquatic Acute: 
10 - Aquatic Chronic: 1 
<= 100 % 
 
Polyethylene glycol, average MW 8,000 
     >= 1 - < 5 % 
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SECTION 4: First aid measures 
4.1 Description of first aid measures 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of 
dangerous area. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Consult a physician. 
In case of eye contact 
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult 
a physician. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 
2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 




SECTION 5: Firefighting measures 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
Carbon oxides 
Combustible. 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 




SECTION 6: Accidental release measures 
6.1 Personal precautions, protective equipment and emergency procedures 
Use personal protective equipment. Avoid breathing vapours, mist or gas. Ensure 
adequate ventilation. Evacuate personnel to safe areas. 
For personal protection see section 8. 
6.2 Environmental precautions 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. 
Discharge into the environment must be avoided. 
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6.3 Methods and materials for containment and cleaning up 
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in 
suitable, closed containers for disposal. 
6.4 Reference to other sections 




SECTION 7: Handling and storage 
7.1 Precautions for safe handling 
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place. Containers which are 
opened must be carefully resealed and kept upright to prevent leakage.  
Packaged under inert gas.  
Storage class (TRGS 510): 10: Combustible liquids 
7.3 Specific end use(s) 




SECTION 8: Exposure controls/personal protection 
8.1 Control parameters 
Components with workplace control parameters 










TWA 10 mg/m3 USA. Workplace Environmental 
Exposure Levels (WEEL) 
8.2 Exposure controls 
Appropriate engineering controls 
Handle in accordance with good industrial hygiene and safety practice. Wash hands 
before breaks and at the end of workday. 
Personal protective equipment 
Eye/face protection 
Tightly fitting safety goggles.  Faceshield (8-inch minimum). Use equipment for eye 
protection tested and approved under appropriate government standards such as 
NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove 
removal technique (without touching glove's outer surface) to avoid skin contact 
with this product. Dispose of contaminated gloves after use in accordance with 
applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
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Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail 
sales@kcl.de, test method: EN374 
If used in solution, or mixed with other substances, and under conditions which 
differ from EN 374, contact the supplier of the CE approved gloves. This 
recommendation is advisory only and must be evaluated by an industrial hygienist 
and safety officer familiar with the specific situation of anticipated use by our 




Complete suit protecting against chemicals, The type of protective equipment must 
be selected according to the concentration and amount of the dangerous substance 
at the specific workplace. 
Respiratory protection 
Where risk assessment shows air-purifying respirators are appropriate use a full-
face respirator with multi-purpose combination (US) or type ABEK (EN 14387) 
respirator cartridges as a backup to engineering controls. If the respirator is the sole 
means of protection, use a full-face supplied air respirator. Use respirators and 
components tested and approved under appropriate government standards such as 
NIOSH (US) or CEN (EU). 
ABEK-filter 
Control of environmental exposure 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. 
Discharge into the environment must be avoided. 
 
 
SECTION 9: Physical and chemical properties 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: liquid, clear 
Colour: colourlesslight yellow 
b) Odour characteristic 
c) Odour Threshold No data available 
d) pH 9.7 
e) Melting 
point/freezing point 
Melting point: 6 °C (43 °F) 
f) Initial boiling point 
and boiling range 
> 200 °C > 392 °F at 1,013 hPa 
g) Flash point 251 °C (484 °F) - closed cup 
h) Evaporation rate No data available 
i) Flammability (solid, 
gas) 
No data available 
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No data available 
k) Vapour pressure < 1.33 hPa at 20 °C (68 °F) 
l) Vapour density No data available 
m) Relative density 1.065 g/cm3 at 20 °C (68 °F) 
n) Water solubility soluble 
o) Partition coefficient: 
n-octanol/water 
No data available 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 




SECTION 10: Stability and reactivity 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong acids, Strong bases, Strong oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides 
Other decomposition products - No data available 




SECTION 11: Toxicological information 
11.1 Information on toxicological effects 
Acute toxicity 
No data available 
LD50 Oral - Rat - 1,900 - 5,000 mg/kg 
Remarks: (External MSDS) The value is given in analogy to the following substances: 
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Inhalation: No data available 
Inhalation: No data available 
LD50 Dermal - Rabbit - > 3,000 mg/kg 
LD50 Dermal - Rabbit - > 3,000 mg/kg 
Remarks: (External MSDS) The value is given in analogy to the following substances: 
No data available 
No data available 
Skin corrosion/irritation 
No data available 
Skin - Rabbit 
Result: irritating - 4 h 
(OECD Test Guideline 404) 
Remarks: The value is given in analogy to the following substances: 
Serious eye damage/eye irritation 
No data available 
Eyes - Rabbit 
Result: Risk of serious damage to eyes. 
(Draize Test) 
Risk of corneal clouding. 
Respiratory or skin sensitisation 
No data available 
Sensitisation test: - Human 
Result: negative 
Remarks: (External MSDS) The value is given in analogy to the following substances: 
Germ cell mutagenicity 
No data available 
No data available 
Mutagenicity (mammal cell test): 




IARC: No component of this product present at levels greater than or equal to 0.1% is 
identified as probable, possible or confirmed human carcinogen by IARC. 
NTP: No component of this product present at levels greater than or equal to 0.1% is 
identified as a known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is 
 OSHA  li  f eg la ed ca ci ge . 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
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RTECS: Not available 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not 
been thoroughly investigated. 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not 
been thoroughly investigated. 
 





SECTION 12: Ecological information 
12.1 Toxicity 
 
Toxicity to fish LC50 - Pimephales promelas (fathead minnow) - 4 - 8.9 mg/l  - 96 h 
 
Toxicity to fish semi-static test LC50 - Leuciscus idus (Golden orfe) - 0.26 mg/l  - 96 
h 
(OECD Test Guideline 203) 
Remarks: The value is given in analogy to the following substances: 
 
Toxicity to daphnia 
and other aquatic 
invertebrates 
LC50 - Daphnia magna (Water flea) - 18 - 26 mg/l  - 48 h 
 
Toxicity to daphnia 
and other aquatic 
invertebrates 
static test EC50 - Daphnia magna (Water flea) - 0.011 mg/l  - 48 h 
Remarks: (ECOTOX Database)The value is given in analogy to the 
following substances: 
 
Toxicity to algae static test EC50 - Pseudokirchneriella subcapitata (green algae) - 1.9 
mg/l  - 96 h 
Remarks: (ECHA)The value is given in analogy to the following 
substances: 
12.2 Persistence and degradability 





12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not 
conducted 
12.6 Other adverse effects 
Very toxic to aquatic life with long lasting effects. 
An environmental hazard cannot be excluded in the event of unprofessional handling or 
disposal. 
Causes endocrine disruption. 
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SECTION 13: Disposal considerations 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a 
licensed professional waste disposal service to dispose of this material.  
Contaminated packaging 




SECTION 14: Transport information 
DOT (US) 
Not dangerous goods 
 
IMDG 
UN number: 3082 Class: 9 Packing group: III EMS-No: F-A, S-F 
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. 
(Triton-X-100) 
Marine pollutant : yes 
 
IATA 
UN number: 3082 Class: 9 Packing group: III 
Proper shipping name: Environmentally hazardous substance, liquid, n.o.s. (Triton-X-100) 
Further information 
EHS-Mark required (ADR 2.2.9.1.10, IMDG code 2.10.3) for single packagings and 
combination packagings containing inner packagings with Dangerous Goods > 5L for liquids 




SECTION 15: Regulatory information 
 
SARA 302 Components 
This material does not contain any components with a section 302 EHS TPQ. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that 
exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 
313. 
SARA 311/312 Hazards 
Acute Health Hazard 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
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SECTION 16: Other information 
Further information 
Copyright 2020 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies 
for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive 
and shall be used only as a guide. The information in this document is based on the 
present state of our knowledge and is applicable to the product with regard to 
appropriate safety precautions. It does not represent any guarantee of the properties of 
the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any 
damage resulting from handling or from contact with the above product. See 
www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional 
terms and conditions of sale. 
 
The branding on the header and/or footer of this document may temporarily not visually 
match the product purchased as we transition our branding. However, all of the 
information in the document regarding the product remains unchanged and matches the 
product ordered. For further information please contact mlsbranding@sial.com. 
 
Version: 6.6 Revision Date: 04/16/2020 Print Date: 08/29/2020 
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(54) Title: A METHOD FOR PRODUCING AND PURIFYING RNA, COMPRISING AT LEAST ONE STEP OF TANGENTIALo FLOW FILTRATION
(57) Abstract: The present invention relates to method for producing and purifying RNA comprising the steps of providing DNA
encoding the RNA; transcription of the DNA into RNA; and conditioning and/or purifying of the solution comprising transcribed
RNA by one or more steps of tangential flow filtration (TFF).
A method for producing and purifying RNA, comprising at least one step of
tangential flow filtration
Technical field
The present invention relates to methods of tangential flow filtration (TFF) for
producing and purifying RNA.
Background of the Invention
RNA is emerging as an innovative candidate for a variety of pharmaceutical
applications, but efficient purification is continuing to be a challenge. This is partly
due to the different types and combinations of undesired contaminants in a sample
that need to be separated from a desired RNA species to obtain a pure RNA
sample. Such contaminants are typically components and by-products of any
upstream processes, for example RNA manufacture. Where in vitro transcription is
used to manufacture large RNA, following successful transcription the sample
typically contains the desired RNA species alongside various contaminants such as
undesired RNA species, proteins, spermidine, DNA or fragments thereof,
pyrophosphates, free nucleotides, endotoxins, detergents, and organic solvents.
Commercial downstream applications (e.g. formulation and use as a pharmaceutical
composition and/or vaccine) pose further constrains on any purification method for
RNA requiring (i) a high degree of purity while retaining RNA stability and
functionality; (ii) compatibility with any formulation requirements of the RNA for in
vivo delivery; and (iii) compliance with good manufacturing practices. Furthermore,
in order to facilitate industrial applications, any RNA purification method must enable
consistent, cost- and time-efficient operation (e.g. quick, easy, reproducible, high
Table 8 : Plasmid concentration
The dsDNA concentration in the retentate was photometrically determined to be
1.05 g/l in a final volume of 22 ml. The diafiltration of the linearized pDNA using TFF
yielded 96.6 % of input DNA.
Agarose Gel Electrophoresis:
Only a negligible amount of plasmid DNA is visible in the permeate of the
concentration step and of the diafiltration step.
13.3 - RNA in vitro transcription
800 ml of in vitro transcription mix as described in Example 4 was incubated for 3 h
at 37°C.
Next, CaC and DNase I was added and subsequently incubated for 2 h at 37°C.
13.4 - Diafiltration of the transcription reaction
The TFF system Sartoflow 200 with two PES membranes (Sartorius, 200 cm2, 100
kDa) was used to exchange the buffer of three aliquots (400 ml each) of the
transcription reaction to WFI (process parameters indicated in Table 9). First,
container and tubes were cleaned with ultrapure water, ethanol and WFI. Then the
setup was assembled and the filter cassette was mounted on the Sartocon holder
according to the manufacturer's instructions. The whole system was cleaned with
ultra-pure water. Subsequently, the system was chemically sanitized by a 1 hour
wash with 1 M NaOH. Then, the setup was washed with WFI until a pH of 7 was
measured in the retentate and the system was equilibrated with 500 ml WFI. After
that, 400 ml transcription reaction (see 13.3) were added to the retentate reservoir,
pressures (dp and TMP) were set to 1 bar, and the diafiltration procedure was
started against 10 diafiltration volumes (DFV) water for injection (WFI). After
diafiltration by TFF the RNA concentration was measured photometrically.
Table 9 : TFF parameters used for diafiltration of the transcription reaction
Results:
The final concentration of the RNA after diafiltration was 5 g/l and the total recovery
rate of the RNA after buffer exchange via diafiltration was 98%.
Example 13.5 - RP-HPLC purification of the conditioned transcription reaction
The RNA solution obtained from Example 13.4 was diluted to 100 mM TEAA and a
concentration of 1 g/l by addition of 1 M triethylammonium acetate (TEAA) and WFI.
The RNA was step-wise purified according to Example 5 . The HPLC fractions were
collected, the product-containing fractions were pooled and divided in three pools I
to III.
Moreover, fractions were analyzed for RNA content (UV260/280) and every fraction
was analyzed for RNA integrity.
Results:
Table 10: Determination of RNA concentration and RNA integrity after RP-HPLC
purification
Pools Volume RNA RNA integrity
cone. amount
Pool I Ca. 7.2 L 0.12 g/l Ca. 840 mg 97.8%
Pool I I Ca. 7.3 L 0.12 g/l Ca. 840 mg 97.7%
Pool III Ca. 6.2 L 0.12 g/l Ca. 744 mg 95.7%
Compared to the starting material (TFF conditioned RNA), the integrity could be
increased by >10 % (86.5% RNA integrity before RP-HPLC) by separating aborted
RNA species.
Example 13.6 - Concentration and diafiltration of the RP-HPLC pool via TFF
The three RP-HPLC purified RNA pools were processed separately using an
additional concentration and diafiltration step with TFF to further separate the RNA
from impurities (e.g. spermidine contaminations) and to exchange the solvent.
First, every pool was concentrated from 0.12 g/l to approximately 5 g/l using TFF.
5M NaCI solution was added to the retentate to get a final concentration of 0.2 M
NaCI. Then, a diafiltration was performed against 0.2 M NaCI (10 DFV) to remove
spermidine impurities. Next, the diafiltration solution was exchanged to WFI (10
DFV). The process parameters are shown in Table 11. After TFF RNA concentration
was determined by measuring the absorption at 260 nm. For agarose gel
electrophoresis the indicated amounts of RNA were used for gel electrophoresis.
Table 11: Parameters used for TFF of the RP-HPLC pools
Results:
The yield after the diafiltration was spectrometrically determined to be 94.44%,




Membrane load 0.1 - 0.6 mg DNA/cm2
Feed flowrate [l/h/m2] 750 - 900
Permeate flux rate [l/h/m2] 30 - 100
14.2 - Diafiltration of the RNA IVT reaction by TFF:
RNA in vitro transcription was performed as described in Example 4 . For tangential
flow filtration of the RNA IVT reaction (conducted according to Example 4), a
Hydrosart filter cassette (cellulose based membrane, MWCO 100 kDa, Sartorius)
was used. The conditioning of the RNA IVT reaction was performed as explained
above (see Example 13). The result of the diafiltration of the RNA IVT reaction is
provided in Figure 14. Relevant process parameters are summarized in Table 17.
Table 17: TFF Process parameters of the RNA IVT reaction diafiltration
- Concentration and diafiltration of the RP-HPLC RNA pool
The in vitro transcribed RNA was purified by RP-HPLC as described in Example 5 .
For tangential flow filtration of the RP-HPLC RNA pool, a Hydrosart filter cassette
(cellulose based membrane, MWCO 100 kDa, Sartorius) was used. The
concentration of the RP-HPLC RNA pool was performed as explained above (see
Example 13). The result of the concentration of the RP-HPLC RNA is provided in
Figure 15. The diafiltration of the RNA into 0.2 M NaCI and a further diafiltration of
the RNA into WFI was performed as explained above (see Example 13). The result
of the diafiltration of the RP-HPLC RNA pool is provided in Figure 16. Relevant
process parameters are summarized in Table 18.
Table 18: TFF process parameters of the RP-HPLC RNA concentration and
diafiltration
Embodiment list:
1. A method for producing and purifying RNA, comprising the steps of
A) providing DNA encoding the RNA;
B) transcription of the DNA to yield a solution comprising transcribed RNA; and
C) conditioning and/or purifying of the solution comprising transcribed RNA by one
or more steps of tangential flow filtration (TFF).
2 . The method according to item 1, wherein in step A) plasmid DNA is provided as
DNA encoding the RNA and the method comprises subsequently to step A) the
steps:
A1) linearization of the plasmid DNA in a linearization reaction;
A2) optionally termination of the linearization reaction; and
A3) conditioning and/or purifying of the linearization reaction comprising linearized
plasmid DNA by one or more steps of TFF.
3 . The method according to item 1 or 2 , wherein step C) comprises at least one
diafiltration step and/or at least one concentration step using TFF.
4 . The method according to item 3, wherein the at least one diafiltration step using
TFF in step C) comprises diafiltration with an aqueous salt solution.
5 . The method according to item 4, wherein the aqueous salt solution is a NaCI
solution, preferably an aqueous solution comprising from about 0.1 M NaCI to about
1 M NaCI, more preferably a solution comprising from about 0.2 to about 0.5 M
NaCI.
6 . The method according to item 3, wherein the at least one diafiltration step using
TFF of step C) comprises diafiltration with water.
7 . The method according to any one of items 1 to 6 , wherein the method does not
comprise a step of phenol/chloroform extraction and/or DNA and/or RNA
precipitation.
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
(19) World Intellectual Property
Organization
International Bureau
(10) International Publication Number
(43) International Publication Date WO 2016/138175 Al
1 September 2016 (01.09.2016) P O P C T
(51) International Patent Classification: (74) Agent: LAWSON, Lleweliyn Rhys; Christensen O'Con
G01N35/08 (2006.01) G01N35/10 (2006.01) nor Johnson Kindness, 1201 Third Avenue, Suite 3600,
Seattle, WA 98101 (US).
(21) International Application Number:
PCT/US2016/019414 (81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,(22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
24 February 2016 (24.02.2016) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
(25) Filing Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
(26) Publication Language: English KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
(30) Priority Data: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
62/120,179 24 February 2015 (24.02.2015) US PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
62/275,630 6 January 2016 (06.01 .2016) US SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
(71) Applicant: THE UNIVERSITY OF BRITISH
COLUMBIA [CA/CA]; #103 - 61 0 Agronomy Road, (84) Designated States (unless otherwise indicated, for every
Vancouver, British Columbia, V6T 1Z3 (CA). kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
(72) Inventors: RAMSAY, Euan; 1606 - 1005 Beach Avenue, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
Vancouver, British Columbia, V6E 3W2 (CA). TAYLOR, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
Robert James; 201 - 1240 West 10th Avenue, Vancouver, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
British Columbia, V6H 1J3 (CA). LEAVER, Timothy; LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
4772 London Green, Delta, British Columbia, V4K 4X1 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
(CA). WILD, Andre; 2861 West 3rd Avenue, Vancouver, GW, KM, ML, MR, NE, SN, TD, TG).
British Columbia, V6K 1M8 (CA). OU, Kevin; 137 Cor
Published:inthian Blvd., Toronto, Ontario, M1W 1B7 (CA).
WALSH, Colin; 2836 Benson Way, Belmont, CA 94002 — with international search report (Art. 21(3))
(US).
(54) Title: CONTINUOUS FLOW MICROFLUIDIC SYSTEM
00
(57) Abstract: The present disclosure is directed towards improved systems and methods for large-scale production of nanoparticles
© used for delivery of therapeutic material. The apparatus can be used to manufacture a wide array of nanoparticles containing thera -
peutic material including, but not limited to, lipid nanoparticles and polymer nanoparticles. In certain embodiments, continuous flow
operation and parallelization of microfluidic mixers contribute to increased nanoparticle production volume.
microfluidic mixers arrayed in parallel in a single device illustrated in FIGURE 3
(4X On-Chip). The total flow rates through the microfluidic device are shown in the
legend. Error bars represent the standard deviation of the mean.
In this Example, 0.231 mg/mL siRNA in 50 mM sodium acetate buffer (pH 4.0)
and lipid mix (12.5 mM l,17-bis(2-octylcyclopropyl)heptadecan-9-yl 4-
(dimethylamino)butanoate/DSPC/Chol/PEG-c-DMA at mole ratios of 50:10:38.5:1.5 in
ethanol) in separate syringes were loaded into independent Harvard PHD Ultra syringe
pumps (Harvard Apparatus, Holliston, MA). The siRNA-total lipid ratio was 0.06 wt/wt.
Mixing volumes ratios of siRNA to lipid mix was 3:1, with 5 mL total volume processed
per mixer (i.e., total formulation volumes: IX = 5 mL, 2X = 10 mL, 4X = 20 mL). Flow
rate per mixer was 12 mL/min at siRNA to lipid mix flow rate ratio of 3:1 (i.e., 9 mL/min
siRNA and 3 mL/min lipid mix in IX). The first 2 mL of volume collected from the
mixer outlet at the beginning of each formulation run was discarded as waste, and the
remaining volume was collected as the sample. The 1 mL of the collected sample was
further diluted into 3 mL of Dulbecco's Phosphate Buffered Saline (without calcium and
without magnesium) before particle sizing.
Particle size measurement was performed as follows: siRNA-LNP were diluted to
appropriate concentration with Dulbecco's Phosphate Buffered Saline (without calcium
and without magnesium) and mean particle size (intensity-weighted) was determined by
dynamic light scattering (DLS) using a Malvern Zetasizer Nano ZS two angle particle
sizer (Malvern Instruments Ltd., Malvern, Worcestershire, UK).
Example 2 : siRNA-Lipid Nanoparticles (siRNA-LNP) Manufactured Using Eight Single
Microfluidic Mixer Devices Arrayed in Parallel Using a Manifold
In this example, 520 mL volume of siRNA-LNP was produced using eight single
microfluidic mixer devices arrayed in parallel using an external manifold. Each mixer in
the array was identical, thus the process conditions for forming siRNA-LNP in each
mixer was identical. The purpose of this experiment was to demonstrate the effect of a
large number of parallel mixers on siRNA-LNP size and quality. This example
significantly demonstrates the successful utilization of a large number of microfluidic
mixers used in parallel in the same system to produce a large volume batch of siRNA-
LNP using an exemplary system as disclosed herein.
FIGURE 5 shows particle diameter (nm) and polydispersity index (PDI) for
representative siRNA-Lipid Nanoparticles (siRNA-LNP) as a function of the
manufactured volume. The siRNA-LNP were composed of l,17-bis(2-
octylcyclopropyl)heptadecan-9-yl 4-(dimethylamino)butanoate/DSPC/Chol/PEG-c-DMA
at mole ratios of 50:10:38.5:1.5 and a siRNA-total lipid ratio of 0.06 wt/wt, and the
nanoparticles were produced using the illustrative continuous flow system shown in
FIGURE 2 with eight single microfluidic mixer device arrayed in parallel using a
manifold. Nanoparticles were sampled every 100 mL from 0 mL to 500 mL and the
results compared to a 2 mL preparation of the same siRNA-LNP prepared using the
NanoAssemblr™ Benchtop Instrument. The NanoAssemblr™ Benchtop Instrument is
commercially available laboratory apparatus that uses microfluidics to manufacture fixed
volume batches of nanoparticles. Error bars represent the standard deviation of the mean.
In this Example, 0.231 mg/mL siRNA in 50 mM sodium acetate buffer (pH 4.0)
and lipid mix (12.5 mM l,17-bis(2-octylcyclopropyl)heptadecan-9-yl 4-
(dimethylamino)butanoate/DSPC/Chol/PEG-c-DMA at mole ratios of 50:10:38.5:1.5 in
ethanol) loaded in separate Flash 100 metering pump (Scientific Systems, Inc., State
College, PA). The siRNA-total lipid ratio was 0.06 wt/wt. Mixing volumes ratios of
siRNA to lipid mix was 3:1, with 65 mL total volume processed per mixer (ie: total
formulation volumes in 8X = 520 mL). Flow rate per mixer was 12 mL/min at siRNA to
lipid mix flow rate ratio of 3:1 (total flow rate = 96 ml/min, thus flow rates for siRNA
and lipid mix were 72 mL/min and 24 mL/min respectively). The first 20 mL of volume
collected from the mixer outlet at the beginning the formulation run was discarded as
waste, and the remaining volume was collected as the sample. After the first 20 mL
priming waste was collected, the particle formulation was diluted in-line with Dulbecco's
Phosphate Buffered Saline (without calcium and without magnesium), 1 part particle
solution to 3 part DPBS, driven by a Masterflex L/S peristaltic pump with dual Easy-load
II pump heads (Cole-Parmer Instrument Company, Montreal, QC, Canada). The
resulting particle formulation was collected in aliquots and sized.
While illustrative embodiments have been illustrated and described, it will be
appreciated that various changes can be made therein without departing from the spirit
and scope of the invention.


